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Hematopoietic stem cell transplantation has become a well-established life- 
saving treatment procedure for many patients with hematological malignan-
cies, inborn errors, or bone marrow failure syndromes. Starting more than 60 
years as an “ultima ratio” option, hematopoietic stem cell transplantation is 
now integrated as an essential part in many treatment concepts and protocols. 
The rapid development in the field with changing in transplant practices and 
the increasing numbers of long-term survivors require a continuous education 
for physician, nurses, and healthcare providers who are involved in stem cell 
transplantation and cellular therapies.
This new formatted EBMT Handbook, which is part of a broader EBMT 
educational strategy, addresses the most recent developments and innova-
tions in stem cell transplantation and cellular therapy presented by more 
than 170 authors, known as experts and well-recognized authorities in the 
field. In more than 90 chapters, all types of stem cell and bone marrow trans-
plantation including haplo-identical stem cell and cord blood transplanta-
tion, indication for transplantation, and management of complications as 
well as the new rapidly evolving field of cellular therapies are covered. Other 
important issues such as quality management and JACIE accreditation, stem 
cell collection, conditioning, donor selection, HLA typing, graft manipula-
tion, ethical issues, psychological support, and quality of life are also prop-
erly addressed.
The aim of this new EBMT Handbook, which follows the long tradi-
tion of the ESH-EBMT Handbook on Haematopoietic Stem Cell 
Transplantation, is not to provide an in-depth knowledge like a textbook 
but rather to describe the state of practice to enhance the reader’s knowl-
edge and practice skills. Major key points are summarized at the end of 
each chapter.
The EBMT Board wants to express their great gratitude to the strong 
effort of the Working Party chairs and all authors in planning and writing 
the chapters and the tremendous work of the project leader Enric Carreras 
and the secretarial work of Marta Herrero Hoces from the Barcelona 




A heartfelt thanks goes to the Fondation José Carreras pour la lutte contre 
la leucémie, Geneve for the unconditioned educational grant, which permits 
the open-access publication as well as the printed version of this EBMT 
Handbook.
On behalf of the EBMT board, we hope this EBMT Handbook will be of 
help in your daily practice.
Barcelona, Spain Enric Carreras 
Geneva, Switzerland  Carlo Dufour 
Paris, France  Mohamad Mohty 
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AID Autoimmune disease
AIHA Autoimmune hemolytic anemia




ALL Acute lymphoblastic leukemia
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FFS Failure-free survival
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ICU Intensive care unit
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IPI International Prognostic Index
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MMUD Mismatched unrelated donor
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MODS Multiple-organ dysfunction syndrome
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HSCT has evolved from a field that was declared 
dead in the 1960s to the amazing clinical results 
obtained today in the treatment of otherwise fatal 
blood disorders. This chapter will reflect upon 
how HSCT has progressed from the laboratory to 
clinical reality.
1.2  Early Enthusiasm 
and Disappointment
Research efforts on how to repair radiation effects 
resulted from observations on radiation damage 
among survivors of the atomic bomb explosions 
in Japan (reviewed in van Bekkum and de Vries 
1967). In 1949, Jacobson and colleagues discov-
ered protection of mice from TBI by shielding 
their spleens with lead. Two years later, Lorenz 
and colleagues reported radiation protection of 
mice and guinea pigs by infusing marrow cells. 
Initially many investigators, including Jacobson, 
thought that the radiation protection was from 
some humoral factor(s) in spleen or marrow. 
However, by the mid-1950s, this “humoral 
hypothesis” was firmly rejected, and several lab-
oratories convincingly demonstrated that the 
radiation protection was due to seeding of the 
marrow by donor cells.
This discovery was greeted with enthusiasm 
because of the implications for cell biology and 
for therapy of patients with life-threatening blood 
disorders. The principle of HSCT was simple: 
high-dose radiation/chemotherapy would both 
destroy the diseased marrow and suppress the 
patient’s immune cells for a donor graft to be 
accepted. Within 1  year of the pivotal rodent 
studies, Thomas and colleagues showed that mar-
row could safely be infused into leukemia patients 
and engraft, even though, in the end, the leuke-
mia relapsed. In 1958, Mathé’s group attempted 
the rescue, by marrow transplantation, of six 
nuclear reactor workers accidentally exposed to 
TBI.  Four of the six survived, although donor 
cells persisted only transiently. In 1965, Mathé 
and colleagues treated a leukemia patient with 
TBI and then marrows from six relatives, absent 
any knowledge of histocompatibility (Mathe 
et al. 1965). A brother’s marrow engrafted. The 
patient went into remission but eventually suc-
cumbed to a complication, GVHD. Following up 
on early observations by Barnes and Loutit in 
mice, Mathé coined the term “graft-vs.-leukemia 
effect.” In 1970, Bortin summarized results of 
200 human marrow grafts reported between 1957 
and 1967 (Bortin 1970). All 200 patients died of 
either graft failure, GVHD, infections, or recur-
rence of leukemia.
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These transplants were performed before a 
clear understanding of conditioning regimens, 
histocompatibility matching, and control of 
GVHD.  They were based directly on work in 
inbred mice, for which histocompatibility match-
ing is not absolutely required. In 1967, van 
Bekkum and de Vries stated, “These failures have 
occurred mainly because the clinical applications 
were undertaken too soon, most of them before 
even the minimum basic knowledge required to 
bridge the gap between mouse and patient had 
been obtained.” Clinical HSCT was declared a 
total failure and prominent immunologists pro-
nounced that the barrier between individuals 
could never be crossed.
1.3  Back to the Laboratory: 
Focus on Animal Studies
Most investigators left the field, pronouncing it a 
dead end. However, a few laboratories continued 
animal studies aimed at understanding and even-
tually overcoming the obstacles encountered in 
human allogeneic HSCT. Van Bekkum’s group in 
Holland used primates, George Santos at Johns 
Hopkins chose rats, and the Seattle group chose 
outbred dogs as experimental models. One reason 
behind using dogs was that, besides humans, only 
dogs combine unusual genetic diversity with a 
widespread, well-mixed gene pool. Also, dogs 
share spontaneous diseases with humans, such as 
non-Hodgkin lymphoma and X-linked SCID.  In 
addition to determining the best ways to  administer 
TBI, new drugs with myeloablative or immuno-
suppressive qualities were introduced, including 
cyclophosphamide, ATG, and BU (Santos 1995). 
These agents improved engraftment and provided 
for tumor cell killing similar to TBI. Based on the 
mouse histocompatibility system defined 10 years 
earlier, in vitro histocompatibility typing for dogs 
was developed. Studies from 1968 showed that 
dogs given grafts from dog leukocyte antigen 
(DLA)-matched littermates or unrelated donors 
survived significantly longer than their DLA-
mismatched counterparts, even though typing 
techniques were very primitive and the complex-
ity of the genetic region coding for major antigens 
was far from understood (Epstein et  al. 1968). 
Serious GVHD was first described in H-2 mis-
matched mice and in randomly selected monkeys. 
However, the canine studies first drew attention to 
fatal GVHD across minor histocompatibility 
barriers.
These pivotal observations drove the search 
for Post transplant drug regimens to control 
GVHD. The most promising drug was the folic 
acid antagonist, MTX (Storb et al. 1970). Further 
work in canines showed that transfusion-induced 
sensitization to minor antigens caused rejection 
of DLA-identical grafts (reviewed in Georges 
and Storb 2016). Subsequent canine studies 
eventually led to ways of understanding, prevent-
ing, and overcoming transfusion-induced sensiti-
zation. Next, mechanisms of graft-host tolerance 
were investigated. It turned out that IS could 
often be discontinued after 3–6  months, and 
donor-derived T lymphocytes were identified that 
downregulated immune reactions of other donor 
T cells against GVHD targets. Immune reconsti-
tution was found to be complete in long-term 
canine chimeras, enabling them to live in an 
unprotected environment. Techniques for isolat-
ing transplantable stem cells from peripheral 
blood were refined in dogs and primates. 
Importantly, studies in pet dogs with non- 
Hodgkin lymphoma showed cures, in part due to 
graft-vs.-tumor effects.
1.4  Resuming Clinical 
Transplantation: 
1968–1980s
The second half of the 1960s saw the refinement 
of high-intensity conditioning regimens, includ-
ing fractionated TBI and maximally tolerated 
doses of CY or BU (Santos 1995). 
Histocompatibility matching was confirmed to be 
of utmost importance for reducing both graft 
rejection and GVHD (Thomas et  al. 1975). 
However, even when donor and recipient were 
well matched, GVHD was a problem unless post- 
grafting MTX was given, which slowed donor 
lymphocyte replication. Rapid progress in under-




matching of donor recipient pairs.
By 1968, the stage was set to resume clinical 
trials. The first successful transplants were for 
patients with primary immune deficiency disor-
ders. A 5-month-old boy with “thymic alympho-
plasia and agammaglobulinemia” was not perfectly 
matched with his sister (Gatti et al. 1968). Marrow 
and peripheral blood cells were infused intraperi-
toneally without conditioning. After a booster 
infusion several months later, the patient fully 
recovered with donor hematopoiesis and is well. A 
patient with Wiskott-Aldrich syndrome received a 
first unsuccessful marrow infusion from an HLA-
identical sister without conditioning (Bach et  al. 
1968). A second transplant following CY condi-
tioning resulted in full T- and B-cell recovery, but 
thrombocytopenia persisted.
During the first 7 or 8  years, most clinical 
studies were for patients with advanced hemato-
logical malignancies and SAA, who were in poor 
condition and presented tremendous challenges 
in supportive care (Thomas et  al. 1975). They 
required transfusions and prophylaxis or treat-
ment of bacterial, fungal, and viral infections. 
Therefore, in addition to discoveries made in 
marrow transplantation, these early trials stimu-
lated advances in infectious diseases and transfu-
sions (reviewed in Forman et  al. 2016). The 
longest survivors from that era are patients with 
aplastic anemia who are approaching their 47th 
anniversary from HSCT with fully recovered 
donor-derived hematopoiesis and leading normal 
lives. Chronic GVHD emerged as a new problem 
among long-term survivors.
The initial studies saw GVHD among approx-
imately half of the patients, despite HLA match-
ing and despite receiving methotrexate. This 
stimulated further research in the canine system. 
Major improvements in GVHD control and 
patient survival were made when combining 
MTX with CNI inhibitors such as CSA or TAC 
(Storb et al. 1986). Combinations of drugs have 
remained a mainstay in GVHD prevention. 
GVHD treatment with PRD was introduced.
Early results with marrow grafts from HLA- 
identical siblings after CY for SAA showed 
45% long-term survival (reviewed in Georges 
and Storb 2016). The major cause of failure was 
graft rejection as expected from canine studies 
on transfusion-induced sensitization to minor 
antigens. Canine studies identified dendritic cells 
in transfusions to be the key element in sensitiza-
tion. Depleting transfusions of white cells, there-
fore, reduced the rejection risk. Further canine 
studies generated a clinical conditioning regi-
men that alternated CY and ATG, which greatly 
reduced the rates of both graft rejection and 
chronic GVHD (Storb et al. 1994). Finally, irra-
diation of blood products with 2000 cGy in vitro 
almost completely averted sensitization to minor 
antigens. Consequently, graft rejection in trans-
plantation for AA has become the exception, and 
current survivals with HLA-identical sibling and 
HLA-matched unrelated grafts range from 90% 
to 100%. First successful grafts for thalassemia 
(Thomas et al. 1982) and sickle cell disease were 
reported.
For patients with leukemia and other malig-
nant blood diseases, disease relapse after HSCT 
has remained a major problem. Attempts to 
reduce relapse by increasing the intensity of sys-
temic conditioning regimens have met with suc-
cess, but this benefit was offset by higher 
non-relapse mortality. Reports by Weiden and the 
Seattle group in 1979/1981 firmly established the 
existence of graft-vs.-leukemia (GvL) effects in 
humans (Weiden et  al. 1979). DLI to combat 
relapse were introduced by Kolb and colleagues 
in 1990 (Kolb et al. 1990) (see Chap. 59).
Some investigators have removed T cells from 
the marrow as a means of preventing GVHD 
(reviewed in Soiffer 2016). Early studies showed 
high incidences of graft rejection, relapse of 
underlying malignancies, and infections. More 
recent studies showed that relapse seemed a lesser 
problem in patients with acute leukemia. Others 
have used T-cell depletion with close disease 
monitoring and treating recurrence with DLI in 
hopes of initiating GvL responses without caus-
ing GVHD. Most recently, younger patients have 
been given high-intensity conditioning for grafts 
which were depleted of naïve T cells with a result-
ing decrease in GVHD (Bleakley et al. 2015).
The late 1980s saw the introduction of G-CSF- 
mobilized PBSC (reviewed in Schmitz and 
1 HSCT: Historical Perspective
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Dreger 2016). These were equivalent to marrow 
as far as engraftment and survival were con-
cerned; however, they seemed to increase the risk 
of chronic GVHD. For patients with nonmalig-
nant diseases, marrow has therefore remained the 
preferred source of stem cells in order to keep the 
rate of chronic GVHD low.
Only approximately 35% of patients have 
HLA-identical siblings. Therefore, alternative 
donors have been explored, predominantly HLA- 
matched unrelated volunteers. The first successful 
unrelated transplant for leukemia was reported in 
1980. In order to expand the donor pool, national 
registries were established, with currently more 
than 30 million HLA-typed unrelated volunteers 
(reviewed in Confer et al. 2016). The likelihood of 
finding suitable unrelated donors is approximately 
80% for Caucasians, although this percentage 
declines dramatically for patients from minority 
groups. A second, important alternative stem cell 
source has been unrelated cord blood (Gluckman 
et al. 1989), not requiring complete HLA match-
ing and resulting in encouraging outcomes among 
patients with malignant blood diseases. First 
attempts with yet another donor source have 
included TCD megadose CD34+ cell grafts from 
related HLA- haploidentical donors to treat acute 
leukemia (Aversa et al. 1998).
1.5  Moving Ahead: The 1990s 
and Beyond
Conventional HSCT following high-intensity 
conditioning is risky and requires specialized 
intensive care wards. The associated toxicities 
restrict the therapy to younger, medically fit 
patients. To allow the inclusion of older (highest 
prevalence of hematological malignancies), med-
ically infirm or very young immunodeficiency 
patients, less intensive conditioning programs 
have been developed. In patients with malignan-
cies, these rely less on high-dose chemoradiation 
therapy and more on graft-vs.-tumor effects. 
One outpatient transplant strategy combines FLU 
and 2–3  Gy TBI conditioning with Post trans-
plant IS using an inhibitor of purine synthesis 
MMF and CSA or TAC. Figure 1.1 illustrates the 
spectrum of current conditioning regimens 
(reviewed in Storb and Sandmaier 2016).
A transplant regimen combining fludarabine 
and 2  Gy TBI conditioning with additional 
 cyclophosphamide before and after HSCT has 
encouraged widespread use of unmodified HLA-
haploidentical grafts (Luznik et  al. 2008). It is 
well tolerated with low incidences of graft rejec-
tion and of acute and chronic GVHD, but relapse 
remains a problem. Strategies addressing relapse 
have included infusion of donor lymphocytes or 
NK cells. Retrospective multicenter analyses 
show comparable outcomes after HLA- matched 
vs. HLA-haploidentical HSCT.
While reduced-intensity regimens have been 
well tolerated, relapse and GVHD need improv-
ing. Adding targeted radioimmunotherapy 
against host hematopoietic cells, using anti-
 CD45 antibody coupled to beta and alpha emit-
ting radionuclides to standard conditioning, has 
the potential to decrease the pre-transplant tumor 
burden, thereby lessening the relapse risk (Chen 
et al. 2012; Pagel et al. 2009). As for GVHD, a 
recent phase III randomized trial convincingly 
demonstrated that a triple combination of MMF/
cyclosporine/sirolimus significantly reduced 
both acute GVHD and non-relapse mortality and 
improved survival (Sandmaier et al. 2016).
Survival of patients with primary immune 
deficiency diseases given NMA conditioning 
before HLA-matched and HLA-mismatched 
grafts between 1998 and 2006 has stabilized at 
82% (Moratto et al. 2011).
In the future, better understanding of hemato-
poietic cell-specific polymorphic minor histo-
compatibility antigens might result in ways of 
directing donor immune cells toward hematopoi-
etic targets, thereby controlling relapse without 
inducing GVHD. Another major research target 
is containment of chronic GVHD.
R. Storb
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Fig. 1.1 Spectrum of current conditioning regimens. 
Reproduced with permission from Sandmaier, B.M. and 
Storb, R.  Reduced-intensity allogeneic transplantation 
regimens (Ch. 21). In Thomas’ Hematopoietic Cell 
Transplantation, fifth edition (ed. by Forman SJ, Negrin 
RS, Antin JH, & Appelbaum FR) 2016, pp. 232–243. John 
Wiley & Sons, Ltd., Chichester, UK
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“Only he/she who knows the past has a future” is 
a proverb attributed to Wilhelm von Humboldt 
(1767–1835), a great historian, scientist, and phi-
losopher (Spier 2015). It appears as an ideal 
introduction to a chapter on the history of 
EBMT. The context by which HSCT evolved in 
the middle of last century fits with modern views 
on history. The novel “big history” concept 
attempts to integrate major events in the past, 
beginning with the “big bang” up to today’s 
industrial revolution number IV (Spier 2015). 
According to this model, nothing “just happens.” 
Progress occurs when the conditions fit, at the 
right time and at the right place. Such circum-
stances are called “Goldilocks conditions,” 
according to the novel by Robert Southey (https://
en.wikipedia.org/wiki/Goldilocks_and_the_
Three_Bears. accessed November 6, 2018). They 
hold true for the formation of galaxies, suns, and 
planets, for the appearance of life on earth, or for 
the evolution of mankind. They apply specifically 
to the latter: as the one and only species, Homo 
sapiens managed to create “Goldilocks condi-
tions” by him or herself. They allowed man to fit 
religion, art, or beliefs in such ways to master 
society. In our perspective, big history thinking 
helps to understand the development of HSCT 
and EBMT and to view it in a broader frame-
work. It provides as well a caveat for the future.
2.2  The Past: Development 
of HSCT and EBMT
The use of bone marrow (BM) for healing purposes 
dates back long in history, and BM from hunted 
animals might have contributed as rich nourish-
ment to the evolution of Homo sapiens (McCann 
2016). Its recognition as primary hematopoietic 
organ in adult life with a hematopoietic stem cell 
as source of the circulating blood cells began in the 
middle of the nineteenth century (Schinck 1920). 
It did result in some early recommendations on 
the potential therapeutic use of bone marrow 
(JAMA 1997; Osgood et  al. 1939), but with no 
broader application. All changed after the explo-
sions of atomic bombs in Hiroshima and Nagasaki 
in World War II, when survivors of the immedi-
ate exposure died from BM failure (Van Bekkum 
and De Vries 1967). Research was directed to find 
ways to treat this lethal complication. It led to the 
discovery that bone marrow- derived stem cells 
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from a healthy donor could replace hematopoiesis 
after total body irradiation (TBI); it provided at 
the same time, a tool, TBI, to eradicate aberrant 
hematopoiesis (Van Bekkum and De Vries 1967; 
Jacobson et  al. 1949; Lorenz et  al. 1951; Ford 
et al. 1956). The concept of HSCT was born, and 
“the conditions were right.” It is to no surprise that 
the first clinical BMT centers in Europe started in 
hospitals with close links to radiobiology research 
institutes in the UK, the Netherlands, France, and 
Germany. Funding of radiobiology fostered basic 
research and stimulated clinical application. In 
the first series of patients reported in the NEJM in 
1957 by the late Nobel Prize winner ED Thomas, 
all six patients died but two of them with clear 
signs of donor chimerism (Thomas et  al. 1957). 
And, BMT “saved” accidentally irradiated work-
ers of a radiation facility in Vinca, a town in for-
mer Jugoslawia (Mathé et  al. 1959). Hence, the 
clinical results confirmed the “proof of principle” 
obtained in mice: TBI could eradicate normal and 
malignant bone marrow cells, and the infusion of 
healthy donor bone marrow cells could restore 
the recipient’s depleted hematopoiesis with func-
tioning donor cells. In reality, of more than 200 
patients reported by M. Bortin for the IBMTR, all 
patients with leukemia had died, many of them free 
of their disease. Three patients survived, all with 
congenital immune deficiency and transplanted 
from HLA-identical sibling donors (Bortin 1970). 
Despite the dismal results, Goldilocks conditions 
prevailed. Armed forces were convinced of the 
need for a rescue tool in the event of a nuclear war, 
physicians viewed BMT as an instrument to treat 
hitherto incurable blood disorders, and patients 
envisioned a cure of their lethal disease.
In order to improve outcome, the “believers” 
joined forces. They met each other, openly 
reviewed their cases and charts one by one, 
exchanged views on hurdles and opportunities, 
spent time together on the slopes in the Alps, and 
became friendly rivals: EBMT was born. 
Goldilocks conditions still prevailed. Leukemia 
could be eradicated. BMT with haploidentical 
donor bone marrow for SAA after conditioning 
with ATG yielded spectacular results (Speck 
et  al. 1977). Today, we know that ATG, rather 
than the cells, was responsible for the outcome. 
The introduction of intensive induction regimens 
for AML enabled stable phases of complete first 
remission (CR1) (Crowther et al. 1970). The dis-
covery of CSA, as the first of its kind of novel IS 
agents, opened new dimensions in BMT and 
other organ transplantation (Kay et al. 1980). It 
became acceptable to transplant patients in early 
phase of their disease, e.g., CR1 or first chronic 
phase (CP1) (Thomas et al. 1975). The boom of 
BMT began (Thomas 2007; Gratwohl et  al. 
2015a). The first patient in the EBMT database 
dates back to 1965. In 1973, at the first informal 
gathering in St. Moritz, the database comprised 
13 patients; 4 transplanted in that year. In 1980, a 
total of 285 HSCT were performed, increasing to 
4025 10 years later.
HSCT rapidly diversified in terms of donor 
type, by including autologous and allogeneic 
stem cells from related and unrelated donors, and 
of stem cell source, from bone marrow and 
peripheral blood to cord blood. Indications 
expanded from the early congenital immunodefi-
ciency, leukemia, and aplastic anemia to a full 
variety of severe congenital disorders of the 
hematopoietic system, to other hematological 
malignancies such as myeloma and lymphoma, 
and to non-hematological malignancies, e.g., 
germ cell tumors. The HSCT technology 
improved to encompass a variety of in vivo and 
ex  vivo GvHD prevention methods and condi-
tioning regimens of varying intensities with or 
without TBI. HSCT became open to centers with 
no links to radiobiology institutes and was no 
longer bound to “sterile units” and to selected 
countries (Gratwohl et al. 2015a; Copelan, 2006).
The previously informal gatherings and the 
database no longer sufficed to share the urgently 
needed information exchange. EBMT became a 
formal structure, with elections for presidents and 
working party chairs. It was listed in PubMed for 
the first time in 1985 (EBMT 1985). The meetings 
were no longer confined to ski resorts and became 
open to all involved in patient care and scientific 
analyses (Table  2.1). Obviously, organization of 
the annual meeting is today a major undertaking 
and only possible with the support of corporate 
sponsors. Still, the initial spirit remains.
A. Gratwohl et al.
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Table 2.1 List of EBMT meetings and presidents
Year Location annual meeting Participating groups EBMT president
1974 Informal gathering
1975 St. Moritz, Switzerland 1st P
1976 St. Moritz, Switzerland 2nd P B. Specka
1977 Courchevel, France 3rd P B. Specka
1978 Courchevel, France 4th P B. Specka
1979 St. Moritz, Switzerland 5th P E. Gluckman
1980 Sils-Maria, Switzerland 6th P E. Gluckman
1981 Courchevel, France 7th P E. Kubanek
1982 Courmayeur, Italy 8th P E. Gordon-Smith
1983 Oberstdorf, Germany 9th P E. Gordon-Smith
1984 Granada, Spain 10th P J. Barrett
1985 Bad Hofgastein, Austria 11th P, 1st N J. Barrett
1986 Courmayeur, Italy 12th P, 2nd N A. Marmonta
1987 Interlaken, Switzerland 13th P, 3rd N A. Marmonta
1988 Chamonix, France 14th P, 4th N G. Gharton
1989 Bad Hofgastein, Austria 15th P, 5th N G. Gharton
1990 The Hague, Netherlands 16th P, 6th N J. Goldmana
1991 Cortina d’Ampezzo, Italy 17th P, 7th N J. Goldmana
1992 Stockholm, Sweden 18th P, 8th N J. Goldmana
1993 Garmisch- Partenkirchen, 
Germany
19th P, 9th N J. Goldmana
1994 Harrogate, UK 20th P, 10th N A. Gratwohl
1995 Davos, Switzerland 21st P, 11th N A. Gratwohl
1996 Vienna, Austria 22nd P, 12th N A. Gratwohl
1997 Aix-les-bains, France 23rd P, 13th N A. Gratwohl
1998 Courmayeur, Italy 24th P, 14th N A. Bacigalupo
1999 Hamburg, Germany 25th P, 15th N A. Bacigalupo
2000 Innsbruck, Germany 26th P, 16th N A. Bacigalupo
2001 Maastricht, Netherlands 27th P, 17th N A. Bacigalupo
2002 Montreux, Switzerland 28th P, 18th N, 1st DM J. Apperley
2003 Istanbul, Turkey 29th P, 19th N, 2nd DM J. Apperley
2004 Barcelona, Spain 30th P, 20th N, 3d DM J. Apperley
2005 Prague, Czech Republic 31st P, 21st N, 4th DM J. Apperley
2006 Hamburg, Germany 32nd P, 22nd N, 5th DM D. Niederwieser
2007 Lyon, France 33rd P, 23d N, 6th DM, 1st P&F D. Niederwieser
2008 Florence, Italy 34th P, 24th N, 7th DM, 2nd P&F D. Niederwieser
2009 Goteborg, Sweden 35th P, 25th N, 8th DM, 3rd P&F D. Niederwieser
2010 Vienna, Austria 36th P, 26th N, 9th DM, 4th P&F A. Madrigal
2011 Paris, France 37th P, 27th N, 10th DM, 5th P&F A. Madrigal
2012 Geneva, Switzerland 38th P, 28th N, 11th DM, 6th P&F, 1st QM, 1st Ped A. Madrigal
2013 London, UK 39th P, 29th N, 12th DM, 7th P&F, 2nd QM, 2nd Ped A. Madrigal
2014 Milan, Italy 40th P, 30th N, 13th DM, 8th P&F, 3d QM, 3d Ped A. Madrigal
2015 Istanbul, Turkey 41st P, 31st N, 14th DM, 9th P&F, 4th QM, 4th Ped M. Mohty
2016 Valencia, Spain 42nd P, 32nd N, 15th DM, 10th P&F, 5th QM, 
5thPed, 1stPha
M. Mohty
2017 Marseille, France 43rd P, 33rd N, 16th DM, 11th P&F, 6th QM, 
6thPed, 2nd Pha
M. Mohty
2018 Lisbon, Portugal 44th P, 34th N, 17th DM, 12th P&F, 7th QM, 
7thPed, 3d Pha
M. Mohty
2019 Frankfurt, Germany 45th P, 35th N, 18th DM, 13th P&F, 8th QM, 8th 
Ped, 4th Pha
N. Kröger
Participating groups: P physicians, N nurses, DM data manager, P&F patient and family day, QM quality manager, 
Ped pediatricians, Pha pharmacists
adeceased
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2.3  The Present
Today, EBMT (www.ebmt.org) is a nonprofit orga-
nization with a clear mission statement: “To save the 
lives of patients with blood cancers and other life-
threatening diseases by advancing the fields of blood 
and marrow transplantation and cell therapy world-
wide through science, education and advocacy” 
(https://portal.ebmt.org/Contents/About-EBMT/
Mission-Vision/Pages/Mission%2D%2DVision.
aspx. Accessed 26 Feb 2018). It is formally a profes-
sional society with legal residence in the Netherlands 
and an administrative office in Barcelona, Spain. 
EBMT is chaired by the president, who is elected by 
the members for 2 years and for a maximum of two 
terms. He/she is supported by the board of associa-
tion as the executive committee and the board of 
counselors as external advisors. The scientific coun-
cil which represents the 11 working parties, the 
seven committees, and the groups guides the scien-
tific work with the help of the seven offices 
(Table  2.2). The main task of the organizational 
body of EBMT is to collect, analyze, and dissemi-
nate scientific data; to conduct clinical trials; to 
improve quality through the close cooperation with 
JACIE and FACT; to plan the annual meeting, the 
educational events, and training courses, including 
the EBMT Handbook; and to provide assistance to 
patients, donors, physicians, and competent 
authorities.
Members of the EBMT are mainly centers 
active in transplantation of hematopoietic stem 
cells (HSC) or any other organization involved in 
the care of donors and recipients of 
HSC. Currently (January 1, 2018), EBMT holds 
509 full center members and 55 associate center 
members, 122 individual, and 35 honorary mem-
bers, from 65 different countries. EBMT is sup-
ported in its activities through the membership 
fees and the revenue of the annual meetings and 
by its corporate sponsors (https://www2.ebmt.
org/Contents/Members-Sponsors/Sponsors/
Lis tofcorpora tesponsors /Pages /Lis t -of -
corporate-sponsors.aspx. Accessed 26 Feb 2018). 
EBMT is part of the global network of organiza-
tions involved in HSCT, the Worldwide Network 
for Blood and Marrow Transplantation (WBMT), 
and in close link with national and other 
 international professional organizations involved 
in HSCT, such as AFBMT, APBMT, CIBMTR, 
EMBMT, LABMT, or WMDA. The EBMT data-
base now holds information on more than 
500,000 transplants. Over 35,000 new patients 
were treated annually over the last 5  years and 
more than 40,000 HSCT performed (Fig.  2.1). 
An estimated number of more than 400,000 
patients are currently alive after HSCT in Europe; 
they reflect the EBMT achievements and the 
challenges ahead.
Table 2.2 EBMT working parties, committees, groups 
and offices
Working parties
ADWP Autoimmune Diseases Working Party
ALWP Acute Leukemia Working Party
CMWP Chronic Malignancies Working Party
CTIWP Cellular Therapy & Immunobiology Working 
Party
IDWP Infectious Diseases Working Party
IEWP Inborn Errors Working Party
LWP Lymphoma Working Party
PDWP Paediatric Diseases Working Party
SAAWP Severe Aplastic Anaemia Working Party
STWP Solid Tumors Working Party








Legal & Regulatory Affairs Committee
Groups




EBMT Executive Office, Barcelona, Spain
JACIE Accreditation Office, Barcelona, 
Spain
EBMT Central Registry Office, London, UK
EBMT Data Office, Leiden, The Netherlands
EBMT Clinical Trials Office, Leiden, The 
Netherlands
EBMT Data Office/CEREST-TC, Paris, 
France
EBMT Activity Survey Office, Basel, 
Switzerland
Courtesy: EBMT office Barcelona, Marta Herrero Hoces
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2.4  The Future
Again, according to the Big History concept, pre-
dicting the future is a difficult task: “There are no 
data about the future; from an empirical scientific 
point of view, it is impossible to say what lies 
ahead of us.” (Spier 2015). But we can project 
scenarios; we know the past, and we see the 
today. We live in the rapidly evolving world of 
the industrial revolution IV, dominated by global-
ization, digitization, and personalized medicine. 
Targeted therapies promise cures; gene-modified 
cells destroy hitherto untreatable cancers; 
 immunomodulation with checkpoint inhibitors 
has become a reality (Hochhaus et al. 2017; Tran 
et al. 2017; Le et al. 2015). If HSCT is to remain 
a valuable treatment, mentalities and methods of 
the past no longer suffice. The idea of beliefs, 
hence physicians creating their own Goldilocks 
conditions, will lead to the end of HSCT. It has to 
be replaced by a stringent scientific approach. 
The sad story of HSCT for breast cancer, with 
more than 40,000 transplants but no clear answer, 
must not to be repeated (Gratwohl et al. 2010).
Hence, prediction number one: The idea of “a 
donor for everybody” will be abandoned. HSCT 
has to provide for the individual patient the best 
outcome regarding overall survival, quality of life 
and costs. The outcome after HSCT must be supe-
rior, in these three aspects, to any of the modern 
drugs or treatments, including “watch and wait” 
strategies or palliation. Assessment of risks needs 
to integrate risk factors relating to the patient, his 
or her disease, the donor, the stem cell source, the 
transplant technology, as well as micro- and mac-
roeconomic risk factors (Gratwohl et  al. 2015b; 
Gratwohl et  al. 2017). For some patients, early 
transplant will be the optimal approach; for oth-
ers, HSCT may need to be delayed. For others, 
HSCT will never be the preferred option. 
Obviously, the transplant physician is no longer in 
a position to adequately assess risk in comparison 
to the multiple alternative strategies, as it was pos-
sible in the old times of the simple EBMT risk 
score. Machine-learning algorithms will replace 
risk assessment; the competent physician will still 
be needed to discuss the results with his or her 
patients and their families and to conduct the 
transplant (Verghese et al. 2018).






































































Fig. 2.1 Numbers of patients with a first HSCT by main 
donor type and year of transplant. The lines reflect the dif-
ference in patient numbers with and without information 
in the database (megafile). Courtesy: Carmen Ruiz de 
Elvira, EBMT megafile office, London; Helen Baldomero, 
EBMT activity survey office, Basel
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Hence, prediction number two: The WHO 
guiding principles for cell, organ, and tissue 
transplants, “data collection and data analysis are 
integral parts of the therapy”, need to become a 
mandatory reality for all transplant teams (WHO 
2010). The gap between transplant numbers and 
reports (Fig. 2.1) has to be closed. Reporting has 
to become real-time and life-long. The EBMT 
and transplant centers have to adapt. Data and 
quality management will become a “condition 
sine qua non” for all, with close interactions 
between local, national, and international organi-
zations. Machine learning will end the individu-
alistic center unique transplant techniques. It will 
no longer be possible to apply hundreds of differ-
ent GvHD prevention methods and a multitude of 
conditioning regimens, just by the argument “I 
have good experience with my method.” 
Standardization will permit correct personalized 
medicine, as outlined above. Obviously, assess-
ment of outcome can no longer be restricted to 
transplanted patients; it will need the correct 
comparison with non-transplant strategies on a 
routine basis.
Hence, prediction number three: HSCT cen-
ters and the EBMT will no longer be isolated in 
the treatment landscape. HSCT will need to be 
integrated into the treatment chain, from diagno-
sis to early treatment, transplant decisions, and 
secondary treatment, up to life-long follow-up. 
Not all of these steps have to occur at the trans-
plant center, but they need to be coordinated by 
the expert team. Data have clearly shown that 
transplant experience, as measured in patient 
numbers and years, is associated with outcome 
(Gratwohl et al. 2015b). No center will have suf-
ficient expertise for all diseases amenable to 
HSCT or for all transplant techniques, e.g., bone 
marrow harvest. HSCT centers will have to 
decide on their priorities, jointly with their refer-
ral and their after-care chain, within their city, 
their country, or with neighboring countries for 
coordination.
Hence, final prediction: EBMT can take the 
science-based lead for coordination and stan-
dardization, guide in reorganization of networks 
with non-transplant treatment chains, and priori-
tize comparative studies, independent of pressure 
groups. Then, history will tell, whether the prov-
erb from a contemporary of von Humboldt, 
Georg Wilhelm Friedrich Hegel (1770–1831) 
“History teaches us that man learns nothing from 
history.” (Spier 2015), can be overcome. The 
potential is here.
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3.1.1  From Anthony Nolan to 32 
Million Volunteer Donors 
Worldwide
Bone marrow donor registries (hereinafter 
referred to as registries) have been playing an 
important role in developing the treatment of 
HSCT for more than four decades. In 1974, the 
world’s first registry was founded by Shirley 
Nolan in London. Shirley’s son, a 3-year-old, 
Anthony, had been diagnosed with Wiskott- 
Aldrich syndrome and needed a transplant. 
Following the example of Anthony Nolan, a 
large number of registries have been established 
around the world, mainly in the late 1980s to 
early 1990s and have increased over the years. 
The growing pool of donors has contributed to 
the development of stem cell transplantation as 
a treatment method and a field of science 
(Fig. 3.1).
3.1.2  Registry: Structure and Duties
A registry is “an organisation responsible for 
coordination of the search for haematopoietic 
progenitor cells from donors (including cord 
blood) unrelated to the potential recipient” 
(WMDA International Standards 2017).
Registries play the main role in communica-
tion between the physician in the transplant cen-
tre and the healthcare professional contacting the 
donor at national and international level. Search 
requests for adult unrelated donors (AUDs) and 
cord blood units (CBUs) are usually sent to the 
national registry, which facilitates all stages of 
search and provision of the graft for a patient.
A typical registry performs different interre-
lated functions, including donor recruitment and 
management and search and interact with HLA- 
typing laboratories, apheresis and marrow collec-
tion centres, cord blood banks (CBBs), stem cell 
couriers and transplant centres.
Some registries recruit donors themselves, 
while others have an agreement with blood banks, 
donor centres or donor recruitment groups. The 
donor’s or cord blood information is provided by 
the donor centre or CBB to a registry. The regis-
try is responsible for listing the donors on the 
global database and handling communication 
with national and international transplant centres 
(through their national registries) if a potential 
match for a patient has been found.
The search for a suitable stem cell source 
is  based on the HLA-type of the patient. 
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Transplant centres and search coordinators within 
donor registries have access to the Search & 
Match Service of WMDA (https://search.wmda.
info/login), where they can register patient data 
and get a match list to see if there is a potential 
stem cell source in the global database.
When the transplant centre identifies a poten-
tially matched stem cell source, the national reg-
istry will contact the relevant organisation and 
facilitate the delivery of stem cells for the patient. 
Annually, more than 20,000 stem cell products of 
different sources are shipped within and across 
borders to patients in need of a HSCT (see 
Fig. 3.2).
3.2  Current Landscape
3.2.1  Ethnic Diversity and Chance 
to Find a Donor
As of January 2018, more than 32 million poten-
tial AUDs and CBUs are listed in the global 
Search & Match Service of WMDA. Almost 95% 
Fig. 3.1 Volunteer donors and cord blood units recruited around the wold (data from WMDA web page)
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Fig. 3.2 Unrelated HSC from bone marrow, peripheral blood and cord blood shipped annually (data from WMDA)
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of these donors have DNA-based HLA-A, HLA-B 
and HLA-DRB1 phenotype presented, and more 
than half are listed with additional information on 
HLA-C, HLA-DQB1 and HLA- DPB1. Every 
year, registries across the world add approxi-
mately two million new volunteer donors to the 
worldwide pool, with the vast majority being 
HLA-typed at high and allelic level resolution.
The chance of finding a well-matched donor 
varies for patients belonging to different ethnic 
groups. In 2014, the National Marrow Donor 
Program (NMDP) study demonstrated that 
whereas approximately 75% of Caucasian 
patients are likely to identify an 8/8 HLA- 
matched AUD, the rate is much lower for ethnic 
minority and mixed-race patients. This is due to 
the higher genetic diversity of HLA haplotypes in 
African and Asian populations compared to 
Europeans and the lower representation and 
poorer availability of ethnic minority donors in 
the worldwide pool (Gragert et al. 2014).
3.2.2  Donor Profile
WMDA defines an unrelated donor as “a person 
who is the source of cells or tissue for cellular 
therapy product. Donors are unrelated to the 
patient seeking a transplant”.
Donor centres recruit volunteer donors from 
16 to 55 years of age with variations in individual 
policies. Although donors can remain on the 
database until they are 60, donor centres try to 
recruit more young volunteers, as donor age has 
been proven to be linked to better HSCT out-
comes (Kollman et  al. 2016). According to the 
World Marrow Donor Association (WMDA) 
data, approximately 50% of donors listed glob-
ally are younger than 35 (see Fig. 3.3).
Medical suitability for donation, gender diver-
sity, behaviour and psychological risks are con-
stantly changing factors in donor recruitment and 
management. Donor centres align their policies 
with national and international standards and rec-
ommendations, including donor suitability guide-
lines produced by the WMDA on https://share.
wmda.info/x/FABtEQ and published in 2014 
(Lown et al. 2014).
Unrelated donors are acting voluntarily and 
altruistically and have a right to withdraw from 
the process at any stage. To avoid such cases, 
donor centres focus on informing volunteers 
about all aspects of donation, including risks, at 
the very early stage of recruitment. When a donor 
is identified as a potential match for a patient and 
is asked to provide a blood sample for verifica-
tion or extended testing, healthcare professionals 
will have further detailed conversations with the 
donor addressing any possible questions and con-
cerns. Full informed consent is usually given at 
the donor’s medical, prior to the conditioning of 
the patient for transplant.
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Fig. 3.3 Age and gender of unrelated donors and percentage of donors in each category
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3.2.3  Recruitment, Retention 
and Data Confidentiality
Recruiting volunteer donors is challenging. 
Registries and donor centres must ensure they are 
recruiting the preferred donors (usually younger 
donors) who are appropriately counselled to fully 
understand their commitment.
Registries and donor centres use a combination 
of methods to recruit potential donors including 
patient-related drives, targeting special groups, 
e.g. universities, uniformed services, engaging 
blood donors or online recruitment. The approach 
depends on the laws of the country and takes tra-
ditions, religion and habits into account. The same 
factors influence donor retention. Considering 
several options and alternative donors in urgent 
cases is a recommended practice.
By signing to a donor centre or registry, a 
potential donor agrees that his/her data are regis-
tered in the global database. The donor also pro-
vides biological material (blood sample, saliva or 
buccal swab) for tests, such as HLA typing and 
infectious disease markers, along with their per-
sonal details, in order to be searched as a match 
for a patient. The registry or donor centre has an 
obligation to adhere to national and international 
data protection laws and to keep donor personal 
and medical information confidentially and use it 
strictly in line with the donor’s informed consent.
While social media helps enormously with 
donor recruitment and retention, it can present a 
challenge for confidentiality of both the donor 
and the recipient. Registries and donor centres in 
different countries have different policies on 
donor/patient post-donation contact and on the 
level of information provided to each other. These 
should be respected by all sides involved.
3.3  Connections and Worldwide 
Collaboration
3.3.1  WMDA
In 1988, three pioneers in the field of transplanta-
tion, Professors John M.  Goldman (United 
Kingdom), E.  Donnell Thomas (United States) 
and Jon J. van Rood (the Netherlands), informally 
initiated the WMDA, which became a formal 
organization in 1994. It is made up of individuals 
and organizations who promote global collabora-
tion and best practices for the benefit of stem cell 
donors and patients requiring HSCT.  It aims to 
give all patients worldwide equal access to high-
quality stem cells from donors, whose rights and 
safety are carefully protected.
3.3.2  Quality and Accreditation
In 2017, WMDA took the lead role in the merg-
ing of three key organizations: WMDA, BMDW 
and the NetCord Foundation. This allowed 
WMDA to streamline resources to provide a 
global platform for facilitating international 
search, to support members to develop and grow 
and to promote safety, quality and global collabo-
ration through accreditation and standardisation. 
Eighty-four percent of AUDs available for search 
are provided by WMDA qualified/accredited reg-
istries (WMDA Annual Report 2017). WMDA 
accreditation of the registries along with FACT- 
NetCord accreditation of the CBBs reassures 
recipients in the quality of product and services 
provided. A complete list of the accreditation sta-
tus of organisations can be found on WMDA 
Share: https://share.wmda.info/x/4gdcAQ.
3.3.3  Network Formalities
All registries, donor centres and CBBs providing 
stem cells for HSCT nationally and internation-
ally have legal agreements and contracts with 
each other within the network. The contracts 
cover legal, financial and ethical questions of col-
laboration in respect of obtaining, testing and 
shipment of stem cells.
3.4  Challenges and Opportunities
3.4.1  Donor Attrition
Time to transplant is reported to be a factor of 
overall survival (Craddock et  al. 2011). Formal 
search for an unrelated donor on average takes 
I. Evseeva et al.
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about 2 months. However, more and more urgent 
search requests are made to the registries, where 
transplant centres are hoping to get a donor work-
 up in weeks rather than months.
Not all potential donors listed on the database 
will be available for donation due to different rea-
sons, including medical or personal circumstances 
or loss of contact with the registry. It varies in dif-
ferent countries. According to WMDA annual 
questionnaire, in 2017, the recommended target 
for donor availability at verification typing stage 
was 80% and at work-up stage 95%. Registries 
and donor centres are working hard to keep in 
contact with their donors to have updated infor-
mation to help reach the donor without delays. 
Some donor centres use private healthcare provid-
ers to speed-up blood sample collection and 
increase the number of apheresis centres in order 
to meet desirable turnaround times.
3.4.2  Ethical Challenges
HSCT is an evolving field of medical science. 
Volunteer donors can be asked to be a subject of 
research and clinical trials as part of their stem 
cell donation for a particular patient or not. In the 
majority of cases, this is covered by the informed 
consent given at the recruitment and donor medi-
cal stages, but in some cases, additional consent 
is required. It is the obligation of registries and 
donor centres to make sure that donors are well 
informed and free to withdraw.
3.4.3  Donor Pool HLA Diversity
Current trends in HSCT (with high requirements 
for patient/donor matching, complexity of stan-
dard and research protocols and a growing index 
of indications) present challenges for registries, 
donor centres and CBBs. Different strategies need 
to be applied to recruit not only a larger number of 
potential donors but also increase HLA diversity 
of the pool. As HLA allele and haplotype frequen-
cies have population-specific patterns, there are 
limitations to how many different phenotypes can 
be obtained by adding new donors. In 2016, the 
WMDA reported no more than 50 different phe-
notypes per thousand new AUDs and CBUs sub-
mitted to the global database. This can be 
addressed by recruiting among ethnic minority 
groups or in parts of the world with a wider 
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Fig. 3.4 Relative percentage of unique HLA-A, HLA-B and HLA-DR split phenotypes of stem cell donors per country 
contributed to the entire database of BMDW
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Although the majority of stem cell provisions 
worldwide are currently coming from Northern 
America and Europe, a few large registries arose 
in South America and Asia over recent years. 
WMDA is encouraging and supporting new and 
growing registries. The WMDA handbook: 
“A gift for life: the essential WMDA handbook 
for stem cell donor registries & cord blood banks” 
(2016) provides all necessary information and 
advice for starting a registry in your country.
3.5  Future Developments
3.5.1  New Level of HLA Matching
As of January 2018, classic criterion for HLA 
matching with a patient is 10/10 at HLA-A, 
HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 
for AUDs and 8/8 on HLA-A, HLA-B, HLA-C 
and HLA-DRB1 for CBUs, all at high-resolution 
level, with mismatches associated with infe-
rior patient outcome (Shaw et  al. 2017, Eapen 
et al. 2017). Many transplant centres are now con-
sidering HLA-DPB1 allele or epitope matching 
(Fleischhauer et  al. 2012). There are also trends 
to include other genes like MICA and MICB in 
donor selection (Fuerst et al. 2016; Carapito et al. 
2016; Kitcharoen et al. 2006).
The resolution of HLA matching is important. 
The advantage of allelic/ultrahigh-resolution 
HLA matching on OS and NRM compared to 
high-resolution level was presented by Anthony 
Nolan at the 2018 BMT Tandem meetings (Mayor 
et  al. 2018). Full/extended gene sequencing 
results in fully phased phenotypes, thus signifi-
cantly reduced allelic ambiguity, and can reveal 
mismatches not otherwise identified by high- 
resolution typing.
Following these developments, some regis-
tries and donor centres have already implemented 
HLA allelic level typing for their donors and 
make additional non-HLA genetic information 
available for transplant centres at the search 
stage. It is expected that transplant centres will 
also be able to type patients at this level of resolu-
tion to achieve better matching and additional 
survival advantages.
3.5.2  Related Donors Provision 
and Follow–Up
Historically, registries have not been closely 
involved with the provision of related donors. 
However, in recent years, many registries have 
begun to support related donors internationally 
(i.e. where the patient is living in one country and 
their related donor is living in another) and 
domestically (e.g. where the patient and donor 
live far apart or the transplant centre cannot facil-
itate a collection). Some registries also provide 
support in following-up related donors post- 
collection and in providing information and sup-
port for related donors.
3.5.3  Advisory Services Provided by 
Registries
Nowadays, many registries are taking additional 
advisory roles in supporting transplant centres in 
stem cell searches as they accumulate knowledge 
and expertise over an ever-growing number of 
stem cell provisions. Working closely with clini-
cal teams, national registries may offer advice 
and consultancy in donor selection, product qual-
ity evaluation, education and training.
As part of research and business development 
strategy, registries are looking at other products 
and services to further support HSCT. A range of 
cell therapy products may be provided along with 
standard stem cell donation or under a separate 
service agreement.
I. Evseeva et al.
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Key Points
• International collaboration over the last 
four decades resulted in more than 32 
million unrelated donors potentially 
available to donate stem cells for 
patients requiring HSCT.
• Donor search and provision are carried 
out via national registries to ensure 
quality and legal compliances.
• Unrelated donors act voluntarily and 
altruistically; their availability varies 
due to medical and personal reasons.
• Big efforts are made to increase HLA 
diversity of the donor pool to address 
the lower chance of finding a well-
matched donor for ethnic minority and 
mixed-race patients.
• Registries continue to develop HSCT by 
contributing to research, enhancing ser-
vices and extending the range of cell 
products provided.
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HSCT is an advanced therapeutic intervention 
that is required for a number of malignant and 
nonmalignant medical conditions, often for criti-
cally ill patients. The establishment of an HSCT 
program requires the efforts of experienced and 
appropriately trained personnel to lead the pro-
gram. Clearly, this also requires financial, legal, 
ethical, and other institutional support. For newly 
starting programs, it would be essential to iden-
tify minimal requirements for establishing an 
HSCT unit in order to optimize resource utiliza-
tion as well as maintain safe patient care. While 
these minimal requirements also apply to well- 
established units, its structure helps to understand 
and implement additional steps for larger units 
which plan to offer additional transplant services 
and have access to more resources.
Approximately 20 years ago, the EBMT and the 
ISCT (International Society for Cellular Therapy) 
formed the Joint Accreditation Committee—
ISCT and EBMT (JACIE) based on the FACT 
(Foundation for the Accreditation of Cellular 
Therapy) program. Efforts of these bodies have cul-
minated in the establishment of standards related 
to HSCT and cellular therapies to assure quality 
and safety in the practice of HSCT. Although pro-
gram accreditation with JACIE is not mandatory 
worldwide, these standards are very helpful as 
guidelines to understand requirements to establish 
an HSCT unit. Table 4.1 summarizes basic mini-
mal requirements of an HSCT unit, which are dis-
cussed in more details in the following sections.
4.2  Inpatient Unit
The inpatient HSCT unit should have a minimum 
number of single-bedded rooms with isolation 
capability. The number and space of rooms 
should be adequate for the type and volume of 
transplant activity performed at the transplant 
center. These rooms must adhere to the standards 
of safety and comfort of patients in a tertiary care 
hospital facility. Every location or room should 
have a sink and tap for hand washing.
There needs to be a working station or room for 
nurses involved in patient care. A similar working 
space for physicians is required. Medical and nurs-
ing staff coverage should be available 24 h a day, 
including public holidays. The ratio of nurses to 
patient beds depends on the type and intensity of 
transplants being performed, e.g., autologous versus 
allogeneic, but generally, a ratio one nurse to three 
patients is reasonable. Emergency cart with drugs for 
resuscitation should be available in the inpatient unit.
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Infections, including bacterial, viral, or fungal 
infections, are potential significant complications 
in transplant recipient and may lead to significant 
morbidity and mortality. Therefore, HSCT units 
should have established measures for infection 
control. Guidelines for infection prevention and 
prophylaxis in HSCT patients, endorsed by sev-
eral scientific organizations, are available and 
highly recommended to follow. HSCT recipients 
should be placed in single-patient rooms. 
Furthermore, at a minimum, standard precautions 
should be followed in all patients including hand 
hygiene and wearing of appropriate protective 
equipment (gloves, surgical masks or eye/face 
protection, gowns) during procedures/activities 
that are likely to generate splashes or spray of 
blood, body fluids, or secretions. Hand hygiene is 
essential, using alcohol-based hand rubs or wash-
ing with soap and water. In patients with sus-
pected or proven of having an infection, additional 
precautions are required accordingly, e.g., air-
borne, droplet, or contact isolation. HSCT units 
should be cleaned at least daily with special atten-
tion to dust control. During building construction, 
intensified mold control measures are required, 
and a multidisciplinary team should be involved.
Other important infection control measures 
include well-sealed rooms, positive pressure 
Table 4.1 HSCT unit minimal requirements
Inpatient unit – Clean single-bedded rooms with isolation capability
Ancillary medical 
services
– Intensive care unit
– Emergency room service
– Gastroenterology and pulmonary servicea
Outpatient clinic – Single patient examination rooms
Blood bank –  Twenty-four hour on-site blood bank service: ABO typing and cross match, RBC, and 
platelets for transfusion
– Irradiation and leukocyte depletion of blood products
Laboratory – Hematology cell count and chemistry lab
– Serology for viral screen
– Microbiology for basic bacterial and fungal cultures
– CMV PCR or antigenemiaa
– Access to CSA/tacrolimus levelsa
HLA typing laba – Access to ASHI or similarly accredited HLA typing lab
Stem cell collection – PBSC apheresis capability
– Bone marrow harvesting facility and expertise for matched sibling donora
Stem cell processing 
facility
– FACS CD34 enumeration
– Refrigerator for blood and bone marrow
– Controlled cryopreservation capability for freezing of autologous stem cell product
– Equipment and expertise to process ABO-mismatched cellular producta
Radiology – Routine x-ray radiology, ultrasound, and CT scanner
– Placement of central venous catheters
Pharmacy – Availability of conditioning chemotherapy drugs
–  Availability of antimicrobial agents (broad-spectrum antibiotics, antiviral, and antifungal 
drugs)
– Availability of immunosuppressive agents for GVHD prophylaxis and treatmenta
Human resources – Medical director: Licensed physician with adequate training and experience in HSCT
–  Nursing staff with training in chemotherapy administration, infection control, and 
handling of stem cell products
– Clinical laboratory director: Clinical pathology trained.
– Appropriately trained lab scientist and technicians
–  Multidisciplinary medical staff (radiology, pathology, ICU, surgery, gastroenterologya, 
pulmonarya)
Outcome database – Monitor patient demographics, treatment, and outcomes (level I data reporting)
Quality management – Written institutional protocols/guidelines
– Regular audits of various HSCT procedures and patient treatment outcomes
– System to detect errors or adverse events for corrective or preventative actions
aRequirements for allogeneic HSCT programs
W. Rasheed et al.
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 differential between patient rooms and the hall-
way, self-closing doors, more than 12 air 
exchanges per hour, and continuous pressure 
monitoring. HEPA (high efficiency particulate 
air) filters have shown efficacy in providing pro-
tection against acquisition of fungal infections in 
immune- compromised hematology patients, 
including HSCT patients, and during hospital 
construction or renovation works. While HEPA 
filters are not absolutely required as a minimal 
requirement in newly established centers with 
less complicated transplant activities, they are 
certainly preferred and highly recommended as 
newly established centers expand their activities 
to include more complicated (especially alloge-
neic) transplant activities.
There is no agreed upon minimum number of 
transplants to be performed in a program. 
However, to ensure continuing proficiency in a 
transplant program, the ASBMT recommends for 
programs performing only one type of HSCT 
(autologous or allogeneic), at least ten transplants 
of that type are to be performed per annum; pro-
grams performing both allogeneic and autolo-
gous transplantations should perform a minimum 
of ten transplants of each kind per annum.
4.3  Ancillary Medical Services
HSCT patients often require other medical spe-
cialties involvement in their complicated care. 
This includes the risk of developing life- 
threatening infections or other post transplant 
complications, hence the importance of having 
access to emergency room as well as intensive 
care services at the same tertiary care hospital 
facility where transplant program is being estab-
lished. Intensive care units should have the abil-
ity of providing inotropic support, respiratory 
support (including mechanical ventilation) as 
well as renal replacement (hemodialysis) if 
required.
Input from infectious disease physicians can 
be valuable in HSCT patients who are at risk of a 
multitude of opportunistic and potentially life- 
threatening infections; this is especially impor-
tant for programs that perform allogeneic 
transplants. Availability of gastroenterology spe-
cialist with endoscopy services is critical for allo-
geneic programs, as often diagnostic endoscopy 
is required to differentiate GVHD from other 
 etiologies of gastrointestinal complications. 
Similarly, pulmonary medicine service with 
access to diagnostic bronchoscopies is required 
for such patients with pulmonary abnormalities.
HSCT programs that perform transplants 
using radiotherapy as part of conditioning regi-
men (total body irradiation) should have avail-
able radiation oncology service on site. The 
radiation oncology team, including the radiation 
oncologist and physicist, should have adequate 
training in the technique of total body irradiation 
and appropriate equipment, and procedures must 
be in place to deliver successful and safe radia-
tion component of these conditioning regimen.
4.4  Outpatient Unit
HSCT patients attend to the outpatient unit, both 
for pretransplant assessment and work-up and 
post transplant follow-up and management. 
Single patient examination rooms are a minimal 
requirement for the outpatient service of the pro-
gram. These rooms should be adequately 
equipped to allow clinical assessment of patients. 
It is important to implement infection control 
measures to minimize risk of transmitting infec-
tions, including hand hygiene measures and 
availability of appropriate room to isolate patients 
who are identified to be potentially infectious to 
others, e.g., due to herpes zoster infection. A ded-
icated infusion area would be ideal as transplant 
recipients often require IV fluid and electrolyte 
replacement or blood product administration.
4.5  Blood Bank
Availability of blood banking services is a critical 
component of a successful transplant program. A 
24-h on-site blood banking service is required for 
ABO typing, cross match, and urgent supply of 
red blood cells and platelets for transfusion. 
Meeting minimal standard criteria according to 
4 The HSCT Unit
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recognized international blood bank societies 
such as the American Association of Blood Banks 
(AABB) or equivalent is important. Blood bank 
staff, including blood bank director, scientists, 
and technicians should be adequately qualified 
and trained in blood banking procedures.
Transplant recipients are severely immune- 
compromised and are at risk of transfusion- 
associated GVHD, caused by unrestricted 
proliferation of donor lymphocytes in the 
immune-compromised host. Hence, it is critical 
that transplant recipients receive irradiated blood 
products to prevent this complication. The use of 
leukocyte-depleted blood products is recom-
mended to reduce the risk of HLA alloimmuniza-
tion in the multiply transfused hematology 
patients, as well as to reduce the incidence of 
transfusion reactions. In allogeneic programs, 
clear documented pathways for transfusion sup-
port in cases of ABO mismatch should be avail-
able for both blood bank and clinical staff as 
guidance.
4.6  Laboratory
A 24-h on-site hematology cell count and basic 
chemistry lab are required. Furthermore, micro-
biology laboratory service is essential in the clin-
ical management of transplant recipients, 
including routine bacterial and fungal cultures of 
various patient specimens. Serology screening 
for relevant viral and bacterial infections is also 
required for pretransplant work-up of recipients 
as well as donor screening. For allogeneic trans-
plant recipients, monitoring for cytomegalovirus 
(CMV) reactivation is essential, and results must 
be available in a timely manner to allow thera-
peutic intervention; both molecular technique by 
quantitative PCR (preferable) and antigenemia 
method are acceptable. In the allogeneic setting, 
monitoring drug levels, e.g., cyclosporine or 
tacrolimus, is required, and same-day service is 
recommended to allow interventions aiming at 
keeping levels of these important drugs within 
the target therapeutic range.
4.7  HLA Typing Lab
Access to HLA typing laboratory is mandatory 
for allogeneic programs. Such service can be 
available on-site or alternatively provided in refer-
ence laboratory. JACIE standards state that clini-
cal programs performing allogeneic 
transplantation shall use HLA testing laboratories 
that are capable of carrying out DNA-based inter-
mediate and high-resolution HLA typing and are 
appropriately accredited by the American Society 
for Histocompatibility and Immunogenetics 
(ASHI), European Federation for Immunogenetics 
(EFI), or other accrediting organizations provid-
ing histocompatibility services appropriate for 
hematopoietic cellular therapy transplant patients.
4.8  Stem Cell Collection
Access to peripheral blood stem cell apheresis 
service on-site is a minimal requirement in each 
program. This is often part of the blood bank ser-
vice or alternatively under the administration of 
the clinical program. Having at least two cell 
separators would be beneficial, as the second cell 
separator would be a backup in situations of 
unexpected machine faults and for routine servic-
ing. Daily operation of apheresis facility requires 
appropriately trained and experienced nursing 
staff and a medical director with adequate quali-
fication and experience in clinical and laboratory 
aspects of the apheresis procedure. Institutional 
written protocols and policies covering all aspects 
of apheresis procedure should be available for 
guidance. JACIE standards require a minimum 
average of ten cellular therapy products collected 
by apheresis per year for program accreditation.
A bone marrow stem cell source is sometimes 
recommended for better patient outcome, e.g., 
patients with bone marrow failure. Programs per-
forming allogeneic transplants for such indica-
tion should have a bone marrow harvest facility 
on-site. This requires convenient and easy access 
to surgical operating room with anesthesia 
 service. Appropriate equipment for the bone mar-
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row harvest procedure are required. Physicians 
with adequate training and experience in bone 
marrow harvesting are crucial to perform the pro-
cedure successfully.
4.9  Stem Cell Processing Facility
The stem cell processing facility requires a desig-
nated area, usually within the laboratory. It should 
be appropriately equipped for the processing of 
various stem cell products depending on the types 
of transplants performed and the size of the pro-
gram. Availability of flow cytometry for the enu-
meration of CD34 cell count is mandatory. 
Controlled cryopreservation capability, using liq-
uid nitrogen, for freezing of autologous stem cell 
product is essential. This may also be used in allo-
geneic sibling products. Standard quality control 
measures, including systems to closely monitor 
and record the temperature in all freezes and 
refrigerators, are critical. Allogeneic programs 
should have appropriate equipment and expertise 
on-site for the timely and safe processing of ABO-
mismatched stem cell products as required, 
including the need to perform red cell or plasma 
depletion procedures when indicated. The pro-
cessing facility should be operated by adequately 
trained staff, including scientist, technicians, and 
a medical director. Written standard operating 
procedures explaining all aspects of stem cell pro-
cessing performed at the facility are required.
4.10  Radiology
Standard routine (X-ray), ultrasound, and com-
puted tomography (CT scan) imaging services 
are the minimal requirements and should be 
available on site for the routine diagnostic imag-
ing. Availability of magnetic resonance imaging 
(MRI) is preferred, as it is often useful in the 
diagnosis of specific clinical conditions relevant 
to stem cell transplant recipients, such as iron 
overload, CNS infections, and posterior revers-
ible encephalopathy syndrome (PRES) related to 
calcineurin inhibitor toxicity. Placement of cen-
tral venous catheters in transplant recipients is 
obviously required in each program. Depending 
on the institutional setting, this service may be 
provided by various hospital services; often this 
is done by the radiology service under ultrasound 
guidance. Having well trained and experienced 
interventional radiologist to perform this proce-
dure is crucial for the safety of patients.
4.11  Pharmacy
Pharmacy services are essential in each HSCT 
program. Availability of conditioning chemother-
apy agents is clearly required; specific drugs 
depend on the type and complexity of transplant 
procedures performed in each program. 
Commonly used agents in conditioning regimens 
include BU, CY, FLU, and MEL. ATG may also 
be required in the allogeneic setting (e.g., in 
aplastic anemia) and requires special attention 
and training by nursing, pharmaceutical, and 
medical staff in relation to its administration.
Broad-spectrum antibiotics should be available 
for urgent use as required in transplant recipient. 
Likewise, access to antiviral and antifungal agents 
is important for both prophylaxis and treatment. 
Allogeneic programs should also have access to 
immunosuppressive drugs used for GVHD pro-
phylaxis such as CSA, MTX, and TAC.
A trained pharmacist is crucial for the HSCT 
program. The pharmacist should review all con-
ditioning chemotherapy protocols and ensure 
appropriate dispensing and administration of 
cytotoxic agents.
4.12  Staffing and Human 
Resources
Appropriately trained and experienced medi-
cal and nursing staffs are crucial for the HSCT 
 program. The clinical medical director of 
the  program should be a licensed physician 
 (specialty certification in hematology, oncol-
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ogy, or immunology) with adequate training at 
a BMT program. A minimal BMT training dura-
tion of 6–12 months is suggested. JAICIE stan-
dards indicate that the clinical program director 
shall have 2 years of experience as an attending 
physician responsible for the direct clinical man-
agement of HSCT patients in the inpatient and 
outpatient settings. A minimum of one (1) addi-
tional attending transplant physician is required 
in the program.
The success of a transplant program relies 
heavily on the presence of appropriately trained 
and experienced nursing staff. This includes 
training in chemotherapy administration, infec-
tion control, management of neutropenic patients, 
and handling of stem cell products.
Other important staff includes appropriately 
trained and experienced personnel in the labora-
tory (including laboratory director, scientist, and 
technicians), trained pharmacist, as well as medi-
cal professionals of ancillary medical services. 
Continuous education activities are required for 
all healthcare professionals involved in the man-
agement of HSCT patients.
4.13  Institutional Database 
and Data Manager
Monitoring patient demographics, treatment 
details, and outcomes is an essential minimal 
requirement. Each program should keep com-
plete and accurate patient records, and a database 
containing relevant patient data should be estab-
lished and regularly maintained. Appropriate 
patient consent needs to be obtained for such 
database. An example of the minimal data 
required to be obtained on each transplant patient 
is the information required in the CIBMTR or 
EBMT mid A forms. Having a data manager in 
a transplant program to initiate and maintain this 
institutional transplant database is highly rec-
ommended. Often data managers have nursing 
background with experience in stem cell trans-
plantation. Attending training data management 
courses during international meetings or through 
links with other experienced and well- established 
programs would be valuable.
4.14  Quality Control
The JACIE standards require that all essential 
clinical collection and processing facilities in the 
transplant center evaluate and report patient out-
comes. Regular audits of various HSCT proce-
dures and patient treatment outcomes are 
required. Essentially, a system is required to be in 
place to detect errors/adverse events, so that these 
can be evaluated in order to implement preventa-
tive measures to minimize the risk of recurrence 
of these incidents. Furthermore, each program 
should have written institutional clinical proto-
cols in relation to the various aspects of the trans-
plant patient care to standardize practice. 
Likewise, stem cell collection and processing 
facilities should have standard operating proce-
dures that serve as a guidance for all staff to fol-
low to enhance patient’s safety. Access to or 
relationship with experienced HSCT program is 
often very helpful and highly recommended via 
shared protocols/telemedicine and/or web-based 
conferencing.
4.15  Transplant Coordinator
HSCT is a complex therapeutic intervention, and 
coordination of the pretransplant, transplant, and 
post transplant patient care is important. A trans-
plant coordinator can play pivotal role in this 
context, acting as a facilitator, educator, as well 
as a point of contact for the patient and their fam-
ilies. Transplant coordinators ensure the smooth 
and safe running of the HSCT service starting 
from scheduling and arranging pretransplant 
work-up of patient and planning the roadmap for 
the transplant recipient with continued involve-
ment and education of the patients and their fami-
lies until the time of admission. Furthermore, 
transplant coordinator would play a significant 
role in the coordination of post HSCT follow-up 
and care in clinics. For allo-HSCT, the transplant 
coordinator would be very valuable in arranging 
donor search starting from HLA typing of the 
recipient and his/her family members, in addition 
to initiating and following a search for unrelated 
donor in national or international registries. 
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The  transplant coordinator involvement may 
extend to organizing the logistics of getting the 
stem cells from the donor from the donor center 
where the recipient may be in another health 
facility (national or international). Moreover, 
transplant coordinators will often lead the HSCT 
team weekly planning meetings and discussions 
with the arrangement of the HSCT waiting list. 
Typically, transplant coordinators have nursing 
background with significant experience in stem 
cell transplantation.
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Key Points
• The inpatients unit should have single- 
bedded rooms with isolation capabili-
ties. Single outpatient examination 
rooms are also required.
• Laboratory, blood bank, and pharmacy 
services are critical to the success of 
HSCT programs.
• Stem cell collection and processing 
capabilities are minimal requirements 
for any HSCT program; the level of 
such capabilities depends on the type 
and complexity of HSCT performed in 
each center.
• Ancillary medical services are essential 
components of successful HSCT pro-
grams, including intensive care and 
emergency and radiology services. 
Additional medical services are required 
in allogeneic programs.
• Appropriately trained and experienced 
staff (medical, nursing, laboratory, phar-
macy) are crucial for the HSCT program.
• Monitoring patient characteristics and 
transplant outcomes is essential.
• A local quality control system is 
required in all aspects involved in the 
HSCT procedure.
• Having a data manager for the HSCT 
program, to initiate and maintain institu-
tional minimal transplant data base is 
highly recommended.
• Transplant coordinators play pivotal 
role the management of HSCT patients, 
starting from pre SCT work up, right 
through post transplant care.
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The complexity of HSCT as a medical technol-
ogy and the frequent need for close interaction 
and interdependence between different services, 
teams, and external providers (donor registries, 
typing laboratories, etc.) distinguish it from many 
other medical fields. Approximately 20  years 
ago, this complexity led to efforts by transplanta-
tion professionals to standardize processes based 
on consensus as a way to better manage inherent 
risks of this treatment. HSCT was, and continues 
to be, a pioneer in the area of quality and 
standards.
5.2  Background
In 1998, EBMT and the International Society for 
Cell & Gene Therapy (ISCT) established the 
Joint Accreditation Committee, ISCT and EBMT 
(JACIE), aimed to offer an inspection-based 
accreditation process in HSCT against estab-
lished international standards. JACIE is a com-
mittee of the EBMT, its members are appointed 
by and are accountable to the EBMT Board, and 
ISCT is represented through two members of the 
Committee. JACIE collaborates with the 
US-based Foundation for the Accreditation of 
Cellular Therapy (FACT) to develop and main-
tain global standards for the provision of quality 
medical and laboratory practice in cellular 
therapy.
The JACIE and FACT accreditation systems 
stand out as examples of profession-driven initia-
tives to improve quality in transplantation and 
which have subsequently been incorporated by 
third parties, such as healthcare payers (health 
insurers, social security) and competent authori-
ties (treatment authorization). The JACIE 
Accreditation Program was supported in 2004 by 
the European Commission under the public 
health program 2003–2008 and was acknowl-
edged as an exemplary project in a 2011 review 
of spending under the public health program.
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5.3  Impact of Accreditation 
in Clinical Practice
Much literature indicating a better clinical out-
come in teaching hospitals and centers of excel-
lence has been available since the 1990s (Hartz 
et al. 1989; Birkmeyer et al. 2005; Loberiza et al. 
2005). Initial evidence of a positive relationship 
between the implementation of a quality manage-
ment system and outcome of HSCT in Europe 
was published in 2011 (Gratwohl et al. 2011). In 
this paper, patients’ outcome was systematically 
better when the transplantation center was at a 
more advanced phase of JACIE accreditation, 
independent of year of transplantation and other 
risk factors.
Another analysis (Gratwohl et  al. 2014) was 
performed on a large cohort of patients who 
received either an allogeneic or an autologous 
transplantation between 1996 and 2006 and 
reported to the EBMT database. The authors 
showed that the decrease of overall mortality in 
allogeneic procedures over the 14-year observa-
tion period was significantly faster in JACIE- 
accredited centers, thus resulting in a higher 
relapse-free survival and overall survival at 
72  months from transplant. Such improvement 
was not shown in autologous transplantation.
Similar results published by Marmor et  al. 
(2015) in an American study showed that centers 
accredited by both FACT and Clinical Trial 
Network (CTN) demonstrated significantly bet-
ter results for more complex HSCT such as HLA- 
mismatched transplants.
These data reinforce the concept that clinical 
improvement is driven by the implementation of 
a quality management system embedded in exter-
nal accreditation standards, especially in the con-
text of more complex procedures. This process 
also results in a wider standardization of proce-
dures across different countries and geographic 
areas, therefore contributing to providing patients 
with similar treatment expectations even when 
accessing different health management systems. 
A comprehensive review of this was recently 
published (Snowden et al. 2017).
5.4  JACIE-FACT Accreditation 
System
JACIE and FACT accreditation systems are based 
on the development and continuous update of 
standards covering the entire transplantation pro-
cess, from selection of the donor/patient to fol-
low- up, including collection, characterization, 
processing, and storage of the graft. Considering 
the different competences included in the pro-
cess, the standards are articulated in four parts:
• Clinical Program,
• Bone Marrow Collection,
• Apheresis Collection and
• Processing Facility.
A quality management (QM) section is 
embedded in each section, aimed at providing a 
tool for both the applicants to develop a compre-
hensive system of quality assessment and for the 
inspectors to check the compliance of the pro-
gram to the standard. Stand-alone processing labs 
can apply; however, the target of the accredita-
tion is the transplantation program, intended as a 
process in its entirety, thus requiring a full inte-
gration of units, laboratories, services, and pro-
fessionals. Each section focusses on the 
competence of personnel, listing topics for which 
the evidence of a specific training is required 
which also includes the minimum experience 
requirements for positions of responsibility. 
Maintaining these competences is also required 
for all professionals.
The standards are revised on a 3-year basis 
by a commission formed of experts appointed by 
JACIE and FACT, including HSCT administra-
tion, cell processing and storage, blood aphere-
sis, transplant registries, and QM specialists. The 
standards are based on published evidence and, 
when this is not available, on expert consensus. 
A legal review and comparison with current reg-
ulations are carried out for each version. When 
the developmental phase is finalized, the stan-
dards are published for public review and com-
ment and finally approved by JACIE and FACT. 
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The   standards incorporate sound principles of 
quality medical and laboratory practice in cellu-
lar therapy, but do not cover legal requirements of 
local competent authorities.
The compliance to the standards is ensured 
through an inspection system, carried out by vol-
untary inspectors, trained and coordinated by the 
JACIE office in Barcelona. The JACIE inspection 
is a multistep procedure: the applicant center is 
provided with all the application documents and 
is then required to submit a set of documentation 
to the JACIE accreditation coordinators. If the 
first review is positive, the on-site inspection is 
then planned in agreement with the applicant.
JACIE inspections are carried out in most 
cases in the language of the applicant. The 
inspectors’ report is then assessed by the JACIE 
accreditation committee, which may request sup-
plementary information, modifications, or 
another on-site visit. If all aspects are shown to 
be compliant, accreditation is awarded. An 
accreditation cycle is 4  years for JACIE, and 
facilities must complete an interim desk-based 
audit after 2 years post-accreditation. Accredited 
facilities must reapply for reaccreditation and 
may also be reinspected in response to com-
plaints or information that a facility may be non- 
compliant with the standards, in response to 
significant changes in the program and/or facility 
or as determined by JACIE.
Many tools are made available to prepare 
the accreditation through the JACIE website, 
including a quality management guide, the wel-
come guide, and webinars. JACIE runs training 
courses throughout the year, and the Barcelona-
based staff are available to support the appli-
cants. An accreditation manual provides detailed 
explanations and examples for each single item 
of the standards. A special approach is under 
development for transplant programs in low- 
and middle- income countries (LMICs), where 
full accreditation might not be feasible due to 
resources and/or cultural issues. In this case, a 
stepped process toward accreditation is being 
developed, based on the selection of organiza-
tional items of the standard which may be ful-
filled by the implementation of a QM system, 
without requiring specific investments in infra-
structures and/or equipment. This “stepwise” 
option will also encourage the programs to con-
nect with an international network of profession-
als and may also stimulate local authorities to 
support further progress toward full accredita-
tion in the interests of patients, donors, and the 
professional community.
The standards cover the use of different 
sources of hematopoietic stem cells and nucle-
ated cells from any hematopoietic tissue source 
administered in the context of the transplant pro-
cess, such as DLI. The term “hematopoietic” in 
the title is to define the scope of these standards, 
due to an increasing number of accredited facili-
ties that also support non-hematopoietic cellular 
therapies. Starting with version 6.1, the standards 
include new items specifically developed for 
other cellular therapy products, with special ref-
erence to immune effector cells (IECs). This 
reflects the rapidly evolving field of cellular ther-
apy through mainly, but not exclusively, geneti-
cally modified cells, such as CAR-T cells. The 
standards do not cover the manufacturing of such 
cells but include the chain of responsibilities 
where the product is provided by a third party and 
ensure the competence of the personnel in the 
management of adverse events related to the 
infusion.
Another recent development has been the 
introduction of “benchmarking” standards related 
to 1-year survival and other patient outcomes. If 
center performance is below the expected range, 
then a corrective action plan is mandated. The 
requirement for a risk-adapted “benchmarking” 
system is being addressed in the development of 
the new EBMT MACRO registry, which will 
enable centers to address these new JACIE stan-
dards within their own BMT community and 
across international boundaries.
JACIE is run on a non-profit basis, resourced 
almost entirely on application fees. Fees depend on 
the configuration of the program and its EBMT 
membership status. At the time of writing in 
February 2018, the application fee for a transplant 
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program made up of collection, processing, and 
clinical units is €14,600 for EBMT members and 
€29,200 for non-EBMT members. Supplementary 
fees for additional sites and discounts for active 
 inspectors in the team are applied (see JACIE web-
site for details).
Overall, over 600 accreditation inspections 
have been carried out in 25 countries, represent-
ing over 40% transplant centers in Europe 
(Figs.  5.1 and 5.2), many of which have been 
through more than one accreditation cycle. JACIE 
accreditation is now mandatory in several 
European countries, to apply for reimbursement 
of the procedure and/or to be authorized to per-
form HSCT.  JACIE also represents an opportu-
nity for centers in LMICs to align their 
organizations with practice in the more advanced 
HSCT programs.
Fig. 5.1 JACIE-accredited programs March 2018
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Fig. 5.2 JACIE activity 2012–2017
Key Points
• JACIE accreditation is based on an 
internationally agreed quality standard 
system led and delivered by HSCT and 
cell therapy professionals.
• The standards are regularly updated, 
incorporating advances in the evidence 
base while reflecting the practical view 
of experienced experts on clinical and 
laboratory practice of HSCT and cell 
therapy.
• Published data support a positive 
improvement in the clinical outcome 
related to the accreditation process, also 
promoting a progressive standardization 
of HSCT practice across different 
countries.
• Recent developments in the standards 
include development of standards for 
CAR-T and other immune effector cells 
(IEC), “benchmarking” of patient sur-
vival and access of centers in LMIC to 
the “stepwise” accreditation.
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The analysis of data describing the outcomes of 
patients who have received an HSCT is not only 
fundamental to assessing the effectiveness of the 
treatment but can provide invaluable information 
on the prognostic role of disease and patient fac-
tors. Thus, the appropriate analysis and under-
standing of such data are of paramount 
importance. This document provides an overview 
of the main and well-established statistical meth-
ods, as well as a brief introduction of more novel 
techniques. More insight is provided in the EBMT 
Statistical Guidelines (Iacobelli 2013).
6.2  Endpoints
The outcomes most commonly studied in HSCT 
analyses are the key events occurring at varying 
times post HSCT, e.g., engraftment, GVHD, 
relapse/progression, and death. Besides the clini-
cal definition of the event of interest, it is impor-
tant to define the corresponding statistical 
endpoint and to use a proper method of measur-
ing the occurrence of the event (Guidelines 2.1).
The main distinction is between events that 
occur with certainty during a sufficiently long 
observation period (follow-up), like death, and 
events which are precluded from occurring once 
another event occurs, e.g., not all patients will expe-
rience a relapse of their disease because some die 
before. We define death without prior relapse (usu-
ally called NRM; see Guidelines 2.1.2) as the “com-
peting event” of relapse. The name “NRM” is 
preferable to TRM, the proper analysis of which 
requires individual adjudication of causes of death.
Survival endpoints: In addition to death, other 
examples of events of the first type are the com-
binations of (negative) events of interest, which 
in total have 100% probability of occurrence, for 
example, PFS which considers as failure of the 
event “either relapse/progression or death.” The 
components of PFS are the two competing events 
mentioned above, relapse/progression and NRM.
Competing risks endpoints: In addition to 
relapse/progression and NRM, other examples 
are death of a specific cause and all intermediate 
events during a HSCT history (engraftment, 
GVHD, achievement of CR, CMV infection) 
including the long-term (secondary malignancy). 
Notice that the definition of an endpoint requires 
specifying which are the competing events. 
Usually, this will be death without prior event of 
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interest, but depending on the disease and the 
aims of the analysis, other competing events 
might be included in the analysis, e.g., a second 
transplantation or other treatment can be consid-
ered as competing event for achievement of 
response.
6.3  Analysis of Time-to-Event 
Outcomes
Each event of interest may occur at variable times 
post transplant, so in statistical terms, it has two 
components—whether it occurs at all and, if it 
does, when. However, at the end of the follow-up, 
there can be patients who have not yet had the event 
of interest but are still at risk for it: their observa-
tion times are called “censored.” Censoring occurs 
at different timepoints for different patients. The 
inclusion of censored data precludes the use of 
simple statistical methods such as the Chi-Squared 
or T-test and requires the methods of survival (or 
competing risks) analysis. The crucial assumption 
of most methods in survival analysis is that the 
patients censored at a timepoint are “represented” 
by those who remain under follow-up beyond that 
timepoint. In other words, the fact that a patient is 
censored should not indicate that his/her prognosis 
is worse or better than the prognosis of a similar 
patient who remains under observation. This 
assumption is called “independent and uninforma-
tive” censoring.
6.3.1  Kaplan-Meier Curves
The main method to summarize survival end-
points is the Kaplan-Meier curve (Kaplan and 
Meier 1958), estimating for each point in time t 
after HSCT the probability S(t) of surviving 
beyond that time. This curve is decreasing from 
100% and will reach 0% with complete follow-
 up. A long flat tail of the curve (often called “pla-
teau”) is often based on a few censored 
observations at late times, corresponding to very 
unreliable estimates of the long-term survival. It 
is useful to report each S(t) with its 95%CI (con-
fidence interval at 95% level, best obtained using 
the Greenwood formula) or at least the number of 
patients still at risk at different timepoints. The 
median survival time is the minimum time when 
S(t) is equal to 50% (Fig. 6.1).
6.3.2  Cumulative Incidence Curves
The appropriate method to summarize endpoints 




































Fig. 6.1 Probability curves of the four main outcomes 
after HSCT. CIR Cumulative Incidence of Relapse. CIR 
and NRM add up to 1-RFS. Number at risk indicates the 
number of patients in follow-up who have not experienced 
an event so far. The grey zones indicate 95% confidence 
intervals
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(CI) curve (Gooley et  al. 1999), estimating for 
each point in time t the probability F(t) of having 
had the event of interest before that time. This 
curve is increasing from 0% and will not reach 
100% even with complete follow-up if the com-
peting event was observed for some patients. It is 
always useful to interpret CI curves of competing 
events together, to understand, e.g., when a cate-
gory of patients has a small risk of relapse, if this 
means that they have a good prognosis or that 
they died too early from complications to experi-
ence a relapse (shown by a high NRM curve) 
(Fig. 6.1).
6.3.3  Comparison of Groups
The main method to compare survival curves for 
two or more independent groups is the Log-Rank 
test. This test is based on the comparison of the 
underlying hazard functions, which express the 
instantaneous probability of the event at a time t 
among patients currently at risk. It has good 
properties in the situation of proportional hazards 
(PH, described in the next section), but it should 
be avoided (or considered carefully) when the 
survival curves cross; with converging curve 
alternatives like the Wilcoxon Signed-Rank test 
should be preferred.
In the comparison of cumulative incidence 
curves, the main method is the Gray test. Also the 
Log-Rank test can be applied to compare groups 
in the case of competing risks, when the object of 
interest is not the cumulative probability of 
occurrence of the event but its instantaneous 
probability among the cases at risk at each time, 
which is called “cause-specific hazard.” For the 
interesting difference of the two approaches to 
the analysis of competing risks endpoints, see 
Dignam and Kocherginsky (2008).
We refer to Sects. 1.3 and 1.4 of the Guidelines 
for remarks on statistical testing and about proper 
settings for comparisons of groups. Importantly, 
the simple methods described in this chapter can 
be applied only to groups defined at or before the 
time origin (e.g., transplantation); assessing 
 differences between groups defined during the 
follow- up requires other approaches, as those 
described in Sect. 6.4.1 (Guidelines page 14).
6.3.4  Proportional Hazards 
Regression Analysis
The above tests do not give a summary measure 
of the difference in outcomes between groups, 
nor can they be used when the impact of a con-
tinuous risk factor (e.g., age) has to be assessed. 
Furthermore, any comparison could be affected 
by confounding. These limitations are typically 
overcome by applying a (multivariable) regres-
sion model. The one most commonly used for 
survival endpoints is the proportional hazards 
(PH) Cox model (Cox 1972). Results are pro-
vided in terms of hazard ratios (HR), which are 
assumed to be constant during the whole follow-
 up (Guidelines 4.3.1). The Cox model in its sim-
plest form is thus not appropriate when a factor 
has an effect that strongly decreases (or increases) 
over time, but time-varying effects can be accom-
modated for in more complex models. Effects of 
characteristics which change during follow-up 
can be assessed by including them as time- 
dependent covariates.
For endpoints with competing risks, two 
methods can be used, which have a different 
focus: the Cox model can be used to analyse 
cause-specific hazards, whereas a regression 
model for cumulative incidence curves was pro-
posed by Fine and Gray (1999).
The use of these regression models requires a 
sound statistical knowledge, as there are many 
potential difficulties with the methods both in 
application and interpretation of results.
6.4  Advanced Methods
Many more advanced methods than the ones 
described above exist that help to get more insights 
from the available data. A good application of 
these needs expert statistical knowledge. The brief 
introductions given below are primarily meant to 
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help understanding papers where these methods 
have been applied. For a more in-depth discussion, 
see, e.g., Therneau and Grambsch (2000).
6.4.1  Multistate Models
The methodology of multistate models (Putter 
et al. 2007) has been developed to understand the 
interplay between different clinical events and 
interventions after HSCT and their impact on 
subsequent prognosis. Their primary advantage 
is that sequences of events, such as HSCT, DLI, 
GVHD, and death, and competing events, such as 
relapse and NRM, can be modelled simultane-
ously (see Fig.  6.2 for an example). This is in 
contrast to analysing composite survival out-
comes such as GVHD-free survival where all 
failures are combined and resolution of GVHD is 
not considered. Some studies applying this 
method that offer new insights into the outcomes 
after HSCT are Klein et al. (2000) about current 
leukemia-free survival, Iacobelli et  al. (2015) 
about the role of second HSCT and CR for MM 
patients, and Eefting et al. (2016) about evalution 
of a TCD-based strategy incorporating DLI for 
AML patients.
6.4.2  Random Effect Models
In standard methods, all patients are considered 
as independent, and each patient only contributes 
one observation for each endpoint. There are, 
however, situations when this does not hold, for 
instance, when patients within the same centre 
tend to have more similar outcomes than those 
from another centre or when one patient can 
experience more than one outcome of the same 
kind, e.g., infections. In these cases, the outcomes 
within one “cluster” (a centre or a patient) are 
more correlated than the outcomes between clus-
ters, which has to be accounted for in the analy-
sis. This is usually done by random effect models, 
which assume that each cluster shares an unob-
served random effect. In survival analysis, these 
are called frailty models (Therneau and Grambsch 
2000, Chap. 9). If the outcome is not an event but 
a value measured over time, e.g., CD8 counts, the 
appropriate regression models are called mixed 
models.
6.4.3  Long-Term Outcomes: 
Relative Survival/Cure Models
With improved long-term outcomes and increas-
ing numbers of older patients, a substantial num-
ber of patients will die from other causes than the 
disease for which they have been transplanted 
and the direct and indirect consequences of its 
treatment. This so-called population mortality 
can be quantified by methods from relative sur-
vival, based on population tables describing mor-









Fig. 6.2 Example of a 
multistate model. All 
patients start in state 1 
(event-free after HSCT). 
They can then proceed 
through the states by 
different routes. Each 
arrow indicates a 
possible transition
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Especially for transplanted children, a period 
with a high risk of mortality can be followed by a 
very long and stable period where the death risk 
is (almost) zero. When the focus of an analysis is 
on the probability of long-term cure, cure models 
can be used that assess the impact of risk factors 
on this but only if follow-up is sufficiently long 
(Sposto 2002).
6.4.4  Propensity Scores
Propensity scores (PS) are useful to compare the 
outcomes of two treatments in the absence of ran-
domization, to control confounding due to the 
fact that usually the choice of the treatment 
depends on patient’s characteristics (confound-
ing by indication) (Rosenbaum and Rubin 1983). 
First, the PS, defined as the probability of receiv-
ing one treatment instead of the other, is esti-
mated for each patient. Then PS can be used in 
various ways (mainly stratification or pair match-
ing), allowing comparison of treatment outcomes 
among cases with a similar risk profile.
6.4.5  Methods for Missing Values
Missing values in risk predictors are a common 
problem in clinical studies. The simplest solu-
tion is to exclude the patients with missing val-
ues from the analysis (complete case analysis). 
This solution is not optimal, however: firstly, not 
all information is used (an excluded patient 
might have other characteristics known), and 
secondly, this approach can lead to bias if 
patients with missing values have on average a 
different outcome from the patients with 
observed values.
If values can be imputed on the basis of 
observed values in the dataset, these patients can 
be retained in the analysis to increase precision of 
estimates and avoid bias. The method most com-
monly used is called multiple imputation (White 
et al. 2011). A major advantage of this method is 
that it properly takes into account the uncertainty 
caused by the imputation in the estimates. If data 
are missing not at random—meaning their values 
cannot be predicted from the observed  variables—
multiple imputation can at most decrease the bias 
but not fully remove it.
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Hematopoiesis—from the Greek term for “blood 
making”—is the adaptive process by which 
mature and functional blood cells are continu-
ously replaced over the entire lifetime of an indi-
vidual. Erythrocytes, platelets, and the various 
subsets of leukocytes all have finite although dif-
ferent life spans. As a consequence, the daily pro-
duction of red blood cells, platelets, and 
neutrophils in homeostatic conditions amount to 
more than 300 billion cells.
In mammals, after the emergence of the first 
hematopoietic progenitors in extra-embryonic 
structures such as the yolk sac in mice, cells of 
hematopoietic nature are first detected in the 
aorto-gonado-mesonephric (AGM) region of the 
developing embryo (Costa et al. 2012). The site 
of hematopoiesis then moves to the fetal liver and 
next to the BM where it remains established until 
the death of the individual. Extramedullary 
hematopoiesis in humans denotes a myeloprolif-
erative syndrome.
The considerable knowledge accumulated over 
more than a century of experimental hematology 
led to the early understanding that all hematopoietic 
lineages are derived from a small subpopulation of 
undifferentiating and self- renewing stem cells. HSC 
represent the most accurately explored model of 
somatic stem cells that are present in most if not all 
tissues and organs, contributing to tissue homeosta-
sis and repair. Existence of a population of HSC 
also has practical implications in terms of develop-
ing innovative therapies aiming at the definitive 
replacement or enhancement of a function in cells 
from one or several hematopoietic lineages, includ-
ing the possibility to establish durable hematopoi-
etic chimerism in recipients of allogeneic HSCT.
7.2  Self-Renewal
A general property of stem cells is self-renewal, 
assuming that when these cells divide, at least 
one of the “daughter cells” fully recapitulate the 
biological properties of the “mother stem cell.” 
Self-renewal of the HSC population prevents 
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exhaustion, while the hematopoietic tissue 
 extensively proliferates and differentiates in 
steady- state conditions, as well as to repair vari-
ous damages. Demonstration of self-renewal at 
the clonal level remains an arduous task, even 
though high-throughput analytical tools have 
been adapted. There is a growing body of evi-
dence suggesting aging of the HSC population 
and decline of stem cell function with age (for a 
review, see Goodell and Rando 2015; de Haan 
and Lazare 2018). Appearance of “passenger 
mutations” in clonal hematopoiesis is one hall-
mark of aging (Cooper and Young 2017); the sig-
nificance of such observations remains to be fully 
elucidated, but obviously raises questions when it 
comes to solicit elderly individuals to donate 
HSC for the benefit of a related patient.
7.3  Commitment 
and Differentiation: New 
Data Challenge the Historical 
View of Hematopoietic 
Hierarchy
The traditional view of HSC differentiation is a 
hierarchical representation of an inverted tree, 
where discrete and homogenous populations 
branch from one another, with successive restric-
tions in differentiation potentials. This oversim-
plifying view is increasingly challenged by recent 
studies reporting on noninvasive genetic experi-
ments and clonal analyses in mice (for a review, 
see Laurenti and Göttgens 2018; Busch and 
Rodewald 2016). These studies suggest that 
hematopoietic differentiation uses different mech-
anisms under steady-state and stress conditions 
(Goyal and Zandstra 2015); however, both in 
steady-state conditions and transplantation mod-
els, only a small fraction of HSC contribute to 
long-term and stable reconstitution without com-
promising reestablishment of hematopoiesis 
(Schoedel et al. 2016; Höfer and Rodewald 2016), 
while most stem cells remain quiescent or prolif-
erate infrequently. Single-cell transcriptional 
landscapes also suggest that differentiation occurs 
as a continuous rather than discrete physiological 
process and that restriction of differentiation is 
not the result of a “symmetric split” between the 
myeloid and lymphoid compartments as long 
thought through the phenotypic identification of 
“common myeloid progenitors” (CMP) and 
“common lymphoid progenitors” (CLP).
Commitment to one or several lineages, or 
conversely restriction in differentiation abilities, 
results from the expression of a controlled genetic 
and epigenetic program (Pouzolles et  al. 2016; 
Antoniani et  al. 2017; Gottgens, 2015); these 
mechanisms remain partially understood and 
thus can only be partially harnessed for in vitro 
engineering of HSC and their progeny (Rowe 
et al. 2016). The fate of HSC and their progeny is 
additionally regulated by extrinsic signals, among 
which hematopoietic growth factors and cyto-
kines play an important role in survival, prolifer-
ation, and amplification (Kaushansky, 2006).
7.4  The Bone Marrow Niches 
and Maintenance 
of Stemness (Fig. 7.1)
Recent years have witnessed considerable prog-
ress in our understanding of organization and 
function of the bone marrow microenvironment. 
HSC establish interactions in the context of 
microanatomical organizations termed “niches.” 
Progress has been made both in understanding the 
heterogeneity of niches at and within successive 
hematopoietic sites and in identifying various cat-
egories of cells—either of non-hematopoietic or 
of hematopoietic origin—that interact with 
HSC. The various types of bone marrow niches 
closely associate with the neurovascular network 
that infiltrates the central bone marrow as well as 
the endosteal region. The nature of the signaling 
between these different cell populations is also 
increasingly deciphered and involves many path-
ways, some of them unexpected at first (for a 
review, see Crane et  al. 2017; Calvi and Link 
2015). Replicating some of these interactions 
in vitro is key to successful expansion or genetic 
engineering of isolated HSC.  Among the many 
molecular actors that govern interactions between 
HSC and the various cells present in niches, the 
CXCL12 chemokine and its most important 
A. Aiuti et al.
51
receptor CXCR4 are of particular interest: direct 
or indirect modulation of this axis is clinically 
exploited to amplify the compartment of circulat-
ing stem cells that exist at low numbers in steady-
state conditions.
7.5  Preclinical Models of HSCT
Most of the current knowledge on the biology of 
HSC and on therapeutic mechanisms of HSCT 
derives from studies in animal models (Eaves, 
2015; Sykes and Scadden 2013). Classical 
murine transplantation studies showed that single 
or few engrafting HSC were sufficient and neces-
sary to sustain long-term hematopoiesis in a 
reconstituted mouse. Human-in-mouse xeno-
grafts have become a fundamental tool to study 
hematopoietic dynamics upon HSCT.  The gen-
eration of immune-deficient mice bearing a dele-
tion of the interleukin-2 receptor gamma chain on 
the NOD-SCID background (NSG mice) was 
instrumental for studying HSC homing, engraft-
ment, lineage differentiation, and serial trans-
plantation capacity. This model has been further 
modified by introducing human myeloid cyto-
kine genes to increase myeloid differentiation 
(Doulatov et al. 2012) or loss-of-function muta-
tion in KIT receptor to efficiently support engraft-
ment of human HSC without the need for 
conditioning therapy (Cosgun et  al. 2014). To 
overcome the lack of human components in the 
murine BM, humanized-BM niche systems have 
been recently developed which are based on 
human stromal cells implanted on specific scaf-
fold or directly injected with extracellular matrix 
to generate BM micro-ossicles (Di Maggio et al. 
2011; Reinisch et al. 2016). These strategies pro-
vide novel tools to study the behavior of human 
HSC in their physiological context and to dissect 


























Fig. 7.1 HSC properties and BM niche components
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the role of the niche upon transplantation. 
However, homing and engraftment parameters in 
xenografts may be different from the natural set-
ting, and most HSCT models follow recipient 
mice for few months after transplantations, thus 
making long-term outcome difficult to assess.
Dogs provide an ideal preclinical modeling 
system for HSCT studies due to their large body 
size, life span, and high genetic diversity, which 
more appropriately recapitulate the human sce-
nario. Preclinical canine modeling has been funda-
mental for the clinical translation of conditioning 
regimens and the importance of MHC donor/
recipient matching. However, the lack of canine 
reagents and the logistic difficulties of working 
with large animal models have precluded wide-
spread availability (Stolfi et al. 2016). Auto-HSCT 
in nonhuman primates is arguably the experimen-
tal model most closely resembling humans; their 
treatment conditions—including the use of CD34+ 
cells, mobilization, and conditioning regimens—
all parallel those commonly exploited in human 
transplantation. While the ethical issues and costs 
have limited their use to selected centers, these 
animals are able to maintain long-term hematopoi-
esis up to several years after transplantation allow-
ing the study of HSCT dynamics in a 
close-to-human fashion (Koelle et al. 2017).
7.6  Gene Transfer/Gene Editing/
Gene Therapy Targeting HSC 
(Fig. 7.2)
Ex vivo HSC gene therapy (GT) is based on the 
genetic modification of autologous HSC to cor-
rect monogenic disorders or to provide novel fea-
tures to hematopoietic cells for treating infectious 
diseases or cancers (Naldini, 2011). It is now 
well established that HSC can be efficiently gene 
modified to continuously produce a cell progeny 
expressing the therapeutic gene while maintain-
ing the ability to engraft long-term, for at least 
15 years (Cicalese et al. 2016). Potential advan-
tages of this approach over allogeneic HSCT 
include the lack of GVHD or rejection and the 
possibility of engineering HSC in order to achieve 
supra-physiological level of the corrected protein 
(Naldini, 2011; Aiuti and Naldini 2016).
Currently, integrating vectors derived from ret-
roviruses represent the most efficient platform for 
engineering HSC and to provide permanent and 
heritable gene correction. γ-Retroviral vectors 
(RV) have been used in many clinical applications 
including GT of inherited blood disorders and can-
cer therapy. HSC-GT in primary immunodeficien-
cies was shown to provide clinical benefit, but the 
use of γ-RV was associated with risks of inser-
tional mutagenesis due to activation of proto-
oncogenes with the exception of ADA deficiency 
(Cicalese et  al. 2016). Self-inactivating (SIN)-
lentiviral vectors (LV) are currently the tools of 
choice for most of the HSC-GT applications given 
their ability to transduce at higher efficiency non-
dividing cells, to carry larger and more complex 
gene cassettes, and to display a safer insertion site 
(InS) pattern in human HSC (Naldini, 2011). The 
recent development of designer endonucleases led 
to the advent of gene targeting approaches. In con-
trast to viral vectors, which can mediate only one 
type of gene modification (gene addition), 
genome-editing technologies can mediate gene 
addition, gene disruption, gene correction, and 
other targeted genome modifications (Dunbar 
et al. 2018). These strategies have the potential to 
overcome vector InS genotoxicity and to handle 
diseases due to dominant negative mutations. 
Despite the great promises, several challenges 
need to be addressed. Primitive, slow-cycling 
human BM-derived HSC are very resistant to 
ex vivo manipulations required for gene targeting, 
and the current efficiency of gene editing into 
repopulating HSC may not be suitable for clinical 
applications requiring high levels of correction 
(Dunbar et al. 2018; Kohn, 2017).
Thus, there remains a pressing need to develop 
methods to expand HSC or gene-corrected HSC 
while maintaining their repopulating capacity. 
Various cytokines and growth factors derived from 
BM niche, such as SCF, TPO, and Flt-3 ligand, are 
able to regulate HSC stemness and differentiation 
and are commonly used in HSC transduction pro-
tocols. However, even efficiently supporting GT, 
the balance between self-renewal/differentiation 
still hangs toward differentiation. High-throughput 
screening of chemical compounds has resulted in 
the identification of two promising molecules 
(StemRegenin1, SR1 (Wagner et al. 2016) and a 
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pyrimidole derivative UM171 (Fares et al. 2014)) 
that are able to achieve great expansion of long-
term repopulating HSC. Several small molecules 
have been identified that may support modest 
degrees of HSC expansion, but the ideal drug or 
combination has not yet been reported.
7.7  Studying Dynamics 
of Hematopoietic 
Reconstitution upon  
HSCT (Fig. 7.3)
Upon gene correction, each transduced cell and its 
progeny become univocally marked by a specific 
insertion site (InS). The analysis of RV or LV InS 
has emerged as one of the most effective strategies 
allowing tracing the activity of genetically engi-
neered hematopoietic cells directly in vivo in ani-
mal models as well as in GT-treated patients. 
Retrieving InS from mature blood cells after 
HSCT allowed studying the kinetics of blood cell 
production from individual stem cells within a het-
erogeneous population (Scala et al. 2016).
In the murine setting, the finding that the vast 
majority of the InS after transplant were present in 
either lymphoid or myeloid cells with few InS 
shared by both lineages led to the concept that 
murine HSC are heterogeneous and already biased 
for their fate. The possibility to directly translate 
these models on human beings is currently under 
investigation (Lu et al. 2011; Yamamoto et al. 2013).
Clonal tracking studies in nonhuman primates 
have been pivotal in studying HSCT dynamics in 
an experimental setting close to humans. The 
results of these works showed common pattern of 
hematopoietic reconstitution upon transplanta-
tion: clonal fluctuation in the early phases post- 
HSCT, potentially due to the initial contribution 
to the hematopoiesis of short-term unilineage 
progenitors, followed by a recovery of a stable 
hematopoietic output likely related to the take- 
over of long-term multipotent HSC contribution. 
Thus, differently from murine studies, long-term 
HSC are able to provide multi-lineage engraft-
ment, and there is no evidence of predetermined 
lineage choice at stem cell level in primates 
(Koelle et al. 2017; Kim et al. 2014).
Integrating vectors
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Fig. 7.2 Gene correction of HSC for cell-based therapies
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To date, few cutting-edge studies have exploited 
InS retrieval from GT-treated patients allowing for 
the first time to study the complexity of hemato-
poietic system and hematopoietic reconstitution 
upon HSCT in humans (Biasco et al. 2016; Wang 
et  al. 2010). These studies showed that trans-
planted gene-repaired HSC are able to engraft and 
to generate polyclonal multi- lineage output over-
time. Longitudinal analyses allowed unveiling that 
unilineage clones active during the first 6 months 
after GT tend to be replaced by multilineage long-
term clones, indicating HSC-derived activity. 
Finally, based on the number of InS recaptured 
overtime, it has been estimated that about 1  in 
105–106 infused gene- corrected cells had the 
potential to engraft long term. Recently our group 
unveiled for the first time that primitive HSPC 
have a distinct role in sustaining human hemato-
poiesis after transplantation.  While MPP are more 
active in the early phases, long-living HSC are on 
top of the hematopoietic hierarchy at steady state. 
Importantly we found that long-term HSC, that 
were activated in vitro, were capable of homing 
and resilience upon re-infusion (Scala et al. 2018). 
These approaches represent a prototypical exam-
ple of the power of translational studies, providing 
information relevant on human  hematopoietic sys-
tem complementing and expanding the data 
derived from animal models.




As already stressed in this brief review, a consid-
erable amount of knowledge has accumulated 
over years allowing us to understand part of the 
mechanisms that control HSC behavior and take 
advantage of this knowledge; many of these 
observations cross-fertilized other disciplines. A 
large gap however persists between the techno-
logical sophistication of research tools and the 
rudimentary nature of clinical grade reagents, 
devices, and laboratory tests. In clinical trans-
plantation or even in the most modern forms of 
hematopoietic cellular therapies, stem cells 
remain identified as “CD34+ cells,” which can at 
best be considered as a gross approach to stem-
ness; functional assays are limited to clonogenic 
cultures in routine practice; flow cytometry- 
activated cell sorting barely entered the clinical 
field, and most cell selection procedures rely on 
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Fig. 7.3 Clonal tracking for studying the hematopoietic reconstitution dynamics upon HSCT
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immune selection with magnetic beads. Despite 
these limitations, and as can be seen from the 
content of the other chapters in this book, HSCT 
remains as the only example of a worldwide and 
widely used cell transplant procedure, with many 
of its underlying conceptual aspects and tech-
niques being used to design innovative and highly 
personalized somatic cell therapy or gene therapy 
medicinal products.
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Biological Properties of Cells  
Other Than HSCs
Attilio Bondanza, Ulrike Koehl, Andrea Hoffmann, 
and Antoine Toubert
8.1  Introduction
The array of cellular players involved in the biol-
ogy of HSCT clearly extends beyond HSC them-
selves and, in the case of transplantation from 
allogeneic sources, importantly includes cells of 
the innate and adaptive immune system. 
Historically, the discovery of the HLA system and 
the functional characterization of the different 
immune cell types had a transformational impact 
on our current understanding of the pathobiologi-
cal sequelae of allo-HSCT (rejection, GVHD, the 
GVL effect). This body of knowledge coupled to 
the most recent exploit of biotechnology nowadays 
allows us to design strategies for in vivo stimula-
tion or adoptive transfer of specific immune cell 
types with the potential to dramatically improve 
transplantation outcome.
In this chapter, we will review the biological 
properties of cells other than HSCs that so far 
have Since apart from vaccination antigen pre-
senting cells and myeloid cells at large have sel-
dom been subject of this type of studies been 
therapeutically investigated in human allo-HSCT, 
they will not be discussed here. Conversely, we 
will briefly touch on mesenchymal stromal cells 
(MSCs), which, although not classifiable as 
immune cells stricto sensu, have been widely 
employed in allo-HSCT.
8.2  Conventional or Alpha-Beta 
T Cells
The majority of mature T cells is characterized 
by the expression of the αβ TCR, which endows 
MHC-restricted recognition of peptides derived 
from non-self-proteins. Mutually exclusive co- 
expression of CD8 or CD4 further conveys speci-
ficity for MHC class I/MHC class II/peptide 
complexes, respectively. CD8+ T cells recognize 
intracellular peptides, mainly derived from 
viruses or mutated genes, mediating cytotoxicity 
of infected or transformed cells, thence the name 
cytotoxic T lymphocytes (CTLs). Conversely, 
CD4+ T cells recognize extracellular pathogen- 
derived peptides, providing antigen-specific 
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 specific “help” to bystander immune cells, such 
as B cells in antibody production and phagocytes 
in killing of engulfed pathogens. Alloreactivity 
occurs because of αβ TCR-mediated recognition 
of mismatched HLAs or of non-HLA polymor-
phic peptides presented in the context of matched 
HLAs, e.g., those derived from H-Y (male- 
specific histocompatibility antigen). The latter 
are known as minor histocompatibility antigens 
(mHag) and play a major role in GVHD and the 
GVL effect after HLA-matched transplantation.
The adoptive transfer of CTLs specific for 
important opportunistic viruses in allo-HSCT 
(CMV, EBV, ADV) has been one of the first 
manipulated cellular immunotherapies to be 
tested in humans (Bollard and Heslop 2016) and 
in some EU countries is now available as an off- 
the- shelf therapy from HLA-matched donors. 
Conversely, it has been proposed that naïve T 
cells, i.e., cells that have never encountered their 
cognate antigen, may be more alloreactive than 
memory T cells, i.e., antigen-experienced cells 
that have persisted after clearing the infection. 
This concept is at the basis of protocols for the 
depletion of naïve T cells from the graft as a way 
to prevent GVHD while retaining a strong GVL 
effect (Bleakley et al. 2015). Promising are also 
attempts at translating this approach against 
hematological tumor antigens for treating overt 
leukemia relapse after allo-HSCT (Chapuis et al. 
2013). On a different page, given the overall com-
plexity of immune responses, it is not surprising 
that during evolution, some immune cell types 
have evolved with the specific task of immune 
regulation. T regulatory cells (Tregs) are thymus-
derived cells characterized by constitutive expres-
sion of the transcription factor FoxP3. Tregs are 
potent suppressors of alloreactivity and are now 
being investigated for GVHD management after 
their ex vivo expansion (Brunstein et al. 2016).
8.3  Unconventional T Cells
Unconventional T cells include T cells express-
ing the γδ TCR, invariant natural killer T cells 
(iNKT) cells, and mucosal-associated invariant 
(MAIT) T cells—which will not be treated 
here—and are an abundant component of the 
immune system. Although originating from the 
thymus, they all share lack of MHC-restricted 
peptide recognition and mainly reside within epi-
thelial tissues. They have a limited TCR reper-
toire diversity and get activated quickly, bridging 
innate to adaptive immunity.
 1. A subset of γδ T cells (Vγ2Vδ9) are activated 
by phosphoantigens, non-peptidic metabolites 
produced by mammalian cells and intracellular 
pathogens (M. tuberculosis, M. leprae, Listeria 
species, Plasmodium species) after interacting 
with intracellular butyrophilin 3A1. Gamma-
delta T cells can also recognize stress mole-
cules such as MICA, MICB, and ULBPs 
through the NK receptor NKG2D. The possi-
bility to expand Vγ2Vδ9 effector T cells in vivo 
by administering the therapeutic bisphospho-
nate zoledronate has originated many clinical 
trials in hematological tumors, also in the con-
text of transplantation (Airoldi et al. 2015).
 2. Type I invariant NKT is a distinct population 
of αβ T cells characterized in humans by the 
expression of α24-Jα18 preferentially paired 
to Vβ11. They recognize lipids presented in 
the context of broadly distributed CD1d 
(monocytes/macrophages, B cells, epithelial 
cells). Upon activation, iNKT cells produce 
immune regulatory cytokines and kill tumor 
targets. Failure to reconstitute iNKT cells 
after Allo-HSCT (Rubio et al. 2012) or lower 
iNKT cells in the graft (Chaidos et al. 2012) 
has been linked to GVHD and relapse. Alpha- 
galactosyl ceramide is a marine sponge- 
derived lipid antigen known to expand iNKT 
cells in vivo and is currently under investiga-
tion in Allo-HSCT (Chen et al. 2017).
8.4  NK Cells
Natural killer (NK) cells belong to the innate 
immune system and provide immediate reactiv-
ity against virally infected, as well as tumor tar-
gets. NK cytotoxicity is controlled by a balance 
of several germ-line encoded inhibitory and 
activating receptors, such as killer immunoglob-
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ulin-like receptors (KIRs) and natural cytotox-
icity receptors (Vivier et  al. 2011). The 
importance of NK cells in allo-HSCT has sur-
faced after the demonstration of their pivotal 
role in preventing leukemia relapse and decreas-
ing GVHD risk after grafting from HLA-
haploidentical donors (Ruggeri et  al. 2002). 
Since then, there has been a growing interest in 
using both autologous and allogeneic NK cells 
in patients with leukemia or other high-risk 
hematological tumors, also in the non-transplant 
setting (Koehl et  al. 2016). These trials have 
uniformly shown safety and potential efficacy of 
infused NK cells. Nevertheless, they have also 
documented the emergence of powerful immune 
escape mechanisms, raising the question on how 
to improve NK cell-based therapies (Koehl et al. 
2018). Various trials are under way in order to 
investigate ways to achieve better NK cell cyto-
toxicity and overcome the immunosuppressive 
tumor microenvironment, including:
 1. Combination of novel checkpoint inhibitors 
with activated NK cells
 2. Bi- or tri-specific antibodies for directly bind-
ing NK cells to cancer cells
 3. Chimeric antigen receptor (CAR)-modified 
NK cells for direct targeting of cancer cells
The latter strategy is particularly interesting 
since CAR-NK cells are expected to retain their 
natural antitumor reactivity, opening for poten-
tially synergistic effects. The first clinical 
CAR-NK cell studies targeting CD19 and 
NKG2D ligands have been initiated (ClinGov. 
No NCT03056339, NCT01974479, 
NCT00995137, NCT03415100) and will likely 
be instrumental to demonstrate proof of concept.
8.5  Mesenchymal Stromal Cells
Mesenchymal stroma cells (MSCs) are multipo-
tent cells capable of differentiating into cells and 
tissues of the mesodermal lineage (bone, carti-
lage, and adipose cells) (Pittenger et  al. 1999). 
Apart from their regenerative properties, MSCs 
have been discovered to secrete a variety of solu-
ble factors and exosomes with paracrine actions. 
Instead of focusing on MSC regenerative proper-
ties, most clinical studies have investigated their 
immunomodulatory (often immunosuppressive) 
properties, as well as their trophic influence on 
tissue repair, especially in GVHD (Fibbe et  al. 
2013). Interestingly, subsequent to hematopoietic 
stem cells, MSCs are the second most frequently 
used cell source for therapeutic applications. 
Notwithstanding their widespread use, MSCs are 
currently the stem cell population with the least 
defined identity and properties (Hoffmann et al. 
2017).
Important studies have demonstrated that the 
physiological counterpart of ex  vivo-expanded 
MSCs can be both CD146+ adventitial reticular 
cells in the subendothelial layer of microvessels 
(Tormin et al. 2011) and CD146- pericytes sur-
rounding large vessels (Corselli et  al. 2013). 
MSC biological functions are also highly debated 
and conflicting results were reported in vitro and, 
more importantly, in clinical trials (Fibbe et  al. 
2013). Considerable lack of consensus exists 
within the field as to how MSCs exert their multi- 
pronged effects. This is due to several facts: 
Firstly, MSCs are isolated from many tissues and 
by different protocols. Secondly, due to the mode 
of isolation, these cells present heterogeneous 
cell populations. Thirdly, protocols for in  vitro 
expansion, including the culture conditions (cul-
ture vessels, media, additives, passaging), are dif-
ferent. Fourthly, MSCs have often been reported 
to survive in vivo only for short time (days). A 
recent comparison of MSC preparations from 
eight different centers using BM aspirates as 
starting material for GMP-guided processes 
revealed considerable variability between the 
centers (Liu et al. 2017). Cells from six centers 
were compared in  vivo for bone formation and 
hematopoiesis support. The quantity of deriving 
bone was highly variable, and only MSCs from 
three centers supported hematopoiesis. A critical 
reappraisal of these cell populations and harmo-
nization of the methods for their isolation and 
expansion, as well as the development of vali-
dated potency assays, is therefore necessary for 
harnessing their full therapeutic potential.
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Key Points
• HSCT rather than a solo play is an 
orchestral concert, where different cel-
lular players contribute to the overall 
final result of the symphony.
• Besides obviously HSCs, key contributors 
are cells of the innate and adaptive immune 
system. Both have evolved for the key task 
of self/non-self- discrimination, each how-
ever focusing on the recognition of differ-
ent class of molecules, from proteins to 
glycolipids.
• The tremendous knowledge in immuno-
biology acquired in the last few decades 
has enabled to start exploiting the prop-
erties of these cells or ameliorating the 
outcome of HSCT.
A. Bondanza et al.
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Immune-mediated rejection of tissue allografts 
was first described in 1945 by the British immu-
nologist Peter Medawar, followed by the discov-
ery of the major histocompatibility complex 
(MHC) carrying the histocompatibility genes by 
Peter Gorer and George Snell in 1948, and of the 
human leukocyte antigen (HLA) molecules by 
Jean Dausset, Jon van Rood, and Rose Payne a 
decade later (Thorsby 2009). The importance of 
these discoveries was recognized by the Nobel 
Prices in Physiology and Medicine to Medawar, 
Snell, and Dausset in 1960 and 1980, respec-
tively. Since then, the MHC has emerged as the 
single most polymorphic gene locus in eukary-
otes, with 17,695 HLA alleles reported to date in 
the IMGT/HLA database, Release 3.31.0, 
2018/01/19 (Robinson et  al. 2015). While the 
main barrier to successful tissue grafting remain 
the HLA incompatibilities, also non-HLA poly-
morphisms have been recognized as important 
players, in particular minor histocompatibility 
antigens (mHAg), killer immunoglobulin-like 
receptors (KIR), and other polymorphic gene 
systems (Dickinson and Holler 2008; Gam et al. 
2017; Heidenreich and Kröger 2017; Spierings 
2014).
9.2  The Biology 
of Histocompatibility
9.2.1  Major Histocompatibility 
Antigens
The human MHC is located within ~4  Mbp of 
DNA on the short arm of chromosome 6 (6p21.3) 
and contains ~260 genes, many of which with 
immune-related functions (Trowsdale and Knight 
2013). The MHC falls into three main regions, 
class I, II, and III, containing HLA A, B, and C; 
HLA DR, DQ, and DP; and complement factor as 
well as tumor necrosis factor genes, respectively. 
MHC genes are codominantly expressed and 
inherited following Mendelian rules, with a 
resulting 25% probability for two siblings to be 
genotypically HLA identical, i.e., to have inher-
ited the same MHC from both parents. An addi-
tional hallmark of the MHC is linkage 
disequilibrium (LD), i.e., the nonrandom associa-
tion of alleles at different HLA loci, and rela-
tively high recombination rates of over 1%, also 
referred to as “crossing over” (Martin et al. 1995).
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9.2.2  HLA Class I and II Structure 
and Function
The classical HLA class I and II molecules are 
cell surface immunoglobulins (Ig) presenting 
peptides in their highly polymorphic antigen- 
binding groove (Madden 1995). HLA class I A, 
B, and C molecules are heterodimers of a poly-
morphic α chain of higher molecular weight 
(MW) than the monomorphic β2 microglobulin 
(heavy and light chain of 45  kDa and 12  kDa, 
respectively). The α-chain contains three hyper-
variable Ig-like domains, two of which form the 
antigen-binding groove while the third is involved 
in contacting the CD8 coreceptor on T cells, and 
the transmembrane region. HLA class I mole-
cules are expressed on all healthy nucleated cells. 
They present peptides, i.e., protein fragments of 
mostly intracellular origin generated by protea-
somal cleavage and transported to the endoplas-
mic reticulum via the transporter associated with 
antigen processing (TAP) (Vyas et al. 2008). Cell 
surface HLA class I peptide complexes can be 
recognized by the T cell receptor (TCR) of CD8+ 
T cells, leading to the activation of cytotoxic and/
or cytokine effector functions, or by KIR on natu-
ral killer (NK) cells, leading to the inhibition of 
effector functions. HLA class II DR, DQ, and DP 
molecules are heterodimers of an α- and a β-chain 
of similar MW of approximately 30 KDa each, 
both with a transmembrane part anchored to the 
cell membrane. Most of the polymorphism is 
clustered in the β-chain Ig-like domain forming 
the antigen-binding groove, whose overall struc-
ture is similar to that of HLA class I, and the 
region contacting the CD4 coreceptor on T cells 
is also located in the β-chain. HLA class II pro-
teins are expressed on professional antigen- 
presenting cells, as, for example, B cells, 
macrophages, and dendritic cells. Moreover, 
HLA class II protein expression on various cell 
types can be upregulated by proinflammatory 
cytokines such as IFNγ and TNFα. HLA class II 
presents peptides generally of extracellular origin 
generated through degradation of proteins in the 
phagolysosome (Vyas et al. 2008). Peptide load-
ing onto HLA class II molecules takes place in 
the dedicated MIIC compartment and is  catalyzed 
by two nonclassical HLA molecules equally 
encoded in the MHC, HLA DM, and DO. After 
transport to the cell surface, HLA class II peptide 
complexes can be recognized by the TCR of 
CD4+ T cells, leading to the activation of cyto-
kine-mediated helper or regulatory functions. 
HLA class II receptors on NK cells, analogous to 
KIR for HLA class I, have not been described to 
date.
9.2.3  HLA Polymorphism and Tissue 
Typing
HLA molecules were first detected by serological 
methods, through the ability of sera from sensi-
tized individuals to agglutinate some but not all 
leukocytes (hence the term “human leukocyte 
antigen”) (Thorsby 2009). Until the mid-1990s, 
serological typing was the main method for tissue 
typing. With the advent of polymerase chain 
reaction (PCR) techniques, molecular tissue typ-
ing took over and unraveled a far greater degree 
of HLA allelic polymorphism than previously 
appreciated (Erlich 2012). HLA nucleotide poly-
morphism is clustered in so-called hypervariable 
regions (HvR) mainly in exons 2, 3, and 4 of 
HLA class I and exons 2 and 3 of HLA class II, 
encoding the functional antigen-binding groove 
and CD4/CD8 coreceptor-binding regions. 
Therefore, PCR-based molecular typing focused 
on these exons, leading to different levels of typ-
ing resolution (Table  9.1). With the advent of 
next-generation sequencing (NGS) for tissue typ-
ing purposes (Gabriel et  al. 2014), allelic or at 
least high-resolution typing can be achieved in 
most cases. Moreover, NGS enables high- 
throughput sequencing of the entire HLA coding 
and noncoding regions, unraveling an additional 
layer of polymorphism with hundreds of new 
alleles reported to the IMGT/HLA database every 
month.
9.2.4  T Cell Alloreactivity
The ability of T cells to specifically recognize 
non-self, allogeneic tissues is called T cell 
E. Spierings and K. Fleischhauer
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 alloreactivity. It can be either direct or indirect. 
Direct T cell alloreactivity is targeted to intact 
mismatched HLA peptide complexes expressed 
on the cell surface of allogeneic cells and can be 
mediated by both naïve and memory T cells 
(Archbold et al. 2008). Indirect T cell alloreactiv-
ity refers to the recognition of peptides derived 
by proteasomal cleavage from mismatched HLA 
and presented in the antigen-binding groove of 
self HLA molecules (Gokmen et al. 2008). These 
peptides are also referred to as Predicted 
Indirectly ReCognizable HLA Epitopes 
(PIRCHE, see Sect. 9.3.3) (Geneugelijk and 
Spierings 2018). A special form of indirect T cell 
alloreactivity is the recognition of foreign pep-
tides not deriving from mismatched HLA but 
from any other expressed polymorphic gene and 
presented by self HLA molecules. These peptides 
are referred to as minor histocompatibility anti-
gens (mHAg) (Spierings 2014). mHAg are the 
only targets of T cell alloreactivity in HLA- 
matched hematopoietic cell transplantation 
(HSCT) and are mainly recognized by naïve T 
cells. T cell alloreactivity is the main mediator of 
both the major benefit and the major toxicity of 
allogeneic HSCT, represented by immune con-
trol of residual malignant disease (graft versus 
leukemia; GvL) and immune attack of healthy 
tissues (graft versus host disease; GvHD), 
respectively.
9.3  HLA Matching in Allogeneic 
HSCT
9.3.1  Donor Types
In HLA identical sibling HSCT, patient and 
donor have inherited the same parental MHCs, an 
event occurring with a likelihood of 25% accord-
ing to Mendelian rules. Genotypic HLA identity 
should be confirmed by family studies for all six 
HLA loci (to exclude recombination). 
Haploidentical donors share only one MHC hap-
lotype while the other haplotype is different. 
These donors are available for more than 90% of 
patients and can be found in parents or offsprings 
(100% likelihood), siblings (50% likelihood), as 
well as the extended family. Also HLA 
Key Points
• HLA molecules are encoded by highly 
polymorphic genes in the human MHC 
and play a crucial role for peptide anti-
gen recognition by T cells.
• HLA tissue typing can be performed at 
different levels of resolution, the highest 
being attainable only by NGS-based 
methods, which are unraveling an 
unprecedented degree of polymorphism 
in the MHC.
• Alloreactive T cells can recognize non- 
self HLA molecules on healthy and 
malignant cells after Allo-HSCT, medi-
ating both toxic GvHD and beneficial 
GvL.
Table 9.1 HLA typing resolution and appropriate typing 
methods
HLA typing resolutiona Appropriate typing methodsb
Low (first field) Serology, SSP, SSOP, others
High (second field) NGS, SBT
Allelic (all fields) NGS, SBT
Intermediate SSP, SSOP, SBT
aAs defined in (Nunes et al. 2011). Low: A serological typ-
ing result or DNA-based typing at the first field in the 
DNA-based nomenclature. High: A set of alleles that 
encode the same protein sequence in the antigen binding 
site and that exclude alleles not expressed at the cell sur-
face. High resolution thus includes alleles reported with 
the suffix G (set of alleles with identical nucleotide 
sequence across the exons encoding the antigen binding 
site) or the suffix P (set of alleles encoding the same pro-
tein sequence at the antigen binding site). Allelic: Unique 
nucleotide sequence for a gene as defined by the use of all 
of the digits in a current allele name. Intermediate: A level 
of resolution that falls between high and low resolution, as 
agreed with the entity requesting the testing. Examples 
are restriction to common and well-documented (CWD) 
alleles (Sanchez-Mazas et  al. 2017) or reporting by 
NMDP codes (https://bioinformatics.bethematchclinical.
org/hla-resources/allele-codes/allele-code-lists/).
bSerology complement-dependent cytotoxicity of specific 
antisera, SSP sequence-specific priming, SSOP sequence- 
specific oligonucleotide probing, Others additional 
molecular typing approaches including quantitative PCR 
and restriction fragment length polymorphism (RFLP), 




 haploidentity should be confirmed by family 
studies wherever possible. Unrelated donors 
(UD) can be found among over 30 million volun-
teers enrolled in the worldwide registries or from 
over 700,000 banked cord blood units. The prob-
ability to find a volunteer UD matched for 8/8 
HLA A, B, C, and DRB1 alleles varies according 
to the ethnic group of the patient between 30% 
and over 90% (Gragert et  al. 2014). For UD 
HSCT, HLA identity should be confirmed at the 
highest resolution level possible (allelic, high, or 
intermediate resolution, Table 9.1), to be agreed 
between the transplant center and the tissue typ-
ing laboratory.
9.3.2  Clinical Impact of HLA 
Mismatches
The clinical relevance of histocompatibility for 
the outcome of HSCT is significantly influenced 
by different patient-, donor-, and transplant- 
related factors (Table  9.2). The most striking 
example for the impact of these confounding fac-
tors is the advent of haploidentical HSCT, in 
which successful transplantation across an entire 
mismatched haplotype was rendered possible by 
extensive T cell depletion of the graft and, more 
recently, by innovative schemes of pharmacolog-
ical GvHD prophylaxis (Slade et  al. 2017). On 
the other hand, haploidentical HSCT has been 
associated with a particular form of immune 
escape relapse characterized by the selective 
genomic loss of the mismatched HLA haplotype, 
with important implications for treatment strate-
gies (Vago et  al. 2012). In UD HSCT, high- 
resolution matching for 8/8 HLA A, B, C, and 
DRB1 alleles has been shown to be associated 
with the best clinical outcomes, with an approxi-
mately 10% decrease in survival probabilities for 
every (antigenic or allelic) HLA mismatch at 
these four loci (Lee et  al. 2007). On the other 
hand, the impact of HLA disparity was shown to 
be significantly reduced by advanced disease sta-
tus at transplant, again demonstrating the inextri-
cable link between HLA mismatches and 
confounding factors. The notion that there will be 
no “one-size-fits-all” solution to the question on 
the impact of histocompatibility in HSCT has to 
be taken into account when critically interpreting 
studies in this complex field.
9.3.3  Models of High-Risk/
Nonpermissive HLA 
Mismatches
HLA mismatches that are clinically less well tol-
erated than others are referred to as high risk or 
nonpermissive. This is based on the observation 
that limited T cell alloreactivity is generally suf-
ficient for the beneficial effect of GvL without 
inducing clinically uncontrollable GvHD, while 
intolerable toxicity can be induced by excessive 
T cell alloreactivity leading to severe treatment 
refractory GvHD.  Therefore, high-risk or non-
permissive HLA mismatches are those associated 
with excessive T cell alloreactivity compared to 
their low-risk or permissive counterparts. 
Different models have been developed over the 
past years for their identification (Table  9.3). 
They rely on the presence of shared or nonshared 
T cell epitope (TCE) groups between mismatched 
HLA DPB1 alleles (Fleischhauer and Shaw 
2017), genetically controlled expression levels of 
mismatched HLA C or DPB1 alleles in the 
patient (Petersdorf et  al. 2014, 2015), specific 
high-risk HLA C and DPB1 allele mismatch 
combinations identified by retrospective statisti-
cal association between mismatch status and 
clinical outcome (Fernandez-Vina et  al. 2014; 
Kawase et  al. 2009), and the total number of 
PIRCHEI (presented by HLA class I) and 
PIRCHEII (presented by HLA class II) as a mea-
sure of the potential level of indirect alloreactiv-
ity after transplantation (Geneugelijk and 
Table 9.2 Confounding factors of HLA/non-HLA 




Age, sex, ABO, CMV serostatus, 
diagnosis, disease status
Donor related Age, sex, ABO, CMV serostatus
Transplant 
related
Conditioning, GvHD prophylaxis, stem 
cell source, and composition
aThe impact of HLA matching is additionally confounded 
by non-HLA immunogenetic factors and vice versa
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Spierings 2018). It should be noted that HLA 
DPB1 mismatches are present in over 80% of 8/8 
matched UD HSCT, and models for high-risk or 
nonpermissive mismatches at this locus are there-
fore of particular practical relevance. The 
PIRCHE model is attractive since it is potentially 
applicable to any HLA-mismatched donor trans-
plantation including <8/8 matched UD and hap-
loidentical HSCT; on the other hand, clinical 
evidence for its validity in HSCT has so far been 
obtained only on relatively limited transplant 
cohorts. As stated above (Sect. 9.3.2), it is crucial 
that any of these or future models be tested in 
independent cohorts of sufficient statistical size 
and that they be continuously revalidated as clini-
cal transplant practice and hence potential con-
founding factors evolve.
9.3.4  Guidelines for UD Selection 
by Histocompatibility
Consensus guidelines for donor selection have 
been established in many countries both in 
Europe and overseas, through the collaboration 
between donor registries and national immuno-
genetic societies. The general recommendation is 
the selection of an 8/8 HLA A, B, C, and DR (in 
Europe often 10/10, i.e., including the HLA DQ 
locus) matched UD if an HLA identical sibling is 
not available, followed by a 7/8 (or 9/10) UD or a 
haploidentical donor. Avoidance of high-risk or 
nonpermissive HLA mismatches according to 
any of the models outlined in Table 9.3 is usually 
regarded as optional, with particular emphasis on 
the avoidance of nonpermissive HLA DPB1 TCE 
mismatches since the TCE model is the only one 
to have been validated in different independent 
clinical studies to date (Fleischhauer and Shaw 
2017). Also the inclusion of some of the non- 
HLA immunogenetic factors outlined in Sect. 9.4 
can be considered, in particular with regard to 
donor KIR typing in haploidentical HSCT 
(Heidenreich and Kröger 2017).
Table 9.3 Models of high-risk/nonpermissive HLA 
mismatches
Model
HLA locus, donor type, and 
clinical association
T cell epitope 
(TCE) groupsa
HLA-DPB1; 8/8 UD; mortality 
and acute GvHD




HLA C and DPB1; 7–8/8 UD; 
mortality, acute GvHD and 
relapse
PIRCHEd HLA C and DPB1; 8/8 UD; acute 
GvHD
aTCE groups: HLA DPB1 mismatches involving alleles 
from the same (permissive) or different (nonpermissive) 
TCE groups (Fleischhauer and Shaw 2017)
bExpression levels: HLA C or DPB1 mismatches involv-
ing a high-expression allele in the patient, as predicted by 
noncoding single nucleotide expression polymorphisms 
(Petersdorf et al. 2014, 2015)
cMismatch combinations, high-risk allele mismatches 
defined by statistical associations (Fernandez-Vina et al. 
2014; Kawase et al. 2009)
dPIRCHE, predicted indirectly recognizable HLA epitope 
numbers as predicted by online tools (Geneugelijk and 
Spierings 2018) Key Points
• HSCT donor types (in parenthesis the % 
probability of their identification for a 
given patient) include genotypically 
HLA identical siblings (25%), HLA 
haploidentical family donors (>90%), 
UD (30–90%), and cord blood donors 
(>80%).
• HLA typing strategies including family 
studies for related donors and typing 
resolution level for UD should be agreed 
between the transplant center and the 
tissue typing laboratory.
• The clinical relevance of HLA matching 
for the outcome of HSCT is critically 
dependent on numerous patient-, donor-, 
and transplant-related factors.
• In UD HSCT, survival probability 
decreases by 10% with every mismatch 
at HLA A, B, C, and DRB1, in patients 
transplanted at early disease stage.
• Models for high-risk nonpermissive 
HLA mismatches eliciting excessive T 
cell alloreactivity with intolerable tox-
icity include structural TCE, expres-
sion levels, specific allele 
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9.4  Non-HLA Immunogenetic 
Factors
9.4.1  Overview
HLA alleles are the most but not the only poly-
morphic genes in humans. Overall, interindi-
vidual gene variability by single nucleotide 
polymorphism (SNP) or copy-number varia-
tion (CNV) affects 0.5% of the 3 × 109 bp in 
the human genome. Although most of these 
polymorphisms are probably nonfunctional, 
some of them can give rise to polymorphic pro-
teins that can be mHAg as described in Sect. 
9.2.2, affect the expression of different genes 
including those encoding immunologically 
active cytokines, or act themselves as immune 
ligands or receptors relevant to transplantation 
biology. Among the latter, the KIR gene locus 
on the long arm of human chromosome 19 dis-
plays considerable polymorphism, with 907 
alleles reported to the IPD/KIR database, 
Release 2.7.0, July 2017 (Robinson et  al. 
2005). Similar to high-risk or nonpermissive 
HLA mismatches, the role of non- HLA poly-
morphism in allo-HSCT is still incompletely 
defined. It is impossible to give a comprehen-
sive overview of all non-HLA factors under 
study, and the list of factors listed in Table 9.4 
and discussed in Sect. 9.4.2 is only a selection 
based on existing evidence for their clinical 
impact in certain transplant settings.
9.4.2  Clinical Impact of Non-HLA 
Immunogenetic Factors
mHAg are the only targets of T cell alloreactivity 
in HLA identical HSCT (see Sect. 9.2.2) and as 
such play an important role for both GvHD and 
GvL (Spierings 2014). This dual function is 
related to their different modes of tissue and cell 
expression, i.e., hematopoietic system restricted 
or broad. Broadly expressed mHAg can cause 
both GvHD and GvL, and donor-recipient match-
ing for these mHAg is therefore desirable yet vir-
tually impossible due to their large number, with 
many of them probably currently undefined. In 
contrast, mHAg restricted to hematopoietic cells 
are more prone to induce selective GvL. The lat-
ter are being explored as targets for HSCT-based 
immunotherapy of hematological malignancies, 
in which mHAg-specific responses are specifi-
cally enhanced to promote GvL.
KIR are predominantly expressed by NK cells 
and recognize certain HLA class I specificities on 
target cells. KIR have either long inhibitory or 
short activating cytoplasmic domains and are sto-
chastically coexpressed on NK cells. The even-
tual outcome of KIR interaction (or lack thereof) 
with its HLA class I ligand (inhibition or activa-
tion) is a complex process that depends on the 
relative number of inhibitory or activatory KIR 
Table 9.4 Non-HLA immunogenetic factors and HSCT 
outcome
Non-HLA 
factor Clinical outcome association
mHAga GvHD and relapse
KIRb Relapse and mortality
MICc GvHD, relapse, and transplant-related 
mortality
Othersd GvHD and transplant-related mortality
aMinor histocompatibility antigens (Spierings 2014)
bKiller Ig-like receptors (Heidenreich and Kröger 2017; 
Shaffer and Hsu 2016)
cMHC class I-related chain (Isernhagen et al. 2016)
dCytokine, chemokine, and immune response gene polymor-
phisms including tumor necrosis factor, interleukin (IL)10, 
the IL1 gene family, IL2, IL6, interferon γ, tumor growth 
factor β and their receptors, NOD-like receptors (NOD2/
CARD15), toll-like receptors, micro-RNAs (Dickinson and 
Holler 2008; Gam et al. 2017; Chen and Zeiser 2018)
combinations, and PIRCHE. All these 
and future models need to be tested in 
independent cohorts of sufficient sta-
tistical size and be continuously reval-
idated as clinical transplant practice 
evolves.
• Consensus guidelines established at the 
national level between donor registries 
and immunogenetic societies aid in the 
selection of HSCT donors.
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and on the state of education of the NK cell. 
Educated NK cells from individuals expressing 
the cognate HLA ligand are strongly reactive 
against cells missing that ligand. This “missing 
self” reactivity is at the basis for the potent GvL 
effect attributed to NK cells in the setting of 
HLA-mismatched transplantation, in particular 
haploidentical HSCT (Heidenreich and Kröger 
2017). Depending on the donor KIR gene asset, a 
role for NK cell-mediated GvL has also been 
postulated in the HLA-matched setting (Shaffer 
and Hsu 2016). Based on all this evidence, KIR 
typing is increasingly being adopted as an addi-
tional criterion for donor selection.
MHC class I chain-related (MIC) A and B are 
nonclassical MHC class I genes. MICA encodes 
a ligand for NKG2D, an activating NK receptor. 
The SNP Val/Met at position 129 of the MICA 
protein results in isoforms with high (Met) and 
low affinities (Val) for NKG2D.  Consequently, 
various studies suggest a role for this SNP in SCT 
outcome, including GvHD, relapse and survival 
(Isernhagen et al. 2016).
Immune response gene polymorphisms have 
also been reported to contribute to the risks associ-
ated with HSCT (Dickinson and Holler 2008; Gam 
et al. 2017; Chen and Zeiser 2018). They often com-
prise SNPs in cytokine or chemokine- coding genes 
or their regulatory elements such as micro-RNAs 
(miRNAs). These variations in both the donor and 
the recipient can have a significant impact on trans-
plant outcome and the development of GvHD; how-
ever, their relative role in different transplant settings 
is not yet fully elucidated.
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The main mechanisms of action resulting in a 
long-term cure, but also in many life-threatening 
side effects after HSCT, are mediated by the rap-
idly reconstituting immune repertoire, which 
depends on the conditioning regimen, cell dose 
and graft composition, as well as the type of 
immune suppression. However, knowledge of 
these mechanisms is limited, due to many varia-
tions in clinical programs, including the specific 
type of transplantation procedure, as well as a lack 
of standardized immune monitoring after HSCT.
To date, only the process of donor selection 
has been significantly impacted by new biologi-
cal insights, but little attention has been given to 
the design of the cell product in terms of numbers 
and composition, to avoid variations between dif-
ferent patients. In addition, high variations 
between patients in the clearance of agents used 
during the conditioning are rarely investigated. 
Given the dearth of prospective clinical studies 
addressing these important concepts, and the fact 
that such studies will most likely never be per-
formed, due to the lack of interest from pharma-
ceutical companies, we aim to initiate a consensus 
discussion. Our goal is to harmonize the inter-
vention HSCT by exploring how individual dif-
ferences between patients and overall 
transplantation strategies impact the final effector 
mechanisms of HSCT, namely, a timely and well- 
balanced immune reconstitution.







Various groups have recently demonstrated that 
agents administered as part of the conditioning 
regimen, as well as after HSCT, will influence 
both short-term and long-term immune reconsti-
tution (Soiffer and Chen 2017; Admiraal et  al. 
2015). These agents may, therefore, have an 
unknown effect on also other cell-based thera-
peutics. In the context of HSCT, “predictable” 
immune reconstitution is important when study-
ing maintenance therapies with novel drugs, DLI, 
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and advanced cell therapy interventions. 
Therefore, it is essential to understand the impact 
of the agents used on the immune reconstitution. 
Comprehensive pharmacokinetic (PK) and phar-
macodynamic (PD) information can help to illu-
minate the effects that exposure of agents in the 
conditioning have on immune reconstitution and 
subsequent outcomes (e.g., GvHD, relapse and 
non-relapse mortality).
The recent discovery that the pharmacokinet-
ics of serotherapy (e.g., ATG and ATLG) is highly 
dependent on receptor load (represented by abso-
lute lymphocyte count; ALC) before the first dos-
ing is one example. In adults, receptor load was 
the only predictor for ATG clearance, while in 
pediatric patients (<40  kg), weight also influ-
enced clearance. While prospective validation tri-
als of novel ATG nomograms currently include 
patients linked to defined transplantation regi-
mens, initial recommendations for dosing sero-
therapy on lymphocyte count rather than body 
weight seem to be reasonable, e.g., within the 
context of T cell-replete reduced conditioning 
regimens (Admiraal et  al. 2015) (Table  10.1). 
From a post hoc analysis of a recent randomized 
controlled trial allowing three different types of 
regimens, we learned that different regimens had 
the reverse effects of ATLG on the outcomes, 
resulting in overlapping curves for the primary 
endpoint, chronic-GvHD-free, leukemia-free 
survival (Soiffer et al. 2017).
Serotherapy is not the only agent in a condi-
tioning regimen with variable PK that can have a 
dramatic impact on the chances for survival. In a 
recent retrospective cohort analysis that included 
more than 650 pediatric and young adult patients, 
cumulative exposure to BU was found to influ-
ence outcomes (Bartelink et al. 2016). The opti-
mal BU exposure, for the main outcome of EFS, 
was found to be independent of indication, com-
bination (BU/FLU, BU/CY, or BU/CY/MEL), 
age, and donor source. BU/FLU within the opti-
mal BU exposure (80–100 mg*h/L) was associ-
ated with the highest survival chances and lowest 
toxicity compared to other combinations. More 
recently, fludarabine exposure was also found to 
influence survival (in an ATG-FLU/BU: Boelens 
et al. 2018). These studies further illustrate that 
pharmacokinetic variations in individuals can 
have significant effects on survival. Historically, 
and still in daily practice, a variety of condition-
ing regimens are used, which complicates com-
parisons of HSCT outcomes across different 
centers and even within trials.




Although transplant physicians carefully monitor 
the levels of many drugs, such as CSA or antibi-
otics, an additional opportunity to further harmo-
nize the transplantation procedure arises from the 
surprising clinical observation that substantial 
cell dose variations are currently accepted across 
patients. The hesitation to monitor cell numbers 
in the graft or after HSCT, and to act on them, is 
of course partially driven by the confusing mag-
nitude of immunological subsets, the narrow 
nature of many immunological programs with a 
lack of consensus on immune monitoring, and 
also rather limited immunological education 
across the majority of transplant physicians. 
However, currently available retrospective and 
prospective studies can provide guidance. A ret-
rospective EBMT study indicated that T cell 
numbers vary frequently between 50 and 
Table 10.1 Suggested novel ATG dosing nomograms 
based on PK-PD modeling for (non-)myelo-ablative set-
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ALC absolute lymphocyte count, AUC area under the 
curve
aLevel C evidence (retrospective studies)
J. Kuball and J. J. Boelens
71
885 × 106/kg and the highest quartile in CD34+ 
cells, as well as T cells associate with an inferior 
clinical outcome (5). As we cannot expect in the 
future randomized trials addressing the impact of 
different graft compositions in T cell-replete 
transplantations on clinical outcomes, avoiding 
higher numbers of CD34 and T cells within the 
highest quartile might be reasonable (Czerw 
et  al. 2016). Higher numbers of NKT cells 
(Malard et al. 2016) and γδT cells (Perko et al. 
2015) in the graft have been reported to associate 
with favorable immune reconstitution, and a pos-
itive clinical outcome, most likely due to their 
impact on controlling GVHD (Du et  al. 2017) 
and acting on CMV, as well as on leukemia 
(Scheper et  al. 2013; de Witte et  al. 2018). 
However, these variables are more difficult to 
control in daily clinical practice. Direct ex vivo 
graft engineering provides an elegant solution to 
further control immune subsets in the graft and 
the consecutive immune reconstitution. It also 
allows for the standardization of cell numbers, as 
well as subsets per patient, e.g., selecting CD34- 
positive stem cells alone has been reported to 
associate with less chronic GVHD, while the 
graft versus leukemia effect is maintained 
(Pasquini et al. 2012). As the next generation of 
graft engineering, depletion of αβT cells has been 
reported to associate with lower frequencies of 
infection and very low GVHD rates (Locatelli 
et al. 2017).
10.4  Immune Monitoring
10.4.1  Immune Cell Phenotyping
The most important questions that arise when 
monitoring immune therapeutic interventions 
are:
 1. How many cells within each leukocyte subset 
are present in patients at different stages of 
disease, before immune intervention?
 2. What is the immune composition of the graft?
 3. Which immune subsets are reconstituting at 
what points in time?
 4. What is the functional response of these cells 
to additional immunotherapeutic or drug inter-
ventions after transplantation (Table 10.1)?
These questions are particularly important in an 
era when post-HSCT pharmaceutical maintenance 
interventions and DLI or the administration of 
other ATMPs (advanced therapy medicinal prod-
ucts) have become daily practice for many differ-
ent disease categories (Soiffer and Chen 2017).
Flow cytometry is often available for compre-
hensive immune phenotyping, usually in accred-
ited laboratories within transplant centers. 
Markers identifying the most common leukocyte 
subsets are broadly used and can therefore be 
considered as a “standard” panel: CD45 (lym-
phocytes), CD3 (T cells), CD19 (B cells), 
αβTCR, γδTCR, and CD16/CD56 (NK) cells. In 
some centers/studies, this panel has been 
extended to identify the differentiation and acti-
vation state of subsets of T (T-helper, regulatory 
T cells), B, and NK(T) cells, as well as cells from 
the myeloid lineage (monocytes, dendritic cell 
subsets). This knowledge is important because 
the success of cell-based immunotherapies, as 
well as agents modulating the immune system 
after transplantation, will significantly depend on 
the presence or absence of different immune sub-
sets. Mastering the diversity might allow for the 
definition of subpopulations who would benefit 
from checkpoint-inhibitor treatment after HSCT, 
as well as characterize patients who would be at 
high risk for GVHD, while currently this inter-
vention is considered to be very toxic (Davids 
et al. 2016). Also, other subsets may be suitable 
as biomarkers to predict clinical efficacy. Given 
the potential impact of sorafenib on post-HSCT 
outcomes through the induction of IL15 (Mathew 
et al. 2018), additional immune subsets associat-
ing with improved leukemia control need to be 
identified. In another study, high baseline fre-
quencies of peripheral blood dendritic cells (DC) 
correlated with a clinical response to high-dose 
IL-2 (Finkelstein et al. 2010). These data empha-
size the importance of DC in endogenous and 
therapy-induced antitumor immunity and 
 arguably warrant the incorporation of DC 
 markers in immune-monitoring panels.
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Taken together, a variety of specialized sub-
sets may have potential as predictive markers for 
clinical efficacy, but they require more sophisti-
cated staining protocols, making more cumber-
some staining techniques less broadly applicable 
for harmonized panels across centers or in multi-
center clinical trials. Furthermore, it is important 
to note that trials using whole blood assays may 
produce different percentages of cell subsets 
when compared with studies using PBMCs. The 
same is true when comparing freshly isolated 
PBMCs with biobanked material, which has been 
subjected to freeze/thaw procedures that affect 
expression levels of various markers. Even when 
the same samples are collected, variations can be 
introduced by the selection of antibody clones, 
combination of clones and fluorochromes, and 
the gating strategies. In sum, minimizing the 
variability in sample handling and the pre- 
analysis phase is critical for standardization.
10.4.2  Immune Monitoring: 
Secretome Analyses
Measuring the production of cytokines, chemo-
kines, and growth factors and their profiles (i.e., 
the secretome) represents an integral part of 
immunomonitoring during immunotherapeutic 
treatments. These biomarkers may distinguish 
diverse disease/response patterns, identify surro-
gate markers of efficacy, and provide additional 
insight into the therapeutic mode of action. 
Peripheral blood is often the only source for pro-
tein analysis, which may lack the sensitivity to 
reflect local responses in affected tissues. As 
examples, proteins, such as interleukin-6, 
granulocyte- macrophage colony-stimulating fac-
tor (GM-CSF), hepatocyte growth factor (HGF), 
ST2 (suppressor of tumorigenicity), and soluble 
IL-2a, have been suggested as potential biomark-
ers for GvHD, whereas increased levels of TNF-a 
and IL-6 are associated with robust immune 
responses to viral reactivation (de Koning et al. 
2016).
The most commonly used methods to identify 
these markers include antibody-based ELISA or 
multiplex platforms, such as protein microarrays, 
liquid chromatography-mass spectrometry (LC- 
MS), electro-chemiluminescence, and bead- 
based multiplex immunoassays (MIA). Again, 
different technologies and reagents (e.g., anti-
bodies and recombinants for standard curves) 
may lead to different concentrations and dramatic 
variability in results, depending on how the pre- 
analytic samples are handled (e.g., differences in 
processing and storage, including duration of 
storage). Cytokine levels differ considerably 
between serum and plasma samples obtained 
from the same donor, due to release of platelet- 
associated molecules into serum. Moreover, the 
type of anticoagulant used in plasma isolation 
and time- and/or temperature-sensitive changes 
need to be considered (Keustermans et al. 2013). 
These phenomena underscore the need for exten-
sive documentation with respect to all biomarker 
analysis before any conclusions can be made 
when comparing patient cohorts treated at multi-
ple sites.
10.5  Summary
The failure or success of HSCT is significantly 
impacted by the patient’s immune status. 
However, only a minority of HSCT programs 
systematically consider individualized drug 
 monitoring during conditioning, graft design, and 
immune monitoring as key for patient surveil-
lance, in order to maximally control and cap-
ture essential details of the intervention 
HSCT. Therefore, guidelines are needed to fur-
ther harmonize the procedure HSCT as well as 
standardized immune monitoring to allow for 
distillation of key features for success and failure. 
First, careful recommendations for individual-
ized drug dosing as well as graft compositions 
can be made based on available data sets. 
However, it will be key to register within the new 
cellular therapy registry of EBMT additional 
details of drug dosages, graft compositions, as 
well as immune reconstitution, to capture clinical 
variations in programs, as well as defined immune 
reconstitutions. This will enable a retrospective 
J. Kuball and J. J. Boelens
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increase in insight into daily clinical practice, and 
its impact on immune reconstitution, as well as 
clinical outcome. Also, clinical trials should 
adopt such consensus measurements. 
Nevertheless, the markers and phenotypes stud-
ied in one setting may not be considered relevant 
in another, supporting the definition of a set of 
general recommended protocols and a set of add-
 on trial-specific parameters (Table 10.2). A con-
sensus panel is currently prepared by the cellular 
therapy and immunobiology working party 
(CTIWP) of EBMT (Greco et al. 2018). A har-
monization procedure to achieve a more balanced 
immune reconstitution might have a more pro-
found impact on patient survival than any other 
novel maintenance therapy (Admiraal et al. 2017; 
Boelens et al. 2018) and allow for a better suc-
cess rate for novel drugs tested as maintenance 
therapy.







αβTCR, CD45RO/RA, CD3, CD4, 
CD8, CD27
γδTCR, CD45RO/RA, CD3, CD27
CD45, CD4, CD25, CD127, FoxP3
CD45, CD19, CD38, CD27, 
IgM/G/D, CD21
CD45, CD3, CD56, TCRα24/β11)
Intracellular cytokines
after PMA/ionomycin stimulation
Specific TCR by multimer 
approach
Cell phenotyping 








αβTCR, CD45RO/RA, CD3, CD4, 
CD8, CD27
γδTCR, CD45RO/RA, CD3, CD27
CD45, CD4, CD25, CD127, FoxP3
CD45, CD19, CD38, CD27, 
IgM/G/D, CD21
CD45, CD3, CD56, TCRα24/β11)




Specific TCR by multimer 
approach
αβTCR and γδTCR repertoire
Secretome – Multiplex panel (e.g., IL-7, ST2, 
TNF-a, IL-6, HGF, IL-2R, IL-8, 
GM-CSF, etc.)
Cell function – NK cell lyses
T cell proliferation upon antigens 
and mitogens
B cell maturation
PK BU, FLU, ATG, Campath (if part of conditioning) Trial drug
MRD qPCR (targets expressed, flow cytometry) Next-generation sequencing
Viral load CMV, EBV, HV6, adenovirus –
aGeneral parameters that could be included in harmonized immune-monitoring protocols across most studies/centers 
and advanced parameters that may be of great value in specific studies and that can only be performed in specialized 
immunology labs or analyzed in a central laboratory
Key Points
• The failure or success of HCT is signifi-
cantly impacted by the patient’s immune 
status.
• Harmonizing individualized drug moni-
toring during conditioning, graft design, 
and immune monitoring is key for 
patient surveillance and needs to be reg-
istered within the new cellular therapy 
registry of EBMT.
• A harmonization procedure to achieve a 
more balanced immune reconstitution 
might have a more profound impact on 
patient survival than any other novel 
maintenance therapy and allow for a 
better success rate for novel drugs tested 
as maintenance therapy.
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The evaluation of candidates and the analysis of 
individual risk factors for HSCT permit to estab-
lish four fundamental aspects:
 1. The HSCT indication
 2. To inform the patient properly
 3. To choose the best donor, conditioning, and 
post-HSCT IS
 4. To evaluate the results of the transplant in 
large series
11.1.2  Candidates’ Evaluation Work 
Flow
11.1.2.1  First Visit
The most relevant aspects to take into account in 
this first visit are:
• Medical history (past and present) and physi-
cal examination (see Sect. 11.1.2.4).
• Review of diagnostic tests (in referred patients).
• Revaluate HLA typing of patient and potential 
donors (if allo-HSCT).
• Preliminary information on:
 – Therapeutic options and results
 – HSCT procedure
 – Possible complications and side effects 
(see specific chapters in Part V)
• Schedule reevaluation of the current status of 
the disease (see Sect. 11.1.3).
• Schedule visits with radiation therapist (if 
TBI), dentist, gynecologist, blood bank (list of 
blood/platelet donors), HSCT unit supervisor 
nurse, etc.
• Signature of the informed consent for HSCT 
and for procurement of HSC (if auto-HSCT).
11.1.2.2  Visit Preharvesting 
(Auto-HSCT)
•  Assess the results of complementary 
explorations.
•  Complete information on the procedure.
11
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•  If PBSC, assess the status of venous accesses. 
Program CVC (if necessary) and mobilization 
schedule.
•  If BM: preanesthetic visit.
•  Program manipulation of HSCT (if applica-
ble) and/or cryopreservation.
11.1.2.3  Last Visit Before Admission
• Final and complete patient information (see 
Sect. 11.1.2.5).
• Evaluate reevaluation studies performed (see 
Sect. 11.1.3).
• Schedule admission and conditioning 
treatment.
• If necessary, program CVC placement.
• If allo-HSCT: confirm that the donor’s evalua-
tion is correct and there are no contraindica-
tions for donation (see Chap. 12).
• If auto-HSCT: confirm that the cryopreserved 
cellularity is correct.
• Submit donor and recipient information to the 
blood bank (group, CMV serology, previous 
transfusions, etc.).
• If TBI: confirm that the dosimetry has been 
carried out and the RT has been programmed.
• Confirm storage of patient and donor samples 
for serotheque and cellular library.
11.1.2.4  Medical History
Collect information on:
Medical background; childhood illnesses and 
vaccines; allergies and adverse drug reactions; 
surgical interventions (previous anesthesia); med-
ications not related to the basic process; previous 
transfusion history, family tree, and family history 
valuable; in women, menarche/menopause, preg-
nancy and childbirth, contraceptive methods, date 
last rule, and gynecological checkups
Travel to malaria, trypanosomiasis, and 
HTLV-I/II endemic areas
Previous relevant infections
Data about the current illness:
• Start date and initial symptomatology
• Diagnostic methodology used (staging)
•  Chemotherapy and radiotherapy treat-
ments (doses and dates)
• Complications from such treatments
• Result of these treatments
• Recurrences and their treatment
• Transfusions received
• Current state of the disease
Social aspects
•  Smoking, alcoholism, and other drug use
• Sexual habits
•  Availability of accommodation close to the 
center and means of transport
• Support family members
• Ethnic, cultural, and intellectual aspects
11.1.2.5  Information to Provide  
(See Detailed Information 
in Counseling Section)
Ask the patient (privately) which escorts he or 
she wishes to have present in this session. For 
adolescents follow the rules of each country 
respecting the right of information. Transmit as 
much information as possible in writing. She/he 
must be informed about:
• Most frequent early and late complications (see 
specific chapters in Parts V and VI) including 
graft failure, GI complications, alopecia, SOS/
VOD, acute GVHD, early infections, chronic 
GVHD, late infections, relapse of the disease, 
infertility, endocrine complications, neoplasms, 
and other secondary.
• Treat specifically serious complications (ICU 
admissions) and possibility of death. Inform 
about the advance directive registry. Agreeing 
with the patient on an interlocutor in case at some 
point they may not be able to make decisions.
• Estimated duration of admission, approximate 
day of admission.
• Most frequent complications on discharge, 
outpatient follow-up, likelihood of readmis-
sion, and need for caregivers at discharge.
11.1.3  Complementary Explorations
All the following studies must be performed 
within 30 days prior to the HSCT except the 
assessment of baseline disease status (7–15 days) 
and the pregnancy test (7 days):
• CBC and basic coagulation; complete bio-
chemistry (including ferritin); blood type and 
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Rh/irregular antibodies; dosage of Igs; serol-
ogy CMV, EBV, VHS, VVZ, toxoplasma, 
syphilis, HBsAg, HBcAb, and anti-HBsAb 
(HTLV-I/II, and Chagas disease according to 
the patient’s origin); NAT for HCV, HBV, and 
HIV; pregnancy test
• Chest x-ray; respiratory function tests (includ-
ing FEV1 and DLCO); electrocardiogram; 
echocardiogram or isotopic ventriculography 
(depending on previous treatment)
• Reevaluation of the disease (MRD) (see spe-
cific chapters in part IX)
• Dental evaluation; gynecological evaluation; 
psychological/psychiatric evaluation
• Nutritional assessment
• HLA typing (recheck) (see Chap. 9)
11.1.4  Risk Assessment
11.1.4.1  Individual Risk Factors
There are a group of variables that have a prog-
nostic value in all predictive models
Variables High risk
Age Older. Do not use as a single 
criterion. Relative importance
General condition Karnofsky index <80%
Disease Not in remission. See specific 
chapters
Type of donor Others than HLA-identical 
siblings
HLA compatibility Any HLA-A, HLA-B, HLA-C, 
and DRB1 difference
CMV serology Different serology than the donor
Donor Age >35–40 years




Prolonged (relevant in CML and 
SAA)
Comorbidities See HCT-CI model
Iron overload Present




11.1.4.2  Predictive Models
Disease Risk Index (DRI) (Armand et al. 
2012, 2014)
Prognostic index based in the disease and its sta-
tus at HSCT. It doesn’t take into account factors 
as age or comorbidities. This score index classi-
fies the disease in four prognostic groups and 
anticipates overall survival, progression-free sur-
vival, cumulative incidence of relapse, and cumu-
lative incidence of non-relapse mortality (see 
Table 11.1).
EBMT Risk Score (Gratwohl et al. 1998, 
2009)
This predictive score, validated with 56,505 
patients, permits to predict approximately the 
5-year probability of OS and the TRM for the 
main diseases (see Tables 11.2, 11.3, and 11.4).
EBMT risk score is also useful to predict OS 
and TRM in patients receiving a second HSCT 
(Rezvani et  al. 2012) and in those receiving a 
TCD HSCT (Lodewyck et al. 2011).
Some authors have introduced modifications 
in this risk score (including the concept of dis-
ease stage) to improve its predictivity (Terwey 
et  al. 2010; Hemmati et  al. 2011). Similarly, it 
has been associated with the HCT-CI (Barba 
et al. 2014).
This score has been validated by many groups 
and for many diseases (AML, ALL, PMF, CLL, 
and CML, among others).
Table 11.1 Disease risk index (Armand 2012, 2014)
Risk Disease
Low AML with favorable cyt., CLL, CML, 
indolent B-cell NHL
Intermediate AML intermediate cyt., MDS 
intermediate cyt., myeloproliferative 
neoplasms, MM, HL, DLBCL/
transformed indolent B-NHL, MCL, 
T-cell lymphoma nodal
High AML adverse cyt, MDS adverse cyt, 
T-cell lymphoma extranodal
Risk Stage
Low CR1, CR≥2, PR1, untreated, CML CP, 
PR≥2 (if RIC)
High PR≥2 (if MAC), induction failure, active 
relapse, CML AP or BP
Disease risk Stage risk Overall risk OS at 4 years
Low Low Low 64% 
(56–70%)
Low High Intermediate 46% 
(42–50%)Intermediate Low
Intermediate High High 26% 
(21–31%)High Low
High High Very high 6 (0–21%)
Adapted from Armand (2012). Cyt. cytogenetics
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Table 11.2 EBMT risk score (Gratwohl 2009)
Variables Value of variables Points
Age <20 years 0
20–40 years 1
>40 years 2













Female to male 1
Other combinations 0
Adapted from Gratwohl (2009)
aDo not apply in patients with SAA. Early = AL in CR1; 
MDS in CR1 or untreated; CML in 1st chronic phase; 
NHL/MM untreated or in CR1. Intermediate = AL in CR2; 
CML in other status than accelerated phase or blastic 
phase; MDS in CR2 or in PR; NHL/MM in CR2, PR, or 
stable dis. Late = AL in other stages; CML in blastic crisis; 
MDS in all other stages; NHL/MM in all other stages
bDo not apply to patients in CR1
Table 11.3 Probability (%) of TRM at 5 years applying 
the EBMT risk score
Points 0 1 2 3 4 5 6–7
AML 14 20 25 30 36 40 41
ALL 15 23 24 30 40 47 53
CML 15 22 30 38 45 52 55
AA 18 26 40 49 52
MDS 25 28 30 35 38 46 50
MM 29 35 40 42 52
NHL 15 24 28 30 34 36 38
Extracted from Gratwohl (2009)
Table 11.4 Probability (%) of OS at 5 years applying the 
EBMT risk score
Points 0 1 2 3 4 5 6–7
AML 68 59 52 38 30 23 18
ALL 66 52 43 38 22 16 14
CML 76 72 60 51 39 26 14
AA 81 72 60 49 45
MDS 56 52 46 40 35 28 25
MM 48 40 36 22 17
NHL 75 59 50 48 43 40 38
Extracted from Gratwohl (2009)
HCT-Comorbidity Index (HCT-CI) (Sorror 
et al. 2005)
Developed in Seattle in 2005. It is an adaptation to 
the HSCT of the classical Charlson Comorbidity 
Index (CCI). Validated in several cohorts and 
widely used. The score analyzes 17 comorbidities 
as well as their degree (see Table 11.5).
Given the impact of age on outcomes, the 
authors modified the model (Sorror et al. 2014), 
including a 1-point score for patients aged 40. 
This modification significantly improved the pre-
dictive capacity of the model. Consequently, the 
patients could be classified in three different risk 
groups (0 points, low risk; 1–2 points, intermedi-
ate risk; 3 or more, high risk) that clearly corre-
lated with 2-year NRM.
Other authors re-stratified the HCT-CI index 
(flexible HCT-CI) as low risk, 0–3 points; inter-
mediate risk, 4–5 points; and high risk, >5 points, 
being this classification a better predictor for 
NRM.  In RIC setting, the 100-day and 2-year 
NRM incidence in these risk categories was 4%, 
16%, and 29% and 19%, 33%, and 40%, respec-
tively. They do find this predictive NRM value 
using neither the original HCT-CI nor the PAM or 
CCI models. Regarding the 2-year OS, this flexi-
ble HCT-CI score was also associated with the 
highest predictive hazard ratio (Barba et al. 2010).
HCT-CI has also been validated in CD34+ 
selected HSCT (Barba et al. 2017) and associated 
with the EBMT risk score that permits a better 
stratification (Barba et al. 2014).
Pretransplantation Assessment 
of Mortality (PAM) Score (Parimon et al. 
2006; Au et al. 2015)
Developed in Seattle in 2006 but underused and 
poorly validated. It combines eight variables 
from patients and HSCT. Only useful for assess-
ing mortality at 2 years.
Variables included age, type of donor, risk of 
disease, intensity of conditioning, DLCO, FEV1, 
creatinine, and ALT.
EBMT Machine Learning Algorithm 
(Shouval et al. 2015)
Based in an alternating decision tree able to 
detect variables associated with the primary 
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outcome, assigning weights and ignoring 
redundancies. This score was developed to ana-
lyze the NRM at day +100  in patients with 
acute leukemia but also predict NRM, LFS, and 
OS at 2 years.
The variables included in the model are age, 
Karnofsky (≥80; <80), diagnostic (AML; ALL), 
disease stage (CR1; CR2; all other stages), inter-
val diagnostic-HSCT (<142 days; ≥142 days), 
donor-recipient CMV status (both (sero +); both 
(sero -); any other combination), donor type 
(MSD; MUD), conditioning (MAC; RIC), and 
annual allo-HSCT performed in the center (<20; 
≥21). The total +100 NRM and 2-year NRM, 
LFS, and OS could be obtained through a web 
page: http://bioinfo.lnx.biu.ac.il/~bondi/web1.
html.
Recently this algorithm has also been vali-
dated by an independent set of data from GITMO 
(Shouval et al. 2017).
11.1.4.3  Predictive Capacity of These 
Models
Unfortunately, all these models have a relatively 
low predictive capacity, and none of them stand 
out more than the rest.
Table 11.5 HSCT-comorbidity index including age variable (Sorror 2005, 2014)
Comorbidity/definition Points
Age ≥ 40 years 1
Arrhythmia
Atrial fibrillation, flutter, sick sinus node syndrome, or ventricular arrhythmias
1
Cardiac
Coronary heart disease, congestive heart failure, IAM, FEVE ≤50%
1
Inflammatory bowel disease
Crohn’s disease or ulcerative colitis that has required treatment
1
Diabetes
Requiring insulin or oral antidiabetic medication in the 4 weeks prior to HSCT
1
Cerebrovascular
CVA or TIA or cerebral thrombosis
1
Psychiatric
Depression or anxiety or others requiring ongoing treatment (not on demand)
1
Mild liver
Chronic hepatitis, elevated bilirubin <1.5 × NV or AST/ALT <2.5 × NV






Infection in admission requiring continuation of treatment beyond day 0
1
Moderate lung
DLCO and/or FEV1 66–80% or minimal stress dyspnea
2
Rheumatology
Systemic lupus, rheumatoid arthritis, polymyositis, polymyalgia rheumatica, connective tissue disease
2
Peptic ulcer
Endoscopic or radiological diagnosis (does not score if only reflux or gastritis)
2
Renal
Creatinine >176 mcmol/L, dialysis, or previous kidney transplant
2
Previous tumora
Neoplasia at some point (excludes non- melanoma skin tumor)
3
Heart valve
Diagnosed (except mitral prolapse)
3
Severe pulmonary
DLCO and/or FEV1 ≤%, dyspnea at rest or oxygen at home
3
Severe liver disease
Bilirubin ≥0.5 for VN or AST or ALT ≥0.5 for VN or cirrhosis
3
aA most recent version also includes in this category hematological/tumors of a different lineage to that which motivates 
the transplant (e.g., lymphoma in an AML patient but not previous MDS in AML patient)










Xhaard (2008) rHCT-CT, PAM 0.49, 0.57
Gratwohl (2009) EBMT 0.63
Barba et al. 
(2010)
fHCT-CI, PAM 0.67, 0.63
Barba et al. 
(2014)
HCT-CI, EBMT 0.60, 0.54
Versluis (2015) (HCT-CI-EBMT) 0.58, 0.58 (0.64)
Courtesy of P.  Barba, MD. rHCT-CI  =  reduced model, 
without PFTs; fHSCT = flexible model (modified scale)
11.1.5  Practical Applications of Risk 
Assessment
Election of the 
conditioning
In patients with a high risk of NRM 
following one of the mentioned risk 
scores, a RIC should be considered
Relative 
contraindications
Uncontrolled infection, severe or 
chronic liver disease (excluding 
cirrhosis), severe disturbances in 
heart function (FEV <40%), 





Cirrhosis. Even compensated 
cirrhosis receiving RIC have a high 
likelihood of hepatic 
decompensation (Hogan et al. 
2004)
11.2  Counseling of Candidates
Alessandro Rambaldi
11.2.1  Introduction
Allo-HSCT is a potentially curative treatment 
modality for otherwise incurable diseases. 
Unfortunately, after transplantation patients 
may experience not only the persistence or 
recurrence of their own disease but also some 
dramatic clinical complications and toxicities, 
including death. The clinical indications to 
transplant have been addressed in the section 
“indications” of this book, but in general, when 
the allo-HSCT is advised, the strength of the 
indication (the likelihood to be cured by trans-
plant), the patient fitness, and his/her personal 
commitment to transplant must be carefully 
evaluated for each candidate.
Obviously, a first distinction must be done 
between patients with a neoplastic versus a 
non- neoplastic disease, and the transplant 
option should be progressively discussed with 
the patient during the course of the disease, 
particularly in the case of hematologic malig-
nancies. Many professionals should concur to 
illustrate the patients the curative potential of 
an allo- HSCT and to help understanding the 
severe complications that can eventually 
develop. It is clear that different indications 
remarkably affect the way a patient is advised. 
However, there is a time when the transplant 
option must be formally presented and advised. 
Therefore, evaluation of each transplant candi-
date must be based on well- predefined formal 
standard operating procedures to collect 
exhaustive clinical, instrumental, and labora-
tory data that may lead to a robust definition of 
the risks and benefits related to allo- HSCT. All 
in all, the counseling is to tailor such evalua-
tion to the individual patients (Shouval et  al. 
2015), according to both objective data and 
subjective data such as patient propensity and 
fear of side effects. At the end of this process, 
the patient should be aware of the rationale, the 
Key Points
•  The evaluation of a candidate must be 
carried out according to a preestablished 
work plan designed by each institution. 
The use of standardized procedures 
reduces the risk of errors or omissions
•  Several pretransplant variables (such as 
age) have a clear impact on the results of 
the procedure but, when assessed in iso-
lation, are highly insufficient to predict 
the results
•  Predictive models (DRI, EBMT risk 
score, HCT-CI, PAM) allow a much 
more realistic approach to the real possi-
bilities of a given candidate and adapt the 
procedure to their needs
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benefit and the toxicity associated with each 
step, and component of the transplant proce-
dure. In this chapter, I will hereby summarize 
the main topics I cover with my patients when 
they come to my office to discuss the option of 
the allo-HSCT.
11.2.2  Understanding the Benefit 
and Risk of Allogeneic 
Transplant
Patients must be informed that allo-HSCT is a 
therapeutic option that is always proposed with 
the intent to achieve a permanent cure of the 
underlying disease, but despite this premise, dis-
ease progression or relapse may eventually hap-
pen. The indication to allo-HSCT depends not 
only on the disease characteristics but also on 
patient-related factors such as age and comor-
bidities (Sorror et al. 2007) so that the transplant 
proposal is the result of an accurate and wise 
evaluation of both these factors (Sorror et al. 
2013; Wang et al. 2014).
The patient should understand the specific 
risk/benefit balance associated with a conven-
tional versus a transplant-based proposal, and 
this may be remarkably different if he has been 
diagnosed with a non-neoplastic disease such 
as thalassemia or sickle cell anemia, a bone 
marrow failure syndrome like aplastic anemia, 
or a blood cancer, such as an acute leukemia. 
Even when allo-HSCT may in theory represent 
the most efficacious treatment modality to get a 
permanent cure of a specific disease, an accu-
rate description of the available alternatives 
must be presented. This is particularly impor-
tant when the non- transplant options, albeit not 
curative, may have the chance to keep the 
patient alive for a long time (Samuelson 
Bannow et al. 2018) or, even more importantly, 
when the conventional treatment may lead to a 
definitive cure such as in the case of some 
patients with acute leukemia with intermediate-
risk genetic factors or those achieving a deep 
molecular remission after conventional chemo-
therapy (Cornelissen and Blaise 2016).




Once the indication to transplant has been con-
firmed, patients and their relatives must be 
informed on how the transplant is performed. 
Patients should understand that identifying a stem 
cell donor is an absolute prerequisite to perform a 
transplant. Accordingly, patients should be 
informed about the human leukocyte antigen 
(HLA) genetic system, its specificity for each indi-
vidual, how it is inherited by parents according to 
the Mendelian laws, and what is the probability to 
find a compatible donor in the family group. 
Understanding the HLA system is crucial to 
explain why the use of a HLA family-matched sib-
ling donors is considered standard and when such 
a sibling is not available; an international search 
has to be performed to identify a HLA- compatible 
unrelated donor. It is important to underline that 
more than 30 million of potentially available 
donors are registered by the World Marrow Donor 
Association (WMDA), and the probability to find 
a compatible donor is between 50 and 80% accord-
ing to the ethnical origin of each patient.
Once such matched unrelated donor is identi-
fied, this type of transplant is considered a stan-
dard of care, and its clinical outcome is fully 
comparable to what was observed when using an 
HLA-identical sibling. In patients for whom a 
MSD or a MUD is not available, the patient 
should be informed that two additional options 
are available, namely, the use of HSC obtained by 
a family mismatched donor (commonly defined 
as haploidentical because sharing only one of the 
patient’s HLA haplotypes) or a banked cord 
blood units. Patients should understand how the 
HLA diversity between patient and donor has 
been overcome by specific programs of in vitro 
or in vivo manipulation of the graft.
Patients should be reassured that the incidence 
and severity of GvHD, the most important side 
effect of allo-HSCT, seems not to be higher than 
observed with MUD. In addition, patients should 
know that many single-arm studies reported that 
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transplants performed with these alternative stem 
cell sources proved to be effective and safe even 
when offered to patients of advanced age and/or 
with existing accompanying illnesses or when the 
disease was refractory to conventional treatment. 
All in all, at the present time, the clinical out-
come of these alternative types of transplants 
compares reasonably well with those achieved 
with MUD.  Therefore, the decision to use this 
type of stem cell source only when an HLA- 
matched donor is not available is mostly related 
to the lack of randomized clinical trials that are 
planned to be performed in the near future.
The goal of an allo-HSCT is to eradicate the 
patient’s hematopoiesis either neoplastic or nor-
mal. This is achieved by the delivery of the con-
ditioning regimen and by the lifelong in  vivo 
effect played by the donor’s immune system. 
Most often, high doses of chemotherapy and/or 
radiation are included in the preparations 
although remarkable differences exist depending 
on the disease needing transplant and patient tol-
erance. The patient should understand that the 
intensity of the conditioning regimen may be par-
ticularly important in the case of hematologic 
malignancies when the aim to remove most of the 
neoplastic cells present in the patient’s body is 
the first goal. However, to avoid at least part of 
the treatment toxicity, the intensity of the prepar-
ative regimen can be down-modulated leading to 
the definition of this preparative regimen as non- 
myeloablative or reduced intensity. The depletion 
of the patient bone marrow stem cells induces a 
prolonged pancytopenia and the need of donor- 
derived healthy stem cells to grow and establish a 
new blood cell production system.
The allogeneic HSC, collected from the 
donor’s BM or PB or a frozen CBU, are infused 
through the central venous catheter into the 
bloodstream: HSCT is not a surgical procedure 
and it is very similar to receiving a blood transfu-
sion. The stem cells find their way into the bone 
marrow and begin reproducing and growing new, 
healthy blood cells. It is very important to explain 
how the donor immune system will develop pro-
gressively after transplantation and will either 
exert a crucial beneficial role against residual 
neoplastic cells or restore the immune compe-
tence against infections, but it could mediate the 
most harmful GvHD effect against the patient.
After the transplant, supportive care is given to 
prevent and treat infections, side effects of treat-
ments, and complications. Prolonged anemia, 
thrombocytopenia, and leukopenia can be danger-
ous and even life-threatening. A low platelet count 
can be potentially associated with bleeding in the 
lungs, GI tract, and brain. Leukopenia, including 
either a defect of neutrophils and lymphocytes, 
leads to the development of frequent infections, the 
most common clinical complications after trans-
plantation. Infections can include not only bacte-
rial, most likely when the patient has a severe bone 
marrow suppression, but also viral and fungal 
pathogens. Infections can require an extended hos-
pital stay, prevent or delay engraftment, and/or 
cause permanent organ damage. On average the 
time to hematologic engraftment (recovery of the 
neutrophil and platelet function) is about 2–3 
weeks, but a protective recovery of the immune 
system can take months and sometimes years. High 
doses of chemotherapy and radiation can cause 
remarkable toxicities that include but not limited to 
severe mucositis (inflammation of the mouth and 
GI tract) that favors bacterial translocation with 
related infections and GvHD and multi- organ fail-
ure mainly the lung, heart, liver, and kidney.
A particular attention should be paid to risk of 
graft failure that can occur early or late after trans-
plantation. A graft failure is more frequent in some 
diseases such as myelofibrosis or as the results of 
infections or when the stem cell content of the 
graft is insufficient to guarantee a durable engraft-
ment. A graft rejection can also happen after 
reduced intensity conditioning regimen (when the 
immune system of the host is not completely erad-
icated and can actively reject the donor stem cells).
Finally, and most importantly, patients must 
be aware of what GvHD is, when and how it may 
develop, and why it represents the most serious 
complication of a HSCT, being not only life- 
threatening but also the principal reason of a 
long-lasting poor quality of life. Transplant can-
didates should be aware that GvHD is the nega-
tive counterpart of the deep interaction of the 
donor immune system within patient body that at 
the same time may lead to definitive cure of an 
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otherwise incurable disease. In other words, 
when transplant is advised, patients must realize 
that they are accepting the possible onset of a 
chronic, often invalidating, autoimmune disease. 
GVHD can appear at any time after transplant. 
GvHD is conventionally distinguished in an acute 
form that usually develops within the first 100 
days after transplant and the chronic form that 
occurs later in the transplant course. Patients who 
develop acute GVHD are more likely to also 
develop the chronic form of GVHD.  Patients 
must understand the importance of their compli-
ance to all the treatments given post transplant to 
prevent GvHD and how this is instrumental for a 
successful transplant. GvHD occurs when the 
donor’s immune system reacts against the recipi-
ent’s tissue. At variance to what happens after a 
solid organ transplant where the patient’s immune 
system is driven to reject only the transplanted 
organ, in GVHD, the donor immune system can 
react against many different organs of the recipi-
ent. This is why the new cells do not recognize 
the tissues and organs of the recipient’s body as 
self. Over time, thanks to the effect of immune 
suppressive drugs, a progressive tolerance can 
develop. The most common sites for GVHD are 
the GI tract, liver, skin, and lungs.
11.2.4  Logistics
After discharge for the transplant ward, patients 
are followed up in the outpatient clinic two to 
three times per week until day +100. Patients 
should be helped to realize how complex is the 
transplant procedure and that the time spent in the 
hospital represents only the first part of the treat-
ment program. All allo-HSCT patients should ide-
ally stay within 1 h of the hospital until it is about 
3 months from the day of the transplant. Patients 
and their families should also realize that the 
overall recovery time varies from person to per-
son and in general this process takes about 1 year 
to be satisfactory. Allogeneic transplantation is 
therefore a long-lasting immunotherapy, and the 
interaction between the donor immune system 
and the patient requires a careful and prolonged 
medical assistance, quite often long life.
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It is known that multiple factors impact on trans-
plantation outcome; the heaviest ones are disease- 
related (disease refractoriness, phase, clonal 
abnormalities, etc. in malignancies and disease 
type and associated rejection risk in non-malig-
nant diseases) and patient-related (age, comor-
bidities, infectious diseases/colonization, etc.). 
Moreover, donor-related issues and stem cell 
source may influence the extent of disease con-
trol and transplant-related mortality.
The availability of a suitable stem cell graft is 
an absolute prerequisite for the performance of 
allo-HSCT.  Beyond donor-recipient histocom-
patibility, other factors such as stem cell source, 
donor age and gender, donor-recipient CMV sta-
tus, and ABO compatibility may play a role on 
transplant outcome.
In this chapter we discuss results of studies 
investigating these factors and conclude with an 
algorithm for donor selection. Issues which are 
peculiar to pediatric recipients are also analyzed 
and discussed.
12.2  Donor HLA Compatibility 
(See Chap. 9)
The outcome of HSCT depends in part on the 
matching between the donor and the recipient for 
the human leukocyte antigens (HLA), encoded 
by a group of genes on chromosome 6; genes and 
products are labelled as major histocompatibility 
complex (MHC). The HLA system is the most 
polymorphic genetic region known in the human 
genome. A set of HLA gene alleles, called haplo-
type, is inherited from each parent; therefore, the 
probability that a child inherited and shares both 
parental haplotypes with a full sibling is 25%. 
Such HLA-identical sibling is still considered an 
optimal donor.
The most relevant genes for transplantation 
belong to class I (HLA-A, HLA-B, and HLA-Cw) 
and class II (HLA-DR, HLA-DQ, and HLA-DP). 
HLA compatibility with the donor is usually 
defined by high-resolution typing (four digits) for 
ten alleles, HLA-A, HLA-B, HLA-C, HLA-DR, 
and HLA-DQ (Petersdorf 2013), even though 
there is an increasing evidence supporting the rel-
evance of DPB1 matching (reviewed by 
Fleischhauer and Shaw 2017).
The concept of “compatibility” for CB 
donor- recipient pairs is still under debate. Any 
CB unit which was 6/6 or 5/6 matched was 
labelled HLA compatible (MD), in the past as 
defined by low-resolution typing at A and B loci 
and high- resolution typing at the DRB1 locus; 
more recently, high resolution for at least A, B, 
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C, and DRB1 loci is requested, and progres-
sively the same criteria used for volunteer 
donors are considered to define CB HLA match-
ing (Eapen et al. 2017).
12.3  Donor Selection for Adult 
Patients
12.3.1  Donor Type (Summarized 
in Fig. 12.1)
12.3.1.1  Matched Related Siblings 
and Unrelated Donors
Donor-recipient histocompatibility is one of 
the key variables in allo-HSCT.  An HLA-
identical sibling donor is generally considered 
the best donor for allo-HSCT; however less 
than a third of patients will have one available. 
Unrelated donor registries worldwide now 
include more than about 30 million volunteer 
donors, most of them in North America and 
Europe (www.bmdw.org). The probability of 
finding a fully MUD (8/8 or 10/10) varies on 
average between 16% and 75% (Gragert et al. 
2014; Buck et al. 2016) depending on ethnic-
ity, with lowest and highest probabilities in 
patients of African and European descent, 
respectively. Increasing ethnic diversity will 
with time further limit the chances of finding a 
fully matched unrelated donor.
Till date no randomized trial has compared 
outcome of transplants from different donors. 
However, one prospective (Yakoub-Agha et al. 
2006) and several retrospective analyses indi-
cate that outcomes after MSD and fully MUD 
(8/8 or 10/10) HSCT are comparable (Schetelig 
et al. 2008; Szydlo et al. 1997; Arora et al. 2009; 
Ringden 2009; Gupta et  al. 2010; Woolfrey 
et al. 2010; Saber et al. 2012). Increase in donor-
recipient HLA disparity in HLA-A, HLA-B, 
HLA-C, or HLA-DRB1 is associated with 
poorer outcome after unrelated donor transplan-
tation (Lee et  al. 2007; Shaw et  al. 2010; 
Woolfrey et  al. 2011; Horan et  al. 2012; Fürst 
et  al. 2013; Pidala et  al. 2014; Verneris et  al. 
2015). The overall decrease in survival can be 
explained by the increase in NRM with no posi-
tive effect on relapse. Disparities in HLA-DQB1 
as well as C-allele disparities in C*03:03 vs 
03:04 have been reported to be permissive with 
no negative effects on outcome (Lee et al. 2007; 
Fürst et al. 2013; Morishima et al. 2015; Pidala 
et al. 2014; Crivello et al. 2016). Disparities in 
HLA-DPB1 are observed in the majority of 
HLA-A, HLA-B, HLA-C, and  HLA- DQB1 
Algorithm for donor selection for adult patients with hematological malignancies
HLA-identical sibling donor
HLA-10/10 matched unrelated donor
Beyond HLA: donor age> CMV-matching, sex-matching, ABO-matching
HLA-9/10 matched unrelated donor;
HLA-mismatched related donor; cord blood Beyond HLA: donor specific antibodies, specific center experience
Fig. 12.1 Algorithm for donor selection
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(10/10) MUD transplants. Nonpermissive mis-
matches in DPB1 defined according to T-cell 
epitope matching (Zino et al. 2004; Crocchiolo 
et  al. 2009; Fleischhauer et  al. 2012; Pidala 
et al. 2014; Oran et al. 2018) or allele cell-sur-
face expression levels (Petersdorf et  al. 2015) 
are associated with poorer outcome compared to 
full matches or permissive mismatches. 
Associations of permissive DPB1 mismatches 
with lower relapse incidence are currently being 
explored (Fleischhauer and Beelen 2016; 
Fleischhauer and Shaw 2017).
12.3.1.2  Haploidentical Related 
Donors
Improvements in transplant technology including 
pre-transplant ATG (Huang et al. 2006), PT-CY 
(Luznik et  al. 2008), and alpha-beta TCD 
(Bertaina et al. 2014) have led to improved out-
come and rapidly increasing use of haploidenti-
cal related donor transplantation (Passweg et al. 
2014). Several retrospective comparison studies 
have reported similar outcome for haploidentical 
and MUD transplants (summarized by Fuchs 
2017). The results of prospective comparative tri-
als are eagerly awaited.
12.3.2  Role of Non-HLA Donor 
Characteristics
Besides donor-recipient histocompatibility, 
donor age is now considered one of, if not the 
most relevant, the non-HLA donor characteristics 
in unrelated donor HSCT (Kollman et al. 2001, 
2016; Wang et  al. 2018) with a 2-year survival 
being 3% better when a donor 10 years younger 
is selected (Shaw et  al. 2018). These findings 
have impacted daily practice such that the per-
centage of selected donors under 30 years of age 
has increased from 36% in the period 1988–2006 
to 51% in 1999–2011 up to 69% in 2012–2014 
(Kollman et al. 2016).
Matching for patient/recipient CMV serosta-
tus also seems to be a determinant of transplant 
outcome with best outcome seen in seronegative 
patients receiving seronegative grafts (Ljungman 
2014; Kalra et al. 2016; Shaw et al. 2017).
The impact of sex mismatch on outcome is 
more controversial, possibly reflecting different 
definitions of sex mismatch, which has been con-
sidered only for male recipients (Gratwohl et al. 
2009, 2017; Nakasone et  al. 2015) or for both 
male and female in others (Kollman et al. 2016). 
Interestingly, all three studies confining sex mis-
match to male recipients reported a significant 
impact for this variable, albeit possibly depen-
dent on conditioning regimen.
The impact of ABO (blood group) compatibil-
ity on outcome has been reported to be modest 
and seems to have further diminished in recent 
years probably due to changes in transplant prac-
tice including less frequent use of bone marrow 
grafts (Seebach et al. 2005; Kollman et al. 2016; 
Shaw et al. 2018).
The impact of non-HLA donor characteristics 
may be less conspicuous in matched and mis-
matched related donor transplantations using 
PT-CY. It must however be taken into consider-
ation that the close association of donor age and 
donor-patient relation on the one hand with 
patient age on the other hand makes these analy-
ses more complex (McCurdy et  al. 2018; 
Robinson et al. 2018). Larger patient cohorts and 
prospective studies are required for more definite 
conclusions.
12.3.3  Donor Choice According 
to Stem Cell Source
The three graft sources for allo-HSCT are BM, 
PBSC, and CB.  In matched related donor and 
unrelated donor HSCT, survival outcome has 
been similar for BM and PBSC. However hema-
tological recovery is more rapid and graft rejec-
tion less frequent after PB compared to BM 
HSCT, while the incidence of chronic GvHD 
and, to a lesser extent, acute GvHD tends to be 
higher after PB HSCT (Bensinger et  al. 2001; 
Couban et al. 2002; Schmitz et al. 2002; Couban 
et al. 2016; Anasetti et al. 2012). In allo-HSCT 
for nonmalignant diseases, in particular for SAA, 
BM is still the preferred stem cell source in high- 
income countries, despite improvements in out-
come after PB HSCT (Schrezenmeier et al. 2007; 
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Chu et al. 2011; Bacigalupo et al. 2012; Kumar 
et al. 2016).
Traditionally BM has been used as stem cell 
source for haploidentical HSCT with PT-CY 
(Luznik et al. 2008), while GCSF-stimulated BM 
has been used for haploidentical HSCT with ATG 
(Huang et al. 2006) and PBSC for haploidentical 
HSCT with alpha-beta T-cell depletion (Bertaina 
et  al. 2014). There are no prospective studies 
comparing different stem cell sources within 
these strategies. When PT-CY is used, PBSC 
seems to be associated with a higher risk of acute 
and chronic GvHD and lower risk of relapse in 
patients with leukemia (Bashey et al. 2017).
The use of umbilical CB grafts continues to 
decrease with the rise in numbers of haploidenti-
cal transplants performed (Passweg et al. 2014). 
Due to the limited number of stem cells per unit, 
CB grafts have been more frequently used in 
pediatric HSCT and will be discussed in that sec-
tion and in the specific CB Chapter.
12.3.4  Anti-HLA Antibodies
The abovementioned improvements in transplant 
technology have led to an increased use of grafts 
from HLA-mismatched donors. Detection of 
donor-specific anti-HLA antibodies in the 
patients’ serum has been associated with 
increased risk of graft failure and also poorer sur-
vival of those patients with graft failure (Ciurea 
et al. 2015) after haploidentical HSCT. The risk 
of graft failure and overall mortality may how-
ever also depend on the type and intensity of 
TCD used. The EBMT recently published a con-
sensus guideline on detection and treatment of 
donor-specific antibodies in haploidentical HSCT 
(Ciurea et al. 2018).
12.4  Donor Selection for Pediatric 
Patients
Donor selection criteria may vary between adult 
and pediatric recipients. According to the “motto” 
of the Pediatric Disease Working Party, “children 
are not small adults,” besides the size, what 
makes HSCT in children different is mainly 
related with indications and the biology of a 
growing individual.
12.4.1  Pediatric Recipient Size
In terms of size, the recipient weight may vary 
between few Kg in most patients transplanted for 
immunodeficiencies and a full adult size in some 
adolescents. The recommended cell dose in the 
graft is shown in Table 12.1 (Gluckmann 2012). 
The lower the recipient weight, the smaller is the 
amount of the requested absolute count in the 
graft, which makes the harvest easier, often 
matching the transplant center requests. An 
appropriate cell dose in the graft yields a lower 
risk of rejection, which is actually lowest in 
pediatrics. On the other hand, the lower amount 
of cells requested to ensure engraftment in chil-
dren makes CB a more valuable source than in 
adults.
12.4.2  Indications
In terms of indications, according to the EBMT, 
nowadays 46% of the patients younger than 18 
years who undergo HSCT are affected with non-
malignant diseases (Passweg et  al. 2014), which 
are mainly inherited disorders, namely, immuno-
deficiencies, hemoglobinopaties, inborn errors of 
Table 12.1 Number of cells according to stem cell source
Volume collected Med CD34 content Med CD3 content Target cell dose
Bone marrow 10–20 mL/kg 2–3 × 106/kga 25 × 106/kg >2 × 108 TNC/kg
Peripheral blood 150–400 mL 8 × 106/kg 250 × 106/kg 5–10 × 106 CD34+/kg
Umbilical cord blood 80–160 mL 0.2 × 106/kg 2.5 × 106/kg >3 × 107 TNC/kg
aPer kg recipient body weight
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metabolism, and congenital bone marrow failures. 
As nonmalignant diseases do not benefit of any 
alloreactivity, the closest HLA matching (possibly 
“10 out of 10” HLA alleles) is recommended. On 
the contrary, a small degree of HLA incompatibil-
ity is tolerated in malignancies, as the detrimental 
effect of HLA disparity, triggering higher risk of 
GvHD and consequent higher risks of toxicity and 
mortality, might be counterbalanced by the so-
called “graft-versus- leukemia” or “graft-versus-
tumor” effect, which is the alloreactivity of 
immunocompetent donor cells potentially eradi-
cating residual malignant cells in the patient and 
playing a role in the prevention of malignant dis-
ease recurrence.
12.4.3  Donor Type
Due to the decreasing size of modern families in 
the so-called Western countries, HLA-identical 
siblings are available in less than 25% of the chil-
dren in need of a transplant, as shown by the few 
studies performing a “randomization by genetic 
chance,” based on the availability of an HLA- 
identical sibling or not (Balduzzi et al. 2005). As 
a consequence, 75% of the patients may need to 
run a search for an unrelated donor.
Eligibility criteria for HSCT in malignant dis-
eases varied overtime, resulting from the balance 
between the outcome of frontline and relapse 
chemotherapy protocols and the outcome of 
transplantation, which partially depends on the 
degree of compatibility within each donor- 
recipient pair. Similarly, the eligibility for trans-
plantation in nonmalignant diseases increased as 
the safety profile of the procedure improved. 
Some patients are considered eligible for trans-
plantation only in case an HLA-identical sibling 
is available; as the risk profile of the patient wors-
ens, a broader degree of HLA mismatching is 
considered acceptable.
Within the International BFM Study Group, 
regardless of their relationship with their recipi-
ent, donors are defined as HLA-matched (MD) if 
the donor-recipient pairs are fully matched 
(10/10) or have a single allelic or antigenic dis-
parity (9/10) or are defined mismatched donor 
(MMD) if the donor-recipient pairs have two 
(8/10) or more allelic or antigenic disparities, up 
to a different haplotype (Peters et al. 2015). Any 
donor who is not an HLA-identical sibling or a 
MD, as defined above, is considered a MMD. Both 
MD and MMD could be either related or unre-
lated to their recipient. A related donor who is not 
an HLA-identical sibling is actually regarded as a 
MD, and GvHD prophylaxis is planned accord-
ingly (Peters et al. 2015).
Recently, results from a BFM study showed 
that transplantation from a “10 or 9 out of 10” 
matched donor, either related or unrelated, was 
not inferior to transplantation from an HLA- 
identical sibling in terms of EFS, OS, and CIR in 
pediatric patients with ALL (Peters et al. 2015). 
As a consequence eligibility criteria for HSCT 
might be reviewed and extended to those for 
MSD HSCT, at least in ALL, and, possibly, con-
sidered for other malignant diseases. Therefore, 
an unrelated donor search activation and trans-
plantation might be recommended in the future 
virtually for every child for whom an allo-HSCT 
is indicated. Disparities within donor-recipient 
pairs are progressively accepted as the risk pro-
file of the patient increases.
Unfortunately some inherited disorders, in 
particular sickle cell disease (Gluckman et  al. 
2017) or other recessively inherited disease, 
which incidence is highly increased by a parental 
blood relation, have higher incidences in non- 
Caucasian ethnicities, which are less represented 
within stem cell donor banks. The consequence is 
that well-matched donors often lack when a per-
fect matching is crucial; progresses in haploiden-
tical HSCT broadened its indications and may 
overcome this issue.
Depending on each transplant center experi-
ence, MMD might be preferred, carrying the 
advantage of prompt donor availability and flex-
ible schedule and bringing higher degree of allo-
reactivity, potentially associated with lower 
relapse risk. HSCT from MMD is widely recom-
mended when timing adjustment is crucial, as in 
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advanced disease phase in malignancies and in 
case of post transplant relapse.
12.4.4  Haploidentical Donors 
in Pediatrics
Successful haploidentical HSCT mainly evolved 
in pediatrics over the last two decades from 
ex vivo T-cell depletion by CD34+-positive selec-
tion, to CD34+-negative selection, up to selective 
CD3 αβ depletion, to allow other cells in the 
graft, potentially protecting from viral infections 
(Handgretinger et  al. 2001; Klingebiel et  al. 
2010). In pediatrics, an improved immune recov-
ery after TCR αβ-depleted haploidentical HSCT 
(Lang et  al. 2015), a similar outcome between 
TCR αβ-depleted and matched sibling and 
matched unrelated donors HSCT in children with 
acute leukemia (Locatelli et al. 2017) and in non-
malignant diseases (Bertaina et  al. 2014), was 
recently reported and confirmed by a multicenter 
phase I/II study (Lang et  al. 2017). Moreover, 
some reports of PT-CY in pediatric show promis-
ing results (Jaiswal et  al. 2016; Sawada et  al. 
2014; Wiebking et al. 2017).
One of the parents mostly serves as a donor in 
haploidentical donors for pediatric recipients. 
The choice between the mother and the father is 
still debated. Better survival was shown in 
patients transplanted from the mother than from 
the father (51% vs 11%; P < 0.001), due to both 
reduced incidence of relapse and TRM, with a 
protective effect on the risk of failure (HR 0.42; 
P = 0.003), possibly explained by transplacental 
leukocyte trafficking during pregnancy, inducing 
long-term, stable, reciprocal microchimerism in 
mother and child (Stern et al. 2008).
As donor-derived alloreactive NK cells have 
been shown to play a key role in the eradication 
of leukemic cells, favorable NK matching should 
guide donor selection (Stringaris and Barrett 
2017; Mavers and Bertaina 2018). Moreover, 
anti-HLA antibodies should be checked and 
accounted for to guide donor selection.
12.4.5  Stem Cell Source
BM is usually recommended as stem cell source. 
A donor with a body weight allowing for a graft 
containing at least 3  ×  108 nucleated cells/kg 
recipient body weight and 3 × 106 CD34+ cells/
kg body weight should be selected, in order to 
yield more than 95% neutrophil engraftment 
chances at a median of 21 days in the setting of 
hematological malignant diseases (Simonin et al. 
2017).
It is rare in pediatrics to require PB just in 
order to obtain an adequate amount of cells to 
ensure engraftment, as the absolute cell dose 
needed rarely overcomes the maximum amount 
which could be harvested from a donor. As higher 
numbers of CD3 cells are obtained in PB grafts, 
it is recommended not to exceed an amount of 
10 × 108 CD3+ cells/kg recipient body weight.
The increased risk of chronic GvHD, and pos-
sibly acute, after PBSC transplantation, as com-
pared to BM, is commonly reported. In a recent 
European retrospective study, including 2584 
pediatric patients transplanted from 2003 to 2012 
for ALL, both TRM and chronic GvHD appeared 
significantly higher after PBSC, as compared 
with other SC sources, despite the overall sur-
vival was similar for both stem cell sources 
(Simonin et  al. 2017). In the prospective ALL- 
SCT- BFM 2003 study, the same OS was reported, 
and no difference could be demonstrated in TRM, 
acute GvHD, and relapse, whichever the stem 
cell source in the two cohorts of patients trans-
planted from HLA-identical siblings and other 
matched donors. Nevertheless, within patients 
transplanted from HLA-identical siblings, the 
cumulative incidence of chronic GvHD was 
higher in PB compared with BM recipients 
(Peters et al. 2015).
Reinforced GvHD prophylaxis may be recom-
mended when PBSC are used, mainly when no 
serotherapy is included as for GvHD prophy-
laxis, as in most protocols in the HLA-identical 
sibling setting in malignancies (Simonin et  al. 
2017).
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Nowadays, in the ongoing prospective ALL-I- 
BFM HSCT trial (FORUM), the algorithm for 
choosing stem cell source recommends BM as 
the first choice. To date, there is no demonstration 
for a better GVL effect after PB HSCT in the 
pediatric population.
Due to the increased risk of cGvHD after PB 
transplant, which is almost consistent among 
investigators, it is definitely recommended to 
avoid PB in nonmalignant disorders.
From the first CB transplantation performed 
for a Fanconi anemia patient in 1987, CB 
appeared as a useful and an efficient stem cell 
source, due to two major features: high prolifera-
tive capacity, allowing engraftment despite 1-log 
fewer cells, and immune plasticity, allowing a 
wider HLA disparity within each donor recipient 
pair (Gluckman et al. 1989).
The possibility to adopt less stringent HLA- 
matching criteria enlarged the availability of 
grafts to at least 90% of the pediatric patients in 
need of an allogeneic transplant (Eapen et  al. 
2017). According to Eurocord consortium rec-
ommendations, unrelated CB with two or less 
HLA disparities typed in low resolution (i.e., two 
digit) for class I (A and B loci) and high resolu-
tion (i.e., four-digit) for class II (DRB1 locus) 
and with more than 2.5 × 107 nucleated cell dose/
kg or 2  ×  105 CD34+ cells/kg are suitable for 
engraftment (Gratwohl et al. 2009). Recent stud-
ies from both Eurocord, NetCord, EBMT, and 
CIBMTR recommend high-resolution HLA typ-
ing for A, B, C, and DRB1 and a maximum of 1 
or 2 mismatched loci with a cellularity of 3 × 107 
TNC/kg or higher (Eapen et al. 2014).
Two prospective studies could demonstrate no 
benefit of double CB in pediatric patients trans-
planted for malignant diseases (Wagner et  al. 
2014; Michel et al. 2016).
12.4.6  Other Donor-Recipient- 
Related Factors
Besides HLA compatibility and stem cell source, 
also donor age, gender, female parity, weight, 
ABO blood group, and viral serological status 
should be considered in the decision-making pro-
cess for donor selection, whenever more than one 
donor were available, which may not be often the 
case (Wang et al. 2018).
Most studies report that a young donor is better 
than an older one. Few studies also report that a 
male donor is better for a male recipient and better 
than a multiparous woman for any recipient, even 
though this finding is not consistent through the 
literature. The donor gender effect may be mild 
and need larger series of patients to be demon-
strated (Friedrich et al. 2018). Unfavorable weight 
disparity, with donors weighing less than their 
recipient, should be avoided, when possible 
(Styczynski et  al. 2012). CMV- IgG, as well as 
EBV-positive patients, should be grafted from 
CMV- and EBV-positive donors, respectively 
(Jeljeli et  al. 2014; Bontant et  al. 2014). ABO 
matching is usually preferred, especially instead 
of a major or even minor incompatibility (Booth 
et al. 2013). Donor location might also be consid-
ered, as oversea deliveries increase the time elaps-
ing between collection and infusion, thus reduce 
cell viability and potentially jeopardize engraft-
ment. More recently, KIR genotyping would 
allow to identify alloreactive donors who may 
contribute to prevent relapse also in the non-hap-
loidentical setting (Mavers and Bertaina 2018).
Even though it is mainly clear which variant 
should be preferred within each variable, there is 
no consensus regarding the hierarchical order by 
which the factors above should be combined. In a 
recent survey within the Pediatric Diseases 
Working Party of the EBMT, the features above 
were listed in the following order of importance, 
on the average, but evaluations widely differed 
among responders:
 1. HLA compatibility, with 10/10 better than 
9/10 or worse matching
 2. CMV serological status of positive donors in 
case of positive recipients
 3. BM as stem cell source
 4. Donor age, being preferable a younger donor 
compared with an older one
12 Donor Selection for Adults and Pediatrics
94
 5. Donor gender, with a male donor preferred, 
particularly for a male recipient
 6. ABO major compatibility
 7. Donor center location
 8. ABO minor compatibility (unpublished data)
Moreover, the presence of anti-HLA antibod-
ies directed to any mismatched HLA alleles 
should be ruled out, mainly in heavily transfused 
nonmalignant diseases, such as hemoglobinopat-
ies or bone marrow failures (Ciurea et al. 2018).
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HSCT is a therapeutic procedure that can cure and/
or prolong life in a broad range of hematologic dis-
orders including malignant and nonmalignant 
pathologies. Conditioning is the preparative regi-
men that is administered to the patients undergoing 
HSCT before the infusion of the stem cell grafts. 
Historically, the pre-HSCT conditioning had to:
 1. Eradicate the hematologic malignancy in case 
of malignant indication for HSCT.
 2. Provide sufficient IS to ensure engraftment 
and to prevent both rejection and GVHD.
 3. Provide stem cell niches in the host BM for 
the new stem cells.
The third purpose is controversial as it was dem-
onstrated in animal models that with mega doses of 
HSC and repeated administrations engraftment can 
be achieved without conditioning.
From the theoretic point of view, the condi-
tioning consisted of two components:
 1. Myelo-depletion which targets the host stem 
cells
 2. Lymphodepletion which targets the host lym-
phoid system, respectively
Some of the compounds used in the condition-
ing are more myeloablative (MA) in nature, for 
example, MEL or BU, while some are more lym-
phodepleting like FLU or CY. The pretransplant 
conditioning may include TBI or in rare and spe-
cific instances other types of irradiations like TLI 
that is applied, for example, in haplo-HSCT, or 
TAI that was used in the past in Fanconi anemia. 
Alternatively, the pre-HSCT conditioning can be 
radiation-free including only chemotherapy. In 
recent years, serotherapy, specific targeted novel 
compounds, and MoAb and radiolabeled Ab 
started to be incorporated into specific disease- 
oriented conditioning regimens.
Not just the constituents but also the schedule 
(days) of administration and doses may differ in 
the various conditioning regimen protocols. The 
pretransplantation conditioning regimens depend 
on the type of the HSC donor. For example, in 
auto-HSCT, the pre-HSCT conditioning consisted 
of chemotherapy alone, and in some transplant 
centers, it may include also irradiation, while, in 
allo-HSCT from unrelated or mismatched donors 
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as well as in HSCT from alternative donors, the 
pre-HSCT conditioning usually includes serother-
apy with ATG or ALEM (Campath; anti-CDW52 
MoAb). Similarly, the intensity of the condition-
ing is traditionally higher in unrelated and mis-
matched transplants as well as in transplants from 
alternative donors in comparison to transplants 
from HLA MSD.  The pre-HSCT conditioning 
regimen takes into account also the specific dis-
ease for which the HSCT is being performed, 
more so in auto- HSCT than in the allogeneic set-
ting aiming to include an effective anti-disease-
specific chemotherapy, for example, MEL for MM 
or BCNU and CY in lymphoma.
Other factors to be taken into account while 
choosing the optimal conditioning for a specific 
patient besides the disease he is afflicted with and 
the type of donor are age, comorbidities, and 
organ-specific toxicity risk. The conditioning pro-
tocols also differ between pediatrics and adults as 
in pediatric more emphasis should be given to 
growth and puberty issues. It also differs between 
nonmalignant and malignant disorders; the former 
are not just more frequent in pediatrics, but of 
major importance is the fact that in nonmalignant 
indications, there is no need for the GVL, and a 
main goal is to ensure absolutely no GVHD.
Historically, the conditioning protocols were 
MA in nature, and the two most popular ones 
were the CY/TBI (TBI 12Gy followed by IV CY 
60 mg/kg × 2 days) and the BU/CY protocol (BU 
4 mg/kg × 4 days and CY 60 mg/kg × 2 days). 
However, MAC is associated with significant 
organ- and transplant-related toxicity (TRT), lim-
iting allo-HSCT to younger patients in good 
medical conditioning, typically up to age of 55 
and 50 years old in allo-HSCT from sibling and 
URD, respectively. During the past two decades, 
non-MA (NMA), RIC, and reduced toxicity con-
ditioning (RTC) regimens have been developed 
aiming in reducing the organ and TRM while 
keeping the anti-malignant effect and allowing 
allo-HSCT in elderly and medically infirm 
patients. These are relatively nontoxic and toler-
able regimens designed not to maximally eradi-
cate the malignancy but rather to provide 
sufficient IS to achieve engraftment and to allow 
induction of GVL as the primary treatment. 
Furthermore, special conditioning protocols have 
been developed for allo-HSCT from alternative 
donors including from MMUD, CB donors, and 
haploidentical family-related donors. These rela-
tively new pre-HSCT conditioning typically 
includes new drug formulations like IV BU, com-
pounds from the oncology field that are newcom-
ers in HSCT like TREO or TT, new compounds 
like clofarabine (CLO), or new schedules sequen-
tially administrating novel chemotherapy combi-
nation (FLAMSA) to be followed by RIC 
containing reduced doses of TBI.
13.2  Total Body Irradiation
TBI is a major constituent of MAC regimens. 
Historically, TBI combined with CY has been the 
standard regimen used to condition patients with 
acute leukemia prior to HSCT. TBI is typically 
given at a dose of 12 Gy (Thomas et al. 1982). 
Higher doses of TBI up to 14.25 Gy resulted in 
improved antileukemic effect, but this was coun-
terbalanced by increased toxicity and TRM (Clift 
et al. 1990). TBI provides both MA and IS ensur-
ing engraftment in combination with optimal 
antileukemic effect. It provides homogeneous 
dose distribution in the whole body including 
sanctuaries for systemic chemotherapy such as 
the CNS and testicles. Fractionation of 12  Gy 
TBI in six doses of 2 Gy delivered twice a day 
over 3 days became the standard over time 
(Thomas et al. 1982).
The Acute Leukemia Working Party (ALWP) 
of the EBMT recently showed that 12 Gy frac-
tionated TBI dose delivered either in two frac-
tions or in one fraction per day over 3 or 4 days 
prior to HSCT resulted in similar outcome, in 
both ALL and AML patients (Belkacemi et  al. 
2018). Dose fractionation and dose rate have 
been shown to be of importance determining both 
efficacy and toxicity which includes mucositis, 
interstitial pneumonia, SOS/VOD, hemorrhagic 
cystitis, and long-term toxicity including growth 
retardation, endocrine problems, cataracts, and 
secondary malignancies.
As for mode of TBI administration across 
Europe, the ALWP of the EBMT performed a 
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questionnaire-based study focusing on technical 
practices across 56 EBMT centers and 23 coun-
tries demonstrating an extremely high heteroge-
neity of fractionation schedules. The total doses 
delivered ranged between 8 and 14.4  Gy with 
dose per fraction varying between 1.65 and 8 Gy. 
The dose rate at the source ranged between 2.25 
and 37.5 Gy/min. This resulted in 40 different 
reported schedules, to which variations in beam 
energy, dosimetry, in vivo techniques, and organ 
shielding disparities had to be added (Giebel 
et al. 2014). Regarding TBI-mediated antileuke-
mic effect, most studies have shown the equiva-
lence of chemotherapy-based MAC mostly BU/
CY and CY/TBI conditioning for AML (Nagler 
et  al. 2013). In contrast, despite the absence of 
consensus, TBI has remained the first choice in 
many centers for ALL (Cahu et al. 2016).
13.3  Myeloablative Non-TBI- 
Containing Conditioning
The MAC are a high-dose chemotherapy mostly 
alkylating agent-based regimens used in both 
auto- and allo-HSCT.  They cause by definition 
profound and prolong cytopenia that lasts up to 
21 days and necessitates stem cell graft in order 
to recover (Bacigalupo et al. 2009). Historically, 
BU/CY is the prototype of chemotherapy-based 
MAC.  It was developed by the Johns Hopkins 
group as early as 1983 as an alternative to TBI in 
an effort to reduce the incidence of long-term 
radiation-induced toxicities and improve the 
planning of HSCT in institutions lacking easy 
availability of linear accelerators (Tutschka et al. 
1987). A considerable number of studies have 
shown the equivalence of BU/CY and CY/TBI 
for allo-HSCT in AML (Nagler et al. 2013) and 
recently also in ALL (Mohty et al. 2010) although 
most centers still use TBI-based MAC as the pre-
ferred pre-HSCT conditioning for ALL in fit 
patients with low comorbidities.
The original studies used oral BU that has an 
erratic and unpredictable absorption with wide 
inter- and also intra-patient variability with the 
risk of increased toxicity mainly SOS/VOD in 
patients with a high area under the curve of BU 
plasma concentration versus time, while low BU 
concentrations may be associated with a higher 
risk of graft rejection and relapse (Hassan 1999). 
The common solution was monitoring of BU lev-
els and dose adjustments that allowed for better 
control of the dose administered and reduction of 
the abovementioned risks (Deeg et al. 2002). The 
development of the IV BU with more predictable 
pharmacokinetics, achieving tight control of 
plasma levels, and less need for plasma level test-
ing and dose adjustments significantly reduced 
BU-mediated SOS/VOD and TRM (Nagler et al. 
2014).
Some other MAC regimens include MEL in 
combination with BU (Vey et  al. 1996), while 
others incorporated VP (Czyz et  al. 2018). 
Subsequently, in an attempt to further reduce 
regimen-related toxicity, CY was replaced with 
FLU, a nucleoside analog with considerable IS 
properties that also has a synergizing effect with 
alkylators by inhibiting DNA repair. The combi-
nation of BU and FLU used in patients with AML 
was found to have more favorable toxicity profile 
with similar efficacy. Recently a well-designed 
two-arm study compared BU/CY to BU/FLU, 
demonstrating a significant reduction of TRM in 
the FLU/BU arm with no difference in RI 
(Rambaldi et al. 2015). Recently, other alkylators 
like TT (Eder et al. 2017) and CLO (Chevallier 
et  al. 2012) have been incorporated into MAC 
protocols for both AML and ALL in an attempt to 
reduce risk of relapse with equivalent results to 
TBI-containing conditioning protocols.
13.4  Nonmyeloablative, Reduced 
Intensity and Reduced 
Toxicity Conditioning
NMA and RIC have been widely introduced over 
the past 20 years in an attempt to reduce organ 
toxicity and TRM allowing HSCT in elderly and 
medically infirm patients not eligible for standard 
MAC (Slavin et al. 1998). In addition, RTC based 
on FLU and MA alkylating agent doses were 
designed to allow safer administration of dose- 
intensive therapy. Multiple such protocols have 
been reported over the years with somewhat 
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overlapping dose intensity and to a certain extent 
unclear categorization among NMA versus RIC 
and RTC.
A group of experts had an attempt to define 
and dissect the conditioning regimen intensity 
based on the expected duration and reversibility 
of cytopenia after HSCT (Bacigalupo et al. 2009). 
MAC was defined as a conditioning regimen that 
results in irreversible cytopenia in most patients, 
and stem cell support after HSCT is required. 
Truly NMA regimens cause minimal cytopenia 
and can theoretically be given without stem cell 
support. RIC regimens cause profound cytopenia 
and should be given with stem cells, but cytope-
nia may not be irreversible. The original NMA 
conditioning protocols were the TBI 2  Gy in 
combination with MMF and CSA (the so-called 
Seattle protocol that subsequently incorporated 
FLU 90 mg because of high non-engraftment in 
the original protocol) (McSweeney et  al. 2001) 
and the FLAG conditioning protocol (FLU, Ara- 
C, idarubicin, and G-CSF) pioneered in MD 
Anderson (Giralt et al. 1997).
Additional very popular protocol is the FLU/
BU conditioning regimen we pioneered in 
Jerusalem initially with oral but subsequently 
with the IV formulation of BU that is given 2–4 
days determining the intensity of the condition-
ing being NMA, RIC/RTC, and MAC, respec-
tively (Kharfan-Dabaja et  al. 2014). Overall 
multiple studies indicated that the conditioning 
dose intensity is highly correlated with outcome 
after HSCT.  Increased dose intensity is associ-
ated with reduced RI but also with higher NRM 
(Aoudjhane et al. 2005). For example, few stud-
ies compared the FLU/BU RIC to another fre-
quently used RIC regimen, namely, the FLU/
MEL protocol demonstrating lower RI but higher 
toxicity with the FLU/MEL protocol which is 
more intense (Shimoni et al. 2007). Subsequently 
TREO (L-threitol-1,4-bis-methanesulfonate, 
dihydroxybusulfan) with activity against both on 
committed and noncommitted stem cells as well 
as potent IS properties (Danylesko et  al. 2012) 
was combined with FLU as an effective condi-
tioning regimen pre-HSCT for both myeloid and 
lymphatic malignancies with a favorable toxicity 
profile with little extramedullary toxicity (Nagler 
et al. 2017).
Overall outcome comparing these low- 
intensity conditioning protocols versus MAC was 
determined by the net effect of the opposing 
effects, i.e., reduction in TRM, while higher RI, 
leading to similar LFS and OS with patient age, 
comorbidities, and disease status at transplanta-
tion being significant prognostic factors. 
Retrospective comparative trials showed that 
while outcome may be similar with the various 
regimens in patients given HSCT in remission, 
NMA/RIC are inferior when HSCT is given in 
advanced disease, due to high RI. These observa-
tions were confirmed in some of the long-term 
studies but not in others (Shimoni et  al. 2016). 
Interestingly, no disadvantage was observed for 
the low-intensity protocols in comparison to 
MAC even in high-risk disease like AML with 
monosomal karyotype or secondary leukemia 
(Poiré et  al. 2015). RTC regimens are typically 
with more intensive antileukemic activity but 
limited toxicity and thus better tolerated by 
patients not eligible for myeloablative condition-
ing (Shimoni et al. 2018).
New novel conditioning protocols that may be 
categorized in this family of conditioning 
although no consensus was established are the 
regimens that incorporate CLO and TT and espe-
cially the TBF regimen (TT, BU, FLU) (Saraceni 
et  al. 2017). Another worth mentioning condi-
tioning that was developed for high-risk leuke-
mia with encouraging results is the FLAMSA 
conditioning which comprised sequential chemo-
therapy including FLU, Ara-C, and amsacrine 
followed by RIC pre-allo-HSCT (Malard et  al. 
2017). Only few randomized studies compared 
head-to-head MAC to RIC or RTC regimens 
mostly confirming the above findings. A French 
well-designed two-arm study compared BU/FLU 
to TBI (low dose)/FLU demonstrating less RI 
with the BU/FLU regimen but higher TRM 
resulting in similar LFS and OS (Blaise et  al. 
2013). Similarly, a German randomized study 
compared RIC regimen of four doses of 2 Gy of 
TBI and 150  mg/m2 FLU versus MAC of six 
doses of 2 Gy of TBI and 120 mg/kg CY demon-
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strating reduced toxicity in the RIC arm but 
 similar RI, TRM, LFS, and OS between both 
study arms (Bornhäuser et  al. 2012). These 
results were recently confirmed with longer 
follow-up.
Finally, a recent CTN phase III randomized 
trial compared MAC (BU/CY, FLU/BU, or CY/
TBI) with RIC (FLU/BU or FLU/MEL) in 
patients with AML and MDS (Scott et al. 2017). 
RIC resulted in lower TRM but higher RI com-
pared with MAC, with a statistically significant 
advantage in RFS and a trend to an advantage in 
OS with MAC. Another randomized study com-
paring RIC and MAC in patients with MDS dem-
onstrated similar 2-year RFS and OS with no 
difference between the two conditioning regi-
mens (Kröger et  al. 2017). As for the issue of 
higher risk of RI post RIC, novel immunological 
and pharmacologic approaches are being cur-
rently explored (as will be discussed in Chap. 
69). Treatment options include second HSCT or 
DLI with similar results (Kharfan-Dabaja et  al. 
2018).





Historically, these types of allo-HSCT were 
the  most challenging ones with relatively 
high  incidence of non-engraftment and high 
TRM. Notably, recent development in the field of 
transplantation including novel conditioning reg-
imens resulted in major improvement in the 
results of allo-HSCT from alternative donors 
with the haplo-HSCT being of the most interest 
(Lee et al. 2017). A key component of the condi-
tioning regimen for MMUD and haplo-HSCT is 
ATG, recently reviewed for the ALWP of the 
EBMT (Baron et  al. 2017). In previous well- 
designed randomized clinical trials in allo-HSCT 
from URD and in a single study also from MSD, 
ATG was demonstrated to reduce GVHD and 
TRM without jeopardizing the GVL effect, and 
thus there is no increase in RI (Baron et al. 2017). 
In contrast and somewhat still puzzling in CBT, 
ATG is a negative factor associated with 
decreased OS and EFS rates and a high incidence 
of NRM (Pascal et al. 2015).
In an analysis performed by Eurocord, the 
MAC regimen for CBT included TBI 12 Gy—or 
BU—with or without FLU, TBI 12 Gy + CY, and 
more recently TBF (TT, BU, FLU) (Ruggeri 
et al. 2014). Comparing these regimens in single 
(s) (with >2.5 × 107 cells/kg) and double (d) CBT 
resulted in similar outcomes, NRM and RI inci-
dence, which were not statistically different 
among the groups. LFS was 30% for sUCBT 
using TBI- or BU-based MAC compared with 
48% for sUCBT TBF and 48% for dUCBT 
(P = 0.02 and P = 0.03, respectively), and it was 
not statistically different between sUCBT with 
TBF and dUCBT. They concluded that the choice 
of TBF conditioning regimen for sUCBT may 
improve results, and whether this regimen may 
be effective in dUCBT should be further ana-
lyzed (Ruggeri et al. 2014). In the haploidentical 
setting, the field moved from T-depleted to 
T-repleted haplo-HSCT and in recent years from 
ATG-based anti-GVHD prophylaxis to PT-CY 
pioneered by the Baltimore group (reviewed in 
Lee et al. 2017). Initial conditioning protocols in 
the Baltimore approach were RIC with BM 
grafts, but subsequently MAC regimens and PB 
grafts were introduced. In recent years, the TBF 
condoning is increasingly used for haplo-HSCT 
in Europe. Similarly, the PT-CY strategy for 
GVHD prophylaxis is being adopted to allo- 
HSCT from MUD, MMUD, and sibling donors 
(Ruggeri et al. 2018). In general comparing RIC 
to MAC for MMUD, CBT, and haplo-HSCT 
demonstrated in large similar transplantation 
global outcome for RIC versus MAC with some 
differences in the various alternative donors 
(Baron et  al. 2016). For example, in the allo- 
HSCT from MMUD in patients >50 years, RIC 
resulted in reduced TRM and better LFS and OS 
in comparison to MAC, while in those <50 years, 
no difference was observed (Savani et al. 2016). 
In CBT, RIC resulted in a higher RI and a lower 
NRM, translating to comparable LFS, GVHD 
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and relapse-free survival (GRFS), and OS (Baron 
et  al. 2016). In the haplo-setting, no significant 
difference was observed (Rubio et al. 2016).
13.6  Preparative Conditioning 
for Autologous HSCT
Auto-HSCT are performed mainly for malignant 
lymphoma and MM.  The most popular condi-
tioning protocol for auto-HSCT in lymphoma is 
BEAM (BCNU, VP, Ara-C, and MEL) (Mills 
et al. 1995) or BEAC (with CY instead of MEL), 
while some centers substitute the BCNU with 
TT (the so-called TEAM or TECAM protocol), 
especially in patients with pulmonary problems 
in order to prevent the BCNU-mediated lung 
toxicity. Others tried to replace the BCNU by 
bendamustine (the so-called BeEAM protocol). 
Adding anti-CD20 radiolabeled MoAb like 
yttrium- 90- ibritumomab tiuxetan (Zevalin) to 
the condition improved results in some studies, 
but a large randomized multicenter study with 
131I-tositumomab (Bexxar) was negative (Vose 
et al. 2013).
As for auto-HSCT in MM, high-dose MEL 
has been shown to be superior to TBI/
MEL. Recently some centers incorporated IV BU 
into the auto-HSCT in MM, while others included 
BOR. The numbers of auto-HSCT in acute leuke-
mia went down in the last two decades in parallel 
to the increase in the numbers of allo-HSCT with 
RIC and from alternative donors (Gorin et  al. 
2015). The most popular preparative regimen for 
AML is BU/CY. Recently on behalf of the ALWP 
of the EBMT, we demonstrated that BU/MEL is 
a better preparative regimen as compared to BU/
CY with lower RI, better LFS and OS, and no 
difference in TRM. Similar results were obtained 
in the subgroup of patients with high-risk 
AML. Patients with negative MRD before auto- 
HSCT did better (Gorin et al. 2017).
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Bone Marrow Harvesting for HSCT
Norbert Claude Gorin
14.1  Introduction
Historically, the bone marrow (BM) has been the 
first source of stem cells considered since the 
early 1960s for HSCT (Santos 1990; Thomas 
et  al. 1979; Mathe 1964; Gorin et  al. 1990). 
Parallel attempts at using fetal liver cells at that 
time have remained unsuccessful. In 1986 the 
first success of an unrelated cord blood (UCB) 
transplantation in a child promoted UCB 
(Gluckman et al. 1997) as an alternative source in 
certain settings.
Since 1994 and the initial demonstration that 
PBSC mobilized by cytokines (G-CSF first and 
more recently when needed plerixafor) could be 
used as well as BM, the proportion of PB trans-
plants has considerably increased to reach about 
70–95% of all stem cell transplants (Passweg 
et al. 2012, 2016), so that nowadays BM trans-
plantation accounts for a minority of transplants.
There remain however several situations 
where and when a marrow harvest can still be of 
interest or even is highly recommended.
This chapter indicates the principal indica-
tions of BM transplantation, compares schemati-
cally the advantages of BM versus PB, and details 
the technique of BM harvesting.
14.2  Indications for Considering 
and Possibly Selecting BM 
as a Preferred Source of HSC
It is not the purpose of this chapter to review the 
benefit/risk ratio of BM versus peripheral mobi-
lized blood as sources of HSC. Several studies, 
including prospective randomized studies, have 
shown in general with BM when compared to PB 
slower engraftment but lower incidence and 
lower severity of acute and chronic GVHD with 
in the end similar disease free and overall surviv-
als (Schmitz et al. 2005). However, some retro-
spective studies for both auto- and allo-HSCT 
have shown better survival with rich BM collec-
tions (Gorin et al. 2003) or BM versus PB (Gorin 
et al. 2009, 2010). Also, the quality of life has not 
been carefully analyzed (Sun et  al. 2010), and 
further studies may be in favor of BM (Ruggeri 
et al. 2018; Lee et al. 2016).
Time and cost constraints have however in 
general favored leukaphereses and PB transplants 
which represent about 95% of all auto-HSCT and 
70% of allo-HSCT (Passweg et  al. 2016). 
Table  14.1 lists the situations when nowadays 
marrow may appear as a better choice.
For allo-HSCT, BM is preferred/mandatory 
whenever the wish to reduce toxicity, NRM, and 
most of all GVHD (particularly  extensive chronic) 
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is considered as priority, such as for children with 
aplastic anemia and for some teams for haploi-
dentical transplantation (see Table 14.1). The out-
come considered to favor this choice is the GRFS 
(GVHD and relapse-free survival) as defined by 
EBMT (Ruggeri et al. 2016).
Conversely, PB can be a first choice in patients 
with hematological malignancies at high or very 
high risk of progression/relapse, such as AML 
FLT3ITD positive, lymphomas in progression 
after relapse from auto-HSCT, etc. for whom the 
risk of relapse is considered as first priority 
despite the risk of increasing NRM. Usually, this 
choice is made in parallel to the decision whether 
the conditioning regimen should be MAC or RIC 
(Gilleece et al. 2018).
For autologous HSCT (Table 14.2) the two 
major reasons for using BM are autologous trans-
plantation for AML in remission and attempts at 
increasing the stem cell dose infused following 
poor marrow collections.
14.3  Mobilized or Primed Marrow
Following the discovery of cytokines, G-CSF in 
particular, the use of BM collected after 2–4 days 
of GCSF administration has been investigated in 
the year 2000–2005. G-CSF-primed marrow har-
vesting results in a graft with more mononuclear 
cells collected and higher CD34(+) stem and pro-
genitor cell doses s (Grupp et al. 2006). The clini-
cal significance of different HSC sources (primed 
marrow, mobilized blood, and steady- state mar-
row) in auto- and allo-HSCT was reviewed in 
2004 (Elfenbein and Sackstein 2004). Mobilized 
marrow speeds up engraftment for both auto- and 
allo-HSCT, with a possible (unproven) reduction 
of GVHD rate and severity. Its use nowadays is 
rare, but it is for some teams the preferred stem 
cell source or part of a combination of primed 
marrow + PB as stem cell source for haploidenti-
cal donor transplantation (Huang et al. 2009; Ly 
et al. 2015).
14.4  Technique of BM Collection 
and Impact of the Dose 
of Nucleated Cells Infused
Marrow is collected from the posterior superior 
iliac crests, usually under general anesthesia, 
although few teams have used sedation or locore-
gional anesthesia (Fig. 14.1).
Marrow is aspirated with bone needles with 
multiple holes all around, which makes collec-
tion easier and the procedure more rapid. 
However, to avoid large dilution with blood, it is 
recommended to limit each aspiration to a vol-
ume of less than 5  mL, before transferring the 
Table 14.1 Preferences for BM as source of stem cells in ALLO-HSCT




GCSF to and 
leukapheresis of the 
donor more difficult to 
set
More cGVHD and 
NRM after PB 
compared with BM
In some countries, 
the use of GCSF 
(and plerixafor) is 
not allowed in 
children
Simonin et al. (2017)
Aplastic anemia BM mandatory, 
associated with better 
results
Higher risk of 
GVHD with PB
Included in EBMT 
and CIBMTR 
guidelines
Bhella et al. (2018), 
Schrezenmeier et al. 
(2007), Bacigalupo et al. 
(2012), Eapen et al. (2011), 
and Barone et al. (2015)
MAC with a 
MUD and no 
ATG
BM associated with 
better results and less 
cGVH
Randomized trial 
with no ATG 
showing less cGVH 
and better QOL with 
BM
If a suitable BM 
donor is available. 
Otherwise PB with 
ATG
Anasetti et al. (2012), Lee 
et al. (2016), Eapen et al. 




BM or combination of 
PB and BM favored by 
some teams
Team choice or 
clinical trial
High-dose CY for 
GVH prevention




aspirate through a three-way tap to the collection 
bag. The collection bag contains ACD anticoagu-
lant solution and the syringes are rinsed with 
heparin (5.000 U/mL).
The goal is nowadays to obtain typically at 
least 3 × 108 nucleated cells/kg, although 2 × 108 
nucleated cells/kg has long been in the past the 
usual target and remains acceptable. However, it 
should be kept in mind that old studies in the 
early development of BMT have indicated better 
results both in terms of engraftment but also 
decrease in NRM and RI and better outcome, 
with higher marrow doses (Gorin et  al. 1999, 
2003; Sierra et al. 1997):
• For Allo-HSCT with identical siblings, an 
early EBMT retrospective study evaluated 
the impact of the marrow cell dose infused: 
The median BM cell dose was 2.7 × 108/kg 
(0.17–29 × 108/kg). In multivariate analyses, 
high- dose BM compared to PB was associ-
ated with lower NRM, better LFS, and better 
OS (RR  =  0.64; 95% CI, 0.44–0.92; 
P  =  0.016). Results in patients with AML 
receiving allografts in CR1 indicated a better 
outcome with BM as compared to PB, when 
the dose of BM infused was above the median 
value.
• For Allo-HSCT fully with matched unrelated 
donors (Sierra et al. 1997), transplantation of a 
marrow cell dose above the median value of 
3.65 × 108/kg was associated with faster neu-
trophil and platelet engraftment and decreased 
incidence of severe acute GVHD. Transplant 
in remission of acute leukemia with a high 
dose of marrow cells was associated with the 
best outcome in both children and adults.
If the targeted goal cannot be achieved, addi-
tional collection can be made from the anterior 
iliac crests, although it is time consuming and 
potentially more harmful for the patient or the 
donor, who must be turned over with all sterile 
fields to be reinstalled.
All things considered the maximum accepted 
volume collected should not go over 20  mL/kg 
donor body weight. Depending on the volume col-
lected, three attitudes regarding transfusion during 
marrow collection may be followed: no transfu-
sion and liquid replacement is the first option for 
many teams. Autotransfusion (to prepare before-
hand in the 3 weeks preceding marrow collection, 
which adds some constraint) is the other recom-
mended transfusional option. In rare circum-
stances allo-transfusion remains possible; usually 
two packs of concentrated red cells are enough.
Another option to consider to increase the 
stem cell dose to infuse when marrow collection 
has been insufficiently productive is the addition 
of PBSC. This however can be a complex deci-
sion which should take into account the disease 
and disease status, whether it concerns an auto-
graft or an allograft or in this last situation 
whether a possible increase in the incidence and 
severity of GVHD associated with GVL/tumor is 
potentially beneficial or harmful. Two examples 
of this dilemma are summarized below:
 1. In the context of auto-HSCT for leukemias or 
lymphomas, when analyzing patients receiving 
combinations of BM and PBSC (either because 
PBSC were collected to supplement poor BM 
or the reverse), outcomes are poor. One likely 
explanation is the existence of a bias since in 
most of these patients, poor collections (either 
BM or PBSC or both) are surrogate markers of 
multiple previous lines of chemotherapy for 
resistant/progressing diseases.
 2. In contrast, for some teams, the combination 
of BM and PBSC has become the standard 
stem cell source for HSCT (see Table 14.1).
Fig. 14.1 Bone marrow harvest
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14.5  Complications of Bone 
Marrow Collections
One cannot ignore that on theoretical grounds 
two major hazards of marrow collection although 
very rare are death secondary to general anesthe-
sia (<1/200,000) and major organ damage by 
mechanical mismanipulation of the bone needles 
that may sideslip if sufficient expertise and cau-
tion are not present.
The NMDP analyzed in 1993, 493 volunteers 
who donated unrelated marrow from October 
1991  in 42 centers (Stroncek et  al. 1993). 
The median volume of marrow collected was 
1050 mL (range 180–2983 mL). Autologous red 
blood cells were transfused to 90% of donors, 
but only three donors received allogeneic blood. 
Apnea during anesthesia occurred in one donor. 
Other acute complications related to the col-
lection procedure occurred in 6% of donors. 
Following marrow collection 75% experienced 
tiredness, 68% experienced pain at the marrow 
collection site, and 52% of the donors experi-
enced low back pain. Mean recovery time was 
16 days, but 42 donors felt that it took them at 
least 30  days to recover fully. The duration of 
the marrow collection procedure and duration of 
anesthesia both positively correlated with donor 
pain and/or fatigue following the  collection. The 
recommendation of this study was the duration 
of the collection procedure and probably the 
duration of anesthesia, and therefore the vol-
ume of marrow collected should be kept to a 
minimum, but this conclusion is to be weighed 
against the wish to collect stem cell doses as 
high as possible to ensure fast engraftment and 
improve outcome.
14.6  Bone Marrow 
Cryopreservation
In the context of auto-HSCT, BM and PBSC are 
almost always cryopreserved and stored either in 
liquid nitrogen (−196 °C) or the gas phase of liq-
uid nitrogen (−140 °C). The technique of freez-
ing at −1  °C/min with dimethyl sulfoxide 
(DMSO) and the technique of rapid thawing are 
well established (Gorin 1986). Harmless long 
duration of storage has been reported up to 
11  years (Aird et  al. 1992). Recently some 
attempts at avoiding cryopreservation to replace 
it by storage at 4 °C in the refrigerator have pro-
duced interesting results, but using refrigerator 
storage is not presently validated and cannot be 
recommended by EBMT (Sarmiento et al. 2018).
Cryopreservation and storage of a marrow in 
view of an allo-HSCT is possible. However, it 
should be kept in mind that any cryopreservation 
procedure, would it seem perfect, results in some 
measurable (CFU-GM, BFU-E) and many less 
measurable (immune functions, etc.) damages. 
Therefore, it should be reserved to special situa-
tions when, for instance, the donor cannot be 
available at the very time of the transplantation 
procedure. As a rule, fresh marrow is preferable 
to frozen marrow.
14.7  Quality Control  
for BM Harvesting 
and Cryopreservation
The major indicator for successful BM collection 
is the dose collected, as discussed above, i.e., the 
number of nucleated cells expressed per kg of 
Table 14.2 Preferences for BM as source of stem cells in 
AUTO-HSCT
Auto- 
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*Although there are biases, data from the EBMT regis-
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body weight for the recipient. It is very usual to 
have a blood count done at the mid time of the 
collection to ensure proper richness. With a goal 
of a minimum of 3 × 108 nucleated cells/kg, any 
richness above this value can be seen as a bonus. 
Harvest below this level, around 2 × 108 or even 
lower, however has been associated with correct 
engraftment.
CD34+ evaluation is not routinely performed 
for BM, while it is the rule for PB.
For cryopreserved marrow, some teams rou-
tinely cryopreserve small samples in minibags or 
ampoules, enabling viability testing before thaw-
ing the graft (usually an autograft). However, and 
importantly, a technical bias has been observed 
with ampoules since differences in cooling rates 
prevent ampoules from being a reliable index of 
HSC cryopreservation in large volumes (Douay 
et al. 1986a).
More pertinent testing consists in the evalua-
tion of CFU-GM which represents in this setting 
the most reliable functional viability indicator 
(Douay et al. 1986b). Although there is no guide-
line, experience has shown that the results in 
CFUGM/kg are about 1–1.5 log below the 
expected or calculated results in CD34+ cells /kg 
(therefore expressed in 105/kg). CFU-GM evalu-
ation is not a consensual prerequisite since it is an 
additional time-consuming effort, but it may 
bring important information in some cases, for 
instance, when dealing with marrow collections 
below 2 × 108/kg.
14.8  Conclusions
PB collections and transplantation nowadays rep-
resent 70–90% of all stem cell sources for 
transplants.
However, BM transplantation has not disap-
peared and is likely to persist in some limited 
situations and indications.
Further studies may revisit and increase the 
choice of marrow as stem cell source.
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The intravenous infusion of patient’s own HSC to 
restore BM damage is the basic principle of high- 
dose chemotherapy, since otherwise the patient 
would expect long-lasting aplasia with life- 
threatening infections. Therefore, a sufficient 
collection of HSC before application of high- 
dose therapy is mandatory. Since HSC expresses 
CD34 on their surface, the number of CD34+ 
cells in the transplant material is considered as an 
indicator of the HSC content.
In principle, there are two ways how to collect 
stem cell: by repeated aspiration of BM from the 
pelvic crest or by leukapheresis after mobiliza-
tion of HSC into the PB. The latter one is favored 
and considered as standard because it is less 
stressful for the patient and leads to faster engraft-
ment and hematologic reconstitution which may 
improve patient outcomes (Gertz 2010).
Usually, HSC circulates in a very small num-
ber in the PB.  Therefore, mobilization of HSC 
from the BM to the PB is an essential part of 
auto-HSCT programs. Following sufficient 
mobilization, patient will need leukapheresis 
which is often performed by central lines to facil-
itate the procedure. Finally, HSC will be cryopre-
served using dimethyl sulfoxide (DMSO) until 
transfusion.
15.2  Strategies of Mobilization
There are two different strategies to mobilize 
HSC from the BM to the PB: the so-called 
“steady-state” mobilization and the mobilization 
by chemotherapy.
15.2.1  Mobilization Without 
Chemotherapy  
(“Steady State”)
Using this approach, HSC will be mobilized by 
the use of cytokines only. The only recommended 
cytokine for mobilization is G-CSF, since 
GM-CSF is no longer available in many coun-
tries after commercial failure and withdrawal. 
G-CSF induces myeloid hyperplasia and the 
release of CD34+ cells into the circulation 
through proteolytic cleavage of adhesion mole-
cules (Lapidot and Petit 2002). Currently, the 
G-CSF cytokines filgrastim and lenograstim have 
market approval for mobilization of HSC in 
Europe.
The recommended doses are filgrastim 10 μg/
kg/day SC for 5–7 consecutive days and leno-
grastim 10  μg/kg/day SC for 4–6 consecutive 
days. The use of biosimilar G-CSF has equivalent 
efficacy (Schmitt et al. 2016).
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Leukapheresis usually is performed on day 5 
independent whether filgrastim or lenograstim 
was used for mobilization. The measurement of 
CD34+ cells in the PB before leukapheresis is not 
mandatory but could help to estimate the expected 
collection yield and the duration of leukapheresis. 
If the number of cells collected is inadequate, 
mobilization with G-CSF may be continued for 
1–2  days. However, if the collection goal is not 
reached after the third leukapheresis, a successful 
mobilization is unlikely.
The major advantages of steady-state mobiliza-
tion are the relatively low toxicity, the predictable 
time of leukapheresis, the outpatient administration, 
and the reduced costs compared to chemo-mobiliza-
tion. The major disadvantages are variable mobiliza-
tion failure rates and the lower CD34+ cell yields 
compared to chemo- mobilization. Mobilization 
with G-CSF only may be used in patients without 
further need of chemotherapy, e.g., in patients with a 
stable remission of the underlying disease.
15.2.2  Mobilization 
with Chemotherapy
The use of chemotherapy in combination with 
G-CSF is the preferred way of mobilization for 
all patients who will need further decrease of 
tumor burden and/or who have to collect a high 
number of HSC.
CY in a dose of 2–4 g/m2 is widely used for 
HSC mobilization. It is also possible to mobilize 
HSC not by a separate chemotherapy but as part 
of the disease-specific chemotherapy, e.g., to 
mobilize HSC following salvage treatment with 
R-DHAP or R-ICE in lymphoma patients. The 
choice of a specific chemo-mobilization approach 
is based on patient’s disease characteristics and 
local clinical practice guidelines.
Approved doses of G-CSF for HSC mobiliza-
tion after myelosuppressive therapy are filgrastim 
5 μg/kg/day SC and lenograstim 150 μg/m2/day 
SC. There are reports of the use of higher doses 
of G-CSF (Romeo et al. 2010), but there are no 
randomized trials and additional side effects are 
possible. Mobilization with G-CSF should start 
after completion of chemotherapy at the earliest 
and at the leukocyte nadir at the latest and should 
continue until the last leukapheresis. Most proto-
cols recommend the initiation of G-CSF within 
1–5 days after the end of chemotherapy.
The major advantage of adding chemother-
apy to cytokines, besides the effect on the tumor, 
is the expected improvement of the collection 
yield with fewer apheresis sessions (Sung et al. 
2013). The major disadvantages of chemo-
mobilization are the therapy-related toxicity, the 
requirement of in-hospital treatment in most 
cases, the bone marrow damage by the chemo-
therapy which may impair future mobilizations, 
and higher mobilization costs. Furthermore, an 
exact prognosis of the CD34+ cell peak in the 
PB and the optimal start of leukapheresis are 
difficult and require daily monitoring of CD34+ 
cells in the PB. Table 15.1 summarizes a recom-
mendation of timing of G-CSF following most 
used chemotherapy regimens and start of moni-
toring of CD34+ cells in the PB.
In several clinical trials, it was documented 
that relapse rate after auto-HSCT following 
mobilization with and without chemotherapy is 
comparable (Tuchman et al. 2015).
Table 15.1 Recommended start of G-CSF and start of 





CY 2 g/m2 Day 5 Day 10
CAD Day 9 Day 13
(R)CHOP/CHOEP Day 6 Day 11
(R)DHAP Day 9 Day 14
(R)ICE Day 6 Day 12
(R)AraC/TT Day 5 Day 10
Day 1: first day of chemotherapy application (without 
rituximab). Adapted from (Kriegsmann et al. 2018)
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15.3  CD34+ Cell Count and Timing 
of Leukapheresis
Up to date, CD34+ cell count in mobilized periph-
eral blood product is the most important parame-
ter of graft quality, as it is the only  recognized 
predictor of stable hematopoietic engraftment 
after auto-HSCT (Saraceni et  al. 2015). 
Monitoring of CD34+ cells in the PB is optional 
in steady-state mobilization but an essential part 
of chemo-mobilization. Following chemotherapy, 
the daily measurement of leukocytes and throm-
bocytes is recommended. If not otherwise speci-
fied by the protocol, CD34 monitoring should be 
initiated at the latest if leukocytes increase up to 
1000/μL during recovering from aplasia. This 
increase of leukocytes is mostly accompanied 
with an increase of thrombocytes. A prompt start 
of leukapheresis is required of CD34+ cell count 
of ≥20/μL (Mohty et al. 2014); for more details, 
please see Sect. 15.6.
15.4  Target HSC Collection Count
The target quantity of HSC to be collected is 
dependent on the underlying disease. Most 
patients with NHL or HL (expect for rare case of 
patients with HL who require double auto-HSCT) 
will need one autograft. The generally accepted 
minimum CD34+ cell yield to proceed to trans-
plantation is 2 × 106 cells/kg (Mohty et al. 2014); 
however, higher yields of 4–5 × 106 CD34+ cells/
kg are aimed for at many centers since they have 
been associated with faster neutrophil and plate-
let recovery, reduced hospitalization, blood trans-
fusions, and antibiotic therapy (Stiff et al. 2011; 
Giralt et  al. 2014). Patients mobilizing 
>8–10  ×  106  cells/kg are called “super mobi-
lizer”; however, the reported positive effect after 
infusion of such a high number of HSC on the 
outcome and prognosis of the patient is highly 
speculative. For patients with a chance of two or 
even more transplantations (mainly patients with 
MM), it is essential to collect the required num-
ber of HSC before the first high-dose therapy 
since mobilization after high-dose therapy has an 
increased risk of failure. For tandem transplanta-
tion, the required cell dose for one transplanta-
tion is also at least 2 × 106 CD34+ cells/kg.
15.5  Leukapheresis
Collection of peripheral HSC for auto-HSCT is a 
well-established process. The duration of one 
leukapheresis session should not exceed 5 h, and 
the total number of leukapheresis session should 
not exceed four procedures since more sessions 
are useless in most cases and will stress the 
patient. CD34+ cell collection has been shown to 
be more effective with larger apheresis volume 
(4.0–5.3 times the patient’s total blood volume), 
and no difference in CD34+ cell viability was 
observed compared with normal-volume aphere-
sis (2.7–3.5 times the patient’s total blood vol-
ume) (Abrahamsen et  al. 2005). Enhanced 
volumes are especially recommended for patients 
with a high risk of mobilization failure or for 
patients with a high individual CD34+ cell col-
lection goal. However, not all patients are eligible 
for enhanced volume strategies. Larger transfu-
sion volumes and related higher DMSO contents 
have been associated with increased risk of car-
diac side effects (Donmez et al. 2007).
15.6  Poor Mobilizer
Despite widespread and established practice, cur-
rent mobilization strategies vary between centers 
and differ in terms of feasibility and outcome. 
Although the majority of patients are able to 
mobilize sufficient CD34+ cells for at least a sin-
gle auto-HSCT, approximately 15% fail to do so 
(Wuchter et al. 2010).
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Poor mobilizers are usually defined as patients 
with less than 2 × 106 CD34+ cells/kg collected 
or patients mobilizing less than 10–20 CD34+ 
cells/μl into the PB.  In general, there are two 
groups of poor mobilizers: predicted poor mobi-
lizers and proven poor mobilizers (Olivieri et al. 
2012). Proven poor mobilizers have low CD34+ 
peripheral counts circulating or do not achieve 
adequate HSC on day 1 of apheresis. Based on 
CD34+ cells, it is possible to identify the follow-
ing subgroups: “borderline poor mobilizer” (11–
19 CD34+ cells/μL), “relative poor mobilizer” 
(6–10 CD34+ cells/μL), and “absolute poor 
mobilizer” (0–5 CD34+ cells/μL) (Wuchter et al. 
2010). If a patient has ≥20 CD34+ cells/μL at 
time of apheresis, the collection process should 
start. Between 15 and 20 CD34+ cells/μL, collec-
tion might be sufficient if not more than two 
transplantations are planned and the patient has 
no risk factors for poor mobilization (see below).
Otherwise, the use of plerixafor (recommended 
dose 0.24 mg/kg/day SC) should be considered. If 
a patient has 10–15 CD34+ cells/μL, plerixafor 
application should be discussed. Below 10 CD34+ 
cells/μl, the use of plerixafor is clearly indicated to 
avoid mobilization failure. That means that there is 
a “gray area” between 10 and 20 CD34+ cells/μL, 
and the decision to use plerixafor in this situation 
is based on disease characteristics and treatment 
history (Fig. 15.1). Furthermore, if it is not possi-
ble to collect at least one third of the collection 
goal with the first apheresis, plerixafor should be 
applied because of high risk of mobilization fail-
ure (Mohty et al. 2014; Cheng et al. 2015).
Predicted poor mobilizers are defined by base-
line patient or disease characteristics which are 
CD34+ cell count prior to apheresis







Apheresis (target cell count = 2.0 Mio CD34+ cells/kg BW)
<10 cells/µL




associated with poor mobilization. These factors 
are listed in Table 15.2. In patients with one or 
more of these risk factors, the preemptive use of 
plerixafor should be considered. It is generally 
accepted that the most robust predictive factor for 
poor mobilization is the CD34+ cell count in PB 
before apheresis.
The use of plerixafor is not only valuable to 
avoid a failed mobilization in the described risk 
groups, bit it has also a documented effect on the 
resources of the centers. With the use of plerixa-
for, patients spend less time on apheresis with 
less blood volume processed and collect more 
CD34+ cells with the first apheresis, leading to a 
decreased number of apheresis sessions needed 
(Mohty et al. 2018). This has a direct effect on 
reducing mobilization costs. In case of a failed 
first mobilization attempt, the use of plerixafor 
for remobilization is clearly indicated (Hubel 
et al. 2011).
15.7  Future Directions
At this time, the number of CD34+ cells in the 
graft is the major and most important indicator 
for graft quality. A sufficient number of CD34+ 
cells are essential to overcome the toxicity of 
high-dose chemotherapy and to facilitate hema-
topoietic recovery. However, there is an increas-
ing understanding that other graft subsets, e.g., 
CD34+ subpopulations or immune cell subsets 
(B cells, T cells, NK cells, dendritic cells), influ-
ence immune recovery. There are also reports 
that the mobilization regimen has a major impact 
on graft immune composition and patient’s out-
come (Saraceni et al. 2015). Therefore, stem cell 
mobilization could not only be an important part 
of high-dose therapies but could also be part of an 
effective immunotherapy. The delineation of this 
approach has just been started.
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Collecting or harvesting HSCs from children is a 
challenge, not only because children have differ-
ent physiological and therefore anatomical situa-
tions but also because psychological, legal and 
ethical concerns in minors are sometimes more 
difficult compared to adult donors. In addition, 
parents and/or legal guardians have to be 
addressed in all issues. This chapter will focus on 
the technical, physiological, and ethical problems 
in the field of HSC collection from children 
rather than indications.
The main difference to the adult setting is the 
small bodyweight; the difficulties in accessing 
venous access, especially in the leukapheresis 
setting; and the need for blood cell substitution in 
case of BM harvest. In children the indications 
for autologous HSC harvesting is well- established 
(Passweg et al. 2014). Using children in the allo-
geneic setting as donors is a complete different 
issue (Bitan et  al. 2016). Children should not 
donate HSCs if a comparable compatible adult 
volunteer HSC donor is available, if the indica-
tion for the stem cell therapy is not first line, or if 
the therapy is experimental (Sheldon 2004; 
Zinner 2004).
The main resources to harvest HSCs are BM 
and PBSCs. The basic techniques are quite simi-
lar to the techniques used in adults. For BM col-
lection punctures of the iliac crests or in very 
small children, the tibia is used. For harvesting 
HSCs from the PB, leukapheresis is used with the 
same apheresis systems as in adults.
To perform these procedures in children, phy-
sicians and nursing practitioners must have work-
ing knowledge about the normal age-dependent 
physiological parameters, like vital signs, growth, 
and psychological and motorical development, 
and should be trained in the communication with 
children, parents, and/or their legal guardians 
(Anthias et al. 2016).
16.2  Bone Marrow Harvest  
(See Chap. 14)
The collection of HSCs from the BM is the his-
torical oldest technique. Multiple punctures of 
the iliac crest are performed in general anesthe-
sia by experienced physicians and practitioners. 
The bone marrow is harvested by aspirations 
through adequately dimensioned needles. In 
very small children and if the iliac crest is ana-
tomically not suitable for punctures, the aspira-
tions could also be performed by punctures of 
the proximal tibia.
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For successful HSCT, it is necessary to obtain 
enough progenitor cells during the BM  harvesting 
procedure. Most centers are using multiple aspira-
tions of maximum 2 mL BM, while other centers 
are using few larger amount aspirations for BM har-
vesting (20–100–250 mL). It could be shown that 
the latter methods result in comparable grafts for 
transplantation (Witt et al. 2016). For some young 
donors with anatomically tiny situations or in dis-
eases where a suitable donor should be used for 
more than one recipient a minimal harming proce-
dure is warranted for the bone marrow harvest 
(Biral et al. 2008; Furey et al. 2018).
More recently, adult donors have received 
G-CSF because stimulated BM is richer in HSCs 
and therefore results in quicker engraftment (Ji et al. 
2002). Experience with G-CSF-mobilized BM in 
pediatrics is limited. Recent data showed that a dose 
of 3–5  ×  106 CD34+ HPC/kg of recipient body-
weight is the optimal CD34+ cell dose infused to 
attain GVHD relapse-free survival in children with 
an HLA-matched sibling donor. A higher CD34+ 
cell dose did not impact clinical outcome. G-CSF-
primed BM harvest might have a better impact on 
smaller amount of BM harvest volume needed for a 
sufficient stem cell graft, but the study was under-
powered to give an answer on this urgent question 
(Frangoul et al. 2007; Furey et al. 2018).
16.3  Peripheral Blood Stem  
Cell Harvest
PBSCs are harvested by leukapheresis in very 
small children even below 6 kg bodyweight and 
are described since the 1990s of the last century 
(Kanold et al. 1994; Klingebiel et al. 1995; Diaz 
et al. 1996; Moon et al. 2013). Special experience 
and techniques are required to perform safe leuka-
pheresis procedures in pediatric patients using 
apheresis systems who are constructed for the use 
in adults. Due to the large extracorporeal volume 
of the apheresis systems available on the market 
(ca. 160–220 mL), there is a need to calculate the 
expected blood loss in the set during procedure 
(Witt et al. 2007). This has to be done in each pro-
cedure to decide whether a priming of the set is 
needed with blood (Moon et al. 2013). In most of 
the newest versions of the apheresis systems, an 
algorithm guides the user through this pediatric 
priming procedure. For priming only irradiated 
and leukodepleted packed RBCs should be used. 
In order to gain enough flow for the apheresis sys-
tems in very small children, a central venous cath-
eter is needed, but also alternative line management 
with arterial lines is possible (Goldstein 2012; 
Even-Or et al. 2013; Hunt et al. 2013). It is impor-
tant to know that in reports from registries, up to 
50% of vascular access lines were peripheral 
venous access lines only in pediatric patients (Witt 
et  al. 2008). For anticoagulation, citrate is used 
even in very small children. To avoid side effect, a 
calcium substitution is recommended (Kreuzer 
et al. 2011; Maitta et al. 2014).
For mobilization of the HPC into the PB, the 
longest experience exists with G-CSF in combi-
nation with chemotherapy in the autologous set-
ting, but also plerixafor is reported in case series 
as suitable and safe in the use in children 
(Chambon et al. 2013). As in adults, a leukapher-
esis should be performed if a meaningful number 
of CD34+ HPCs are mobilized in the peripheral 
blood, to achieve the harvest of 2–5  ×  106/kg 
recipient with a minimum number of procedures 
(Fritsch et al. 2010).
16.4  Risk Analysis BM Versus 
PBMNC
A study from the EBMT Pediatric Diseases 
Working Party describes which factors influ-
enced the safety of HSC collection. In this pro-
spective evaluation, 453 pediatric donors were 
included. The children donated either BM or 
PBSCs according to center policy. A large vari-
ability in approach to donor issues was observed 
between the participating centers. Significant dif-
ferences were observed between BM and PBSC 
donors regarding pain, need for blood allo- 
transfusion, duration of hospital stay, and iron 
supplementation; however, differences between 
the groups undergoing BM vs PBSC donation 
preclude direct risk comparisons between the two 
procedures. The most common adverse event was 
pain, reported mainly by older children after BM 
V. Witt and C. Peters
125
harvest but also observed after CVC placement 
for PBSC collection. With regard to severe 
adverse events, one patient developed a pneumo-
thorax with hydrothorax after CVC placement 
for PBSC collection. The risk of allo-transfusion 
after BM harvest was associated with a donor age 
of <4 years and a BM harvest volume of >20 mL/
kg. Children <4  years were at higher risk than 
older children for allo-transfusion after BM har-
vest, and there was a higher risk of complications 
from CVC placement before apheresis. It was 
concluded that PBSC and BM collection are both 
safe procedures in children (Styczynski et  al. 
2012).
16.5  Pediatrics as Allogeneic 
Donors
Pediatric-aged donors vary widely in their ability 
to assent or consent to the risks of a donation pro-
cedure. There are key regulations and ethical 
imperatives, which must be addressed in decid-
ing which donation procedure is appropriate for 
minors (van Walraven et  al. 2013). In order to 
have general guidance, the American Academy 
of Pediatrics published in 2010 a recommenda-
tion on this issue. The authors strongly recom-
mend the inclusion of the potential child donor in 
all decision-making process to the extent that 
they are capable. A minor’s advocate should be 
an independent person who will help to prevent 
the delay of the donation procedure (Chan and 
Tipoe 2013).
The decision to take a minor family donor 
especially in inherited diseases is complicated to 
the fact that phenotypically healthy or minor 
symptomatic siblings with mild carrier status 
might be eligible for the severely ill recipient. 
One simple example is a sibling with thalassemia 
minor for a recipient with a thalassemia major 
(Biral et al. 2008). There are many other major 
diseases, including primary immunodeficiencies, 
chronic granulomatous disease, or sickle cell dis-
ease, where carriers are used as HSC donors. 
Potential family sibling donors with medical or 
psychological reasons not to donate should not 
be HLA typed (Bitan et al. 2016).
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17.1  Assessment of HSCs  
by Measuring CD34 
and the Presence of Other 
Cell Subsets
The efficiency of an autologous, as well as an 
allogeneic, HSCs graft is mainly determined by 
the number of CD34+ cells present. The dose of 
transplanted CD34+ cells per kg body weight 
(BW) determines the kinetics of the neutrophil 
and platelet engraftment after auto-HSCT 
(Weaver et al. 1995). The measurement of CD34+ 
cells by flow cytometry is, therefore, an impor-
tant method to assess the graft quantity.
The minimal number of CD34+ cells for an 
autologous transplant is ≥2.0 × 106 CD34+ cells/
kg BW. Transplants below this threshold should 
only be used in cases where no additional stem 
cell collection is feasible and there is a vital indi-
cation for the autologous stem cell transplanta-
tion. Most transplant centres regard a cell dose of 
2.5–6 × 106 CD34+ cells/kg BW as optimal, based 
on published clinical data (Duong et  al. 2014; 
Perez-Simon et  al. 1999; Giralt et  al. 2014; 
Lisenko et al. 2017b; Mohty et al. 2014). For an 
allo-HSCT, a cell dose of ≥4.0 × 106 CD34+ cells/
kg BW is regarded as adequate.
In the autologous setting, it has been specu-
lated that the quality of CD34+ cells from poor 
mobilizers may be inferior. However, studies 
have found that the proportions of primitive and 
quiescent CD34+ subsets were comparable across 
mobilization groups (Jiang et al. 2012), and leu-
kocyte and platelet recovery after transplantation 
was not different (Wuchter et al. 2010).
The application of plerixafor in order to over-
come insufficient HSCs mobilization not only 
increases the number of CD34+ cells but also the 
proportion of more primitive HSCs subsets, the 
absolute lymphocyte count and the numbers of 
lymphocytes in various subsets (CD19+ cells, CD3+ 
cells, T-cells and NK-cells) in the autograft 
(Fruehauf et al. 2009; Taubert et al. 2011; Varmavuo 
et al. 2013). However, these variances do not trans-
late into relevant clinical differences regarding hae-
matopoietic recovery. Taken together, the graft 
quality from poor mobilizers can be regarded 
equivalent compared to that from good mobilizers, 
regardless of the use of plerixafor.
It was further speculated that the composition 
of cellular subsets in the transplant may have an 
influence on the haematopoietic reconstitution. 
However, based on the currently published data, 
no final conclusion can be drawn, and further 
investigations are warranted to determine the 
potential effects of autograft cell subsets on the 
patients’ clinical outcomes. As delineated in an 
EBMT position statement from 2014, determina-
tion of cell subsets other than CD34+ cells is not 
routinely performed in clinical practice but only 
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in clinical trials (Mohty et al. 2014). Accordingly, 
assessment of tumour cell contamination is usu-
ally not part of the clinical routine but can be of 
interest in clinical trials.
17.2  HSCs Cryopreservation
HSCs should be processed and stored in accor-
dance with the respective Medical Council, 
responsible local and overarching authorities as 
well as scientific society’s guidelines (e.g. EU: 
Guideline 2004/23/EG and 2006/17/EG, 
EU-GMP-Guideline).
If necessary, collected cells can be stored for a 
maximum of up to 72 h at 2–6 °C before cryo-
preservation. However, cryopreservation within 
48 h or less is recommended to maintain an opti-
mal viability of the cells. In the case of storage 
for >24 h prior to cryopreservation, the maximum 
nucleated cell (NC) concentration should not 
exceed 2 × 108/mL.
For cryopreservation, a number of different pro-
tocols are used worldwide. Usually, the maximum 
accepted NC concentration is ≤4 × 108/mL. If nec-
essary, PBSC products can be diluted with autolo-
gous plasma or commercial resuspension medium. 
Increasing the cell concentration by volume deple-
tion minimizes the number of cryostored bags 
needed, but the upper limit of the NC concentration 
needs to be considered. The final product includes 
5–10% dimethyl sulfoxide (DMSO) as a cryopro-
tectant and 0.05–0.25  mL of ACD-A stabilizer 
solution per ml of transplant. Freezing at a con-
trolled rate of 1–2 °C per minute is recommended. 
Cells need to be stored in vapour phase nitrogen at 
a temperature of ≤−140 °C. Cross-contamination 
while preparing and storing the cells must be pre-
vented by taking appropriate measures.
At the time of auto-HSCT, cryopreserved bags 
must be thawed at the site of transplantation, and 
PBSCs should be reinfused within a maximum 
time span of 10–20 min of thawing using stan-
dard transfusion filters in order to minimize the 
detrimental effect of DMSO upon HSCs. Previous 
washing for purposes of DMSO depletion is not 
routinely performed, as the loss and damage of 
HSCs are regarded as too high.
Several studies demonstrated that under these 
storage conditions, CD34+ HSCs remained viable 
for up to 19  years (Fernyhough et  al. 2013; 
McCullough et  al. 2010; Spurr et  al. 2002). In 
addition, a recent study demonstrated that the 
duration of cryostorage of the transplant had no 
impact on the haematologic reconstitution after 
transplantation (Lisenko et al. 2017a).
17.3  HSCs Quality Assessment
HSCs product quality assessment needs to be 
performed at several time points during cell pro-
cessing and storage. Volume measurement, enu-
meration of NC and red blood cells and flow 
cytometry-based CD34+ cell quantification 
should be performed directly after PBSC collec-
tion in accordance with the Stem Cell 
Enumeration Committee Guidelines of the 
International Society of Hematotherapy and 
Graft Engineering (ISHAGE) (Sutherland et  al. 
1996). A validated protocol and external quality 
control (e.g. the round robin test) is strongly rec-
ommended (Whitby et al. 2012).
Shortly before freezing, microbiological cul-
ture samples must be obtained. NC enumeration 
and NC viability measurement (e.g. by staining 
with trypan blue, 7-aminoactinomycin D 
[7-AAD] or propidium iodide) should be per-
formed from aliquots of the final cell product 
after freezing and thawing. This viability testing 
is only valid for a defined and limited time span, 
often 2–5 years based on local guidelines, before 
it needs to be repeated prior to transplantation. As 
a result, a sufficient number of reference samples 
should be prepared for each HSCs product (the 
recommended minimum number is 3).
Target values need to be defined for the final 
product, mostly in accordance with local authori-
ties. In most transplant centres in Europe, the fol-
lowing criteria are mandatory (together with 
additional criteria) for the release of an autolo-
gous transplant: NC concentration ≤4 × 108/mL, 
CD34+ cell number ≥2 × 106/kg BW, red blood 
concentration ≤0.1 mL per mL of transplant, no 
microbial growth and minimum NC viability of 
>50% after freezing and thawing.
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17.4  Collection of Reference 
(Retention) Samples 
for Quality Control
Reference samples for quality control must be 
taken and stored from the cell product. These 
samples allow the proof of quality and potency of 
the transplant in terms of sterility, purity and via-
bility of the cells. In the case of an allo-HSCT, 
reference samples may also need to be collected 
from the donor, depending on the respective local 
legal situation, to allow for a retrospective analy-
sis in terms of serological testing.
Reference samples are prepared in parallel 
with the cell product and stored under the same 
cryoconditions until they are analysed. As a 
release criterion for an autologous stem cell 
transplant, a reference sample should be cryopre-
served for >24 h under the identical conditions as 
the cell product before the viability of CD34+/
CD45+ cells is analysed. Performing a clonogenic 
assay (e.g. colony-forming assay) from the refer-
ence samples can assess the haematopoietic 
potency of the cells. However, this is not regarded 
as a release criterion but should be performed for 
process validation or in the case of prolonged 
cryostorage of a transplant (>2–5 years).
The final cell product must be labelled in 
accordance with respective legal requirements. In 
order to transport cryopreserved HSCs products, 
a validated shipping container is required, prefer-
ably with continuous temperature monitoring. 
The treating physician is responsible for applica-
tion of the HSCs transplant after evaluating its 
integrity and the accompanying documents.
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Umbilical cord blood (UCB) cells for allogeneic 
use are collected and frozen in more than 130 public 
CB banks worldwide. More than seven hundred and 
fifty thousands CB units (CBU) are available for 
transplantation. In this chapter we will describe 
some procedures for cord blood collection, process-
ing, banking and recommendations on how to 
choose a single or double UCB unit for transplanta-
tion (Garcia 2010).
18.2  Collection
Donor recruitment usually starts during the antena-
tal period, with objective information given by 
woman’s health-care provider. After consent, 
trained personnel need to determine donor eligibil-
ity to ensure that donation is safe for future patients. 
To assess donor eligibility, a donor medical history 
interview shall be conducted identifying risk factors 
for transmissible and genetic disease. In addition, 
infectious disease markers (IDM) performed to 
maternal blood samples will be obtained within 
7  days before or after the collection of the UCB 
unit. These samples will be tested for evidence of 
infection of HIV-1, HIV-2, hepatitis B, hepatitis C, 
HTLV-I, HTLV-II, syphilis and any additional 
markers according to local regulations.
Collection must not interfere with normal 
delivery attention. A successful collection should 
have a high collection volume and a high total 
nucleated cell count, be non-contaminated and 
have the proper documentation. A UCB collec-
tion typically involves cord clamping (delayed 
clamping up to 1–2 min is still compatible with 
public donations) (Frändberg et al. 2016), disin-
fection, venipuncturing of umbilical vein and 
draining by gravity avoiding clotting. Collection 
bag should be appropriately labelled.
There are two main techniques to collect UCB 
from the cord vein: before the placenta is deliv-
ered (in utero) or after the placenta is delivered 
(ex utero). Both collection techniques have their 
own unique advantages and disadvantages, but 
both techniques require that the individuals per-
forming the collections be adequately trained.
After collection, typically health-care provider 
will complete a report describing labour and com-
pleting variables that could be useful to release the 
unit like the presence of fever, complications, type 
of delivery, etc. In case of unexpected adverse 
reactions during collection they need to be com-
municated to the competent authority. After col-
lection, it may be required a follow-up of the donor 
including health questionnaires. Additionally, if 
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any abnormal result is detected during testing, a 
counseling process should be in place.
UCB units shall be transported to the process-
ing facility, and sometimes, these facilities could 
be far away from the collection sites. A validated 
procedure for transportation between these two 
facilities is needed to demonstrate a reliable 
method. Standard procedures shall be in place to 
describe time and temperature of storage and 
transportation methods. All transportation 
records shall allow tracking back from the collec-
tion site to the UCB bank, and any deviation 
should be recorded.
18.3  Processing and Banking
18.3.1  UCB Cell Processing
Unrelated UCB unit must arrive at the processing 
laboratory in time to allow initiation of cryo-
preservation within 48 h of collection (this time 
is extended to 72 h for related or directed UCB 
donations). The decision as to whether a col-
lected UCB unit will be acceptable for process-
ing and banking will be made based on the 
acceptance criteria specified by the UCB bank. 
Many banks have further refined their acceptance 
criteria based on economics and the desire to 
build an international inventory of UCB units 
with very high TNC or percentage of ethnic 
minorities. Many UCB banks are now committed 
to processing and storing only those UCB units 
with high TNC (e.g. >20 × 107 TNC or higher), 
based on the greater likelihood of these units 
being used (Saccardi et al. 2016).
Volume reduction of UCB is considered 
essential to the provision of a high-quality prod-
uct and cost-effective UCB banking. Reducing 
the volume of the final product allows for storage 
efficiency in terms of space and cost and, most 
importantly, reduces the risk of ABO incompati-
bility and DMSO toxicity to the potential recipi-
ent. Despite some loss of cells, volume reduction 
has additional practical and clinical benefits; the 
process yields RBC and plasma components as 
waste products that can be used for immediate or 
future testing, thereby minimizing the loss of the 
actual stem cell product for testing purposes. 
Different methods for volume reduction are 
available (Hough et al. 2016).
The selection of a suitable protocol for cryo-
preservation of UCB for use in transplantation 
is critical to optimize the recovery of function-
ally viable progenitor cells, most of which lie 
within the CD34+ compartment. Some important 
 considerations that are potential sources of cell 
damage include the type and concentration of cryo-
protectant, the cell concentration and the cooling 
and warming rates. UCB units must be stored in 
freezing bags designed and approved for the cryo-
preservation of human cells and placed into metal 
canisters to afford protection during freezing, stor-
age, transportation and shipping. It is important that 
after filling, each freezing bag is visually examined 
for possible leaking and breakage of seals.
UCB units should be cryopreserved using a 
controlled rate freezer with a validated freezing 
programme. Liquid nitrogen-based controlled 
rate freezers have been used to ensure long-term 
maintenance. Minimizing transient-warming 
events is very important for that. Stability pro-
grammes should be designed in order to establish 
the expiration time of the UCB stored.
18.3.2  Testing and Quality 
Assessment
Table 18.1 shows release specification for UCB 
units. Quality assessment is written below:
Safety It is essential that UCB is screened for 
those infectious diseases which can be transmit-
ted via blood (as described above). In addition, 
product should be free of microbial contamina-
tion (or with an appropriate antibiogram for 
related uses). Prior to release for administration, 
each UCB unit must have undergone hemoglo-
binopathy screening.
Identity At least, HLA-A, HLA-B, HLA-C and 
DRB1 loci must be determined using DNA-
based methods and result included when listing 
a UCB unit on the search registries. It is recom-
mended that HLA typing is performed in an 
accredited laboratory. ABO blood group and Rh 
type must be reported prior to listing a UCB 
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unit for search. Prior to release of a UCB unit 
for administration, it is imperative that HLA 
identity is confirmed. Ideally, confirmatory typ-
ing will be performed on a sample taken from a 
contiguous segment. HLA typing on maternal 
blood may also be performed prior to release of 
a UCB unit. Haplotype matching between 
maternal donor and infant donor confirms link-
age between the two and serves as a secondary 
confirmation of identity.
Purity UCB unit specifications report total 
nucleated cells, total nucleated RBC count and 
CD34+ cells, and a cell blood count with differen-
tial should be performed, with parameters for 
neutrophils, lymphocytes, monocytes and plate-
lets defined.
Potency Potency testing to determine the growth 
potential and viability of progenitor cells in a 
UCB unit should be performed post-processing 
(prior to cryopreservation), in addition to being 
performed on a representative thawed sample 
prior to release for administration.
18.4  Selecting CBU 
for Transplantation
The success of the UCB transplantation (UCBT) 
will depend on the characteristics of the 
CBU. Tables 18.2 and 18.3 list the recommenda-
tion of choosing single and double cord blood 
units, respectively, for transplantation.
Table 18.1 Lists the specification requirements for CBU stored for clinical application, according to the sixth edition 
NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration (www.
factwebsite.org)
Specification requirements for cord blood units stored for clinical administration
Test


















Should be ≥60% Should be ≥60%










CFU (or other 
validated 
potency assay)a
Growth (or positive 
result for potency)
Growth (or positive 
result for potency)
Sterility Negative for aerobes, 
anaerobes, fungus
Negative for aerobic and 
anaerobic bacteria and 
fungi—OR—identify and 






Applicable Law and 
NetCord-FACT 
standards
Acceptable as defined by 
Applicable Law and 
NetCord-FACT standards
Identity Verified Verified
aThere should be evidence of potency by CFU or other validated potency assay on a fresh post-processing sample
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Table 18.2 Recommendations for unrelated CBU selection and transplantationa
Initial selection of single CBU should be based upon
 (a) HLA matching of the recipient and CBU
(b) CBU collected cell dose (TNC ± CD34+)
 (c) Patient’s diagnosis (malignant versus non-malignant)
 (d)  Avoiding CBU containing Ag that match the specificity of any pre-transplant donor-specific anti-HLA Ab in the 
recipient
HLA matching
• Malignant disorders (Eapen et al. 2014)
HLA matching should be based upon allelic typing for HLA-A, HLA-B, HLA-C and HLA-DRB1 for single CBT
 1. Select an HLA-matched (8/8) CBU. TNC dose should be >3 × 107/kg
 2.  If an HLA-matched (8/8) CBU is unavailable, select a CBU matched at 7/8 HLA loci. HLA-A or HLA-B 
mismatches are preferable to HLA-DRB1 mismatches. TNC dose should be >5 × 107/kg for 5–7/8 matched units
 3.  If a CBU matched at 8/8 or 7/8 HLA loci is unavailable, consider a CBU matched at 5 or 6/8 HLA loci. Avoid 
mismatches in HLA-DRB1
 4.  If CBU 4/8 matched, CBU may rarely be considered as a single CB graft if no other option is available. TNC dose 
should be >5 × 107/kg for 4/8 matched units
 5. CBU 3/8 HLA-matched CBU are not recommended
• Non-malignant disorders (Eapen et al. 2017)
 1. CBU with HLA 8/8 or 7/8 give same survival results
 2. CBU with HLA 6/8 and 5/8 give inferior survival rates and are alternative options
 3. We do not recommend selecting cord blood units with more HLA disparities
TNC and CD34+ cell dose
• Malignant disorders
Nucleated cell doseb At freezing, minimum TNC dose 3.0 × 107/kg, or
After thawing, minimum TNC of 2.0–2.5 × 107/kg
CD34+ cell dosec At freezing, 1.0–1.7 × 105/kg, or
After thawing, around 1.0–1.2 × 105/kg
• Non-malignant disordersd
Nucleated cell dose At freezing, minimum cell dose 3.5 × 107/kg, or
After thawing, minimum cell dose 3.0 × 107/kg
CD34+ cell dose At freezing or after thawing, >1.7 × 105/kg
Colony-forming unit assay: This assay is important to evaluate the functional capacity of HPCs after thawing an 
aliquot or after thawing the product; however it is difficult to establish a generalized CFU-GM dose due to variations 
of colony setup and counting between centres
Other considerations when selecting single CB units
If many CBU meeting the criteria above are available, the following factors should also be considered
 •  Use accredited cord blood banks. For safety, only accredited banks recognized by national and international 
organizations should be used
•  ABO compatibility: ABO compatibility may be associated with improved outcomes, although the data are 
conflicting
 •  NIMA: If the cord banks have the mother’s HLA typing, the potential effect of NIMA should be noted in context of 
clinical trials
 • KIR ligand: Due to conflicting data, KIR ligand matching should not be used in the selection of CBUs
 • Sex matching: Sex matching between CBUs and patients in single or double UCBT is not necessary
aBased on Eurocord and British Society of Blood and Marrow Transplantation recommendations (Hough et al. 2016, 
modified)
bIf the infused TNC dose is 1.0–2.0 × 107/kg, the number of CD34+ cells or CFU-GM should be taken into consideration 
to predict the probability of neutrophil recovery and to discuss the possibility of a second transplant. If both cell doses 
are lower than recommended, a BM aspirate and chimerism analysis should be performed between days +20–28. The 
absence of engraftment indicates the need for a second transplant; preliminary data shows that haploidentical or double 
CBT should be considered
cDue to variation in counting CD34+ cells, this recommendation should be taken with caution. However, if colonies are 
not growing, the transplant physicians should consider a second transplant after day +30
dFor patients with BMF syndromes (aplastic anaemia or congenital bone marrow failure states) or haemoglobinopathies, 
the number of TNC at freezing should be greater than 5 × 107/kg
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Key Points
• Cord blood donation comprises the fol-
lowing steps: informative and consent 
process, revision of eligibility criteria, 
cord blood collection and finally fresh 
storage before a standardized transpor-
tation to the processing cell lab.
• Cell processing labs require coordination 
of production and quality control labs to 
transform the altruistically donated raw 
material in a medicinal product with pre-
defined specifications that ensure its 
safety, identity, purity and potency.
• A public cord blood bank is a stem cell 
registry that provides ready-to-use 
banked medicinal products for any 
patient in need through international 
networking of stem cell donor 
organizations.
• Cord blood selection is based on sorting 
CB units using primary criteria (cell 
content and HLA matching) followed 
by ranking based in secondary criteria 
depending on disease status, condition-
ing, age and recipient’s weight.
Table 18.3 Additional criteria for double CBU selection
–  When a single CBU unit contains insufficient cells (as specified above), double UCBT is recommended for the 
treatment of malignant disorders
–  There are currently insufficient data to make recommendations for double UCBT in the treatment of non-
malignant disorders
HLA matching
•  The historical stringency of HLA matching for CBUs with the recipient for double UCBTs should be used, i.e. the 
minimum acceptable HLA matching between either CBU and the recipient is 4/6 using low/intermediate typing 
(antigen) for HLA-A and HLA-B and high- resolution typing (allelic) for HLA-DRB1
• There is no requirement for inter-cord HLA matching
• The role of high-resolution (allele) typing is not yet defined for double CBT
Cell dose
Nucleated cell dose At freezing, the sum of both CBUs >3.5 × 107/kg
The minimum cell dose of each unit should be >1.5 × 107/kg
CD34+ cell dose At freezing or after thawing, the sum of both CBUs >1.8 × 105/kg
ABO matching
Recently, a retrospective study of Eurocord of almost 1000 double UCBT recipients has shown an important 
association between ABO compatibility of 2 units with the patient on acute GVHD, NRM and OS. Thus, ABO 
compatibility between units and patients should be preferred over minor or major compatibility of one of the units 
between CB and patient (V Rocha on behalf of Eurocord, personal recommendation)
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Graft manipulation is performed to define and to 
optimize the volume and cellular composition of 
stem cell sources like apheresis products, bone 
marrow, or umbilical cord blood.
Basic manipulations comprise centrifugation 
procedures for depletion of erythrocytes and vol-
ume reduction and are required to cryopreserve 
grafts in the presence of cryoprotectants like 
DMSO (Dimethylsulfoxide) (Rowley 1992). 
These are standard procedures for BM and CB, 
while apheresis products usually can be cryopre-
served without further manipulation.
More complex manipulations are used to opti-
mize the cellular composition and to meet 
requirements of the individual transplant regi-
men. Selection of CD34+ or AC133+ progenitors 
from apheresis or BM has been used to produce 
concentrated stem cell grafts. In recent years, the 
selective depletion of unwanted cells like CD3+ 
T cells, TcRαβ+ T cells, and others provides a 
custom-tailored graft. For both enrichment and 
depletion, immunomagnetic cell sorting using 
monoclonal antibodies and paramagnetic micro-
beads in combination with semi- or fully auto-
mated devices has become the standard technique 
in most laboratories.
19.2  Graft Manipulation
19.2.1  Physical Manipulations
19.2.1.1  Volume Reduction
Volume reduction might be necessary in small 
children and is done by a simple centrifugation 
process and removal of the supernatant.
19.2.1.2  Washing to Reduce Plasma 
Antibodies or 
Anticoagulants
Washing might be necessary in case of unwanted 
isoagglutinins or to lower the heparin concentra-
tion and is also done by centrifugation in a bag or 
dedicated devices and by exchange of plasma 
with a suitable solution like 0.9% NaCl. Addition 
of anticoagulant is not necessary as coagulating 
agents are washed out by the treatment.
19.2.1.3  Depletion of Erythrocytes
Depletion of erythrocytes is necessary in case 
of blood group incompatibilities and usually 
confined to bone marrow. Several procedures 
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are employed including centrifugation with 
an apheresis device or centrifugation in bags 
or tubes and subsequent harvest of the buffy 
coat. In special cases, a separation using den-
sity gradient centrifugation (e.g., Ficoll) might 
be useful with an even stronger depletion of 
erythrocytes.
19.2.2  Immunomagnetic Procedures
19.2.2.1  CD34 Enrichment
Enrichment of CD34+ stem cells was the first 
method which provided grafts with a very low 
number of T cells and therefore allowed to avoid 
GvHD highly effective even in haploidentical 
HSCT (Ringhoffer et  al. 2004; Handgretinger 
et al. 2001).
The method has also been successfully used in 
MSD and MUD HSCT to minimize the rate of 
GvHD (Pasquini et  al. 2012; Lang et  al. 2003) 
and showed a clear advantage regarding com-
bined cGVHD-free and relapse-free survival 
compared to unmanipulated grafts in myeloid 
diseases (Tamari et al. 2018).
Moreover, CD34 selection is used as a graft 
backbone to which other cell types (unmanipu-
lated DLI, CD45RA depleted DLI, and others) 
can be added.
Enrichment can be performed with the 
Miltenyi Biotec CD34 reagent system which uses 
a mAb for the CD34 class 2 epitope and therefore 
has to be detected by an Ab to a different epitope 
(normally class 3). Stem cells after separation 
normally show a high purity with extremely low 
amounts of other contaminating cell types. In 
some cases various amounts of monocytes are 
found without detrimental effect on the graft. 
Due to the small size of the graft, absolute num-
bers of contaminating T cells remain low even if 
a significant percentage persists. B cells are pas-
sively depleted as well, whereas CD34+CD19+ 
B-cell precursors are retained: 1–3% in PB, up to 
30% in BM preparations.
Recovery of CD34+ cells is in the range of 
50–90% (Schumm et al. 1999).
19.2.2.2  CD133 Enrichment
CD133 detects a slightly smaller subpopulation 
of CD34+ cells and can also be used for enrich-
ment of stem cells with similar results (Koehl 
et al. 2002; Lang et al. 2004).
19.2.2.3  T-Cell Depletion
Immunomagnetic TCD is technically more 
demanding than CD34+ enrichment as the pro-
cessed grafts contain a much higher overall num-
ber of cells and even extremely low percentages 
of contaminating T cells can endanger the suc-
cess of the manipulation. Moreover, the correct 
enumeration of T cells in a depleted graft is chal-
lenging and needs special protocols.
CD3 Depletion
Depletion of CD3+ T cells provides almost 
untouched grafts with potential antileukemic 
effectors (e.g., NK cells) enabling fast engraft-
ment and reliable prevention of GvHD. Prospective 
phase I/II trials showed low TRM rates after 
haplo-HSCT in combination with toxicity- and 
intensity-reduced conditioning regimens in chil-
dren and adults (Lang et  al. 2014; Federmann 
et al. 2012).
Depletion can be done using the CliniMACS 
LS tubing set or the DTS tubing set. In both cases 
the depletion efficacy can be 0.5 log lower than in 
CD34+ selection. Since in haplo-HSCT residual 
T cells should not exceed 50 × 103/kg, it might be 
occasionally necessary to perform a CD34+ 
selection with parts of the apheresis to remain 
below the requested thresholds and to guarantee a 
sufficient number of progenitor cells (Lang et al. 
2014; Federmann et  al. 2012; Huenecke et  al. 
2016).
It should be ensured that during the incubation 
process, all cells come into contact with the CD3 
reagent to avoid unstained T cells which can 
impair the result of the depletion significantly. 
This may happen when transferring stained cells 
into a second bag system leaving unstained cells 
in the tubing ends and crinkles of the bag behind. 
Even smallest amounts of 20–50 μL can contain 
more T cells than the whole graft should have.
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Analysis of CD3 depleted grafts needs special 
protocols and has to take into account the rare 
number of T cells among the huge overall num-
ber of cells. Therefore, a multigating strategy 
should be implemented and validated, and T cells 
should be determined using several parameters. 
Exclusion of myeloid cells by CD33 could be 
helpful as well as the use of CD3 in a bright fluo-
rochrome like APC. Gating can be facilitated by 
using a “spiked” probe with cells of the negative 
fraction and a small percentage of cells from the 
positive fraction added to set the gate for subse-
quent analysis of the negative fraction. For statis-
tical reasons, a minimum of 1 × 106 events should 
be acquired. To prevent takeover of cells from a 
previous tube, special care should be taken like 
flushing the cannula with water before the actual 
acquisition or to clean the cannula on the outside 
(Schumm et al. 2013).
TcRαβ Depletion
This procedure removes αβ + T lymphocytes via 
a biotinylated anti-TcRαβ Ab followed by an 
anti-biotin Ab conjugated to magnetic micro-
beads while retaining both γδ + T lymphocytes 
and natural killer cells in the graft.
Depletion with the TcRab reagent has been 
shown to be associated with a high depletion effi-
cacy (4.7 log), better than after CD3 depletion 
(4.0 log) and similar to CD34+ enrichment (4.6 
log). Moreover, the results differ less than those 
after CD3 depletion, resulting in <50  ×  103/kg 
infused residual TCRαβ+ T cells, even in small 
children (Schumm et al. 2013).
Compared to CD34 selected grafts, a faster 
expansion was seen for CD3+ and for CD56+ 
in the early phase after haplo-HSCT, probably 
caused by expansion of co-transfused γδ T cells 
and NK cells (Lang et  al. 2015). Moreover, 
clinical trials in children and adults demon-
strated a very low incidence of acute and 
chronic GvHD as well as favorable engraftment 
and TRM rates (Locatelli et  al. 2017; Kaynar 
et al. 2017). The method was successfully used 
to avoid GvHD also in MUD HSCT (Maschan 
et al. 2016).
Detection of TcRαβ+ T cells should be done 
with the same precaution used for CD3 depleted 
cells, with a minimum of 1 × 106 events and sev-
eral parameters for the identification of the 
TcRαβ+ cells. Pregating on CD3-PE vs 7-AAD 
has been shown to be very helpful as well as gat-
ing on TcRαβ and TcRγδ cells in the consecutive 
dot plot (Schumm et al. 2013).
CD19 Depletion
Depletion of CD19+ B cells can be done together 
with CD3 or TcRαβ depletion and prevents effec-
tively the occurrence of EBV-associated 
PTLD. Although the threshold dose of contami-
nating B cells is still not defined, no cases of PTLD 
were observed in two multicenter trials with 104 
children and adults after infusion of median num-
bers of 28 and 7 × 103 CD20+ cells/kg BW, respec-
tively (Lang et al. 2014; Federmann et al. 2012).
Alternatively, B-cell depletion can be done 
in  vivo by infusion of therapeutic anti-CD20 
mAbs (Locatelli et al. 2017).
Detection of CD19+ B cells needs special 
attention as the binding of fluorescence-labeled 
antibody is impaired when cells were preincu-
bated with the CD19 reagent. Therefore, the 
detection has to be done with an antibody for 
CD20 which is co-expressed on B cells (Schumm 
et al. 2006).
Stem Cell Boosts
Poor graft function after HSCT is a relevant com-
plication and is defined as at least bilinear severe 
cytopenia and/or transfusion requirement, which 
occurs in a situation of full donor chimerism.
Administration of stem cell boosts from the 
original donor offers a therapeutic option 
(Remberger et al. 1998).
To reduce the risk of GvHD, ex vivo TCD pro-
cedures as mentioned above are recommended 
(Olsson et al. 2013). Most experience exists with 
CD34 selected boosts. Response rates of 80% 
and a low risk of de novo GvHD between 6% and 
22% were observed, even in the case of mis-




19.2.3  DLI and T Cells
T cells may be added to a graft or administered 
post transplant to provide T cell immunity in var-
ious situations. The tolerable dose of T cells var-
ies strongly depending on the HLA disparity, the 
T cell chimerism in the patient, and the time after 
transplantation. In MUD HSCT or in haploiden-
tical HSCT, it can be helpful to cryopreserve a 
number of vials with a defined number of T cells 
(i.e., 100 × 103 CD3+/kg and 25 × 103 CD3+/kg, 
respectively) for easy access in case of increasing 
recipient chimerism.
19.2.3.1  CD45RA Depletion
DLI with CD45RA+-depleted T cells takes 
advantage of the CD45R0+ T cells which obvi-
ously exert little graft-versus-host reaction but 
can provide antileukemic and antiviral activity. 
Depletion can be done using the same equipment 
and reagents for depletion. Depletion is highly 
effective, and contaminating CD45RA+ cells 
cannot be found at all (Teschner et al. 2014).
19.2.3.2  DLI in Relapse
DLI has been first used in CML patients after 
relapse and was given as unmanipulated non- 
mobilized apheresis in the HLA-matched 
setting.
19.2.3.3  DLI in Mixed Chimerism
Repetitive DLI can be used to revert a mixed T 
cell chimerism. Depending on the type of the 
donor, various cell numbers are employed. In 
MSD or MUD HSCT, doses between 1 × 105 and 
1 × 106/kg are usual, whereas after mismatched 
or haploidentical HSCT, starting doses of 
25 × 103 CD3/kg are recommended (Haines et al. 
2015) (and own experience).
19.2.3.4  Virus-Specific T Cells
Virus-specific T cells can be enriched from 
peripheral blood or an unstimulated apheresis of 
the original (seropositive) stem cell donor or—if 
not possible—alternatively from a partially 
matched third-party donor.
Donor-derived-specific T cells against ADV-, 
CMV-, or EBV-associated antigens have been 
already used in many patients suffering from life- 
threatening infections post transplant, and clini-
cal or virological response rates between 70% 
and 86% were observed (Icheva et  al. 2013; 
Feucht et al. 2015; Feuchtinger et al. 2010).
The most common technique in the field of 
graft manipulation is the cytokine capture system 
which employs the secretion of IFNg after stimu-
lation with appropriate Ag or peptide mixtures 
for immunomagnetic selection of specific T cells. 
Simultaneous stimulation with several Ag is pos-
sible and generates multispecific T cells.
The selection procedure can be done with a 
CliniMACS Prodigy® from a maximum of 
1 × 109 cells from a non-mobilized or a mobilized 
apheresis and yields 6–7  ml of cells, with 
0.1–2 × 106 CD3+IFNg+ target cells.
Accompanying debris and dead cells require 
an accurate analysis. Moreover, the small amount 
of target cells limits the sample size available for 
analysis, and therefore a single platform proce-
dure including cell count and viability in one 
measurement is recommended. The first step 
should be done without washing and includes a 
cell gate to exclude debris. CD45 and 7-AAD can 
be used for proper determination of cell viability. 
A second sample can be analyzed after washing 
for CD3+, CD4+, and CD8+ numbers and the 
percentage of IFNg+ cells in these subsets. 
Bystander cells like B cells, monocytes, and 
granulocytes can be found in low numbers 
(Feuchtinger et al. 2006).
19.3  Regulatory Issues
Graft manipulation is regarded as drug manufac-
turing in most countries and has to follow the 
requirements of the EU GMP guidelines, the 
European Pharmacopoeia, and several EU direc-
tives. Therefore clean room areas are required for 
the manufacturing and a manufacturing license, 
and a marketing authorization is mandatory for 
distribution of the product. A quality assurance 
system has to be implemented, and specifications 
have to be in place for both raw material and drug 
product. In most cases, volume, cell number, cell 
dose, viability, and composition are minimum 
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parameters. Sterility in the form of microbiologi-
cal examination of cell-based preparations 
according to Pharm. Eu. 2.6.27 has to be shown 
either before release of the product or, in the case 
of limited stability, after release.
Peripheral blood stem cells from both blood 
and bone marrow for hematopoietic reconstitu-
tion are regarded as non-ATMP.
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It is of central interest to document that the newly 
developing hematopoiesis post-transplant is of 
donor or recipient origin. The investigations of 
the genotype origin of post-transplant hemato-
poiesis are called chimerism analysis. The term 
“chimerism” was first introduced into medicine 
in 1951. Andresen wrote that an organism with 
cells from two or more distinct zygote lineages is 
a “chimera.” Since 1956 this term was used in 
field of transplantation (Ford et  al. 1956). 
Chimera refers itself to the Greek mythology 
where Homer described a fire-spitting monster 
with the head of a lion, a tail of a serpent, and the 
body of a goat terrorizing Lycia, a region in 
Minor Asia.
For a long time, it was believed that complete 
donor hematopoiesis is necessary to maintain 
engraftment after allo-HSCT. A few decades ago, 
it became apparent that donor and recipient 
hematopoiesis may coexist. This state of coexis-
tence of hematopoietic cells is called mixed chi-
merism (MC). If all cells are of donor origin, the 
patient is referred to as “complete chimera,” and 
he shows a “complete chimerism.”
It is important to note that the state of hemato-
poietic chimerism may underlay a certain 
dynamic. Patients with a complete chimerism 
may develop a “mixed chimerism” at a later time 
point or vice versa. In the later patients, the 
amount of autologous cells may “increase” or 
“decrease.” The patients then develop an “increas-
ing mixed chimerism” or a decreasing mixed chi-
merism. To avoid misunderstandings as to 
whether donor or recipient hematopoiesis 
changes, it is recommended to report “increasing 
mixed donor chimerism” or “increasing mixed 
recipient chimerism.”
Nowadays, it has become possible to analyze 
hematopoietic chimerism also in single cell sub-
populations. If a patient’s hematopoiesis is mixed 
only in different cell lines, these patients are 
referred to have a “split chimerism.” Finally the 
applied method for chimerism analysis has also 
an impact on the degree of chimerism. A patient 
could be complete chimera with a method detect-
ing about 1% autologous cells, whereas recipient 
cells could have been detected with a more sensi-
tive technique (Bader et al. 2005).
20.2  Methods for Chimerism 
Analysis
Different methods have been developed for the 
assessment of hematopoietic chimerism. All 
these methods followed the same principle using 
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differences in polymorphic genetic markers and 
their products. Historically restriction fragment 
length polymorphism (RFLP), cytogenetics, red 
cell phenotyping, and fluorescence in situ hybrid-
ization techniques were used for the assessment 
of hematopoietic chimerism. All of these tech-
niques have been very time-consuming and did 
not always offer the possibility to be used in 
every patient-donor constellation.
Widespread and timely clinical applicability 
has become possible after polymerase-chain-
reaction (PCR) techniques were developed. 
During the 1990s, these analyses were mainly 
performed by amplification of variable number 
of tandem repeats (VNTR). Later in the decade 
short tandem repeats (STR) were used. 
Fluorescent labeling of the primers and resolu-
tion of PCR products with capillary electrophore-
sis allowed immediate and accurate quantification 
of the degree of chimerism. Semiautomated PCR 
analysis using the appropriate hardware allowed 
moreover high sample throughput. This made it 
possible to study chimerism in all patients and in 
short time intervals already early after transplan-
tation. Accurate monitoring of engraftment as 
well as surveillance of impending graft rejection 
in patients transplanted for nonmalignant disease 
has become possible (McCann and Lawler 1993; 
Alizadeh et al. 2002; Thiede et al. 2001).
Recently, real-time PCR (rPCR) approaches 
using single nucleotide polymorphism (SNP) 
have also become available for the detection of 
chimerism. SNPs are biallelic variants that differ 
from each other only at a single nucleotide and 
occur on average every 1.3  kb in the human 
genome. This rPCR has an even higher sensitiv-
ity compared to STR-PCR assays, but their quan-
titative accuracy with a variation coefficient of 
only 30–50% is lower compared to 1–5% of the 
STR systems.
The latest developments for the detection of 
chimerism are the analysis using digital PCR 
(dPCR) procedures. This technology allows 
accurate and absolute quantification of DNA. This 
dPCR system is based on deletion/insertion poly-
morphism (DIP/INDEL) analysis. Clinical stud-
ies using this technique, however, are not yet 
performed (Jacque et al. 2015; Clark et al. 2015).
Based on these issues, the STR-PCR with 
fluorescent- labeled primers and resolution of the 
fragments with capillary electrophoresis is cur-
rently still considered to be the gold standard for 
the assessment of post-transplant chimerism. It is 
important to stress that whatever method is 
employed to study chimerism, it is important that 
the procedure is standardized and the chimerism 
laboratory is accredited and is participating in 
quality control rounds (Lion et al. 2012).
20.3  Chimerism Investigation 
in the Clinical Setting
20.3.1  Chimerism in Nonmalignant 
Diseases
Allo-HSCT is the only curative treatment option 
for many patients with inherited or acquired non-
malignant diseases such as immunodeficiency, 
storage diseases, osteopetrosis, thalassemia, 
sickle cell disease, severe aplastic anemia, bone 
marrow failure syndromes, and many others.
The aim of the transplant procedure in these 
diseases is to achieve stable and durable engraft-
ment to (1) improve the hematopoietic function, 
to (2) correct the immune competence, and/or to 
(3) increase or normalize the respective enzyme 
shortage. As a consequence, it is not always nec-
essary to replace the recipient hematopoiesis 
completely. For many diseases, it is sufficient to 
implement a state of mixed hematopoietic chi-
merism to improve the patients’ well-being. To 
minimize toxic side effects intensity of condi-
tioning regimens in these diseases is often 
reduced and therefore less myeloablative. MC is 
more likely, and graft rejection or non-engraft-
ment remained the major causes of treatment 
failures in these patients (Bader et  al. 2005; 
Thiede et al. 2001).
It could be shown that rapid donor cell pres-
ence and maintenance of early complete donor 
chimerism in NK and T cells may play an impor-
tant role in achieving sustained engraftment 
especially in patients who were treated with 
reduced intensity conditioning regimens. 
Analysis of chimerism in disease characterizing 
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cell subpopulations in patients with  nonmalignant 
disease, e.g., in patients with severe combined 
immune deficiencies (SCID) or in patients with 
storages disease, enables the documentation of 
success of the transplant procedures (Preuner 
et al. 2016).
20.3.1.1  Intervention to Influence 
the Evolution of Chimerism: 
Transfusion of DLI
In patients with nonmalignant diseases, MC 
occurs frequently. The question whether individ-
ual patients with MC are at risk to reject their 
graft depends on the diagnosis and on the condi-
tioning regimens. Studies have clearly shown that 
MC can be influenced by DLI. MC can be stabi-
lized or even converted to complete donor chime-
rism by DLI. However, in treating patients with 
MC and DLI, physicians have to bear in mind the 
potential risk to induce GVHD which should be 
avoided in patients with nonmalignant disease 
with all efforts.
Hemoglobinopathies
In thalassemia patients, large studies have been 
published already from the Pesaro group of 
Guido Lucarelli, evaluating the influence of MC 
and disease recurrence. In general it was found 
that patients whose recipient MC increased to 
>30% autologous cells were by far more likely to 
ultimately reject and be transfusion dependent. 
However, there are patients with persisting high 
level MC who remained transfusion independent. 
Retrospective studies have been performed eval-
uating the possibility of influencing MC by 
DLI. It could be shown that a state of MC may be 
sufficient to remain transfusion independent. It 
was also shown that DLI is capable to convert 
MC to CC.  However, no general recommenda-
tion could be given at the time being (Fitzhugh 
et  al. 2014; Karasu et  al. 2012; Abraham et  al. 
2017).
In sickle cell disease (SCD), the impact of MC 
has been studied intensively as more and more 
patients with SCD were transplanted from 
matched but also from mismatched donors. In the 
late 1990s, first studies concluded that 10% of 
donor cell engraftment and persistence were 
needed for effective treatment of SCD in patients 
who were treated with a homozygous healthy 
donor; however, if the patient was grafted with 
the stem cells of a heterozygous HbAS donor, 
30–40% donor cells are required. The presence 
of MC in patients transplanted for sickle cell dis-
ease does not warrant DLI per se. In patients with 
less than 30% of donor chimerism, DLI might be 
considered. In a most recent study, Fitzhugh and 
colleagues developed a mathematical model by 
which they could show that a donor chimerism in 
the myeloid compartment of 20% is necessary to 
reverse the sickle cell phenotype and to prevent 
patients from disease recurrence (Fitzhugh et al. 
2017).
20.3.2  Chimerism in Malignant 
Diseases
Chimerism detected by molecular methods 
allows the assessment of persisting or reappear-
ing recipient cells after allo-HSCT.  These cells 
might be a reflection of either survival of malig-
nant cells or of survival or recurrence of recipient 
hematopoietic cells or a combination of both. It 
could be shown by prospective studies already in 
the early 1990s that a MC frequently occurs in 
the mononuclear cell fraction, weakens thereby 
the GvL effect, and facilitates recurrence of the 
underlying leukemia.
Chimerism analysis does provide information 
about the alloreactivity and/tolerance induction 
of the graft and thereby serves more likely a 
“prognostic factor” than as an indirect marker for 
MRD.  It has become evident that the develop-
ment of post-transplant chimerism is a dynamic 
process. Hence, if chimerism analyses are per-
formed in the intention to detect impending 
relapse, investigations need to be performed in 
short time intervals (Bader et al. 2004b; Thiede 
et al. 2001; Kröger et al. 2010a, b).
Initially, many pediatric studies using serial 
analysis of chimerism could clearly demon-
strate that patients who develop a MC Post 
transplant have an increased risk for future 
relapse of their leukemia. This could later also 
be confirmed by studies in adult patients. 
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Moreover these and subsequent studies 
undoubtedly showed that by immunotherapeu-
tic interventions, e.g., withdrawal of IS or 
transfusion of DLI, MC could be converted to 
complete chimerism, GvL effect restored, and 
many patients prevented from developing overt 
hematological relapse (Platzbecker et al. 2012; 
Bader et al. 2004a).
Based on its limited sensitivity to detect 
minor cell population of about 1%, chimerism 
analysis in the whole blood is not suitable to 
serve as a MRD marker. For the assessment of 
MRD, other techniques should be used, if pos-
sible. In patients and diseases lacking a dis-
ease-specific marker, for example, regularly in 
patients with MDS and often in patients with 
AML, chimerism analysis could be performed 
in cell subpopulations. Thiede et  al. could 
clearly demonstrate that by the characteriza-
tion of chimerism in the CD34- positive cell 
fraction, leukemia relapse could be anticipated 
in advance in many patients with AML and 
MDS.  In ALL patients, several studies have 
been performed investigating the impact of 
MC after enrichment of entity specific subpop-
ulation, e.g., CD 10, CD19, and CD 34 for pre-
cursor B ALL and CD3, CD4, CD5, and CD8 
for T-lineages. Remarkable correlation between 
MRD and chimerism in different subsets could 
be proven (Platzbecker et al. 2012; Bornhäuser 
et al. 2009; Rettinger et al. 2011).
Serial and quantitative analysis of chimerism 
allows the identification of patients at highest risk 
for relapse. Not all patients can be identified, and 
time interval between the onset of MS and relapse 
is often short. It is essential to perform the analy-
sis frequently and ideally: chimerism should be 
combined with MRD analysis to optimize the 
predictive value. These investigations can form 
the basis for individual preemptive immunother-
apy strategies to prevent recurrence of the under-
lying disease.
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Patients undergoing HSCT (mainly allo-HSCT) 
have a risk of developing complications related to 
pre-, peri-, and post-HSCT. The resulting morbid-
ity of the HSCT process makes it necessary for 
patients to adopt a healthy lifestyle that promotes 
health and contemplate preventive measures for the 
detection and treatment of possible complications.
The short- and long-term controls allow for 
regular and systematic screening and at the 
same time are an opportunity to give advice on 
healthy lifestyle habits. Monitoring should be 
 multidisciplinary with involvement of hematology, 
other medical specialties, physicians of primary 
care, nursing, and mental health professionals.
Early and late complications, as well as psy-
chological problems, are discussed in Parts IV, V 
and VI of the Handbook.
After discharge, it is important that the patient 
has a summary of the treatment received and a 
long-term follow-up plan appropriate to the 
exposure and individual risk factors.
The recommendations related to screening 
and prevention post-HSCT can be consulted in 
several web pages (see references).
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21.2  Monitoring Depending 
on the Type of HSCT
21.2.1  Autologous HSCT
Timing Monitoring
From discharge to 
day +100
Until full hematologic recovery, it is recommended to live near the hospital
Recommended controlsa:
 –  Clinical evaluation and transfusions when necessary
 –  Basic hematological and biochemical tests
 –  Specific markers for different diseases
At +3 months Evaluate the status of the primary disease
Recommended controlsa:
 –  Hematological and biochemical tests, specific tumoral markers
 –  MRD evaluation: Immunophenotype and molecular specific adapted to each disease
 –  BM biopsy in case of NHL, HL, MPS, and solid neoplasms with previous marrow affectation, in 
the remaining disease BM smears (see specific chapters)
 –  Imaging tests depending on primary disease
Long term Visits every 6 months up to 2 years and then annually
Recommended controlsa:
 –  Analytical and complementary explorations: See Table 21.1
 –  Baseline disease: Control of possible progression or relapse during at least 5 years
 –  In patients treated with chemotherapy + radiotherapy, assess the risk of second malignancies 
or MDS after HSCT
aVariable frequency depending on the patient’s condition





It is recommended that the patient resides near the transplant center during the first 3–6 months after 
HSCT
Recommended controlsa:
 –  Weekly clinical evaluation, during the first month, every other week until 2 m, and then monthly up 
to 6–12 m, unless problems arise. It must include complete physical examination, with special 
emphasis on data of acute GvHD, infections, and pulmonary complications
 –  Blood samples: Complete blood count, liver and kidney function, Mg, levels of IS agents, quantify 
CMV by PCR (and EBV if ATG); chimerism evaluation at 1 month




Usually, this moment marks the turning point so that, if the patient does not have major problems, he/
she can be monitored by the referring doctor. However, the patient should be periodically reevaluated 
at the transplant center (every 3–4 months during the first year, every 4–6 months during the second 
year, and annually after the third year)
Recommended controlsa:
 –  Visit and complete physical exploration with special emphasis on the signs of acute and chronic 
GvHD (assessment by organs as indicated in Chaps. 43 and 44 and paragraph 21.3)
 –  Blood test: Complete blood count, kidney function, liver function, clearance creatinine, IS 
levels; chimerism and sample for MRD follow-up. In patients aged <17 years, weight and height 
every 3 months
Long term It depends on the complications that arise during follow-up. If there are no complications, it is 
recommended that a patient visits to the center every 6 months up to 3 years and annually thereafter
Recommended controls:
 –  Visit and complete physical examination including gynecological evaluation and endocrinological, if 
appropriate
 –  Analytical and complementary explorations: See Sect. 21.3
 –  Specific controls: Specific MRD studies on diseases with markers (see corresponding chapters)
 –  In patients treated with chemotherapy + radiotherapy, the risk of secondary neoplasms
aVariable frequency depending on the patient’s condition
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21.3  Organ-Specific Long-Term 
Monitoring
Table 21.1 analyzes organ by organ the long-term 
follow-up recommendations.
Table 21.1 Organ-specific monitoringa
Recommended screeningb 6 months 1 year An. Comments
Ocular (see Chap. 48)
–  Clinical symptom evaluation 1 1 1 –  Immediate exam if visual symptoms
–  Visual acuity and fundus exam + 1 + –  Special attention to sicca syndrome
Oral (Chap. 50)
–  Preventive oral health and dental 
maintenance
1 1 1 –  Avoid smoking, sugar beverages, or oral 
piercing
–  If oral cGvHD, high-risk squamous cell cancer; 
evaluation every 6 months
–  Clinical assessment 1 1 1
–  Dental assessment (+children) + 1 1
Respiratory (Chap. 52)
–  Clinical pulmonary assessment 1 1 1  * Active or passive
–  If cGVHD, spirometry test in each control 
(recommended for many authors)
–  Smoking tobacco avoidance* 1 1 1
–  PFT (+chest Rx if symptoms) + + +
Cardiac and vascularc (Chap. 55)
–  CV risk factor assessment + 1 1 –  Counseling on heart healthy lifestyle
–  Active treatment of risk factors
Liver (Chaps. 38 and 49)
–  Liver function testing 1 1 1 –  Monitor viral load by PCR if HCV or HBV
–  Additional testing if high ferritin levels (MRI/
FerriScan®)
–  Serum ferritin testing 1 +
Kidney (Chap. 51)
–  Blood pressure screening 1 1 1 –  Hypertension should be investigated and 
treated appropriately
–  Avoid nephrotoxins
–  Urine protein screening 1 1 1
–  BUN/creatinine testing 1 1 1
Muscle and connective (Chap. 54)
–  Physical activity counseling 1 1 1 –  If risk of cGvHD, test joint mobility and touch 
skin to detect sclerotic changes
–  Treat cramps symptomatically
–  Evaluation muscle weakness 2 2 2
Skeletal (Chap. 54)
–  Bone density testingd 1 + –  Prevent bone loss and fractures with exercise, 
vitamin D, and calcium
Nervous system (Chap. 53)
–  Neurologic clinical evaluation + 1 1  *  Special attention of cognitive development in 
pediatric patients–  Cognitive development* 1 1
Endocrine (Chap. 56)
–  Thyroid function testing 1 1 –  Annual gynecological evaluation in women
–  Hormonal replacement if necessary–  Growth speed in children 1 1
–  Gonadal function assessmente 1 1 1
–  Gonadal function assessmentf 1 +
–  Gonadal function assessmentg + +
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21.4  Fertility (See Chap. 56)
21.5  Quality of Life (See Chap. 34)
Recommended References
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Table 21.1 (continued)
Recommended screeningb 6 months 1 year An. Comments
Mucocutaneous (Chap. 54)
–  Skin self-exam, sun counseling 1 1 1 –  Avoid sunlight without adequate protection
–  Gynecological exam in women 1 1
Immunity
–  Encapsulated Microorg. Prophylaxis* 2 2 2  *  If chronic GvHD and IS therapy, consider 
endocarditis prophylaxis in high-risk patients–  PJP prophylaxis (see Chap. 39) 1 2 2
–  Immunizations (see Chap. 29) 1 1 1
Secondary neoplasia (Chap. 47)
–  Counseling and autoexamination 1 1 –  Reduce UV skin exposure
–  Special attention to high-risk organs
–  If TBI, increase frequency mammography
–  Same population screening 1 1
Psychosocial and sexual
–  Psychosocial assessment (see Chap. 30) 1 1 1 –  Add spousal/caregiver psychological 
adjustment and family functioning–  QOL assessment (see Chap. 34) 1 1 1
–  Evaluation of Sexual function 1 1 1
An. annually, 1 recommended for all transplant recipients, 2 recommended for patients with ongoing chronic GvHD or 
IS, + reassessment recommended for abnormal testing in a previous time period or for new signs/symptoms
aAdapted from Majhail et al. (2012). Similar recommendations but focused in children have been elaborated by the 
Children’s Oncology Group http://www.survivorshipguidelines.org
bIn patients with chronic GVHD, these controls should be tightened, and their frequency increased
cFollow the American Heart Association for endocarditis prophylaxis in high-risk HSCT recipients
dAdult women, all allo-HSCT, and patients at high risk for bone loss




• Patients auto- and mainly allo-HSCT 
have a risk of developing complications 
related to pre-, peri-, and post-HSCT
• The resulting morbidity of the HSCT 
process makes it necessary for patients 
to adopt a healthy lifestyle that pro-
motes health and contemplate preven-
tive measures for the detection and 
treatment of possible complications
• The short- and long-term controls allow 
for regular and systematic screening and 
at the same time are an opportunity to 
give advice on healthy lifestyle habits
• Monitoring should be multidisciplinary 
with involvement of hematology, other 
medical specialties, physicians of pri-
mary care, nursing, and mental health 
professionals
M. Rovira and M. Suárez-Lledó
153
Dyer G, Gilroy N, Bradford J, et  al. A survey of fertil-
ity and sexual health following allogeneic haemato-
poietic stem cell transplantation in New South Wales, 
Australia. Br J Haematol. 2016;172:592–601.
Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral 
care for hematology-oncology patients and hemato-
poietic stem cell transplantation recipients: a position 
paper from the joint task force of the Multinational 
Association of Supportive Care in Cancer/International 
Society of Oral Oncology (MASCC/ISOO) and the 
EBMT. Support Care Cancer. 2015;23:223–36.
Fred Hutchinson Cancer Research Center/Seattle Cancer 
Care Alliance Version June 03, 2015. Long-Term 
Follow-Up After Hematopoietic Stem Cell Transplant 
General Guidelines For Referring Physicians.
Heimall J, Buckley RH, Puck J, et al. Recommendations 
for screening and management of late effects in 
patients with severe combined immunodeficiency 
after allogenic hematopoietic cell transplantation: a 
consensus statement from the Second Pediatric Blood 
and Marrow Transplant Consortium International 
Conference on Late Effects after Pediatric HCT. Biol 
Blood Marrow Transplant. 2017;23:1229–40.
Inamoto Y, Shah NN, Savani BN, et  al. Secondary 
solid cancer screening following hematopoietic 
cell transplantation. Bone Marrow Transplant. 
2015;50:1013–23.
Majhail NS, Rizzo JD, Lee SJ, et  al. Recommended 
screening and preventive practices for long-term 
 survivors after hematopoietic cell transplantation. Biol 
Blood Marrow Transplant. 2012;18:348–71.
National Marrow Donor Program Guidelines.: www.
BeTheMatch.org/md-guidelines. For patients: www.
BeTheMatch.org/Patient; For Pediatric patients: 
www.survivorshipguidelines.org.
Parsons SK, Tighiouart H, Terrin N.  Assessment of 
health-related quality of life in pediatric hematopoietic 
stem cell transplant recipients: progress, challenges 
and future directions. Expert Rev Pharmacoecon 
Outcomes Res. 2013;13:217–25.
Persoon S, Kersten MJ, van der Weiden K, et al. Effects 
of exercise in patients treated with stem cell trans-
plantation for a hematologic malignancy: a system-
atic review and meta-analysis. Cancer Treat Rev. 
2013;39:682–90.
Shenoy S, Gaziev J, Angelucci E, et  al. Late effects 
screening guidelines after Hematopoietic Cell 
Transplantation (HCT) for hemoglobinopathy: con-
sensus statement from the Second Pediatric Blood 
and Marrow Transplant Consortium International 
Conference on Late Effects after Pediatric HCT. Biol 
Blood Marrow Transplant. 2018;24(7):1313–21.
Tichelli A, Rovó A.  Survivorship after allogeneic 
transplantation- management recommendations for 
the primary care provider. Curr Hematol Malig Rep. 
2015;10:35–44.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
21 Short- and Long-Term Controls After HSCT
Part IV
General Management of the Patient
Topic leaders: Carlo Dufour, Silvia Montoto and John Murray
157© EBMT and the Author(s) 2019 




The central venous catheter (CVC) is a key tool 
for patients undergoing a HSCT, and its introduc-
tion in the oncology setting has represented a 
clear improvement in the quality of patient health 
care. The use of a CVC requires correct mainte-
nance to prevent malfunctioning due to partial or 
complete occlusion, dislodgement, kinking, rup-
ture, thrombosis, or life-threatening complica-
tions such as catheter-related bloodstream 
infections (CRBSI).
CVCs are being designated by:
• Duration (e.g., temporary or short-term versus 
permanent or long-term)
• Site of insertion (e.g., subclavian vein, femo-
ral vein, jugular vein, basilic vein)
• Number of lumens (single, double, or triple 
lumen)
• Characteristic of tip (open tip or closed tip)
• Materials to reduce complications (e.g., 
impregnation with heparin, antibiotics, or 
silver)
Table 22.1 shows the main maintenance 
actions for CVC (Cesaro et al. 2016).
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Table 22.1 CVC maintenance: suggested main rules
1.  Assessment of line functionality and dressing site 
daily for inpatients or every 2–3 days for 
outpatients
2.  CVC care and maintenance as dictated by local 
policy or standard operating procedurea
3.  Vigorous mechanical scrub for manual disinfection 
prior to each CVC access and allow it to dry. 
Acceptable disinfecting agents include 70% 
isopropyl alcohol, iodophors (i.e., povidone-iodine), 
or >0.5% chlorhexidine in alcohol solution
4.  Change gauze dressing every 7 days or before in 
case of soiled, dampened, and loosened
5.  Change the transfusion administration set and filter 
after the completion of each unit or every 4 h. If 
more than 1 unit can be infused in 4 h, the 
transfusion set can be used for a 4-h period
6. Change intermittent administration sets every 24 h
7.  Replace administration sets for parenteral nutrition 
solutions at least every 24 h
8.  Replace administration sets used for intravenous fat 
emulsions infused separately every 12 h
9.  Change caps every 72 h (or 7 days if pressure- 
positive device is used)
aThere may be a variability among EBMT centers 
regarding the practice of CVC care and maintenance 
such as the use of sterile gloves and mask by provider/
assistant, the adoption of aseptic technique for all cath-
eter entries, the use of prepackaged dressing change kit, 
the frequency of flushing, and the type of solution used 
for flushing CVC
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22.2  Type of CVC Materials
Catheter materials should be biocompatible, kink 
resistant, inherently chemically resistant and 
neutral, biostable, soft, and deformable and 
should have a high tensile strength (Lim et  al. 
2018; Frasca et  al. 2010). The most commonly 
used materials are polyurethane, polyethylene 
and polytetrafluoroethylene (Teflon), polyvinyl-
chloride (PVC), silicone, and Vialon (Borretta 
et al. 2018). Silicone catheters are flexible, chem-
ically stable, and well tolerated. Polyurethane 
catheters are preferred to those made of polyeth-
ylene or PVC because of their lower rate of 
CRBSI and their lower friability (Frasca et  al. 
2010). Polytetrafluoroethylene catheters are rigid 
and lose X-ray transparency when injected with 
opaque solutions. Polyurethane has a superior 
tensile strength.
Non-tunneled, semirigid catheters are usually 
made of polyurethane, while tunneled catheters 
are usually made of both silicone and polyure-
thane (Lim et al. 2018). The superiority of poly-
urethane catheters compared with silicone is 
debated. The two catheter types have no differ-
ence in surface degradation; however, silicone 
catheters are more prone to material failure as a 
result of the development of surface irregularities 
due to loss of barium sulfate molecules and 
thrombotic occlusion. Conversely, polyurethane 
catheters have a higher susceptibility for catheter- 
induced venous thrombosis and CRBSI (Blanco- 
Guzman 2018; Wildgruber et al. 2016).
22.3  Type of CVC
CVCs are classified in two main categories: tun-
neled and non-tunneled, according to whether or 
not they follow a subcutaneous route before 
accessing the central vein. Non-tunneled cathe-
ters are directly inserted into a peripheral or large 
central vein. Both tunneled and non-tunneled 
CVCs may have a single or multiple lumen. 
Tunnelization of CVCs was introduced to reduce 
the risk of infectious and mechanical (dislodge-
ment) complications, and this type of CVC is 
ideal for long-term care (Cesaro et al. 2009). 
Non-tunneled CVCs are usually inserted for a 
short to medium period (from 2–4  weeks to 
1–3  months) (Lee and Ramaswamy 2018; 
Padmanabhan 2018). Tunneled CVCs are in turn 
classifiable in two subgroups: partially implanted 
and totally implanted. Partially implanted CVCs 
are characterized by an external part outside the 
patient’s body whose extremity (hub) is used to 
draw blood sampling or to connect the infusion 
lines, a tunneled subcutaneous part with a Dacron 
cuff at a few centimeters from the skin entry 
point, and a final intravenous part with the tip 
positioned at the border between the superior 
vena cava and the right atrium (Padmanabhan 
2018; Blanco- Guzman 2018). The Dacron cuff 
stimulates a fibrotic reaction of the subcutaneous 
tissues over 2–4  weeks ensuring stability and 
CVC securement. Both cuff and subcutaneous 
course are fundamental to prevent the CVC from 
becoming infected due to the migration of exter-
nal microbes along the CVC. Broviac, Hickman, 
and Groshong CVCs belong to this group. 
Broviac-Hickman CVCs have an open tip and 
require the clamping of the external part of the 
CVC when they are not in use to avoid the back-
flow of the blood from the tip with breath or body 
movements. Groshong CVCs have a closed tip 
with lateral valves on their terminal part that open 
as fluid is withdrawn or infused, while they 
remain closed when the CVC is not in use. The 
CVC has to be clamped only if the catheter does 
not have a needle-free connector. The ideal situa-
tion to avoid backflow of blood is a neutral pres-
sure needle-free connector with an open clamp 
(Padmanabhan 2018).
Totally implanted catheters (porth) consist 
of a reservoir (port) placed in a pocket in the 
subcutaneous tissue anteriorly on the chest 
wall, below the clavicle, that is connected to the 
catheter (Padmanabhan 2018; Blanco-Guzman 
2018). This type of CVC has no part outside 
of the body, thus preserving the patient’s body 
image and ensuring almost no limitations on 
sports activities, and body hygiene. The main 
drawback of this type of CVC is that its access-
ing needs a skin puncture with a special “non-
coring” needle (Huber needle or gripper system). 
In case of frequently repeated port accesses, the 
S. Cesaro and F. Minniti
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procedure can be painful or discomforting for 
the patient, requiring the application of topical 
skin anesthetics for its prevention. Moreover, 
the needle does not permit the  infusion or the 
extraction of high volumes making it less suit-
able for patients requiring high infusion or 
blood extraction rates. The recent introduction 
of port models with a modified reservoir cham-
ber (vortex, tidal, power port) has allowed to 
obtain a higher flow rate suitable for leukapher-
esis, red blood cell exchange, extracorporeal 
photopheresis, and therapeutic plasma exchange 
(Blanco- Guzman 2018; Lim et al. 2018).
The peripherally inserted central catheter 
(PICC) is a CVC inserted into a vein of the arm, 
usually the basilic or cephalic veins; its tip is 
advanced through the axillary and subclavian 
veins up to the cavoatrial junction (Hashimoto 
et  al. 2017; Cornillon et al. 2017). For more 
information on PICCs, see Chap. 32.
22.4  Venous Access
Central lines are usually inserted through the 
subclavian, the jugular, or, less frequently, the 
femoral vein. This last venous access is associ-
ated with a higher risk of infectious complica-
tions (O’Leary 2016), and it is more commonly 
used in critically ill patients admitted to intensive 
care units who require a non-tunneled 
CVC. Using the subclavian or jugular access, the 
tip of the catheter has to lie in the superior vena 
cava, just before the entrance of the right atrium, 
about 29–55 mm below the level of trachea carina 
(in adults). The incidence of pneumothorax after 
CVC insertion is about 1.5–3.1%, and it is higher 
with subclavian vein catheterization, whereas the 
risk of hemorrhage and bruise is slightly more 
common with the jugular venous line access.
In the positioning of a PICC, the incannula-
tion of the basilic vein is preferred to that of the 
cephalic vein as it has low risk of complications. 
To minimize the risk of complications due to 
venous catheterizations, the routine use of ultra-
sound guidance to cannulate the vein is recom-
mended instead of the classical (blind) technique 
(Cornillon et al. 2017; Crocoli et al. 2015).
A chest X-ray must be performed at the end of 
the CVC insertion procedure to confirm that the 
line is positioned inside the superior vena cava 
and, for the cannulation of subclavian or jugular 
veins, no pneumothorax was inadvertently 
caused. Recently, the use of intracavitary ECG 
(electrocardiographic method) has also been 
approved for clinical use to evaluate the correct 
position of the catheter tip (Borretta et al. 2018).
22.5  CVC Complications
Catheter-related complications may be classified 
into infectious (local or systemic) and mechani-
cal (occlusion, rupture, dislodgement, acciden-
tal self-removal, and thrombosis) (Cesaro et al. 
2009). As the catheter is itself a risk for develop-
ing complications, when there is no further need 
for a catheter, it should be removed. Removal of 
the catheter must also be considered in the event 
of catheter dysfunction; CRBSI by Candida 
spp., Pseudomonas spp., Klebsiella spp., and 
Staphylococcus aureus; persistent bacteria colo-
nization or recurrent CRBSI; or contraindica-
tions against anticoagulant therapy.
22.5.1  Special Measures to Prevent 
Catheter-Related Infections
The key rules to prevent infections are proper 
handwashing by the performing provider, the use 
of aseptic technique over the patient at insertion 
time, thorough cleaning of the insertion site, and 
periodic review of the CVC exit site (Cesaro 
et al. 2016). Impregnation of the CVC with hepa-
rin may reduce the incidence of infectious and 
thrombotic complications. To prevent CRBSI and 
tunnel or exit-site infection, medication- 
impregnated dressings with different antimicro-
bial materials were developed to decrease the 
production of the biofilm by microorganisms and 
decrease the adhesion of them to the catheter 
walls. The most commonly used impregnating 
medications are chlorhexidine gluconate, silver 
sulfadiazine, rifampin, and minocycline (Frasca 
et  al. 2010). Chlorhexidine gluconate impreg-
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nates the whole dressing or is applied using an 
impregnated sponge (e.g., Biopatch®) and cov-
ered by a transparent polyurethane semiperme-
able transparent dressing (Ullman 2015).
22.6  Catheters for Leukapheresis
The procedure of stem cell collection by aphere-
sis is performed both for auto- and allo-HSCT to 
obtain PBSC (O’Leary 2016). As the procedure 
requires sustained high blood flow rates (50–
100  mL/min), an adequate venous access is 
needed (O’Leary 2016). Peripheral access placed 
in the basilic, cephalic, brachial, median cubital 
and radial veins is recommended (Padmanabhan 
2018; Lim et  al. 2018; Hölig et  al. 2012). 
Considering that the placement of a central CVC 
is associated with potentially life-threatening 
complications such as pneumothorax, bleeding, 
and embolism (Hölig et al. 2012), its use is not 
recommended for PBSC collection of a healthy 
volunteer donor. Conversely, in the case of auto- 
PBSC, if the patient has no adequate peripheral 
or central venous access, a temporary non- 
tunneled CVC may be placed in the internal jugu-
lar, subclavian, or femoral veins (Padmanabhan 
2018; Lim et al. 2018; Vacca et al. 2014; Hölig 
et al. 2012; Cooling 2017a). Catheter removal is 
performed on donor laboratory values (PLT 
>50 × 109/L) or after the assessment of an ade-
quate CD34+ dose and successful cryopreserva-
tion of the HPC product (O’Leary 2016; Vacca 
et al. 2014).
Partially implanted silicone CVCs are often 
used by pediatric oncologists-hematologists 
because they are most suitable for long-term 
complex treatment (Wildgruber et  al. 2016). In 
the case of leukapheresis procedure, silicone 
CVCs are not ideal because they are more prone 
to collapse during automatic apheresis (Ridyard 
et  al. 2017). On the other hand, the harvesting 
procedure of PBSC, which requires high blood 
flow rates and a large needle, may be difficult in 
children below 10 kg using a temporary periph-
eral venous access due to the small size of veins 
(Padmanabhan 2018; Cesaro et al. 2016). In this 
case, the placement of a short-term CVC made of 
polyurethane may be needed (Cooling 2017a, b). 
However, in younger children, the rigidity of 
such material and the narrower lumens of the 
veins may represent a potential risk for thrombo-
sis and infection (Ridyard et  al. 2017; Cooling 
2017b; Vacca et al. 2014).
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23.1  General Aspects
Transfusions are an essential part of supportive 
care in the context of HSCT.  RBC and platelet 
concentrates (PCs) are the main blood products 
transfused in the peri-transplant period. Many 
recommendations in this chapter are based on 
evidence from studies including a broad variety 
of diseases. Only a few studies addressed transfu-
sion strategy specifically in patients undergoing 
HSCT (see review Christou et  al. 2016). Many 
recommendations are derived from patients with 
cytopenia in non-transplant settings. There are 
both need and opportunity to address issues 
regarding transfusion of HSCT patients in clini-
cal trials. So far, there is a paucity of studies on 
the impact of transfusion on HSCT-specific 
outcomes.
RBC, PC, and FFP for patients who are candi-
dates for HSCT should be leukocyte-reduced, 
i.e., should contain <1  ×  106 leukocytes/unit. 
Leukocyte reduction reduces febrile non- 
hemolytic transfusion reactions and decreases the 
incidence of alloimmunization to leukocyte anti-
gens and the risk of CMV transmission. Also all 
cellular blood components (RBC, PC, granulo-
cyte transfusions) must be irradiated (see below).
23.2  Irradiation for Prevention 
of Transfusion-Associated 
GvHD (ta-GvHD)
Ta-GvHD is a rare complication of transfusion 
wherein viable donor T lymphocytes in cellular 
blood products mount an immune response 
against the recipient (Kopolovic et  al. 2015). 
Some of the clinical presentations of ta-GvHD 
resemble that of GvHD (fever, cutaneous erup-
tion, diarrhea, liver function abnormalities). Also 
many patients develop pancytopenia. Since mor-
tality is high (>90%), prevention of ta-GvHD is 
critical (Kopolovic et al. 2015). HSCT recipients 
are at risk of ta-GvHD and should receive irradi-
ated cellular blood products (Kopolovic et  al. 
2015). It is recommended that no part of the com-
ponent receives a dose <25  Gy and >50  Gy 
(European Committee (Partial Agreement) on 
Blood Transfusion (CD-P-TS) 2017). Some 
pathogen-reduction technologies have been 
shown to inactivate lymphocytes, and additional 
gamma-irradiation is not required (Cid 2017).
There is no consensus on the duration of the 
use of irradiated blood products in HSCT 
 recipients. Standard practice is (1) auto-HSCT, at 
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least 2 weeks prior to stem cell collection until at 
least 3 months after HSCT, and (2) allo-HSCT, at 
the latest starting with conditioning until at least 
6 months after HSCT or until immune reconstitu-
tion. However, some centers recommend lifetime 
use of irradiated products since it is difficult to 
confirm complete and sustained immunological 
reconstitution.
23.3  Prevention of CMV 
Transmission
The highest risk of transfusion-transmitted CMV 
(TT-CMV) remains in CMV-seronegative recipi-
ents of matched CMV-negative HSCT (Ljungman 
2014). Risk of TT-CMV can be reduced by trans-
fusion of leukocyte-reduced blood products (i.e., 
<1 to 5 × 106 residual leukocytes per unit) or by 
transfusion of blood components from CMV- 
seronegative donors (Ziemann and Thiele 2017). 
However, it is unclear whether the “belt and sus-
pender approach,” i.e., the use of both leukocyte- 
reduced and seronegative products, further reduces 
the risk of TT-CMV. Donations from newly CMV-
IgG-positive donors bear the highest risk for trans-
mitting CMV infections (Ziemann and Thiele 
2017). Currently no international consensus on 
risk mitigation for CMV transmission exists. A 
recent snapshot of current practice revealed that 
about half of the countries use either leukocyte-
reduced or seronegative products and the other 
half use the combination of both (Lieberman et al. 
2014). Also, there is no consensus how long CMV-
seronegative products should be given to trans-
plant recipients: the current practice ranges from 
100  days after transplant till lifelong (or until 
CMV seroconversion) (Lieberman et al. 2014).
23.4  Red Blood Cell Concentrates 
(RBCs)
A restrictive RBC transfusion threshold of 7–8 g/
dL hemoglobin is recommended for adult patients 
who are hemodynamically stable. A restrictive 
RBC transfusion threshold of 8  g/dL is recom-
mended for patients with existing cardiovascular 
disease (Carson et  al. 2016). These cutoffs are 
derived from studies on a broad range of 
 indications. Only one randomized clinical trial is 
available specifically for patients undergoing 
HSCT (TRIST trial, NCT01237639). It com-
pared a liberal strategy (Hb threshold <90  g/L) 
with a restrictive strategy (Hb threshold <70 g/L). 
Health-related quality of life was similar between 
groups, and no appreciable differences in HSCT- 
associated outcomes were reported (Tay et  al. 
2016). The median number of RBC units trans-
fused was lower in the restrictive strategy com-
pared to the liberal strategy group, but this did 
not reach statistical significance (Tay et al. 2016).
In adult recipients, one unit of RBC increases 
the hemoglobin concentration by about 1 g/dl. In 
children, the dose should be calculated by the 
formula:
Volume (mL RBC): Target Hb after transfusion (g/
dL) − pretransfusion Hb (g/dL) × 4 × weight (kg)
In recent years, several randomized trials 
showed no evidence that transfusion of fresh 
RBC reduced morbidity or mortality compared to 
standard issue RBCs. Thus, the AABB recom-
mends that patients should receive RBC selected 
at any point within their licensed dating period 
(Carson et al. 2016).
Chronic RBC transfusions result in iron over-
load. Hyperferritinemia and iron overload before 
HSCT are associated with reduced overall sur-
vival and incidence of non-relapse mortality after 
allo-HSCT.  However, a meta-analysis (Armand 
et al. 2014) and a prospective cohort study sug-
gest that iron overload, as assessed by liver iron 
content, is not a strong prognostic factor for over-
all survival in a general adult HSCT population. 
Thus, ferritin alone is an inadequate surrogate for 
iron overload in HSCT.
23.5  Platelet Concentrates (PCs)
PC should be transfused prophylactically to non- 
bleeding, nonfebrile patients when platelet counts 
are ≤10 × 109/L (Schiffer et al. 2018). Prophylactic 
platelet transfusions may be administered at 
higher counts based on clinical judgment (Schiffer 
H. Schrezenmeier et al.
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et al. 2018). Patients with active bleeding, febrile 
conditions, or active infections should receive 
prophylactic PC transfusions at a threshold of 
20 × 109/L. Also, in case of specific transplant- 
related toxicity which might increase the risk of 
bleeding (acute GvHD, mucositis, hemorrhagic 
cystitis, or diffuse alveolar hemorrhage), a thresh-
old of 20 × 109/L or even higher, based on careful 
clinical observation, might be justified.
Two prospective randomized control trials 
comparing prophylactic versus therapeutic PC 
transfusion in adult patients (≥16 years) suggest 
that a therapeutic transfusion strategy might be 
feasible in patients after auto-PBSCT but cannot 
be easily transferred to other indications (AML, 
allo-HSCT) for whom special attention to the 
increased risk of bleeding, in particular, CNS 
bleeding, is needed (Stanworth et al. 2013; Wandt 
et al. 2012). The results may not be generalizable 
to children since a subset analysis of the PLADO 
trial demonstrated that bleeding rates were sig-
nificantly increased among children, particularly 
among those undergoing autologous HSCT 
(Josephson et al. 2012).
The randomized PLADO trial compared dif-
ferent doses of PC transfusions (“low dose,” 
“medium dose,” and “high dose” defined as 
1.1 × 1011, 2.2 × 1011, and 4.4 × 1011 platelets per 
m2 BSA) (Slichter et al. 2010). While a strategy 
of “low-dose” transfusion significantly reduces 
the overall quantity of platelets transfused, 
patients required more frequent PC transfusion 
events (Slichter et  al. 2010). At doses between 
1.1 × 1011 and 4.4 × 1011 platelets/m2, the number 
of platelets in the prophylactic transfusions had 
no effect on the incidence of bleeding.
Both apheresis PC and pooled PC from whole 
blood donations are safe and effective. Available 
data suggest equivalence of the products in non- 
allosensitized recipients (Schrezenmeier and 
Seifried 2010). A clear advantage of apheresis 
PCs can only be demonstrated in allosensitized 
patients with HLA- and/or HPA-antibodies who 
receive antigen-compatible apheresis PCs.
Some patients experience inadequate incre-
ment after PC transfusions, i.e., a corrected count 
increment (CCI) below 5000/μL at 1 h after trans-
fusion of fresh, ABO-identical PCs on at least 
two subsequent transfusions. Refractoriness can 
be caused by non-immunological factors (>80%) 
or immunological factors (<20%) (Fig. 23.1). If 
platelet refractoriness is suspected and no appar-
ent nonimmune causes can be identified, screen-
ing for the presence of HLA-Ab is recommended. 
If HLA-Ab are present, the patient should receive 
apheresis PCs from matched donors (Juskewitch 
et  al. 2017; Stanworth et  al. 2015): ideally all 
four antigens (HLA-A, HLA-B) of donor and 
Platelet refractoriness
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Fig. 23.1 Etiology of platelet transfusion refractoriness (modified according to Pavenski et al. 2012)
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recipient are identical. Also PCs from donors 
expressing only antigens which are present in the 
recipient can be used. If PCs from such donors 
are not available, donors with “permissive” mis-
matches in HLA-A or HLA-B shall be selected 
(e.g., based on cross- reactive groups or computer 
algorithms that determine HLA compatibility at 
the epitope level). If no better-matched donor 
is available, antigen-negative platelets, i.e., not 
expressing the target antigen(s) of the recipients’ 
HLA allo-Ab, can be transfused. Screening for 
antibodies against human platelet antigens (HPA) 
should be performed if refractoriness persists 
also after transfusion of HLA-matched PCs and 
nonimmune causes are unlikely. Approaches for 
patients without compatible platelet donors are 
autologous cryopreserved platelets (e.g., col-
lected in remission prior to allogeneic HSCT), 
IS (e.g., rituximab), and high-dose IVIg and 
plasmapheresis.
23.6  Immunohematological 
Consequences of ABO- 
Mismatched Transplantation
About 40–50% of allo-HSCT are ABO mis-
matched. While transplantation across the ABO 
barrier is possible, immunohematological 
 problems have to be taken into account. There is 
a risk that ABO incompatibility between donor 
and recipient causes hemolytic transfusion reac-
tions. In case of major ABO mismatch and a 
recipient anti-donor isoagglutinin titer ≥1:32, the 
red cell contamination in PBSC graft should be 
kept <20 mL, and RBC depletion of BM grafts 
must be performed. If recipient anti-donor isoag-
glutinin titers are low (≤1:16), no manipulation 
of the PBSC graft is required, and RBC depletion 
of a BM graft might be considered in this situa-
tion but is not mandatory. In case of minor ABO 
incompatibility and a high donor anti-recipient 
isoagglutinin titer (≥1:256), plasma depletion of 
both PBSC and BM grafts should be performed. 
If the donor anti-recipient isoagglutinin titer is 
low (≤1:128), no manipulation of the PBSC graft 
is required, and plasma depletion of a BM graft 
might be considered but is not mandatory. In case 
of bidirectional ABO incompatibility and high 
titers of anti-recipient isoagglutinins, both RBC 
and plasma depletion is required.
Delayed hemolysis can occur in minor ABO- 
mismatched HSCT, in particular after RIC, due to 
hemolysis of remaining recipient red cells by iso-
agglutinins produced by donor B lymphocytes.
Major or bidirectional ABO-incompatible 
HSCT can cause pure red cell aplasia (PRCA), 
delayed engraftment, and increased RBC transfu-
sion requirement. The risk is higher if a group O 
recipient with high-titer anti-A isoagglutinins 
receives a group A graft. If no spontaneous remis-
sion of PRCA occurs and anti-donor isoagglutinins 
persist, various treatments to remove isoagglutinins, 
to reduce their production, or to stimulate erythro-
poiesis can be used (see review Worel 2016).
23.7  Transfusion in ABO- or 
RhD-Incompatible HSCT
The change of blood group and the persistence of 
recipient isoagglutinins require a special 
approach for transfusion support in ABO- 
incompatible HSCT considering several aspects: 
isoagglutinins might target engrafting progeni-
tors and transfused platelets to which variable 
amounts of ABO antigens can be bound. ABO 
blood group antigens are expressed in many non- 
hematopoietic tissues which continue to express 
the recipients’ ABO antigens also after engraft-
ment. ABO antigens can be secreted into body 
fluids. If possible, exposure of HSC recipients to 
isoagglutinins should be avoided. RBCs which 
are ABO compatible with both HSC donor and 
recipient are mandatory. Plasma and PCs which 
are compatible with both the donor and the recip-
ient should be preferred. Table 23.1 summarizes 
the recommendation for ABO preference of 
transfusions in ABO-incompatible HSCT.
For PCs, some choices of blood groups might 
not always be available. To reduce the risk of 
adverse events due to isoagglutinins, apheresis 
PC donors with high-titer ABO antibodies should 
be excluded. However, a preferred strategy is the 
use of plasma-reduced PC (both for apheresis PC 
and pooled PC from whole blood donations). 
These are suspended in platelet additive solution 
with only about 30% plasma volume remaining.
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HSC recipients should receive RhD-negative 
RBC and also RhD-negative PC except when 
both HSC donor and recipient are RhD-positive. 
If the HSC donor is RhD-positive and the recipi-
ent is RhD-negative, platelet transfusion can be 
switched to RhD-positive products after ery-
throid engraftment, i.e., appearance of RhD- 
positive red cells.
Whenever possible, RBC should be compati-
ble both with HSCT donor and recipient for CcEe 
antigens. If Rh antigens of HSCT donor and 
recipient differ in a way that compatibility with 
both is not possible (e.g., recipient CCD.ee, 
donor ccD.EE), then RBC compatible with the 
recipient shall be chosen in the period until 
engraftment. After the appearance of donor- 
derived red cells, RBC supply should switch to 
compatibility with the graft. Patients should 
receive K-negative RBC except when both recip-
ient and donor are K positive.
23.8  Granulocyte Concentrates
In life-threatening non-viral infections during 
neutropenia, the use of irradiated granulocyte 
transfusions should be considered. Response 
and survival after granulocyte transfusion cor-
relate strongly with hematopoietic recovery. 
Thus, granulocyte transfusions may mainly 
bridge the gap between specific treatment and 
neutrophil recovery. Granulocyte transfusions 
can help to control active fungal infections in 
a very high- risk population of patients who 
otherwise are denied by transplant program. A 
retrospective study suggested that granulocyte 
transfusion might maintain the mucosal integ-
rity and thus reduces bacterial translocation 
and triggers for GvHD.  In the randomized 
RING trial, success rates for granulocyte and 
control arms did not differ within any infec-
tion type. The overall success rates for the 
control and granulocyte transfusion group 
were 41% and 49% (n.s.) (Price 2015). 
However, patients who received high dose 
(≥0.6  ×  109 granulocytes/kg per transfusion) 
fared better than patients who received lower 
doses. The collection center should ensure to 
provide a high-dose concentrate by appropri-
ate donor selection, pre-collection stimula-
tion, and apheresis techniques. The optimal 
number of granulocyte transfusions is unclear. 
Adverse events of granulocyte infusions are 
fever, chills, pulmonary reactions, and alloim-
munization. Studies demonstrated that overall 
risk of alloimmunizations was low and there 
Table 23.1 RBC, platelet, and plasma transfusion support for patients undergoing ABO-incompatible HSCT














Major O A Recipient O A AB, B, O A AB
O B Recipient O B AB, A, O B AB
O AB Recipient O AB A, B, O AB –
A AB Recipient A, O AB A, B, O AB –
B AB Recipient B, O AB B, A, O AB –
Minor A O Recipient O Ab AB, B, O A AB
B O Recipient O Bb AB, A, O B AB
AB O Recipient O ABb A, B, O AB –
AB A Recipient A, O ABb A, B, O AB –
AB B Recipient B, O ABb B, A, O AB –
Bidirectional A B Recipient O AB B, A, O AB –
B A Recipient O AB A, B, O AB –
– not applicable
aChoices are listed in the order of preference
bFor practical reasons, the use of donor type platelets might be defined as first choice, in phase III, i.e., after complete 
engraftment
cPhase I until preparative regimen, phase II until complete engraftment, phase III after complete engraftment.
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was no effect of alloimmunization on the 
 primary outcome (survival, microbial 
response), the occurrence of transfusion reac-
tions, or post transfusion neutrophil incre-
ments. Alloimmunization remains a problem 
because of its negative impact on increments 
after platelet transfusion and potential increase 
of graft failure after HSCT.  Donor- specific 
HLA-Ab might be implicated in early graft 
failure (Spellman et  al. 2010). If granulocyte 
transfusions are used prior to a planned unre-
lated HSCT, recipients should be monitored 
for the development of HLA-Ab, and the 
search algorithm for the UD should take into 
account donor-specific antibodies. All granu-
locyte concentrates must be gamma-irradiated 
and should be obtained from CMV-
seronegative donors, ideally also confirmed by 
CMV-PCR to avoid donations in the serologi-
cal window period.
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Patients undergoing HSCT, particularly allo- 
HSCT, are at risk for malnutrition (Fuji et  al. 
2012). Malnutrition is associated with poor clini-
cal outcome, decreased OS, higher risk of infec-
tious and immunologic complications, delayed 
neutrophil engraftment and prolonged hospital 
stay (Baumgartner et al. 2016, 2017). Importantly, 
most patients are well-nourished or even over-
weight upon admission to HSCT but experience 
rapid deterioration of nutritional status during 
treatment (Fuji et  al. 2014). Weight loss results 
from a complex interplay of toxic, inflammatory 
and immunological mechanisms leading to 
caloric deficits by anorexia as well as a catabo-
lism of the metabolism.
Nutritional support is meant to reduce 
caloric deficit and reduce the risks for negative 
metabolic effects. However, there is a lack of 
large-scale trials proving benefit of nutritional 
interventions in this setting (Baumgartner et al. 
2017). The current nutritional approach is thus 
based on physiological considerations and 
results of observational and some smaller inter-
ventional trials and needs to be adapted to an 
individual patient’s situation.
24.2  Screening for Malnutrition
Pre-existing malnutrition is an important addi-
tional risk factor in patients undergoing 
HSCT.  International guidelines such as the 
European Society of Enteral and Parenteral 
Nutrition (ESPEN) recommend screening for 
malnutrition at admission for transplantation 
(Bozzetti et al. 2009). There is no international 
consensus on how to assess malnutrition in this 
patient population. For reasons of practicability, 
the use of the NRS 2002 is generally recom-
mended (Bozzetti et al. 2009). In the acute set-
ting, weight assessment may be inaccurate 
because of inflammatory fluid retention.
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24.3  Nutritional 
Recommendations (See 
General Recommendations 
in Table 24.1 and Fig. 24.1; 
Monitoring in Table 24.2 
and Nutritional Strategies 
in Fig. 24.1)
24.3.1  Nutrition in Allo-HSCT
24.3.1.1  Route of Administration
Due to its positive effects on GI integrity and 
microbiome, enteral nutritional (EN) support is 
generally preferred over parenteral nutrition (PN) 
in case of a functioning GI tract.
During allo-HSCT, patients often experience 
GI failure so PN is used instead. Yet, higher risk 
of central line infections as well as hyperglycae-
mia associated with PN demand restricted use 
(Seguy et al. 2012).
Small, prospective, non-randomized trials on 
EN found satisfying results on feasibility and safety 
with lower infection rates as well as beneficial 
effects such as earlier neutrophil engraftment and 
lower rates of severe GI GvHD (Seguy et al. 2012; 
Guièze et al. 2014). Some studies even report higher 
OS (Seguy et al. 2012). Results of a large prospec-
tive trial are expected (Lemal et al. 2015).
We encourage the use of EN as a first-line 
measure. Indication for PN should be limited to 
Table 24.1 Summary of general recommendations for nutritional support
Screening for malnutrition
Indication All patients to estimate risk for pre-existing malnutrition
Tools NRS 2002
Nutritional support
General management 1.  Early involvement of dietitians
2.  Consider placement of nasogastric tube on day +1
3.  Standardized monitoring of nutritional intake
4.  Nutritional reassessment every 3 days using the NRS 2002
Indication of intervention 1.  Oral intake <60% for 3 days consecutively
2.  Consider nutritional support in all patients with preexisting malnutrition and/or 
BMI < 18
Discontinuation Oral intake >50% for 3 days consecutively
Estimation of caloric needs According to Harris Benedict formula (ideal body weight)
OR BASA-ROT table/(25–30 kcal/kg ideal body weight)
Route of nutritional support 1.  Intensification of oral nutrition
2.  Enteral nutrition
3.  Parenteral nutrition
Forms of nutritional support
Intensified oral nutrition Indication: Malnutrition or underweight (BMI < 18 kg/m2) and preserved oral 
intake
Options: Additional snacks rich in proteins and energy, protein or calorie 
enrichment of main courses, additional protein and energy drinks (ONS)
Standardized supplementation: None
Enteral nutrition Indication: If nutritional goals cannot be reached by oral support alone
Standardized supplementation:
  Vitamin K once weekly
Parenteral nutrition Indication: If nutritional goals cannot be reached in patients with gastrointestinal 
failure and/or intolerance for NGT
Standardized supplementation:
  Lipid-soluble vitamins (ADEK)
  Water-soluble vitamins
  Trace elements
Vitamin and trace elements Multivitamin generally recommended
Vitamin D: Supplementation recommended (Bolus of 40000E at admission, 
maintenance therapy with 1500E orally per day
Other vitamins or trace elements if overt deficiency
Immunonutrition Generally not recommended
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1. Placement of NGT at Day +1
2. Standardized documentation of consumed calories and proteins
3. Nutritional reassessment every 3 days
4. Daily trial of oral food tolerance
5. Stop EN or PN if oral food intake >50% daily needs












STEP 2: enteral nutritional Support (EN)
STEP 3: parenteral nutritional Support (PN)
Nutritional aims not met
OR severe malabsorption
OR Intolerance for NGT*










STEP 1: oral nutritional Support (ON)
Intervention if
NRS ≥4
NRS <4 BUT underweight (BMI ≤ 18kg/m2)
NRS <4 BUT oral food intake ≥ 60% 

























- Harris Benedict formula
- OR indir. calorimetry
- OR Basa-Rot Table
- Generally 1.2-1.5g/kg/d
- 1.5-2.0g/kg/d in severe
- enteral GvHD
- Vitamin D
- Rest according to
laboratory values
Protein Micronutrients
Fig. 24.1 Algorithm for guided nutritional support
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intolerance for nasogastric tube and GI failure 
including severe malabsorption or limited gastro-
enteral passage.
24.3.1.2  Indications and Timing
There are few study data regarding optimal tim-
ing of nutrition. The ESPEN guidelines recom-
mend implementation of nutritional support if 
oral caloric intake falls below 60–70% of basic 
requirements for 3 days consecutively (Bozzetti 
et al. 2009).
Discontinuation of EN or PN should be con-
sidered, if >50% of daily requirements are met by 
oral intake (Bozzetti et  al. 2009). To enhance 
early return to oral food intake patients should be 
encouraged to maintain minimal oral intake 
throughout therapy.
24.3.1.3  Estimation of Caloric Needs
Most studies investigating energy expenditure by 
indirect calorimetry have been performed in small 
paediatric populations. Validity of the data for adults 
therefore is limited, and results are controversial 
(Sharma et al. 2012; Duro et al. 2008).
Determination of energy requirements based 
on calculations, e.g., by the BASA-ROT table or 
Harris-Benedict Formula, does not differ signifi-
cantly from results by indirect calorimetry 
(Sharma et  al. 2012; Valentini 2012; Harris 
1918). Therefore, we recommend estimation of 
energy requirements according to an adjusted 
Harris-Benedict formula.
24.3.2  Nutrition in Auto-HSCT
In general, effects of auto-HSCT on nutritional 
status are less pronounced. Nutritional support is 
not generally recommended and has to be evalu-
ated individually in patients experiencing severe 
complications or in patients with pre-existing 
malnutrition.
Table 24.2 Monitoring of nutritional parameters
Parameter Frequency of assessment Significance and implications
Anthropometry
Weight Daily Correlation with fluid balance
Evaluation of diuretics and  
Albumin supplementation
Bioimpedance assessment Individually Uncontrolled, unexplained weight loss
Severe, prolonged inflammation
Nutritional assessment
Oral food consumption 3× daily Evaluation of nutritional support
Laboratory parameter
Albumine Weekly Evaluation of supplementation in anasarca
Sodium, Potassium Daily Adaptation of potassium supplementation
Calcium, Magnesium, Phosphate Twice weekly Adaptation of supplementation
CAVEAT refeeding, gastrointestinal  
loss
INR, Quick Twice weekly Evaluation of supplementation
CAVEAT low content in certain products for 
EN/PN
Glucose 3–6× daily if PN or preexisting 
diabetes mellitus otherwise 
twice weekly
Adaptation of insulin dose
Creatinine Daily Correction of fluid balance
CAVEAT toxic damage
Liver function tests Twice weekly Evaluation of toxic damage, infection, hepatic 
GvHD, VOD or relapse
Triglycerides Twice weekly if PN Adaptation of PN
Vitamin D At admission Begin routine supplementation
Vitamin B12 At admission Supplementation pretransplantational 
individually
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24.3.3  Nutrition in Acute 
Gastrointestinal GvHD
GvHD of the digestive tract leads to excessive 
diarrhoea, abdominal pain, nausea, vomiting, 
gastrointestinal bleeding, dysphagia and malab-
sorption. Patients experience malnutrition to a 
higher extent and show significantly more addi-
tional complications (van der Meij et al. 2013).
Caloric demands are mainly driven by energy 
loss through diarrhoea. Enteral solutions should be 
low in fibre and fat and not contain lactose. 
Maintaining a minimal amount of oral or enteral 
nutrition facilitates early dietary recovery (Imataki 
et  al. 2006; Andermann et  al. 2016). Complete 
bowel rest and total PN are indicated in severe 
GvHD grade IV and stool volume >1500  ml in 
24 h (Bozzetti et al. 2009; Imataki et al. 2006).
Protein requirements are elevated. 
Recommendations range from 1.2 to 2.5  g/kg/
day. We recommend aiming for 1.5–2 g/kg/day 
in the absence of severe renal impairment 
(Bozzetti et al. 2009; Muscaritoli et al. 2002).
Vitamin and trace elements are often deficient 
and need to be measured regularly to evaluate 
need of supplementation.
24.3.4  Low Bacterial Diet/Low 
Microbial Diet/Neutropenic Diet
A low microbial diet has been installed in the 1980s 
to prevent potential threat of food-borne infections 
from organisms colonizing the gastrointestinal tract.
There is no standardized protocol, and varia-
tions amongst centres, contradictions even, are 
high. Yet, there is no proof of efficacy in prevent-
ing infections or death.
In line with most current publications, we rec-
ommend safe food handling and strict hand 
hygiene as proposed by the FDA or the EC over a 
neutropenic diet.
24.4  Immunonutrition
A meta-analysis on glutamine found reduced 
severity and duration of mucositis and GvHD 
(Kota and Chamberlain 2017). To date, no ran-
domized controlled trial showed a benefit on over-
all survival or reduction of infection rates 
(Crowther et al. 2009).
Pre- and probiotics may enhance diversity of the 
GI microbiome. So far, no study has evaluated their 
effects compared to placebo. Again, there might be 
a benefit on severity of GvHD (Ladas et al. 2016). 
Safety has been evaluated in a pilot study in chil-
dren and adolescents and proved satisfying.
There are no randomized controlled trials 
assessing the benefits of omega-3 fatty acids or 
trace elements. Except for vitamin D, there is no 
proven benefit of a routine supplementation 
(Hall  and Juckett 2013). Based on this data, we do 
not recommend routine use of immunonutrients.
24.5  Long-Term Follow-Up
Follow-up should include regular nutritional 
screening and documentation of weight, BMI, 
appetite and functional status based on patients’ 
history. A balanced, Mediterranean diet can be rec-
ommended along with regular physical training to 
regain muscle mass. An increase in weight should 
be addressed early to avoid full development of a 
metabolic syndrome because of high baseline car-
diovascular risk in transplanted patients.
Persisting malnutrition, especially in chronic 
GvHD, should be handled by an interdisciplinary 
team. Caloric needs seem to be elevated and often 
require in- and out-hospital nutritional support.
Key Points
• There is high risk for malnutrition upon 
HSCT treatment
• Malnutrition is an independent risk fac-
tor in these patients
• The potential benefit of all nutritional 
interventions remains largely unproven
• All dietary recommendations are based 
on physiological considerations and 
results of mainly observational trials
• Adherence to a systematic approach to 
nutritional support improves transparency, 
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• Oral and enteral nutritional support is 
recommended over parenteral support in 
case of functioning gastrointestinal tract
• A minimal oral or enteral food intake is 
beneficial for recovery of mucosa and 
microbiome
• Immunonutrients did not show signifi-
cant beneficial effects and therefore are 
not recommended for routine use
• Neutropenic diets did not show a benefit 
over safe food handling approaches
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The most life-threatening complication of allo- 
HSCT is the graft-versus-host disease (GVHD) 
which occurs when T cells from the recipient 
recognize the host as foreign. Despite 50 years 
of history and nearly half a million of proce-
dures performed worldwide, GVHD remains the 
most challenging issue physicians are facing on 
a daily basis.
Overall, 30–50% of the patients will develop 
acute GVHD, and around 15% will have severe 
GVHD (grades III–IV). The main risk factor for 
developing chronic GVHD is the previous devel-
opment of the acute form of the disease.
The pathophysiology, diagnosis, and man-
agement of both acute and chronic GVHD will 
be covered by other chapters in this Handbook 
(Chaps. 43 and 44). This chapter will summa-
rize the use of IS to prevent the development of 
acute GVHD since attempt to prevent chronic 
GVHD basically rely on the ability to prevent 
the acute disease. Readers with interest on a 
more detailed overview of the acute GVHD 
biological process, prevention, and therapy can 
refer to an excellent recent review (Zeiser and 
Blazar 2017).
25.2  GVHD Prophylaxis After 
MAC; The “Gold” Standard; 
CNI in Combination 
with MTX
Back in the mid-1980s, Storb and colleagues 
reported that the combination of CSA/MTX 
(Table 25.1) was superior to CSA in a series of 
prospective randomized phase 3 trials (Storb 
et al. 1986). This gold standard regimen remains 
the most widely used in Europe today as prophy-
laxis regimen especially after MAC.
In the late 1990s, another CNI-based prophy-
lactic regimen using tacrolimus (TAC) in con-
junction with MTX was developed, and two 
randomized phase 3 trials were published after 
MAC in HLA-identical and URD, respectively 
(Ratanatharathorn et al. 1998; Nash et al. 2000). 
Although both reported a significant decreased 
in the incidence of grade II–IV acute GVHD, 
none of the two could demonstrate an improved 
survival rate with TAC/MTX as compared to 
CSA/MTX. The reasons for this lack of improve-
ment are twofold: (1) in the trial performed from 
HLA- identical sibling D, there was an imbal-
anced of disease risk among the two groups with 
higher risk patients with leukemia among 
patients receiving TAC/MTX, and (2) for the 
trial in URD, the HLA-typing methodology at 
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that time was serologically based and thus 
included a very high proportion of patients with 
almost certainly high degree of mismatching. 
Nevertheless it should be stressed that the TAC/
MTX regimen is currently considered as the 
American gold standard, while it never reached 
popularity in Europe.
CSA and TAC inhibit GVHD by preventing 
the activation of the nuclear factor of activated 
T-cell (NFAT) family of transcription factors, 
thereby reducing the transcription of interleukin-
 2 and the activation of effector T cells, albeit with 
a concurrent reduction in levels of interleukin- 2- 
dependent anti-inflammatory Tregs.
25.3  GVHD Prophylaxis After RIC; 
Is CNI Plus MMF Standard?
From the early development of the RIC, two regi-
mens have been used in the setting of RIC, CSA 
(or TAC) alone or in combination with MMF 
(reviewed in; Zeiser and Blazar 2017). Somewhat 
surprisingly the association of CSA/MMF while 
largely used worldwide has never been tested 
stringently in the setting of a large randomized 
prospective randomized trial. CNI in this setting 
are usually used at the same dose (and share the 
same toxicity profile) as after MAC. MMF’s tox-
icity mainly relies on sometimes unpredictable 
hematological toxicity. Attention must be paid to 
the use of ganciclovir (for CMV reactivation) in 
addition to MMF because of the risk of severe 
pancytopenia. MMF is usually delivered at the 
dose of 30  mg/kg/day split into two to three 
doses. Anecdotal evidence suggests depending 
on the transplant situation (i.e., HLA-identical 
vs. URD) that MMF should be delivered (till 
day + 80?) in recipients from URD.






There is a recent bloom in the use of haploidenti-
cal donor during the past few years worldwide. 
While initial attempt was to use megadose of 
CD34+ selected HSC, the advent of PT-CY has 
really revolutionized this procedure. The PT-CY 
designed by Baltimore’s group includes CY 
50 mg/kg on day +3 and +4 followed by TAC/
MMF.  Toxicities include those associated with 
CNI and MMF. Specific toxicity associated with 
CY includes hemorrhagic cystitis and the rare but 
potentially serious early cardiologic dysfunction. 
Although the incidence of acute GVHD remains 
significant (in around 1/3 of the patients), there is 
now some evidence that PT-CY might be associ-
ated with low rate of chronic GVHD (reviewed 
in; Fuchs 2017).
Furthermore, beyond the setting of haploiden-
tical transplant, PT-CY has gained popularity in 
other setting including transplantation from URD 
and HLA-identical sibling. Although it seems 
unlikely today that any formal randomized trial 
(vs. ATG) will be launched after haplo-HSCT, it 
would be of major scientific interest to prospec-
tively compare within a phase 3 trial ATG vs. 
PT-CY.
Finally, whether PT-CY is equally effective 
after RIC and MAC regimen is currently unknown 
as it is unknown if other combination like siroli-
mus (SIR) + MMF can be as effective as (or less 
effective as) CNI/MMF in addition to PT-CY in 
the haploidentical situation or even if PT-CY can 
safely be used as a single agent after HLA- 
identical sibling transplants, as recently reported 
(Mielcarek et al. 2016).












Target dose to 
150–200 ng/mL; 
adjust to renal 
function
Day 11 may be 
omitted if grade 
III/IV mucositis
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CY administered in two doses scheduled soon 
after transplantation depletes highly proliferating 
alloreactive conventional T cells while helping to 
preserve Tregs.
25.5  ATG or Alemtuzumab 
for GVHD Prophylaxis 
in HSCT
Since almost two decades, both ATG and alem-
tuzumab (ALEM) have been used to prevent 
GVHD especially after transplantation from 
URD. ALEM although efficacious in preventing 
acute GVHD has never been tested prospec-
tively in a randomized phase 3 trial and has 
almost exclusively been developed in the 
UK. ATG however has been tested in four pro-
spective randomized phase 3 trials. Three out of 
these four used anti-T-lymphocyte globulin 
(ATLG) and one rabbit ATG (rATG). However, 
the design, the time period, patients’ selection, 
donor type, and primary end point of these four 
randomized trials differ (see Table 25.2 for ref-
erences). From the perspective of GVHD pro-
phylaxis efficacy, all four trials demonstrated a 
significant decrease in chronic GVHD rate and 
in three out of the four a statistical significant 
decrease in the rate of acute GVHD. Other end 
points varied among the four trials. In particular 
the American trial by Soiffer et al. was the only 
one in which patients who received ATLG expe-
rienced an increased rate of relapse mainly in 
patients with AML who received TBI as part of 
a MAC pre-transplant.
25.6  New Immunosuppressive 
Regimens for GVHD 
Prophylaxis
With current treatment strategies summarized 
above, the rate of moderate to severe acute 
GVHD remains of concern in the range of 
20–50%. As reviewed elsewhere in the 
Handbook, the treatment of acute and of chronic 
GVHD with high-dose steroids remains unsatis-
factory with 30–50% of the patients being steroid 
resistant or dependent. There is thus an unmet 
clinical need in GVHD prophylaxis. After years 
of lack of new agent in this setting, the better 
knowledge of basic T-cell immunology, of the 
pathophysiology of the disease, and new drug 
development by the industry, new agents have 
been tested mostly in phase 2 trials which 
appeared to be promising. This section summa-
rized the drugs with most advanced development 
that reported an acute GVHD incidence in the 
20% range (i.e., a range that may warrant devel-
opment of subsequent phase 3 trials). Readers 
with interest on a more detailed portfolio of cur-
rent drug development and new targets could 
refer to a recent review (Zeiser and Blazar 2017).
In contrast to CNI, SIR, an mTOR inhibitor, is 
a more potent suppressor of the expansion of con-
ventional T cells than Tregs, owing to the greater 
dependence of conventional T cells on the mTOR-
protein kinase B pathway. This was the basis of 
the development by the Dana-Farber Cancer 
Institute (DFCI) group of a regimen that leads to 
an estimated cumulative incidence of acute 
GVHD grades II–IV of 20.5% and of less than 5% 
Table 25.2 Four randomized trials using ATG as a GVHD prophylaxis
Finke et al. (2009) Kroger et al. (2016) Soiffer et al. (2017) Walker et al. (2016)
N 202 168 254 203
Product ATLG ATLG ATLG rATG
Primary end 
point
GVHD cGVHD cGVHD-free survival Freedom from all IST
Conditioning MAC MAC MAC MAC+RIC
Donor URD Id. Sibling URD URD
GvHD 
prophylaxis
CSA +MTX CSA +MTX TAC +MTX CSA or TAC+MTX or 
MMF
Acute GVHD 33 vs. 51% (grade 
II–IV)
11 vs. 18% (grade 
II–IV)
23 vs. 40% (grade 
II–IV)
50 vs. 65% (any grade)
Chronic GVHD Decreased Decreased Decreased Decreased
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grades III–IV. This prompted a large trial of the 
BMTCTN comparing TAC/SIR to TAC/
MTX. The primary end point of the trial was to 
compare grade II–IV acute GVHD-free survival 
using an intention-to-treat analysis of 304 ran-
domized subjects. There was no difference in the 
probability of day 114 grade II–IV acute GVHD-
free survival (67% vs. 62%, P = 0.38). Grade II–
IV GVHD was similar in the TAC/SIR and TAC/
MTX arms (26% vs. 34%, P = 0.48) (Cutler et al. 
2014). A smaller randomized single-center phase 
2 study found however less cumulative incidence 
with 43% grade II–IV after TAC/SIR (as com-
pared to an unexpected high rate of 89% after 
TAC/MTX) (Pidala et al. 2012).
Encouraging rates have also been reported by 
two other compounds: Bortezomib (BOR) (Koreth 
et al. 2012) and Maraviroc in 2012 (Reshef et al. 
2012) delivered in addition to TAC/MTX. These 
two drugs as well as CY have been then tested in 
randomized phase 2 trials in the setting of HSCT 
(BMTCTN 1203 trial) after RIC in a pick-the-win-
ner-designed trial (i.e., aimed to test in a multi-
center setting the three drugs) and compared to 
prospective contemporary cohort of patients who 
received TAC/MTX. The final results of this trial 
closed for recruitment will be available in 2018. 
Finally, in an open-label three- arm phase 2 ran-
domized controlled trial, investigator at the DFCI 
compared grade II–IV acute GVHD between con-
ventional TAC/MTX (A) vs. BOR/TAC/MTX (B) 
and vs. BOR/SIR/TAC (C), in RIC-HSCT recipi-
ents from URD in 138 patients. Day +180 grade 
II–IV acute GVHD rates were similar (A 32.6%, B 
31.1%, C 21%) as was the 2-year NRM. Overall, 
the BOR-based regimens evaluated did not seem 
to improve outcomes compared with TAC/MTX 
therapy (Koreth et al. 2018).
Finally, based on preclinical works in mice 
models, two drugs Vorinostat and Tocilizumab 
provided exciting results and were supported by 
ancillary biological data in humans.
• Vorinostat, a histone deacetylase inhibitor, at 
low concentration has anti-inflammatory and 
immunoregulatory effects. Pavan Reddy’s 
group in Michigan provided compelling evi-
dences that in preclinical models Vorinostat 
reduced GVHD rate, suppressed pro- 
inflammatory cytokines, regulated APCs, and 
enhanced Treg functions. In two separate tri-
als (Choi et al. 2014, 2017), authors translated 
their findings in the clinical setting. In one 
trial where Vorinostat was added to standard 
prophylaxis after RIC in HLA-identical sib-
lings, acute GVHD grade II–IV rate was 22% 
and that of grades III–IV of 6%. In another 
trial after MAC in URD, the acute GVHD 
rates were similar.
• The addition of Tocilizumab to CNI+ MTX 
standard prophylaxis has been tested by two 
different groups (Kenedy et  al. 2014; 
Dorobyski et  al. 2018). Tocilizumab is a 
humanized anti-IL-6 receptor monoclonal 
antibody. IL-6 levels are increased early dur-
ing GVHD and are present in all target tissues. 
Blockade of the IL-6 signaling pathway has 
been shown to reduce the severity of GVHD 
and to prolong survival in experimental mod-
els. Investigators in Milwaukee and in 
Brisbane conducted two separate phase 2 tri-
als using Tocilizumab, and both found very 
low rate of grade II–IV acute GVHD (less 
than 15%).
Other new agents are currently either tested in 
preclinical models or are in the early stage of 
development in clinical trials (reviewed in Zeiser 
and Blazar 2017). New strategies that have shown 
efficacy in preclinical models of GVHD include 
the inhibition of Janus kinase (JAK) and rho- 
associated protein kinase 1 (ROCK-1). The 
blockade of phosphatidylinositol 3-kinase 
(PI3K), mitogen-activated protein kinase (MEK) 
proteins 1 and 2, aurora A kinase, and cyclin- 
dependent kinase 2 (CDK2) have been shown to 
reduce acute GVHD in murine models.
25.7  Conclusion and Perspective
Despite decades of experience with transplanta-
tion, GVHD still occurs in over 40% of the 
patients. When acute GVHD develops, the main 
treatment is high-dose steroids. However around 
one third of the patients will be steroid resistant. 
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Steroid resistance remains associated with a dis-
mal prognosis (30–40% 1-year survival). These 
data urge for developing new strategies to prevent 
GVHD. Fortunately enough, based on preclinical 
findings and improved knowledge on the immune 
biology of HSCT, recent drug combination opens 
the gate for future development.
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Key Points
• Current GVHD prophylaxis relies on 
CNI + short-term MTX after MAC and 
of CSA ± MMF after RIC
• ATG has been demonstrated to decrease 
acute GVHD after URD transplant and 
of chronic GVHD
• Despite the above two points, new pro-
phylactic regimens are clearly war-
ranted since severe GVHD rates still lie 
on the 25% range
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Currently horse and rabbit anti-lymphoglobulins 
(ATLG) or antithymocyte globulin (ATG) is 
available; the main, although not exclusive, use is 
for the treatment of aplastic anemia (horse) and 
for GVHD prophylaxis (rabbit). They differ in 
the manufacturing process (i.e., used animal, 
pulsed antigens, antibody specificities, and cel-
lular targets): for this reason, dose, timing, and 
setting cannot be interchangeable, and also clini-
cal results are different. As they are polyclonal 
serum-derived products from nonhuman organ-
isms, they can cause serum sickness and infusion 
reactions.
26.2  ATLG/ATG Infusion Protocol 
(See Table 26.1)
ATLG/ATG infusion should be performed in 
trained centers. Standard hygienic handling of 
the injection site, careful evaluation of the infu-
sion speed, and appropriate choice of the venous 
access are crucial. Medical personnel should 
carefully watch over patients for adverse events 
not only during but also after infusion.
During administration, the patient needs to be 
monitored for symptoms related to infusion reac-
tions or anaphylaxis. The first dose should be 
administered at a reduced speed for the first 
30  min. If no symptoms of intolerance occur, 
infusion rate may be increased. In case of ana-
phylactic or anaphylactoid reactions, physicians 
must be prepared to promptly manage this event, 
and appropriate medical treatment has to be 
implemented.
A central venous catheter is preferred, 
although a peripheral large high-flow access may 
be acceptable, if a central line is not available. 
Thrombophlebitis is the major risk when a 
peripheral vein is used. The availability of a high- 
flow access is important in case of treatment of 
infusion reactions.
Premedication is mandatory in order to 
improve systemic and local tolerance (see later). 
Stability, compatibility, and dilution are different 
for each product, and specific manufacturer rec-
ommendations should be followed carefully.
Preinfusion intraepidermal tests are not yet 
validated for rabbit ATG but, according to manu-
facturer indications, are recommended for horse 
ATLG.
— Although standard infusion time is between 
4 and 12 h, a longer administration time corre-
lates with milder side effects, thus making infu-
sions of 12 h highly advised.F. Bonifazi (*) 
Institute of Hematology “Seràgnoli”, University 





26.3  ATLG/ATG Dose
Dose and timing of ATLG/ATG administration 
vary substantially among transplant centers 
(Bacigalupo et al. 2001; Finke et al. 2009; Walker 
et  al. 2016; Kröger et  al. 2016; Soiffer et  al. 
2017).
The currently used doses of ATLG/ATG are 
calculated and validated in clinical trials, accord-
ing to body weight. A strong rationale and some 
preliminary data (Admiraal et al. 2017) suggest 
that calculating the ATG/ATLG dose according 
to the cellular target, i.e., the number of total lym-
phocyte before infusion of the first dose, can pro-
vide the optimal drug exposure and therefore 
maximize the benefit (GVHD decrease) over the 
potential risks (increase of relapses and infec-
tions). Since ATLG and ATG are different prepa-
rations arising from different manufacturing 
processes and different pulsed antigens, no dose 
equivalence can be established.
26.4  Infusion Reactions
ATLG/ATG administration can be complicated 
by several infusion reactions including fever, 
chills, erythema, dyspnea, oxygen desaturation, 
nausea/vomiting, diarrhea, abdominal pain, 
hyperkalemia, tachycardia, hypo- or hyperten-
sion, malaise, rash, urticaria, headache, arthral-
gia, myalgia (serum sickness, after 5–15  days 
from infusion), hepatic cytolysis, and even sys-
temic anaphylaxis.
Even if the NCI Terminology Criteria for 
Adverse Events (CTCAE) use different scales for 
grading reactions to infusion of chemotherapy 
and allergic/anaphylaxis reactions, there are no 
specific symptoms enabling to distinguish “stan-
dard” infusion reaction from an allergic one that 
can evolve to anaphylaxis.
Anaphylaxis and acute allergic reactions are 
based on IgE effect and histamine release by mas-
tocytes, but the vast majority of symptoms can be 
Table 26.1 Infusion of ATLG/ATG
Factors Comments
Infusion site – Central line is highly preferred
–  Risk of thrombophlebitis and drug precipitation are higher in peripheral 
veins
Dilution Avoid to inject undiluted preparation; follow the manufacturer instructions for 
each ATLG/ATG type
Compatibility –  rATLG-Grafalon: avoid to mix concentrate solution with glucose, blood, 
blood derivatives, sodium heparin, and lipid-containing solutions
– rATG-Thymoglobulin: avoid dilutions with other than saline and dextrose
–  Horse ATGAM: avoid dextrose injection or acidic solution because of 
precipitation or instability
Stability Diluted solutions up to 24 h (infusion time included) stored in refrigerator
Duration of infusion 4–12 h
–  Slower infusion results in a lower incidence and severity of infusion 
reactions; therefore ≥12 h infusion is recommended
Start first administration at low infusion rate (at least for the first 30–60 min)
Drug interactions Not reported
Premedication Mandatory; steroids, acetaminophen, antihistamines
Preinfusion test – Not advised for rabbit sera
– Recommended for ATGAM
– Skin and conjunctival tests not extensively validated
Criteria for permanent 
discontinuation
What does D/C stand for?
Anaphylaxis: severe anaphylaxis, always. De-sensitization protocols: not 
validated
SIRS: depending on grading and clinical evaluation of pros and cons. In case 
of rechallenge, more stringent monitoring is required
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attributed to the cytokine release syndrome (CRS) 
and are generally reversible. CRS is a form of sys-
temic inflammatory response syndrome (SIRS) 
(Matsuda and Hattori 2006; Balk 2014). CRS can 
follow not only ATG/ATLG infusion but also che-
motherapy, MoAb (Remberger et al. 1999; Feng 
et al. 2014), bispecific antibodies, or CAR-T cell 
therapies (Lee et al. 2014). All these (both allergic 
and nonallergic, such as CRS) are infusion reac-
tions. Serum sickness is a hypersensitivity phe-
nomenon that can develop after 5–15 days after 
the infusion, and it is well responsive to steroid 
treatment.
26.5  SIRS
SIRS is a clinical syndrome due to dysregulated 
inflammation. SIRS may occur in several condi-
tions, such as infection, autoimmune disorders, 
vasculitis, thromboembolism, chemotherapy 
infusion, surgery, and burns. The denomination 
originates from changes of some parameters 
(temperature, heart and respiratory rates, and 
white blood cell count) occurring after infection/
sepsis according to Bone (Bone et  al. 1992). A 
pediatric version tailored on patient age is also 
available (Goldstein 2005). More recently, some 
authors (Lee et al. 2014) revised the classification 
of the cytokine release syndrome according to the 
treatment required (oxygen, vasopressors, organ 
toxicity).
26.5.1  Risk Factors for SIRS
SIRS after ATLG/ATG infusion cannot be pre-
dicted and the risk factors are not well known.
The binding of ATLG/ATG to the surface of 
target cells (lymphocytes, monocytes, dendritic 
cells) elicits cytokine production and systemic 
inflammation (Bone et al. 1992).
Thus, that the higher the number of lympho-
cytes at the moment of the (first) infusion, the 
more likely is the risk of systemic activation of 
inflammation and then SIRS.
Accordingly, RIC regimens are reported to be 
associated with greater cytokine release syn-
drome (Remberger and Sundberg 2004) because 
of the likely higher number of residual lympho-
cytes in RIC in comparison with MAC 
regimens.
26.5.2  Management of SIRS
26.5.2.1  Prophylaxis
ATLG/ATG infusion reactions can be reduced in 
frequency and severity by two factors: premedi-
cation and speed of infusion. Premedication is 
performed with steroids, antihistamine, and acet-
aminophen. The optimal schedule of premedica-
tion is not yet well established. Doses of 
prednisolone of 250 mg (higher than 1 mg/kg), 
given before the first infusion and followed by an 
additional dose in the same day, reduce the inci-
dence of infusion reactions and cytokine release 
as reported (Pihusch et al. 2002).
The rate of infusion is one of the most impor-
tant factors to reduce the incidence and severity 
of infusion reactions since lower infusion rates 
are associated with a lower incidence and the 
severity of reactions. Administration time ≥12 h 
is the preferred schedule to yield high compli-
ance to ATLG/ATG infusion.
26.5.2.2  Treatment
If symptoms of SIRS appear, the drug should be 
discontinued, at least temporarily.
Treatment is symptomatic and depends upon 
the clinical manifestations. Intensive care for 
respiratory and hemodynamic support should be 
given according to international guidelines for 
critical patients, and the intervention of an inten-
sive specialist may be requested. SIRS after 
ATLG/ATG is different from sepsis-induced 
SIRS where steroids failed to achieve a signifi-
cant benefit (Cronin et al. 1995). Symptoms due 
to ATLG/ATG-related SIRS are more pronounced 
on day +1 and then tend to decrease. Steroids, 
widely used preemptively, provide high response 
rates also as a treatment measure.
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Permanent Discontinuation/Rechallenge
Rechallenge after anaphylaxis and after standard 
infusion reactions >3 is strongly discouraged.
Non-controlled life-threatening infections are 
contraindications to transplant and should not 
modify ATLG/ATG administration per se.
Desensitization protocols are not yet clearly 
validated.
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Key Points
• SIRS is a systemic reaction related to 
cytokine release after ATLG/ATG 
infusion.
• The infusion reactions can be reduced 
by premedication (steroids, antihista-
mines, and acetaminophen) and by a 
low infusion rate (12 h or longer).
F. Bonifazi
187
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
26 Management ATG (SIRS)
189© EBMT and the Author(s) 2019 
E. Carreras et al. (eds.), The EBMT Handbook, https://doi.org/10.1007/978-3-030-02278-5_27




Infection control is defined as a set of measures 
aimed at preventing or stopping the spread of 
infections in healthcare settings. All HSCT 
recipients should follow general guidelines (e.g. 
CDC) for preventing healthcare-associated infec-
tions through hand hygiene, disinfection and 
sterilization, environmental infection control, 
isolation precautions and prevention of intra-
vascular catheter- related infection (Sehulster 
et  al. 2004; Guidelines for Hand Hygiene in 
Healthcare Settings (2002), Guideline for 
Isolation Precautions: Preventing Transmission of 
Infectious Agents in Healthcare Settings (2007), 
Guidelines for Environmental Infection Control 
in Health-Care Facilities (2003), all available at 
https://www.cdc.gov/infectioncontrol/guidelines/
index.html; Freifeld et al. 2011).
Dedicated and detailed international recom-
mendations for HSCT recipients on preventing 
infectious complications have been published in 
2009 (Tomblyn et al. 2009; Yokoe et al. 2009). As 
there were no well-executed randomized or con-
trolled trials and little evidence to hand from 
cohort case-controlled or multiple time-series 
studies or uncontrolled experiments, reliance had 
to be placed on descriptive studies, reports of 
expert committees or on the opinions of respected 
authorities. Hence, most of these recommenda-
tions on infection control could only be graded as 
level III.
Isolation procedures in HSCT recipient com-
prise precautions universal for all healthcare 
settings (Standard Precautions and 
Transmission-Based Precautions) and those 
specific for HSCT and employed to prevent 
transmission of spores of filamentous fungi, 
mainly Aspergillus, with unfiltered air.
There is no consensus on specific protective 
environment, called also reverse isolation, for 
neutropenic patients. HSCT recipients should be 
placed in single-patient room, with adequate ven-
tilation system (see below), if possible. However, 
no clear benefit of routine footwear exchange, or 
use of disposable gloves and gowns on the rate 
of infections have been demonstrated, and pro-
cedures vary significantly between institutions, 
with routine use of masks and disposable gloves 
and gowns in some but not others. On the con-
trary, the negative effect of strict protective iso-
lation on patient’s quality of life and well-being 
should be acknowledged and weighted against 
the evidence of benefits of single protective mea-
sures (Abad et al. 2010).
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27.2  Standard Precautions
Should be used universally for all patients and 
they include:
 1. Proper hand hygiene
 2. Use of standard personal protective equip-
ment (PPE)
 3. Appropriate cleaning and disinfection proto-
cols (including those for shared equipment or 
toys and play areas in paediatric units)
 4. Safe injection practices
 5. Infection control practices for special proce-
dures (e.g. surgical masks for lumbar puncture)
27.2.1  Hand Hygiene
It is by far the most effective means of prevention 
of pathogen transmission (Freifeld et  al. 2011; 
Tomblyn et  al. 2009). The preferred method of 
hand decontamination is with an alcohol-based 
hand rub, due to its superior convenience and 
reduced drying of the skin. Handwashing with 
soap and water is recommended if hands are visibly 
soiled, for example, with blood or body fluids, or 
after potential contact with spores of Clostridium 
difficile or with Norovirus. Of note, 15–30 s is the 
minimum necessary handwashing time.
PPE used routinely by healthcare workers 
during patient care and procedures are gloves, 
gowns (used if direct contact with patient’s flu-
ids is expected) and mouth, nose and eye protec-
tion (used during procedures which are likely to 
generate splashes or sprays of blood, body flu-
ids, secretions and excretions). Routine donning 
of gowns upon entrance into a high-risk unit, 
including HSCT unit, is not indicated.
27.3  Transmission-Based 
Precautions
These are the measures used in addition to stan-
dard precautions for patients with documented or 
suspected infection or colonization with highly 
transmissible or epidemiologically important 
pathogens for which additional precautions are 
necessary to prevent transmission. The main 
types of transmission-based precautions are con-
tact precautions, airborne precautions and drop-
let precautions. The specific PPE and the 
examples of pathogens which require each type 
of transmission-based precautions are outlined in 
Table 27.1.
Contact precaution should be also applied in a 
pre-emptive way, e.g. in case of patients trans-
ferred from high-risk facilities, pending the 
results of surveillance cultures. Clear criteria 
should be provided for appropriate discontinua-
tion of contact precautions (usually when three 
different swabs from a known multidrug-resistant 
(MDR) positive site, taken 1–7  days apart, are 
negative). In case of contact precautions, and par-
ticularly if a patient is still colonized with a resis-
tant pathogen, this information should be clearly 
stated on the discharge information form for the 
centres which will care for this patient subse-
quently. In case of MDR Gram-negative patho-
gens, full antibiotic susceptibility results should 
be provided to allow appropriate empirical ther-
apy in case of severe subsequent infection.
Cough etiquette should be promoted. 
Additionally, transplant recipients, particularly 
those with respiratory symptoms, should use sur-
gical masks and maintain special separation from 
others in common waiting areas, ideally a dis-
tance of at least 1 m.
Upon entering HSCT unit, visitors should be 
screened for the presence of symptoms of easily 
transmissible diseases such as viral respiratory 
tract infections, gastroenteritis, etc. and, if pres-
ent, advised to postpone their visit until no lon-
ger symptomatic. Also, healthcare workers with 
respiratory symptoms should refrain from direct 
patient care until the symptoms resolve. Sero 
negative persons who were exposed to commu-
nicable diseases such as measles or chickenpox 
should refrain from contact with HSCT recipi-
ents or transplant candidates until the incubation 
period passes without developing the disease. 
Instructional materials for patients and visitors 
on recommended hand hygiene, respiratory 
hygiene/cough etiquette practices and the appli-
cation of transmission-based precautions should 
be provided. Vaccination of healthcare workers 
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and household contacts is paramount and dis-
cussed in the dedicated chapter.
27.4  Management of the Threat 
of MDR Bacteria
In the era of increasing bacterial resistance, an 
important part of infection control deals with pre-
vention of colonization and infection with MDR 
bacteria (Siegel et al. 2007). Active surveillance, for 
example, with rectal swabs for detecting coloniza-
tion with vancomycin-resistant enterococci (VRE) 
or carbapenem-resistant Enterobacteriaceae or 
nasal swabs for methicillin- resistant Staphylococcus 
aureus, should be performed in institutions where 
these pathogens are regularly encountered or in 
patients coming from such institutions.
The need for screening for different pathogens 
may vary according to local epidemiology. For 
instance, Italian statement on the management of 
carbapenem-resistant Klebsiella pneumoniae 
(CR-Kp) infections in HSCT was published 
(Girmenia et al. 2015). Briefly, they recommended 
active detection of CR-Kp carriers before and after 
HSCT, since the carriers have approximately 30% 
risk of developing CR-Kp bloodstream infection; 
staff education and monitoring of adherence to 
contact precautions; a cautious approach to declare 
a patient no longer colonized and a need for coor-
dinated effort to intra- or inter-hospital transmis-
sion. HSCT is not contraindicated in MDR 
Table 27.1 Transmission-based precautions, to be applied in addition to standard precautions
Type of 
precaution
Patients placement and PPE to be used 
by patients
PPE for healthcare 
personnel Example of pathogens and comments
Contact –  Single room; if not available, 
cohorting of those colonized/infected 
by the same pathogen
–  During transport, cover patient’s 
colonized/infected areas
–  Disposable gloves 
and gowns
–  Use patient- 
dedicated or 
disposable 
equipment; if not 
feasible, clean and 
disinfect 
thoroughly
–  Infection with Clostridium difficile
–  Colonization or infection with MDR 
pathogens
–  Infectious diarrhoea due to pathogens 
such as Salmonella, Norovirus, 
Rotavirus, etc
All the units or other hospitals involved 
in patient’s care should be notified 
about all the isolated pathogens 
requiring contact precautions
Droplet –  Single room; if not available, 
cohorting of those infected by the 
same pathogen
–  Surgical mask
–  Follow CDC’s respiratory hygiene/
cough etiquette in healthcare setting
–  Mask (surgical)
–  Disposable gloves 
and gowns
–  Pathogens transmitted by respiratory 
droplets (i.e. large-particle droplets 
>5 μ in size) that are generated by a 
patient who is coughing, sneezing or 
talking, e.g. influenza or other 
respiratory viruses
In case of transplant recipients, the 
duration of precautions should be 
extended due to the possibility of 
prolonged shedding caused by 
immunodeficiency
Airborne –  Rooms with at least 6 (existing 
facility) or 12 (new construction/
renovation) air changes per hour and 
direct exhaust of air to the outside (if 
not possible, the air may be returned 
to the air-handling system or adjacent 
spaces if all air is directed through 
HEPA filters)
–  Surgical mask
–  Follow CDC’s respiratory hygiene/
cough etiquette in healthcare setting
–  N95 or higher- 
level respirator for 
respiratory 
protection
–  Mycobacterium tuberculosis (patients 
with respiratory tuberculosis and 
sputum with direct evidence of 
mycobacteria)
–  Measles, chickenpox and 
disseminated herpes zoster
HEPA high-efficiency particulate air, MDR multidrug resistant, PPE personal protective equipment
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carriers, but establishing upfront the appropriate 
empirical therapy to be administered in case of 
fever during neutropenia is mandatory, and careful 
evaluation of the possibility of decolonization in 
selected cases through oral administration of non-
absorbable molecules or faecal microbiota trans-
plantation is warranted (Girmenia et  al. 2015; 
Bilinski et al. 2017).
In order to counteract the threat of MDR 
pathogens and the shortage of agents active 
against Gram-negative MDR bacteria, antimicro-
bial stewardship program should be implemented 
in every centre (Gyssens et al.  2013). Additionally, 
national systems for surveillance, with obligation 
for notification and recommendations for con-
tainment and infection control measures, should 
be put in place (Tacconelli et al. 2014).
The aim of antimicrobial stewardship is to 
limit the negative impact of MDR pathogens on 
patients’ outcome, and its main elements are 
detailed in Table 27.2.
Successful implementation of antimicrobial 
stewardship is based on a multidisciplinary 
approach and close collaboration between the 
treating haematologists, microbiology laboratory 
and infectious diseases consultation service, 
including infection control unit, hospital phar-
macy and hospital authorities who should recog-
nize that this is an important step in high-quality 
management of infectious complications after 
HSCT.
Surveillance of effectiveness of infection con-
trol practices should be put in place, with regular 
monitoring of adherence. In case of contact- 
transmission pathogens, such as Clostridium dif-
ficile or MDR bacteria, laboratory data should be 
regularly analysed to detect any trends indicating 
possible increase in transmission.
27.5  HSCT Environment
Flowers, fountains, water leaks and water- 
retaining bath toys carry the risk of water- 
associated infections with Gram-negative bacilli 
such as Pseudomonas aeruginosa or Legionella 
and thus should be avoided in the areas where 
severely immunocompromised patients are being 
cared for (Yokoe et  al. 2009). In addition, there 
are issues specific for HSCT recipients, such as 
room ventilation, intensified protective measures 
applied during hospital construction and renova-
tions, avoidance of contact with soil (including 
potted plants) and avoidance of dust both perma-
nently (e.g. non-carpeting and no porous surfaces) 
and while cleaning, all aimed at decreasing the 
risk of invasive aspergillosis (Yokoe et al. 2009).
CIBMTR/ASBMT/EBMT global recommen-
dations on protective environment concerning 
hospital room design and ventilation are avail-
able (Yokoe et  al. 2009). Briefly, allo-HSCT 
recipients should ideally be placed in protective 
Table 27.2 Main elements of antimicrobial stewardship 
program
1.  Regularly updated (e.g. every 6–12 months) 
surveillance of local epidemiology of infections in 
HSCT recipients, through reports on:
  (a)  Resistance rates to main antibiotics in top 10 
most frequent pathogens
  (b) Data on antibiotic consumption
 (c)  Data on patient outcomes in case of most 
frequent/difficult infections
2.  Implementation of updated diagnostic methods and 
prompt reporting of microbiologic results by the 
laboratory in order to provide clinicians with
  (a)  Correct and timely diagnosis (e.g. of viral or 
fungal infections or Clostridium difficile, which 
may allow to avoid unnecessary antibiotic 
therapy)
  (b)  Rapid results of antimicrobial susceptibility 
testing to allow choosing the best targeted 
antibiotic therapy
3.  Promoting appropriate antibiotic use, for example
  (a)  Implementing timely de-escalation or 
discontinuation of antibiotic treatment, 
particularly during neutropenia
  (b) Appropriate dosing for different indications
  (c)  Optimized infusion strategies for time- and 
dose-dependent molecules, e.g. use of extended 
or continuous infusion of time-dependent 
molecules such as beta-lactams
4.  Establishing and regularly updating protocols for 
prevention and treatment of infections, e.g. 
identifying antibiotic and antifungal regimens for 
empirical therapy in accordance with local 
epidemiology (e.g. prevalence of extended spectrum 
beta-lactamase (ESBL) producing 
Enterobacteriaceae, methicillin-resistant 
staphylococci, azole-resistant aspergilli, etc.)
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environment rooms that incorporate several fea-
tures including central or point-of-use HEPA 
(high-efficiency particulate air) filters with 
99.97% efficiency for removing particles 
≤0.3  μm in diameter and ≥12 air exchanges/
hours, with directed airflow and consistent posi-
tive air pressure differential between the patient’s 
room and the hallway ≥2.5 Pa. All these  measures 
remove airborne fungal spores and are aimed at 
preventing airborne infections with filamentous 
fungi such as aspergilli. The efficacy of protec-
tive isolation measures in case of auto- HSCT 
recipients is less well established.
Currently HEPA-filtered rooms are probably 
available in almost all centres, while few centres-
fulfilled all the CIBMTR/ASBMT/EBMT require-
ments. However, the knowledge on the details 
and maintenance of protective environments in 
the HSCT setting was recently found inadequate, 
requiring education efforts and cooperation with 
hospital infection control and the hospital mainte-
nance services (Styczynski et al. 2018).
During construction and renovations, due to 
high density of fungal spores, protective environ-
mental measures are particularly important, and 
mould-control measures should be intensified and 
filtration efficiency should be monitored fre-
quently to best determine appropriate time for 
replacement. Specific recommendations are avail-
able and should be followed (Sehulster et  al. 
2004). For example, construction and renovation 
areas should have negative air pressure relative to 
HSCT patient care areas to ensure that air flows 
from patient care areas toward construction areas, 
and a portable, industrial-grade HEPA filter 
should be used between a construction zone and 
the HSCT unit if a large area is under construction 
and negative pressure differential cannot be guar-
anteed. In addition, HSCT recipients may benefit 
from wearing N95 respirators outside HEPA-
filtered areas, particularly during ongoing con-
structions, since unlike surgical masks, higher 
efficiency ones offer protection against Aspergillus 
spores. Active monitoring of cases of invasive 
mould infections should be performed in order to 
detect any possible outbreak.
27.6  Food Safety in Transplant 
Recipients
Drinking water should be safe; thus boiled or 
bottled water is to be preferred. Tap water in 
highly populated areas is usually regarded as safe 
from bacterial contamination because regularly 
tested for it. However, it may still contain 
Cryptosporidiums. Water from private wells 
should be avoided.
The use of low-microbial diet, which pro-
hibits fresh fruits and vegetables and unpro-
cessed food, did not result in a decreased 
incidence of infections in neutropenic patients 
(Sonbol et  al. 2015; van Dalen et  al. 2016). 
Standard food safety practices that emphasize 
safe handling and washing or thoroughly cook-
ing food were found to be just as safe and pro-
duced no increase in infection rates or incidence 
of neutropenic fever. Similarly, to other immu-
nocompromised patients, HSCT recipients 
should avoid foods possibly contaminated 
by  Listeria monocytogenes, Campylobacter 
jejuni, Salmonella enteritidis, Toxoplasma 
gondii, etc. Main high-risk foods to avoid 
include:
• Raw or undercooked meat, poultry, fish or 
shellfish
• Refrigerated smoked fish
• Unpasteurized milk
• Foods with raw or undercooked eggs
• Unwashed fruits and vegetables
• Raw sprouts
• Soft cheeses made from unpasteurized milk 
like brie, camembert and blue-veined and 
fresh cheese (can be eaten if cooked)
• Hot dogs, deli meats and luncheon meats that 
have not been reheated to steaming hot or to 
75 °C
• Unsafe water and ice made of it
Food safety practices for food handling should 
be followed, and specific information for cancer 
patients is available online (https://www.fda.gov/
downloads/Food/FoodborneIllnessContaminants/
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UCM312793.pdf). Too restrictive diet recommen-
dations, in the absence of the clear benefit of 
avoiding foods other than abovementioned, may 
have negative impact on patient’s nutritional sta-
tus and/or quality of life.
References
Abad C, Fearday A, Safdar N. Adverse effects of isolation 
in hospitalised patients: a systematic review. J Hosp 
Infect. 2010;76:97–102.
Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal micro-
biota transplantation in patients with blood disorders 
inhibits gut colonization with antibiotic-resistant 
 bacteria: results of a prospective, single-center study. 
Clin Infect Dis. 2017;65:364–70.
Centers for Disease Control and Prevention. Guideline 
for hand hygiene in health-care settings: recommen-
dations of the Healthcare Infection Control Practices 
Advisory Committee and the HICPAC/SHEA/APIC/
IDSA Hand Hygiene Task Force. MMWR Recomm 
Rep. 2002;51(RR16):1.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical prac-
tice guideline for the use of antimicrobial agents in 
neutropenic patients with cancer: 2010 update by the 
Infectious Diseases Society of America. Clin Infect 
Dis. 2011;52:427–31.
Girmenia C, Viscoli C, Piciocchi A, et  al. Management 
of carbapenem resistant Klebsiella pneumoniae infec-
tions in stem cell transplant recipients: an Italian mul-
tidisciplinary consensus statement. Haematologica. 
2015;100:e375.
Gyssens IC, Kern WV, Livermore DM, ECIL-4, a joint 
venture of EBMT, EORTC, ICHS and ESGICH of 
ESCMID.  The role of antibiotic stewardship in lim-
iting antibacterial resistance among hematology 
patients. Haematologica. 2013;98:1821–5.
Sehulster LM, Chinn RYW, Arduino MJ, et al. Guidelines 
for environmental infection control in health-care facil-
ities. Recommendations from CDC and the Healthcare 
Infection Control Practices Advisory Committee 
(HICPAC). Chicago: American Society for Healthcare 
Engineering/American Hospital Association; 2004.
Siegel JD, Rhinehart E, Jackson M, Chiarello L, 
Healthcare Infection Control Practices Advisory 
Committee. Guideline for isolation precautions: pre-
venting transmission of infectious agents in healthcare 
settings. 2007. http://www.cdc.gov/ncidod/dhqp/pdf/
isolation2007.pdf.
Sonbol MG, Firwana B, Diab M, et al. The effect of a neu-
tropenic diet on infection and mortality rates in cancer 
patients: a meta-analysis. Nutr Cancer. 2015;67:1230–8.
Styczynski J, Tridello G, Donnelly P, et  al. Protective 
environment for hematopoietic cell transplant (HSCT) 
recipients: the Infectious Diseases Working Party 
EBMT analysis of global recommendations on health- 
care facilities. Bone Marrow Transplant. 2018;53:1131. 
https://doi.org/10.1038/s41409-018-0141-5.
Tacconelli E, Cataldo MA, Dancer SJ, et  al. ESCMID 
guidelines for the management of the infection control 
measures to reduce transmission of multidrug- resistant 
Gram-negative bacteria in hospitalized patients. Clin 
Microbiol Infect. 2014;20(Suppl 1):1–55.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for pre-
venting infectious complications among hematopoietic 
cell transplantation recipients: a global perspective. 
Biol Blood Marrow Transplant. 2009;15:1143–38.
van Dalen EC, Mank A, Leclercq E, et al. Low bacterial 
diet versus control diet to prevent infection in can-
cer patients treated with chemotherapy causing epi-
sodes of neutropenia. Cochrane Database Syst Rev. 
2016;4:CD006247.
Yokoe D, Casper C, Dubberke E, et  al. Infection pre-
vention and control in health-care facilities in which 
hematopoietic cell transplant recipients are treated. 
Bone Marrow Transplant. 2009;44:495–7.
Key Points
• General guidelines for preventing 
healthcare-associated infections should 
be followed, and hand hygiene is the 
single most effective measure.
• Mandatory isolation procedures comprise 
Standard Precautions and Transmission- 
Based Precautions if appropriate: air-
borne, contact or droplets.
• Specific recommendations on ventila-
tion, room design and protective envi-
ronment during construction/renovation 
are provided to protect HSCT from 
transmission of spores of filamentous 
fungi, mainly Aspergillus.
• Protocols for prevention of colonization 
and infection with multidrug-resistant 
bacteria should be put in place, particu-
larly in centres where these bacteria are 
already present.
• Antimicrobial stewardship program 
should be implemented in every centre 
to promote optimal use of antibiotics.
• Standard food safety practices should be 
applied, and only selected foods should 
be avoided (e.g. raw/undercook/under-
heated meat, fish or eggs, unpasteurized 
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Many of the conditions requiring allo-HSCT and 
related complications are similar in adults and 
children and are covered in other chapters of this 
handbook.
However, since pediatric age is a continuum 
between newborns and adults, there are at least 
two aspects, psychological and infectious disease 
issues, that may require a dedicated approach for 
the following reason:
 1. Psychological aspects. Childhood encom-
passes different ages and consequently differ-
ent cognitive, decisional, and emotional 
capacities that make psychological interven-
tion far more faceted than in adults. In addi-
tion, psychological intervention should also 
take in charge at higher extent the needs and 
the expectations of the patient’s family.
 2. Infectious diseases. Data on epidemiology 
and management of infections in children are 
far less numerous and consistent than in 
adults. In addition most of the available data 
are derived from studies in adults, and they 
cannot always simply be transposed to chil-
dren for an effective application.
In the following paragraphs, we will analyze 
the specific approaches related to these aspects in 
children undergoing HSCT.
28.2  Psychological Aspects 
(Table 28.1)
Children who undergo HSCT experience sev-
eral numerous psychological reactions: anxi-
ety, depression, behavioral and social problems, 
and post-traumatic stress symptoms. In the 
stages before HSCT, anxiety increases, and the 
emotional distress continues to rise until 
1 week after transplant, whereas depression is 
heightened by hospitalization and physical iso-
lation. Age (<7  years) and severity of the ill-
ness influence the level of emotional reactions. 
Especially, children <5 years are more likely to 
withdraw and to be deprived of their self-help 
skills and even of their mobility and speech 
skills. The level of pre- HSCT emotional distur-
bance is strongly predictive of post-HSCT 
emotional functioning; therefore early inter-
vention appears of critical importance 
(Packman et al. 2010).
The most studied psychological treatments for 
children with cancer are cognitive behavioral 
therapies (CBT) that are considered to improve 
emotional adjustment, compliance with medical 
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treatment, and behavioral problems associated 
with HSCT.  Effective interventions are clearly 
largely dependent on social skills and emotional 
well-being. Techniques such as guided imagery, 
distraction, rhythmic breathing, and relaxation 
are commonly used to decrease the acute psycho-
logical distress due to medical procedures includ-
ing HSCT (Packman et  al. 2010). Psychiatric 
assessment and pharmacological approach 
should be advisable when other approaches are 
not sufficient for children with preexisting psy-
chiatric diagnoses who are vulnerable to worsen-
ing of the psychiatric disorders (Steele et  al. 
2015).
Health-related quality of life (HRQOL) com-
promission is usually evident prior to and soon 
after transplant and starts to improve between 4 
and 6  months after HSCT.  Child psychosocial 
problems, caregiver stress, and social support 
emerged as significant predictors of physical and 
emotional outcome after discharging. Indeed, 
high level of stress of caregivers and/or low per-
ceived social support was associated with higher 
risk of psychologically complicated outcome. 
On the contrary emotional and behavioral prob-
lems of the child at discharge were not associ-
ated to substantially slower improvements in 
overall HRQOL that usually occurred between 3 
and 9  months after discharge. This is because 
reestablishment of usual activities that were pre-
cluded during HSCT outbalances emotional 
problems due to the return to “normal” life 
(Loiselle et al. 2016).
As for neurocognitive functions, long-term 
studies are not fully concordant, but some find-
ings (Kelly et  al. 2018) seem to suggest that 
children’s intelligence quotient (IQ) scores 
post HSCT are inferior to those before 
HSCT.  In particular adaptive skills and social 
competence domains are affected in the first 
year after HSCT and so do self-esteem and 
emotional well-being. Impairment in neuro-
cognitive area is associated with younger age 
at diagnosis and treatment and may occur even 
if school performance remains in normal 
ranges. Children may also experience decre-
ments in executive functioning skills, like defi-
cits in fine motor abilities usually seen in 
patients who received cranial irradiation at 
younger age. Clinical assessment is recom-
mended before the recovery period, at 1  year 
after HSCT and annually thereafter, or, at least, 
at the beginning of each stage of education. In 
the post-HSCT assessment, clinicians should 
also consider the impact of factors such as iso-
lation, missed schooling, and impaired social-
ization with peers. Encouraging results in 
cognitive rehabilitation come from intensive 
therapist- delivered training since the system-
atic use of computer-based training appeared 
to improve working memory and processing 
speed (Kelly et al. 2018).
Table 28.1 Main psychological problems in HSCT in pediatric age
Problems Suggested intervention
Patients Emotional disturbance: anxiety, depression, 
behavioral and social problems, post traumatic 
stess symptoms
HRQOL: compromission is evident before and 
soon after HSCT. Start to improve between 4 
and 6 months after HSCT
Neurocognitive area: impairment is associated 
with younger age at diagnosis and treatment. 
Adaptive skills and social competence are 
affected in the first year after HSCT
–  Individual therapies to improve emotional 
adjustment, compliance with medical 
treatment and behavioral problems 
associated with HSCT
–  Guided imagery, distraction, rhythmic 
breathing, relaxation to decrease the 
distress due to medical procedures
–  Clinical assessment is recommended:
before the recovery period 1 year after HSCT 
annually thereafter
Siblings Post-traumatic stress reactions, anxiety, low 
self-esteem, feelings of guilt and school 
problems
Open communication
Facilitate the access of sibling to the hospital
Parents Parental distress, anxiety, depression, post 
traumatic stress symptoms. Take care of 
additional burden due to medical complications
Familial intervention
Crisis intervention approach
Stress and coping models
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Siblings, either donors or non-donors, are at 
risk of developing emotional disturbances 
such as post-traumatic stress reactions, anxi-
ety, low self-esteem, feelings of guilt, and 
school problems. Indeed, researches are 
needed to identify the most useful intervention 
to cope with negative effects of HSCT on sib-
lings (Packman et  al. 2010; Gerhardt et  al. 
2015). Currently adopted strategies include 
open communication about the patient’s medi-
cal situation and transplant process, favoring 
the idea of accepting help from friends and 
family members, and facilitating the access of 
sibling to the hospital arranging visits in a way 
that they look like a special event or assigning 
a sibling a special role (Gerhardt et al. 2015; 
White et al. 2017).
Parental distress, anxiety, and depression 
levels are often increased as a result of their 
child undergoing HSCT. The distress and anxi-
ety may be even greater for parents whose 
healthy child also becomes part of the HSCT 
process through donating his/her marrow 
(Packman et al. 2010). Significant determinants 
of parental distress include prior parent and 
patient experience of distress associated with 
the child’s illness, the child’s tendency of inter-
nalizing or externalizing behavior problems, the 
family’s attitude to provide support, and a 
parental proneness toward avoidant coping 
behaviors (Phipps et  al. 2005). Parents mostly 
experience post-traumatic stress symptoms that 
manifest in cognitive and behavioral efforts to 
avoid reminders of the HSCT and intrusive 
thoughts about it (Virtue et al. 2014).
Early and late HSCT medical complications 
significantly increase the psychological involve-
ment of the caregiver. HSCT healthcare profes-
sionals should also take care of the additional 
burden that complications generate on the par-
ents and should proactively link parents to 
resources aimed to help them coping with this 
extra load (Heinze et al. 2015). Despite the rec-
ognized needs, very few caregivers seek out psy-
chological service. The most frequent barriers are 
that clinicians prioritize medical patient’s needs 
and cover tasks usually deemed to social support, 
lack of adequate locations, and embarrassment 
about seeking psychological counseling (Devine 
et al. 2016).
Familial interventions aimed to enhance pro-
tective factors, improve communication, and 
decrease parental anxiety and depression are cru-
cial. In this respect, cancer-specific psychologi-
cal interventions may serve as a template to 
delivering HSCT-tailored interventions (Packman 
et al. 2010). Traditional individual therapy is very 
useful even if in adapted forms. Usually it 
includes crisis intervention approach and stress 
and coping models to reduce HSCT-related 
stress. CBT can encompass different strategies 
such as the expression of emotional feelings, 
identification of distorted automatic thoughts, the 
use of problem-focused coping skills, discussion 
of psychosocial impact on the family, and train-
ing in assertiveness and communication skills 
(Steele et al. 2015).
28.3  Infectious Diseases
Infections represent one of the most frequently 
occurring and feared complications of HSCT.
Antibacterial prophylaxis for febrile neutro-
penia is frequently administered in pediatric 
HSCT but never specifically analyzed in a ran-
domized clinical trial. Its use can be associated 
with selection of resistant strains.
In the pre-engraftment phases, empirical 
antibiotic therapy for febrile neutropenia could 
be represented by monotherapy with an anti- 
Pseudomonas beta-lactam, but it is mandatory 
its adaptation to local epidemiological data 
(Lehrnbecher et al. 2017). Moreover, empirical 
antibiotic therapy should be considered also 
after engraftment because of the important risk 
of morbidity and mortality. Antibiotic-resistant 
pathogens represent a new challenge because of 
the high mortality rates (>50%) observed in 
pediatric HSCT (Girmenia et  al. 2015; Caselli 
et al. 2016).
Clostridium difficile may represent a cause 
of severe, and sometimes recurrent, disease, 
but it must be kept in mind that children aged 
below 2  years may harbor this pathogen in 
their intestinal tract (Lees et  al. 2016; 
28 General Management of the Patient: Specific Aspects of Children
200
Enoch  et  al. 2011) and that other pathogens 
(e.g., viruses or Cryptosporidium) could be 
the cause of  gastroenteritis (Castagnola et al. 
2016). Table  28.2 summarizes antibacterial 
drugs for prophylaxis and treatment of inva-
sive diseases.
Invasive fungal disease (IFD) is associated 
with high mortality in pediatric HSCT (Cesaro 
et al. 2017; Castagnola et al. 2018b). Increasing 
age has been identified as a risk factor for the 
development of IFD (Fisher et  al. 2017), but 
recent multivariable analyses showed that age is 
no longer significant in the presence of severe 
acute or chronic extensive GvHD or in cases of 
primary graft failure or rejection (Castagnola 
et al. 2014, 2018a).
Primary prophylaxis should be implemented 
in the highest-risk groups like patients with 
primary graft failure or rejection, or with 
severe acute or chronic extensive GvHD, or in 
centers with high incidence of IFD (Groll et al. 
2014).
Table 28.2 Prophylaxis and therapy of invasive bacterial infections in children undergoing allogeneic HSCT
Prophylaxis for febrile neutropenia
Ciprofloxacin Oral or IV until neutrophil recovery or start of empirical therapy for febrile neutropenia




Oral or IV until neutrophil recovery or start of empirical therapy for febrile neutropenia
Notes: Never analyzed in a randomized clinical trial in HSCT. Risk of selection of resistant 
strains
Empirical therapy for febrile neutropenia, or fever after engraftment, especially in presence of GvHD
Pipera-tazo 100 mg/kg (max 4000 mg) of piperacillin q6h
Cefepime 33 mg/kg (max 2000 mg) q8h
Ceftazidime 33 mg/kg (max 2000 mg)
Meropenem 20 mg/kg (max 1000 mg) q8h
Notes: Risk of selection of resistant Gram-negatives or C. difficile associated disease. Higher 
doses could be necessary for treatment of carbapenem resistant pathogen when MIC is 
≤16 mg/L. For higher MIC values carbapenems are not indicated
Combination 
therapy
Aminoglycoside [e.g. amikacin 20 mg/kg (max 1500 mg) q24h] + beta-lactam
Notes: According to local susceptibility, and proportions of resistance to beta-lactams indicated 
for monotherapy






Gram-positives: vancomycin, teicoplanin daptomycin, linezolid, tigecycline, fosfomycin
Gram-negatives: ciprofloxacin, colistin, tigecycline (not active against P. aeruginosas), 
fosfomycin, ceftazidime-avibactam (not active against metallo beta-lactamases), ceftolozane-
tazobactam (not active against carbapenemases)
Notes:
 –  According to ATB susceptibility tests in documented infections
 –  Beta-lactams should be preferred to glycopeptides in case of infections due to oxacillin- 
susceptible staphylococci
 –  Do not use empirical glycopeptides for persistent fever without signs of localizations 
attributable to Gram-positives or high suspicion or risk by patient’s history or local 
epidemiology of oxacillin-resistant staphylococci or ampicillin-resistant enterococci
 –  For vancomycin resistant staphylococci or enterococci daptomycin, linezolid or tigecycline 
could represent therapeutic options
 –  No PK data for ceftazidime- avibactam or ceftolozane- tazobactam available in children




Oral therapy, vancomycin 10 mg/kg (max 125 mg) q6h as 1st choice
Fidaxomicin is not registered for <18 years
Notes: No data are available for fecal transplantation in immunocompromised children. Different 
dosages proposed for recurrent disease
MIC minimally inhibitory concentration, GvHD graft vs. host disease, Pipera-tazo Piperacillin-Tazobactam
F. Riccardi and E. Castagnola
201
Diagnosis of IFD is based on isolation of 
fungal pathogens from cultures of sterile sites 
or tissue invasion demonstrated by histology 
or by the presence of fungal antigens in blood 
or cerebrospinal fluid or bronchoalveolar 
lavage, associated with suggestive imaging 
(Castagnola et al. 2016; Tomà et al. 2016) in 
children with a compatible clinical picture. 
Detection of galactomannan and 1-3-beta-D-
glucan is widely used for the diagnosis of 
(probable) IFD also in children. However, a 
recent meta-analysis (Lehrnbecher et al. 2016) 
and new clinical data (Calitri et  al. 2017) 
showed highly variable and generally poor 
sensitivity, specificity, and predictive values 
of these tests, especially when used for screen-
ing. PCR should still be considered as an 
investigative test (Lehrnbecher et  al. 2016). 
Also, for the use of antifungal drugs, there are 
caveats.
Treatment: Voriconazole frequently needs 
to be administered at higher dosages in the 
youngest patients (<5  years) to achieve and 
maintain effective plasma concentrations (Xu 
et  al. 2016; Soler-Palacın et  al. 2012; Neely 
et  al. 2015; Castagnola and Mesini 2018). 
Inflammation, steroid administration, or obe-
sity can further modify its concentrations 
(Castagnola and Mesini 2018; Natale et  al. 
2017) and so do genetic factors (Teusink et al. 
2016). Finally, severe cutaneous adverse 
events can be observed also in children when 
voriconazole is administered for prolonged 
periods, especially in concomitance with sun 
exposure (Goyal et  al. 2014; Bernhard et  al. 
2012). Posaconazole oral suspension has vari-
able absorption implying the risk of sub-thera-
peutic concentrations (Jancel et  al. 2017), 
especially in the presence of intestinal acute 
GvHD (Heinz et al. 2016). This can be at least 
partially avoided by fatty meal and/or other 
“bundle” measures or using doses based on 
body surface area (Castagnola and Mesini 
2018). Posaconazole tablets have no absorp-
tion  problems, and pediatric pharmacological 
data show that their use determines effective 
 concentrations also in children (Castagnola 
and Mesini 2018). However, tablets are 
slightly less than 2  cm long and should be 
swallowed whole with water and should not be 
crushed, chewed, or broken (EMA 2018) thus 
limiting their use in youngest patients, but 
alternate day administration could represent 
an effective strategy (Mesini et  al. 2018). 
Triazoles have also many drug interactions 
that must be kept in mind during their use. For 
all these reasons, therapeutic drug monitoring 
is mandatory both for prophylactic and thera-
peutic uses (Groll et al. 2014).
Pneumocystis jirovecii pneumonia is a 
severe, life-threatening fungal infection in allo- 
HSCT recipients. Primary prophylaxis is highly 
recommended in children undergoing allo-
HSCT at least in the post-engraftment. 
Prophylaxis is highly effective, and in case of 
documented failure, especially in adolescents, 
compliance must be checked (Castagnola and 
Mesini 2018). Table  28.3 summarizes dosages 
of drugs for prevention or treatment of IFD in 
children.
Viral Infections No major differences 
between children and adults are expected. 
However, primary viral infections are more 
frequent in pediatrics, and in this setting, it 
must be stressed that healthy household con-
tacts and healthcare workers may represent 
important sources, with possible hospital 
spreading.
Screening and Isolation Application of bun-
dle procedures for patients as well as correct 
hand hygiene, correct vascular access manipu-
lation, correct isolation procedures according 
to the via of pathogen spreading, and the use of 
HEPA filters can be all of great utility in the 
prevention of difficult to treat infections in 
HSCT.
Vaccines represent also an important tool for 
prevention of viral and bacterial (S. pneumoniae) 
infections in the post transplant setting.
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Table 28.3 Prophylaxis and therapy of IFI in children undergoing allogeneic HSCT
Voriconazole
Spectrum of activity: molds, yeasts
Prophylaxis: No evidence to support this indication in children. Dosage in children aged 2 to <12 years or 
12–14 years with weight <50 kg: 9 mg/kg q12h; In children aged ≥15 years or 12–14 years and with weight ≥50 kg: 
4 mg/kg q12h (1st day, 6 mg/kg). Target concentration >1 and <6 mg/L at steady state
Therapy: Dosage in children aged 2 to <12 years or 12–14 years with weight <50 kg: 9 mg/kg q12h; In children 
aged ≥15 years or 12–14 years with weight ≥50 kg: 4 mg/kg q12h (1st day, 6 mg/kg). Target concentration >1 and 
<6 mg/L at steady state.
Notes: Measure serum concentrations (mandatory) before the 5th dose (2 days of treatment); before the 5th dose 
following any dose adjustment; routinely every 1–2 weeks after achievement of steady-state; when interacting drugs 
start or stop in case of potential clinical or laboratory manifestations of toxicity
Posaconazole
Spectrum of activity: molds, yeasts
Prophylaxis: Oral suspension: 120 mg/m2 q8h for children who can not swallow tablets. Tablets: loading dose of 
300 mg q12h (1st day) then maintenance 300 q24h, independently from meal. According with BW:
Body weight Load (1st day) Maintenance
15–21 kg 150 mg q12h 100 mg q24h
22–30 kg 150 mg q12h 150 mg q24h
31–35 kg 200 mg q12h 200 mg q24h
35–40 kg 250 mg q12h 250 mg q24h
>40 kg or 13 years 300 mg q12h 300 mg q24h
Target concentration for prophylaxis 0.7 mg/L at steady state. Not registered for use <18 years
Therapy: Oral suspension: 120 mg/m2 q8h for children who cannot swallow tablets. Tablets: loading dose of 300 mg 
q12h (1st day) then maintenance 300 q24h, independently from meal. According with BW:
Body weight Load (1st day) Maintenance
15–21 kg 150 mg q12h 100 mg q24h
22–30 kg 150 mg q12h 150 mg q24h
31–35 kg 200 mg q12h 200 mg q24h
35–40 kg 250 mg q12h 250 mg q24h
>40 kg or 13 years 300 mg q12h 300 mg q24h
Target concentration for therapy ≥1 mg/L at steady state. Not registered for use <18 years
Notes: When using oral suspension remove acid suppression if possible and use “posaconazole bundle”:
 –  ascorbic acid 500 mg per os with each dose of posaconazole
 –  120–180 mL of carbonated soda beverage (i.e.: cola or ginger ale) or acidic fruit juice (e.g.: cranberry or orange 
juice) with each dose of posaconazole
 –  heavy snack or food with each dose, preferably high-fat, including
–  use a more fractionated schedule (q 6-8h)
With any formulation measure serum concentrations (mandatory): 7 days after initiation of therapy or following 
dose adjustment or when interacting drugs start or stop or in case of concerns about GI absorption, especially for 
prolonged periods of time or in case of potential clinical or laboratory manifestations of toxicity
Itraconazole
Spectrum of activity: molds, yeasts
Prophylaxis: Moderate evidence to support a recommendation in children. Oral solution 2.5 mg/kg per day orally (in 
children aged ≥2 years) q12h, with empty stomach. Target concentration for prophylaxis 0.5 mg/L at steady state
Notes: Measure serum concentrations. For oral administration use oral solution. Administer with empty stomach
Fluconazole
Spectrum of activity: yeast
Prophylaxis: Not highly recommendable because of the narrow spectrum (yeasts only). 6 mg/kg/ day (maximum 
400 mg/ day) intravenously or orally q24h
Therapy: 10–20 mg/kg/day, maximum 800 mg/day) intravenously or orally q24h
Liposomal amphotericin B
Spectrum of activity: molds, yeasts
Prophylaxis: Moderate evidence to support intravenous, no evidence for nebulized administration Intravenous: 1 mg/
kg q24h every other day or 2.5 mg/kg q24h twice weekly; Nebulized: 25 mg q12h on 2 consecutive days per week 
associated with fluconazole
Therapy: Intravenous: 3–5 mg/kg according to etiology. Doses up to 10 mg/kg have been proposed for 
mucormycosis
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Spectrum of activity: yeast (not Cryptococcus) (molds?)
Prophylaxis: Not highly recommendable because of the narrow spectrum (yeasts only)
1 mg/kg (in children weighing ≥50 kg, 50 mg) q24h
Therapy: 2–4 mg/kg (max 100 mg/kg) q24h
Isavuconazole
Spectrum of action: molds, yeasts
Prophylaxis: No evidence for this indication. No data for pediatric use and dosage. Not registered <18 years
Therapy: No data for pediatric use and dosage. Not registered <18 years
Corimoxazole, dapsone, atovaquone, pentamidine
Spectrum of action: P. Jirovecii
Prophylaxis: Cotrimoxazole 1st choice: 2.5 mg/kg of trimethoprim (max 180 mg) q12h, 1–3 days/week
Therapy: Cotrimoxazole 1st choice: 5 mg/kg of trimethoprim q8h
Notes:  In case op pneumonia add prednisone at 2 mg/kg/day. Nebulized pentamidine requires special tools for 
administration
IFI invasive fungal infection
Key Points
Many of the conditions requiring allo- 
HSCT and related complications are simi-
lar in adults and children and are covered in 
other chapters of this handbook.
However, since pediatric age is a con-
tinuum between newborns and adults, there 
are at least two aspects:
• Psychological aspects. Childhood 
encompasses different ages and conse-
quently different cognitive, decisional, 
and emotional capacities that make psy-
chological intervention far more faceted 
than in adults.
• Infectious diseases. Data on epidemiol-
ogy and management of infections in 
children are far less numerous and con-
sistent than in adults. Despite that there 
are many differential aspects in its 
management.
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Vaccinations
Rafael de la Cámara
29.1  General Concepts
Vaccination should be considered a routine prac-
tice for all HSCT receptors, either autologous or 
allogeneic, adults or children. It should be imple-
mented in all HSCT programs. Adult cover is 
particularly important as they represent 90% of 
HSCTs. To obtain this objective, the following 
are necessary:
• To have in place a standardized program spe-
cific for HSCT patients.
• The collaboration of the Preventive 
Department of the hospital and primary care 
physicians.
• The program must be simple, with a clear 
chronology, and convenient for the patient and 
physician (no increase in the number of 
visits).
• FACT-JACIE Standards (version 7.0, March 
2018) require that policies/SOP are in place 
for post transplant vaccination schedules and 
indications.
The vaccination program should include not 
only the patient but also those who live with the 
patient and the healthcare workers (HCWs).
There is no a unique vaccine schedule for all 
HSCT patients. Each center should discuss and 
adapt a specific vaccine program.
• The practical application of the immunization 
programs shows important variations across 
centers (Miller et al. 2017).
• Auto-HSCT is generally vaccinated with the 
schedule used for allogeneic patients with 
small differences (see Tables 29.1 and 29.2).
Reasons for universal vaccination of HSCT 
patients:
• General interest: as a general healthcare 
principle, all the population should be cor-
rectly vaccinated, including adults and of 
course HSCT patients. If an increasing col-
lective of patients, like HSCT, is not well 
vaccinated, that can generate holes of immu-
nity that can be a risk for the health of the 
general population.
• Individual interest for each HSCT patient: 
vaccination protects the patient against infec-
tions that can cause important morbi-mortal-
ity. There are frequent infections in HSCT that 
have safe vaccines (pneumococcus, influenza, 
HBV) and other rare infections associated 
with high mortality that have an unsatisfactory 
prevention/treatment but can be prevented by 
immunization (tetanus, diphtheria, measles, 
polio).
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29.2  General Principles 
of Vaccination in HSCT 
Patients
29.2.1  The Pretransplant Vaccination
The pretransplant vaccination is not effective 
to maintain a prolonged post transplant immu-
nity. In other to protect the HSCT patient, a 
complete series of post transplant vaccinations 
is required. This is different from what is rec-
ommended for solid organ transplant (SOT) 
recipients for whom pretransplant vaccination 
is an essential part of the vaccination program. 
Post-HSCT patients should be viewed as 
“never vaccinated” regardless of the pre-HSCT 
vaccination history of the patient or the donor 
(Rubin et al. 2014).
29.2.2  The Pre-HSCT Immunity
The pre-HSCT immunity for a specific pathogen 
is not a reason to withhold vaccination after 
transplant. The majority of patients will lose their 
immunity after HSCT.
As general rule, live vaccines should be con-
sidered contraindicated (there are exceptions, see 
later). The inactivated, subunit, or  protein/poly-
saccharide vaccines can be safely administered.
There are few randomized trials in HSCT 
patients, and many of the studies have been 
done in patients transplanted with BM/PB, using 
Table 29.1 International consensus recommendations (Ljungman et al. 2009)
Vaccine No. of doses
Time post-HSCT to 
initiate vaccine Grading
Influenza (inactivated) 1
2 for children <9 years, or if 







Rubellaa (in adults for sero(-) females 
with pregnancy potential)





Hepatitis B virus (HBV) (follow country 
recommendations for general 
population)b
3 6–12 months BII
Human papillomavirus Follow recommendations for general population in each 
country
CIII
Inactivated polio 3 6–12 months BII
Pneumococcal conjugate (PCV)
  –  polysaccharide pneumococcal 
vaccine (PPS)
  –  in case of GVHD, use PCV instead 









Meningococcal conjugate (follow 
country recommend for general 
population)
1 6–12 months BII
Haemophilus influenzae conjugate 3 6–12 months BII
Diphtheria-tetanus (DT preferred over 
Td)
3 6–12 months BII
Pertussis (acellular) (DTaP preferred 
over Tdap)
3 6–12 months CIII
aMMR. These vaccines are contraindicated (EIII) before 24 months post-HSCT or in case of active GVHD or IS. These 
vaccines are usually given together as a combination vaccine
bVHB. Vaccination is recommended for HBV surface Ag-negative or HBV core Ab-positive patients, as vaccination can 
reduce the risk of reverse seroconversion (BII). For HBV surface Ag-negative or HBV core Ab-negative HSCT patients, 
recommendations for the general population in their country of residence should be followed
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Table 29.2 ECIL recommendations for allo-HSCT recipients (Cordonnier et al. 2017)
Vaccine No. of dosesa Time post-HSCT to initiate vaccine Grading




As long as patient is judged to be IS






 •  Measles
In sero(-) patients, with no GVHD, no 
IS, no REL of underlying disease, and 
no IGIV at least 8 months
 •  Rubella
In sero(-) women and of childbearing 







≥12 months in case of measles outbreak in 






 •  Sero(-) patients before HSCT and 
patients vaccinated pre-HSCT but 
lost their immunity at 6 months)
 •  Previously infected and anti-HBs 
<10 IU/L








Human papilloma virus (HPV)
 Follow recommendations for general 




Inactivated polio 3e 6–12 months BIIu
Live-attenuated varicella vaccine 1 Can be considered in sero(-) patients, with ALL 
the following: >24 m from HSCT, no GVHD, no 
IS, no REL of the underlying disease, and no IGIV 
in the last 8 months
BIIr
2 The addition of a second dose in adults may be 
considered in patients who were sero(-) before 
HSCT or had no history of VZ infect
Live-attenuated zoster vaccine Not recommended DIII
Pneumococcal conjugate (PCV)
 Polysaccharidic vaccine
 In case of GVHD, use PCV instead of 




12 months (no earlier than 8 weeks after last PCV)
AI
BI
Meningococcal conjugate (in 
accordance with country 
recommendations and local 
prevalence)
2 From 6 months
For men-C or tetravalent vaccine
  For men-B vaccine
BIIu
BIII
Haemophilus influenzae conjugate 3 3 months or 6 months BIIr
Diphtheria-tetanus (DT is preferred to 
Td)
3e From 6 months BIu
Pertussis (acellular) (DTaP is 
preferred over Tdap)
3 From 6–12 months CIII
aIf not specified otherwise, the interval between dose is 1 month
bInfluenza: A second dose of influenza vaccine, after 3–4 weeks from the first, may have a marginal benefit and should 
preferably be considered in patients with severe GVHD or low lymphocyte count (B II r) and also for the patients vac-
cinated early (from 3 months after transplant) (B II r). Children ≥6 months through 8 years, receiving influenza for the 
first time after transplant, should receive a second dose at least 4 weeks after the first dose
cHBV. After post transplant vaccination, if anti-HBs is <10 mIU/ml, an additional three doses should be considered, but the 
benefit of this second series of vaccination is uncertain. IDSA guidelines (Rubin et al. 2014) give the same recommendations 
(strong, low). For adolescents and adults, a high dose of vaccine (40 μg) is recommended for these booster doses (strong, low)
dThree doses: interval 0, 1, and 6 months
eAt 1–2 months interval




MAC. The experience with other sources (CBU), 
conditioning regimens (RIC), and donors (haplo) 
is scarce.
Many vaccines are administered by intramus-
cular route, which can be a problem for severe 
thrombocytopenic patients (less than 50  ×  109 
platelets/L). For severe thrombocytopenic patients, 
some vaccines can be safely administered SC 
(inactivated poliomyelitis, conjugate pneumococ-
cal vaccine) or even intradermic route (for influ-
enza vaccine). Clinical experience suggests that 
intramuscular injections are safe if the platelet 
count is ≥30 to 50 × 109/L, a ≤23-gauge needle is 
used, and constant pressure is maintained at the 
injection site for 2 min (Rubin et al. 2014).
29.2.3  The Dose of Vaccine
The dose of vaccine used is the same for general 
population, with some exceptions (see Table 29.2). 
A uniform specific interval between doses cannot 
be recommended, as various intervals have been 
used in studies. As a general guideline, a minimum 
of 1 month between doses may be reasonable.
29.2.4  Several Patient and Vaccine 
Characteristics Impact 
on the Vaccine Response
Time from Transplantation As a general rule, the 
later time a vaccine is administered, the better 
response is obtained (there are exceptions; see pneu-
mococcal vaccine section). Usually >12 months 
from transplant is associated with better responses.
Type of Vaccine T-cell-dependent vaccine 
obtains better response than T-cell-independent 
vaccines, because it triggers memory response 
that leads to a longer protection compared with 
T-cell-independent vaccine.
The presence of GVHD or ongoing IS treat-
ment has been associated with a decrease in 
vaccine response, particularly for polysaccha-
ride-based vaccines.
• Some vaccine responses seem to be not 
impaired by the presence of GVHD/IS treat-
ment. This is the case of conjugated 
Haemophilus vaccine, conjugated pneumo-
coccal vaccine, conjugated meningococcal 
vaccine, inactivated polio vaccine, and diph-
theria-tetanus vaccine.
• International guidelines recommend different 
attitudes in patients with GVHD for the 
moment of vaccine administration.
• The international consensus guidelines 
(Ljungman et  al. 2009) recommend to not 
postpone vaccinations with non-live vaccines 
in patients with ongoing active or resolved 
cGVHD of any severity grade.
• However, the International Consensus 
Conference on Clinical Practice in chronic 
GVHD (Hilgendorf et  al. 2011) recom-
mends postponing vaccination in patients 
with GVHD: if patients receive prednisone 
>0.5 mg/kg bodyweight as part of a combi-
nation therapy or a three-agent IS treatment 
is given, vaccination may be postponed 
until IS is reduced to a double combination 
or prednisone <0.5  mg/kg bodyweight in 
order to achieve better vaccine response. In 
any case, IS therapy should not lead to 
postponing vaccination for more than 
3 months, and this applies for patients with 
ongoing active or resolved cGVHD of any 
severity grade.
• In practices, the majority of centers seems to 
delay vaccinations if GVHD is present (Miller 
et al. 2017).
The use of rituximab decreases serological 
vaccine response at least to tetanus and 
influenza.
• ECIL 2017 guidelines (Cordonnier et  al. 
2017): patients who have received rituximab 
from transplant should have their vaccine 
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program delayed at least more than 6 months 
after the last dose.
• As the antibody response is uncertain, specific 
antibody assessment after vaccination can be 
helpful.
29.2.5  Types of Vaccines in HSCT 
Patients
Generally recommended for all HSCT (auto and 
allogeneic)
• Influenza (inactivated/subunit), poliomyelitis 
(inactivated), human papillomavirus, pneu-
mococcus, Haemophilus influenzae, hepatitis 
B, meningococcus, tetanus, diphtheria, pertus-
sis, and measles–mumps–rubella (special con-
ditions, see Sects. 29.4 and 29.5).
Optional/special situations, to cover situa-
tions such as after disease exposure or before 
travel to areas endemic for infections:
• Hepatitis A, tick-borne encephalitis, Japanese 
B encephalitis, rabies, yellow fever (live), var-
icella (Varivax®, live).
Contraindicated: As general rule, all live 
vaccines:
• Oral polio vaccine, bacillus Calmette-Guérin, 
oral typhoid, zoster vaccine (Zostavax®), 
intranasal influenza vaccine, oral rotavirus 
vaccine.
• The exceptions for this rule are live vaccines 
for measles–mumps–rubella that are recom-
mended following strict safety rules (see Sect. 
29.4), yellow fever (live) (see specific section), 
and varicella (Varivax®, live); all these vac-
cines are contraindicated (EIII) before 24  m 
post-HSCT or in case of active GVHD or IS.
Use of IVIG and Vaccines For inactivated vac-
cines, Ig do not inhibit immune responses. For 
live virus vaccines, vaccination should be delayed 
8 months after the last dose of Ig administration.




Direct Benefits The prevention of the specific 
infectious disease, as shown by influenza and 
varicella vaccination. Nonetheless, the majority 
of the efficacy studies in HSCT patients are based 
on surrogate markers (serology response) and not 
on the demonstration of a reduced risk of the 
infectious disease.
Indirect Benefits The benefits of vaccination 
can go beyond the prevention of a particular 
infection, as shown by influenza vaccine. 
Influenza immunization with inactivated vaccine 
is recommended by cardiologists as part of com-
prehensive secondary prevention with the same 
enthusiasm as the control of cholesterol, blood 
pressure, and other modifiable risk factors (Davis 
et al. 2006). It reduces cardiovascular mortality 
(risk ratio (RR) 0.45) (Clar et al. 2015), all-cause 
mortality (odds ratio (OR) 0.61), myocardial 
infarction (OR 0.73), and major adverse cardio-
vascular events (OR 0.47) (Loomba et al. 2012). 
Although all these studies were performed in 
general population, it is logical to assume a simi-
lar trend in HSCT patients.
29.3.2  Risks
Limited evidence indicates that inactivated vac-
cines have the same safety profile in immunocom-
promised patients as in immunocompetent 
individuals (Beck et  al. 2012; Rubin et  al. 2014; 
Cordonnier et  al. 2017), and there is no evidence 




Live vaccines represent a real risk for HSCT 
and should not be used except in special situations 
with strict requirements (see section of varicella 
vaccine and ECIL vaccination guidelines table). 
Fatal disseminated VZV infections due to vaccine 
strain have been reported in HSCT patients after 
varicella vaccine and zoster vaccine, even when 
vaccine was administered several years after 
transplant (Cordonnier et al. 2017).
29.4  Vaccination 
Recommendations
There are several international recommendations 
focused on HSCT patients. The best known are 
those by the Infectious Disease Working Party 
(IDWP) of the EBMT, ECIL, CDC, and Infectious 
Diseases Society of America (IDSA).
The IDWP of the EBMT was one of the first 
cooperative groups that published recommenda-
tions specific for HSCT patients. The first ones were 
published in 1995, with updates in 1999 and 2005. 
In 2017 guidelines were reviewed and updated 
under the umbrella of the ECIL group, available 
online (Cordonnier et al. 2017) (Table 29.2).
In 2009 an international consensus guideline 
was published cosponsored by the main groups 
involved in HSCT and immunocompromised 
hosts (Ljungman et al. 2009) and probably is the 
most widely used in practice (Table 29.1).
The IDSA published their last recommenda-
tions in 2014 (Rubin et al. 2014).
There are other more specific guidelines 
focused on one pathogen (Engelhard et al. 2013) 
or on patients with GVHD (Hilgendorf et  al. 
2011).
29.5  Specific Vaccines
29.5.1  Influenza
29.5.1.1  Clinical Manifestations 
(Ljungman et al. 2011; 
Engelhard et al. 2013)
Twenty percent of HSCT with confirmed influ-
enza are afebrile.
It is a serious disease in HSCT: One third 
develop pneumonia, 10% require mechanical 
ventilation, and 6% died (Ljungman et al. 2011) 
(i.e., 100–300 times higher the mortality of influ-
enza in general population). Other complications 
include encephalitis that can be lethal and 
myocarditis.
29.5.1.2  Influenza and Cardiovascular 
Disease (CVD)
The majority of influenza deaths are related to 
lung complications. Nonetheless, in general pop-
ulation up to a third of deaths related to influenza 
are CV deaths (Loomba et al. 2012).
The risk of acute myocardial infarction is sig-
nificantly increased after laboratory-confirmed 
influenza infection (Kwong et al. 2018).
HSCT patients are at high risk of developing 




• A retrospective study showed a protection rate 
of 80% in the rates of virologically confirmed 
influenza (Machado et al. 2005).
• A systematic review and meta-analysis 
showed significantly lower odds of influ-
enza-like illness after vaccination in trans-
plant recipients (HSCT and SOT) compared 
with patients receiving placebo or no vac-
cination (Beck et  al. 2012). Seroconversion 
and  seroprotection were lower in transplant 
recipients compared with immunocompetent 
controls.
• Given the suboptimal immunogenicity in 
HSCT patients, family members and health-
care professionals involved in the care of these 
populations should be vaccinated.
Vaccine Response (Engelhard et al. 2013; 
Cordonnier et al. 2017)
• Longer interval from transplant is associ-
ated with better serology response. 
Vaccination within the first 6  months after 
transplant produces poor serology responses. 
Nonetheless, seasonal vaccination against 
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influenza can boost the cellular immune 
response in HSCT patients as early as 
3  months after HSCT, but the protective 
effect is lower compared with healthy con-
trols (Engelhard et al. 2013).
• Conflicting data exist on the benefit of a sec-
ond dose of vaccine, and marginal benefit was 
seen with the use of GM-CSF.
• In HSCT the superiority of high-dose influ-
enza vaccine has not been demonstrated 
(Halasa et al. 2016).
• Rituximab administration during the year 
before vaccination was associated with a lack 
of seroprotective titer.
• Active GVHD and low lymphocyte counts at 
vaccination are associated with poor immune 
response.
Live, attenuated influenza vaccine is contrain-
dicated in HSCT patients (Rubin et al. 2014).
There is a difference in the duration of influ-
enza vaccine recommendation in the European 
(Cordonnier et  al. 2017) and US guidelines 
(Rubin et al. 2014):
• ECIL recommends vaccination as long as 
patient is judged to be immunosuppressed (A 
II r) although considered, with a lower 
strength, the use of yearly, lifelong (B II r) 
(Cordonnier et al. 2017).
• IDSA recommends lifelong immunization 
(Rubin et al. 2014).
• There are no trials to support one or other rec-
ommendations, but a lifelong immunization 
seems logical as fatal influenza illness can 
occur several years after HSCT, without clear 
risk factors in some patients, particularly in 
auto-HSCT (Ljungman et  al. 2011), and the 
proved safety of influenza vaccine in this pop-
ulation. Moreover, for general population, the 
CDC recommends routine annual influenza 
vaccination for all persons aged ≥6  months 
(Grohskopf et al. 2017).
For severe thrombocytopenic patients, the 
intradermic influenza vaccine can be safely 
administered although it has not yet been evalu-
ated in transplant recipients.
29.5.2  Measles, Mumps, and Rubella
The clinical impact and the reasons for immuni-
zation in HSCT patients differ among these 
viruses:
• Measles: Severe and also fatal measles infec-
tions (pneumonia, encephalitis) have been 
reported in SCT recipients. The aim of vacci-
nation is to protect the patient of severe conse-
quences of infection.
• Rubella: There are no reports of severe 
rubella disease occurring in HSCT recipi-
ents. The main indication for rubella vaccina-
tion is prevention of congenital rubella in 
fertile women.
• Mumps: There are no reports of severe mumps 
occurring in HSCT recipients. The indication 
for mumps vaccination is therefore weak. 
There is no indication for routine mumps vac-
cination after HSCT.  However, mumps is 
included in combination vaccines with mea-
sles and rubella.
Vaccines Only live-attenuated vaccines are 
available. Presentations: measles alone, com-
bined measles–mumps–rubella, combined mea-
sles–mumps–rubella–varicella (live).
29.5.3  Hepatitis B Virus (HBV)
Prevention of infection and reverse 
seroconversion:
• Approximately 40–70% of HSCT patients 
obtain a titer of anti-HBs of >10 mIU/mL after 
post-HSCT vaccination, a rather low response 
compared with healthy controls. Even those 
who fail to obtain a response may benefit from 
vaccination as it can prevent reverse 
seroconversion.
• Patients that have evidence of a previously 
resolved hepatitis B infection prior to the 
transplant (i.e., HBsAg negative but anti-HBs 




• Immunization for HBV can prevent HBV 
reverse seroconversion even in non-respond-
ers to hepatitis B vaccine after allo-HSCT 
(Takahata et al. 2014). Probably, antigen-spe-
cific memory T cells and cytotoxic T cells 
induced by hepatitis B vaccine are largely 
responsible for prevention of reverse serocon-
version in non-responders to the vaccine. This 
reinforces the need of HBV vaccination.
29.5.4  Human Papilloma Virus (HPV)
In HSCT women nearly 40% will have genital 
HPV infection in long-term follow-up (Shanis 
et al. 2018). HPV is associated with cervical, vul-
var, and vaginal cancer in females, penile cancer 
in males, and anal cancer and oropharyngeal can-
cer in both females and males.
In long-term survivors, second neopla-
sias are a significant complication after allo-
HSCT. Cervix cancer is one of the most frequent. 
Squamous cell cancers, the commonest post 
transplant solid tumors, are associated with HPV 
infection. Genital HPV disease is a significant 
late complication of allo-HSCT, occurring in one 
third of women. Prolonged systemic IS treatment 
for cGVHD is associated with a higher risk of 
developing HPV-related squamous intraepithelial 
lesions.
Regular gynecologic examination, cervical 
cytology, and HPV testing after HSCT is recom-
mended for all women (Majhail et  al. 2012) as 
preventing measure for HPV-related cancer and 
as a tool for early diagnose and treatment of geni-
tal GVHD.
29.5.4.1  Vaccine
• HPV vaccine is a noninfectious, virus-like 
particle (VLP) vaccine. There are three formu-
lations of HPV vaccines that differ in the num-
ber of HPV covered: a 9-valent HPV vaccine 
(6, 11, 16, 18, 31, 33, 45, 52, and 58 VLPs) 
(Gardasil 9®), quadrivalent HPV vaccine (6, 
11, 16, and 18 VLPs) (Gardasil®), and bivalent 
vaccine (16, 18 VLPs) (Cervarix®).
• The experience with HPV vaccine in HSCT is 
limited, 20 children (MacIntyre et  al. 2016) 
and 64 adults (Stratton et al. 2018), but shows 
a good immune response, similar to health 
women, with no specific safety issue.
• HPV vaccine is recommended in all guide-
lines (Ljungman et al. 2009; Hilgendorf et al. 
2011; Rubin et  al. 2014; Cordonnier et  al. 
2017) but with a low grade of recommenda-
tion (B II u to C III) due to the limited experi-
ence in HSCT patients. The recommended 
number of doses is three (Hilgendorf et  al. 
2011; Rubin et al. 2014).
29.5.5  Poliovirus
The WHO European Region was declared polio-
free in 2002. Imported wild-type and vaccine-
type polioviruses still remain a threat to 
unvaccinated people in the EU/EEA. Maintaining 
high vaccination coverage in all population 
groups remain an essential tool for keeping 
Europe polio-free.
Only inactivated poliovirus vaccines are used 
in all EU/EEA countries.
Oral polio vaccine (OPV) is contraindicated 
for HSCT patients due to the risk of paralytic 
poliomyelitis. This complication has occurred 
after vaccination of patients with severe com-
bined immune deficiency but has not been 
described in HSCT patients.
29.5.6  Varicella Zoster Virus (VZV)
Prevention of VZV After HSCT Antiviral pro-
phylaxis (acyclovir/valacyclovir) is the primary 
mode of prevention. It should be given for at least 
1 year after allo-HSCT and for 3–6 months after 
auto-HSCT (Cordonnier et al. 2017).
Types of Vaccines There are three types of 
available vaccines and one not commercially 
available. None is licensed for use in IS patients.
• Live-attenuated varicella vaccine, a low-titer 
VZV vaccine (Varivax®, Varilix®). It is also 
available in combination in the same vaccine 
with measles, mumps, and rubella.
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 – Varicella vaccine can be used in HSCT 
following strict requirements (see ECIL 
and IDSA vaccination guidelines) 
(Cordonnier et  al. 2017; Rubin et  al. 
2014). Although vaccination with vari-
cella-attenuated vaccine is indicated/con-
sidered in guidelines, in practice it is 
rarely used due to concerns of safety, par-
ticularly in adults (Miller et  al. 2017). 
The commercial availability of the VZ 
subunit vaccine and maybe in the future 
the inactivated vaccine will make the use 
of the attenuated vaccines even lower.
• Live-attenuated zoster vaccine, a high-titer 
vaccine (Zostavax®). It contains more than 14 
times more virus than varicella vaccine. In all 
guidelines, this vaccine is contraindicated in 
HSCT patients.
• New phase III studies with new VZL vaccines 
in auto-HSCT.
 – Adjuvanted VZV subunit vaccine 
(Shingrix®) (de la Serna et  al. 2018; 
Sullivan et al. 2018) consists of recombi-
nant VZV gE antigen mixed with AS01B 
adjuvant. It was recently approved by the 
FDA (October 2017) and EMA (March 
2018) for prevention of herpes zoster 
(HZ) and post-herpetic neuralgia, in 
adults 50  years of age or older. It is 
administered IM in two doses separated 
by 60 days.
 – Inactivated VZV-vaccine (V212), in auto-
HSCT (Winston et  al. 2018), is not yet 
commercially available. It is administered 
in four doses by SC injection, beginning 
~5 days prior to chemotherapy or ~30 days 
prior to auto-HSCT and the remaining 
doses being administered at 30, 60, and 
90 days later.
 – Both vaccines showed a high vaccine 
efficacy for preventing zoster which 
was 68–64%, post-herpetic neuralgia 
89–84%, VZV-related hospitalizations 
85%, and for other VZV complications 
78–75%. The positive results of these 
studies probably are going to change the 
prevention of VZV complications after 
auto-HSCT.
29.5.7  Pneumococcus
Pneumococcus is a frequent and serious compli-
cation in HSCT. The incidence of invasive pneu-
mococcal disease (IPD) in HSCT is 50 times 
higher compared to the general population 
(Shigayeva et al. 2016). In spite of this high inci-
dence of IPD, less than one in five HSCT patients 
with IPD had received pneumococcal vaccine.
29.5.7.1  Types of Vaccine
• Polysaccharidic (PS) vaccine
 – 23-valent polysaccharidic (PS) vac-
cine (Pneumo 23®, Pneumovax23®): 
poor immunogenic, T-cell-independent 
response, no boost benefit
 – Poor responses, particularly in patients 
with GVHD
 – PS after PCV vaccine increases and 
expands the response obtained with 
PCV.  Some non-responders to PCV will 
achieve a response with PS vaccine.
• Conjugate vaccine (PCV): highly immuno-
genic, T-cell-dependent response, with boost 
benefit
 – 13-valent in the majority of countries 
(Prevenar 13r®) (that replace the previous 
7-valent vaccine) or 10-valent available in 
some countries (Synflorix®).
 – Five trials have shown a good response to 
PCV after three doses (range 54–98%). 
Four trials used 7-valent conjugated vac-
cine and one the 13-valent vaccine 
(Cordonnier et al. 2017). These responses 
are much better compared with what is 
obtained with PS vaccine.
 – Early vaccination at 3 months is not infe-
rior to late vaccination (9  months) after 
allo-HSCT.
 – PCV should always be administered before 
PS vaccine.
29.5.8  Diphtheria-Tetanus-Pertussis
The exposure to tetanus in the environment is a 
real risk for HSCT patients, so the aim of vacci-
nation after transplant is to protect the patient.
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Diphtheria has essentially been eradicated 
but ongoing vaccination is critical for immu-
nity. Diphtheria cases are still happening in 
Europe with an increase of 280% from 2009 to 
2014. The reappearance of diphtheria cases in 
countries like Spain diphtheria-free for more 
than 30 years (Jane et  al. 2018) is alarming 
and another reason to vaccine all our HSCT 
patients.
There are very limited published data of per-
tussis in HSCT and no reported case of severe or 
fatal pertussis infection after SCT in adults. 
Therefore, the objective of vaccination in these 
patients is avoiding pertussis transmission by 
HSCT patients.
29.6  Vaccinations Before Travel 
to Areas Endemic 
for Infections  
(See Table 29.3)  
(Ljungman et al. 2009)
29.7  Serological Testing
For the majority of vaccines, no pre- or postvaccina-
tion serology is recommended. Nonetheless, there 
are exceptions for this rule (Ljungman et al. 2009).
29.7.1  Pre-Vaccination
Testing for Abs to measles is recommended in 
adults, with vaccination performed only if the 
patient is seronegative (CIII).
If vaccination against varicella is contem-
plated, testing of immunity should be carried out 
and vaccination should be administered to sero-
negative patients only (CIII).
29.7.2  Postvaccination
Pneumococcal vaccine: Testing to assess the 
response to vaccination is recommended at 
Table 29.3 Vaccinations before travel to areas endemic for infections (Ljungman et al. 2009)
If contraindications for the vaccine exist, the patient should be advised not to travel to endemic areas (CIII)
Vaccination is one of the precautions that the HSCT patients should observe. There are other equal important 
measures that should be followed: chemoprophylaxis against malaria; mosquito-oriented precautions; food safety to 





•  According to local policy in endemic areas (CIII)No data exist regarding the time after HCT when 
vaccination can be expected to induce an immune response
Rabies •  Rabies vaccine is made from killed virus and cannot cause rabies. Nonetheless, there are no data 
regarding safety, immunogenicity, or efficacy among HCT recipients
•  Preexposure rabies vaccination should probably be delayed until 12–24 months after HCT
•  Postexposure administration of rabies vaccine with human rabies Ig can be administered any time 
after HCT, as indicated
Yellow fever 
(live)
•  Limited data regarding safety and efficacy (C III). Yellow fever vaccine has been safely 
administered to a limited number of post-HSCT patients (Rubin et al. 2014)
•  The risk–benefit balance may favor the use of the vaccine in patients residing in or traveling to 
endemic areas
Hepatitis A •  Follow recommendations for general population in each country (CIII)
•  Ig should be administered to hepatitis A-susceptible HCT recipients who anticipate hepatitis A 




•  No data were found regarding safety, immunogenicity, or efficacy among HCT recipients. 
DIII. Remember that typhoid oral vaccine is live attenuated and is contraindicated in HSCT 
patients (EIII)
Cholera •  No data were found regarding safety and immunogenicity among HCT recipients. Vaccine is not 
recommended (DIII)
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1 month or later after the third or fourth dose of 
pneumococcal vaccine (BIII). As a widely 
accepted definition of adequate response to 
pneumococcal vaccine is lacking, guidelines 
for revaccination of non-responders are not 
given. Testing for immunity to pneumococcus 
might reasonably be repeated every 2 years for 
the first 4 years (BIII).
Hepatitis B: Testing should be carried out 
1  month or later after the third vaccine dose 
(BIII). A second three-dose vaccination sched-
ule is recommended in non-responders 
(CIII)
Testing should be conducted approximately 
every 4–5  years to assess for immunity to 
HBV, measles, tetanus, diphtheria, and polio 
(BIII).
29.8  Vaccinations for Donors, 
Close Contacts/Family, 
and HCWs of HSCT 
Recipients (See Table 29.4) 
(Ljungman et al. 2009; 
Cordonnier et al. 2017;  
Rubin et al. 2014)
Table 29.4 Vaccinations for donors, close contacts/family, and HCWs of HCT recipients
General comments
Inactivated vaccines can be safely given for donors, close contacts, and HCWs of HSCT patients
For live vaccines a careful evaluation should be done (see below). Some have no safety issues for HSCT recipients 
but other can cause severe damage
Donors
Guidelines do not recommend donor vaccination for the benefit of the recipienta,b
 •  Only vaccines that are indicated and recommended based on the donor’s age, vaccination history, and exposure 
history should be administered
 •  Nonetheless, vaccination of the donor has been shown to improve the post transplant immunity of the patient in 
the case of tetanus, diphtheria, 7-valent pneumococcal conjugate vaccine (PCV), and Haemophilus influenzae type 
b-conjugate vaccines. Donation is an opportunity to update the donor vaccination calendar. If the donor has to 
receive any of these vaccines in his/her own interest, the administration of at least one dose pre-collection of stem 
cells could benefit also the receptor
Administration of MMR, MMRV, varicella, and zoster vaccines should be avoided within 4 weeks of stem cell 
harvestb. By extension, all live vaccines should be avoided before stem cell collection due to the risk of transmission 
of the pathogen with the graftc




•Annually, as long as there is contact with an IS recipienta: Close contacts: AIIa-AIIIc; 
HCWs: AIa-AIItc
All sero(-) VZ Varicella: 
AIIIa
•  2 doses, separated by at least 28 days
HCWs 
Sero(-)
Measles •  AIIIa; recommended, not gradedb,c
Live vaccines given for close contacts or HCWs of HCST patients: precautions
Intranasal influenza 
vaccine
•  If live influenza vaccine is administered to a close contact/HCWs, contact between 
the IS patient and household member should be avoided for 7 days (weak, very low)b
Measles-mumps-rubella •  No risk for the HSCT patient
Varicella •  The vaccination dose or doses should be completed >4 weeks before the conditioning 
regimen begins or >6 weeks (42 days) before contact with the HCT recipient is 
planned (BIII)a
•  If a varicella vaccinee develops a postvaccination rash within 42 days of vaccination, 
the vaccinee should avoid contact with HCT recipients until all rash lesions are 
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• Vaccination should be considered a rou-
tine practice for all HSCT receptors, 
either autologous or allogeneic, adults 
or children. It should be implemented in 
all HSCT programs.
• There is no a unique vaccine schedule for 
all HSCT patients. Each center should dis-
cuss and adapt a specific vaccine program.
• To obtain this objective, it is necessary 
to have in place a standardized program 
specific for HSCT patients with a simple 
and clear chronology and the collabora-
tion of the Preventive Department of the 
hospital and primary care physicians.
• The vaccination program should include 
not only the patient but also those who 
live with the patient and the healthcare 
workers (HCWs).
• There are two main reasons for universal 
vaccination of HSCT patients: (a) the gen-
eral interest as all the population should be 
correctly vaccinated to avoid holes of 
immunity that can be a risk for the health 
of the general population and (b) individ-
ual interest for each HSCT patient.
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Allo-HSCT is associated with significant physical 
and psychological morbidity that may have a neg-
ative impact on patients’ and on their relatives’ 
health-related quality of life (HRQoL) (Majhail 
and Rizzo 2013). Patients suffer a broad range of 
acute and chronic impairments of health- related 
quality of life (HRQoL), concerning physical, 
emotional, cognitive and social constraints. 
Psychosocial difficulties have been identified 
throughout the HSCT process, from pre-trans-
plant to recovery phase and even for long-term 
survivors. Insofar, psychological support of 
HSCT recipients and caregivers is based on a—
where ever possible—preventive, concrete and 
sustainable approach, comprising a broad range 
of aspects of HRQoL.  Psychooncological inter-
ventions are planned and conducted regularly in 
an interdisciplinary approach, taking into consid-
eration medical, social and nursing issues.
30.2  The Period Preceding HSCT
Since HSCT often appears to be the only therapeu-
tic cure, this can cause high expectations in patients 
and their families, who may overestimate HSCT’s 
benefits and underestimate the procedure’s mor-
bidity and mortality risks. Several authors are ada-
mant about the importance of pragmatic 
information, specifically regarding prognosis, post 
transplant effects and the impact of HSCT on 
QOL.  This information not only could guide 
patients in their decision to undergo the treatment 
(or not) but could also help them and their close 
relatives to face the persistent side effects post-
HSCT (Jim et al. 2014). Studies show that specific 
pre-transplant distress predicts psychosocial prob-
lems during and after HSCT (Schulz-Kindermann 
et al. 2002). This suggests a thorough medical as 
well as psychosocial preparation about risks and 
challenges with concomitant illustration of possi-
ble coping resources. Understanding of the infor-
mation about the prognosis can be associated with 
depression and a worsening QOL over time 
(Applebaum et al. 2016).
Frequently described are anxious-depressive 
symptoms and sleep disruption pre-HSCT, linked 
to the burden of uncertainty about treatment out-
comes. Baseline anxiety and depression predict 
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worsening HRQoL during hospitalisation and 
post-treatment adjustment, even identifying these 
symptoms as risk factors for survival (Artherholt 
et al. 2014). This suggests a thorough survey of 
the psychosocial anamnesis and a brief screening 
in the course of treatment and survivorship. To 
avoid evitable strain, short instruments to mea-
sure distress, anxiety, depression and HRQoL—
like the Distress Thermometer, Patient Health 
Questionnaire, Cancer Treatment-Related 
Distress Scale and EORTC QLQ-C30—should 
be implemented. Attention should always involve 
caregivers as well as minor children of patients. 
Finally, HSCT teams should screen patients’ and 
families’ met and unmet needs, including psy-
chosocial support. Regarding preparation for 
HSCT, patients who are in a fairly stable physical 
state should take advantage of psychological sup-
port before admission to inpatient treatment. 
Psychological interventions cover different 
approaches like psychodynamic interviews, 
introduction in relaxation techniques, communi-
cation skills (regarding problem- focused com-
munication with staff and with caregivers) and 
coping with side effects (pain, nausea, fatigue, 
restlessness, sleep disorder; see Syrjala et  al. 
2012).
30.3  Hospitalisation for HSCT
During hospitalisation, patients grapple with 
considerable changes, including a loss of physi-
cal abilities and autonomy. HSCT hospitalisation 
constraints, combined with poor physical condi-
tion, may increase patients’ feelings of isolation 
and dependence, negatively affecting psycholog-
ical well-being (Tecchio et al. 2013). Symptoms 
of depression, anxiety, sleep disruption and 
adjustment disorders are frequently reported (El 
Jawahri 2015). Unlike anxiety, which does not 
change over time, depression levels increase 
more than twofold after 2  weeks of isolation 
(Tecchio et al. 2013).
These symptoms can go unrecognised and 
have been known to interfere with HSCT medical 
treatment. Depression during hospitalisation is 
associated with longer hospital stay, increased 
risk of mortality (Prieto et  al. 2005), post 
 transplant anxio-depressive symptoms and post 
traumatic stress syndrome (PTSS) (El-Jawahri 
et al. 2016).
Depressive symptoms are risk factors for a 
poorer outcome after HSCT. It is noteworthy to 
follow a precise diagnostic process, differentiat-
ing depression and demoralisation. The latter 
focuses on an attitude of senselessness and hope-
lessness, while depression has a pronounced 
somatic level, overlapping with fatigue. Recent 
research has explored psychoneuroendocrinol-
ogy and psychoneuroimmunology to identify 
pathways that may mediate between psychoso-
cial factors and disease outcomes (Costanzo et al. 
2013). These authors have recommended the 
treatment of sleep and circadian disturbances, as 
well as the option of psychotropic medications 
and cognitive-behavioural interventions in the 
HSCT setting.
A significantly positive correlation between 
the presence of a family caregiver (FC) during 
hospitalisation and HSCT survival has been 
established (Foster et al. 2013). The support pro-
vided by the HSCT team can also help patients to 
better cope with hospitalisation and facilitate 
psychological adjustment after discharge, reduc-
ing difficulties in the transition towards outpa-
tient care.
Psychooncological interventions concerning 
depressive and anxious symptomatology rely on 
psychoeducational, psychodynamic and biobe-
havioural approaches, incorporating adequate 
coping potential. Specific techniques to amelio-
rate anxiety but also side effects like pain, sleep-
lessness, nausea or restlessness comprise 
relaxation, imagery and hypnotherapeutic 
approaches. Particularly in cases of fear and 
panic, pharmacological approaches with benzo-
diazepines and certain antidepressants should be 
taken into account.
Precise and repeated pain diagnostics are par-
amount, deriving multidisciplinary pain manage-
ment, including medication, ongoing information 
about pain management and psychological inter-
ventions. There is some evidence for effective-
ness of relaxation, imagery, hypnosis and 
cognitive-behavioral therapy (Syrjala 2014).
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30.4  Post-HSCT
Data show that patients in remission for 2–5 years 
post-HSCT have a high probability of long-term 
survival. Nevertheless, HSCT-related morbidity is 
substantial, negatively affecting psychological 
functioning and social integration. HSCT’s late 
effects on physical and psychic well-being have 
been well described, notably for chronic graft ver-
sus host disease, the severity of which is signifi-
cantly related to impaired psychosocial functioning 
and diminished QOL (Majhail and Rizzo 2013).
Regarding psychopathology post-HSCT, sev-
eral studies reported high rates of anxiety and 
depression, even several years after transplanta-
tion. Notwithstanding, research on psychological 
issues after HSCT has shown inconsistent results 
due to varying outcome measures, participation 
biases and cohort size and composition (Sun 
et al. 2011).
Although some studies have shown that 
depression and anxiety rates do not differ signifi-
cantly from those of siblings or population 
norms, others reveal rates of psychological dis-
tress of 14% to 90% in survivors of HSCT (Sun 
et  al. 2011). Even though some results demon-
strate that physical morbidity tends to decrease 
by 1-year post-HSCT and psychosocial condition 
improves gradually over 1–5  years (Sun et  al. 
2013), other research reports depressive symp-
toms as long as 5 or even 10 years after HSCT 
(Jim et al. 2016). An unsettling fact is that depres-
sion post-HSCT has been associated with higher 
mortality and increased risk of suicide (Tichelli 
et al. 2013).
Depressive symptoms and sleep disorders are 
related to cognitive dysfunctions. Sleep disrup-
tion remains an issue for 43% of HSCT patients 
after transplant (Jim et al. 2016). These rates of 
disruption are substantially higher than those of 
the general population. Incidence of cognitive 
dysfunction in the first 5 years after HSCT is up 
to 60% (Scherwath et al. 2013). Poor neurocogni-
tive functioning and psychosocial outcomes lead 
to lax medication management and adherence to 
recommended monitoring guidelines, which in 
turn may increase post-treatment morbi- mortality 
risks (Mayo et al. 2016).
Psychological interventions for depressive 
symptoms focus on dysfunctional, exagger-
ated cognitions and on an increase of activities. 
Psychopharmacological treatment is often rec-
ommended additionally, offering a broad range 
of substances, which can and should be adapted 
to respective indications and to the broad range 
of further medication. In the case of severe 
demoralisation, existential and meaning-cen-
tred approaches are advisable and show some 
evidence.
Concerning lasting traumatic experiences, in 
cross-sectional studies between 5 and 19% ful-
filled a diagnosis of post-traumatic stress disor-
der (PTSD). In one of the rare prospective studies, 
PTSD symptomatology was observable at all 
time points (Esser et al. 2017a). Therefore, psy-
chological support should not only be offered in 
the acute phase but already before HSCT and in 
the long term. Impairment by pain and pain inten-
sity were risk factors for elevated levels of PTSD 
symptomatology. This highlights the importance 
of informing patients early enough that pain 
might occur and to introduce techniques for deal-
ing with it. Since medical complications pre-
dicted severity of PTSD symptomatology 1 year 
after HSCT, medical professionals should be 
aware of psychological strain among patients suf-
fering from long-term medical complications.
Psychosocial issues have also been explored 
in QOL research. Some studies in this domain 
stated that even if medical problems remain, the 
patients’ emotional well-being seems to improve 
throughout the rehabilitation period. Nonetheless, 
fatigue, sleep disorders, neurocognitive impair-
ment, neurobehavioural problems and sexual 
dysfunction persist. Esser et  al. (2017b) identi-
fied in a prospective study three stable symptom 
complexes: exhausted (incl. fatigue), affective 
(incl. irritability and depressive symptoms) and 
gastrointestinal (incl. nausea). Fatigue was most 
persistent and also most severe and predictive for 
HRQoL.  Fear of relapse, feelings of disability 
and barriers to social rehabilitation are frequent 
concerns, even several years after the procedure, 
with only a minority of disease-free transplant 
survivors consider themselves having ‘returned 
to normal’ (Syrjala et al. 2012).
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These psychosocial difficulties are not sys-
tematically approached in current HSCT follow-
up: despite their incidence, anxious-depressive 
symptoms are not often reported which should 
be treated by HSCT physicians. Barriers to 
approaching psychosocial issues are, on one 
hand, patients’ fear of being stigmatised and, on 
the other hand, doctors who tend to prioritise 
strictly medical aspects. Health professionals 
often poorly evaluate psychological symptoms: 
anxiety is overrated, depression is underesti-
mated, and consistency between the patients and 
the medical team’s evaluations seems insuffi-
cient. Most patients receive prescriptions for 
these lingering symptoms, even over long peri-
ods, yet half of them benefit of follow-up by spe-
cialised professionals due to organisational and 
emotional obstacles (Mosher et al. 2010).
Anxieties after HSCT may be treated in a 
cognitive- behavioural approach, relying on work-
ing directly with fear-related contents and applying 
this to the broad range of oversimplified anxieties. 
For progression anxiety, manualised psychoonco-
logical therapies are well-tried, combining psy-
choeducational elements with group- format 
psychological therapy. Cognitive-behavioural 
therapy has demonstrated effectiveness in the 
treatment of PTSD with cancer patients in a sig-
nificant number of studies, including patients with 
HSCT (DuHamel et al. 2010). Concerning fatigue, 
there are several promising approaches combining 
psychosocial counselling with physical training.
30.5  Close Relatives
Family caregivers (FC) can contribute to patients’ 
recovery and to better survival following HSCT 
(Ehrlich et al. 2016). That said, the HSCT impact 
on FC has not been sufficiently explored, with 
most studies suffering from limitations due to 
small and heterogeneous samples.
Current research shows that FC experience a 
significant burden across the treatment trajectory. 
At the time of transplant, FC report high levels of 
fatigue, sleep disorders, depression and anxiety 
(El Jawahri 2015). FC may have more emotional 
difficulties than patients, and their well-being can 
be impaired well past post transplant. FC face 
negative effects in their own family and profes-
sional and social lives and express marital dis-
satisfaction after HSCT (Langer et al. 2017).
Qualitative data indicate that the main FC dif-
ficulties are related to long-term HSCT conse-
quences and the unpredictable, uncertain 
character of their evolution. Assuming not only 
daily tasks but also the patients’ psychological 
support, FC may feel overwhelmed by the com-
plex demands of the caregiving role and the 
social impact of a lengthy rehabilitation 
(Applebaum et al. 2016).
In spite of the obstacles met during this 
post  transplant period, FC rarely benefit from 
regular psychosocial support. Attention 
should also involve patients’ minor children. 
The current trend has been to outsource part 
of the patient care. Research should better 
explore FC’s real- life experience in order to 
propose targeted interventions during HSCT’s 
various stages.
30.6  Related Donors
Related donors (RDs) deserve particular atten-
tion. Although positive effects of related dona-
tion have been demonstrated—such as deep 
personal satisfaction and a higher degree of self- 
esteem—there is also a negative impact. The 
incidence of pain and depressive symptoms is 
higher in RDs than in unrelated donors. 
Unexplained chronic pain could be associated 
with psychological distress related to the recipi-
ent’s medical condition and HSCT outcomes. 
Data suggest that psychological support and fol-
low- up should also be offered to RD (Garcia 
et al. 2013).
Like for patients, sufficient information, prep-
aration and guidance should be available for FC 
and RD.  That is, not only the tremendous task 
should be emphasised but also probable prob-
lems and risks, as well as available resources of 
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care. Several interventions were developed to 
support FC, like problem-solving skills, 
cognitive- behavioural interventions and expres-
sive talking (Applebaum et al. 2016).
30.7  Adolescents and Young 
Adults (AYA)
The adolescent and young adult group (AYA) 
represents a particular group that significantly 
varies from non-AYA patients, especially in psy-
chosocial aspects (Pulewka et al. 2017). Research 
reveals that a quarter of AYA patients who expe-
rienced HSCT reported depression and anxiety 
symptoms, with nearly half meeting the criteria 
for post-traumatic stress (Syrjala et al. 2012).
HSCT appears to be a risk factor for poor 
health-related quality of life (HRQoL) and social 
functioning in AYA cancer survivors (Tremolada 
et al. 2016). Qualitative studies show that this pop-
ulation encounters difficulties in physical (sexual-
ity and fatigue), psychological (depression, 
adherence and dependency issues, fear of the 
future, uncertainty) and social domains (changes 
in roles and relationships, educations and financial 
issues, family problems). Evidence- based psycho-
social interventions in this population are sparse 
and should include specific problems, such as fam-
ily relationships and social integration (school and 
work). Recent approaches use group formats 
enhancing self-help resources of peers, activity 
coaching and motivational interviewing.
30.8  Paediatric Patients
In their review of the literature, Packman et  al. 
(2010) shows that HSCT paediatric patients 
experience acute psychological symptoms such 
as anxiety and depression before and during hos-
pitalisation, as well as significant peer isolation, 
behavioural problems and post-traumatic stress 
symptoms after HSCT.  Declines in cognitive 
abilities, social functioning and self-esteem have 
also been observed.
It is noteworthy that the accord between par-
ent and child is better regarding physical condi-
tions than it is with psychological issues. This 
discrepancy between the child’s and the parents’ 
evaluations also holds true regarding HRQoL 
post-HSCT (Chang et al. 2012).
HSCT may lead to disruptions in family 
life: parents and siblings (notably, donors) also 
report high levels of anxiety, depression and 
post- traumatic stress symptoms (Packman 
et al. 2010).
Paediatric HSCT survivors report psychoso-
cial difficulties and decreased QOL with a high 
risk for anxiety, depression and behavioural 
problems. Childhood survivors’ specific issues 
are related to sexual dysfunction, impoverished 
self-image and social adjustment. As follow-up 
of childhood HSCT patients is fundamental, spe-
cial attention should be paid to the risk of with-
drawal as they journey towards adulthood (Cupit 
et al. 2016).
Key Points
• The previously discussed rates of psy-
chological morbidity in HSCT patients 
emphasise the need for clinical assess-
ment throughout the procedure and at 
regular intervals.
• Given their vital role in the patients’ 
recovery process, HSCT teams should 
also assess FC for psychological adjust-
ment and family functioning.
• Particular attention should be given to 
RDs, who do not benefit systematically 
from a medical and psychological 
follow-up.
• Regardless of the overwhelming evi-
dence of psychological morbidity in 
HSCT patients and in FC, barriers still 
exist in discussing psychosocial issues 
in routine care.
• Systematic screening may contribute to 
stimulate discussion of psychological 
symptoms, but quality psychosocial 
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Patients undergoing HSCT often receive poly-
medication which carries the potential to result in 
drug interactions. To avoid unexpected outcomes, 
attention to drug interactions is crucial especially 
when drugs with a narrow therapeutic index or 
inherent toxicity profile are involved (Leather 
2004; Glotzbecker et  al. 2012; Gholaminezhad 
et al. 2014).
Drug interactions can be defined as changes in 
a drug’s effect due to recent or concurrent use of 
another drug, food, or environmental agent. The 
net effect of the combination can result in 
enhanced activity of the affected drug, possibly 
leading to toxicity, or reduced activity leading to 
therapeutic failure (Thanacoody 2012).
In general, drug interactions can be catego-
rized as being pharmacodynamic, pharmacoki-
netic, or pharmaceutical in nature.
31.1.1  Pharmacodynamic 
Interactions
Pharmacodynamic interactions occur when the 
effect of one drug is changed by the presence of 
another drug at its site of action. They compete 
for specific receptor sites or interfere indirectly 
with physiological systems.
The effect can be additive/synergistic or 
antagonistic. An example of an additive interac-
tion is the concurrent use of QT-prolongating 
drugs (e.g., ciprofloxacin and fluconazole) which 
substantially increases the risk of torsades de 
pointes or other ventricular tachyarrhythmias.
Specific antagonists can be used to reverse the 
effect of another drug at the receptor site (e.g., 
naloxone, an opioid receptor antagonist which 
reverses signs of opioid intoxication) (Lexicomp 
Drug® Interactions 2018).
31.1.2  Pharmacokinetic Interactions
Pharmacokinetic interactions (PK) occur when 
one drug alters the rate or extent of absorption, 
distribution, metabolism, or elimination of 
another drug resulting in diminished effects or 
drug potentiation (Palleria et al. 2013). The most 
frequent and significant drug interactions relate 
to drug metabolism. These will be further dis-
cussed here.
31.1.2.1  Cytochrome P450 Enzyme 
System
Several enzyme families are involved in drug 
metabolism, cytochrome P450 (CYP450) being 
the most important one. CYP450 consists of a 
unique group of isoenzymes grouped into fami-
lies (1–3) and divided into subfamilies (A–E). 
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They are primarily found in the liver and are 
genetically encoded (Ingelman-Sundberg and 
Rodriguez-Antona 2005; Lynch and Price 2007).
The effect of a CYP450 isoenzyme on a par-
ticular substrate can be altered by interaction 
with other drugs. Drugs can be substrates for a 
CYP450 isoenzyme and/or may inhibit or induce 
the isoenzyme (Larson 2018; Glotzbecker et al. 
2012; Leather 2004):
 Inhibition: Leads to reduced metabolism of 
the substrate with an increase in the steady-state 
concentration. It potentiates the effect and might 
lead to enhanced or toxic effects, especially in 
drugs with a narrow therapeutic index like cyclo-
sporine and tacrolimus. Its onset occurs within 
1–3 days for drugs with a short half-life, while 
the maximal effect may be delayed for drugs with 
a long half-life.
 Induction: Increases the activity of CYP450 
enzymes and usually results in decreased concen-
tration/effect of the affected drug with the risk of 
therapeutic failure. Since the process of enzyme 
induction requires new protein synthesis, the 
effect usually occurs over days to weeks after 
starting an inducer.
Prodrugs rely on CYP450 enzymes for con-
version to their active form(s). The combination 
of a prodrug (e.g., CFM) with a CYP450 inhibi-
tor may result in therapeutic failure because of 
little or no production of the active drug. 
Conversely, an exaggerated therapeutic effect or 
adverse effect can be expected when a CYP450 
inducer is added (Lynch and Price 2007).
In general, any drug metabolized by one of the 
CYP450 enzymes has the potential for PK- inter-
action, and concurrent use should be done with 
caution. As CYP3A4 is responsible for the 
metabolism of more than 50% of clinically 
administered drugs (Ingelman-Sundberg and 
Rodriguez-Antona 2005; Larson 2018), exam-
ples of CYP3A4 substrates, inhibitors, and induc-
ers used in HSCT are presented in Table 31.1.
Mutations in CYP genes give rise to four 
major phenotypes: poor metabolizers, intermedi-
ate metabolizers, extensive metabolizers, and 
ultrarapid metabolizers (Ingelman-Sundberg and 
Rodriguez-Antona 2005; Ahmed et  al. 2016). 
Polymorphisms in CYP450 are of concern in the 
study of interindividual altered drug metabolisms 
and/or adverse drug reactions.
31.1.2.2  Drug Transportation
P-glycoprotein (PgP) is a plasma membrane 
transporter involved in the excretion of drugs. 
Table 31.1 CYP3A4 substrates, inhibitors and inducers commonly used in HSCT (non-limitative list) (Flockhart 





































dClarithromycin, erythromycin, NOT azithromycin
eAtorvastatin, NOT pravastatin, simvastatin
fEstradiol, progesterone, testosterone
gAprepitant, fentanyl, ondansetron, thiotepa, zolpidem
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Its activity can be inhibited or induced by 
other drugs, resulting in increased or decreased 
bioavailability/clearance of PgP substrates 
(Ingelman-Sundberg and Rodriguez-Antona 
2005; Thanacoody 2012).
 Monoclonal Antibodies
Metabolism of monoclonal antibodies (MABs) 
does not involve CYP450 enzymes or drug trans-
porters; therefore, PK interactions between MABs 
and conventional drugs are very limited. However, 
current information in this area is not abundant 
and more research is needed (Ferri et al. 2016).
31.1.3  Pharmaceutical Interactions
Pharmaceutical interactions manifest when two 
or more drugs and their diluents are mixed in the 
same infusion bag/syringe or when infusion lines 
meet at a Y-site junction. They are the result of 
incompatibilities as physicochemical reactions 
(changes in color, turbidimetry, and precipita-
tion). Amphotericin B, for example, should not 
be diluted or mixed with physiological saline as 
microprecipitation will occur immediately.
31.2  Drug Interactions in HSCT 
Practice
Drug interactions can occur as early as during the 
conditioning regimen. Drugs as etoposide and 
thiotepa rely on CYP450 enzymes for metabo-
lism, while cyclophosphamide needs to be con-
verted to become functional. A non-limitative list 
of PK interactions with busulfan and recommen-
dations for management are summarized in 
Table 31.2.
Many clinically relevant interactions have 
been reported with calcineurin inhibitors 
 (cyclosporine and tacrolimus) and sirolimus. A 
non-limitative overview of PK interactions with 
these drugs is presented in Table 31.3.
31.3  Interactions with Herbal 
Drugs and Food
31.3.1  Herbal Drugs
The use of herbal drugs is growing worldwide, 
and a number of serious interactions with con-
ventional drugs have been reported (Enioutina 
et  al. 2017). Patients often do not perceive 
herbal supplements as drugs and prescribers 
are not always aware that patients are taking 
these products. A thorough drug history anam-
nesis is important and should be performed by 
asking very specific questions about herbal 
drug use.
An example of an herbal drug frequently 
involved in major drug interactions is St John’s 
wort (SJW) (Hypericum perforatum). SJW is an 
over-the-counter product commonly used in 
HSCT patients for the treatment of mild depres-
sion. SJW can reduce the serum concentration of 
CYP3A4 substrates as cyclosporine and tacroli-
mus by induction of CYP3A4 or by increasing 
PgP expression, resulting in lack of response. 
Concomitant use of SJW with drugs metabolized 
by CYP3A4 should be avoided or monitored if no 
Table 31.2 Drug interactions with busulfan (BU) (non-limitative list)a
Interacting drug Proposed mechanism Effect Recommended action
Paracetamol Competition for glutathione Increased BU 
levels
–  Avoid paracetamol within 72 h prior to or 
concurrently with BU
–  Monitor for increased BU concentrations/
toxicity when used concurrently
Metronidazole CYP3A4 inhibition
Competition for glutathione
–  Monitor for increased BU concentrations/
toxicity when used concurrently
Itraconazole 
voriconazole






–  Use alternative antiepileptic (levetiracetam)
aLexicomp® Drug interactions (2018) and Glotzbecker et al. (2012)
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Table 31.3 Pharmacokinetic interactions with cyclosporine (C), tacrolimus (T) and sirolimus (S) (non-limitative list)a
Interacting drug
Proposed 







– ▼ C/T/S level •  Monitor C/T/S levels
•  Increased C/T/S doses will likely be needed
•  Consider therapy modification 
(levetiracetam)
Antifungals
Caspofungin Unknown –  C: ▲ adverse/toxic effect 
of caspofungin
–  ▼ T/S levels
•  Monitor liver function/hepatotoxicity in 
combination with C







–  ▲ C/T/S levels •  Monitor clinical response of C/T/S closely
•  Monitor C/T/S levels closely
•  Decreased C/T/S doses will likely be 
needed
•  Itraconazole: consider therapy modification 
(C/T/S)
•  Posaconazole/voriconazole: consider 







–  ▲ C/T/S levels •  Monitor C/T/S levels
•  Decreased doses of C/T/S might be needed
•  Monitor for decreases in blood pressure (C)




–  T: ▲ levels/nephrotoxicity 
of C/T
–  S: ▲levels of S (of specific 
concern with modified C)
•  Discontinue C/T therapy at least 24 h prior 
to initiating therapy with the other agent
•  C/T: avoid combination
•  Monitor for toxic effects of S
•  S: ▲ risk of C-induced HUS/TTP/TMA
•  Administer oral doses of S 4 h after doses 
of C
•  C/S: consider therapy modification
Tacrolimus –  C: ▲ levels/nephrotoxicity 
of C/T
–  S: ▲ adverse/toxic effect 
of T/S, ▼ level of T






–  ▲/▼ C/T levels
–  ▲ corticosteroid levels
•  Monitor for changes in C/T levels (likely 
initial increase, possibly decrease 
thereafter) and toxic effects of 
corticosteroids and/or C/T if used 
concomitantly





–  ▲ C/T/S levels
–  S: ▲ level of erythromycin
•  Monitor C/T/S levels and adjust dose 
accordingly
•  Avoid concurrent use







–  ▲ C/T level • Monitor C/T levels closely when starting or 
stopping therapy with PPI and adjust dosage 
if necessary (T)
• Inconsistent data (omeprazole), rabeprazole 

















–  C: ▲ level of atorvastatin/
simvastatin
–  T: limited effect
•  Monitor for increased risk for statin-related 
toxicities (myopathy and rhabdomyolysis)
•  C: Avoid concurrent use atorvastatin / 
simvastatin
•  Consider changing to pravastatin or 
fluvastatin (less sensitive to this interaction) 
or alternative therapy
•  Warn patients to report any unexplained 
muscle pains or weakness
•  T: No action needed
Miscellaneous
Grapefruit juice CYP3A4 
inhibition 
(intestinal)
–  ▲ C/T/S levels (C/T: 
primarily limited to orally 
administered C/T)
•  Monitor C/T/S levels
•  Avoid combination with C/S/T
Metronidazole CYP3A4 
inhibition






–  C: ▲ glucuronide 
metabolite concentrations 
(associated with 
mycophenolate  adverse 
effects)
–  MMF: ▼ C exposure in 
children
–  T: does not affect PK of 
mycophenolic acid (one 
study suggests ▲ T 
exposure)
•  Monitor MMF dosing and response to 
therapy particularly closely when  
adjusting concurrent C (starting, stopping, 




–  ▼ C/T/S levels •  Monitor levels, increase dose C/T/S 
accordingly
•  Avoid combination if possible




–  ▼ C/T/S levels •  Consider alternatives to SJW
•  If it cannot be avoided, monitor C/T/S 
levels
▼ = decreased; ▲ = increased
aLexicomp® Drug Interactions (2018) and Glotzbecker et al. (2012)
alternative for SJW is available (Enioutina et al. 
2017; Lexicomp® Drug Interactions 2018).
31.3.2  Food
Drug interactions with food and drinks are 
known to occur. Grapefruit juice is a potent 
inhibitor of intestinal CYP3A4, and many clini-
cally relevant interactions have been reported 
(e.g., with simvastatin and calcineurin inhibi-
tors). Cruciferous vegetables (Brussels sprouts, 
cabbage, and broccoli) contain substances that 
are inducers of CYP1A2 but do not appear to 
cause clinically important drug interactions 
(Thanacoody 2012).
31.4  Resources for Drug 
Interactions
Drug interactions in HSCT can be numerous. 
Whenever a potential clinically relevant drug 
interaction is recognized, a management plan 
should be recommended (modification in drug 
therapy or closer monitoring of efficacy and 
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adverse reactions) (Tannenbaum and Sheehan 
2014). A number of resources are available to 
help identifying and managing drug interactions 
(e.g., Lexicomp® Drug Interactions 2018; 
Clinical Pharmacology® 2018; Medicines 
Complete® 2018). Interpretation of interactions 
must be performed carefully to avoid the risk of 
over-alerting. The patient’s clinical status, comor-
bidities, and severity of the drug interactions pre-
sented should always be taken into account.
31.5  Conclusion
Drug interactions can occur at all levels during 
HSCT. Attention to and management of interac-
tions is crucial to prevent severe clinical conse-
quences. Due to the complexity of the therapy 
and the risk of drug interactions, an active col-
laboration in a HSCT multidisciplinary team, 
including physicians, pharmacists, and nurses, is 
of paramount importance.
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Key Points
• Drug interactions in HSCT are common 
and can occur at all levels
• Knowledge of mechanisms involved in 
drug metabolism might help in antici-
pating interactions
• A multidisciplinary approach is impor-
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Role of Nursing in HSCT
Aleksandra Babic and John Murray
32.1  Introduction: HSCT Nursing
With the progress of HSCT in the early 1960s, it 
became clear that nurses play a crucial role within 
the multidisciplinary team (MDT) caring for 
patients and their families undergoing this intense 
treatment. The distress during the time prior to 
undergoing HSCT, during isolation, in the recov-
ery phase and the time after (long-term recovery) 
is not to be underestimated.
The best compliment towards nursing was 
made by Prof. Edward Donnall Thomas, the 1990 
Nobel Prize winner in Medicine who stated that 
‘nurses and nursing are my secret weapon with-
out whom I could not have achieved my goals’ 
(Appelbaum 2013).
Continuity of care is vital to patient’s right 
from their initial attendance in hospital. Nurses 
are an advocate throughout the transplant and 
often act as a motivating force, supporting and 
advising as well as supplying physical, psy-
chological and emotional care whilst patient’s 
transition from acute care to long-term follow-
up clinics. Experienced nurses with high levels 
of technical competencies offer patients and 
families excellent care and support in this chal-
lenging area.
Patient preparation for HSCT involves the 
use of chemotherapy and/or radiotherapy to 
eradicate the underlying disease of the patient. 
Throughout the transplant procedure, the patient 
needs special care to overcome the complica-
tions associated with treatment. Nurses must be 
aware of the possible complications in order to 
play a role in prevention or early detection of 
alarming signs, such as sepsis, fluid overload 
and organ dysfunction, taking appropriate mea-
sures to minimize adverse effects and restore the 
clinical balance of the patient. This care is very 
complex and requires a high level of skill 
(Wallhut and Quinn 2017).
The field of nursing research in HSCT has 
evolved from reflecting on symptom manage-
ment and service development to quality of life 
and long-term survival topics. The FACT-JACIE 
International Standards Accreditation requires 
that the clinical programme has access to per-
sonnel who are formally trained, experienced 
and competent in the management of patients 
receiving cellular therapy (JACIE 7th edition 
n.d.). Thus, it is important that training and com-
petency programmes are structured and ongoing, 
with documented evidence of training topics and 
dates (Babic 2015).
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32.2  Role of Nursing Throughout 
HSCT Patient Pathway
HSCT is a standard therapy in a number of malig-
nant and non-malignant conditions.
Pre-transplant assessments must be under-
taken, and the results of these along with suitable 
donor medical clearance and cell availability are 
essential to ascertain that transplant is a valid 
option and can proceed safely.
Nurses are pivotal in implementing practices 
to prevent and manage infections and other seri-
ous effects following HSCT (Sureda et al. 2015; 
Kenyon and Babic 2018) as:
• Bleeding risk caused by thrombocytopenia
• Tiredness and fatigue caused by the decreased 
haemoglobin levels and lasting effects 
of chemo-/radiotherapy and associated 
medications





32.2.1  The Role of the Transplant 
Coordinator (TC)
Many transplant coordinators are nurse special-
ists who focus their role on the individual needs 
of the patient and families; however, some cen-
tres have medical staff that organize transplants. 
TC is the person who should:
• Ensure that timely events occur for each 
patient and their families undergoing HSCT 
and that the patients are physically and psy-
chologically prepared for the treatment.
• Provide a high level of care and management, 
inform and educate the patient, have holistic 
knowledge of the patient, participate in spe-
cific or advanced nursing practices (bone mar-
row sampling, HLA typing, transplant 
recipient care) and coordinate all the trans-
plant logistics.
• Ensure that a suitable source of cells is avail-
able following the high-dose chemotherapy or 
immunosuppressive treatment that the patient 
will receive. Make requests to donor search 
panels, and order cells once the ideal match 
has been identified by the transplant 
physician.
• Support the patient with verbal and written 
information, and educate them about the 
whole process from typing to transplant. The 
TC will coordinate all of the care and embod-
ies a clinical nursing function where emphasis 
is placed on specialization in a clearly defined 
area of care.
• Actively participate in the JACIE process of 
accreditation of transplant centres by writing 
and evaluating SOPs and being a valued mem-
ber of the MDT and ward team offering teach-
ing and advice.
32.3  Specific Aspects 
with a Prominent Role 
for Nurses
32.3.1  Venous Access Device (VAD)
Education and training should not be limited to 
the care and maintenance after insertion of the 
VAD but should be focused on well-being and 
patient safety. An algorithm for choosing the 
right VAD for the right patient should start with 
the diagnosis and treatment plan. The best VAD 
should be chosen based on the pH and osmolar-
ity of the drugs used during the whole treatment 
period and the vein condition and should 
include the option for (partial) home infusion 
treatment.
Within the range of CVAD (central VAD), a 
peripherally inserted central catheter (PICC) is 
seen frequently in haematology patients, often as 
an alternative for a tunnelled CICC (centrally 
inserted central catheter) such as a Hickman 
catheter (see Chap. 22).
Nurses are responsible for the safe administra-
tion of drugs such as chemotherapy, IS immuno-
suppressive drugs and blood products as well as 
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parenteral nutrition and symptom control drugs. 
The accurate handling and taking care of the cen-
tral venous catheter and infusion pump systems 
are vital in the process because the catheter is 
related to the highest risk of infections. The use 
of an Aseptic Non Touch Technique (ANTT) 
(Pratt et  al. 2007) and its ten principles of care 
have led to a decrease in catheter-related 
infections.
GAVeCeLT (Gli Accessi Venosi Centrali a 
Lungo Termine) (Pittiruti and Scoppettuolo 2017) 
has developed an algorithm for the choice of the 
most appropriate VAD, based on the best evi-
dence available in the international guidelines, 
the bundle for the safe implantation of PICCs 
(see Table 32.1).
32.3.2  Early and Acute Complications
They occur following transplantation when the 
patient has reduced tolerance due to neutrope-
nia and/or increased intestinal permeability. In 
neutropenia, the number of white blood cells 
decreases significantly, resulting in aplasia 
with an increased risk of infection. An 
increased permeability of the intestinal wall is 
caused by intensive chemotherapy damaging 
the gastrointestinal mucosa. As a result, patho-
genic bacteria (bodily bacteria or bacteria from 
the diet) can enter the bloodstream and cause 
sepsis.
Early complications generally occur within 
100 days post HSCT. In the early phase of HSCT, 
the main risk factors for infections are 
neutropenia- barrier breakdown due to mucositis, 
indwelling catheters, depressed T-cell and B-cell 
function and aGvHD.
Two of the most common early complications 
are oral mucositis and sepsis. Some other rela-
tively rare complications are HC, ES, IPS and 
DAH.  TAM and SOS/VOD are analysed in 
Chaps. 42, 49 and 50. For all complications there 
are locally agreed recommendations for preven-
tion and principles for nursing care, with moni-
toring and prompt intervention that may have an 
influence on patients’ morbidity and mortality.
32.3.2.1  Oral Mucositis (OM)
Oral mucositis (OM) has been defined 
(Rubenstein et al. 2004) as the inflammation of 
the mucosal membrane, characterized by ulcer-
ation, which may result in pain, swallowing dif-
ficulties and impairment of the ability to talk. The 
mucosal injury caused by OM provides an oppor-
tunity for infection to flourish and in particular 
putting the severely immunocompromised patient 
in the HSCT setting at risk of sepsis and 
septicaemia.
OM and oral problems in the HSCT setting 
can be expected to occur in as many as 68% of 
patients undergoing autologous HSCT and 98% 
of patients undergoing allogeneic HSCT (EORTC 
Guidelines). With the increasing use of targeted 
drug therapies and approaches in the cancer and 
Table 32.1 The bundle for the safe implantation of 
PICCsa
The goals of the bundle are to minimize
1.  Complications related to venipuncture: failure, 
repeated punctures, nerve injury, arterial injury
2.  Malposition
3.  Venous thrombosis
4.  Dislocation
5.  Infection
In order to reach the goal, the SIP protocol was 
developed and needs to be followed
1.  Bilateral US scan of all veins at the arm and neck
2.  Handwashing, aseptic technique and maximal 
barrier protection
3.  Choice of the appropriate vein at the midarm (vein 
mm = or >cath Fr)
4.  Clear identification of median nerve and brachial 
artery
5.  Ultrasound-guided venipuncture
6.  US tip navigation during introduction of the PICC
7.  Electrocardiography method for assessing tip 
position
8.  Securing the PICC with cyanoacrylate glue, 
sutureless devise and transparent dressing
Infections in PICCs to be close to zero if a bundle of 
preventive measures are takenb
•  Site selection
•  Skin disinfection with 2% chlorhexidine in 70% 
gluconate
•  Hand hygiene
•  Maximum barrier precautions
•  Daily control on indication and on complications
aPittiruti and Scoppettuolo (2017)
bHarnage (2012)
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haematology setting, problems in the oral cavity 
will increase and become even more of a chal-
lenge (Quinn et al. 2015).
All treatment strategies aimed at improving 
mouth care are dependent on four key princi-
ples: accurate assessment of the oral cavity, 
individualized plan of care, initiating timely 
preventative measures and correct treatment 
(Quinn et  al. 2008). The assessment process 
should begin prior to HSCT by identifying all 
the patient risks most likely to increase oral 
damage.
The choice of prevention regimens should be 
guided by evidence based on expert opinion 
interventions, working with the patient to reduce 
their potential risk of oral mucositis occurring.
All treatment plans should be based upon the 
grading of oral damage and patient reports, and 
these may include the use of topical analgesics 
and the use of opiates (Elad et al. 2015).
32.3.2.2  Sepsis
Sepsis is a life-threatening condition caused by 
aberrant and dysregulated host response to infec-
tion (Elad et al. 2015). The most important action 
to prevent infections acquired by exogenous 
organisms is good hand hygiene performed cor-
rectly (Hand Hygiene Guidelines). Appropriate 
clean work clothes, with short sleeves, no jewel-
lery and no neck tie are the responsibility of all 
staff. Protective isolation during the neutropenic 
phase is recommended, and the patient should 
not be in contact with any staff or visitors with 
symptoms of infection. For prevention of endog-
enous infections, oral hygiene and skin care to 
maintain the mucosal and skin barrier and use of 
prophylactic antibiotics are the most important 
actions. Correct handling of any indwelling cath-
eters is also a key nursing responsibility in infec-
tion control.
Other areas where infections can be prevented 
are air and water quality, food hygiene and envi-
ronmental cleaning. Environmental cleaning 
includes medical equipment as well.
Early recognition and treatment are vital for a 
successful outcome of sepsis. Temperature, 
pulse, blood pressure, respirations and saturation 
(vital signs) should be frequently monitored. 
Signs of infection are not always obvious, but if 
the patient has a temperature ≥38.0 °C, cultures 
should be taken, IV antibiotics and IV fluids 
started or increased and oxygen therapy 
initiated.
The goal is always to start antibiotic treatment 
within 1 h from detection of fever and is the most 
critical period in the patient’s survival from sep-
sis. Early recognition and intervention are 
achieved by frequent monitoring of the patient’s 
vital signs and general condition and paying 
attention to subtle changes that should be 
promptly reported, such as mental state alteration 
or mottled skin.
Alert for immediate action are when a previ-
ously well patient only responds to pain or 
becomes unresponsive, becomes confused and 
has a systolic blood pressure of <90 mmHg or a 
fall of >40  mmHg from baseline; an elevated 
heart rate >130 bpm; a respiratory rate of >25 per 
min, requiring oxygen to maintain saturations 
>92%; a non-blanching rash or mottled, ashen or 
cyanotic skin, not passed urine in the last 18 h; an 
output of <0.5 ml/kg/h; a lactate of >2 mmol/l; or 
received recent chemotherapy.
Immediate action is required at the first indi-
cation of sepsis. The concept of the sepsis six and 
the severe sepsis resuscitation bundle (Daniels 
et al. 2011) has been developed as a guide to pri-
oritize interventions in patients where sepsis is 
suspected:
 1. Oxygen therapy aims to keep saturations 
>94% (88–92% if at risk of CO2 retention, e.g. 
COPD).
 2. Blood cultures, at least a peripheral set, con-
sider CSF, urine, sputum, chest X-ray and 
urinalysis.
 3. IV antibiotics, according to hospital policy, 
consider allergies prior to administration.
 4. Fluid resuscitation, if hypotensive or lactate 
>2 mmol/l, 500 ml bolus stat, may be repeated 
if clinically indicated. Do not exceed 30 ml/
kg.
 5. Serial serum lactates corroborate high VBG 
lactate with arterial sample. If lactate 
>4  mmol/l, call critical care for support. 
Recheck after each 10 ml/kg challenge.
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 6. Assess urine output which may require cathe-
terization, and ensure fluid balance chart com-
menced and completed hourly.
When treatment has been initiated, the patient 
must be continually monitored to determine the 
effect of treatment or worsening of the condition. 
This includes vital signs, fluid balance including 
weight and assessment of identified and/or poten-
tial infection sites (mouth, skin, all indwelling 
catheters, urine, stools, etc.), mental status, signs 
of bleeding, pain and general appearance and 
well-being.
Antibiotics should be delivered with strict adher-
ence to the prescribed time schedule. Antipyretic 
agents should be avoided since they may mask fever 
but may under certain circumstances be used to alle-
viate patient discomfort and pain.
32.3.2.3  Pain
Pain in the HSCT setting is most commonly expe-
rienced as a result of mucositis, but patients will 
also report other pain such as bone pain associ-
ated with G-CSF, abdominal pain due to diarrhoea 
or general discomfort with fluid accumulation. A 
comprehensive evaluation of the pain, location, 
characteristics, onset, duration, frequency and 
severity, exacerbating and relieving factors, 
should be included. This assessment should be 
supported by the patient’s non-verbal reactions 
such as facial expression, pallor, tempo of speech, 
body position, etc. as well as their vital signs.
32.3.2.4  GvHD
GvHD remains a leading cause of non-relapse 
mortality and is associated with a high morbidity 
that increasingly affects quality of life (Lee et al. 
2003; Dignan 2012). Nursing care of patients 
with GvHD is highly complex and extremely 
stressful especially in the acute setting in patients 
with grades 3–4 skin and GI involvement 
(Table 32.2). Supportive nursing care to comple-
ment medical interventions aims to offer symp-
tomatic comfort and relief.
There are many manifestations of GvHD, and 
nurses are able to advise patients with respect to 
many of these including eye, mouth and genital 
care. Further readings: GvHD chapter in the 
EBMT Textbook for nurses 2018 (Kenyon and 
Babic 2018).
32.3.3  Long-Term Complications 
and Side Effects Post 
Allo-HCST
Long-term side effects after allo-HSCT include 
non-malignant organ or tissue dysfunction, 
changes in quality of life, infections related to 
abnormal immune reconstitution and secondary 
cancers. Many of these can be attributed to effects 
of chronic graft-versus-host disease (Dignan 2012; 
Bhatia 2011; Mohty and Mohty 2011). With 
advances achieved in terms of supportive care, it is 
reasonable to expect outcomes to improve steadily, 
and consequently increasing numbers of trans-
plant survivors will be facing life after the initial 
Table 32.2 Nursing care of patients with skin and gas-
trointestinal GvHD
Skin care
1.  Maintain integrity of the skin; regular application of 
cream, ointment or gel; patient choice of vehicle
2.  Emollient application, high or low water content to 
be considered, QV, hydromol or diprobase
3.  At least 30-min gap between emollient and steroid 
cream applications
4.  Topical steroids, strength decided by site and length 
of treatment
5.  Menthol cream for painful and pruritic skin, cooling 
effect
6.  Use high-factor sunscreen SPF 50+
7.  Always apply creams to make the skin appear shiny; 
adult body will require 500 g per week
8.  Apply in one direction, direction of hair growth, do 
not scrub on
9.  Medical grade silk clothing
10.  Good fluid intake and nutrition
11.  Organic coconut oil or other natural lipids
12.  Aloe vera gels; do not use alone as they will dry 
the skin
Gastrointestinal
1.  Ensure stool samples are taken to exclude infection
2.  Adequate oral intake with strict fluid balance
3.  Small and frequent high-calorie food and drinks
4.  Antiemetics
5.  Loperamide, codeine and octreotide may be used to 
stem diarrhoea
6.  Rest bowel and use parenteral feeding
7.  Consider the use of radiologically inserted 
gastrostomy (RIG) feeding
8.  Flexi-seal faecal collection device
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transplant experience. For some survivors the bur-
den of long-term morbidity is substantial, and 
long-term follow-up of patients who received allo-
HSCT is now widely recommended.
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Key Points
• Specific technical care activities require 
nursing knowledge and specific skills in 
the field of HSCT such as instrument 
manipulation, knowledge of technolo-
gies and the use of special protocols to 
effectively intervene in complex situa-
tions and deal with acute and chronic 
HSCT complications.
• As patients become more complex, so 
does the care that they require.
• It is essential that nursing adapts to these 
challenges and improves in both the qual-
ity and expertise that is vital to improve 
patient survival and overall experience of 
this life-changing treatment.
• The predominant role for nurses is 
focused to vascular access device, oral 
mucositis and other early complications 
as HC, ES, IPS and DAH.  TAM and 
SOS/VOD, sepsis, pain, GVHD and 
several late complications.
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Ethics is a branch of philosophy, and, like 
mathematics, moral philosophy does not give 
ready- made answers to questions but teaches 
how one could systematically analyse and 
resolve a problem. Philosophy’s main tool, to 
achieve this, is logic, where accurate premises 
are linked together to support a conclusion 
within a sound and valid ethical argument 
(West 2009). This chapter aims to explain this 
process using examples from blood and mar-
row transplantation practices.
Ethical discourse requires a theory of ethics 
(Thompson 2005). One requires a landmark to 
understand their ethical position. One needs to 
know on what basis one can decide if an action is 
wrong or right, bad or good; a theory of ethics 
should help this. It will also allow better under-
standing of common threats to ethics such as 
appealing to religion, using relativism to justify 
accepting different truths to different situations 
or explaining that ethical stands are unreasonably 
demanding (Blackburn 2001).
The most known ethical theories are Kant’s 
deontological theory and Bentham and Mill’s 
utilitarianism (Vardy and Grosch 1999). Kant 
argued for our duty to pursue a set of intrinsically 
ethical rules that can be universally applied. 
Ethics is the search for such rules. On the other 
hand, utilitarianism argues that an action or a rule 
is moral if their outcomes bring the greatest plea-
sure and happiness to the greatest numbers of 
people. No doubt, these theories would ignite an 
interesting discussion on transplant ethics but 
may not provide clear enough guidance to health-
care practitioners to help tackle the dilemmas 
that they regularly encounter.
During the last four decades, Beauchamp and 
Childress (2013) defended, and significantly 
developed, the four principles ethical theory for 
healthcare profession. These principles include:
 1. Respect for autonomy: respecting the 
decision- making capacity of autonomous 
persons
 2. Non-maleficence: avoiding the causation of 
harm
 3. Beneficence: providing benefits as well as bal-
ancing such benefits against risks and cost
 4. Justice: distributing benefits, risks and costs 
fairly.
According to Beauchamp and Childress 
(2013)
K. El-Ghariani (*) 
Department of Hematology, Sheffield Teaching 




Department of Pediatric Hematology-Immunology, 
Hospital Robert-Debré, Assistance Publique- 




Beneficence is the primary goal of medicine 
and healthcare, whereas respect for autonomy, 
along with non-maleficence and justice, sets the 
moral limits on the professional’s actions in pur-
suit of this goal.
Ethical obligations towards patients (and 
sometimes their relatives) are well known to 
healthcare professionals. In the field of transplan-
tation, management of donors adds another 
dimension to the ethical complexity. Two more 
areas of work are morally challenging, and 
although less well argued for, they are critical and 
have wide implications: firstly, the moral obliga-
tions of professionals to engage with fund hold-
ers, commissioners and insurers to ensure fair 
funding of service and, secondly, the ethical role 
of experts in the management, reporting and pub-
lishing of data and information to ensure accurate 
practice evidence to inform decision-making. 
Ethical practice requires one to apply the above 
four principles to all field of work, every time an 
ethical issue is raised. Transplantation practice is 
full with issues that can raise serious and some-
times disturbing ethical concerns. The following 
is a discussion of some aspects of the ethical 
implications of high-risk treatment, lack of 
enough funding for healthcare and issues with 
donor care.
33.2  Ethical Challenges of High- 
Risk Treatment
Blood and marrow transplantation is mostly 
used to treat life-threatening illnesses, but also 
it carries serious complications that are them-
selves life threatening. Resistance disease or a 
recipient with significant comorbidities can 
make transplant risks too high and brings risks 
of futility to the equation. Although guidelines 
and outcomes data are available in the litera-
ture, the application of such evidence may 
require the support of colleagues or other 
experts within a multidisciplinary team. This 
should help in striking the desirable balance 
between expected benefits and possible harm 
(the beneficence and the non- maleficence prin-
ciples). Although risks may be too high, one 
ought to ask ‘is it the best option available for 
that particular patient with that particular dis-
ease?’ (Snyder 2016). Moreover, the implica-
tions of undertaking a transplant procedure 
with limited benefits on resources and other 
patients ought to be considered. The limitation 
of transplant rooms, for example, may explain 
how a decision to transplant a particular patient 
could affect another.
A transplant procedure that carries only 
10–20% chance of success can be a source of 
worry to staff as it brings the beneficence/non- 
maleficence balance to a critical point. However, 
the other two ethical principles may help. What 
the patient wants to do? And will such a trans-
plant jeopardise other patients care or face 
funding rejection? Obviously for a keen patient 
and supportive healthcare payers, the decision 
is less problematic. The balance of forces may 
be different in another situation with the same 
clinical ground. This brings uncomfortable 
variations into practice which can only be mini-
mised by the development of constructive ethi-
cal discourse.
An unbiased list of options ought to be dis-
cussed with the patient (and possibly with their 
relatives and even healthcare payers). To obtain 
an autonomous consent, staff have to ensure that 
the patient has fully understood all options and 
has made a choice that is not influenced by any 
coercive factors. Obtaining such a valid consent 
requires arrangements and it will take some 
time and effort. This, however, not only meets 
our moral obligations but also has practical ben-
efits, as a well-consented patient is likely to 
cooperate with the demand of treatment and 
work with staff to fight complications. Respect 
of autonomy dictates that patients are well 
informed about decisions that they make, and it 
also dictates that staff accept such decisions 
even if decisions sound counterintuitive. A self-
funding patient who refuses life-saving trans-
plant to save the money for their young children 
may pose difficult and very uncomfortable chal-
lenges to staff. This patient can be helped 
through exploring charitable funds for their 
treatment, but ignoring their autonomous deci-
sions is not an ethical option.
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33.3  Engagement with Funding 
Issues as a Professional 
Moral Obligation
Establishing funding rules for transplantation 
treatment has been, on many occasions, consid-
ered the job of healthcare payers or insurers. 
Medical staff are involved in setting up guide-
lines, publishing data on outcomes and advising 
in some complex cases. However, an ethical 
assessment of the issue will put medical staff in 
the centre of decision-making. After all, health-
care payers and insurers will base all their deci-
sions not only on medical information but also 
on the interpretation of such information as pro-
vided by medical staff. It is prudent to think that 
it is unethical that medical staff do not engage 
actively in this process. The same ethical desire 
that drives staff to treat illness and complica-
tions ought to drive their engagement in mend-
ing funding practices that do not meet patients’ 
needs, as both issues are detrimental to patients’ 
outcomes.
The respect to autonomy principle dictates 
involvement of patients’ representatives in fund-
ing decisions. Most healthcare services have 
such an arrangement, and the job of the medical 
staff is to educate representatives to be able to 
make valid and informed decisions. The princi-
ple of beneficent, in this setting, can be applied 
by gathering, analysing and publishing good 
data to support funding decisions. Whilst pub-
lishing papers may have been considered as an 
option for academic progression, it seems that it 
has become an ethical obligation. Non-
maleficence means that delays in introducing 
new development in the field must be avoided. 
Transplant field is rapidly changing (for the bet-
ter), and such delays could devote patients from 
a helpful treatment modality that could make a 
difference to them. The principle of justice is in 
the heart of healthcare funding. However, this 
ought to not mean ‘sticking to the rule’. Most 
rules have legitimate exceptions and the job of 
the transplant physician to fight the corner of the 
patients in this regard. Some healthcare services 
support cord transplant but not the use of double 
cord, because of cost implications. This would 
disadvantage many adult patients with body 
weight that is too high for a cord blood unit to 
support. The desire to establish an ethical pro-
cess of funding may have led the English 
National Healthcare Service to establish Clinical 
Reference Groups, including one for transplan-
tation. This group is composed of a medical 
chair, eight other transplant physicians and three 
members to represent patient and public voice 
(NHS England 2018). Medical ethics is mainly 
seen as a direct issue between a professional and 
a patient. This discussion showed the ethical 
obligations of professionals outside the clinic 
and the hospital ward. This is obviously demand-
ing but also more helpful to patients.
33.4  The Ethical Issues in Donor 
Management
Transplant donation is a fertile subject for ethical 
debate as all types of donation carry some moral 
concerns. These are mainly around respect of donor 
autonomy, risk of exploitation or possible harm to 
donor. Unrelated donors are supported by profes-
sionals other than staff who look after the recipient, 
and this is according to national and international 
guidance. Unrelated donations have some financial 
and reputational benefits to the donor registries. 
However, given existing professionalism and code 
of practice, this has rarely raised concerns. On the 
other hand, family donors receive less structured 
protection. The recent success in haploidentical 
transplantation means that more family donors will 
be involved, and so ethical grounds of such process 
needs to be established.
Whilst the balance of risks and benefits of 
most types of treatment offered to a particular 
patient can be established, a major dilemma in 
donor ethics is the fact that assessing harm and 
inconvenience to one person (the donor) in rela-
tion to expected benefits to another (the recipient) 
is highly problematic. Staff occasionally make 
the decision themselves and argue that some tem-
porary aches and pains and minimal risks of rup-
tured spleen (G-CSF side effects) are acceptable 
risks to justify a life-saving donation, particularly 
to a family member. Staff position makes ‘some 
33 Ethical Issues in HSCT
248
sense’, but it does not respect donor autonomy, 
and so it cannot be accepted as a universal rule 
that could be practiced widely, i.e. it lacks ethical 
grounds.
Child donors, pregnancies conceived for HCT 
and donation from a family member who lack 
capacity have been debated. Minor sibling donors 
require particular consideration as their auton-
omy is harder to prove. There is evidence that a 
child donor is subjected to both physical and psy-
chological implications. This prompted (the) 
American Academy of Pediatrics Committee on 
Bioethics to recommend that five conditions are 
met to ensure morally justified donations from 
children (AAP 2010). These include lack of suit-
able adult donor, the expected benefit to recipient 
is reasonably high, strong relationship between 
donor and recipient, potential physical and psy-
chological harms to donor must be minimised 
and, finally, obtaining parents’ consent and child 
assent. Child assent and agreement are hard to 
confirm, and the availability of independent com-
mittee or assessor to look after such donors has 
been recommended.
Moreover, a family donation from an adult 
with full capacity can be morally challenging for 
two reasons. Firstly, not all family members want 
to donate. Some of them find the process too 
demanding, and if they were ‘given the choice’, 
they will rather not. The story of one such donor 
was in the news. A newspaper (the Daily Mail, 
UK) reported the situation using the following 
headline: ‘Sentenced to die by my sister, leuke-
mia victim refused her only chance of transplant’ 
(Oldfield 1997). The sister refused to donate 
bone marrow because of the phobia of hospitals. 
The subsequent media debate led the donor to 
reconsider her position. This is a moral position 
that is hard to defend. Secondly, the health risks 
to family donors are not minimum or negligible. 
They are more likely to encounter significant 
complications than unrelated donors (Halter et al. 
2009). Documented experience from unrelated 
donations cannot be used to advise family donors, 
and the comparison between harm to donor and 
benefit to recipient is even harder in the family 
donor situation. Many authors (van Walraven 
et al. 2010; Brand et al. 2011) attempted to raise 
awareness of these issues, and many argued that 
a system that is separate to and not influenced by 
patient care ought to be in place to manage fam-
ily donors.
Transplantation, like other healthcare prac-
tices, requires an accurate balance between 
expected benefits and possible harm as well as 
valid patient consent. Given limited resources, 
the implication of one transplant on another 
ought to be considered. Given the life-saving and 
life-threatening nature of this modality of treat-
ment, ethical issues with transplantation are 
likely to be challenging. Staff are expected to let 
patients decided for themselves. Moreover, staff 
ought to escalate complex issues to the legal sys-
tem or more commonly to the ethics committee 
within their institution. In the European Union, 
Directive 2001/20/EC established ethics commit-
tees as an independent body to agree complex 
ethical challenges.
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• Clinical ethics teaches skills to tackle 
moral dilemmas but does not provide 
ready-made answers.
• Clinical ethics now extends, beyond 
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Methodological advances in the HCT field have 
increased the population of survivors worldwide. 
However, HCT is associated with significant 
morbidity that impairs survivors’ recovery and 
adversely affects their QoL. A significant body of 
literature has addressed QoL after HCT and high-
lights significant deficiencies in physical, psy-
chological, social, and role functioning both in 
adult and pediatric survivors (Pidala et al. 2010). 
These data are clinically relevant as they help to 
understand the impact of HCT on patient’s lives. 
Clinically, assessment of QoL can inform patient 
education and be used to evaluate the benefit of 
supportive care interventions.
34.2  QoL Assessment
QoL can be considered a patient-reported out-
come (PRO). PROs are defined by the US Food 
and Drug Administration (FDA) as the “measure-
ment of any aspect of a patient’s health status that 
comes directly from the patient, without the 
interpretation of the patient’s response by a clini-
cian or anyone else” (US Food and Drug 
Administration 2009). Thus, PROs specifically 
describe the impact that HCT has on patients’ 
lives and provide information unavailable from 
other sources (Kurosawa et  al. 2017; Russell 
et al. 2006). PROs are also used in pediatric pop-
ulations, although parents or other proxies might 
be used as source of information when children 
are unable to report their own QoL. However, the 
use of patients’ own reports is clearly recom-
mended because significant discrepancies are 
found when comparing patients’ self-reported 
QoL to reports of physicians, parents, or other 
proxies (Kurosawa et  al. 2017; Russell et  al. 
2006). In general, measures to assess patient- and 
proxy-reported QoL are questionnaires.
These instruments can be broadly categorized 
as general or disease- or procedure-specific. 
General measures assess QoL of the general pop-
ulation and can also be administered to specific 
populations, such as HCT recipients. These ques-
tionnaires allow comparisons of QoL across pop-
ulations, such as between HCT survivors and 
individuals without cancer. In contrast, disease- 
and procedure-specific instruments examine 
 specific aspects of the health conditions assessed. 
These measures capture specific PROs that are 
likely to be important to patients.
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34.3  Measures to Assess QoL 
in Adults and Pediatric 
Patients Undergoing HCT
There are numerous measures assessing QoL on 
adults and pediatric HCT recipients. Measures 
used have been both general and disease-spe-
cific. The following sections list some of the 
most common used questionnaires in the field of 
HCT.
34.3.1  Adults
Interest in assessing QoL in adult HCT recipients is 
reflected in the variety of measures used to assess 
this outcome. However, there is a need for the sci-
entific community to reach consensus about which 
questionnaires to use in order to facilitate compari-
son across studies (Shaw et al. 2016). Table 34.1 
summarizes alphabetically some of the most com-
mon questionnaires to assess QoL in adults.
Table 34.1 QoL questionnaires assessing QoL in adult HCT survivors
(a) General
European Quality of Life- 5 Dimensions (EQ-5D-5L) (van Reenen and Jansen 2015)
Aim Health status
Items 6
Domains/subscales Mobility, self-care, usual activities, pain, anxiety, depression
Results Profile of each of the domains assessed, and an index of the health status. 
Higher scores indicate better health status
Translations Available in more than 130 languages
Medical Outcomes Study-Short Form (MOS SF-36) (Ware et al. 1994)
Aim QoL
Items 36; shorter versions feature 12 items (SF-12) or 8 items (SF-8)
Domains/subscales General health, physical, role, emotional and social functioning, mental 
health, pain, vitality
Results Physical Component Score; Mental Component Score and Global Score. 
Higher scores indicate better QoL
Translations Available in more than 170 languages
Patient-Reported Outcomes Measurement Information System (PROMIS) (Cella et al. 2010)
Aim Mental, physical, and social health and QoL in healthy populations as well 
as those with chronic conditions
Items Multi-item measures varying  
in length and complexity;  
for example, PROMIS-29  
has 29 items, PROMIS-43  
has 43 items, PROMIS-57  
has 57 items
Domains/subscales Each subscale measures a single domain; PROMIS Profile measures 
assess multiple domain
Results Higher scores indicate more of the concept being measured. Measures use 
standardized T-score metric against normative data for the US population
Translations Available in Spanish and several other languages
(b) Cancer and HCT specific
European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30) 
version 3.0 (Aaronson et al. 1993)
Aim QoL in cancer
Items 30 items
Domains/subscales Functional scales, symptom scale and a QoL scale
Results Higher scores in functional and QoL scales indicate better wellbeing. 
Higher scores in the symptom scale indicate worse symptomatology
Translations Available in more than 100 languages
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34.3.2  Pediatrics
There is less research on QoL on pediatric patients 
than adult patients. Initial pediatric studies focused 
on a single aspect of functioning, such as psycho-
social and physical limitations. It was not until the 
early 1990s that pediatric QoL began to be 
addressed as a multidimensional construct. Most of 
the measures used in pediatric studies were origi-
nally developed to be used in the general popula-
tion or in children with specific illnesses. Table 34.2 
lists alphabetically the most common measures 
used to assess QoL in pediatric population.
34.4  Challenges when 
implementing QoL 
assessment
Improvement in patients’ QoL is included among 
the strategic goals of major cancer organizations 
such as the American Society of Clinical 
Oncology and regulatory agencies such as the 
FDA and the European Medicines Agency. 
Recognition of the importance of the patient 
experience is reflected in the increasing incorpo-
ration of patient-reported QoL measures in obser-
vational research and clinical trials. However, 
some aspects should be considered when imple-
menting patient-reported QoL measures.
Historically, studies and clinical trials per-
formed in the USA have often used the FACT 
instruments, whereas studies performed in 
Europe have chosen the EORTC. This divergence 
makes results difficult to compare (Shaw et  al. 
2016), although efforts are underway to map 
common QoL measures such as the EORTC 
QLQ-C30 and FACT-G to one another (Young 
et al. 2015). Second, the mode of administration 
should also be considered. PRO measures have 
traditionally been administered by paper and 
pencil, but new technologies offer the potential to 
use electronic measures. Electronic measures 
administered before or during a clinic visit allow 
results to be available at the time of consultation 
and may facilitate symptom monitoring to guide 
supportive treatment. One example is the 
PROMIS instrument, which is available using 
computer adaptive testing or through REDCap 
software. Computer adaptive testing selects ques-
tions based on the previous responses that patients 
have provided to approximate the construct being 
measured in the fewest number of questions. The 
implementation of routine assessment of patients’ 
QoL on clinical care and clinical trials has the 
potential to improve patients’ well-being.
Table 34.1 (continued)
Functional Assessment of Cancer Therapy—Bone Marrow Transplant (FACT-BMT) (McQuellon et al. 1997)
Aim QoL in HCT
Items 47
Domains/subscales Consists of the FACT-G (Cella et al. 1993) and the BMT concerns 
subscale
Results Higher scores indicate better QoL
Translations Available in more than 38 languages
Functional Assessment of Cancer Therapy—General Scale (FACT-G) (Cella et al. 1993)
Aim QoL in cancer
Items 33
Domains/subscales Physical, functional, social and emotional well-being
Results Higher scores indicate better wellbeing and global QoL
Translations Available in more than 60 languages
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Table 34.2 QoL questionnaires assessing QoL in pediatric HCT survivors
(a) General
Child Health Questionnaire (CHQ) (Landgraf et al. 1996)
Aim QoL
Versions Parent-reported versions feature 50 items (CHQ-PF50) or 28 items (CHQ-PF28) and are 
intended for parents of children aged 5–18 years. The child-report version (CHQ-87) has 87 
items and is appropriate for children aged 10–18
Domains/subscales Global health, physical functioning, role/social-physical functioning, bodily pain/
discomfort, role/social-emotional functioning, role/social -behavior, parental impact 
-time, parental impact -emotional, self-esteem, mental health, global behavior, family 
activities, family cohesion, and changes in health
Results Higher scores indicate higher physical and psychosocial wellbeing
Translations The CHQ-PF50 and CHQ-PF28 are available in more than 80 languages, and the CHQ-87 to 
34
Patient-Reported Outcomes Measurement Information System (PROMIS) (Hinds et al. 2013)
Aim Health and QoL in healthy populations as well as those with chronic conditions
Versions Multi-item measures varying in length and complexity: PROMIS-25 has 25 items, PROMIS-37 
37 items, and PROMIS-49 49 items. PROMIS measures are child- and parent- reported. 
Child-report measures are intended for children aged 8–17, and parent-report for children 5–17
Domains/subscales Physical, mental and social health, and a global QoL score
Results Higher scores indicate more of the concept being measured. PROMIS use standardized 
T-score metric against normative data for the US population
Translations Children and proxy measures are available in Spanish and in several other languages
Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Score Scales (Varni et al. 2001)
Aim QoL in healthy children or those diagnosed with an acute or chronic disease
Versions Parent-report form for children aged 2–4 has 21 items, and child and parent reports for 
children aged 5–18 have 23 items
Domains/subscales Physical, emotional, social, and school functioning
Results Physical health summary score; Psychosocial health summary score; Total score. Higher 
scores indicate better QoL
Translations Available in more than 70 languages
(b) Cancer and HCT specific
Child Health Rating Inventories (CHRIs)-and Disease- Specific Impairment Inventory-Hematopoietic Stem Cell 
Transplantation (DSII-HCT) (Parsons 2005)
Aim The disease specific (DSII-HCT) module assesses QoL of childhood HCT survivors
Versions 10-item module intended to child-report (aged 5–12), adolescent-report (13–18) and 
parents-report (5–18)
Domains/subscales Items are grouped in three domains reported by parents and patients to be most salient to the 
HCT experience: worry, hassless, and body image
Results Higher scores indicate better QoL
Translations The questionnaire is available in English
Peds Quality of Life Cancer Module 3.0 (PedsQL CM™) (Varni et al. 2002)
Aim QoL in children with cancer
Versions Parent-report form for children aged 2–4 has 25 items, child and parent reports for children 
aged 5–7 has 26 items, and child and parents reports for children more than 8 years has 27 
items
Domains/subscales Pain and hurt, nausea, procedural anxiety, treatment anxiety, worry, cognitive problems, 
perceived physical appearance and communication
Results Higher scores indicate better QoL
Translations Available in more than 100 languages
The Behavioral, Affective and Somatic Experiences Scales (BASES) (Phipps et al. 1994)
Aim QoL during the acute phase of HCT
Versions There are separate versions to be completed by nurses (BASES-N), parents (BASES-P) and 
children (BASES-C). The BASES-N and BASES-P have 38 items and the BASES-C has 14 
items. The questionnaire is intended to be used in child aged 5–17
Domains/subscales Somatic distress, mood disturbance, compliance, quality of interactions and activities
Results Higher scores indicate more distress/impairment
Translations Available in English
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Key Points
• Assessing HCT survivors’ QoL is essen-
tial in order to know the impact that the 
HCT, its morbidity, its treatments, and 
related interventions have on survivors’ 
well-being.
• Enhanced efforts should be made to in 
order to include QoL assessment in rou-
tine clinical practice. Engaging clinicians 
in using QoL assessments, potentially by 
means of electronic administration, as 
well as broadening the interpretation of 
their scores into the clinical field, might 
facilitate incorporation.
• Further efforts should elucidate to what 
extent QoL results are incorporated into 
management decisions, treatment rec-
ommendations, and patients’ education.
• Additional efforts should also be made 
to include QoL outcomes in clinical 
trials.
• The incorporation of QoL assessment 
into clinical and research practice has 
the potential to improve HCT outcomes.
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Fever during neutropenia is almost universal after 
a HSCT. In neutropenic HSCT recipients, clini-
cians are faced with a unique combination of two 
issues: (1) high incidence of bacterial blood-
stream infections and (2) high mortality in case 
of infections due to Gram-negative bacteria 
unless effective antibiotic treatment is provided 
promptly.
Additionally, in the absence of neutrophils 
which are responsible for most of clinical signs 
or symptoms during a localized bacterial infec-
tion (abscess formation, prominent lung infil-
trates, pyuria, etc.), fever is frequently the only 
symptom present also in these cases. On the other 
hand, fever is a highly unspecific sign, and there 
are numerous causes of fever during neutropenia 
other than bacterial infections, including (a) viral 
infections, (b) fungal infections, (c) drug reac-
tions (e.g. ATG), (d) transfusion reactions, (e) 
mucositis, (f) underlying disease, (g) engraftment 
syndrome, (h) GvHD, (i) cytokine release syn-
drome, (j) rejection and (k) haemophagocytosis.
However, since infection due to Gram- 
negative bacteria, including Pseudomonas aeru-
ginosa, can result in rapid deterioration of clinical 
conditions and death, this possibility should be 
always considered and appropriate empirical 
antibiotic therapy started while awaiting the 
results pointing to the actual cause of fever. The 
issue of prevention of fever and infections during 
neutropenia through antibiotic prophylaxis with 
fluoroquinolones has been seriously challanged 
by a worldwide increase in antibiotic resistance 
(Mikulska et al. 2018).
35.2  Initial Management of Fever 
During Neutropenia
Initial management of fever during neutropenia 
should include all the following (Freifeld et  al. 
2011; Averbuch 2013; Lehrnbecher et al. 2017).
35.2.1  Diagnostic Procedures
(a).  Two sets (1 set = 1 aerobic and 1 anaerobic bottle) 
of blood cultures
  1.  Including at least one set from the central venous 
catheter (CVC), if present
  2.  Using an aseptic methodology to reduce the risk 
of contamination
  3.  Providing adequate blood volume (20 ml in each 
bottle), since the volume of blood is essential to 
ensure optimal detection of bacteraemia or 
candidaemia
(b)  Clinical exam with particular attention to subtle 
signs of a localized infection
  4.  Signs of infection of exit/entry of CVC
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  5.  Perineal pain suggestive of an abscess
  6.  Skin or nail lesions suggestive of fungal infection
  7.  Abdominal defence or diarrhoea
  8.  Upper respiratory tract symptoms such as 
rhinorrhoea suggestive of viral respiratory 
infection
  9.  Mucosal lesions
  10.  CNS sings or symptoms (focal lesions, e.g. with 
fungal infection or bacteria abscess vs. being 
confused in severe systemic infection or viral 
encephalitis)
(c).  Any other microbiological exams based on the 
clinical presentation (e.g. sputum culture, 
pharyngonasal swab for respiratory viruses, 
urinary antigen for Legionella, CMV DNA, 
Clostridium difficile toxin, etc)
(d).  Radiological exams based on the clinical 
presentation (for suspected lung involvement, lung 
CT should be used since chest X-ray has too low 
sensitivity for detecting pneumonia in neutropenic 
patients)
35.2.2  Evaluation of the Risk 
of Clinically Severe Infection
Such an evaluation, based on comorbidities, cur-
rent clinical presentation, etc. leads to the decision 
on hospital admission and the need for close moni-
toring for sings of further clinical deterioration.
35.2.3  Evaluation of the Risk 
of Infection Due to Resistant 
Bacteria
This risk is considered high in case of:
 (a) Colonization with a resistant bacterial strain
 (b) Previous infection caused by resistant bacte-
rial strain
 (c) Local epidemiology with high incidence of 
infections caused by resistant pathogens
35.2.4  Choice of the Appropriate 
Empirical Antibiotic Therapy
It comprised the choice between escalationa and 
de-escalation strategy (see Table  35.1) and the 
subsequent choice of antibiotic agent(s). 
35.2.5  In High-Risk Patient’s 
Assessment of the Need 
for Antifungal Therapy
 (a) Assessing the risk of candidaemia in patients 
not receiving antifungal prophylaxis and pre-
senting with septic shock
 (b) Assessing the risk of invasive aspergillosis 
(IA) based on the incidence of IA (taking 
into account risk factors, mould-active pro-
phylaxis, etc.) and the results of galactoman-
nan (GM) screening or targeted testing.
Empirical antifungal therapy (adding anti-
fungal agent in patients persistently febrile 
despite broad-spectrum antibiotics) could be 
replaced by diagnostic-driven strategy based on 
the use of diagnostic tools, such as a chest com-
puted tomography scan, fungal serum markers 
(mainly GM, possibly also β-d-glucan or PCR) 
and targeted treatment following diagnosis (see 
Chap. 37).
35.3  Main Changes in the Last 
Decade and Empirical 
Therapy Modalities
The main change in the management of febrile 
neutropenia is due to an increasing rate of 
multidrug- resistant (MDR) bacteria in certain 
countries or centres, in particular Gram-negative 
rods resistant to almost all antibiotics available 
(e.g. Enterobacteriaceae resistant to third- 
generation cephalosporins  ±  piperacillin- 
tazobactam, i.e. producers of extended-spectrum 
β-lactamases [ESBLs]; Enterobacteriaceae or 
Pseudomonas aeruginosa or Acinetobacter bau-
mannii resistant to carbapenems).
35.3.1 De-escalation Strategy
Thus, it might be no longer possible to imagine a 
single empirical antibiotic regimen which would 
be appropriate for all the patients and to use a 
traditional escalation approach, which means 
changing empirical antibiotic regimen in case of 
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persistent (48–72 h) fever. Indeed, patients who 
are at high risk of infections due to resistant bac-
teria, particularly if presenting in severe clinical 
conditions, should immediately receive agents 
targeting these strains since any delay in starting 
effective antimicrobial therapy has been associ-
ated with an increased mortality (Tumbarello 
et al. 2008). Therefore, a de-escalation strategy, 
typically used in critically ill patients in intensive 
care units, has been proposed also for neutrope-
nic haematology patients (Averbuch et al. 2013).
Traditional escalation empirical therapy is 
defined as starting with piperacillin-tazobactam 
or ceftazidime or cefepime and then changing/
adding antibiotics if necessary. This approach is 
still appropriate in most of cases, especially in 
countries or centres when resistance rates are 
low among pathogens commonly causing infec-
tions in neutropenia. With this approach, car-
bapenems are used as second-line therapy in 
patients either failing the initial therapy or in 
case of a documented infection, and adding an 
aminoglycoside to a β-lactam, which has been 
shown in numerous studies as associated with 
more toxicity and no clinical advantage, is 
avoided (Averbuch et  al. 2013; Drgona et  al. 
2007). The empirical use of an antibiotic active 
against resistant Gram-positive bacteria (such as 
vancomycin) is not recommended neither as ini-
tial therapy nor in persistently febrile patients, 
unless the patient has signs or symptoms sug-
gesting a Gram-positive aetiology (e.g. skin or 
CVC involvement or pneumonia) or a docu-
mented Gram-positive infection (Freifeld et  al. 
2011; Beyar-Katz et al. 2017).
De-escalation strategy consists of starting 
with a very broad initial empirical regimen, 
chosen due to on the severity of the patient’s 
clinical presentation and the risk of infection 
due to resistant (mainly Gram-negative) bacteria 
based on individual factors for harbouring MDR 
bacteria and the local bacterial epidemiology. 
Table 35.1 The main characteristics of escalation and de-escalation strategy
Strategy Escalation De-escalation
Definition Empirical treatment active against 
susceptible Enterobacteriaceae 
and P. aeruginosa
Starting upfront an empirical coverage of MDR bacteria, 
particularly Gram-negatives, which is later (72–96 h) reduced 
(de-escalated) if a MDR pathogen is not isolated:
• Susceptible strain isolated
• No microbiological results
Antibiotics 
usually used
Monotherapy with anti- 
pseudomonal cephalosporin 
(cefepime, ceftazidime) or 
piperacillin-tazobactam
•  Carbapenem or potentially a new β-lactam such as 
ceftolozane/tazobactam or ceftazidime/avibactam (although 
none of them studied in neutropenic patients yet), to cover 
ESBL-producers and some resistant P. aeruginosa
Combinations, examples
• β-lactam + aminoglycoside




Less induction or selection of 
resistant strains (carbapenem 
sparing). Less toxicity




In case of infection due to a 
resistant Gram-negatives, 
prognosis is significantly worsened
Overuse of broad-spectrum antibiotics/combinations > high 
antibiotic pressure, particularly in case of failure to de-escalate
Who All patients, unless criteria for 
de-escalation approach are present
Patients at risk for infections due to resistant bacteria, such as:
• Colonization with a resistant pathogen
• Previous infection with a resistant pathogen
•  Centres in which resistant pathogens are frequently isolated




The key issues of de-escalation approach are (1) 
providing immediately effective treatment of a 
potentially life-threatening MDR pathogen and 
(2) reducing as much as possible the unneces-
sary use of precious broad-spectrum drugs, such 
as carbapenems, colistin, novel beta- lactams 
or anti-MRSA agents. Data from neutropenic 
cancer patients in ICU, and more recently from 
neutropenic haematopoietic stem cell transplant 
recipients, showed that de-escalation approach 
is safe and feasible (Mokart et al. 2014; Snyder 
et al. 2017; Gustinetti et al. 2018). Main char-
acteristics of escalation and de-escalation 
approach are reported in Table 35.1.
35.3.2 Antibiotic Discontinuation
Another issue of management of febrile neutrope-
nia is the length of antibiotic therapy, particularly 
in the absence of clinically or microbiologically 
 documented infection. Traditionally, antibiotic 
treatment was continued until neutrophil recov-
ery, with the aim of avoiding infection relapse. In 
the last decade, this issue has been challenged by 
IDSA and ECIL guidelines, with the latter stating 
that antibiotics can be safely discontinued after 
≥72 h of IV therapy in patients that are and have 
been haemodynamically stable since the onset of 
fever and are without fever for ≥48 h, irrespec-
tive of the granulocyte count and the expected 
duration of neutropenia. The rational for this 
recommendation was the fact that alteration of 
patient’s microbiota leads to an increased risk 
of colonization/selection of resistant pathogens, 
which might subsequently cause life-threatening 
infections.
The safety of discontinuation of empirical 
antibiotic therapy after few days of treatment, 
provided the antibiotic treatment is restarted 
immediately if case of fever reappearance, has 
been reported and demonstrated  in several studies 
(Orasch et al. 2015). Recently, the first random-
ized multicentre, open-label superiority trial was 
performed in 157 high-risk haematology patients 
with febrile neutropenia without etiological diag-
nosis. It showed that antimicrobial therapy can be 
safely discontinued after 72  h of apyrexia and 
clinical recovery, irrespective of the neutrophils 
count, and it saves exposure to antimicrobials 
(mean difference of 4.5 days of antibiotics in the 
per-protocol analyses). Of note, there were no dif-
ferences in the number of total days of fever and 
the crude mortality, and the incidence of recurrent 
fever during neutropenia and secondary infections 
was also similar in both groups (Aguilar-Guisado 
et al. 2017).
35.4  Fever Persistent Despite 
Empirical Antibiotic Therapy
Fever persistent despite empirical antibiotic ther-
apy is not an infrequent event. Patient’s general 
clinical conditions are the most important factor 
to consider.
If no signs or symptoms of clinical deterio-
ration (e.g. septic shock, confusion, worsening 
respiratory function) are present, slow response 
to antibiotic treatment should be considered, 
particularly if accompanied by improvement in 
inflammatory markers such as C-reactive pro-
tein, or procalcitonin (particularly for Gram-
negative bloodstream infections). In alternative, 
nonbacterial infections (e.g. viral) or non-
infectious causes, such as mucositis, should be 
considered. Usually, changes in antibiotic regi-
men are not necessary if clinical conditions are 
stable. Routine addition of antibiotics against 
resistant Gram-positives (glycopeptides) has 
not been shown effective (Beyar-Katz et  al. 
2017).
Results of GM or other non-invasive fungal 
tests, performed either in screening or at the onset 
of fever, should be available by day 2–3 of fever 
and should guide antifungal treatment. In selected 
patients at high risk of IA, lung CT scan may be 
performed to exclude pulmonary fungal disease. 
Empirical antifungal treatment has been intro-
duced when non-invasive diagnostic tests were 
not available and CT scan availability was 
extremely limited. When these diagnostic mea-
sures became available, pre-emptive approach 
has been shown able to provide earlier treatment 
than empirical approach (Maertens et  al. 2005) 
(see Chap. 37). Empirical antifungals might be 
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provided while awaiting the results of diagnostic 
tests or, in case of mould-active prophylaxis, the 
confirmation of adequate blood levels, but every 
effort should be made to confirm or exclude the 
presence of invasive fungal disease. Two meta- 
analyses in which  empirical treatment was com-
pared with no treatment or pre-emptive therapy 
confirmed that empirical antifungal treatment 
was associated with a lower rate of (diagnosed) 
invasive fungal diseases and higher exposure to 
antifungals but gave no significant advantage in 
terms of overall mortality (Goldberg et al. 2008; 
Fung et al. 2015). Similar results were provided 
by a randomized trial comparing empirical vs. 
pre-emptive antifungal treatment in which 30% 
of patient received autologous SCT (Cordonnier 
et al. 2009).
If clinical conditions deteriorate, usual man-
agement steps are:
 1. Aggressive diagnostic workup (repeated blood 
cultures, CT scan, BAL lavage in case of 
pneumonia, lumbar puncture in case of CNS 
symptoms, etc.)
 2. Escalation of antibacterial treatment
 3. Starting an antifungal therapy
There is no universal scheme for antibiotic 
escalation therapy, but it usually covers resis-
tant Gram-negatives (including those producing 
extended-spectrum beta-lactamases, ESBLs, 
e.g. with a carbapenem or an addition of ami-
noglycoside) and methicillin-resistant staphy-
lococci or ampicillin-resistant enterococci (e.g. 
with a vancomycin or novel agents). Coverage 
of other resistant bacteria should be based on 
the local epidemiology, the epidemiology of a 
centre where the patient was cared for before 
transplant and on patient’s past history of infec-
tions and colonization. Less frequent agents, 
such as legionella, mycobacteria, Nocardia 
and nonbacterial infections (viral, fungal and 
parasitic) should be considered in differential 
diagnosis and tested for, based on clinical pre-
sentation and patient’s past exposure. Empirical 
antifungal treatment in this setting might be 
warranted while awaiting the results of all diag-
nostic workup.
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Bloodstream infections (BSI) are the most fre-
quent bacterial infections in HSCT patients; 
they occur in 5–10% of auto-HSCT and 
20–50% of allo-HSCT patients, with higher 
rates before engraftment, and are associated 
with increased morbidity and mortality 
(Tomblyn et  al. 2009; Girmenia et  al. 2017; 
Weisser et  al. 2017; Mikulska et  al. 2018a). 
Microbiological documentation of skin and 
soft tissue infection, pneumonia, and typhlitis 
is frequently missing.
Patient-related risk factors for bacterial infec-
tions include older age, comorbidities, low func-
tional capacity, and high-risk hematological 
disease (active malignancy, aplastic anemia).
Transplant-related risk factors are specific 
to the post-HSCT period. During the early pre- 
engraftment phase, neutropenia and disrup-
tion of anatomical barriers (mucosal damage 
and vascular devices) predispose to infections 
resulting from Gram-positive cocci (GPC) and 
Gram- negative bacilli (GNB)—mainly bactere-
mia/sepsis, pneumonia, sinusitis, proctitis, and 
cellulitis. In regimens with minimal myelosup-
pression and mucosal toxicity, as with some 
non- myeloablative protocols, the risk of infec-
tion in the immediate post transplant period is 
reduced. Conversely, CBT is associated with 
slower engraftment delayed immune recon-
stitution, and higher infection risks. During 
the intermediate phase, starting at engraft-
ment (days +30 to +100), the main risk factors 
are CVC, GVHD-related organ damage and 
its treatment, and lack of immune reconstitu-
tion. Later, incompetent humoral and cellular 
immunity (resulting from GVHD, among other 
factors) predisposes to encapsulated pathogen- 
associated infections (Streptococcus pneu-
moniae and Haemophilus influenzae).
36.2  Epidemiology of Bacteremia
GNB has become an increasingly common cause 
of bacteremia. They almost equal GPC in a 
review of studies and ECIL-4 survey (2011) on 
bacteremia surveillance in European centers. A 
remarkable variation between centers was shown, 
from 85%/15% to 26%/74% GPC to GNB ratio 
(Mikulska et  al. 2014). Attribute mortality and 
TRM are usually higher in patients with GNB- 
BSI compared with GPC-BSI (Girmenia et  al. 
2017; Mikulska et al. 2018a).
Emergence of antibacterial resistance com-
plicates treatment of infections. An increase 
in infections caused by multidrug-resistant 
(MDR) bacteria (non-susceptible to ≥1 agent 
in ≥3 therapeutically relevant antimicrobial 
categories) has been observed in some centers. 
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Extensively, drug-resistant bacteria (susceptible 
to ≤2 antimicrobial categories) have also been 
reported (Averbuch et  al. 2017). Prevalence of 
resistance is influenced by local antibiotic use 
policies in prophylaxis and treatment, infection 
control measures, as well as local resistance 
patterns throughout the specific hospital and 
countrywide.
In this session, we address infections caused 
by the most frequent GPC and GNB.
36.3  Gram-Positive Infections
Coagulase-negative Staphylococcus (CoNS) is 
the most frequent etiology of BSI (Mikulska 
et al. 2014). True CoNS BSI, defined as at least 
two consecutive positive blood cultures, is usu-
ally CVC-related. Methicillin resistance is fre-
quent (>50%), prompting treatment with 
glycopeptides. The prognosis is usually good.
Staphylococcus aureus is rare, reported in 
a median 6% of HSCT patients, and its attri-
bute mortality is high (12–40%). Cefazolin 
and oxacillin are the therapeutic mainstays 
against methicillin- susceptible Staphylococci. 
Methicillin-resistant Staphylococcus aureus 
(MRSA) is frequent; these bacteria are usually 
susceptible to glycopeptides (vancomycin and 
teicoplanin). Reduced vancomycin susceptibility 
has, however, been reported (VISA). Other active 
agents include daptomycin, linezolid, and tige-
cycline. The main disadvantages of these agents 
include:
 (a) Linezolid: myelosuppression.
 (b) Daptomycin: inactivation by surfactant, it 
should not be used to treat pneumonia; 
reduced susceptibility among VISA.
 (c) Tigecycline: monotherapy for BSI is not rec-
ommended due to low blood levels. Increased 
mortality has been reported, in comparison 
with other agents for treating severe infec-
tions; a better outcome has been, however, 
reported with loading and increased daily 
dosages.
Some newer antibiotics are active against 
MRSA: ceftaroline, ceftobiprole, dalbavancin, 
oritavancin, telavancin, and tedizolid.
Enterococci cause a median 5–8% of BSI in 
HSCT patients, usually occurring later after 
HSCT, near the time of neutrophil recovery; E. 
faecium is more common than E. faecalis (Satlin 
and Walsh 2017). VRE is an increasing threat in 
some centers. Previous colonization, mucositis, 
and broad-spectrum antimicrobial exposure pre-
dispose to VRE BSI, which typically occurs in 
patients in poor clinical condition, perhaps 
explaining high associated mortality. Main treat-
ment options include linezolid and daptomycin, 
with VRE sometimes susceptible to quinupris-
tin–dalfopristin (E. faecium only), tigecycline, 
fosfomycin, tedizolid, oritavancin, dalbavancin, 
and telavancin. Reduced daptomycin susceptibil-
ity was reported among VRE; thus, increased 
dosage (>8 mg/kg/day) is recommended.
Streptococcus viridans (VS) (Freifeld et  al. 
2011) causes median 5–13% of BSI, usually 
occurring soon after HSCT (median 4  days); 
ARDS and septic shock accompany 7–39% of 
episodes. Mucositis, especially following cytara-
bine, exposure to fluoroquinolone or ceftazidime, 
antiacids, MAC, and haploidentical HSCT pre-
dispose to VS infections. VS is usually suscepti-
ble to most β-lactams used in empirical therapy 
for febrile neutropenia, with the exception of 
ceftazidime. The possibility of β-lactam-resistant 
VS infections, mainly observed after exposure to 
β-lactams or in nosocomial BSI, justifies addition 
of vancomycin in neutropenic patients with sep-
tic shock.
HSCT patients are at risk for invasive pneu-
mococcal disease (IPD), mainly bacteremia and 
pneumonia, late (median 17  months, range 
4  months to 10  years) after HSCT (Engelhard 
et  al. 2002), with a mortality rate of 13–20%. 
Predisposing factors include allo- versus auto- 
HSCT, BM versus PBSCT, hypogammaglobu-
linemia, specific antipneumococcal antibody, and 
IgG2 deficiency; memory cell defects, as in 




36.4  Gram-Negative Infections 
(Averbuch et al. 2013a, b, 2017; 
Mikulska et al. 2014, 2018a; 
Trecarichi et al. 2015;  
Girmenia et al. 2017)
GNB infecting HSCT patients include 
Enterobacteriaceae (~70%) and non- 
fermentative GNB (NFGNB, ~24%); others are 
rare. GNB infections may present with bactere-
mia, sepsis, enterocolitis, soft tissue infections, 
such as ecthyma gangrenosum (typically associ-
ated with Pseudomonas aeruginosa), and sep-
tic shock; death may occur within hours in the 
absence of appropriate supportive and antibiotic 
treatment.
Several studies report an increase in MDR- 
GNB infections in HSCT patients, leading to 
inadequate empirical therapy and increased mor-
tality. In the multinational prospective EBMT 
study, half of GNB were resistant to non- 
carbapenem β-lactams, the first-line treatment for 
febrile neutropenia; 18.5% (40% in some south-
western regions) were carbapenem-resistant 
(CR); and 35% were MDR (Averbuch et  al. 
2017). Higher rates of resistance were reported in 
allo- versus auto-HSCT patients and in the south-
eastern Europe, as compared with the northwest. 
The main risk factors for CRGNB are previous 
colonization, breakthrough on carbapenems, and 
hospitalization in an ICU.  The main Gram- 
negatives and their resistance pattern are:
36.4.1  Broad-Spectrum β-Lactamase- 
Producing Enterobacteriaceae
The main resistance mechanism to empirical 
therapy in Enterobacteriaceae is broad-spectrum 
β-lactamase production. This includes (a) 
extended-spectrum β-lactamase (ESBL), reported 
in 2–44% of Enterobacteriaceae in HSCT 
patients, and (b) AmpC enzymes, typically pro-
duced by Serratia, Providencia, Proteus, 
Citrobacter, and Enterobacter spp. These can be 
induced by non-carbapenem β-lactam treatment. 
ESBL- or AmpC-producing organisms may 
appear susceptible in  vitro to third-generation 
cephalosporins (e.g., ceftazidime) or inhibited by 
β-lactam/β-lactamase inhibitors (BLBLI: sulbac-
tam, clavulanate, tazobactam) yet still be func-
tionally resistant to these agents (Satlin and 
Walsh 2017). They are frequently fluoroquinolone- 
resistant. Carbapenems should be the preferred 
option for treating severely ill patients with 
broad-spectrum β-lactamase-producing organ-
isms. High-dose prolonged BLBLI infusion can 
be used under close clinical monitoring in certain 
stable patients infected with ESBL+ bacteria, 
susceptible in vitro to BLBLI (Perez et al. 2014; 
Gudiol et al. 2017).
36.4.2  Carbapenemase-Producing 
Enterobacteriaceae (CPE) 
(Averbuch et al. 2013a, 2017; 
Satlin and Walsh 2017;  
Bassetti et al. 2018)
The main carbapenem resistance mechanism 
in Enterobacteriaceae is production of car-
bapenemases, including Klebsiella pneumoniae 
carbapenemase (KPC), New Delhi metallo-β-
lactamase (NDM), and OXA-type enzymes. 
Among Enterobacteriaceae, carbapenem resis-
tance is more frequent in Klebsiella pneumoniae. 
Delay in appropriate therapy can explain high 
mortality (~60%) in CPE infections in the allo-
HSCT setting. CPE are frequently resistant to 
“last resource” antibiotics, e.g., fluoroquino-
lones (in 80%), amikacin or gentamicin (~40%), 
tigecycline (30%), and colistin (18%). Colistin/
polymyxin B is active against a majority of 
GNB but not Proteus, Serratia, and Providencia 
spp. Increased mortality has been demonstrated 
in some retrospective studies, in comparison 
with other appropriate regimens. Its main side 
effects include nephrotoxicity and neurotoxicity. 
Adequate dosing is important (9 million IU load-
ing dose; 4.5 million IU BID maintenance dose). 
Emergence of plasmid-associated colistin resis-
tance challenges its utility.
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Fosfomycin is in  vitro active against some 
resistant GNB. Intravenous formulation is, how-
ever, unavailable in some countries; resistance 
can develop on treatment.
Two or more active agent combinations, 
including aminoglycosides, polymyxins, tigecy-
cline, fosfomycin, and high-dose (2 g TID), pro-
longed infusion meropenem (if MIC is ≤8 mg/L), 
should be preferred in severely ill patients with 
CPE infections (Gutierrez-Gutierrez et al. 2017). 
Other treatment modalities include:
• For KPC-CPE infections:
 – TDM-guided meropenem treatment for 
more resistant bacteria (MIC >8 mg/L)
 – Double carbapenem therapy (ertape-
nem + meropenem/doripenem)
 – Ceftazidime/avibactam (also active against 
some OXA-producing GNB); resistance 
can, however, develop during treatment
 – Meropenem-vaborbactam
• For NDM-producing GNB: aztreonam + 
ceftazidime/avibactam
36.4.3  Pseudomonas aeruginosa (PA) 
(Mikulska et al. 2014;  
Averbuch et al. 2017;  
Satlin and Walsh 2017)
PA Causes 5–15% of BSI, carrying 39–79% 
mortality, especially in ICU-acquired and resis-
tant PA infections. In a multicenter Italian study, 
<40% of patients with MDR PA BSI survived 
longer than 4 months following HSCT (Girmenia 
et al. 2017). PA in HSCT patients is frequently 
resistant to fluoroquinolones, aminoglycosides, 
and β-lactams; 25–71% are MDR. As prognosis 
is poor, combination therapy, using β-lactam 
with aminoglycoside or fluoroquinolone, is fre-
quently used in treating severe PA infections, at 
least initially until the patient is stabilized. 
Nephrotoxicity is, however, a concern, and no 
survival benefit of combination therapy has 
been demonstrated by meta-analysis (Vardakas 
et  al. 2013). A high- dose extended β-lactam 
infusion regimen was associated with better sur-
vival. Ceftolozane- tazobactam was successfully 
used in severely ill patients with carbapenem-
resistant PA.
36.4.4  Other NFGNB
Other NFGNR rarely cause infections in HSCT 
patients. Stenotrophomonas maltophilia is intrinsi-
cally resistant to carbapenems and frequently resis-
tant to aminoglycosides and β-lactams. While TMP/
SMX should be considered as the primary therapeu-
tic agent, resistance has been reported, and the sul-
fonamide can be poorly tolerated. Experience with 
alternative agents, such as ticarcillin- clavulanate, 
ceftazidime, fluoroquinolones, and minocycline, is 
limited. Combination of TMP/SMX with either 
ticarcillin/clavulanate or ceftazidime can be consid-
ered in severely ill patients.
MDR Acinetobacter infections have been 
associated with 49–95% mortality rate in HSCT 
patients. These bacteria can be susceptible to 
ampicillin/sulbactam, colistin, and tigecycline. 
Combination therapy was not associated with 
decreased mortality.
36.5  Bacterial Infection 
Syndromes
36.5.1  Central Line-Associated BSI 
(CLABSI)
CVC infections should be suspected when blood 
cultures are persistently positive, at the presence 
of exit site or tunnel infection and when fever 
and chills develop during CVC flushing. This 
can be proved by a differential time to positiv-
ity of >120  min in blood cultures simultane-
ously drawn from the CVC and a vein. Catheter 
removal, in addition to systemic antimicrobial 
therapy, is recommended for tunnel or port 
pocket site infection, septic thrombosis, endo-
carditis, hemodynamic instability, persistently 
positive (>72  h) blood cultures under appropri-
ate antibiotics, and CLABSI caused by S. aureus, 
P. aeruginosa, fungi, or mycobacteria (Freifeld 
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et  al. 2011). CVC salvage can be attempted by 
antimicrobial lock.
36.5.2  Pneumonia
Bacterial pneumonia during the neutropenic 
phase is due to GNB (including PA) and GPC 
typical to this stage. Specific entities include 
Stenotrophomonas maltophilia hemorrhagic 
pneumonia, VS-associated ARDS, and nosoco-
mial legionellosis. In the late post-engraftment 
phase, IPD and Haemophilus influenzae should 
be considered. Symptoms and signs can be atypi-
cal and scarce, rapid progression can nonetheless 
occur. Hypoxemia can be the sole finding and 
should prompt chest CT; diagnostic bronchos-
copy, if feasible; and immediate antibiotic ther-
apy. Empirical therapy should reflect the history 
of colonization with resistant bacteria.
36.5.3  Diarrhea
Clostridium difficile-associated infection 
(CDI) is a typical bacterial toxin cause of diar-
rhea, occurring in 5–30% of HSCT patients 
following exposure to broad-spectrum antibi-
otics and chemotherapy. Clinical manifestation 
may paradoxically be mild. Severe complica-
tions, such as toxic megacolon and perforation, 
can, however, occur. Treatment choice is deter-
mined by the severity of CDI, patient’s ability 
to take oral treatment, and recurrence (Debast 
et al. 2014).
Bacterial diarrhea due to Shigella, Salmonella, 
Yersinia, Campylobacter spp., and enterohemor-
rhagic E. coli is rare and usually occurs in a 
community- acquired setting. Routine stool cul-
ture is, thus, recommended for patients with diar-
rhea only within 3 days of admission.
36.5.4  CNS Infections
Bacteria rarely cause brain abscess (Streptococcus 
epidermidis, Staphylococcus aureus, Klebsiella 
pneumonia) or meningoencephalitis (Listeria, 
IPD). Clinical manifestations include fever, 
headache, altered mental state, and focal neuro-
logical signs and seizures. MRI is more sensitive 
than CT in identifying brain lesions.
36.6  Improving Management 
of Bacterial Infection 
(Averbuch et al. 2013a, b;  
Satlin and Walsh 2017)
Empirical therapy for febrile neutropenia should 
be individualized using escalation/de-escalation 
approach based on local epidemiology and 
patients’ risk factors for infection with resistant 
bacteria and for complicated course. Early initia-
tion of appropriate therapy improves prognosis 
and can be achieved by:
 (a) Monitoring local department bacterial resis-
tance patterns.
 (b) Monitoring colonization with resistant bacte-
ria and empirical administration of active anti-
biotics in colonized or previously infected 
febrile neutropenic patients, such as carbapen-
ems in patients colonized with ESBL-
GNB.  Therapy streamlining, de- escalation, 
and discontinuation of unnecessary antibiotics 
should follow culture and susceptibility results.
 (c) Novel laboratory techniques (e.g., matrix- 
assisted laser desorption/ionization–time of 
flight, MALDI-TOF) that reduce the time for 
pathogen identification and antibiotic sus-
ceptibility testing.
Antibiotic therapy should be optimized in 
line with pharmacokinetic/pharmacodynamic 
principles:
 1. A loading dose, followed by prolonged or con-
tinuous infusion of time-dependent antibiotics, 
such as β-lactams, has been associated with 
lower mortality than short-term infusion.
 2. Once-daily infusion for concentration- 




 3. A loading dose, when appropriate (tigecycline 
and colistin).
36.7  Prevention of Bacterial 
Infection (Tomblyn et al. 2009; 
Tacconelli et al. 2014; 
Cordonnier et al. 2015;  
ECIL-meeting 2017)
General measures to prevent infection include 
patient’s personal hygiene, safe diet, bathing 
with chlorhexidine-impregnated washcloths, 
and use of single-patient rooms. Important 
infection control measures include standard 
precautions, especially hand hygiene, use of 
gloves and gowns when soiling is likely, and 
environmental cleaning. Multifaceted inter-
ventions should be practiced to prevent MDR 
bacteria spread, including patient’s screening 
for colonization in the epidemic setting, using 
contact precautions, isolation, and cohorting of 
colonized and/or infected patients and staff 
(this last, for CPE-colonized patients). Routine 
CPE-targeted decolonization with nonabsorb-
able oral antibiotics is not supported; it can 
select for resistance to the last treatment 
options.
Antimicrobial stewardship should aim to limit 
unnecessary antibiotic exposure and to optimize 
antimicrobial therapy, e.g., using escalation 
empirical approach (non-carbapenem monother-
apy) for stable febrile patients without previous 
MDR bacteria colonization/infection.
CLABSI prevention includes sterile insertion 
by a specialized team, avoiding femoral sites, 
chlorhexidine cleaning during use, and removal 
of unnecessary catheters.
Fluoroquinolone prophylaxis is recom-
mended in high-risk neutropenic patients with 
expected neutropenia ≥7  days (Freifeld et  al. 
2011). Meta- analysis of studies published prior 
to 2010 demonstrated significantly reduced all-
cause mortality, fewer febrile episodes, and 
reduced GNB-BSI in patients receiving prophy-
laxis (Gafter-Gvili et  al. 2012). Currently, pro-
phylaxis benefit may be less, as fluoroquinolone 
resistance rates among GNB are high (Averbuch 
et al. 2017). Meta-analysis of studies published 
during 2006–2014 does not demonstrate reduc-
tion in mortality on fluoroquinolone prophylaxis. 
The possible benefits of prophylaxis should be 
weighed against its potential harm, including 
CDI risk, side effects, and association with colo-
nization or infection with fluoroquinolone- or 
multidrug-resistant strains (Mikulska et  al. 
2018b).
Late infection prevention (>100  days post- 
HCT), targeting mainly encapsulated bacteria, 
includes:
 1. Oral prophylaxis with penicillin (or other 
agents, according to local antibiotic resistance 
patterns) in patients with cGVHD or 
hypogammaglobulinemia
 2. IVIg in patients with severe hypogammaglob-
ulinemia (serum IgG level <400 mg/dL)
 3. Vaccinations (Table 36.1; also see Chap. 29)
























DTP vaccines 6–12 1–2 3
MenC or MCV4d 6–12 2 ≥2
Men-Bd 6–12 1–6 2
aA fourth dose (6 months after the third dose) if there is 
GVHD
bIf no GVHD
cCan use combination vaccines
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Key Points
• GNB increasingly cause infections in 
HSCT patients; prognosis is frequently 
poor.
• Resistant bacteria, such as broad- 
spectrum β-lactamase-producing (mainly 
ESBL) Enterobacteriaceae, carbapene-
mase-producing Enterobacteriaceae 
(CPE), MDR Pseudomonas aeruginosa, 
and VRE, are causing an increased num-
ber of infections, leading to delay in 
appropriate therapy and increased 
mortality.
• Targeted therapy against the main resis-
tant bacteria includes:
 – Linezolid and daptomycin against 
VRE
 – Carbapenem preferred against severe 
ESBL+ infections
 – Combination therapy (colistin, ami-
noglycoside, and carbapenem if low- 
level resistance) preferred against 
severe CPE infections
 – β-Lactam with aminoglycoside or 
fluoroquinolone combination pre-
ferred for initial treatment of severe 
Pseudomonas aeruginosa infections
• Antimicrobial stewardship is aimed to 
individualize empirical approach (esca-
lation vs. de-escalation) to patients with 
suspected infection, limit unnecessary 
antibiotic use, and optimize treatment 
based on pharmacokinetic/pharmacody-
namic principles.
• Infection control is crucial to limit the 
spread of MDR pathogens.
• Fluoroquinolone prophylaxis is recom-
mended for high-risk neutropenic 
patients; its efficacy, however, can be 
reduced.
• Encapsulated bacteria (Streptococcus 
pneumoniae and Haemophilus influen-
zae) cause infections during late post-
engraftment period; preventive measures 
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Invasive fungal diseases (IFD) are frequent infec-
tious complications of HSCT. The 12 m cumula-
tive incidence approaches 8–10% in URD or 
mismatched allo-HSCT, 6% in MRD allo-HSCT, 
and less than 2% following auto-HSCT 
(Kontoyiannis et al. 2010). However, higher inci-
dences (up to 17%) have been reported in haplo- 
identical HSCT and CBT.
Classical risk periods for IFD include (a) the 
pre-engraftment period when neutropenia and 
mucosal damage are most profound, (b) the early 
post-engraftment period (days +40 to +100) 
when patients are at highest risk for acute GvHD 
and viral reactivations due to defective T-cell 
immunity, and (c) the late post-engraftment 
period (beyond day +100) complicated by 
chronic GvHD, delayed immune reconstitution, 
and occasionally secondary neutropenia. The 
Gruppo Italiano Trapianto Midollo Osseo 
(GITMO) has identified period-specific risk fac-
tors for proven and probable IFD (Girmenia et al. 
2014). The presence of a proven or probable IFD 
is an independent and strong negative predictor 
of overall mortality at 1  year after allogeneic 
HSCT.
Before the introduction of antifungal prophy-
laxis, Candida infections were prevalent in as 
many as 18–20% of HSCT recipients. However, 
the widespread use of fluconazole prophylaxis 
since the late 1990s has significantly reduced the 
incidence of systemic Candida infections and has 
decreased the transplant-related mortality sec-
ondary to Candida infections and to gut 
GvHD.  But, this successful approach has also 
resulted in an epidemiological shift from 
fluconazole- susceptible Candida albicans infec-
tions to predominantly fluconazole-resistant non- 
albicans Candida infections (including Candida 
glabrata and Candida krusei). Based on a recent 
EBMT study, the incidence of candidemia by day 
+100 has now dropped to 1.2% but remains asso-
ciated with increased NRM and lower short- and 
long-term OS (with candidemia being an inde-
pendent risk factor for NRM and OS) (Cesaro 
et al. 2018).
Over the past two decades, respiratory mould 
infections caused by Aspergillus species (and to a 
much lesser extent non-Aspergillus moulds such 
as Mucorales, Fusarium species, and some rare 
other pathogens) have become much more preva-
lent. Unlike yeasts, which are acquired through 
indwelling lines or via intestinal translocation, 
mould infections are usually acquired by inhala-
tion of airborne spores. In HSCT recipients, the 
primary lines of defence, including phagocytos-
ing alveolar macrophages and neutrophils, are 
often nonfunctional in the presence of IS drugs 
and/or corticosteroids. Hence, Aspergillus spores 
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may germinate and produce hyphae, which then 
invade blood vessels, followed by vascular occlu-
sion and infarction and dissemination to distant 
organs. The crude mortality rate of invasive 
mould disease in HSCT recipients can be as high 
as 60%.
37.2  Diagnosis of Fungal Disease
37.2.1  Mould Infections
Despite a high index of clinical suspicion, diag-
nosing invasive mould disease remains challeng-
ing. The clinical presentation in HSCT patients is 
often nonspecific and difficult to distinguish from 
non-fungal infections and even noninfectious 
complications. A diagnosis of mould disease is 
based on histopathological examination of 
infected tissue, imaging (in particular chest CT 
scan) and microbiological tests, both culture 
based and non-culture based.
Although histopathology remains the gold 
standard for making a definite diagnosis, many 
clinicians are reluctant to ask for invasive proce-
dures with biopsy in these vulnerable patients 
with underlying coagulation problems. As a 
result, the majority of invasive mould diseases 
are categorised as probable or even possible.
Culture and direct microscopic examination 
of sputum, BAL and other body fluids, and skin 
samples, using staining techniques that allow 
diagnosis on the same day (e.g. optical brighten-
ers such as calcofluor white), have been the cor-
nerstones for making a microbiological diagnosis 
of invasive mould disease. Culture has the addi-
tional advantage of allowing fungal species iden-
tification and determining antifungal 
susceptibility. Unfortunately, culture is time- 
consuming and requires considerable expertise. 
In addition, blood cultures are notoriously nega-
tive for moulds, even in disseminated disease, 
and culture from any respiratory specimen has 
only low to moderate sensitivity and predictive 
value.
The (ongoing) development of serological 
tests has been a major advance in the field 
(Maertens et  al. 2016a, b). Galactomannan 
(GM), a fungal cell wall molecule that is released 
during fungal growth, can be detected by a com-
mercial enzyme immunoassay (Bio-Rad 
Platelia™ Aspergillus EIA). Earlier studies used 
an index of ≥1.5 to define positivity. The ECIL 
guidelines now support the use of a single serum 
or plasma value of ≥0.7 or multiple (consecutive) 
values of ≥0.5 to define positivity. This lower 
cutoff permits detection of fungal infection 
before the clinico-radiological manifestations 
appear. However, improved sensitivity with the 
use of lower cutoffs comes with a loss of specific-
ity. In addition, false-positive results as well as 
false-negative results are not uncommon 
(Table  37.1) and cross-reactivity with non- 
Aspergillus moulds (including but not limited to 
Fusarium spp., Penicillium spp., Acremonium 
spp., Alternaria spp., and Histoplasma capsula-
tum) may occur, although the assay does not 
detect Mucorales. GM testing can also be applied 
to other types of specimens, including BAL fluid. 
Cutoff values of 1.0 have been recommended 
although it is likely that higher thresholds are 
needed. Recently, an index cutoff of 1.0 has also 
been suggested for analysing cerebrospinal fluid 
samples from patients with (suspected) cerebral 
aspergillosis.
Unlike GM, β-d-glucan (BDG) is a compo-
nent of the cell wall of many pathogenic fungi 
including Candida spp., Fusarium spp., and 
Pneumocystis (Maertens et  al. 2016a, b). The 
main exceptions are Mucorales and some 
Cryptococcus species. The Fungitell® assay 
(Associates of Cape Cod) has been approved by 
the US FDA and carries the European CE label 
for the presumptive diagnosis of invasive fungal 
infection. Most studies report good sensitivity, 
but specificity and positive predictive value are 
poor due to a high rate of false-positive results 
(Table  37.1), regardless of the specimen. 
However, the negative predictive value is around 
80–90%.
PCR-based methods have also been devel-
oped. Lack of standardisation has for a long time 
hampered the acceptance of these diagnostic 
assays. Fortunately, over the past decade, the 
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European Aspergillus PCR Initiative (EAPCRI) 
has made tremendous progress in standardising 
protocols for efficient DNA extraction and ampli-
fication (White et  al. 2015). Recently a lateral- 
flow device (LFD) was developed for the 
point-of-care diagnosis of invasive aspergillosis 
(Hoenigl et al. 2018); clinical validation studies 
are currently ongoing.
The sensitivity and specificity of conven-
tional radiology are too low to diagnose or to 
exclude a fungal infection. Thin-section multi-
slice CT scan nowadays is the preferred imaging 
technique; more recently, computed tomogra-
phy pulmonary angiography is rapidly gaining 
popularity as an alternative diagnostic technique 
(Stanzani et al. 2015). Nodules, with or without 
a halo sign, are suggestive of invasive mould 
disease; this ‘halo sign’ appears early in the 
course of the infection; thereafter the lesions 
become more nonspecific. Following neutrophil 
recovery, an air crescent sign may develop, usu-
ally associated with a good outcome. An 
inversed halo sign has been described as more 
suggestive of invasive mucormycosis. The 
added value of PET scan is currently being 
investigated.
37.2.2  Yeast Infections
Cryptococcal Ag assays have become very sensi-
tive and should be used where cryptococcal men-
ingitis is suspected.
Microbiologic cultures, the gold standard 
diagnostic method for invasive Candida infec-
tions and candidemia, have low sensitivity (espe-
cially for chronic disseminated candidiasis) and 
take up to 2–5  days to grow (from blood sam-
ples). The T2Candida panel is a novel, fully auto-
mated qualitative diagnostic platform for 
diagnosis of candidemia in whole blood speci-
mens with a mean time to species identification 
of less than 5 h. The negative predictive value is 
almost 100% in a population with 5–10% preva-
lence of candidemia (Mylonakis et  al. 2015). 
Unfortunately, the assay detects only five differ-
ent Candida species.
37.2.3  Pneumocystis jirovecii 
Pneumonia (PJP)
Immunofluorescence assays remain recom-
mended as the most sensitive microscopic 





Aspergillus spp., Fusarium spp., Paecilomyces spp., 
Acremonium spp., Penicillium spp., Alternaria spp., 
Histoplasma capsulatum, Blastomyces dermatitidis, 
Cryptococcus neoformans, Emmonsia spp., Wangiella 
dermatitidis,  Prototheca, Myceliophthora, Geotrichum 
capitatum, Chaetomium globosum
Pneumocystis jirovecii, Aspergillus spp., 
Fusarium spp., Histoplasma capsulatum, 
Candida spp., Acremonium spp., 
Trichosporon sp., Sporothrix schenckii, 





– Semi-synthetic β-lactam ATBa
– Multiple myeloma
–  Blood products collected using Fresenius Kabi bags
– Gluconate-containing plasma expanders
–  Flavoured ice pops/frozen desserts containing sodium 
gluconate
– Bifidobacterium spp. (gut)
– Severe mucositis or GI GvHD
– Enteral nutritional supplements
– Semi-synthetic β-lactam antibiotics
–  Human blood products, including IVIg, 
albumin, plasma, coagulation factor 
infusions, filtered through cellulose 
membranes
–  Cellulose haemodialysis/haemofiltration 
membranes
– Exposure to (surgical) gauze





– Concomitant use of mould-active antifungal agents
– Mucolytic agents
– Concomitant use of antifungal agents
aIncluding ampicillin, amoxicillin clavulanate, and piperacillin/tazobactam (although this problem seems largely abated 
compared with previous experience)
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method. Real-time PCR on BAL fluid can be 
used to rule out the diagnosis of PJP. However, a 
positive PCR test does not necessarily mean that 
the patient has PJP, since low fungal loads will be 
picked up in colonised patients. BDG positivity 
in serum can further contribute to the diagnosis, 
although a positive test result may also indicate 
other fungal infections (Alanio et al. 2016).
37.3  Prevention and Prophylaxis
37.3.1  Protective Environment 
Measures
Protective environment measures (such as the use 
of HEPA-filtered isolation rooms or the use of 
portable HEPA filters) are useful to prevent in- 
hospital acquisition of airborne fungal pathogens. 
However, many patients develop IFD during the 
outpatient follow-up period, when these isolation 
measures are not applicable.
37.3.2  Pharmacological Antifungal 
Prophylaxis
Pharmacological antifungal prophylaxis; 
updated ECIL recommendations are phase- 
specific (ECIL-5 2013).
37.3.2.1  During the (Neutropenic) 
Pre-engraftment Phase
Fluconazole (400 mg/day) is still recommended 
for centres with a low incidence of mould infec-
tions [i.e. below 5%] but only when combined 
with a mould-directed diagnostic approach (bio-
marker and/or CT scan based) or a mould- 
directed therapeutic approach (empirical 
antifungal therapy). Centres with a higher inci-
dence of mould infections are advised to adopt an 
alternative approach.
Voriconazole (400 mg/day following loading) 
failed to show a difference in fungal-free sur-
vival, overall survival, incidence of IFD, inva-
sive aspergillosis, empirical use of antifungals, 
and toxicity compared with fluconazole. When 
tested against itraconazole oral solution, vori-
conazole was superior for the composite end-
point, but the difference was driven by a lower 
use of systemic antifungals with voriconazole, 
which could be given for a longer duration than 
itraconazole, not by better efficacy. Itraconazole 
(200  mg IV q24h, followed by oral solution 
200 mg q12) provided better protection against 
invasive mould infections than fluconazole. 
However, drug toxicities and tolerability limited 
its usefulness as prophylactic agent. Therefore, 
voriconazole and itraconazole were both given a 
B-I recommendation.
Data for the echinocandins are limited to 
micafungin (50 mg IV q24h). The study compar-
ing micafungin versus fluconazole had significant 
shortcomings, including the overrepresentation of 
a low-risk population and the lack of a predefined 
workup for diagnosing IFD. Hence, prophylaxis 
with micafungin received a B-I recommendation 
for centres with a low incidence of mould infec-
tions and C-I for those with a high incidence.
The addition of aerosolised liposomal ampho-
tericin B (AmB) to fluconazole is not recom-
mended for centres with a low incidence of 
mould infections, although there is some evi-
dence to do so in higher-risk centres (B-II). IV 
liposomal AmB for prophylaxis was given a C-II 
recommendation.
Although there are no specific studies of 
posaconazole prophylaxis during the pre- 
engraftment phase, the drug (oral solution 
200 mg q8h or gastro-resistant tablet/IV formula-
tion 300  mg q24h following a loading dose of 
300 mg q12h on the first day) was given a B-II 
recommendation based on results inferred from 
data during the neutropenic phase in AML/MDS 
patients.
37.3.2.2  During the (GvHD) Post- 
engraftment Phase
Given the significantly increased risk of invasive 
mould infection during GvHD (and its associated 
high mortality), ECIL strongly recommends 
against the use of fluconazole for prophylaxis in 
patients with high-risk GvHD.  Based on the 
results of a large, double-blind study, posacon-
azole (oral solution or gastro-resistant tablet/IV 
formulation) is the drug of choice for antifungal 
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prophylaxis (AI), although no difference was 
observed in patients with chronic GvHD.
37.3.2.3  PJP Prophylaxis
Oral TMP/SMX given 2–3 times weekly is the 
drug of choice for the primary prophylaxis of PJP 
and should be given during the entire period at 
risk (from engraftment to ≥6 months and as long 
as IS is ongoing). All other drugs, including aero-
solised or IV pentamidine, atovaquone, and dap-
sone, are considered second-line alternatives 
when TMP/SMX is poorly tolerated or contrain-
dicated (Maertens et al. 2016a).
37.4  Treatment of Fungal Disease
Over the last few decades, three basic strategies 
(apart from prophylaxis) have been developed 
and investigated in clinical studies to deal with 
IFD (Mercier and Maertens 2017). For a long 
time, profound and prolonged neutropenia 
accompanied by persistent or relapsing fever 
after 5–7 days of adequate antibacterial coverage 
has been regarded as a sufficient trigger for start-
ing broad-spectrum antifungals, a strategy 
referred to as empirical antifungal therapy. This 
practice has never been supported by robust sci-
entific evidence and has important drawbacks, 
including drug-related toxicity and increased cost 
due to overtreatment. In spite of this, the empiri-
cal use of antifungals became standard of care in 
many centres. It was also endorsed by consensus 
guidelines and is relied on by centres that have 
limited or no access to radiological and myco-
logical diagnostic tools. If relying on this 
approach, ECIL guidelines recommend the use of 
caspofungin (50 mg/day following 70 mg on day 
1) or liposomal amphotericin B at 3 mg/kg (both 
have an AI recommendation).
A diagnostic-driven approach (also called 
pre-emptive) has been advocated by some centres 
and guidelines following recent improvements in 
diagnostic techniques. The aim is to start antifun-
gal therapy in at-risk patients only when they 
present with an early marker of fungal infections, 
such as a positive GM, BDG, or PCR screening 
assay, or a suggestive lesion on imaging. 
Unfortunately, such a strategy is restricted to cen-
tres that perform non-culture-based testing twice 
weekly and readily have access to chest CT scan 
and other imaging modalities.
Directed antifungal treatment is used for 
patients with documented fungal disease, either 
proven or probable (Table 37.2).
• Voriconazole and isavuconazole are recom-
mended as the first-line treatment for invasive 
aspergillosis, including cerebral aspergillosis 
(Tissot et al. 2017). In a randomised clinical 
trial, voriconazole and isavuconazole had the 
same efficacy (all-cause mortality at day 42 
around 20%), although isavuconazole has a 
better toxicity profile (including hepatotoxic-
ity) and somewhat fewer drug-drug interac-
tions compared to voriconazole (Maertens 
et al. 2016c). The upfront combination of anti-
fungals with different mechanisms of action 
(e.g. an azole plus an echinocandin) is not rec-
ommended because superiority over mono-
therapy could not be demonstrated in a recent 
trial (Marr et  al. 2015). Liposomal AMB at 
3  mg/kg is the recommended alternative for 
primary therapy if these azoles cannot be used 
due to intolerance, drug interactions, prior 
exposure to broad-spectrum azoles (e.g. pro-
phylaxis), or documented azole resistance 
(Resendiz Sharpe et  al. 2018), an emerging 
problem in some European centres. For sal-
vage therapy, the global response is around 
40%, irrespective of the antifungal used. 
Treatment duration is typically between 6 and 
12 weeks, followed by secondary prophylaxis 
in patients with ongoing IS therapy. During 
the first week of treatment, pulmonary lesions 
can grow on imaging; this is in line with the 
normal kinetics of the disease and does not 
correlate with a poor outcome. When elevated 
at baseline, reduction in serum GM correlates 
with treatment response.
• Treatment of mucormycosis includes control of 
the underlying condition, surgical debridement 
(often destructive), and antifungal therapy. At 
present, lipid-based formulations of AmB (at 
doses of 5–10 mg/kg) are the first- line therapy 
of choice (Tissot et  al. 2017; Cornely et  al. 
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2014). Both posaconazole and isavuconazole 
can be used for oral outpatient therapy follow-
ing initial stabilisation of the disease.
• Hyalohyphomycosis constitutes a hetero-
geneous group of fungi, including (but 
not limited to) Fusarium, Scedosporium, 
Acremonium, and Scopulariopsis species. 
Clinical manifestations range from colonisa-
tion to localised infections to acute invasive 
and/or disseminated disease. First-line ther-
apy of fusariosis should include voriconazole 
and surgical debridement where possible; 
posaconazole can be used as salvage treat-
ment. Voriconazole is also the recommended 
the first-line treatment of Scedosporium 
infections (except for Lomentospora pro-
lificans, previously named S. prolificans, for 
which there is no standard treatment avail-
able). The optimal antifungal treatment has 
not been established for Acremonium spp., 
Scopulariopsis spp., and other hyalohypho-
mycosis (Tortorano et al. 2014).
• Echinocandins are the drugs of choice for 
the first-line therapy of invasive candidia-
sis/candidemia, followed by a step-down 
approach in clinically stable patients upon 
receipt of the species identification and anti-
fungal susceptibility testing results (Andes 
et  al. 2012). Catheter removal is strongly 
recommended in patients with candidemia or 
with C. parapsilosis bloodstream infection. 
Treatment duration typically is 14 days after 
the last positive blood culture. Of note, echi-
nocandin resistance is on the rise (particu-
larly for C. glabrata), and recent outbreaks 
of multiresistant C. auris infections have 
been reported (Lamoth and Kontoyiannis 
2018).
• High-dose trimethoprim/sulfamethoxazole 
is the treatment of choice for patients with 
documented PJP; the combination of pri-
maquine plus clindamycin is the preferred 
alternative. Treatment duration typically is 
3 weeks, and secondary anti-PJP prophylaxis 
Table 37.2 ECIL-6 guidelines for the first-line antifungal treatment of IA and mucormycosis in HSCT patients
Grade Comments
Invasive aspergillosis
Voriconazole AI Daily adult dose 2 × 6 mg/kg on day 1 followed by 
2 × 4 mg/kg (initiation oral therapy: CIII)
Need for therapeutic drug monitoring
Check for drug-drug interactions
Isavuconazole AI Adult dose 200 mg t.i.d. for 2 days, thereafter 200 mg 
daily
As effective as voriconazole but better tolerated
Liposomal amphotericin B BI Daily adult dose, 3 mg/kg
Amphotericin B lipid complex BII Daily adult dose, 5 mg/kg




Combination anidulafungin + voriconazole CI
Other combinations CIII
Recommendation against the use of 
amphotericin B deoxycholate
AI Less effective and more toxic
Invasive mucormycosisa
Amphotericin B deoxycholate CII
Liposomal amphotericin B BII Daily adult dose, 5 mg/kg. Liposomal AmB should be 
preferred in CNS infection and/or renal failure
Amphotericin B lipid complex BII
Amphotericin B colloidal dispersion CII
Posaconazole CIII No data to support its use as first-line treatment
Combination therapy CIII
aManagement of mucormycosis includes antifungal therapy, surgery, and control of the underlying condition
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is indicated thereafter. The administration of 
 glucocorticoids must be decided on a case-by-
case basis (Maschmeyer et al. 2016).
• Of note, uncertainty about exposure and drug 
interactions is common when using azole anti-
fungals. Therapeutic drug monitoring for vori-
conazole (plasma target 1–6  mg/L for 
prophylaxis and treatment) and posaconazole 
(plasma target >0.7  mg/L for prophylaxis; 
>1  mg/L for treatment) is therefore recom-
mended (ECIL-6 guidelines).
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Key Points
• Aspergillus, Candida, and Pneumocystis 
jirovecii are the cause of almost 90% of 
the invasive fungal diseases following 
HSCT.  Most infections are diagnosed 
post-engraftment during episodes of 
acute and/or chronic GvHD.
• Chest and sinus CT scan and non- invasive 
mycological tools (serology, PCR) are 
crucial for making an early diagnosis.
• Antifungal prophylaxis, targeting yeast 
and/or mould infections depending on 
the post transplant risk period, is highly 
recommended. TMP/SMX remains the 
drug of choice for preventing PJP.
• Echinocandins are the preferred first-
line therapy for invasive Candida infec-
tions and candidemia. Voriconazole or 
isavuconazole is the recommended first-
line options for invasive aspergillosis, 
whereas lipid-based formulations of 
AmB are the recommended first-line 
option for mucormycosis.
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38.1  Herpes Viruses
38.1.1  Cytomegalovirus (CMV)
38.1.1.1  Clinical Symptoms
CMV can cause symptoms from almost any 
organ as well as unspecific symptoms such as 
fever, malaise, and bone marrow suppression 
in stem cell transplant patients. However, the 
most important clinical entities in allo-HSCT 
patients are pneumonia, gastroenteritis, and 
retinitis.
The likelihood for symptomatic infection is 
much higher after allo-HSCT compared to auto- 
HSCT.  Being CMV seropositive (CMV (+)) is 
also associated with decreased OS after allo- 
HSCT as is the use of a CMV (+) donor to a 
CMV-seronegative (CMV (−)) patient.
In patients undergoing MAC allo-HSCT, the 
use of a CMV (−) donor to a CMV (+) patient has 
been associated with an increased risk for NRM 
and decreased OS.  In addition, proof of CMV 
replication is associated with increased NRM, 
while the effect on the risk for leukemia relapse is 
controversial.
38.1.1.2  Diagnostics
CMV antibody status should be determined pre-
transplant in all patients undergoing HSCT and in 
allogeneic stem cell donors.
Allo-HSCT patients should be monitored 
weekly for CMV replication with a sensitive 
diagnostic technique at least the first 3  months 
after HSCT. Patients with GVHD and those with 
documented CMV replication should be moni-
tored longer. There is no need to routinely moni-
tor patients after autologous HSCT.
The most commonly used technique is qPCR, 
but also the so-called pp65 antigenemia assay 
and other tests detecting CMV nucleic acids can 
be used. Recently tests detecting CMV-specific 
T-cells have become available, but further evalu-
ation of these tests’ usefulness in routine care is 
necessary.
To diagnose CMV disease, it is important to 
combine symptoms and signs with documenta-
tion of the presence of CMV in affected tissue. 
An exception is CMV retinitis where ophthalmo-
logic findings are characteristic although to detect 
CMV in vitreous fluid can be helpful. Established 
techniques for detection of CMV in tissue are 
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histopathology, immunohistochemistry, and 
DNA hybridization. High levels of CMV DNA in 
BAL are associated with CMV pneumonia, while 
its absence almost excludes CMV pneumonia. 
PCR in CSF supports the diagnosis of CMV 
encephalitis. For other end-organ diseases, qPCR 
needs additional study.
38.1.1.3  Prophylaxis
Letermovir has been shown in a placebo- 
controlled randomized trial to decrease the risk 
for clinically significant CMV infection (need for 
preemptive antiviral therapy and/or CMV dis-
ease) and also decrease all-cause mortality in 
CMV (+) patients.
Ganciclovir can reduce the risk for CMV dis-
ease but is associated with significant toxicity.
High-dose acyclovir/valaciclovir can reduce 
the risk for CMV replication.
The data regarding prophylactic Ig is conflict-
ing and its use is currently not recommended.
38.1.1.4  Treatment
Ganciclovir, valganciclovir, and foscarnet have 
all been shown to be effective to prevent develop-
ment of CMV disease in allo-HSCT recipients 
when used for so-called preemptive therapy 
based on detection of CMV in blood. Their effi-
cacy is similar, so the choice should be based on 
the risk for side effects and practical aspects.
It is not possible to give a recommendation on 
what CMV DNA level preemptive therapy should 
be initiated since this depends on patient factors, 
the material used for monitoring (plasma/whole 
blood), and the performance of the assay used.
Therapy is usually given for at least 2 weeks, 
but longer therapy courses might be needed. 
Second episodes of CMV replication are com-
mon, and second-line therapy can be given with 
either the same or other antiviral drugs mentioned 
above.
Ganciclovir (valganciclovir) and foscarnet are 
the most used drugs for CMV disease. The addi-
tion of high-dose Ig for treatment of CMV pneu-
monia has been commonly used, but the data 
supporting this combination is limited. There is 
no data supporting the addition of Ig to antiviral 
treatment for other types of CMV disease. 
Cidofovir can be considered as failure therapy. 
The duration of therapy has to be decided on a 
case-by-case basis, but normally longer therapy 
is needed compared to preemptive therapy 
(6–8 weeks).
Cidofovir is also a possibility for second- or 
third-line antiviral therapy. New antiviral drugs 
are in development but have not been proven effi-
cacious on this indication. Leflunomide and arte-
sunate have been tested, but data supporting their 
use is very limited.
38.1.1.5  Cellular Immunotherapy
Several groups have tried to prevent or treat CMV 
infection and disease following allo-HSCT by 
the transfer of CMV-specific T-cells. The T-cell 
lines and clones specific for CMV were mostly 
derived from the HSC donor but in some studies 
also from a third-party donor or even patient- 
derived CMV-specific T-cells obtained from the 
patient prior to conditioning therapy.
New strategies were applied to select CMV- 
specific T-cell without long-term in  vitro cul-
ture. Thus, techniques like the cytokine capture 
assay combined with the Miltenyi CliniMACS 
system or tetramers, pentamers, or streptamers 
were applied to generate CMV-specific T-cells 
for prophylactic or therapeutic transfer. The 
transfer of these cells was shown to reconsti-
tute virus- specific T-cell immunity. When given 
therapeutically to patients with chemotherapy-
refractory CMV infection, a drop in the viral load 
after an increase in the number of CMV-specific 
T-cells could be documented. In patients with 
chemotherapy- refractory CMV infection post- 
HSCT, adoptive T-cell therapy is a valid thera-
peutic option.
The efficacy in patients receiving high-dose 
(≥2 mg/kg) corticosteroids is likely to be low.
38.1.2  HHV-6
38.1.2.1  Clinical Symptoms
HHV-6A primary infection has so far not been 
associated with specific symptoms.
HHV-6B primary infection is the main cause 
of exanthema subitum in young children. It has 
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also been associated with febrile seizures. Almost 
all children are infected by the age of 2 years.
HHV-6B is the main cause of viral encepha-
litis after allo-HSCT, but HHV-6A has also 
been documented. Patients undergoing CBT 
are at an increased risk. Other symptoms sug-
gested to be associated with HHV-6 are bone 
marrow suppression, pneumonia, and acute 
GVHD.
38.1.2.2  Diagnostics
Serology is not helpful. HHV-6 DNA can be ana-
lyzed in blood by qPCR. The usefulness of moni-
toring is not established. HHV-6 can be integrated 
in germline, and these individuals are strongly 
positive in qPCR, and this is not a proof of viral 
replication.
MRI is recommended for diagnosis of HHV-6 
encephalitis. The typical finding is of limbic 
encephalitis, but other patterns are also seen. 
HHV-6 DNA is usually positive in the CSF in 
patients with encephalitis.
38.1.2.3  Prophylaxis
Foscarnet has been used but its usefulness is not 
established.
38.1.2.4  Treatment
Either ganciclovir or foscarnet can be used for 
treatment of HHV-6 encephalitis. There is no 
established treatment for HHV-6 infection or 
patients with other suspected HHV-6-associated 
complications. Cellular immunotherapy was only 
performed in a few patients.
38.1.3  HHV-7
38.1.3.1  Clinical Symptoms
HHV-7 primary infection in young children occa-
sionally causes exanthema subitum (roseola) and 
rarely status epilepticus with fever. Nearly all 
children are infected with HHV-7 by the age of 
5 years.
HHV-7 detection after HSCT is relatively 
infrequent, with rare cases in which HHV-7 has 
been associated with CNS disease (encephalitis, 
myelitis).
The risk of infection in HSCT patients: 
allo  >  auto, TBI-based  >  chemo-based, 
children > adults.
Reactivation of HHV-7 occurs in about 10% 
of patients after allo-HSCT.
38.1.3.2  Diagnostics
HHV-7 DNA by qPCR. HHV-7 might be a cofac-




Infection by HHV-7 does not require specific 
treatment.
38.1.4  HHV-8
38.1.4.1  Clinical Symptoms
HHV-8 (KSHV, Kaposi’s sarcoma-associated 
herpesvirus) is the cause of Kaposi’s sarcoma 
(KS), primary effusion lymphoma, or multicen-
tric Castleman’s disease.
The prevalence of KSHV infection is high in 
Africa and parts of the Amazon basin. KS is very 
rare after HSCT (only 14 cases are described).
Fever and marrow aplasia with plasmacytosis 
after HSCT can occur. Skin involvement is the 
dominant clinical presentation in adults, while 
pediatric cases have visceral involvement.
38.1.4.2  Diagnostics
Detection of HHV-8 DNA by qPCR. KS can be 
clinically defined on the basis of characteristic 





In disease limited to the skin only, surgical exci-
sion or electrochemotherapy is the most prefera-
ble approach.
For visceral or disseminated disease, possible 
options include the use of interferon alpha or 
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 chemotherapy. The use of antiviral treatment is 
considered without benefit. Imatinib showed 
promising results in HIV-related KS patients.
38.1.5  EBV
38.1.5.1  Clinical Symptoms
Syndromes caused by primary EBV infection 
include infectious mononucleosis, chronic active 
EBV infection, and X-linked lymphoproliferative 
syndrome.
In HCT patients EBV can cause life- 
threatening complication: post transplant lym-
phoproliferative disorder (PTLD) or end-organ 
diseases such as encephalitis/myelitis, pneumo-
nia, or hepatitis. Details on EBV-PTLD are pre-
sented in Chap. 45.
Donor EBV seropositivity contributes also to 
the risk of cGVHD in patients with acute 
leukemia.
38.1.5.2  Diagnostics
All allo-HCT patients and donors should be 
tested for EBV Ab before HCT.
38.1.5.3  Prophylaxis
Since EBV sero-mismatch is a risk factor for 
PTLD, the selection of an EBV-matched donor, if 
possible, might be beneficial.
As EBV-PTLD after HCT is usually of donor 
origin and EBV might be transmitted with the 
graft, the risk of EBV-PTLD is higher when the 
donor is seropositive.
38.1.5.4  Treatment
Most EBV reactivations are subclinical and 
require no therapy. Details on treatment of EBV- 
PTLD are presented in Chap. 45.
38.1.6  Herpes Simplex Virus (HSV)
38.1.6.1  Clinical Symptoms
HSV reactivation can be caused by either type 1 
or 2 and is usually associated with localized 
mucocutaneous disease in the orofacial region 
(85–90%) and less frequently in the esophageal 
and genital area. Uncommon manifestations are 
pneumonia, hepatitis, meningitis (HSV-2), and 
encephalitis (HSV-1).
38.1.6.2  Diagnostics
All patients should be tested for HSV antibod-
ies before HSCT. The diagnosis of mucocuta-
neous HSV disease is suspected on clinical 
grounds, and the diagnosis is usually verified 
by PCR. PCR in CSF is the technique of choice 
for the diagnosis of HSV meningitis and 
encephalitis.
38.1.6.3  Prophylaxis
Primary HSV infection in HSCT patients is 
unusual, and antiviral drug prophylaxis is thus 
not recommended in HSV-seronegative patients 
after HSCT (but might be needed against VZV; 
see below).
HSV-seropositive patients undergoing allo- 
HSCT should receive antiviral drug prophylaxis. 
IV acyclovir 250 mg/m2 or 5 mg/kg q12h, oral 
acyclovir 3 × 200 to 2 × 800 mg/day, oral valaci-
clovir 2 × 500 mg/day, or famciclovir 2 × 500 mg/
day can be used.
The duration depends on if also prophylaxis 
against VZV (see below) is indicated but should 
be given for at least 4 weeks after HSCT in VZV- 
seronegative patients.
38.1.6.4  Treatment
IV acyclovir 250  mg/m2 or 5  mg/kg q8h for 
7–10  days is the therapy of choice for severe 
mucocutaneous or visceral HSV disease.
Oral acyclovir, from 5 × 200 to 5 × 400 mg/
day, valaciclovir 2 × 500 mg/day, or famciclovir 
2  ×  500  mg/day for 10  days are considered as 
alternatives for less serious manifestations of 
HSV disease.
For HSV pneumonia or HSV meningitis and 
encephalitis, IV acyclovir 500 mg/m2 or 10 mg/
kg q8h for at least 14–21 days is recommended.
HSV resistance occurs in approximately 
5–15% of patients and is mediated through muta-
tion in the HSV thymidine kinase. Foscarnet or 
cidofovir are second-line therapy.
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38.1.7  Varicella-Zoster Virus (VZV)
38.1.7.1  Clinical Symptoms
Primary infection (varicella) occurs rarely after 
HSCT, but it might have severe clinical course.
Reactivation as herpes zoster is frequently 
complicated by prolonged neuralgia and is com-
mon unless long-term antiviral prophylaxis is 
given.
Clinically, severe symptoms include dissemi-
nated infection similar to varicella, visceral dis-
ease presenting as severe abdominal pain or acute 
hepatitis, and rarely encephalitis, retinal necrosis, 
or pneumonitis.
38.1.7.2  Diagnostics
Patients should be tested for VZV antibodies 
before HSCT.  The rash in clinical varicella or 
zoster is usually characteristic. However, in some 
cases disseminated HSV can have a similar 
appearance. PCR on vesicular material for VZV 
and HSV can differentiate.
Visceral VZV disease can occur without rash 
and then PCR on blood is diagnostic.
38.1.7.3  Prophylaxis
VZV-seropositive patients should be given anti-
viral prophylaxis for at least 12 months or up to 
the end of IS therapy.
Prophylaxis can be given with acyclovir 
(2 × 800 mg; in children 2 × 20 mg/kg) or valacy-
clovir (2 × 500 mg).
In seronegative patients exposed to VZV, post-
exposure prophylaxis with acyclovir or valacy-
clovir is recommended.
Prophylaxis should be started as soon as possi-
ble and continued until 21 days after exposition.
38.1.7.4  Treatment
First-line therapy for varicella, disseminated zos-
ter, and visceral disease is acyclovir 3 × 500 mg/
m2/d IV.
For localized or limited infections, oral valaci-
clovir (3 × 1000 mg), acyclovir (5 × 800 mg; in 
children 4  ×  20  mg/kg), or famciclovir 
(3 × 500 mg) can be given until the lesion crusts 
over (usually 7–10 days).
In case of resistance to acyclovir, second-line 
therapies are foscarnet (60 mg/kg q12h) or cido-
fovir (5 mg/kg weekly, together with probenecid 
and hydration).
VZIg is not recommended. Only case reports 
exist on cellular therapy for VZV infection.
38.2  Adenovirus (ADV)
38.2.1  Clinical Symptoms
ADV is transmitted mainly from person to per-
son; however it can persist in epithelial cells and 
lymphoid tissue and reactivate during IS. Children 
are more frequently affected than adults.
The spectrum of ADV-associated disease in 
HSCT patients ranges from mild gastroenteric or 
respiratory symptoms to severe hemorrhagic 
enteritis, hemorrhagic cystitis, nephritis, hepati-
tis, pneumonia, encephalitis, myocarditis, and 
multiple organ involvement.
Risk factors for ADV infection/disease include 
haploidentical or URD graft, CBT, TCD, GVHD 
III–IV, severe lymphopenia, and treatment with 
alemtuzumab.
38.2.2  Diagnostics
ADV-DNA by qPCR.  Monitoring with qPCR 
of ADV viremia in PB is recommended on at 
least weekly basis for patients with at least one 
risk factor. qPCR is also recommended in case 
of clinical suspicion of ADV infection/
disease.
38.2.3  Prophylaxis
Non-pharmacological prophylaxis is mandatory: 
strict isolation and hygienic measures in patients 
shedding the virus are absolutely necessary to 
prevent horizontal transmission and nosocomial 
outbreaks.
Prophylactic antiviral therapy with available 




Patients especially children, with increasing viral 
load and at least one risk factor, should receive 
preemptive antiviral treatment with cidofovir 
3–5 mg/kg/week for 2–3 weeks and, thereafter, 
every other week.
Patients with probable or proven ADV disease 
should be treated with IV cidofovir (5  mg/kg 
weekly for at least three doses; thereafter, every 
other week), together with hyperhydration and 
oral probenecid.
Ribavirin is not recommended for 
ADV. Donor-derived ADV-specific CTLs are an 
option for clinically non-responding patients. 
Oral brincidofovir 2 mg/kg twice weekly might 
be obtained for compassionate use.
38.3  Respiratory Viruses
38.3.1  Influenza
38.3.1.1  Clinical Symptoms
Influenza is a yearly occurring respiratory viral 
infection with outbreaks of different sizes 
depending on the circulating strain.
Influenza can be a very severe infection in 
HSCT recipients. The risk for lower tract disease 
(LTD) has been reported to be as high as 33%, 
and mortality has varied in different reports 
between 0 and 15%.
The risk for LTD is higher when occurring just 
prior to or during conditioning, very early after 
HSCT, with viruses resistant to neuraminidase 
inhibitors and with new viral strains such as the 
recent H1N1 (“swine flu”).
Symptoms are similar as in the immune- 
competent individual. Respiratory symptoms vary 
from very mild to life-threatening symptoms. GI 
symptoms and CNS symptoms can also occur. 
Secondary bacterial infections are not uncommon.
38.3.1.2  Diagnostics
Several commercial tests detecting either nucleic 
acid or influenza antigens are available. Since the 
symptoms frequently are uncharacteristic, multi-
plex tests detecting different respiratory viruses 
are frequently used.
38.3.1.3  Prophylaxis
The most important prophylactic measure is vac-
cination, which is recommended yearly to all 
HSCT recipients. The efficacy of the vaccine var-
ies from season to season depending on the fit-
ness of the strains used in preparing the vaccine 
to the circulating strains.
The immune response to vaccination is better 
when given at least 6 months after HSCT although 
vaccination can be considered from 3  months 
after HSCT in outbreak situations. A second dose 
of vaccine can be considered.
Antiviral prophylaxis is not generally recom-
mended but can be considered in patients exposed 
to an infected individual.
38.3.1.4  Treatment
Standard therapy is with neuraminidase inhibi-
tors mainly oseltamivir or zanamivir although no 
study has shown efficacy specifically in HSCT 
recipients.
It should be recognized that the normally rec-
ommended duration of 5 days often is too short 
since viral excretion might continue for a long 
time. Resistance to oseltamivir is not rare 
although variable with the strain circulating in 
that particular season.
38.3.2  Other Community-Acquired 
Respiratory Viruses (CARVs)
38.3.2.1  Clinical Symptoms
Infections with CARVs including respiratory 
syncytial virus (RSV), parainfluenza viruses 
(PIV), metapneumovirus, rhinoviruses, and coro-
naviruses are very common in HSCT recipients.
Most infections are mild causing only upper 
respiratory symptoms but LTD occurs. 
Importantly CARV infections occurring before 
start of conditioning have been associated with 
severe symptoms and increased NRM, and there-
fore deferring the start of conditioning shall be 
considered at least in symptomatic patients.
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38.3.2.2  Diagnostics
Multiplex PCR testing of different CARVs is 
today the most used technique.
38.3.2.3  Prophylaxis
The only available measure is to avoid nosoco-
mial spread of these infections.
38.3.2.4  Treatment
No therapy of a CARV has been proven effica-
cious in controlled trials.
Ribavirin either given as inhalation or system-
ically has been suggested to reduce the risk for 
progression of upper respiratory tract RSV infec-
tion to LTD and possibly to reduce mortality in 
RSV pneumonia. No licensed therapy is available 
for any other CARV.
38.4  Polyomaviruses
38.4.1  Polyoma JCV
38.4.1.1  Clinical Symptoms
Reactivation of the ubiquitous, neurotropic John 
Cunningham polyomavirus (JCV) may cause 
PML, a rare, opportunistic, and severe disease of 
the CNS.
PML awareness increased following the 
introduction of new immunomodulatory or IS 
treatments with natalizumab, rituximab, efali-
zumab, infliximab, brentuximab, fingolimod, 
dimethyl fumarate, azathioprine, tacrolimus, 
and MMF.
38.4.1.2  Diagnostics
JCV-DNA by PCR, especially in CSF (also mul-
tiplex PCR).
The new option is high-resolution melting 
analysis (PCR-HRM) for diagnosis of JCV in 
patients with PML.
Profound suppression in cellular immunity 





No specific treatment is currently available.
The application of G-CSF may facili-
tate immune reconstitution and JCV clear-
ance in the CSF.  BKV-specific CTLs might 
demonstrate anti-JCV activity due to virus 
homology.
38.4.2  BKV
BKV (See Chap. 51: Hemorrhagic Cystitis and 
Renal Dysfunction)
38.5  Hepatotropic Viruses
38.5.1  Hepatitis A Virus (HAV)
38.5.1.1  Clinical Symptoms
Enteric transmission via person-to-person con-
tact is the predominant way of spreading.
Infection with HAV in HSCT recipients can 
increase the risk of SOS/VOD, and HAV has 
been associated with aplastic anemia.
Due to the scarcity of chronic HAV infection, 
blood products and HSCT donors are not rou-
tinely tested for HAV.
38.5.1.2  Diagnostics
PCR is the preferred method in HSCT setting.
Liver function tests (LFT) should be per-
formed in donors before HSC harvesting. Donors 
with abnormal LFT should be tested for anti- 
HAV- IgM.  If HAV is detected, donation should 
be delayed until HAV-RNA is no longer detect-
able in the donor.
38.5.1.3  Prophylaxis
HSCT is not recommended if the donor or the 
recipient is viremic for HAV because of an 
increased risk of SOS/VOD.
Vaccination should be considered in HAV- 





38.5.2  Hepatitis B Virus (HBV)
38.5.2.1  Clinical Symptoms
After primary infection, even in case of HBsAg 
seroconversion, HBV probably persists lifelong 
in the nucleus of hepatocytes.
HBV can reactivate after treatment-induced 
loss of immune control.
Hepatitis, including cases of fulminant hepatic 
failure, typically occurs after immune system 
reconstitution, de novo recognition, and destruc-
tion of HBV-infected hepatocytes.
Fibrosing cholestatic hepatitis can be a conse-
quence of HBV reactivation. The case-fatality 
rate of HBV reactivation is high in patients with 
hematological malignancy.
38.5.2.2  Diagnostics
All donors and recipients must be screened for 
anti-HBsAg, anti-HBc, and anti-HBs and HBV- 
DNA if anti-HBc is detected.
38.5.2.3  Prophylaxis
Antiviral prophylaxis should be given to anti- 
HBc- positive patients and those receiving grafts 
from HBV-infected donors. Tenofovir or enteca-
vir are the drugs of choice.
Vaccination of anti-HBc-negative and anti- 
HBs- negative patients before and after HSCT is 
recommended. Double vaccine doses may be 
required to achieve an anti-HBs response in immu-
nocompromised patients (0–1–2–6 months).
Vaccination of anti-HBc-negative and anti- HBs- 
negative stem cell donors before HSCT harvesting 
should be considered; an accelerated single-dose 
3-week (0–10–21 days) schedule may be an alterna-
tive to the conventional 6-month protocols.
38.5.2.4  Treatment
Indication for treatment includes all HBsAg- 
positive patients. Vaccination and the addition of 
hepatitis B immune globulin can be considered in 
this setting.
Antiviral treatment should be started with the 
beginning of IST. Tenofovir or entecavir are the 
drugs of choice. The treatment should be contin-
ued 1 year after withdrawal of IST, longer in 
recipients with cGVHD and patients exposed to 
depleting Ab.
38.5.3  Hepatitis C Virus (HCV)
38.5.3.1  Clinical Symptoms
Assessment of liver fibrosis in HCV-RNA- 
positive recipients is recommended, as close 
monitoring is essential in patients with known 
underlying fibrosis. Liver fibrosis is a risk factor 
for SOS/VOD and drug toxicity.
The risk of acute flare-ups is higher in patients 
on rituximab-containing treatment regimens.
Cirrhosis and a worse outcome have been 
clearly documented after HSCT.
38.5.3.2  Diagnostics
Close monitoring of LFT and HCV-RNA is rec-
ommended in infected patients.
38.5.3.3  Prophylaxis
A HCV-RNA-positive donor could be consid-
ered, if other donor options are considered 
inferior. In this case, the donor should be rap-
idly evaluated by a hepatologist, and treatment 
with directly acting antivirals should be 
considered.
The presence of HCV-RNA positive in the 
recipient does not constitute a contraindication 
for HSCT, but antiviral therapy should be consid-
ered if it is possible to postpone the HSCT to 
allow completion of a treatment course.
38.5.3.4  Treatment
Antiviral treatment should be considered for all 
HCV-RNA-positive hematological patients, once 
the hematological disease has been brought under 
control. This should be done in consultation with 
an expert hepatologist.
38.5.4  Hepatitis E Virus (HEV)
38.5.4.1  Clinical Symptoms
HEV exists in at least four different subtypes that 
can spread either through water, undercooked 
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food, or blood transfusions. The main source of 
spread varies between different parts of the world 
with infected water being the most common route 
in resource-poor areas. In other areas the most 
common route of spread is via undercooked food 
produced from infected animals.
HEV infection in HSCT recipients is usually 
mildly symptomatic although acute hepatitis with 
jaundice has been reported and also fatal infec-
tions in pregnant women.
The probably more important clinical picture 
in HSCT recipients is chronic hepatitis since 
rapid progression to cirrhosis has been reported 
in IS patients.
38.5.4.2  Diagnostics
Serology to detect previously infected patients or 




Ribavirin has been suggested as a treatment for 
chronic infection based on case reports and small 
case series. However, no controlled data exists.
38.6  Norovirus
38.6.1  Clinical Symptoms
Noroviruses are the most common cause of food-
borne disease and acute nonbacterial gastroen-
teritis worldwide.
Its prevalence was 2% in adults and up to 22% 
among pediatric transplant recipients with diar-
rhea, requiring hospitalization in 55% and ICU 
admission in 27%. Recurrence rate 29%.
Risk factors: second HSCT, intestinal GVHD, 
children.
Norovirus can cause severe, prolonged disease 
complicated by enteritis, fever, recurrent hospital-
izations for dehydration, chronic diarrhea, acute 
renal failure, weight loss, malnutrition, pneumato-
sis intestinalis, peritonitis, secondary bacteremia, 
and death.
38.6.2  Diagnostics
Viral RNA by RT-PCT in the stool.
38.6.3  Prophylaxis
Non-pharmacological prophylaxis is mandatory: 
strict isolation and hygiene measures in patients 
shedding the virus are absolutely necessary to 
prevent horizontal transmission and nosocomial 
outbreaks.
38.6.4  Treatment
Symptomatic. Some reports indicate oral human 
immunoglobulin therapy. Specific therapies are 
not available.
38.7  Zika Virus (ZIKV)
38.7.1  Clinical Symptoms
ZIKV infection is transmitted mainly by Aedes 
aegypti mosquitoes, sexual contact, or blood 
transfusion. It is typically a mild, asymptomatic 
disease in the general population.
The disease is a self-limiting febrile illness lasting 
4–7 days. Infection can be followed by neurological 
consequences including Guillain- Barre syndromes 
and microcephaly or other congenital neurological 
syndromes after vertical transmission from an 
infected mother to her fetus during pregnancy.
38.7.2  Diagnostics
Direct detection of ZIKV-RNA or specific viral 
antigens.
38.7.3  Prophylaxis
Blood, tissues, and cells should not be imported 
from areas of ZIKV transmission or should be 
tested negative for the presence of ZIKV.
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Donor diagnosed with ZIKV infection or who 
has just returned from an affected area should be 
deferred for at least 28  days after cessation of 
symptoms. The deferral should be at least 3 
months after sexual contact with person at risk.
38.7.4  Treatment
No specific prophylaxis or therapy is available.
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Key Points
• Epidemiology: Latent (especially 
CMV), endemic (especially CARV), 
and hepatotropic viruses are the main 
problem in patients after HSCT
• Diagnosis: Viral diagnostics after HSCT 
require qPCR or multiplex PCR
• Prophylaxis and treatment: Prophylaxis 
(pharmacological or environmental) or 
preemptive treatment is necessary. All 
patients after HSCT should undergo vac-
cinations according to current 
recommendations
• Outcome: Viral infections contribute to 
non-relapse mortality after HSCT
P. Ljungman et al.
291© EBMT and the Author(s) 2019 




39.1.1  General Concepts
Toxoplasma gondii is a protozoan that commonly 
infects animals and birds. Primary T. gondii 
infection in humans and other mammals is usu-
ally asymptomatic but leads to lifelong latent 
infection. Transmission to humans occurs by 
ingesting tissue cysts from undercooked meat or 
oocysts (released in the feces of cats). Latent 
cysts can give rise during immunosuppression to 
a severe localized reactivation producing, for 
example, toxoplasma encephalitis or chorioreti-
nitis, with dissemination being common. 
(Martino et  al. 2000; Martino et  al. 2005; 
Tomblyn et al. 2009; Martino 2016).
Although toxoplasmosis is the most common 
systemic parasitic infection in EBMT centers, it 
is a relatively rare opportunistic infection follow-
ing HSCT.  Currently we are aware that the 
patients’ seroprevalence explains the wide range 
of incidences published. Table 39.1 summarizes 
selected case series of toxoplasmosis in HSCT 
published to date.
39.1.2  Risk Factors and Incidence 
in HSCT
The seroprevalence for T. gondii varies greatly 
between and even within countries, ranging from 
<15% in Japan and in pediatric wards, 30% in 
urban adults in North America and the UK, and to 
40–80% of adult HSCT recipients in countries 
with high endemicity such as France or Turkey. 
This varying seroprevalence is the main reason 
for the great variability in the incidence of toxo-
plasmosis after HSCT, which has been estimated 
to average 0.8%, with <0.4% in areas of low 
endemicity to 2–3% in those with high-antibody 
prevalence.
Toxoplasmosis occurs mainly in allo-HSCT 
recipients, although cases after auto-HSCT have 
been published. Reactivation of latent tissue cysts 
in previously infected individuals is the usual 
mechanism implicated. Thus, it is important to 
determine the patients’ serostatus prior to trans-
plant. However, the disease may also develop if 
primary (or re-)infection after transplant may 
occur.
Ninety-five percent of the cases occur within 
the first 6 months after the procedure, and acute 
GVHD and its treatment are the main risk factors. 
Late cases may occur, again usually in patients 
with chronic GVHD requiring IST.  In addition, 
seropositive patients without GVHD but with 
severe cellular IS due to in vivo or ex vivo TCD 
are also at risk.
R. Martino (*) 
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39.1.3  Most Common Clinical 
Presentations
The CNS is the main site of disease, but pneumo-
nitis and myocarditis are also frequent findings.
Toxoplasma encephalitis typically presents 
with focal neurologic abnormalities of subacute 
onset, frequently accompanied by non-focal signs 
and symptoms such as headache, altered mental 
status, and fever. Meningeal signs are very rare. 
CT brain scans often show multiple bilateral cere-
bral lesions, although MRI is more sensitive than 
CT in the early diagnosis of this infection. 
Toxoplasma pneumonitis may develop in the 
absence of extrapulmonary disease. Toxoplasma 
chorioretinitis is rare compared to AIDS patients.
39.1.4  Diagnosis
In HSCT recipients, the utility of serology is 
mainly to identify those at risk for developing 
toxoplasmosis post transplant.
PCR techniques are currently the standard 
method for its diagnosis. These techniques are 
applicable in blood, CSF, and BAL, the usual 
samples that are available in HSCT recipients 
with this infection. Most centers use qPCR with a 
level of detection as low as 20 parasites/mL, with 
parasite loads of >600/mL reported in most 
patients with toxoplasmosis.
Since histologically proven toxoplasmosis is a 
very difficult-to-obtain diagnosis, various levels 
of diagnostic certainty have been proposed. 
Histologically defined cases are considered as 
definite cases of toxoplasma disease, PCR- 
defined cases as probable, and CNS imaging- 
defined cases as possible ones.
39.1.5  Treatment and Prognosis
Table 39.2 details the recommended treatment 
and prophylaxis of toxoplasmosis in HSCT 
recipients. Most patients respond to one or 
another of these regimens, and neurologic 
improvement of toxoplasma brain involve-
ment usually occurs within 7  days. If appro-
priately treated, up to 60% of patients may 
show clinical–radiologic improvement or even 
a complete response to therapy. This high-
lights the  importance for a high index of suspi-
cion for toxoplasmosis in immunocompromised 
patients.
Table 39.1 Selected case series of toxoplasmosis after HSCT (Martino 2017)
Author (year)a Cases
Number of HSCT (% 
frequency) % of sero (+) pre-HSCT
Median (range) 
day onset
Derouin et al. (1992) 7 296 allo (2.4) 65 74 (55–180)
Slavin et al. (1994) 12 3.803 allo (0.31)
509 auto (0)
15 59 (35–97)
Bretagne et al. (1995) 2 550 allo (0.3) 70 NS
Maschke et al. (1999) 20b 655 (3.1) NS 73 (14–689)





Small et al. (2000) 10 463 allo (2.2) 23 78 (36–155)
Aoun et al. (2006) 7 121 allo (5)
204 auto (0.4)
69 45 (13–140)
de Medeiros et al. (2001) 9 789 allo-HSCT (1.14) NS 69 (13–265)
Mulanovich et al. (2011) 9 3.626 Allo (0.25)
  – U.S. pt 0.15%




Bautista et al. (2012) and Martino 
et al. (2015)
9 148 adult CBT (4%) 45 39 (7–98)
Sumi et al. (2013) 6 279 allo (1.8%)
87 auto (1.1%)
10 NS
Hakko et al. (2017) 5 170 allo (2.9%) 70 42 (26–119)
aNot all in references
b4 definite and 16 possible cases of toxoplasmosis
R. Martino
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39.1.6  Specific Screening and/or 
Prophylactic Strategies 
Available
Current data suggest that infection may precede 
disease in most cases of toxoplasmosis. Thus, mon-
itoring sero(+) patients with weekly qPCR of blood 
samples has been advocated, especially when pro-
phylaxis is not being used, in an effort of using a 
preemptive-type therapeutic approach, as used for 
CMV infection. Although an optimal qPCR tech-
nique has not been standardized, several studies 
support the usefulness of this approach. Patients on 
TMP/SMX prophylaxis should not be monitored.
TMP/SMX is useful in minimizing the risk of 
reactivation of toxoplasmosis, although there are 
well-reported cases of toxoplasmosis breaking 
through this prophylaxis in HSCT recipients. 
Suboptimal dosing may have contributed to some 
of these “breakthrough” infections, since these 
cases occur when TMP/SMX is taken less than 
3 days per week. Thus, using either one standard- 
dose tablet (80/400 mg) daily or a double-strength 
tablet (160/800 mg) 4 days per week is the recom-
mended dosing, as shown in Table 39.2.
Avoiding primary or reinfection after HSCT is 
always important, avoiding the most common 
sources of infection: uncooked meats of any type 
and drinking contaminated water.
39.2  Tuberculosis (TBC)
(de la Cámara et al. 2000; Cordonnier et al. 2004; 
Yao-Chung et  al. 2016; Young and Weisdorf 
2016; Beswick et al. 2018).
39.2.1  General Concepts
TBC, and especially, multidrug-resistant (MDR) 
TBC, continues to be a worldwide major health 
problem. This may surprise many EBMT HSCT 
physicians, who may have never seen a case of TBC.
39.2.1.1  Mycobacterium Tuberculosis
Mycobacterium tuberculosis causes nearly all 
cases of TBC, and these acid-fast bacilli differ 
from other bacteria in that they can live only in an 
infected human. Outside of the human body, they 
have a very short survival, and infection is trans-
mitted by the inhalation of aerosolized particles 
from a patient. In addition, its isolation from clini-
cal samples should never be considered as a colo-
nization or sample contamination. TBC is not an 
opportunistic infection, and thus its detailed 
description is outside the scope of this manual.
39.2.2  Risk Factors and Incidence 
in HSCT
The risk of developing TBC is directly proportional 
to the TBC present in the geographic area of the 
HSCT center and the patients’ residence (Fig. 39.1). 
A few studies have analyzed its incidence with 
respect to the general population, and most have 
found that allo-HSCT recipients have 2–10 times 
higher risk than the general population, while auto-
HSCT recipients do not have a significantly higher 
risk (De la Cámara et al. 2000) (Table 39.3).
Table 39.2 Suggested treatment and prophylaxis for 




Oral, 200 mg loading dose, then 
50–75 mg q.d. (folinic acid, oral 
or IV, 10–15 mg q.d.) + one of 
the following
Sulfadiazine Oral, 1–1.5 g q6–8h, OR
Clindamycin Oral or IV, 600 mg q6h
Prophylaxis Dose
TMP/SMXa,b 1 double-strength tablet 
(160/800 mg)/day, 4 day × week, 
OR
2 double-strength tablets 
(160/800 mg)/day, 3 day × week, 
OR





2–3 tables per week
Dapsoneb 100 mg daily
Atovaquoneb 1500 mg daily
aAlso effective for PJP prophylaxis, and possibly listerio-
sis, nocardiosis, and, in some geographic areas, partly 
effective in preventing gram-positive cocci and gram- 
negative bacillary (enterobacterial and non-glucose fer-
menting) infections
bThe dose can be reduced in patients with mild renal 
insufficiency












Fig. 39.1 TBC estimate incidence rate 2016 (WHO webpage)
Table 39.3 Selected case series of mycobacterial infections after HSCT before 2018
Author (year)a Country
TBC/HSCT x risk with 
GPb




Lee et al. (2017) Korea 21/824 (allo) × 9.1 GP NA 1 died
Liu et al. (2016)c Taiwan 5/422 (allo) 21/422 (allo) 11 died
Beswick et al. (2018) Canada NA 30/1097 (allo) × 35 GP NA





USA 4/577 (allo) × 10 GP 0 NA





Ku et al. (2001) Taiwan 8/255 (allo) × 13.1 GP
0/95 (auto)
0 ND





Turkey 5/351 (allo) × 3.9 GP 0 No deaths
Gaviria et al. (2000) USA 3 /6529 (3 allo) 0 No deaths
Aljurf et al. (1999) Saudi Arabia 4/641 (allo) 0 2 died










NA Details not available in the study
aNot all in references
bx risk with GP, studies in which the relative risk of suffering TBC was compared to that in age-/sex-matched normal 




39.2.3  Most Common Clinical 
Presentations
The clinical presentation of TBC in HSCT recipi-
ents is the same as in the general population, 
although it may have a more rapid progression, 
and the ratio of pulmonary to extrapulmonary 
disease has been reported 34/5 to 11/10, which 
surely represents a publication bias, with a 
median of 75%/25%. The most common extra-
pulmonary disease is meningitis.
39.2.4  Diagnosis
Culture of even a single colony from an affected 
organ is diagnostic for TBC. Direct microbio-
logic examination for acid-fast bacilli is of 
course mandatory, but its sensitivity is probably 
low. In addition, the results of positive cultures 
take many days to weeks, and the use of highly 
sensitive and specific PCR methods is now the 
usual methods for the initial diagnosis.
The quantiFERON-TB Gold test is not reli-
able in the diagnosis of TBC in HSCT recipients 
due to their T-cell immunodeficiency.
39.2.5  Treatment and Prognosis
With appropriate treatment, TBC in HSCT recipi-
ents has a low attributable mortality (<30%). The 
author suggests that HSCT physicians contact ID 
physicians immediately when diagnosis of TBC is 
made. Empirical treatment should be started if 
this consultation will not be replied immediately, 
but herein we cannot recommend a “one fits all” 
drug combination, since this varies greatly accord-
ing to the level of drug resistance in each geo-
graphical area.
39.2.6  Specific Screening and/or 
Prophylactic Strategies 
Available
Even in areas where TBC is endemic, pre-
HSCT screening with the tuberculin skin test 
or the gamma-interferon quantiFERON-TB 
Gold test is not done in most HSCT centers. In 
addition, specific antibiotic prophylaxis in 
patients with past and cured TBC is not 
warranted.
Two special scenarios do, however, require 
contacting an ID specialist pre- or post-HSCT 
in order to analyze whether “prophylaxis” may 
be indicated, the drugs to use, and their 
duration:
 1. Highly IS HSCT recipients or candidates who 
have been substantially exposed to someone 
with active infectious TBC
 2. HSCT recipients or candidates with a positive 
tuberculin skin test or the gamma-interferon 
quantiFERON-TB Gold test who were not 
previously treated and have radiological evi-
dence of TBC lung disease
39.3  Nontuberculous (or Atypical) 
Mycobacterial (NTM) 
Infections
(Cordonnier et  al. 2004; Young and Weisdorf 
2016; Beswick et al. 2018).
39.3.1  General Concepts
Atypical mycobacteria are fastidious microor-
ganisms that are ubiquitous in nature and can 
simply colonize any body surface and secretions 
and often contaminate clinical samples from the 
environment. There are a very large number of 
NTM species with varying geographical distribu-
tions. However, with respect to infections in 
HSCT recipients, NTM can be divided into two 
different categories:
 (1) Mycobacterium avium-intracellulare complex.
 (2) Anonymous or atypical NTM, subdivided 
into the rapidly growing NTM and the slow 
growing NTM: the most commonly reported 
species from EBMT centers are M. fortui-
tum, M. chelonae, M. abscessus, M. xenopi, 
and M. kansasii.
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39.3.2  Most Common Clinical 
Presentations and Risk Factor
A large number of atypical NTM infections are 
CVC infections, followed by skin infections. 
However, in patients with severe cGVHD, severe 
infections of any organ can occur, as well as dis-
seminated cases. M. avium-intracellulare com-
plex, on the other hand, usually causes pulmonary 
disease or disseminated infections, with blood 
cultures being positive in >50% of cases. Such 
infections almost always occur in severely immu-
nocompromised allo-HSCT recipients, such as 
those with severe steroid-dependent cGVHD.
39.3.3  Diagnosis
Diagnosis requires isolation of a NTM from the 
affected organ(s). Differentiating colonization 
from contamination and disease can be difficult 
with NTM. Depending on the species, cultures can 
be positive in very few days or take many days, as 
with TBC. Thus, the use of specific PCR methods 
and/or special biochemical methods is now the 
usual method for the diagnosis of NTM infections.
39.3.4  Treatment and Prognosis
With appropriate treatment, most NTM infec-
tions have a good outcome and a low attributable 
mortality, although the data are very scarce 
(Table 39.3).
As in the case of TBC, the author suggests that 
HSCT physicians contact ID physicians immedi-
ately when diagnosis of NTM infection is made. 
In CVC infections, the catheter should probably 
always be removed. While awaiting for the ID 
specialists, empirical therapy with a macrolide 
(clarithromycin or azithromycin) plus moxifloxa-
cin or levofloxacin can be started.
39.3.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening and prophylaxis have no role in NTM 
infections.
39.4  Listeriosis
(Safdar et  al. 2002; Boyle 2014; Martino et  al. 
1996).
39.4.1  General Concepts
Only one species, Listeria monocytogenes, pro-
duces all cases of this mostly “bacterial food-
borne” infection. L. monocytogenes is a 
pseudo-“diphtheroid” gram-positive bacillus. 
This organism is widespread in nature and in tap 
water, sewage, the microbiota of pets and farm 
animals, and nearly all types of fresh foods. The 
fact that it grows well in refrigerator tempera-
tures adds yet another variable which favors 
ingestion by humans, which appears to be univer-
sal worldwide. At any specific moment, 5% of 
healthy humans have L. monocytogenes in feces. 
With these premises, it is surprising that listerio-
sis is an uncommon infection in HSCT 
recipients.
39.4.2  Risk Factors and Incidence 
in HSCT
The only risk factor is the combination of ingest-
ing colonized food or water and having a severe 
cellular IS.
Its incidence is unknown, and only two studies 
are available. At the MSKCC in New York, six 
cases occurred in 1315 allo-HSCT recipients 
from 1985 to 1997, with an incidence of 0.47% 
(Safdar et  al. 2002). At the FHCRC in Seattle, 
three cases occurred among 4069 HSCT recipi-
ents (<0.1%) during the first 100 days post trans-
plant (Boyle 2014). Finally, in our center, we 
have had three cases of listeriosis among 2360 
adult HSCT recipients (0.1%) (Martino et  al. 
1996). All other information has been reported as 
isolated case reports.
39.4.3  Most Common Clinical 
Presentations
Listeriosis in HSCT recipients is almost always a 
sepsis syndrome with bloodstream infection, 
R. Martino
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with CNS involvement in 40–60% of cases, 
which can present as meningitis, encephalitis, or 
brain abscess, and with several cases of rhomben-
cephalitis reported (Chang et al. 1995).
39.4.4  Diagnosis
The diagnosis is made after the bacterial microbi-
ology laboratory informs the clinicians that the 
patient has positive blood and/or CSF cultures for 
this organism. The putative source of the infec-
tion cannot be identified in outpatients.
39.4.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening has no role in preventing listeriosis. 
Standard approaches to food safety handling and 
preparation are, of course, the main preventive 
measures.
The routine use of TMP/SMX prophylaxis 
after HSCT surely has a role in preventing liste-
riosis, but its low incidence makes this impossi-
ble to prove.
Cases of listeriosis in long-term inpatients 
should, of course, activate the rapid intervention 
of the hospital infection control/prevention unit 
in the HSCT ward.
39.4.6  Treatment and Prognosis
The treatment of choice is high-dose ampicillin 
(or high-dose TMP/SMX in those allergic to pen-
icillin) combined with an aminoglycoside during 
3 weeks or 6 weeks in case of CNS infection. We 
also recommend consultation with ID 
specialists.
The prognosis of listeriosis in HSCT recipi-
ents is unknown, although 20% of the reported 
cases died, while 10% had a CNS recurrence.
39.5  Nocardiosis
(Coussement et  al. 2017; Shannon et  al. 2016; 
Bambace et al. 2013).
39.5.1  General Concepts
Nocardia spp. (any of the dozens of currently 
accepted species may be involved, but most cases 
in Europe appear to be due to N. asteroides, N. 
brasiliensis, and N. nova) are aerobic gram- 
positive rods that grow in characteristic filamen-
tous, branching chains and being acid fast, and 
their appearance makes them easily identifiable 
by microbiologists, with its acid-fast staining 
properties differentiating it from Actinomyces 
spp. Nocardia spp. grow in soil and decaying 
matter, and human infection usually occurs from 
inhalation of airborne bacilli.
39.5.2  Risk Factors and Incidence 
in HSCT
Nocardiosis is a late post-HSCT infection, occur-
ring months to years after HSCT, mostly allo- 
HSCT.  Patients usually have steroid-dependent 
chronic GVHD, secondary diabetes mellitus, 
and/or bronchiolitis obliterans or bronchiectasis 
from the numerous post-HSCT infections suf-
fered. There are no specific risk factors in HSCT, 
although being at the right time in a place where 
soil-living bacilli are made massively airborne is 
a common-sense mechanism of infection. Similar 
to M. tuberculosis, Nocardia spp. do not colonize 
the airways.
The incidence of nocardiosis has been reported 
to range from 0.3 to 1.7% in allo-HSCT, although 
many large centers have not had a single case. In 
auto-HSCT the median incidence is 0%, although 
occasional cases have been reported and surely 
occur in many centers.
39.5.3  Most Common Clinical 
Presentations
Pulmonary infection, with its accompanying 
signs and symptoms, and radiologically one or 
more nodular lesions with a tendency to cavitate 
occur in 90% of patients with nocardiosis. At pre-
sentation, however, around half of the patients 
have disseminated disease, usually to the skin 
and osteoskeletal organs, but around 1/3 will 
have CNS involvement up front. Since CNS 
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involvement is so common and can initially be 
asymptomatic, a CNS CT or MRI scan is manda-
tory in all HSCT recipients with pulmonary 
nocardiosis (in any IS host, in fact). Brain 
abscesses are the usual presentation, although 
severe hyponatremia due to SIADH is also com-
mon due to basal meningitis.
39.5.4  Diagnosis
Diagnosis, of course, requires culture of an 
affected organ, usually the lungs. Often, the char-
acteristic ramified bacilli can be directly observed 
from sputum or a directed BAL, but culture- 
based diagnosis is made in at least 1/3 of the 
cases. This is of utmost importance, since cul-
tures become positive at a median of 9 days after 
sampling but can take up to 2–4  weeks. 
Molecular-based methods are useful only to 
identify uncommon species of Nocardia with 
known multidrug resistance, but this is rarely 
required in clinical practice. The most common 
differential diagnosis is with invasive pulmonary 
mold infections.
39.5.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening has no role in preventing nocardiosis, 
but its rapid diagnosis does have an impact on 
patient outcome.
The routine use of TMP/SMX prophylaxis 
after HSCT may prevent more cases of nocardio-
sis, but the 2–3-day per week schedules are not 
effective in preventing it. Of note, Nocardia spp. 
isolated in patients taking single-strength TMP/
SMX prophylaxis 5–7 days per week have had a 
good in  vitro susceptibility to TMP/SMX and 
have responded well to high doses of the drug.
39.5.6  Treatment and Prognosis
High-dose TMP/SMX is still the treatment of 
choice, although there have been good results 
with carbapenems, amikacin, second-generation 
cephalosporins, and/or linezolid.
When treated promptly, nocardiosis usually 
resolves with prolonged antibiotic therapy, but 
directly attributable mortality has been reported 
in up to 40% of cases; these are, of course, those 
cases that affect extremely debilitated allo-HSCT 
recipients due to prolonged severe GVHD and its 
numerous complications, as well as those with 
disseminated infection and extensive CNS 
involvement, including the brain stem. Overall 
mortality, however, is high, since around 40% of 
patients have severe coinfections when nocardio-
sis joins the club.
Treatment of nocardiosis usually requires at 
least 6 months of specific antibiotic therapy, and 
it is of course recommended that ID specialists 
are actively involved in the treatment and follow-
 up. Of note, most Nocardia isolates are suscepti-
ble to most of the too-often empirically/
prophylactically used antibiotics in HSCT recipi-
ents (levofloxacin, moxifloxacin, amoxicillin- 
clavulanate), as well as tetracyclines and 
tigecycline.
References
Bambace NM, Poirier L, Cohen S, et al. Nocardiosis in 
allogeneic hematopoietic stem cell transplant recipi-
ents: a matched case-control study of risk factors, 
clinical features and outcomes. Biol Blood Marrow 
Transplant. 2013;19:S280.
Beswick J, Shin E, Michelis FV, et al. Incidence and risk 
factors for nontuberculous mycobacterial infection 
after allogeneic hematopoietic cell transplantation. 
Biol Blood Marrow Transplant. 2018;24:366–72.
Key Points
• The intense IS associated with allo- 
HSCT, especially when there is a 
chronic GVHD that requires a pro-
longed IST, favors the development of 
infections by very unusual pathogens.
• Despite its low incidence, it is necessary 
to know these pathologies in order to 
make an early diagnosis and to adapt the 
therapy to the causal pathogen.
R. Martino
299
Chang J, Powles R, Mehta J, et al. Listeriosis in bone mar-
row transplant recipients: incidence, clinical features, 
and treatment. Clin Infect Dis. 1995;21:1289–90.
Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial 
infection: a difficult and late diagnosis in stem cell trans-
plant recipients. Clin Infect Dis. 2004;38:1229–36.
Coussement J, Lebeaux D, Rouzaud C, Lortholary 
O. Nocardia infections in solid organ and hematopoi-
etic stem cell transplant recipients. Curr Opin Infect 
Dis. 2017;30:545–51.
de la Cámara R, Martino R, Granados E, et al. Tuberculosis 
after hematopoietic stem cell transplantation: inci-
dence, clinical characteristics and outcome. Spanish 
Group on Infectious Complications in Hematopoietic 
Transplantation. Bone Marrow Transplant. 
2000;26:291–8.
Martino R. Toxoplasmosis after hematopoietic stem cell 
transplantation. In: Ljungman P, Snydman D, Boeckh 
M, editors. Transplant infections. Printfort: Springer; 
2016. p. 773–80.
Martino R, Lopez R, Pericas R, et  al. Listeriosis in 
bone marrow transplant recipient. Clin Infect Dis. 
1996;23:419–20.
Martino R, Maertens J, Bretagne S, et al. Toxoplasmosis 
after hematopoietic stem cell transplantation. Clin 
Infect Dis. 2000;31:1188–95.
Martino R, Bretagne S, Einsele H, et al. Early detection 
of toxoplasma infection by molecular monitoring of 
toxoplasma gondii in peripheral blood samples after 
allogeneic stem cell transplantation. Clin Infect Dis. 
2005;40:67–78.
Safdar A, Papadopoulous EB, Armstrong D. Listeriosis in 
recipients of allogeneic blood and marrow transplan-
tation: thirteen year review of disease characteristics, 
treatment outcomes and a new association with human 
cytomegalovirus infection. Bone Marrow Transplant. 
2002;29:913–6.
Shannon K, Pasikhova Y, Ibekweh Q, Ludlow S, Baluch 
A.  Nocardiosis following hematopoietic stem 
cell transplantation. Transpl Infect Dis. 2016;18: 
169–75.
Tomblyn M, Chiller T, Einsele H, et  al. Guidelines for 
preventing infectious complications among hemato-
poietic cell transplantation recipients: a global per-
spective. Biol Blood Marrow Transplant. 2009;15: 
1143–23.
Yao-Chung L, Wu C, Chien S, et al. Mycobacterial infec-
tions in adult recipients of allogeneic hematopoietic 
stem cell transplantation: a cohort study in a high 
endemic area. Blood. 2016;128:S2202.
Young JAH, Weisdorf DJ.  Typical and atypical myco-
bacterium infections after hematopoietic stem cell or 
solid organ transplantation. In: Ljungman P, Snydman 
D, Boeckh M, editors. Transplant infections. Printfort: 
Springer; 2016. p. 381–96.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
39 Other Life-Threatening Infections
301© EBMT and the Author(s) 2019 






Bleeding and thrombotic complications are an 
important cause of morbidity and mortality in 
patients undergoing HSCT.  The major throm-
botic complications include venous thromboem-
bolism, such as catheter-related thrombosis, 
sinusoidal obstruction syndrome (SOS), and 
transplant-associated thrombotic microangiopa-
thy (TA-TMA), while bleeding can involve the 
GI or respiratory tracts and is most common in 
thrombocytopenic patients or those with GVHD.
HSCT is associated with multiple risk factors for 
both thrombosis and bleeding including the under-
lying malignancy, thrombocytopenia, high- dose 
MAC and immunomodulatory drugs, GVHD, 
infections, indwelling vascular catheters, and pro-
longed immobilization (Gerber et  al. 2008; 
Chaturvedi et al. 2016; Nadir and Brenner 2007). 
HSCT is also associated with alterations in the 
coagulation system with activation of endothelium- 
dependent coagulation factors, increase in vWF and 
platelet adhesion, increased thrombin generation, 
decreased antithrombin levels, and decreased levels 
of anticoagulant proteins such as protein C 
(Vannucchi et al. 1994). Collectively, major patient-, 
disease-, and therapy- related factors contribute to 
hemostatic complications in HSCT patients. 
Thrombotic and bleeding complications in HSCT 
are discussed separately below.
40.2  Thrombotic Complications
40.2.1  Epidemiology and Risk 
Factors
Thromboembolic complications in HSCT recipi-
ents include venous thromboembolism (VTE), 
catheter-associated thrombosis (CAT), sinusoidal 
obstruction syndrome, and TA-TMA. VTE is the 
most common of these complications, and retro-
spective studies have reported VTE incidence as 
high as 4.6% over 180 days for inpatients undergo-
ing HSCT (Gerber et al. 2008). The rate of VTE is 
higher with allo-HSCT than auto- HSCT and in the 
presence of GVHD with 1-year VTE rates of 
4.8%, 6.8%, and 8.1% reported with auto-HSCT, 
allo-HSCT without GVHD, and allo-HSCT with 
GVHD, respectively (Pihusch et al. 2002). A retro-
spective series of 447 patients undergoing BMT 
reported a 5.7% incidence of VTE in the first 
100  days following transplant despite being on 
heparin prophylaxis (100 U/kg iv daily) for hepatic 
SOS (Pihusch et  al. 2002). Finally, Gonsalves 
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et  al. reported a 1-year symptomatic VTE inci-
dence of 3.7% in patients undergoing HSCT in an 
ambulatory care setting (Gonsalves et al. 2008).
VTE occurs most frequently following engraft-
ment, in patient undergoing allo-HSCT, those with 
a history of previous VTE or GVHD (Labrador 
et al. 2013). The majority of VTE episodes in these 
studies were catheter-associated thrombosis. 
Cortelezzi et al. have previously reported that there 
was a 12% incidence of catheter- related thrombo-
embolic complications in a cohort of 416 patients 
with hematologic malignancies (Cortelezzi 2005). 
Twenty-one percent of these patients were HSCT 
recipients, and 81.2% had platelet counts less than 
50 × 109/L. There was a non-statistically significant 
trend toward lower rates of thrombotic complica-
tions with thrombocytopenia. Prolonged hospital-
ization and inherited thrombophilias (e.g., factor V 
Leiden, prothrombin gene mutation, protein C or S 
deficiency) are associated with an increased risk of 
thrombosis in the general population and may add 
to thrombosis risk in the HSCT population as well.
40.2.2  VTE Prophylaxis
40.2.2.1  Randomized Studies
Randomized studies have not evaluated empiric 
prophylactic anticoagulation in HSCT recipients; 
however, studies in patients with cancer provide the 
next best evidence that can be extrapolated. The 
PROTECHT (nadroparin versus placebo) and 
SAVE-ONCO (semuloparin versus placebo) trials 
showed a significant reduction in the relative risk of 
VTE with prophylactic anticoagulation in patients 
with cancer; however the absolute risk reduction is 
small, and no survival benefit has been demon-
strated. The American Society of Clinical Oncology 
(ASCO) guidelines advise against the use of routine 
prophylactic anticoagulation in ambulatory patients 
with cancer (Lyman et al. 2015). We do not gener-
ally recommend prophylactic anticoagulation in 
thrombocytopenic HSCT recipients with the excep-
tion of those with multiple myeloma (MM) receiv-
ing thalidomide or lenalidomide or hospitalized 
patients at higher risk of thrombosis (Table 40.1).
40.2.2.2  Multiple Myeloma
Patients with MM have a high baseline risk of 
thrombosis of 5–10% that increases several-fold 
in patients being treated with the immunomodu-
lators (IMiDs) THAL and LENA with DEX or 
chemotherapy. Consolidation therapy with 
THAL or LENA after HSCT has been shown to 
improve CR rates and prolong EFS and is thus 
rapidly becoming standard of care (McCarthy 
et  al. 2012; Barlogie et  al. 2006). In patients 
receiving THAL consolidation after auto-HSCT 
for MM, the rate of VTE was 24% and 6% in the 
induction and consolidation periods, respectively, 
Table 40.1 Recommendations for prophylaxis and treatment of VTE in HSCT recipientsa
VTE prophylaxis VTE treatment
Indications for prophylaxis
–  Patients with MM receiving IMiDs
–  During hospitalization or 
postoperatively, as long as platelet 
count is >50 × 109/L
–  Prophylaxis is not recommended in 
outpatients with indwelling vascular 
catheters
Prophylaxis strategy
–  Aspirin in low-risk patients with MM 
receiving IMiDs
–  LMWH (prophylactic dose of 40 mg 
SC daily) for patients with MM on 
IMiDs and >1 risk factor for VTE
–  Prophylactic doses of UFH or 
LMWH in hospitalized patients
General principles
–  Start therapeutic doses of LMWH or IV UFH in patients who have 
platelet count >50 × 109/L and no active bleeding. UFH is preferred in 
case of renal impairment (GFR <30 mL/min) or high bleeding risk
–  Continue LMWH or transition to warfarin (if LMWH is 
contraindicated) for maintenance therapy
–  DOACs are not currently recommended in patients undergoing HSCT
Duration of anticoagulation
–  General: 3–6 months or as long as malignancy or use of IMiDs persists, 
whichever is longer
–  Catheter-related thrombosis: 3 months or as long as catheter is in place
Inferior vena cava filter
Only use to patients in whom anticoagulation is contraindicated or those 
who develop pulmonary embolism on anticoagulation. Remove as soon as 
anticoagulation can be started
DOACs direct oral anticoagulants, IMiDs immunomodulatory drugs, LMWH low molecular weight heparin, MM mul-
tiple myeloma, UFH unfractionated heparin
aAdapted from Chaturvedi et al. (2016)
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despite thromboprophylaxis with low molecular 
weight heparin (LMWH) (Barlogie et al. 2006). 
McCarthy et al. reported no episodes of VTE in 
patients receiving consolidation therapy with 
LENA; however, these patients also received pro-
phylactic anticoagulation (McCarthy et al. 2012). 
Based on studies showing a benefit of thrombo-
prophylaxis in patients with newly diagnosed 
MM receiving LENA- or THAL-based treatment 
(Palumbo et al. 2011) and the ASCO recommen-
dation for thromboprophylaxis in this population 
(Lyman et al. 2015), we recommend either aspi-
rin or LMWH for lower-risk patients and LMWH 
for higher-risk patients receiving THAL or 
LENA.
40.2.2.3  Hospitalized Patients
Though there is a clear benefit of pharmacologic 
thromboprophylaxis in medically ill hospitalized 
patients (Samama et  al. 1999), randomized trials 
have not evaluated thromboprophylaxis in HSCT 
patients. The potential benefit from VTE prophy-
laxis is proportional to VTE risk, and therefore this 
is particularly important in patients with reduced 
mobility and with a history of VTE (if not on long-
term anticoagulation) due to an even higher risk of 
thrombosis. Our practice is to start prophylactic 
anticoagulation for hospitalized patients in the post 
transplant period once the platelet count is 
>50  ×  109/L and there is no active bleeding. For 
very high-risk patients, anticoagulation can be con-
sidered if the platelet count is >30 × 109/L; however 
this must be balanced with the risk of bleeding.
40.2.2.4  Prophylaxis of Catheter- 
Related Thrombosis
HSCT patients, especially those undergoing 
“ambulatory” HSCT, frequently have indwell-
ing vascular catheters with the potential of 
catheter- related thrombosis (CRT). Despite 
multiple randomized and observational studies, 
thromboprophylaxis for the prevention of CRT 
in patients with cancer remains controversial. 
The largest study of thromboprophylaxis in 
CVC randomized 1590 cancer patients under-
going chemotherapy to adjusted-dose warfarin 
(international normalized ratio, 1.5–2.0), fixed- 
dose warfarin (1  mg/day), and no prophylaxis 
(Young et  al. 2009). Symptomatic CRT was 
less frequent in the patients given adjusted-
dose warfarin than in those who received no 
prophylaxis (2.7% vs 5.9%, P  =  0.019); how-
ever, both adjusted-dose and fixed-dose warfa-
rin were significantly associated with increased 
risk of major bleeding (Young et  al. 2009). 
Recent meta- analyses of randomized trials con-
cluded that prophylactic warfarin and LMWH 
do not significantly reduce symptomatic CRT 
in patients with cancer (Akl et al. 2007). Based 
on the available evidence, we do not routinely 
recommend prophylactic anticoagulation to pre-
vent catheter- related thrombosis.
40.2.3  VTE Diagnosis and Treatment
Venous duplex ultrasonography should be per-
formed in patients presenting with extremity 
swelling, redness or tenderness, or pulmonary 
angiography in patients with chest pain, dys-
pnea, or unexplained tachycardia. A clinical 
assessment of bleeding risk is necessary in 
patients who are diagnosed with VTE. Patients 
with no increased risk based on bleeding history 
and platelet count >50 × 109/L should be started 
on therapeutic anticoagulation with either 
LMWH or unfractionated heparin (UFH). The 
use of LMWH is restricted to patients with glo-
merular filtration rate >30 mL/min, while UFH 
is used in patients with impaired renal function 
(glomerular filtration rate <30 mL/min) or those 
with high bleeding risk. Following initiation of 
anticoagulation with LMWH or UFH, patients 
may be continued on LMWH or transition to 
warfarin with a standard INR target of 2–3. 
LMWH is preferred in patients with evidence of 
relapsed malignancy. The direct oral anticoagu-
lants (DOACs) have not been evaluated in HSCT 
recipients, and their use cannot currently be rec-
ommended outside of a research setting. The 
optimal duration of anticoagulation for VTE in 
HSCT patients has not been evaluated in pro-
spective studies. The recommendation for 
patients with cancer-related VTE is anticoagula-
tion for 3–6 months, with ongoing therapy if the 
malignancy persists (Lyman et al. 2015; Kearon 
et al. 2012). We follow an analogous strategy in 
HSCT patients with the caveat that extended 
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anticoagulation is often not feasible in patients 
with relapsed disease and a high likelihood of 
disease-related or treatment-related thrombocy-
topenia (Table 40.1).
The use of inferior vena cava (IVC) filters 
should be restricted to patients with acute deep 
vein thrombosis and a contraindication to antico-
agulation and possibly patients who develop pul-
monary embolism while on therapeutic 
anticoagulation (Kearon et al. 2012). IVC filters 
should not be used for primary prophylaxis of 
pulmonary embolism. In patients with large, 
symptomatic thrombosis and severe thrombocy-
topenia, we sometimes follow a strategy of plate-
let transfusions to reach a threshold of 50 × 109/L 
to allow safer anticoagulation with heparin.
40.2.4  Treatment of Catheter- 
Related Thrombosis
The rate of PE and mortality from CRT is low, and 
the objectives of CRT treatment are to reduce 
symptoms, prevent extension into more central 
veins, preserve access, and prevent chronic venous 
stenosis. There is no evidence that removal of the 
catheter improves outcomes. Therefore, it is rea-
sonable to not to remove the catheter unless it is 
nonfunctional, no longer needed, or may be 
infected. Thrombus reduction by catheter-directed 
thrombolysis is relatively safe and effective and 
may be tried in an attempt to preserve the catheter. 
Anticoagulation is required in patients with acute 
CRT regardless of whether the catheter is removed 
(Kearon et al. 2012; Lyman et al. 2015). We prefer 
LMWH, though vitamin K antagonists (VKA) 
may be used if LMWH is contraindicated. In a 
prospective study of 78 patients with CRT treated 
with full-dose dalteparin bridged to warfarin, there 
were no new thrombotic events at 3 months, and 
57% of catheters were still functional (Kovacs 
et al. 2007). The optimum duration of anticoagula-
tion has not been evaluated in prospective studies. 
Current ACCP guidelines recommend anticoagu-
lation for 3 months or until the catheter is removed, 
whichever is longer (Kearon et al. 2012). Several 
clinicians prefer to continue anticoagulation for 
1–2 weeks after the catheter is removed.
40.2.5  Sinusoidal Obstruction 
Syndrome (SOS)
SOS (see Chap. 49) is a life-threatening compli-
cation that presents usually within the first 
45 days after HSCT with elevated serum biliru-
bin levels, painful hepatomegaly, and fluid reten-
tion (Carreras, 2015). Endothelial injury of the 
hepatic sinusoids in SOS initiates hepatocyte 
injury and liver failure. SOS can occur in as high 
as 8–13% of HSCT recipients, and mortality is in 
excess of 80% (Carreras, 2015). MAC, preexist-
ing liver disease, younger age, and poor perfor-
mance status are associated with increased risk of 
SOS (McDonald et  al. 1993). Ursodeoxycholic 
acid is recommended as prophylaxis for SOS in 
patients undergoing allo-HSCT. Anticoagulation 
with low-dose heparin has also been studied and 
is sometimes prescribed to patients undergoing 
auto-HSCT. Defibrotide, a pro-fibrinolytic agent, 
is a new agent approved for the treatment of 
severe SOS in both children and adults and is 
associated with higher rates of survival than his-
torical controls (20–30% at day 100) (Richardson 
et  al. 2016). Defibrotide prophylaxis has been 
shown to have some efficacy in preventing SOS 
in high-risk children, but whether this benefit 
translates for adults is not known.
40.2.6  Transplant-Associated TMA
TA-TMA (see Chap. 42) is a heterogeneous, fre-
quently fatal disorder that occurs within 100 days 
after HSCT and is caused by treatment- and 
disease- related endothelial damage, coagulation 
activation, and microvascular thrombosis (Nadir 
and Brenner 2007). It is characterized by throm-
bocytopenia, microangiopathic anemia with 
schistocytes on the blood smear, and varying 
organ impairment such as renal failure and 
 neurological symptoms. The diagnosis can be 
challenging since the clinical symptoms overlap 
with other common complications including 
GVHD and infections (Rosenthal, 2016). Risk 
factors for developing TA-TMA include expo-
sure to calcineurin inhibitors, high-dose chemo-
therapy, GVHD, infections, advanced age, female 
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sex, and non-MAC (Elsallabi et  al. 2016). 
Elevated levels of vWF and inflammatory media-
tors such as IL-1, TNF-alpha, thrombomodulin, 
etc. and neutrophil extracellular traps have been 
implicated as causing the endothelial damage in 
TA-TMA. Treatment of TA-TMA is mostly sup-
portive; however, recent data show that some 
patients with severe TA-TMA harbor comple-
ment gene mutations and uncontrolled comple-
ment activation has been demonstrated in 
TA-TMA, which is a potential therapeutic target. 
The complement inhibitor eculizumab has been 
successfully used in some cases of TA-TMA 
(Rosenthal, 2016).
40.3  Bleeding Complications
Bleeding in HSCT recipients is closely asso-
ciated with prolonged and severe thrombocy-
topenia. In retrospective studies, the rate of 
bleeding in HSCT recipients ranges from 15.2% 
to 27.1%, and life-threatening or fatal bleeding 
occurred in 1.1% to 3.6% of patients (Gerber 
et al. 2008; Pihusch et al. 2002, Labrador et al. 
2013). Gerber et  al. reported that the initia-
tion of therapeutic anticoagulation during days 
1–180 after HSCT was the strongest predictor 
of bleeding [OR 3.1 (95% CI 1.8–5.5)] (Gerber 
et al. 2008). Furthermore, GVHD [OR 2.4 (95% 
CI 1.1–3.3)] increased the risk of bleeding, 
while auto-HSCT (versus allo-HSCT) was pro-
tective [OR 0.46 (95% CI 0.33–0.64)]. Bleeding 
can take any form including GI hemorrhage in 
patients with GVHD of the gut, hemorrhagic 
cystitis in patients with genitourinary involve-
ment by GVHD, viral reactivation, and alkyl-
ating agent therapy, or spontaneously. Diffuse 
alveolar hemorrhage (DAH) (see Chap. 52) is 
a devastating bleeding complication that occurs 
in 2–14% of HSCT recipients and presents with 
progressive hypoxia, pulmonary infiltrates, 
and bloody alveolar lavage (Nadir and Brenner 
2007). DAH is more common in thrombocy-
topenic patients and those with acute GVHD, 
and the effects of inflammatory cytokines on 
the alveolar lining have been implicated. There 
are no evidence- based prophylactic and thera-
peutic strategies, reported mortality is around 
80% (range 64% to 100%) (Afessa et al. 2002). 
Platelet transfusions, systemic corticosteroids, 
antifibrinolytics, and recombinant factor VIIa 
have all been used with inconsistent results. It 
is general practice to administer prophylactic 
platelet transfusions for platelet counts less than 
10  ×  109/L in patients undergoing myeloabla-
tive chemotherapy or HSCT, though the supe-
riority of prophylactic over therapeutic platelet 
transfusions is supported by low- to moderate-
grade evidence. Given the competing risks of 
bleeding and thrombosis, identifying patients 
at high risk for these outcomes can optimize 
strategies for prophylaxis. The timing of hemo-
static complications is an important consider-
ation since bleeding events are more likely to 
occur early in the post transplant course when 
patients are profoundly thrombocytopenic, 
while thrombotic events occur more frequently 
after hematopoietic recovery (Gerber et  al. 
2008; Labrador et al. 2013).
Key Points
• Hemostatic complications, including 
both thrombosis and bleeding, are com-
mon in HSCT recipients and contribute 
to morbidity and mortality.
• Indwelling vascular catheters, GVHD 
associated inflammation, and certain 
medications are important risk factors 
for VTE, while prolonged severe throm-
bocytopenia and GVHD predispose to 
bleeding.
• Pharmacologic thromboprophylaxis is 
recommended for patients with MM 
receiving IMiDs and hospitalized 
patients with platelet count >50 × 109/L, 
but not for routine prophylaxis of CRT.
• LMWH (or UFH) is the treatment of 
choice for VTE in HSCT recipients.
• Ursodiol and defibrotide are recom-
mended for the prevention and treat-
ment of SOS, respectively. Defibrotide 
may also have a role in prophylaxis of 
high-risk patients.
40 Bleeding and Thrombotic Complications
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Engraftment is defined as the first of 3 consecu-
tive days with an absolute neutrophil count higher 
than 0.5 × 109/L (sustained >20 × 109/L platelets 
and hemoglobin >80  g/L, free of transfusion 
requirements).
In the setting of RIC protocols, it is also rec-
ommended to confirm the donor origin through 
chimerism studies.
The incidence of GF is <3–5% in the auto- 
and matched allo-HSCT setting, but it increases 
up to 10% in the cases of haploidentical or CBT.
The prognosis of graft failure (GF) is poor, 
and most patients die because of causes related to 
infections or bleeding, with an OS at 3–5 years 




ANC <0.5 × 109/L by day +28
Hemoglobin <80 g/L and platelets 
<20 × 109/L
RIC: Confirmation of donor cell origin 
is required
CBT: Up to day +42
Secondary GF ANC <0.5 × 109/L after initial 
engraftment not related to relapse, 
infection, or drug toxicity




Two or three cytopenias >2 weeks, 
after day +28 in the presence of donor 
chimerism >5%
Graft rejection GF caused by immune rejection of 
donor cells mediated by host cells
41.3  Causes and Risk Factors
The etiology of GF is multifactorial in most of 
the cases (Fig. 41.1, Table 41.1).
41.3.1  Donor Type, HLA Matching, 
and Graft Source
Classical studies showed a close relationship 
between the degree of HLA mismatch and the 
incidence of GF, but it is difficult to draw conclu-
sions because most of them used a limited HLA 
matching including only low-resolution A, B, 
and DR locus (Anasetti et  al. 1989; Petersdorf 
D. Valcárcel (*) 
Department of Hematology, Vall d’Hebron Institute 








et  al. 2001). More recent studies, using high- 
resolution techniques for HLA typing and includ-
ing 10–12 loci (A, B, C, DR, DQ, and DP), did 
not find differences in GF rates between no HLA 
antigen mismatch and a single HLA mismatch in 
both conventional MAC (Lee et al. 2007) or RIC 
(Passweg et al. 2011).
URD transplant was associated with a higher 
risk of GF (HR 1.38, p < 0.001 compared to HLA 
identical sibling) that was even higher when there 
were two or more mismatches (HR 1.79, 
p < 0.001) (Olsson et al. 2015).
In the haploidentical setting, the incidence of GF 
is around 10% which seems higher than the 3–5% 
currently reported MSD or URD HSCT although 
there are not well-designed comparative studies.
41.3.2  Graft Source and Cellular 
Content
BM is consistently associated with delayed neu-
trophil and platelet engraftment across all types 
of transplant; the impact on GF depends on donor 
type. GF incidence is not different for HLA MRD 
(Bensinger, 2012), but it is higher in the setting of 
URD (9% vs 3%, for BM and PB, respectively, 
p  <  0.001) (Anasetti et  al. 2012). There are no 
prospective randomized data either looking at 
MAC or RIC, but retrospective results from 
EBMT and CIBMTR suggest there were no dif-
ferences in GF between BM and PB (less than 
5% in all cases). In contrast, in a study evaluating 
donor characteristics, the use of BM was the only 
factor associated with GF after RIC (HR 2.3; 
p = 0.02) (Passweg et al. 2011).
The minimum cellular content required is still 
a matter of debate. Table 41.2 depicts a conserva-













Fig. 41.1 Causes associated with the development of GF
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41.3.3  Anti-HLA Antibodies
The presence of donor-specific anti-HLA anti-
bodies (DSA) is associated with higher risk of 
GF in the context of haploidentical CBT and 
URD transplants, and it may in fact translate into 
a reduced OS (Spellman et al. 2010; Ciurea et al. 
2009; Ciurea et al. 2015). The high prevalence of 
anti-HLA antibodies (10–40%) (Morin-Zorman 
et al. 2016) and the increasing use of mismatched 
donors prompted the EBMT to write a set of 
advices and recommendations on this issue 
(Table 41.3) (Ciurea et al. 2018).
41.3.4  Conditioning Regimen
Increasing the intensity of MAC conditioning 
protocols does not reduce the incidence of GF. In 
contrast, RIC may be associated with a higher 
risk.
Although it is well accepted that TBI reduces 
the risk of GF, there are no comparative studies 
that confirm this latter point. In combination with 
CY, the use of full-dose TBI does not seem to 
reduce GF in comparison with BU.  The use of 
ATG in the preparative regimen in combination 
Table 41.2 Minimum cell content recommended
Progenitors
Type of 























Cord blood HLA 4–6/6 TNC >2.5–3 × 107/kg
CD 34 >1 × 105/kg
TNC total nucleated cells, MAC myeloablative condition-
ing, RIC reduced intensity conditioning regimen





DSA: 10–20%. Higher in female 
(increase with each pregnancy)
Detection 
methods
 •  Cell based (direct test): Donor 
viable lymphocytes and patient 
serum are needed. Complex and 
time-consuming technique. Low 
specificity and variable sensitivity 
(higher with flow cytometry 
assays than complement-based 
assays)
 •  Solid phase immunoassays 
(virtual test): Only requires 
patient serum, and the technique 
is easy and fast. Sensitivity and 
specificity are intermediate/high 
depending on the type of assay. 
Modified techniques such as C4d 
or Cq1 assays allow to detect 
complement-fixing antibodies, 
which are at higher risk of 
inducing GF. These are the test 
most commonly used nowadays; 
initial DSA testing and 
complement assay in case of 
positivity are recommended
 •  Although not well validated, the 
threshold of positivity for DSA 
can be considered >1000 and 
specially >5000 MFI, which is 
probably associated with the 
presence of complement binding 
antibodies
 •  DSA study should be done during 
donor identification to select a 





 •  No standard scheme is widely 
accepted; different combinations 
have proven to be efficacious
 –  Ab removal: Plasmapheresis 
1–4 procedures days-10 to -17 
and even after transplant
 –  Inhibition of Ab production: 
Rituximab 375 mg/m2 IV days
 –  Ab neutralization: Infusion of 
20–40 platelet units selected to 
share donor antigens or buffy 
coat from 1 unit of blood, on 
day-1. IVIg can also be used
Avoid complement activation: IVIg, 
eculizumab
DSA donor-specific antibodies, MFI mean fluorescence 




with CY seems to reduce the incidence of GF in 
patients with aplastic anemia. Also, in aplastic 
anemia patients, the addition of two Gy TBI to 
FLU/CY did not reduce the incidence of this 
complication.
41.3.5  Other Factors Associated 
with the Development of GF
ABO mismatch: Major incompatibility was asso-
ciated with primary GF (HR 1.24; p = 0.012).
Cryopreservation: Associated with primary 
GF (HR 1.43; p = 0.013).
Female donor to male recipient: Associated 
with primary GF (HR 1.28; p = 0.001).
Splenomegaly: Associated with primary GF in 
MPN (HR 3.92; p = 0.001) and MDS (HR 2.24; 
p = 0.002).
Use of G-CSF: Associated with reduced risk 
of primary GF (HR 0.36; p < 0.001) vs no growth 
factors.
Underlying disease: Nonmalignant diseases 
are associated with higher incidence.
Previous treatments: Impairment engraftment 
through the damage of marrow microenviron-
ment. The absence of treatments may induce 
graft rejection.
Graft manipulation: Ex vivo TCD is associ-
ated with a higher risk of primary GF in most 
studies.
41.4  Management of GF
OS after GF is consistently low, even in those 
patients who receive a salvage transplant; thus, 
the most important measures should be directed 
to avoid graft failure GF and to identify it as soon 
as possible in order to adopt the measures to 
revert it.
41.4.1  Prevention and Early 
Diagnosis of GF
The identification of DSA is of utmost impor-
tance in the mismatch setting. Desensitization 
treatment in patients at higher risk seems reason-
able. Although barely supported by well-designed 
studies, we would probably recommend the fol-
lowing measures to be adopted in patients at high 
risk of GF: the use of PB as stem cell source, 
include low dose TBI and/or ATG in the condi-
tioning regimen, consider the use of G-CSF post 
transplant, and a close evaluation of engraftment 
including marrow chimerism studies shortly after 
transplant (day +14). In a single-CBT study, a 
level of donor chimerism in BM lower than 65% 
was associated with a higher risk of GF (Moscardó 
et  al. 2009); these results cannot be directly 
extrapolated to other types of transplant.
Olson and colleagues developed a score to pre-
dict GF in patients at risk at day +21 post- HSCT 
(Olsson et al. 2015): age (<30, 1 point), Karnofsky 
status (<90%, 1 point), disease (MDS, 1; CLL or 
CML, 2; and MPN, 3 points), status (advanced, 1 
point), HLA matching (mismatched, 2 points), 
graft (BM <2.4 × 108/kg, 1 point; PB, 2 points), 
conditioning (no TBI, 2 points), and GVHD pro-
phylaxis (no CNI + MTX, 2 points; TCD, 3 
points). A score >6 at day +21 had a positive pre-
dictive value of 28–36%, while the negative pre-
dictive value of a score <7 was 81% for GF.
41.4.2  Initial Measures
It is important to apply them as soon as GF is 
suspected.
• Stop as many toxic drugs as possible; treat 
infections; although of limited utility, it would 
be reasonable a trial of G-CSF.
• Adjust post transplant IS. Maintain correct IS 
levels in the early post transplant period. Later 
on, after the third/sixth month and if mixed 
chimerism is present, especially after a RIC 
transplant, a faster tapering of IST could over-
come mixed chimera (in patients with SAA, it 
is commonly recommended to increase IST).
• Data regarding the use of TPO analogues after 
transplant are scarce, but the results of eltrom-
bopag in aplastic anemia and its favorable tox-
icity profile would support, in our view, a trial 
with this drug before considering more com-
plex and risky options as DLI or second 
transplant.
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41.4.3  DLI and CD34 Boost
DLI could be recommended if decreasing levels 
of donor chimerism are observed. A careful risk/
benefit evaluation is warranted as this is not a 
risk-free approach and a high risk of develop-
ment of GVHD is anticipated.
In patients with poor graft function, the use 
of CD34 boost can be offered. Unfortunately, it 
is not clear when to perform it, but probably 
2–3 months without improvement after the ini-
tial measures would be a reasonable cutoff.
41.4.4  Second Transplant
The limited utility and low success of cryopre-
served autologous stem cells do not allow to for-
mally recommend to perform auto-HSC harvest 
in any type of transplant procedure.
Results and recommendations for second allo-
geneic transplantation are detailed in Tables 41.4 
and 41.5.












67.7% (+19) 3 year: 60%




62% (+17) 3 year: 33%




75% (NR) 3 year: 70%




2 BM, 1 CB
100% (+12) 3 year: 35%
Gyurkorcza (2009) 38 (1°, 18; 2°, 20)
Hem Neo, AA
14/24
36 PB, 1 BM, 1 CB
87% (+15) 4 year: 42%
Schreiber (2010) 122 (1°, 122)
Hem Neo, AA
98/24
60 PB, 62 CB
66% (NR) 1 year: 11%




7 PB, 11 BM, 2 CB
90% (+20) 3 year: 60%










1 year PB:58% 
CB: 28%




61 PB, 6 BM, 8 CB
85% (+15) 5 year: 31%
Hem Neo hematological neoplasias, AA aplastic anemia, FA Fanconi anemia, Non-Mal nonmalignant disorders, PB 
peripheral blood, BM bone marrow, CB cord blood, TCD T-cell depletion
Table 41.5 Recommendations to perform a second allo-
geneic HSCT as treatment for GF
Type of donor Similar results using the same/
different donor. Consider different 
donor if it is not associated with 
significant delays. Consider 
haploidentical donors
Always avoid donors if positive DSA
Conditioning 
regimen
It is always required. Better RIC
Post transplant 
IS
It is required; CNI-based schemes are 
the most commonly used
Stem cell 
source
PB or BM show similar results and 
should be preferred to CB
T-cell depletion –  Avoid ex vivo T-cell depletion, 
especially if with immune graft 
rejection
–  In cases of poor graft function, it 
can be a good option as it reduces 
the potential risk of GVHD
–  ATG or alemtuzumab has been used 
to foster IS and also to reduce 
GVHD risk
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Key Points
• Graft failure is an infrequent but often 
fatal complication of HSCT.
• Etiology is complex and very frequently 
multifactorial.
• Preventive measures and early identifica-
tion of potential causes in order to try to 
revert them are the key aspects to treat it.
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A group of complications that occur after trans-
plant share several common characteristics:
 (1) They appear early after HSCT (between day 
0 and day +100).
 (2) Their diagnosis is usually based on the pres-
ence of medical signs and symptoms, and 
consequently they are classified as syn-
dromes. Their clinical manifestations are 
overlapping, making their differential diag-
nosis difficult.
 (3) They seem to begin at the capillary level, in a 
systemic way or in one or more affected 
organs.
 (4) If not properly treated, they can evolve into 
an irreversible MODS/MOF.
The animal models of SOS showed that the 
first morphological alterations observed occurred 
in endothelial cells (EC) of the hepatic sinusoids 
(DeLeve et al. 1996). Similarly, multiple ex vivo 
and in vitro studies have shown that, in auto- and 
allo-HSCT, there is a pro-inflammatory and pro-
thrombotic state secondary to endothelial dam-
age (Carreras et  al. 2010; Palomo et  al. 2009, 
2010; Carreras and Diaz-Ricart 2011). Therefore, 
all these complications are nowadays grouped 
under the name of “early complications of endo-
thelial origin”:
 – Sinusoidal obstruction syndrome (SOS) of the 
liver (formerly denominated VOD)
 – Capillary leak syndrome (CLS)
 – Engraftment and peri-engraftment syndrome 
(ES and peri-ES)
 – Diffuse alveolar hemorrhage (DAH) (see 
Chap. 42)
 – Thrombotic microangiopathy associated with 
HSCT (TA-TMA)
 – Posterior reversible leukoencephalopathy syn-
drome (PRES)
Initially, idiopathic pneumonia syndrome 
(IPS) was included in this group. However, even 
if endothelial damage plays a role in its patho-
genesis, other more relevant factors seem to be 
present.
Probably along the next years, GVHD will be 
included in this group since every day it is more 
evident that endothelial dysfunction is the origin 
and not the consequence of this complication.
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42.2  Sinusoidal Obstruction 
Syndrome (See Chap. 49)
42.3  Engraftment Syndrome
42.3.1  Definition
High and well-tolerated fever of a noninfectious 
origin developed when the first neutrophil 
appears in peripheral blood indicating the 
engraftment. This syndrome has also been called 
CLS of the engraftment, autoaggression syn-
drome, respiratory distress of the engraftment, 
aseptic–septic shock, and autologous GVHD.
42.3.2  Pathogenesis
It seems to appear as a result of a systemic endo-
thelial damage produced by the massive release 
of pro-inflammatory cytokines (IL-2, TNF-α, 
IFN-γ, IL-6), M-GSF, EPO, and products of 
degranulation and oxidative metabolism of neu-
trophils. In some cases, the concomitant adminis-
tration of G-CSF, potent endothelial toxicant, 
contributes to its development.
42.3.3  Clinical/Biological 
Manifestations of ES
Around the day when engraftment startsa
Classical  
(main criteria)
Fever ≥38.3 °C well tolerated
Skin rash (>25% of body surface)b
Pulmonary edema (non- 
cardiogenic) / hypoxia





Creatinine increase (≥2 × N values)
Hepatic dysfunction (bilirubin 
≥2 mg/dL or AST/ALT ≥2 × N)
Diarrhead
Encephalopathy
aFirst day with neutrophil counts greater than 0.5 × 109/L
bVery similar to an acute GVHD
cValues higher than those observed in a febrile neutrope-
nia. Due to its recent description, this parameter is not 
included in the classical diagnostic criteria. The cutoff 
point of 6  mg/dL has a high sensitivity and specificity 
(90%). Additionally, CRP allows monitoring the response 
to the treatment since it normalizes completely in a few 
days (Carreras et al. 2010)
dAt least two fluid depositions per day without microbio-
logical documentation of infection
42.3.4  Diagnostic Criteria
Spitzer 
(2001)
More specific but too much complex.
3 major criteria or 2 major + 1 minor 




Simplest and enough specific.
Noninfectious fever + another major 
criteria or diarrhea since 24 h before 
engraftment
42.3.5  Incidence and Risk Factors
ES is classically observed after autologous HSCT 
although it has also been described after NMA 
allo-HSCT (Gorak et  al. 2005) and after CBT 
(see pre-ES).
Incidence: Ranging between 5 and 50% 
depending of the population analyzed and criteria 
used.
Most relevant risk factors for ES are:
 – Auto-HSCT for diseases not intensively 
treated with chemotherapy before HSCT 
(AID, AL, POEMS, breast cancer, etc.)
 – Intensity of the conditioning (NMA < MEL < 
BEAM < CY/TBI)
 – In myeloma patients, previous treatment with 
BOR or LENA (Cornell et al. 2013)
 – Use of PBSC or G-CSF
42.3.6  Prophylaxis and Treatment 
(Cornell et al. 2015)
Prophylaxis: Avoid the use of G-CSF after HSCT 
in the high-risk patients.
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Treatment:
 – When suspected, stop immediately G-CSF.
 – If fever persists after 48 h of ATB treatment and 
cultures are negative, start methyl-PRD 1 mg/kg 
q12h (3 days) and progressive tapering in 1 week.
 – When PRD is stopped, some recurrences of ES 
could be observed; treat again with steroids.
 – With an early treatment, 90% of CR, any delay 
can favor the evolution to MOF.
42.4  Pre-engraftment Syndrome
ES-like was described in 2003 after CBT.  Its 
pathogenesis is similar to ES + alloreactivity and 
cytokine storm (also denominated “early immune 
reaction” in this scenario) (Lee and Rah 2016).
Main differences with classical ES are:
 – Development in the context of MAC–RIC 
allo-HSCT
 – Earlier presentation (around day +7; up to 
10–11 days before engraftment)
 – Fluid retention in 30% of cases
 – Higher incidence than ES (20–70% of CBT) 
(Lee and Rah 2016)
Patients with pre-ES have less graft failure 
and more GVHD without impact in TRM (Park 
et al. 2013).
42.5  Capillary Leak Syndrome
42.5.1  Definition
Idiopathic systemic capillary syndrome was 
described in healthy patients that presented 
episodic crisis of hypotension/hypoperfusion, 
hypoalbuminemia, and severe generalized edema 
(Clarkson disease). Usually, these manifestations 
could be revered with steroids, vasopressors, fluid, 
and colloids, but some patients could die during 
this recovery phase due to a cardiopulmonary 
failure (Druey and Greipp 2010).
Very similar episodes have also been described 
after the administration of IL-2, IL-4, TNF-α, 
GM-CSG, and G-CSF and in the context of HSCT 
(Nürnberger et al. 1997; Lucchini et al. 2016).
42.5.2  Pathogenesis
Many mechanisms have been suspected, but now-
adays, due to the duration of the capillary leak and 
its reversibility, the endothelial injury seems to be 
the main cause for the capillary damage. The high 
levels of VEGF and angiopoietin-2 (potent induc-
ers of vascular permeability) observed in these 
patients could play a role (Xie et al. 2012).
42.5.3  Diagnostic Criteria 
in the Context of HSCT 
(Lucchini et al. 2016)
Early after HSCT (≈days +10 to 11).
Unexplained weight gain >3% in 24 h.
Positive intake balance despite furosemide 
administration (at least 1 mg/kg) evaluated 24 h 
after its administration.
42.5.4  Incidence and Risk Factors
Mainly observed in children
True incidence unknown (variable diagnostic 
criteria): 5.4% in the largest series (similar inci-
dence between MAC and RIC-HSCT)
Apparently no relationship with G-CSF admin-
istration but higher incidence among patients 
receiving this treatment more than 5 days.
42.5.5  Treatment and Evolution
When suspected, stop immediately G-CSF
Steroids; supportive therapy (catecholamines, colloids, 
and plasma)
A rapid improvement has been observed in a patient 
treated with bevacizumab (Yabe et al. 2010)
Sixty-seven percent of patients required ICU 
admittance and 47% mechanical ventilation
Fourty-seven percent reach a complete remission
TRM at day +100: 43% vs only 5% in patients w/o 
CLS (Lucchini et al. 2016)
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42.6  Thrombotic 
Microangiopathy Associated 
with HSCT (TA-TMA)
42.6.1  Definition and Classification
TMA are a heterogeneous group of diseases 
characterized by microangiopathic hemolytic 
anemia and thrombocytopenia due to platelet 
clumping in the microcirculation leading to 
ischemic organ dysfunction. As this phenome-
non could be observed in different clinical situ-
ations, a consensus on the standardization of 
terminology has been recently proposed by an 
International Working Group (Scully et al. 
2017) (Fig. 42.1).
42.6.2  Pathogenesis
Like in the other vascular–endothelial syndromes 
after HSCT, the endothelial injury due to the 
action of different factors (conditioning, lipopoly-
saccharides, CNI, alloreactivity, GVHD) plays a 
crucial role in its development. Endothelial injury 
generates a prothrombotic and pro- inflammatory 
status that favors capillary occlusion.
However, unlike in other endothelial syn-
dromes, the dysregulation of the complement 
system and the possible presence of specific 
antibodies (donor- or recipient-specific Ab, as 
anti- factor H Ab) could play a relevant role in 
some TA-TMA.  The activation of the classical 
pathway of the complement system (by chemo-
therapy, infections, GVHD) and the activation of 
the alternative pathway (favored by a genetically 
determined mutation of several genes [CFH, 
CFI, CFB, CFHR1,3,5]) produce deposits of 
C4d or C5b-9 (membrane attack complex) frac-
tions, respectively (Jodele et al. 2016b).
Recently, the two-hit hypothesis tries to unify 
all these pathogenetic mechanisms (Khosla et al. 
2018). The first hit will be produced by the nor-
mal input signals that any EC could receive (cell 
interaction soluble mediators, oxygenation, 
hemodynamic, temperature, pH) plus predispos-
ing risk factors as prolonged immobilization, 
bacterial–fungal infection, leukemia not in remis-
sion, G-CSF administration, URD HSCT, HLA 
mismatch, RIC (fludarabine), or high-dose BU. 
TMA




TTP=Thrombotic Thrombocytopenic Purpura; HUS=Hemolytic Uremic Syndrome
Complement







Fig. 42.1 Terminology 
of TMA
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The second hit will be produced by CNI, mTOR 
inhibitors, severe infections, or TBI.  All these 
events would trigger the succession of events that 
are observed in Fig. 42.2.
42.6.3  Clinical Manifestations





Schistocytes in the blood
Decreased haptoglobin
Manifestations of organ damage
Kidney Decreased glomerular filtration rate
Proteinuria
Hypertension; ≥2 medications
Lungs Hypoxemia, respiratory distress





Manifestations of organ damage
Polyserositis Refractory pericardial/pleural 
effusion, and/or ascites, without 
generalized edema
42.6.4  Diagnostic Criteria
The gold standard for diagnosis is a biopsy of the 
damaged organ. However, to obtain these sam-
ples is almost impossible in these patients. 
Consequently, along the last years, several 
attempts have been carried out to reach consensus 
criteria for the diagnosis of this complication. 
The most relevant advance in this area has been 
to recognize some clinical data, not previously 
included in the diagnostic criteria, that could 
appear even before the classical ones and that are 
indicative of very bad prognosis. Unlike other 























RSA and CFH Ab
Gene mutations
(CFH, CFI, CFB, CFHR1,3,5)
→
Fig. 42.2 Pathogenesis of TA-TMA
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Criteria BMT-CTNa IWGb Chaoc Jodeled
Schistocytes ≥2/HPF ≥4%e ≥2/HPF Yes
Elevated LDHf Yes Yes Yes Yes
De novo thrombocytopenia – Yes Yes Yes
Decreased Hbg – Yes Yes Yes
Coombs (−ve) Yes – Yes –
↓ Haptoglobin – Yes Yes –
Renal/neurological dysfunction Yes – – –
Coagulation normal – – Yes –
Proteinuriaf,h ±
Hypertensionf,i ±
Increased serum C5b-9 levels – – – ±







fEarlier clinical signs of TMA
gOr increased red cell transfusion
hOr protein/creatinine ratio ≥2 mg/mg
iHypertension refractory to ≥2 antihypertensive drugs
42.6.5  Clinical Forms, Incidence, Risk 
Factors, and Prognosis
Forms: (1) TA-TMA associated to CNI—the 
most frequent form with good prognosis and a 
real incidence unknown; (2) TA-TMA not associ-
ated to CNI—bad prognosis, requiring specific 
measures.
Clinical manifestations: Onset day, median 
time day +32 to +40 (>92% before day +100).
Incidence: Unknown due to the different diag-
nostic criteria—literature focused on allo-HSCT, 
from 0.5% to 76%; EBMT survey (IWG criteria), 
406 allo-HSCT, 7% (Ruutu et al. 2002); meta-
analysis (variable criteria), 5423 allo-HSCT, 
8.2% (George and Selby 2004); and prospective 
(Cho criteria), 90 allo-HSCT, 39% (Jodele et al. 
2014). Similar incidence in MAC tan in RIC.
Risk factors: Use of CNI (more if associated 
to SIR), viral (CMV, ADV, BK virus, etc.) or fun-
gal infection, active GVHD, URD/mismatch 
HSCT (probably due to more infections and 
GVHD), and several gene polymorphisms (pre-
dominate in non-Caucasian).
Prognosis: Despite the resolution of 
TA-TMA, these patients have an increased rela-
tive risk of chronic kidney disease, 4.3; arterial 
hypertension, 9; and TRM, 5.




LDH 3 times a week
Proteinuria × 3 times per week
Blood pressure (daily)






















→ All the previous 
measures + specific 
treatment (see later)
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42.6.7  Treatment
Supportive Stop CNI (substitute by PRD or 
MMF)





In recent prospective studies, 
59–64% of CR (better if started 
early)
In patients with Ab anti-factor H, 
better/good results with TPE ± 
RTX
RTX should be administered after 
TPE
Do not associate TPE with 
eculizumab
Rituximab (RTX) Reported 12/15 responses to RTX 
+ TPE (Uderzo et al. 2014)
RTX should be administrated 
immediately after TPE
Defibrotide (DF) Recent report with 46 adults and 
children: 77% of CR (Yeates et al. 
2017)
Eculizumab Indicated in TA-TMA with 
proteinuria ± > sC5b-9: 67% of 
responses
Children could require higher 
doses (quantify CH50 to adjust the 
doses) (Jodele et al. 2015, 2016a)
CH50: Total hemolytic complement activity
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Graft-versus-host disease (GvHD) was first 
 recognized in murine models of HSCT, and in the 
absence of knowledge of the HLA system, it was 
termed “secondary” (secondary to recovery from 
irradiation damage) or “runt” disease on the basis 
of anorexia, reduced weight, diarrhea, ruffled fur, 
and eventual death. Billingham established the 
criteria for the occurrence of secondary disease in 
the 1960s, i.e.:
 – The administration of a graft containing 
immunocompetent cells
 – Immunological disparity between host and 
donor
 – The administration of the graft to an immuno-
suppressed host unable to reject the graft cells
In the human setting, we traditionally recog-
nize two forms of GvHD, acute (aGvHD) and 
chronic (cGvHD). The original distinction of 
acute from chronic GvHD, namely, the occur-
rence before or after day 100 post stem cell infu-
sion, has become blurred due to occurrence of 
aGvHD symptoms beyond day 100 after RIC 
regimens and/or after DLI (usually given after 
day 100). Nevertheless, the underlying combina-
tion of symptoms and signs affecting the skin, 
liver, and gastrointestinal tract forms a classical 
clinical syndrome enabling the diagnosis, and a 
helpful guide to the appropriate terminology is 
provided in Table 43.1 (Filipovich 2005).
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aGvHD remains, directly or indirectly, the major 
cause of short-term (day 100 and 1 year) mortality 
after allo-HSCT. The pathophysiology of aGvHD 
has been attributed to a three-phase process com-
prising initial tissue damage from the conditioning 
regimen which in turn leads to activation of host 
antigen-presenting cells by pathogen- associated 
molecular patterns (PAMPs) and damage-associ-
ated molecular patterns (DAMPs) and activation 
and proliferation of donor T cells (afferent phase) 
and finally to the effector phase characterized by 
cytotoxic cell damage and release of inflammatory 
cytokines such as interleukin-1 (IL-1) and tissue 
necrosis factor-alpha (TNFα) that eventually pro-
duce tissue necrosis (efferent phase). The action 
of this pathogenetic process in the induction of 
aGvHD is modulated in part by the presence of 
cells capable of inhibiting immune response, 
such as T-regulatory cells (Tregs), Type 1 regu-
latory T cells (Tr1 cells), invariant NKT cells, 
and myeloid-derived suppressor cells (MDSCs) 
(Ferrara et al. 2009; Teshima et al. 2016).
43.3  Risk Factors
As aGvHD is a result of an alloimmune effect the 
major risk for occurrence is the presence of HLA 
disparity and increasing degrees of HLA- 
mismatching increase the probability of more 
severe disease. Other important and consistent 
risk factors include older patient age, the use of 
female donors for male recipients, prior alloim-
munization of the donor, and the nature of GvHD 
prophylaxis. A number of publications have vari-
ously reported risk factors such as increasing 
donor age, increasing intensity of the preparative 
regimen, the use of PBSC as opposed to BM, and 
recipient seropositivity for CMV.
A recent study of 2941 recipients of allo- 
HSCT in Seattle confirmed the importance of the 
degree of HLA mismatching, the use of URD, 
and the administration of high-dose TBI in pre-
dicting the occurrence of moderate to severe 
aGvHD.  In contrast they found that increasing 
donor age, cytokine-mobilized stem cells, and 
the use of female donors for male recipients did 
not impact on the likelihood of aGvHD but were 
associated with the occurrence of cGvHD 
(Flowers et al. 2011).
More recently we have begun to appreciate the 
importance of non-HLA genetic factors in the 
development of GvHD. Examples include poly-
morphisms in the genes encoding cytokines such 
as the tumor necrosis factors, the interleukins 
(IL-1, IL-6, and IL-10), interferon gamma (IFN- 
γ), and transforming growth factor-β3 (TGF-β3) 
and the expression of the killer cell 
immunoglobulin- like receptors (KIR). 
Interestingly one of the common features of the 
organs involved in aGvHD is that they are all 
exposed to microbial pathogens through the 
intestinal mucosa, epidermis, and portal circula-
tion, and early murine studies confirmed a reduc-
tion in the severity and incidence of GvHD in 
animals that received antibiotic prophylaxis to 
“decontaminate” the GI tract or those kept in 
germ-free environments. This has led to the spec-
ulation that potential differences within individu-
als in the interactions of antigens derived from 
infective organisms and pathogen recognition 
receptors (PRR) might protect or predispose to 
the occurrence of GvHD. To date the most exten-
sively studied of these receptors is N0D2 
(CARD15) which detects muramyl dipeptide 
(MDP), a by-product of peptidoglycan, which is 
itself a cell wall component of most bacteria. 
Single nucleotide polymorphisms (SNPs) in 
N0D2 are present in approximately 15% of the 
population, and several investigators have studied 
their potential association with the occurrence of 
GvHD. Results are so far conflicting, and further 
work is required to determine their real signifi-
cance (reviewed in Penack et al. 2010).
More recently, the availability of non-cultural 
methods to analyze the whole set of bacteria 
(called microbiota) has broadened our view as 
the presence of commensal microbiota and a 
high diversity of the patients’ microbiota associ-
ated with substantial protection not only from 
GvHD but also from systemic and pulmonary 
infectious complications. The exact mechanisms 
of this protection need still to be defined before 
translation into new preventive approaches, but 
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beneficial effects of microbial metabolites (such 
as short-chain fatty acids and indoles) both on 
epithelial integrity and on immunoregulation are 
likely (Shono and van den Brink 2018; Peled 
et al. 2016).
43.4  Diagnosis and Scoring
aGvHD is manifested by one or more of the fol-
lowing features: an erythematous skin reaction, 
cholestatic liver disease, and gastrointestinal dys-
function. The variety of presentations in each 
organ is provided in more detail in Table 43.2; the 
syndrome ranges from a mild self-limiting condi-
tion to a serious and potentially fatal disorder. 
Because of the complexity of care of an allo- 
HSCT recipient, it is often very difficult to distin-
guish the characteristic features of aGvHD from 
those of other complications such as VOD/SOS, 
conditioning, and general drug toxicity and infec-
tion and consequently to determine the appropri-
ate choice of treatment.
For this reason, it is essential to establish the 
diagnosis by biopsy of one or more affected 
organs and confirmation of the characteristic his-
topathological features (Table 43.3). The targets 
of the immune response in aGvHD are the epithe-
lial cells including basal and suprabasal cells of 
the epidermis, the intestinal epithelium, and the 
biliary duct epithelium, and the characteristic 
feature is identical, i.e., the presence of infiltrat-
ing immune cells close to apoptotic cells known 
as “satellite cell necrosis.”
The first classification of aGvHD was devel-
oped by Glucksberg et  al. (1974). Each organ 
was staged from 0 to 4 (Table  43.4), and the 
resultant stages were combined to provide an 
overall grade (Table  43.5) (Glucksberg et  al. 
1974). In 1994 Przepiorka et al. described the 
outcome of a Consensus Workshop to develop 
Table 43.2 Clinical manifestations of acute GvHD
Organ Clinical manifestation
Skin Erythematous maculopapular rash, 
often initially involving the palms 
and soles
May progress to involve the entire 
body surface and may be pruritic 
and/or painful
In severe cases, bullae may form 
leading to desquamation
Liver Cholestasis with or without frank 
jaundice
Cholestatic enzymes comparatively 
more deranged than transaminases
Gastrointestinal 
(GI) tract
Upper: Anorexia, nausea, and 
vomiting
Lower: Diarrhea, typically green and 
watery; in severe case diarrhea 
contains fresh blood and mucosa and 
is accompanied by abdominal 
cramps and, on occasion, paralytic 
ileus
Table 43.3 Histopathological findings in acute GvHD
Organ Histopathological features
Skin The diagnostic feature is a lichenoid 
infiltration of the upper dermis and 
lower epidermis with vacuolation, 
degeneration, and individual cell 
necrosis of the cells of the basal layer 
of the epidermis
Grade I: vacuolation of epidermal 
basal cells
Grade II: presence of individually 
necrotic keratinocytes
Grade III: confluent areas of 
keratinocyte necrosis forming bullae
Grade IV: sloughing of the epidermis
Liver The most consistent histological 
feature is small bile duct damage, 
which is usually seen in association 
with cholestasis and is rare in other 
complications of HSCT
The biliary epithelial cells have 
enlarged hyperchromatic nuclei or 
small pyknotic nuclei and vacuolated 
cytoplasm
Periportal and midzone hepatocellular 
necrosis and minimal lymphocytic 
infiltrates in the portal tract
Although there is a histological 
grading for liver histology, it has no 
proven prognostic value
Gastrointestinal “Exploding crypts” within which are 
necrosis of individual epithelial cells 
at the periphery of the crypts leaving 
fragments of nuclear and 
cytoplasmatic debris
Grade I: Individual cell necrosis
Grade II: Loss of individual crypts
Grade III: Loss of two or more 
adjacent crypts with ulceration
Grade IV: Denudation of epithelium
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an improved scoring system that retained most 
of the characteristics of Glucksberg but dropped 
the use of the clinical performance score and 
included upper intestinal symptoms within the 
definition of aGvHD (Przepiorka et  al. 1995). 
Subsequently, the IBMTR prospectively evalu-
ated a “severity index” against the Glucksberg 
criteria but were unable to identify any particu-
lar advantage for the new system (Rowlings 
et al. 1997). In fact, the Glucksberg score was a 
better predictor of survival and remains in regu-
lar use (Cahn et al. 2005). Currently, electronic 
applications are developed supporting accuracy 
of staging and grading of acute GvHD 
(Schoemans et al. 2018).
43.5  Epidemiology
Moderate to severe aGvHD occurs in approxi-
mately 40% of all recipients of allo-HSCT, but 
the precise incidence varies considerably depend-
ing predominantly on the nature of the donor and 
the method of GvHD prophylaxis. Without effec-
tive prophylaxis, it is an almost inevitable and 
frequently deleterious complication at least in 
unrelated matched donor and mismatched family 
grafts.
43.6  Prevention  
(Also See Chap. 25)
Grade III–IV aGvHD, especially if it turns out to 
be resistant to first-line treatment, has an 
extremely poor prognosis despite therapeutic 
intervention, and consequently considerable 
efforts are made to try and prevent its occurrence. 
The rationale of prophylaxis was originally 
directed toward prolonged IS of donor T-cell 
function through the peri- and post transplant 
administration of IS agents. Early studies identi-
fied the superiority of a combination of the CNI 
and CSA, with MTX over MTX alone. In prac-
tice this combination remains the most frequently 
used method of prophylaxis although some 
investigators have replaced CSA with tacrolimus 
(TAC) since large two phase III randomized stud-
ies reported a reduction in the incidence of grade 
II–IV aGvHD at 32% in recipients of sibling 
transplants and 56% in those who received unre-
lated donor grafts in patients who received TAC 
plus MTX compared to 44% (sibling) and 74% 
(unrelated) in those who were randomized to 
CSA and MTX.  However, there was no differ-
ence in survival that could be attributed to the 
nature of the GvHD prevention (Ratanatharathorn 
et al. 1998; Nash et al. 2000). Recently, investiga-
tors have also reported the efficacy of newer 
agents such as mycophenolate mofetil (MMF) 
and sirolimus (SIR). Whereas MMF has not been 
tested in large randomized trials, the combination 
of TAC and SIR was compared with that of TAC 
and MTX in a phase III randomized study show-
ing equivalent efficacy but differences in toxicity 
(Törlén et al. 2016).
An alternative approach to GvHD prophylaxis 
is to consider removal of donor T cells either 
Table 43.4 Staging of acute graft-versus-host disease
Stage Skin based on maculopapular rash
Liver based on 
bilirubin
Gastrointestinal based on quantity of 
diarrhea
+ <25% of surface 34–50 μmol/L 500–1000 mL
++ 25–50% of surface 51–102 μmol/L 1001–1500 mL
+++ Generalized erythroderma 103–255 μmol/L >1500 mL
++++ Generalized erythroderma with bullae 
and desquamation
>255 μmol/L Severe abdominal pain with and 
without ileus
Table 43.5 Overall grading of acute GvHD
Grade
I Skin + − ++
II Skin + − +++, GI, and/or liver +
Mild decrease in performance
III Skin ++ − +++, GI, and/or liver ++ − +++
Marked decrease in clinical performance
IV Skin ++ − ++++, GI, and/or liver ++ 
− ++++
Extreme decrease in clinical performance
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ex vivo prior to infusion or in vivo before and/or 
after infusion using polyclonal (anti-thymocyte 
globulin, ATG) or MoAb. A similar effect can 
also be achieved by positive selection of CD34+ 
stem cells. These techniques, collectively known 
as TCD, are extremely efficient in preventing 
acute and chronic GvHD and were in widespread 
use in the 1980s and 1990s. Unfortunately, they 
were rapidly identified as contributing to an 
increased risk of infection and disease relapse 
and subsequently became confined to situations 
in which the risk of GvHD is increased, e.g., 
recipients of mismatched and haploidentical 
transplants where the risk of death from GvHD 
outweighs the risk of later disease recurrence. In 
unrelated donor SCT, polyclonal ATG has 
become a major player as two randomized trials 
showed positive effects mainly on chronic GvHD 
(Finke et al. 2009; Walker et al. 2016).
Recently, a prospective, double-blind phase III 
trial to investigate the effect of ATG in the setting 
of MUD HSCT showed that grade II–IV acute 
GvHD and moderate-severe cGvHD were lower 
in ATG recipients but the overall survival was 
lower in ATG recipients (Soiffer et al. 2017). This 
could be related to higher ATG levels in patients 
with low lymphocyte counts following TBI which 
might translate in subsequent infectious compli-
cations and EBV-related post transplant lymphop-
roliferative disease. Thus, balancing suppression 
of long-term GvHD versus suppressing anti-
infectious defense is an ongoing challenge in 
GvHD (Gagelmann et al. 2017).
Other studies have explored alternative meth-
ods of aGvHD prophylaxis including the infusion 
of an expanded population of T-regulatory cells 
at the time of stem cell infusion and partial TCD 
such as depletion of α/β T cells or elimination of 
alloreactive T cells after in vitro or in vivo activa-
tion. In this context, the administration of PT-CY 
in order to eliminate early activated donor T cells 
has gained substantial interest particularly in the 
context of haploidentical transplantation, and 
further studies comparing the more complex 
T-cell depletion approach with the simple 
approach of PT-CY are currently performed 
(Kanakry et al. 2016).
43.7  Treatment
Grade I aGvHD, by definition affecting only the 
skin, can often be effectively treated with topical 
steroids alone. Early systemic treatment of grade 
I GvHD has been tested but showed no long-term 
advantage. More advanced grades require sys-
temic therapy, and the mainstay of treatment 
remains high-dose methyl-prednisolone (or 
equivalent), usually at a dose of 2  mg/kg/day, 
continued for 7–14 days and followed by a grad-
ual reduction in dose (Ruutu et al. 2014). Patients 
with mild upper GI GvHD may start on lower 
doses with concomitant topical treatment; higher 
doses of steroids resulted in more infectious 
complications without superior long-term 
response. The chance of response decreases with 
increasing grade of GvHD, but in general approx-
imately 40–50% of patients will demonstrate a 
response. Reductions in steroid doses may be fol-
lowed by an exacerbation of symptoms that can 
sometimes be settled by simply increasing the 
dose and reducing more slowly on the second 
occasion. Achieving a balance between the levels 
of IS required to control aGvHD and retaining a 
degree of immunocompetence against microbial 
infection is challenging, and viral and fungal 
infections are frequent complications of pro-
longed steroid therapy. Anti- infective prophy-
laxis should be considered for all such patients. 
Among several candidates for first- line combina-
tion treatments, the most promising combination 
of steroids and MMF has been taken forward to a 
phase III study against steroids alone but failed to 
show superiority for the combination again due 
to an increased rate of infectious complications. 
Thus, so far no single agent has shown superior-
ity of results when combined with  corticosteroids 
for first-line treatment (Martin et  al. 2012; 
Rashidi et al. 2016).
Failure to respond to standard steroid doses 
(defined as progression within 3–5 days of start-
ing treatment or an incomplete response by 
7–14 days) or recurrence after initial dose reduc-
tion (steroid dependence) will necessitate second- 
line treatment. In this context many agents have 
been tried alone or in combination with 
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 corticosteroid. None have shown convincing 
long-term efficacy. The most frequent choice of 
second-line therapy involves one or more MoAb 
recognizing T cells or ATG. MoAb include alem-
tuzumab for the pan T-cell marker CD52, dacli-
zumab, or inolimomab for the alpha subunit of the 
IL-2 receptor expressed on activated T cells; and 
infliximab and etanercept for TNF-α. These 
agents often result in short-term control, but dura-
ble effects are relatively infrequent, and the out-
come of refractory aGvHD is dismal with 
approximately 80% mortality, especially if the 
lower GI tract is involved.
Responses have been reported with extracor-
poreal photopheresis administered at least twice 
a week on a weekly basis, and outcome seems to 
be superior with less toxicities occurring (Jagasia 
et al. 2013) (see Chap. 66).
In 2006, Ringden et al. reported the successful 
use of mesenchymal stromal cells (MSC) in a 
small group of patients with refractory severe 
aGvHD, and later this group described a response 
rate of >50% in a larger group of patients (Munneke 
et  al. 2016). MSC exert immunosuppressive 
effects in a non-HLA-restricted manner and like 
Tregs offer interesting and novel strategies for the 
management of this potentially fatal complication 
although long-term results need to be established 
in future trials (Le Blanc et al. 2008).
While classical IS regimens inhibit a signal 
pathway or cytokine receptor, novel strategies 
target the signaling events downstream of cyto-
kine receptors (e.g., Janus-activated kinase JAK 1 
and 2), CD28 (e.g., Aurora kinase), cell migra-
tion (ROCK), or growth factor signaling (e.g., 
MEK). These inhibitors were tested in preclinical 
studies and showed promising activity (Hill et al. 
2018). A prospective study on the JAK1 inhibitor 
itacitinib showed GvHD response rates of over 
70%, and a retrospective survey on ruxolitinib-
treated patients showed that also patients with 
steroid refractory GvHD may respond to JAK1/2 
inhibition (Zeiser et  al. 2015). The therapeutic 
concept of JAK1/2 inhibition is currently tested 
for steroid-refractory (SR) SR-aGvHD and 
SR-cGvHD in randomized phase III trials.
Another novel approach is infusion of alpha-1 
anti-trypsin which exerts anti-inflammatory 
effects and stimulates regulatory T cells. Two 
recent phase II trials showed CR rates of 35% and 
OR rates of 60% of the patients on day 28 after 
treatment starts (Marcondes et al. 2016 Magenau 
et al. 2018). Vedolizumab is an antibody directed 
against α4/β7 integrin which is selectively 
expressed in the GI tract and approved for treat-
ment of Crohn’s disease. A first report indicated 
high response rates for SR-aGvHD (Fløisand 
et al. 2017). However, more recent updates indi-
cate a high treatment-related mortality in patients 
receiving vedolizumab due to infections of over 
70%, and the ongoing phase III trials will provide 
more information.
43.8  Future Perspectives: 
Biomarkers and Risk-
Adapted Treatment
The difficulties to improve results in SR-aGvHD 
underline that steroid resistance might not just 
represent resistance of alloreactive T cells but 
loss of immunoregulation and tissue tolerance 
(Wu and Reddy 2017) which is difficult to over-
come by classical immunosuppressants. Besides 
new approaches of modulation, potential solu-
tions might be earlier risk adapted or even pre-
emptive treatment strategies which require, 
however, reliable and reproducible identification 
of these patients. Recently, clinical risk scores 
(MacMillan et  al. 2015) and novel biomarkers 
have been reported. The strength of these bio-
markers for early identification of high-risk 
patients at day 7 after HSCT or at onset of GvHD 
has been proven in large multicenter consortia 
and needs now confirmation by trials on 
biomarker- guided treatment strategies (Vander 
Lugt et  al. 2013; Hartwell et  al. 2017; Levine 
et al. 2015). The strength of the current biomark-
ers and scores are partially explained by the fact 
that they identify GI GvHD as the most severe 
and deleterious manifestation in an early phase of 
the disease.
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Chronic GVHD (cGVHD) is the most relevant 
cause of late non-relapse morbidity and subse-
quent mortality (approximately 25%) following 
allo-HSCT (Grube et  al. 2016). Its incidence is 
approximately 50% among all patients following 
allo-HSCT and has increased during the last two 
decades due to increasing patient age and increas-
ing use of unrelated and/or mismatched donors, 
RIC regimens, and PBSC (Arai et  al. 2015). 
While the incidence of cGVHD is lower (20–
40%) in children, its incidence rises to 60% as 
age increases (Baird et al. 2010).
The pathophysiology of cGVHD is different 
from aGVHD and mainly characterized by 
impaired immune tolerance mechanisms affect-
ing innate and adaptive immunity. Both autoreac-
tive and alloreactive donor-derived T and B cells 
play a role (Cooke et al. 2017). Other pathophysi-
ological factors are indirect presentations of allo-
antigens through antigen-presenting donor cells 
and mechanisms of chronic inflammation with 
subsequent scar formation and fibrosis. One 
important aspect of GVHD pathophysiology is 
the variability of immune reconstitution, which is 
age-related and dependent on thymic function 
and hormones. This adds to the unpredictability 
of the effects of transplant procedures and com-
plications in a very heterogenous cohort of chil-
dren and adolescents with malignant and 
nonmalignant diseases.
Known risk factors for adult and pediatric 
cGVHD are unrelated and/or mismatched donor, 
PBSCs as donor source, older donor age, female 
donor into male recipient, and the use of total 
body irradiation (Baird et  al. 2010). By far the 
strongest predictor is the history and severity of 
acute GVHD.
In addition to the harm it causes, cGVHD 
also has a protective effect, as patients with 
cGVHD have lower rates of recurrence of their 
underlying malignant disease (Grube et  al. 
2016). Overall survival of patients transplanted 
for malignant diseases developing mild cGVHD 
is therefore better compared to patients without 
cGVHD.  Even OS of patients with moderate 
cGVHD is not different from patients without 
cGVHD, as the slightly increased mortality 
associated with cGVHD is counterbalanced by 
lower disease- associated mortality (Kuzmina 
et al. 2012).
In contrast, the long-term mortality rate of 
patients with severe cGVHD is as high as 50% taken 
into account that the severity is less relevant com-
pared to certain risk factors for mortality consisting 
of low platelets at diagnosis of cGVHD, the direct 
progression of acute GVHD into cGVHD (pro-
gressive onset), and certain organ manifestations 
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(lung, gastrointestinal and cholestatic liver involve-
ment) (Grube et al. 2016). One important pediatric 
aspect involves the high proportion (up to 50%) of 
nonmalignant underlying diseases as HSCT indi-
cation. While malignant diseases benefit from the 
graft-versus-malignancy effect induced by GVHD, 
it only offers harm for the nonmalignant diseases. 
In daily clinical routine, this fact influences GVHD 
prophylaxis and treatment both in regard to intensity 
and duration of immunosuppressants (Lawitschka 
et al., data of a survey by the EBMT pediatric dis-
eases WP, submitted). However, prospective pediat-
ric data of immune reconstitution in GVHD patients 
evaluating the influence of underlying diseases are 
scarce.
44.2  Clinical Manifestations
cGVHD usually begins between 3  months and 
2  years after HSCT, but earlier onset (at least 1 
month after transplantation) is possible (Jagasia 
et  al. 2015). Besides classical manifestations, 
cGVHD can imitate almost any autoimmune dis-
ease, such as myasthenia gravis and myositis. As 
cGVHD can affect a number of organs, and patients 
often do not report changes until functional impair-
ment is recognized, regular examination of all organs 
potentially affected is essential. The following sec-
tion describes the most common clinical organ man-
ifestations of cGVHD.  In general, pediatric 
manifestations are similar to adult cGVHD; when 
indicated, specific aspects are shortly described.
44.2.1  Skin
The skin is the most frequently involved organ 
with different morphology, depending on the dif-
ferent skin layers (epidermis, cutis, subcutis, and 
fasciae) involved. Some manifestations may 
overlap with acute GVHD like erythema, macu-
lopapular rash, and pruritus. Cutaneous cGVHD 
may show many different non-sclerotic and scle-
rotic phenotypes often simulating well-known 
chronic inflammatory and autoimmune diseases 
(Strong Rodrigues et al. 2018).
Diagnostic features of NIH-defined cGVHD 
include poikiloderma, lichen planus-like, lichen 
sclerosus-like, morphea-like, and deep sclerotic 
eruptions, and no biopsy is needed to confirm the 
diagnosis. Distinctive for cGVHD, other or com-
mon skin manifestations like depigmentation and 
papulosquamous lesions or ichthyosis, keratosis 
pilaris, pigmental changes, loss of skin append-
ages, and sweat impairment are not sufficient for 
diagnosis and require histopathological confir-
mation if no diagnostic signs in the skin or other 
organs are present (Jagasia et al. 2015).
In pediatric patients, the incidence of viral reacti-
vation and infection seems higher (although only 
proven for some viruses), and therefore infection has 
to be ruled out. Viral skin infections can worsen or 
activate cGVHD (Jacobsohn 2010). Premature gray-
ing of the hair is even in small children common, 
possibly together with seborrheic scalp changes. Of 
note, if sweat glands are destroyed, this may be of 
importance for phototherapy because of the inability 
to sweat with consequent hyperthermia.
44.2.2  Eyes
cGVHD of the eyes usually manifests as keratitis 
sicca. In addition to atrophy of the lacrimal gland 
with subsequent tear deficiency (sicca syndrome), 
the meibomian glands and eyelids are often 
affected by severe blepharitis which may initially 
present with tearing. Around the conjunctiva 
there are often not only fibrotic alterations but 
also chronic persistent inflammation with visible 
erythema of the conjunctiva. As dry eye symp-
toms are rarely communicated by children, light 
sensitivity is the predominant symptom, some-
times with excessive eye rubbing. Infections have 
to be ruled out. Referral to a pediatric experi-
enced ophthalmologist is recommended.
44.2.3  Oral Mucosa
Oral manifestations may appear as erythema or 
lichenoid changes (the latter are regarded as diag-
nostic) of the oral mucosa as well as ulcera and 
mucoceles. Sicca symptoms may result from 
destruction of the salivary glands. Long-term 
cGVHD may lead to gingivitis, periodontitis, 
increased tooth decay, and tooth loss. In children 
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excessive drinking during eating may be the first 
symptom of oral involvement. Not only mucosal 
problems but abnormal teeth development (e.g., 
hypodontia, root malformation, enamel hypopla-
sia) and caries are often seen as secondary symp-
toms in infants.
44.2.4  Liver
Liver involvement manifests as cholestasis and 
may resemble primary biliary cirrhosis, but hepa-
titic forms with high transaminases are also possi-
ble. Other factors, such as viral infections (hepatitis 
A, B, C, and E, CMV, EBV, ADV, and HHV6/7), 
drug toxicity, or total-parenteral nutrition- related 
cholestasis, should be excluded, but liver biopsy 
may be required to confirm the diagnosis, par-
ticularly in patients with no other symptoms of 
cGVHD and failure to respond to initial treatment 
of suspected GVHD (Stift et al. 2014).
44.2.5  Gastrointestinal Tract
GI manifestations can lead to dysphagia (esopha-
gus), nausea and vomiting (stomach), or chronic 
diarrhea and malabsorption syndrome (intestines, 
pancreas). Occasionally cGVHD may also mani-
fest as immune-mediated pancreatitis. Of note, 
except esophageal involvement, intestinal involve-
ment is regarded as manifestation of acute GVHD, 
and patients are therefore classified as suffering 
from overlap syndrome in which concomitant 
symptoms of chronic and acute GVHD occur.
Infections like ADV or CMV gastroenteritis, 
secondary gluten or lactose intolerance, pancreatic 
insufficiency, and drug-related side effects (e.g., 
mycophenolate mofetil) have to be ruled out.
Malnutition and enteral fluid and protein loss 
in small children require regular laboratory 
monitoring.
44.2.6  Genitals
The symptoms of cGVHD are similar to those of 
genital lichen planus which may occur in males 
and females. Vaginal synechiae, ulceration, and 
fissures can subsequently occur. Genital manifes-
tations are often associated with oral manifesta-
tions of cGVHD.  As symptoms may not be 
reported spontaneously, females suffering from 
cGVHD require regular gynecological follow- up. 
In girls cGVHD may manifest with vulvovaginitis, 
in boys with balanitis or balanoposthitis. Of note, 
healing may occur with fibrosis possibly leading 
to synechia with the risk of hematocolpos during 
puberty in females and of phimosis in males.
44.2.7  Lung
Pulmonary manifestations occur as progressive, 
irreversible obstruction (bronchiolitis obliter-
ans) and less frequently lymphocytic alveolitis 
resulting in interstitial fibrosis or bronchiolitis 
obliterans organizing pneumonia (BOOP) (see 
Chap. 52).
Since the onset of pulmonary symptoms may 
not be symptomatic and obstruction may be irre-
versible, regular evaluations of a serial pulmo-
nary function test (PFT) with body 
plethysmography (from the age of 4–6 years on) 
and diffusion capacity (usually from 8–10 years 
of age on) are required in asymptomatic patients.
While interstitial fibrosis is well known after 
lung transplant (restrictive allograft syndrome), 
prospective data after allogeneic HSCT are lack-
ing, but case reports indicate that restrictive 
immune-mediated lung disease after allo-HSCT 
may occur.
Patients require follow-up by a pediatric expe-
rienced pulmonologist. Of note, the possible 
overlap of (1) myopathy/hypotrophy of the respi-
ratory muscles (glucocorticoid induced, ± central 
obesity, and/or physical inactivity), (2) restriction 
of the chest wall in the context of dermal sclero-
sis, and (3) unproportional chest growth after TBI 
and/or local irradiation may contribute with a 
restrictive ventilator dysfunction leading to a 
mixed picture.
Finally, a thorough diagnostic evaluation 
includes a lung CT scan and a BAL to rule out viral, 
bacterial, fungal, and mycobacterial infections.
Coexisting IgA deficiency and chronic sinusitis 
or sinubronchial syndrome should be considered 
in the diagnostic workup (Hildebrandt et al. 2011).
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44.2.8  Joints and Fasciae
cGVHD-associated fasciitis (diagnostic for cGVHD) 
can result in restricted mobility of joints. This can 
also be caused by deep cutaneous sclerosis. 
Moreover, rheumatoid complaints may be associ-
ated with cGVHD.  In children myositis, muscle 
weakness, cramping, edema, and pain are quite com-
mon. However, iatrogenic glucocorticoid- induced 
myopathy may overlap with fasciitis. Range-of-
motion (ROM) examinations are recommended at 
baseline and at serial intervals with the P-ROM scale 
providing an easy- to- apply tool. (There is a pediatric 
adaption, ped P-ROM; see addendum).
44.3  Diagnosis
cGVHD is diagnosed on the basis of cGVHD 
symptoms of eight organs, laboratory values (for 
hepatic manifestations), and PFTs. Each organ is 
graded between 0 and 3. The overall severity of 
cGVHD is classified as mild, moderate, or severe 
based on this organ-specific grading (number of 
organs and severity). Overall severity is calculated 
on the basis of the number of organs affected and 
the severity of their involvement. Only in case that 
functional involvement is solely due to none GVHD 
causes the impairment is not scored (Jagasia et al. 
2015). Biomarkers of cGVHD are currently 
explored but require validation before clinical use.
44.3.1  Organ Grading of cGVHD 
for Adults and Children  
(See Annex 1 and Addendum)
44.3.2  Grading of Overall Severity 
of cGVHD (Jagasia et al. 2015)
Overall 


















If diagnostic symptoms of cGVHD are absent, his-
tological confirmation of diagnosis may be required. 
This may be particularly the case in gastrointestinal, 
nonspecific cutaneous, hepatic, and pulmonary 
manifestations to rule out toxic or infectious causes 
or comorbidity. Clinicopathologic series indicate a 
significant risk for inappropriate diagnosis and sub-
sequent treatment if diagnosis has been made solely 
by clinical manifestations (and lacking diagnostic 
symptoms) without histological confirmation.
44.4  Treatment
44.4.1  First-Line Therapy
First-line treatment (see Table 44.1) consists of 
steroids given alone or in combination with CNI 
and is based on randomized trials.
As mild cGVHD does not impair organ func-
tion, the use of topical IS (topical steroids, topical 
CNI, or phototherapy) should be considered. If 
this is impossible, PRD treatment at an initial 
dose of 0.5–1 mg/kg body weight/day is recom-
mended. Topical IS can be used in addition to 
systemic IS, to improve efficacy, or to reduce sys-
temic IS, but lack systemic efficacy.
For moderate or severe cGVHD, systemic 
treatment with PRD or methylPRD at an initial 
dose of 1 mg/kg body weight/day should be used. 
In individual cases lower doses of 0.5–1  mg/
kg may be used (Jacobsohn 2010). The com-
bination of steroids with a CNI (CSA or TAC) 
is particularly worth considering for severe 
cGVHD.  Rituximab has been explored in first- 
line treatment of cGVHD in combination with 
steroids and CNI demonstrating an increased 
response rate on the expense of an increased risk 
for late infectious complications and delayed 
B-cell recovery. Currently, ECP and ibrutinib 
are evaluated in first-line treatment of cGVHD 
within randomized clinical trials.
As cGVHD often takes time to respond to IS 
treatment, response should not be assessed until 
at least 8 weeks have elapsed or until 3–6 months 
have elapsed in the presence of deep cutane-
ous sclerosis. Long-term IS treatment lasting at 
least 3–6 months is often required. Dose reduc-
tion of IS agents should be performed stepwise. 
D. Wolff and A. Lawitschka
335
Depending on the patient population, first-line 
therapy achieves complete remission of cGVHD 
in approximately 20% (adults) to 50% (chil-
dren) of cases. If symptoms progress during the 
first 4 weeks of first-line therapy or there is no 
improvement in symptoms within 8–12 weeks, 
second-line therapy should be initiated.
44.4.2  Topical Therapy 
and Supportive Care
In principle, there is no difference between cGVHD 
treatment for children and adults. However, long-
term steroid therapy in children causes major side 
effects in terms of growth, bone density, osteone-
crosis, and organ development, making agents that 
reduce steroid use, entailing the use of topical 
drugs, particularly important. Age-based ancillary 
supportive care is essential in the management of 
pediatric cGVHD with the chance of sparing sys-
temic therapy, often supported by highly compliant 
parents and/or family members as caregivers 
(Carpenter et al. 2015). In small children, the risk 
of systemic effects of topical steroid and CNI treat-
ment must be considered. cGVHD is by itself 
remarkably immunosuppressive intensified by its 
treatment (especially high-dose corticosteroids) 
leading to a high risk for infections: (a) for viral 
reactivation like CMV, ADV, and EBV and (b) for 
fungal infection like candida and aspergillosis. 
Functional asplenia with occurrence of Howell- 
Jolly bodies and a higher incidence of pneumococ-
cal sepsis has to be considered also. Breakdown of 
skin and mucosal barriers adds to this risk.
Revaccinations (see Chap. 29) with inacti-
vated vaccines are strongly recommended after 
consolidation of cGVHD (Hilgendorf et  al. 
2011). Live vaccines should be avoided in this 
patient population. Ursodeoxycholic acid 
reduced liver GVHD and improved survival 
(Ruutu et al. 2014). Supplemental IVIG replace-
ment is recommended in cGVHD patients with 
IgG <400 mg/dL or recurrent infections which is 
of special importance in children but does also 
apply to adults. In case of long-term substitution 
or the history of anaphylactic reactions, we prefer 
to substitute subcutaneously.
44.4.3  Second-Line Therapy
While first-line therapy is based on randomized 
trials, second-line therapy mostly is based on 
phase II trials, and retrospective analyses are 
available (see Table  44.2). In addition, because 
Table 44.1 First-line treatment of cGVHD
Drug









Main drug; strategies to reduce use 
due to SEs very important








C-1 III-112 Increased risk for late 
infectious complications
~75% Randomized data are lacking
MMF + CNI/
steroids
D II GI complaints, 
infections
No increased efficacy compared to 
CNI and steroids, increased risk of 
relapse of malignancy
Azathioprine D II Cytopenia, risk of 
infection
Increased mortality
Thalidomide D II Neurotoxicity, 
drowsiness, constipation
Very little effect in first-line therapy
Adapted from Wolff et al. (2011), A: should always be used; C-1: use in first-line therapy justified, D: moderate evi-
dence of lack of efficacy or unacceptably high risks, should generally not be offered, I: evidence from ≥1 properly 
randomized, controlled trials, II: evidence from more than one well-planned non-randomized clinical trial, from cohort 
or case-controlled, analytic studies (preferably at several sites), III-1: only one non-controlled study, III-2: only one 
retrospective, non-controlled study or retrospective evaluation. (Evidence and recommendations graded according to 
the 2005 NIH Consensus), SE side effect, NIH US National Institutes of Health, MMF mycophenolate mofetil
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Side effects in >25% 
of patients CommentsGrade Evidence
Steroids B III-1 n.a. Osteoporosis, 
osteonecrosis, diabetes 
mellitus
Main drug, strategies to 
reduce use due to SEs very 
important




FDA approved in second-line 
treatment of cGVHD
Photophereses C-1 II ~60–70%
~30% CR
Infections of the CVC 
(if applicable)
Venous access required, 









Increased risk of TMA when 
combined with CNI, regular 
blood levels required
MMF C-1 III-1 ~50%
~10% CR
GI SEs, risk of 
infection (viral) and 
increased risk of 
relapse
Steroid sparing activity
CNI C-1 III-1 n.a. Renal toxicity, 
hypertension
Reduces steroid use, regular 
blood levels required
MTX C-2 III-1 ~50%
~10–20% CR
Cytopenia Best results in mucocutaneous 
cGVHD, reduces steroid use, 
contraindicated in the 
presence of pleural effusions 
or ascites
IL-2 C-2 III-1 ~65% (only 
PR)
Fever, malaise, and 
fatigue
Applied in sclerodermoid skin 
disease
Ruxolitinib C-2 III-1 n.a. 
(retrospective 
analysis)





Bortezomib C-2 III-1 n.a. for 
second-line Tx
Cytopenia, neuropathy Trial was performed in 
first-line treatment
High-dose steroids C-2 III-2 50–75%
(only PR)





Cytopenia Best results for fasciitis and 
mucocutaneous cGVHD
Hydroxychloroquine C-2 III-2 ~25%
~10% CR
GI side effects Best results for 
mucocutaneous and hepatic 
cGVHD
Pentostatin C-2 II ~50%
~10% CR
Cytopenia, risk of 
infection
Best results in children
Rituximab C-2 II ~50%
~10% CR
Risk of infection Effective in manifestations 
associated with autoAb and 
sclerodermoid cutaneous 
involvement
Imatinib C-2 III-1 ~50%
~20% CR
Fluid retention Efficacy demonstrated mainly 
in sclerodermoid cGVHD and 
bronchiolitis obliterans





Treatment for simultaneous 
cGVHD and recurrent 
multiple myeloma
(continued)






Side effects in >25% 
of patients CommentsGrade Evidence
Azathioprine C-3 III-1 n.a. Cytopenia, risk of 
infection, secondary 
malignancies
Increased risk of malignant 
disease of the oral mucosa




Effective in sclerodermoid 
cutaneous involvement
Abatacept C-3 III-2 ~40% Effective in mucocutaneous 
and pulmonary involvement




C-4 III-2 n.a. Repetitive application 
required
Alemtuzumab C-4 III-3 n.a. Infectious risks Last resort for refractory 
cGVHD
Etanercept C-4 III-3 n.a. Infectious risks May be used to treat mixed 
acute and chronic GVHD or 
pulmonary or GI 
manifestations of cGVHD
Adapted from Wolff et al. (2011), B: should generally be used, C-1: use in second-line therapy justified, C-2: use after 
failure of second-line therapy justified, C-3: should only be used in specific circumstances, due to unfavorable risk 
profile, C-4: experimental, should only be used in clinical trials and individual cases, II: evidence from >1 well-designed 
clinical trial without randomization, from cohort or case-controlled analytic studies (preferable from >1 center) or from 
multiple time series, III-1: several reports from retrospective evaluations or small uncontrolled clinical trials, III-2: only 
one report from small uncontrolled clinical trial or retrospective evaluations, III-3: only case reports available, SE: side 
effect, n.a.: not available
the data on disease severity and patient popula-
tions are very heterogeneous (in terms of age, 
conditioning, and stem cell source), the pub-
lished response rates cannot be fully extrapolated 
to the majority of patients currently treated for 
cGVHD. Moreover, many substances have been 
used almost exclusively in combination with 
steroids.
In general, no more than three IS agents 
should be combined, as combinations of more 
drugs often does not lead to improved efficacy 
but results in a significantly increased risk of side 
effects and infections. Because of the substantial 
toxicity of long-term steroid treatment, strategies 
for dose reduction are very important. Since no 
predictors of response for a single agent in indi-
vidual patients are yet available, the choice of 
agent depends mainly on side effect profiles and 
patients’ medical history. The response rates for 
specific agents range between 20% and 70% 
(photopheresis).
Certain drugs such as imatinib and retinoids 
are recommended only for manifestations associ-
ated with sclerosis (bronchiolitis obliterans [ima-
tinib], sclerodermoid cutaneous alterations 
[retinoids, imatinib]), because of their specific 
mechanisms of action.
Response is assessed as for first-line therapy. 
Administration of drugs that have been shown to 
be ineffective should be stopped. As a rule, drugs 
shown to be ineffective should be tapered off 
stepwise with no more than one drug to be 
changed at a time in order to be able to evaluate 
their efficacy.
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 Appendix 1
Annex 1 - Organ Scoring of Chronic GVHD
SCORE 0 SCORE 1 SCORE 2 SCORE 3
PERFORMANCE SCORE:
KPS   ECOG   LPS
Asymptomatic 
and fully active 




restricted only in 
physically 
strenuous 
activity (ECOG 1, 





>50% of waking 
hours out of bed 




care, >50% of 
waking hours in 
bed (ECOG 3-4,




GVHD features to be 
scored     
by BSA:










No BSA involved 1-18% BSA 19-50% BSA >50% BSA
SKIN FEATURES 














Other skin GVHD features (NOT scored by BSA)




Severe or generalized pruritus
Hair involvement
Nail involvement







No symptoms Mild symptoms 
with disease signs





partial limitation of 
oral intake
Severe symptoms 
with disease signs 
on examination 
with major
limitation of oral 
intake
Abnormality present but explained entirely by non-GVHD documented cause (specify):
___________________________________________________________________________________________________
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SCORE 0
Annex 1 - Organ Scoring of Chronic GVHD (continued)














drops ≤3 x per
day) 





drops > 3 x per 










to relieve pain) 
OR unable to
work because of 
ocular symptoms 
OR loss of vision 
due to KCS
Abnormality present but explained entirely by non-GVHD documented cause (specify):
___________________________________________________________________________________________________
GI TRACT
Check all that 
applies:
Esophageal web/ 








Failure to thrive 





























Abnormality present but explained entirely by non-GVHD documented cause (specify):
___________________________________________________________________________________________________
LIVER Normal total 
bilirubin and ALT 
or AP
<3 x ULN 
Normal total
bilirubin with ALT
≥3 to 5 x ULN or








Abnormality present but explained entirely by non-GVHD documented cause (specify):
________________________________________________________________________________
LUNGS**
Symptoms score : No symptoms Mild symptoms 
(shortness of 
breath after 














FEV1≥80% FEV1 60-79 FEV1 40-59% FEV1 ≤39%
Pulmonary function tests 
Not performed
Abnormality present but explained entirely by non-GVHD documented cause (specify):
________________________________________________________________________________
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Annex 1. Organ scoring of chronic GVHD (continued)









No symptoms Mild tightness of 
arms or legs, 
normal or mild 
decreased range 
of motion (ROM) 
AND not
affecting ADL
Tightness of arms 
or legs OR joint
contractures, 
erythema 



























No signs Mild signs‡ and












Abnormality present but explained entirely by non-GVHD documented cause (specify):
___________________________________________________________________________________________
Other indicators, clinical features or complications related to chronic GVHD (check all that apply and
Ascites (serositis)___ Myasthenia Gravis___
Pericardial Effusion___ Peripheral Neuropathy___ Eosinophilia > 500µl___
Pleural Effusion(s)___ Polymyositis___ Platelets <100,000/µl ___





(Opinion of the 
evaluator)
 No GVHD  Mild  Moderate  Severe
Photographic Range of Motion (P-ROM)
Adapted from Jagasia, 2015.
† Skin scoring should use both percentage of BSA involved by disease signs and the cutaneous
features scales. When a discrepancy exists between the percentage of total body surface (BSA) score
and the skin feature score, OR if superficial sclerotic features are present (Score 2), but there is
impaired mobility or ulceration (Score 3), the higher level should be used for the final skin scoring.
* Weight loss within 3 months.
** Lung scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1
should be used in the final lung scoring where there is discrepancy between symptoms and FEV1 scores.
Abbreviations: ECOG (Eastern Cooperative Oncology Group), KPS (Karnofsky Performance Status),
LPS (Lansky Performance Status); BSA (body surface area); ADL (activities of daily living); LFTs
(liver function tests); AP (alkaline phosphatase); ALT (alanine aminotransferase); NUL (normal upper limit).
‡ To be completed by specialist or trained medical providers (see Supplemental Figure).
moderate -2, severe –3)
assign a score to its severity (0-3) based on its functional impact where applicable none –0,mild -1,
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 Appendix 2
Diagnosis and staging cGVHD in children 
patient name
Jagasia et al BBMT 2015
pediatric adaptation A. Lawitschka 11/2015
date:
please score/check the worst manifestation classification:actual onset type ONLY at diagn.:
diagnostic features are marked bold  feat. of acute GVHD de  novo
 feat.of classic cGVHD quiescent
both progressive
Score 0 Score1 Score 2 Score 3
asymptomatic and  sympt., fully amb., sympt., amb., sympt., limited self-care
KPS/LPS: %      fully active     restricted only in     capable of self-care,     >50% of waking hours in bed
     (KPS/LPS 100%)     physically strenous     >50% of waking      (KPS/LPS < 60%)
    activity     hours out of bed
    (KPS/LPS 80-90%)     (KPS/LPS 60-70%)
SKIN
Feat. scored by BSA:   no BSA involved 1-18% BSA 19-50% BSA      > 50%  BSA
Feat. not scored by BSA:
maculopapular rash/erythema














abnormality present but explained
   entirely by non-GVHD cause (specify):
 feature decisive for diagnosis /scoring: 
sclerotic features:
features    sclerotic features
   "not hidebound"
   (able to pinch)
  no  sclerotic  superficial   deep sclerotic features
  "hidebound" (unable to pinch)
  impaired mobility
  ulceration
MOUTH
    no  symptoms   mild sympt with   moderate sympt.   severe sympt. with
    disease signs but     with disease signs     disease signs on examination
 not limiting oral     with partial limitation     with major limitation
    intake significantly     of oral intake     of oral intake
 erythema
 lichen planus-like features
 hyperkeratot.  plaques
 mucoceles   pseudomembranes
 ulcers  mucosal atrophy 
 dryness  pain 
 abnormality present but explained entirely by non-GVHD cause (specify):
 feature decisive for diagnosis /scoring: 
symptoms/features
patient name
child: head front/back    9 / 9
back 18, chest 18, 
arm left 9, arm right 9
leg left  13,5, leg right 13,5
adult: head front/back   4,5 / 4,5
back 18, chest 18
arm left 9, arm right 9
leg left  18, leg right 18
palm: 1,5 
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Score 0 Score1 Score 2 Score 3
EYES
 keratokonjunktivitis sicca (KCS)     no symptoms   mild dry eye sympt.   moderate dry eye sympt.   severe dry eye sympt.
 confirmed by opthalmologist not affecting ADL partially affecting ADL     significantly affecting ADL
 dryness  pain (requirement of (lubricant eye drops     (special eyeware to relieve pain) or
 photophobia   blepharitis lubricant eye drops >3 x/d or punctual plugs)     unable to work because of ocular 
 pseudomembranes  ulcers ≤ 3 x per day) without new vision     sympt or loss of vision due to KCS
impairement due to KCS
 abnormality present but explained entirely by non-GVHD cause (specify):
 feature decisive for diagnosis /scoring: 
GI TRACT
  esophageal web/     no symptoms   symptoms without   sympt. associated with   symptoms associated with
prox stricture or ring     significant weight     mild to moderate     significant weight loss (> 15%)
 dysphagia  abdominal pain     loss (5%)     weight loss (5-15%)     requires nutritional supplement for
 anorexia  failure to thrive     or moderate diarrhea     most calorie needs or
 nausea  vomiting     without significant     esophageal dilatation or
 diarrhea  weight loss ≥ 5%     interference with     severe diarrhea with
    daily living     signif. Interference with daily living
 abnormality present but explained entirely by non-GVHD cause (specify): height:
 feature decisive for diagnosis /scoring: weight:
LIVER
 hepatic pattern     normal total bili   normal total bili    elevated total bili   elevated total bili > 3 mg/dl
  and ALT or AP with ALT ≥ 3-5x ULN  but ≤ 3 mg/dl or
  < 3 ULN     or AP ≥ 3 x ULN  ALT > 5 ULN
 abnormality present but explained entirely by non-GVHD cause (specify):
 feature decisive for diagnosis /scoring: 
LUNGS
 FEV1: _____ % MEF25:_____ %     no symptoms   mild symptoms   moderate symptoms  severe symptoms
  FVC:   _____ % MEF50:_____ %    FEV1  ≥ 80% (shortness of breath (shortness of breath    (shortness of breath at rest;
  DLCO: _____ % MEF75:_____ % after climbing one after walking on  requiring O2)
  RV:     _____  RV/TLC > 120%     flight of steps) flat ground)     FEV1    ≤ 39%
  CT:     FEV1    60-79%     FEV1    40-59%
 abnormality present but explained entirely by non-GVHD cause (specify):
 feature decisive for diagnosis /scoring: 
JOINTS AND FASCIA
  ped P-ROM score (see below)     no symptoms  mild tightness,  tightness or  joint  contractures, fasciitis
 edema  fasciitis    normal or mild ↓ of    contractures, fasciitis,    significant ↓ of ROM, 
 muscle cramps       athralgia    range of motion (ROM)    moderate ↓ of ROM,    significant ↓ of ADL
   not affecting ADL    mild - moderate ↓ of ADL
 abnormality present but explained entirely by non-GVHD cause (specify):
  feature decisive for diagnosis /scoring: 
GENITAL TRACT
 erosions, fissures     no signs  mild signs  moderate signs   severe signs with or without 
 lichen planus-like features    symptoms
 lichen sclerosus-like features
 labial/ vaginal scarring   phimosis
 abnormality present but explained entirely by non-GVHD cause (specify):
  feature decisive for diagnosis /scoring: 
Overall GVHD severity
 no cGVHD
 mild:       
 moderate:  
 severe:    
 ≥3 organ with max score 1 or max. score of 2 in any affected organ, lung score max 1
 score 3 in any affected organ, lung score 2-3
symptoms/features
Appendix 2 - Diagnosis and staging cGVHD in children  (continued)
   Bili:  _____   AST:_____ ALT: _____
   GGT: _____   AP: _____  
 max. score of 1 in any affected organ, max. 2 organs affected, no lung involvement
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Other indicators, clinical features or complications related to cGVHD 
Appendix 2 - Diagnosis and staging cGVHD in children (continued)
biopsy: 
check all that apply and assign a severity score (0-3) based on functional impact organ:
 ascites (serositis)  myasthenia gravis  eosinophilia >500 /ul GVHD confirmed?
 pericardial effusion  peripheral neuropathy  platelets <100 000/ul
 pleural effusion  polymyositis  hypo/hyperglobulinemia
 nephrotic syndrome  weight loss >5% without GI sympt  auto-antibodies
 others (specify)  diabetes
pediatric photographic range of motion (adapted ped P-ROM): 






1 (worst)              2                   3             4 (normal)
1 (worst)             2                    3            4 (normal)
  1 (worst)           2                    3            4 (normal)
  1 (worst)          2               3 (normal)
1 (worst)               2                  3                   4              5 (normal)
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 Appendix 3
Genital Tract GVHD Assessment and Scoring Form
Name:__________________________________________ Date of birth: ___________________
Assessment date: ______________
SCORE 0 SCORE 1 SCORE 2 SCORE 3
GENITAL TRACT
(male or female)











with  or without 
symptoms*
Currently sexually active:
Yes    No
Check all signs that applies:









Urethral meatusscarring/ stenosis (male)
Abnormality present but NOTthought to represent GVHD (specify cause): 
______________________________________________________________________________
Abnormality thought to represent GVHD PLUSother causes(specify cause):
______________________________________________________________________________
* Genital symptoms are not specific to cGVHD and can represent premature gonadal failure or genital tract 
infection.
If a gynecologist is unavailable, external examination may be performed to determine “discomfort on exam”
as follows:
a) Spread the labia majora to inspect the vulva for the above signs. Touch the vestibular gland openings
(Skene’s and Bartholin’s), labia minora and majora gently with a qtip. Vulvar pain elicited by the
gentle touch of a qtip is classified as discomfort on examination. Palpate the vaginal walls with a
single digit to detect bands, shortening, narrowing or other signs of vaginal scarring.
b) If the woman is sexually active, determine whether qtip palpation or gentle palpation of scarred
ridges elicits pain similar to that which the woman experiences during intercourse.
Female genitalia: Severity of signs:
1) Mild (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen-planus or vulvar lichen-sclerosis.
2) Moderate (any of the following); erosive inflammatory changes of the vulvar mucosa, fissures in vulvar folds.
3) Severe (any of the following); labial fusion, clitoral hood agglutination, fibrinous vaginal adhesions,
circumferential fibrous vaginal banding, vaginal shortening, synechia, dense sclerotic changes, and
complete vaginal stenosis.
Male genitalia: Diagnostic features include lichen planus-like or lichen sclerosis-like features and
phymosis or urethral scarring or stenosis. Severity of signs:
1) Mild: lichen planus-like feature;
2) Moderate: lichen sclerosis-like feature or moderate erythema;
3) Severe: phimosis or urethral/meatal scarring.
Biopsy obtained: Yes     No Site  biopsied:______________ GVHD confirmed by histology: Yes      No
Change from previous evaluation: No prior or current GVHD Improved      Stable        Worse   N/A (baseline)
Completed by (spell out name): ________________________________________________
Date form completed: _______________________  
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Post transplant lymphoproliferative disorders 
(PTLDs) constitute a heterogeneous group of 
lymphoproliferative diseases that occur in the 
setting of transplantation and result from the 
uncontrolled neoplastic proliferation of lymphoid 
or plasmacytic cells in the context of extrinsic 
immunosuppression after transplantation.
PTLD in HSCT setting are largely caused by 
latent Epstein-Barr virus (EBV, HHV-4), belong-
ing to the herpesviruses family. It is one of the 
most common viruses in humans, with prevalence 
of 82–84% in overall population. EBV is associ-
ated with development of various diseases, which 
can be categorized as primary syndromes, EBV-
associated tumors, and EBV-associated post 
transplant diseases: PTLD and other end- organ 
diseases (encephalitis/myelitis, pneumonitis, hep-
atitis, or hemophagocytic lymphohistiocytosis).
Comparably to other herpesviruses, there are 
two types of EBV infection: primary and recur-
rent. Primary EBV infection is diagnosed when 
EBV is detected (nucleic acid or serologically) in 
an EBV-naïve individual. Recurrent EBV-DNA- 
emia (previously: latent infection) is diagnosed 
by detection of EBV-DNA in the blood, in a pre-
viously infected individual.
45.2  Types of PTLD
PTLD or end-organ EBV-associated post trans-
plant disease can be diagnosed at the probable or 
proven level. Probable EBV disease is diagnosed 
in case of significant lymphadenopathy, hepato-
splenomegaly, or other end-organ manifestations 
(without tissue biopsy, but in the absence of other 
documented cause) together with high EBV- 
DNA- emia. Proven EBV disease (PTLD or other 
end-organ disease) is diagnosed in case of symp-
toms and/or signs from the affected organ 
together with the detection of EBV-encoded 
RNA by in situ hybridization (EBER-ISH) in a 
tissue specimen (immunohistochemistry for EBV 
proteins have good specificity but lower sensitiv-
ity; these proteins are variably expressed in 
PTLD biopsies). Histological WHO 2016 classi-
fication includes six types of morphological 
PTLD: plasmacytic hyperplasia, infectious 
mononucleosis-like, florid follicular hyperplasia, 
polymorphic, monomorphic (B-cell or  T-/
NK-cell types), and classical Hodgkin lymphoma 
PTLD.
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• EBV-negative PTLD: A growing number of 
cases of EBV-negative PTLD have been 
reported, mainly in SOT recipients. These 
cases tend to present later (>5  years after 
transplant) after transplant, and an increased 
risk is observed as long as 10 years after trans-
plantation. These cases should be regarded as 
malignant lymphoma rather than as PTLD.
• T-lineage PTLD: T-PTLD is usually EBV- 
negative, and the relatively long latency 
between transplantation and T-PTLD onset 
may be explained by molecular events. The 
frequency of T-PTLDs ranges 4–15% of all 
PTLD cases. EBV is present in approximately 
one-third of T-PTLDs.
• Composite B-cell and T-cell lineage PTLD: 
Harboring both B- and T-cell clones either 
concurrently or successively in the same 
patient is extremely rare, and only a few cases 
have been reported in the literature, exclu-
sively after SOT, with poor outcome.
45.3  Pathogenesis
The pathogenesis of PTLDs is a result of EBV- 
induced transformation of B cells in the setting of 
impaired anti-EBV cellular immunity due to iat-
rogenic IS and resulting in an outgrowth of EBV- 
infected B cells. GVHD prevention strategies that 
indiscriminately remove T cells from the graft 
increase the risk of PTLD.
Recurrent EBV infection preceding clinically 
overt PTLD is the consequence of viral latency, which 
is the stage in the viral life cycle in which no virions 
are produced, as opposed to the lytic stage. During 
viral latency of EBV, three associated patterns of viral 
protein expression, so- called latency programs, may 
be expressed. During infection of the B cell, these 
latency programs guide the B cell through the germi-
nal center reaction pushing it toward the resting mem-
ory cell stage. Different latency proteins are implicated 
in EBV-driven lymphomagenesis demonstrated by 
the expression of a particular latency program in dif-
ferent lymphoma subtypes.
B cells in PTLD express a number of latency 
proteins which are highly immunogenic and are 
vigorously targeted by T lymphocytes in immu-
nocompetent hosts. This viral gene program in 
EBV-PTLD is called type III of latency and is dif-
ferent and less immunogenic than in other EBV- 
related diseases with type I or II of latency.
EBV plays also an important role in pathogene-
sis and epidemiology of acute and chronic 
GVHD. As B cells also play a role in the patho-
physiology of chronic GVHD, and B cells are stim-
ulated into activity by EBV infection, and B-cell 
recovery occurs usually after day +100, the impact 
of EBV-infected B cells is stronger for development 
of chronic, and to less extent, acute GVHD.
45.4  Clinical Manifestations
Lymphadenopathy and fever are the most com-
mon symptoms of EBV-PTLD.  Rare EBV- 
associated PTLD manifestations, also referred as 
EBV end-organ disease, include encephalitis/
myelitis, pneumonitis, hepatitis, and hemophago-
cytic lymphohistiocytosis.
 
Time to PTLD Median time of PTLD 
development: 2–4 months
6% PTLD cases are diagnosed 
within first month
90% diagnosed within first 6 
months after HSCT




Median: 29.4% (range: 0.1–63%)
Highest in: MUD/MMUD-HSCT, 
haplo-HSCT without PTCy










Auto-HSCT without TCD: 
casuistic
Target organs Frequently: lymph nodes
Rarely: CNS, GI tract, lungs, liver
aLevel of donor match determined locally as 8/8 or 10/10
45.5  Diagnosis
The diagnosis of EBV-PTLD must be based on 
symptoms and/or signs consistent with PTLD 
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together with detection of EBV by an appropri-
ate method applied to a specimen from the 
involved tissue. Definitive diagnosis of EBV-
PTLD requires noninvasive and invasive tech-
niques (biopsy and histological examination).
Noninvasive diagnostic methods
Quantitative determination of EBV-DNA-emiaa
Imaging: CT or PET-CTb (for avid structures, localized 
in the lymph nodes, spleen, liver, GI tract, skin, lungs, 
bone, BM) or MRI (in CNS disease and non-avid 
histologies)
Invasive diagnostic methods
Biopsy of the lymph node and/or other suspected sites
Endoscopy: when GI symptoms
Histological examination
  (a)  Detection of viral antigens or in situ 
hybridization for EBER (EBV-encoded RNA) 
transcripts
  (b)  Immunohistochemistry
  (c)  Flow cytometry for B cell, T cell, and plasma 
cell lineage-specific antigens
aMonitoring EBV-DNA-emia: Serial quantitative measure-
ment of EBV viral load post transplant is currently the 
method of choice for early detection and monitoring pro-
gression and response to treatment of EBV- 
PTLD. Although the value of the viral load in PTLD risk 
assessment is uncertain, it is recommended to begin the 
screening in patients with risk factors after hematological 
recovery and no later than 4  weeks after the day of 
HSCT.  In EBV-DNA-negative patients, frequency of 
screening should be once a week, while in patients with 
rising EBV-DNA-emia, more frequent sampling might be 
considered, as the calculated doubling time for EBV might 
be as short as 56 h. The screening should be continued at 
least 4 months in high-risk patients. Longer monitoring is 
recommended in patients considered to have poor T-cell 
reconstitution, with severe GVHD, after haplo- HSCT, with 
the use of TCD, after conditioning with ATG/alemtu-
zumab, or in those having experienced an early EBV 
reactivation
bPET imaging: By definition, PTLD is a neoplastic lym-
phoproliferation. Malignant lymphomas have the ability 
to metabolize 18F-fluorodeoxyglucose (FDG), which is 
used by PET imaging. In most cases, PTLD has FDG- avid 
histology; thus FDG-PET is an important diagnostic tool 
for this disease
45.6  Risk Factors
Risk of development of PTLD is essentially pro-
portional to the degree of T-cell depletion/impair-
ment, and this should be regarded as the principal 
risk factor. Thus, the type of donor and type of 
conditioning have secondary value as risk fac-
tors. Since in HSCT setting PTLD usually origi-
nates from donor, the risk of PTLD is obviously 
higher when the donor is seropositive. Risk fac-
tors for PTLD in match family donor (MFD) 
transplants include TCD ex vivo or in vivo, EBV 
serology mismatch between donor and recipient, 
and splenectomy. ECIL-6 classified HSCT 
patients into three groups of the risk for EBV- 
PTLD: low, standard, and high risk.
Risk group Patients
High MUD/MMUD
Alternative donors including CBT
MFD-HSCT with at least one risk factor




No grading system currently exists for PTLD. It 
seems that apart from the findings from biopsy 
material with a histological examination; the 
diagnostic criteria of tissue involvement in PTLD 
should be consistent with those for lymphoma 
(the Ann Arbor and the Lugano classifications). 
Nowadays, the use of FDG-PET-CT has emerged 
as an important imaging tool for PTLD diagnosis 
and staging.
Possible staging of PTLD:
 – Clinical end-organ staging: nodal vs. extrano-
dal disease
 – Clinical severity staging: limited (unifocal) 
vs. advanced (multifocal) disease
 – ECIL-6 staging (based on the Lugano lym-
phoma classification by PET-CT imaging): 
limited (stages I–II), advanced forms (stages 
III–IV)
45.8  Treatment
45.8.1  Prevention: Donor 
and Recipient Issues
As EBV might be transmitted with the graft, 
selection of EBV-seronegative donor might be 
beneficial for EBV-seronegative recipient, if pos-
sible. For EBV-seropositive patients, selection of 
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an EBV-seropositive donor might be justified, as 
transmission of EBV-specific CTLs outweighs 
the risk of transmission of EBV-positive B cells 
from the donor.
45.8.2  Treatment Strategies
PTLD has to be regarded as disseminated disease 
at diagnosis. This is because of the involvement 
of lymphoid tissue, which is localized throughout 
the whole body. Therapeutic approaches applied 
in the prevention and treatment of EBV-PTLD 
include administration of RTX, reduction of 
immunosuppression (RIS), use of EBV-CTL, 
DLI, and chemotherapy, while other methods 
have only historical value. No antiviral drug is 
currently effective against EBV. There are three 
major approaches to EBV infection after HSCT: 
prophylaxis, preemptive therapy (also known as 
preemptive prophylaxis), and treatment of estab-
lished EBV-PTLD.
45.8.2.1  Prophylaxis
Prophylaxis of EBV disease is defined as drug or 
cellular therapy given to an asymptomatic EBV- 
seropositive patient to prevent EBV-DNA-emia. 
This strategy is administered rarely, with the use 
of rituximab (RTX) or EBV-CTL.
The rationale for prophylactic use of RTX 
before or early after allo-HSCT is B-cell deple-
tion. Prophylactic use of post transplant RTX 
reduced the risk of EBV-DNA-emia, with no 
impact on PTLD incidence, TRM, or OS in com-
parison to preemptive therapy.
The prophylactic use of EBV-CTLs resulted 
in excellent efficacy in patients at a high-risk 
group for EBV-PTLD. The obstacle for the use of 
this approach is limited availability of CTLs for 
most transplant centers.
Low risk of EBV-DNA-emia and EBV-PTLD 
was observed after the use of PT-CY and SIR for 
GVHD prophylaxis.
45.8.2.2  Preemptive Therapy
Drugs or cellular therapy is given to a patient 
with EBV-DNA-emia in order to prevent EBV 
disease.
Monitoring for EBV-DNA-emia is essential in 
all patients with risk factors for EBV- 
PTLD. Significant EBV-DNA-emia without clini-
cal symptoms of disease in high-risk patients for 
EBV-PTLD is usually an indication for preemp-
tive therapy.
The goal is to obtain a negative EBV PCR or 
EBV-DNA-emia below the initial threshold with-
out relapse.
Usually, EBV-DNA-emia occurs prior to the 
onset of clinical symptoms. There is a correlation 
between rising or high EBV-DNA-emia in PB 
and the development of EBV-PTLD, but this is 
not the rule.
Currently available data does not allow for the 
determination of an unambiguous EBV-DNA 
threshold value for the diagnosis of EBV-PTLD 
or other end-organ EBV disease in HSCT 
patients.
Apart from EBV-DNA value, also the kinetics 
of a rising EBV-DNA-emia, together with an 
assessment of an individual patient’s immune 
function, are very important when appraising the 
need for preemptive therapy. Local experience 
based on correlation of clinical and laboratory 
data might be a rationale for center-specific cut-
off value.
The primary method for preemptive therapy 
includes RTX, once weekly until EBV-DNA- emia 
negativity. Usually, 1–2 doses of RTX are suffi-
cient. RTX should be combined with reduction of 
the IS (RIS), if possible. A contraindication for 
RIS is severe, uncontrolled acute, or chronic 
GVHD. This approach might have additional ben-
efit of RTX administration, as RTX possibly 
reduces the risk of acute/chronic GVHD. Donor 
or third-party EBV-CTL is another option, 
although it is not widely available.
45.8.2.3  Treatment of Established 
EBV-PTLD
Treatment of established EBV-PTLD means ther-
apeutic interventions for patients with probable 
or proven EBV disease. Due to the consequential 
risk of a rapidly growing high-grade lymphoid 
tumor, together with the potential for EBV to 
cause rapid MOF, therapy should be implemented 
as soon as possible.
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For first-line therapy, three options are recom-
mended: (a) RTX, 375 mg/m2, once weekly; (b) 
RIS, if possible, usually together with adminis-
tration of RTX; (c) adoptive immunotherapy with 
cellular therapy with in vitro generated donor or 
third-party EBV-CTL, if available.
For the second-line therapy, in case of RTX 
failure: (a) cellular therapy (non-specific DLI 
or specific EBV-CTLs, if available); (b) chemo-
therapy ± RTX.  Unselected DLI from EBV-
positive donor is used in order to restore broad 
T-cell reactivity, including EBV-specific 
responses.
Not recommended: IVIg, interferon, and anti-
viral agents should not be used for therapy of 
PTLD.

















RTX rituximab, RIS reduction of immunosuppression
aWith other therapies
45.8.4  Treatment in CNS Disease
CNS localization of PTLD is a special form of 
the disease, due to the risk of neurological conse-
quences even in case of successful eradication of 
EBV from CNS. No standard therapy has been 
accepted up to date.
Possible therapeutic options include (a) RTX, 
either systemic or intrathecal; in the latter case, 
dose of RTX was 10–30 mg in 3–10 mL saline 
administered weekly; (b) T-cell therapy with 
EBV-CTLs; (c) radiotherapy; (d) chemotherapy 
± RTX according to primary CNS lymphoma 
protocols based on high dose of MTX ± Ara-C.
45.8.5  Criteria of Response 
to Therapy in EBV-PTLD
The treatment goal in EBV-PTLD setting is the 
resolution of all signs and symptoms of PTLD 
together with negative EBV-DNA-emia.
The response to RTX therapy can be identified 
by a decrease in EBV-DNA-emia of at least 1 log 
of magnitude in the first week of treatment.
Positive prognostic factors for outcome to 
RTX therapy include age below 30 years, under-
lying non-malignant disease, no acute GVHD 
≥II, RIS at time of PTLD diagnosis, and decrease 
of viral load after 1 or 2 weeks of therapy.
Complete remission of PTLD can be defined 
as resolution of all symptoms of PTLD, including 
clearance of EBV-DNA-emia. Partial response of 
PTLD can be stated with the decrease of at least 
50% of initial changes, including decrease of 
EBV-DNA-emia.
The response to therapy can be confirmed by 
achievement of a PET-negative complete remis-
sion for avid lymphomas and CT/MRI for non- 
avid histologies or CNS localization.
Key Points
• Definition: PTLD results from an 
uncontrolled neoplastic proliferation of 
lymphoid or plasmacytic cells in the 
context of extrinsic IS after HSCT trans-
plantation. PTLDs in HSCT setting are 
largely caused by latent EBV. Risk fac-
tors for EBV-PTLD are proportional to 
the degree of T-cell impairment.
• Diagnosis: Should be based on invasive 
techniques including biopsy of the 
lymph node and/or other sites suspected 
for EBV disease. Noninvasive diagnos-
tic methods have accessory value and 
include the quantitative determination 
of EBV-DNA-emia in blood, plasma or 
serum, and PET-CT/CT/MRI.
• Management strategies: Prophylaxis, 
preemptive treatment, and therapy of 
established EBV-PTLD.  Therapeutic 
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approaches include administration of 
rituximab, RIS, use of EBV-CTL, or 
DLI and chemotherapy, while other 
methods have only a historical value.
• EBV-DNA-emia threshold value: No 
value determines diagnosis of EBV- 
PTLD or other end-organ EBV disease 
in HSCT patients. In order to initiate 
preemptive therapy, transplant centers 
should use own threshold values of 
EBV-DNA-emia.
• Outcome: Administration of rituximab 
results in a positive outcome for over 
90% of patients treated preemptively 
and over 65% when it is used as targeted 
therapy for EBV-PTLD.  RIS when 
applied in combination with rituximab: 
over 80%. The use of EBV-CTLs: >90% 
of patients treated preemptively and 
approximately 75% in therapy of 
EBV-PTLD.
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Iron overload/toxicity is an unavoidable conse-
quence in several diseases characterized by ane-
mia and red blood cell transfusion requirement.
Our knowledge of iron pathophysiology has 
much improved during the last two decades, and 
we now recognize that iron damage is related not 
only to iron level “per se” but to the presence in 
the serum of non-transferrin forms of iron (non- 
transferrin bound iron = NTBI). A component of 
NTBI, called labile plasma iron (LPI), is a potent 
redox-active agent capable of permeating into 
cells in an uncontrolled way, thus inducing cellu-
lar iron overload and impacts the delicate equilib-
rium of labile cellular iron (LCI). The breakage of 
LCI balance catalyzes the formation of reactive 
oxygen species (ROS), which leads to cytotoxic 
cell injury (DNA damage, lipid peroxidation, pro-
tein modification, and mitochondrial damage). 
Iron toxicity depends on many factors in addition 
to the iron level: the quantity of the abovemen-
tioned toxic iron-related species, duration of 
exposure, individual’s antioxidant genetics, and 
environmental factors (Coates 2014). Notably 
NTBI and LPI appear in the serum only when 
transferrin saturation exceeds 60–70% (de Swart 
et al. 2016) and are cheatable forms of iron.
NTBI and LPI are direct markers of ongoing 
cellular iron accumulation and tissue damage. 
Their measurement is today available in selected 
laboratories for research purposes only. A stan-
dardization program is ongoing (de Swart et al. 
2016), and hopefully NTBI and LPI assays will 
be available in the next future for clinical use. 
Transferrin saturation is at the moment a valid 
surrogate indicating, when exceeding 60–70%, 
presence of NTBI /LPI in patient serum.
Here will be discussed the impact of iron tox-
icity on HSCT outcome and therapeutic options 
(Angelucci and Pilo 2016). This chapter will be 
divided in three sections with the following 
meanings:
 – Before transplant: any time before the starting 
of the conditioning regimen
 – During transplant: from the start of condition-
ing regimen up to a sustained engraftment is 
achieved
 – After transplant: after sustained engraftment 
has been achieved
46.2  Iron Overload Before HSCT 
(Before the Start 
of Conditioning)
In thalassemia it has been very well demonstrated 
that HSCT outcome is significantly impacted by 
a story of irregular chelation, presence of liver 
fibrosis, and hepatomegaly (Angelucci 2010). 
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Now we can recognize that all the three risk fac-
tors are related to intensity and duration of tissue 
exposition to the abovementioned iron toxic- 
related species (Angelucci et al. 2017).
Therefore, any effort should be made to regu-
larly suppress NTBI/LPI in the years before 
transplant to prevent tissue damage. This target 
can be achieved with early, regular, and consis-
tent iron chelation. Thus, in any patient receiving 
transfusion therapy who may have an HSCT in 
the future, the decision starting chelation is criti-
cal and should be undertaken as soon as possible. 
Moreover, chelation must regular long life.
Limited data are available on the rationale for 
intensive pre-HSCT chelation therapy unless suf-
ficient time is available to correct iron overload 
and warrant tissue lesions repair.





During conditioning regimen, a huge amount of 
NTBI and LPI enter the circulation due to mas-
sive erythroid marrow lysis (Dürken et al. 1997). 
Moreover, until the erythroid recovery begins, no 
iron can be released by transferrin to the ery-
throid system. Once erythroid recovery initiates 
transferrin-iron is greedily captured by the ery-
throid system and unbound transferrin able to 
receive iron from reticular endothelial system 
and, to a mush less extent, from storages appears 
in the serum. Non-transferrin-iron is uptaken by 
erythroid cells but is not utilized for hemoglobin 
synthesis (Prus and Fibach 2011).
Recent transplant animal studies demonstrated 
that iron toxicity could impair the hematopoietic 
niche by damaging hematopoietic stem cells’ 
self-renewal potential, proliferation, differentia-
tion, and the marrow microenvironment (Pilo and 
Angelucci 2018). These data suggest that iron 
can impact the HSC engraftment, the hemopoi-
etic recovery, and possibly transplant outcome. 
From a clinical point of view, limited evidence is 
available. Visani and colleagues demonstrated, in 
an uncontrolled study, that in cases of poor and 
delayed engraftment, iron chelation can help in 
stabilizing hemopoietic engraftment (Visani et al. 
2014).
Inclusion of chelation therapy during the 
transplant phase to suppress NTBI/LPI should be 
considered an experimental treatment; however, 
in case of slow, delayed, or incomplete marrow 
recovery and high transferrin saturation, chela-
tion should be considered.
46.4  Iron Overload After HSCT 
(After Sustained 
Engraftment Has Been 
Achieved)
After successful transplantation, patients are 
usually free from transfusion support but affected 
by the already acquired iron overload that cannot 
be eliminated without active intervention. In this 
condition the already acquired intracellular iron 
overload continues to disrupt the delicate LCI 
equilibrium and promotes ROS generation. It 
has been prospectively demonstrated in trans-
planted thalassemia patients that elevated trans-
ferrin saturation persists indefinitely without 
treatment and liver disease progresses even in 
the absence of other comorbidities (Angelucci 
et al. 2002). Of course the deleterious effect can 
be worsened by presence of comorbidities even 
with low level of iron accumulation (Angelucci 
et al. 2002).
Therefore, even because of the results of epi-
demiologic studies in thalassemia (Coates et al. 
2016; Puliyel et al. 2015) and in the normal popu-
lation (Ellervik et al. 2011) in the post transplant 
setting, the target iron level should be a normal 
iron level. Normal transferrin saturation exclud-
ing the presence of toxic iron-reactive species 
should be the target level of post transplant iron 
removal.
Because of the acquired effective erythropoi-
esis, phlebotomy (Angelucci et  al. 1997; Inati 
et  al. 2017) can be an alternative to chelation. 
Table 46.1 reports the pros and cons for selecting 
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Table 46.1 Factors to be considered in selecting the 





–  Permits complete iron 
removal and 




–  Immediate effect on 
NTBI/LPI
–  Hospital access not 
required
Cons –  Requires sustained 
engraftment (not 
usable in the early 
post-HSCT period)
–  Immediate effect on 
NTBI/LPI still 
remains to be verified
–  Hospital access 
required
– Expensive
–  Warning of renal 
toxicity in the case 
of concomitant use 
of CSA
–  Possible increase in 
toxicity for low 
level of iron burden
Key Points
• Iron toxicity depends on the presence of 
free iron species: non-transferrin bound 
iron (NTBI) and labile plasma iron (LPI).
• Prevention of tissue damage by regu-
larly and consistently suppressing tissue 
reactive iron species in the years before 
HSCT is the key factor to improve trans-
plant outcome.
• Iron toxicity can impair the bone mar-
row microenvironment, the quantity and 
quality of bone marrow mesenchymal 
stem cells, the ratio of immature HSC, 
and the clonogenic capacity of hemo-
poietic stem and progenitor cells, thus 
impacting hemopoietic recovery and 
possibly transplant outcome.
• After successful HSCT, one should aim 
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Secondary neoplasia (SN) after HSCT includes 
any malignant disorder occurring after HSCT, 
irrespectively, if related or not to transplanta-
tion. For an individual patient, a clear relation-
ship between HSCT and SN often cannot be 
provided. In this chapter, post transplant lym-
phoproliferative disorders are not discussed 
(see Chap. 45).
47.2  Types of Secondary 
Neoplasia After HSCT
A. Tichelli (*) 





neoplasms (t-MN)a Donor cell leukemia (DCL)b Second solid neoplasms (SSN)c
Definition t-MDS or t-AML after exposition 
chemo or radiation therapy
Hematologic neoplasms 
occurring in grafted donor cells
Solid cancers of any site and 
histology occurring after HSCT
Occurrence Mainly after auto-HSCT
Not excluded after allo-HSCTd
After allo-HSCT only After allo-HSCT and auto-HSCT
Appearance Within the first 10 years mainly Variable Increasing incidental rate with 
longer follow-up
Prognosis Poor Poor Depends mainly on the cancer 
type
aPedersen-Bjergaard et al. (2000); Engel et al. (2018)
bSala-Torra et al. (2006); Wiseman (2011)




47.3.1  Therapy-Related Myeloid 
Neoplasms
t-MN are mainly associated with cytotoxic che-
motherapy and radiation therapy that the patient 
has received either before HSCT or as condition-
ing. The causal role of ionizing radiation in the 
development of myeloid neoplasms has been 
demonstrated in atomic bomb survivors of 
Hiroshima/Nagasaki and in medical radiation 
workers employed before 1950.
Responsible cytotoxic drugs:
• Alkylating agents, anthracyclines, and topoi-
somerase II inhibitors.
• To a lesser extent antimetabolites and purines 
analogs.
• Controversy exists on the role of azathioprine, 
methotrexate, hydroxyurea, and 
6- mercaptopurines used for the treatment of 
malignant and nonmalignant diseases.
t-MN occur mainly after auto-HSCT, where 
the healthy HSC has been exposed to cytotoxic 
effect. Rarely t-MN can be observed after allo- 
HSCT, despite the donor cells have not been 
exposed to cytotoxic agents. Persistent microchi-
merism with few exposed residual recipient cells 
may explain the development of t-MN after allo- 
HSCT. The incidence of t-MN after allo-HSCT 
might increase, since chimeric states are observed 
more frequently after RIC-HSCT.
Today, increasingly cytotoxic drugs are 
applied after the allo-HSCT, either as GVHD 
prophylaxis (post transplant CY) or to prevent 
disease recurrence (post transplant maintenance). 
We do not yet know whether these procedures are 
at risk for t-MN after allo-HSCT.
47.3.2  Donor Cell Leukemia
The cause of donor-derived hematological malig-
nancies remains speculative. Two different mech-
anisms may be involved (Sala-Torra et al. 2006; 
Wiseman 2011):
• Malignant clone transmitted from the donor to 
the recipient
• Malignant transformation in the recipient
Malignant clones transferred to the recipient 
are mainly of lymphoid origin, observed in older 
donors, and may evolve into a lymphoid neo-
plasm in the immunosuppressed host. Myeloid 
clone transfer has not been reported. However, 
systematic NGS analysis might allow to detect 
myeloid clones transmitted to the recipient.
Malignant transformation in the donor cells is 
probably of multifactorial causes:
• Premature aging of the donor hematopoiesis 




• Acquired environmental factors
47.3.3  Second Solid Neoplasms (SSN)
Little is known about pathogenesis of SSN after 
HSCT.  An interaction between cytotoxic treat-
ment, genetic predisposition, environmental fac-
tors, viral infections, GVHD, and its 
immunosuppression may play a role.
Two main types of SSN (Rizzo et al. 2009):
• Radiation-related SSN
 – Proven for thyroid, breast, and brain 
cancers
 – Occur after a long latency (≥10 years after 
radiation)
 – Is dose related
• GVHD/immunosuppression-related SSN
 – Squamous cell carcinoma of the skin and 
oropharyngeal area
 – Short latency
 – Can occur at different localizations
Association with viral infection
• HCV infection associated with hepatocellular 
cancer
• HPV associated with cervix cancer
A. Tichelli
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47.4  Frequency and Risk Factors 
(See Table 47.1)
47.4.1  Remarks on SSN
The CI of second solid cancer is 2.2% at 10 years 
and 6.7% at 15 years (Rizzo et al. 2009).
Increased risk for SSN after HSCT has been 
demonstrated from breast, thyroid, skin, liver, 
lung, oral cavity and pharynx, bone and connec-
tive tissues cancers and malignant melanoma.
An individual patient can present several sub-
sequent different SSN after HSCT. Up to five dif-
ferent solid cancers have been observed in a 
patient treated with allo-HSCT.
Table 47.1 Frequency and risk factors
Type of SN Frequency Risk factors
t-MN Great variability on the CI of t-MN after auto-HSCT
 •  In lymphoma patients between 1% at 2 years up 
to 24% at 43 months
 •  Lower CI for patients treated for breast cancer, 
germ cell tumor, and multiple myeloma
 •  Rare n-MN after HSCT for AID
CI depends mainly on pretransplant cytotoxic 
therapy and the use of TBI
CI of t-MN after allo-HSCT: 0.06-0.67% at 3 yearsa
 •  Quantity of pretransplant chemotherapy 
(see pathogenesis) and local 
radiotherapy
 •  Conditioning with TBI
 •  Older age at HSCT
t-MN are mainly observed after HSCT for 
lymphoma (NHL, HL)
DCL Rare complication, with a CI <1% at 15 years
Possibly underestimated (difficulty to prove donor 
type of malignant cells)
Could represent up to 5% of post transplant leukemia 
“relapses”
No clear risk factor defined (too few, 
heterogeneous DCL)
Possible risk factorsb
 • Malignant donor clone in the transplant
 • G-CSF therapy
 • In vivo T cell depletion








Breast cancer: 11% at 25 yearsc
Thyroid cancer: SIR 3.2 compared to general 
populationd
BCC: 6.5% at 20 yearse
Radiation before HSCT or TBI
Younger age at radiation
Longer follow-up
Light-skinned patients (BCC)
SSC of skin, 
oral cavity, and 
esophagus





At any time after HSCT
Hepatocellular 
carcinoma
Patients with HCV infection: CI 16% at 20 yearsg HCV infection
Cirrhosis
Lung cancer SIR 2.59 after BuCyh Conditioning with Bu-Cy
Smoking prior to HCT
Cervix cancer HPV reactivation
Melanoma T cell depletion
BCC basal cell carcinoma of the skin, SSC squamous cell carcinoma, CI cumulative incidence, AID autoimmune 







gPeffault de Latour et al. (2004)
hMajhail et al. (2011)
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Colorectal cancers have not been proven to be 
increased after HSCT. In non-transplanted cancer 
patients, second colorectal cancers are increased 
when treated with abdominal radiation (Henderson 
et  al. 2012; Rapiti et  al. 2008; van Eggermond 
et al. 2017).
So far there are few long-term data on SSN after 
RIC. A single-center study shows an increased rate 
of SSC compared to MAC during the first 10 years 
post-HSCT (Shimoni et al. 2013). There are not yet 
data on CI of SSN >10 years after RIC. SSN asso-
ciated with TBI conditioning (breast, thyroid) 
might be lower after RIC than MAC.
47.5  Screening (Majhail et al. 2012) 
(See Also Chap. 21)
47.5.1  Therapy-Related Myeloid 
Neoplasms
Annual monitoring of full peripheral blood 
counts during the first 10 years after auto-HSCT 
(most t-MN occur within 10 years after HSCT)
In case of unexpected abnormalities 
(increased MCV, cytopenia, dysplasia in periph-
eral blood, monocytosis), extended analysis of 
blood and bone marrow (including cytogenetics 
and NGS)
47.5.2  Donor Cell Leukemia
Chimerism monitoring of the malignant cells in 
case of “relapse” or new hematological malig-
nancy after allo-HSCT.
Whether search of an abnormal clone in the 
donor should be performed in case of donor ori-
gin of the malignancy remains controversial.
47.5.3  Second Solid Cancer (Socie 
and Rizzo 2012)
Lifelong screening for SSN is recommended 
after auto-HSCT and allo-HSCT.
General recommendations are:
• During annual control, clinical screening, 
reviewing for possible symptoms of SSN.
• Receive at least country-specific general popu-
lation recommendations for cancer screening.
• Be informed and counseled about the risk of SSN.
Specific recommendations are included in 
Table 47.2.
Table 47.2 Screening for secondary solid cancer after HSCT
Skin All patients
Encouraged to
•  Perform regularly genital/testicular and skin self-examination
 •  To avoid unprotected UV skin exposure
Skin examination by dermatologist every 1–2 years
Patients at risk
More frequent examination by dermatologist
 • After first skin cancer
 • Patients with chronic skin GvHD
Oral cavity and 
pharynx
All patients
Examination during annual control
Patients at risk
Annual control by specialist if severe oral and pharynx GvHD
Histology in case of suspicious lesion
Thyroid All patients
Annual thyroid palpation to identify suspicious thyroid nodules
Patients at risk (patients at risk after TBI or local radiation)
Regular thyroid ultrasound




Discuss breast self-examination with their physician
Patients at risk
Screening mammography every 1 to 2 years starts at the age of 25 or 8 years after radiation, 
whichever occurs later, but not later than age of 40 years
Cervix All patients
Screening with pap smears every 1–3 years in women older than 21 or within 3 years of initial 
sexual activity, whichever occurs earlier
Lung All patients
Encouraged to avoid smoking and passive tobacco exposure
Patients at risk
Patients at risk (high-dose busulfan conditioning and smoking), chest CT
Liver Patients at risk
Patients with known HCV infection should be assessed for fibrosis/cirrhosis of the liver 8–10 years 
after HSCT (biopsy; fibroscan)
Colorectal All patients
Screening should start at age 50 in absence of a family history (first-degree relative diagnosed with 
colorectal cancer before age 60): annual fecal occult blood testing, sigmoidoscopy every 5 years, 





t-MN Same treatment than de novo myeloid 
neoplasms
Early donor search and rapid allo-HSCTa
Decision-making including consideration 
of cumulative toxicity due to previous 
HSCT
DCL No standard treatment
Treatment depends on the nature of disease
Reported treatmentsb
 • Retransplantation
 • Conventional chemotherapy
 • DLI
 • Palliation
SSN Should be treated as de novo cancers of the 
same type





t-MN Generally very poor
Median survival of 6 m
Identical outcome than t-MN in general
DCL Few data available
In most cases, mortality high and OS poor
In a small series of 47 DCL, median 
survival 32.8% months
Death mainly due to progression or relapse 
of DCL
SSN Mainly dependent on the type of SSNa
Favorable outcome
 •  Thyroid, breast, prostate, melanoma, 
cervix
Intermediate outcome
 •  Oropharyngeal, colorectal, bladder, 
renal, ovarian, endometrial
Poor outcome
 •  Pancreas, lung, brain, hepatobiliary, 
esophageal
aEhrhardt et al. (2016); Tichelli et al. (2018)
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Ocular and Oral Complications
Shahrukh K. Hashmi
48.1  Ocular Complications
48.1.1  Introduction
Ocular complications in HSCT patients include 
both ocular GVHD- and non-GVHD-related late 
effects which, if left untreated, can lead to blind-
ness. Non-GVHD associated complications 
include glaucoma, infections particularly (viral 
retinitis, fungal endophthalmitis), posterior seg-
ment abnormalities, and cataracts. Ocular GVHD 
is considered an umbrella term for both conjunc-
tival disease and keratoconjunctivitis sicca, both 
of which can coexist simultaneously.
The World Health Organization considers blind-
ness as one of the top causes for disability- adjusted 
life years, and it significantly affects the QoL. Thus, 
prevention and prompt management of ocular com-
plications should be a priority of a transplant pro-
gram given the morbidity associated with it.
48.1.2  Ocular GVHD
Though it is considered to be systematic disease, 
the pattern of isolated ocular GVHD manifesting 
later as GVHD in other organs is erratic (Townley 
et al. 2011). The 2014 NIH consensus develop-
ment project on chronic GVHD does not account 
for therapeutic responses based mainly on 
patient-reported outcomes (PRO); thus the devel-
opment of PRO measures (PROM) specific for 
ocular GVHD should be a priority of the GVHD 
research community. The NIH chronic GVHD 
consortium does recommend photoprotection, 
surveillance for infection, cataract formation, and 
increased intraocular pressure for prevention of 
ocular complications in GVHD—these measures 
should be routinely incorporated in the standard 
clinical practice of HSCT patients and are best 
achieved within the context of a multidisciplinary 
survivorship clinic along with ophthalmologists 
as part of the team.
The occurrence of ocular GVHD is variable in 
different series but is approximately 40 to 60% of 
patients receiving HSCT (Nassar et  al. 2013). 
The risk factors for ocular GVHD include donor- 
recipient HLA and gender disparity (female 
donor to male recipient) and an older donor age.
The principles of ocular GVHD management 
include lubrication, drainage control, evaporation 
control, and minimization of ocular surface inflam-
mation. The 2014 NIH chronic GVHD consensus 
panel has excellent recommendations for stepwise 
treatment of ocular GVHD which include preser-
vative-free artificial tears for mild, topical cyclo-
sporine or steroid eye drops for moderate/severe 
and oral pilocarpine or cevimeline for severe/mod-
erate ocular GVHD, respectively (Carpenter et al. 
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2015). Among surgical procedures for moderate/
severe ocular GVHD, punctal occlusion, superfi-
cial debridement of filamentary keratitis, and par-
tial tarsorrhaphy have been recommended as 
surgeries with moderate- quality data on effective-
ness. There is also some evidence on other modali-
ties of treatment which include occlusive eye wear, 
lid care/warm compress/humidified environment, 
bandage contact lens, and gas-permeable scleral 
lenses. What is not clear is the optimal manage-
ment algorithm for ocular GVHD with respect to 
medical versus surgical therapies and, within the 
surgical therapies, which ones would be most 
effective due to lack of clinical trials in this area. 
Thus, ocular GVHD is best managed in conjunc-
tion with ophthalmologist experienced in dealing 
with ocular GVHD.
In addition, special attention should be given to 
other risk factors for ocular complications, among 
which diabetes and hypertension are at the top. 
Thus, if a patient is on CNI or corticosteroids, then 
optimization of blood pressure and glycaemia con-
trol is imperative to reduce the risk of blindness 
due to retinopathy irrespective of the cause.
48.1.3  Posterior Segment 
Complications
Retinal and vitreous hemorrhages are not uncom-
mon in HSCT patients and may happen with or 
without the presence of ocular GVHD (Yoo et al. 
2017). This is complicated by the presence of 
thrombocytopenia early in transplant but also later 
in the course since both drugs and chronic GVHD 
can be associated with thrombocytopenia. Prompt 
referral to ophthalmologist is the key for prevent-
ing blindness; therefore, the practicing transplant 
clinician should have a high suspicion of retinopa-
thy, retinal tears, or vitreous hemorrhages when a 
patient complains of “floaters” or just “decreased 
vision,” which happens suddenly.
48.1.4  Ocular Infections
CMV infection is one the most widely studied 
ocular infections and can rapidly lead to retinitis, 
and since quite often IV antibiotics are required, 
prompt referral to ophthalmologist is mandatory. 
Apart from CMV, adenovirus is also a common 
virus and can lead to viremia if untreated. 
Moreover, unlike immunocompetent individuals, 
varicella zoster infection within hours or couple 
of days can lead to dissemination as well as 
postherpetic neuralgia, cranial nerve palsies, zos-
ter paresis, meningoencephalitis, cerebellitis, 
myelopathy, and irreversible blindness.
Fungal infections in severely IS HSCT patients 
(particularly those on multiple IS for GVHD) can 
quickly lead to mortality; thus prompt referral for 
IV antifungals is indicated. Aspergillosis, mucor-
mycosis, and candida have been reported in 
GVHD patients affecting the ocular tissues.
48.1.5  Glaucoma
Since the most common subtype of glaucoma (pri-
mary open-angle glaucoma) presents with gradual 
symptoms, its diagnosis is frequently missed in 
early phases. However, many risk factors in HSCT 
can predispose to glaucoma and can lead to blind-
ness which include diabetes (allo-HSCT patients 
have four times higher risk of diabetes), retinopa-
thy, and steroid use (for GVHD). Since the diagno-
sis of glaucoma is based in tonometry, gonioscopy, 
perimetry, and ophthalmoscopy, regular screening 
by the ophthalmologist is indicated.
48.1.6  Cataract
Cataract is the most common cause of blind-
ness in the developed world. Risk factors in the 
HSCT patients include steroid use, total body 
irradiation, and diabetes. Since intraocular lens 
implantation (particularly via phacoemulsifica-
tion) has become a widely performed procedure 
worldwide for the treatment of cataracts, early 
recognition and prompt treatment can help in 
preservation of vision. This procedure is asso-
ciated with low rate of complications; however, 
prevention of cataracts by controlling the risk 
factors should be the management strategy in 
HSCT survivors (Table 48.1).
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48.2  Oral Complications
48.2.1  Introduction
Oral complications of HSCT can significantly 
affect the quality of the life (QoL) and can be a 
result of graft-versus-host-disease (GVHD) or 
can occur independent of it. Any oral complica-
tion, if severe, can lead to weight loss due to 
poor nutritional intake, mortality (especially 
due to cancer), aspiration pneumonia (espe-
cially in cases of oropharyngeal disorders), and 
psychologic sequelae (particularly disfigure-
ment due to oral scleroderma, i.e., fish mouth) 
(Table 48.2).
48.2.2  Oral GVHD
Oral GVHD itself can lead to significant mortality 
and morbidity. GVHD-associated oral complica-
tions, e.g., mouth scleroderma, lichenification 
(resulting in lichenoid features and lichen planus), 
oral cancers, dental caries, salivary gland dysfunc-
tion (main manifestation being xerostomia), and 
mucoceles, are common complications of oral 
GVHD. In addition, avascular necrosis (AVN) of 
the mandible can occur as a complication of ste-
roid therapy for GVHD (Treister et al. 2012).
The 2014 National Institutes of Health chronic 
GVHD consensus criteria places the scoring 
based on lichen-like features; however many of 
the associated patient-reported outcomes are not 
captured by this scoring system which can tre-
mendously affect the QoL (Jagasia et al. 2015). 
Thus, involvement of specialists experienced in 
dealing with long-term HSCT complications is 
imperative for management of oral GVHD and 
its complications.
The management of oral GVHD requires both 
topical treatments and systemic therapy. Topical 
treatments may include local tacrolimus (i.e., 
protopic), PUVA, and topical steroids. Among 
systemic treatments for oral GVHD, extracorpo-
real photopheresis has one of the highest response 
rates, along with rituximab (Okamoto et al. 2006; 
Malik et al. 2014).
48.2.3  Oral Cancers
Carcinomas of the oral cavity are predominantly 
of squamous cell carcinoma type; however, other 
Table 48.1 Ocular complications of HSCT
Risk factors/manifestations Management Survivorship issues
GVHD 
associated






–  Topical: artificial tears, 
steroids, CSA, scleral lenses, 
autologous serum, surgical 
procedures
–  Systemic: ECP, rituximab, 
ibrutinib
Presence of ophthalmologist 












• Ocular complications of HSCT are not 
restricted to GVHD, since both non- 
GVHD allo-HSCT and auto-HSCT 
recipients can suffer from cataracts, 
viral/fungal infections, glaucoma, and 
retinopathies.
• QoL compromise by ocular complica-
tions of HSCT is paramount due to 
ensuing blindness.
• Transplant centers should consider a 
close collaboration with ophthalmology 
teams both for treatment and preventative 
strategies. This could ideally be achieved 
in a multidisciplinary team in a long-term 
follow-up or a survivorship clinic.
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histologies can also manifest as oral cancers in 
HSCT survivors. The risks of developing oral 
cancers increase significantly post transplant to 
approximately sevenfold with the highest risk 
being in patients who were transplanted for bone 
marrow failure (BMF) syndromes especially 
dyskeratosis congenita and Fanconi’s anemia 
(Rosenberg et  al. 2003). Besides BMF syn-
dromes, the most important risk factors for oral 
carcinomas include GVHD, radiation, and epi-
genetic factors (smoking). It is of utmost impor-
tant that prevention strategies of oral cancers be 
discussed at each visit with special emphasis on 
smoking cessation (if applicable) and avoidance 
of other known risk factors, e.g., betel nut, 
tobacco chewing, or alcohol intake, since these 
are modifiable risks. Additionally, aggressive 
and early treatment of oral GVHD is essential to 
prevent this complication.
48.2.4  Non-GVHD-Associated Oral 
Manifestations
These include osteonecrosis of the jaw (ONJ), 
dysgeusia, temporomandibular disorders, gingivi-
tis, and oral mucositis early in HSCT. Though cer-
tain symptoms like dysgeusia (Sato et al. 2017a, b) 
may seem trivial, they significantly affect the 
QoL, preservation of which is the sine qua non of 
managing late effects. Similarly, oral mucositis is 
one of the most challenging complications in 
early phases of HSCT with a high incidence in 
both reduced intensity and myeloablative regi-
mens (Chaudhry et al. 2015). Similarly, ONJ can 
lead to multiple late effects of chronic pain and 
poor oral intake and can affect QoL tremendously 
(Hautmann et al. 2011). Thus, prompt referral to 
maxillofacial surgeon for management is impera-
tive as soon as any symptoms start to develop.
48.2.5  Needs Provision for Oral 
Surgery/Dentistry in HSCT
Many experts recommend that dentistry and/or 
oral surgeons should be part of a multidisci-
plinary team managing late effects in both autol-
ogous and allogeneic HSCT survivors, and this 
concept was recently endorsed by the National 
Institutes of Health’s Late Effects Initiative 
(Hashmi et al. 2017). Once the primary disease 
(for which HSCT was performed) is cured, it is 
essential that surveillance and preventative strate-
gies be undertaken to alleviate the burden of 
comorbidities in these survivors; thus we agree 
that a long-term follow-up clinic should opti-
mally have dentistry services available ad hoc if 
not on routine surveillance basis.
Key Points
• Oral GVHD and its associated compli-
cations can lead to significant compro-
mise in QoL and can lead to cancers 
which can lead to fatal outcomes.
• Non-GVHD-associated complications 
also should be vigilantly dealt with as 
they tremendously affect QoL and 
include ONJ, dysgeusia, dental carries, 
gingivitis, and oral mucositis.
• Dentists and/or oral surgeons should 
ideally be a part of multidisciplinary 
teams of a long-term follow-up/survi-
vorship clinic of HSCT survivors.
Table 48.2 Oral complications of hematopoietic stem cell transplantation




– Squamous cell carcinoma
– Aphthous ulcers
–  Fish mouth (scleroderma), carries, 
odynophagia, carries
–  Topical: tacrolimus, 
steroids, PUVA
–  Systemic: extracorporeal 
photopheresis, rituximab, 
ibrutinib
–  Presence of a dentist 
and/or oral surgeon in 




–  Osteonecrosis of the jaw, 
dysgeusia, temporomandibular 
joint disorders, mucositis, carries, 
odynophagia
Dental or oral surgery referral 





Carpenter PA, Kitko CL, Elad S, et al. National institutes 
of health consensus development project on criteria 
for clinical trials in chronic graft-versus-host disease: 
V.  The 2014 ancillary therapy and supportive care 
working group report. Biol Blood Marrow Transplant. 
2015;21:1167–87.
Chaudhry HM, Bruce AJ, Wolf R, et  al. The incidence 
and outcomes of oral mucositis among allogeneic 
stem cell transplantation patients: a systematic review 
and meta-analysis. Biol Blood Marrow Transplant. 
2015;21:S245–6.
Hashmi SK, Bredeson C, Duarte RF, et al. National insti-
tutes of health blood and marrow transplant late effects 
initiative: the healthcare delivery working group report. 
Biol Blood Marrow Transplant. 2017;23:717–25.
Hautmann AH, Elad S, Lawitschka A, et  al. Metabolic 
bone diseases in patients after allogeneic hematopoietic 
stem cell transplantation: report from the consensus 
conference on clinical practice in chronic graft-versus- 
host disease. Transpl Int. 2011;24:867–79.
Jagasia MH, Greinix HT, Arora M, et  al. National 
Institutes of Health consensus development project 
on criteria for clinical trials in chronic graft-versus- 
host disease: I. The 2014 diagnosis and staging work-
ing group report. Biol Blood Marrow Transplant. 
2015;21:389–401.
Malik MI, Litzow M, Hogan W, et  al. Extracorporeal 
photopheresis for chronic graft-versus-host disease: 
a systematic review and meta-analysis. Blood Res. 
2014;49:100–6.
Nassar A, Tabbara KF, Aljurf M.  Ocular manifestations 
of graft-versus-host disease. Saudi J Ophthalmol. 
2013;27:215–22.
Okamoto M, Okano A, Akamatsu S, et  al. Rituximab 
is effective for steroid-refractory scleroderma-
tous chronic graft-versus-host disease. Leukemia. 
2006;20:172–3.
Rosenberg PS, Greene MH, Alter BP. Cancer incidence 
in persons with Fanconi anemia. Blood. 2003;101: 
822–6.
Sato T, Konuma T, Miwa Y, et al. A cross-sectional study 
on late taste disorders in survivors of allogeneic 
hematopoietic cell transplantation. Ann Hematol. 
2017a;96:1841–7.
Sato T, Konuma T, Miwa Y, et al. A cross-sectional study 
on late taste disorders in survivors of allogeneic 
hematopoietic cell transplantation. Ann Hematol. 
2017b;96:1841–7.
Townley JR, Dana R, Jacobs DS.  Keratoconjunctivitis 
sicca manifestations in ocular graft versus host dis-
ease: pathogenesis, presentation, prevention, and treat-
ment. Semin Ophthalmol. 2011;26:251–60.
Treister N, Duncan C, Cutler C, Lehmann L.  How we 
treat oral chronic graft-versus-host disease. Blood. 
2012;120:3407–18.
Yoo YS, Na KS, Shin JA, et  al. Posterior eye segment 
complications related to allogeneic hematopoietic 
stem cell transplantation. Retina. 2017;37:135–43.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
48 Ocular and Oral Complications
373© EBMT and the Author(s) 2019 




The frequency and severity of TPH liver com-
plications have decreased sharply in the last 
decade, with some complications that have 
completely disappeared, such as, for example, 
Candida liver abscesses. The development of 
more effective strategies to preventing SOS/
VOD and GVHD has had a marked effect on its 
clinical presentation (see Chaps. 25 and 49). 
Finally, prophylaxis with antiviral and antifun-
gal drugs has greatly reduced the incidence of 
the most common liver infections (Hockenbery 
et al. 2016). The major liver complications after 
HSCT are:
Early after HSCT 
(<100 days)
Late after HSCT 
(months-years)
SOS/VOD




Chronic GVHD  
(see Chap. 44)
Autoimmune hepatitis
Chronic viral hepatitis  
(see Chap. 38)
Cirrhosis and hepatocellular 
carcinoma
Iron overload  
(see Chap. 46)
Other less frequent
49.2  Sinusoidal Obstruction 
Syndrome
49.2.1  Definition
SOS, formerly called veno-occlusive disease of the 
liver (VOD), is the term used to designate the symp-
toms and signs that appear early after HSCT because 
of conditioning regimen-related hepatic toxicity. 
This syndrome is characterized by jaundice, fluid 
retention, and tender hepatomegaly appearing in the 
first 35–40 days after HSCT (Carreras 2015).
49.2.2  Pathogenesis
The hepatic metabolism of certain drugs (e.g., CY) 
by the cytochrome P450 enzymatic system pro-
duces several toxic metabolites (e.g., acrolein). 
These toxic metabolites are converted into stable 
(nontoxic) metabolites by the glutathione (GSH) 
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enzymatic system and then eliminated. When this 
process occurs in patients with a reduced GSH 
activity, caused by previous liver disease or by the 
action of agents such as BU, BCNU, or TBI, which 
consume GSH, toxic metabolites are not metabo-
lized. Toxic metabolites are predominantly located 
in area 3 of the hepatic acinus (around the centri-
lobular veins) because this area is rich in P450 and 
poor in glutathione. Consequently, damage to hepa-
tocytes and sinusoidal endothelium occurs predom-
inantly in this zone. Many other factors (see risk 
factors) can also contribute to endothelial injury.
The first events after endothelial injury caused 
by toxic metabolites are loss of fenestrae in sinusoi-
dal endothelial cells (SEC), formation of gaps 
within and between SEC, and rounding up or swell-
ing of SEC. Consequently, red blood cells penetrate 
into the space of Disse and dissect off the sinusoidal 
lining, which embolize downstream and block the 
sinusoids, reducing the hepatic venous outflow and 
producing post- sinusoidal hypertension. The 
changes observed in coagulation factors in these 
patients seem to be a consequence of the endothelial 
injury and probably play a secondary role in SOS 
pathogenesis, despite contributing to the sinusoidal 
occlusion (Carreras and Diaz-Ricart 2011).
















aPositive fluid balance not explained by excessive 
hydration
bDifficult to demonstrate by expected thrombocytopenia
49.2.4  EBMT Diagnostic Criteria 
for Adults (Mohty et al. 2016)
Classical SOS 
(Baltimore criteria)a Late-onset SOSb
In the first 21 days 
after HSCT
Bilirubin ≥2 mg/dLc 
and ≥ 2 of the 
following
  –  Painful 
hepatomegaly
  –  Weight gain 
>5%
  –  Ascites




≥2 of the classical criteria  
AND ultrasound (US) or 
hemodynamical evidence of 
SOS
aThese symptoms/signs should not be attributable to other 
causes
bMainly observed after conditioning including several 
alkylating agents (e.g., BU, MEL, or TT)
cObserved in almost 100% of adults but absent in up to 
30% of children
49.2.5  EBMT Diagnostic Criteria 
for Children  
(Corbacioglu et al. 2018)
No limitation for time of onset of SOSa
The presence of two or more of the followingb
  •  Unexplained consumptive and transfusion- 
refractory thrombocytopeniac
  •  Otherwise unexplained weight gain on 3 
consecutive days despite the use of diuretics or a 
weight gain >5% above baseline value
  •  Hepatomegaly (best if confirmed by imaging) 
above baseline valued
  •  Ascites (ideally confirmed by imaging) above 
baseline valued
  •  Rising bilirubin from a baseline value on 3 
consecutive days or ≥2 mg/dL within 72 h
aUp to 20% of children present late SOS
bWith the exclusion of other potential differential 
diagnoses
cWeight-adjusted platelet substitution/day to maintain 
institutional transfusion guidelines
dSuggested: imaging (US, CT, or MRI) immediately 
before HSCT to determine baseline value for both hepato-
megaly and ascites
T. Ruutu and E. Carreras
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49.2.6  Incidence
Variable depending on the diagnostic criteria 
used, center experience, type of patients, and 
year of HSCT




Coppell et al. 2010 
(1979–2007) (R)
8.7% 13%
Carreras et al. (1998) (P) 3.1% 8.9%
Corbacioglu et al. 2012 
(2006–2009) (P)a
6% 14%




R retrospective study, P prospective study
aOnly children and young adolescents
bOnly adults









Status of the 
disease
Remission < relapse














Gemtuzumab or inotuzumab 
ozogamicin
Concomitant drugs Progestogens, azoles
Genetic factors GSTM1-null genotype, MTHFR 
677CC/1298CC haplotype, etc.
Transplant-related factors
Type of HCT Syngeneic/autologous < allogeneic










Busulfan IV < oral targeted < oral
CY-BU < BU-CY
TBI Fractionated < single dose
Low-dose rate < high-dose rate
Less than 12 Gy < more than 12 Gy
Time between CY to TBI 
36 h < CY to TBI 12 h
Fludarabine Not included < included
GvHD prophylaxis CNI (TAC < CSA) 
< CNI + sirolimus
HSCT number First < second HSCT
Bold characters indicate the most relevant factors
aMany factors have been associated with an increased risk 
of SOS, with those in bold letters seem the most relevant
bRemember that the presence of several risk factors in a 
patient has an additive effect
cDue to unknown causes, some malignant or nonmalignant 
diseases, osteopetrosis, adrenoleukodystrophy, thalassemia, 
hemophagocytic lymphohistiocytosis, or neuroblastoma 
are associated with a higher incidence of SOS
49.2.8  How to Confirm 
the Diagnosis?
SOS is a syndrome and must be diagnosed clinically, 




Permits a safe measurement of the 
hepatic venous pressure gradient 
(HVPG), which evaluates the presence 
of intrahepatic post- sinusoidal 
hypertension. A HVPG >10 mmHg is 
highly specific (>90%) and moderately 
sensitive (60%) for SOS
Transvenous 
liver biopsies
Transvenous biopsies may be obtained 
during hemodynamic studies, but 
false-negative results could be 
obtained due to the patchy nature of 
SOS. However, biopsies carry a risk of 
hemorrhagic complications (e.g., into 
the peritoneum and biliary tract). 
Consequently, they are only indicated 
when a crucial differential diagnosis is 





They may be helpful to confirm 
hepatomegaly and/or ascites (relevant 
in overweight patients) and for the 
differential diagnosis. Baseline and 
serial US may be useful for early 
detection of SOS
The US abnormalities observed in 
SOS (hepatomegaly, splenomegaly, 
gallbladder wall thickening, ascites) 
are not specific. Decrease in velocity 
or reversal of the portal venous flow is 
considered more specific for SOS but 
usually occurs late in the disease 
(reviewed in Dignan et al. 2013)
Composite 
biomarkers
Recently some composite markers 
have shown a prognostic value at day 
0 (L-Ficolin, HA, VCAM-1) and at 
diagnosis (ST2, ANG2, L-Ficolin, HA, 
VCAM-1) (Akil et al. 2015)
HA hyaluronic acid, VCAM-1 vascular cell adhesion mol-
ecule- 1, ST2 suppressor of tumorigenicity-2, ANG2 
angiopoietin-2
49.2.9  EBMT Criteria for Severity Grading
Classically the severity of SOS was stablished, 
prospectively, based in a mathematical model or, 
retrospectively, based on its evolution (resolution 
or not at day +100). Later, SOS may be classified 
as severe with the development of multiorgan 
failure MOF. Several systems have been proposed 
for early prognostication of SOS using scales, 
including the following elaborated by the EBMT 
(Mohty et al. 2016).
Mild Moderate Severe Very 
severe
Time since first 
symptoms
>7 days 5–7 days ≤4 days Any time







≤2 >2 to ≤5 >5 to ≤8 >8
Weight gain (%) <5 ≥5 to <10a ≥5 to <10a ≥10
Renal function 
(× baseline at 
HSCT)
<1.2 ≥1.2 to 
<1.5
≥1.5 to <2 ≥2 or 
other data 
of MOF
This severity grading must be applied once SOS/VOD has 
been diagnosed applying the criteria mentioned in 49.2.4
Patients belong to the category that fulfills ≥2 criteria. If 
patients fulfill ≥2 criteria in two different categories, they 
should be classified in the most severe category
In the presence of two or more risk factors for SOS, patients 
should be in the upper grade
N normal values
aWeight gain ≥5% and <10% is considered as a severe 
SOS. However, if the patient does not fulfill other criteria 
for severe SOS, it is therefore considered a moderate SOS
49.2.10  Prophylaxis (Dignan et al. 
2013; Carreras 2015)
Non-pharmacological measures
Avoid modifiable risk factors: Treat Iron overload 
(chelation); treat viral hepatitis; delay HSCT if active 
hepatitis; reduce intensity of conditioning; use 
CY + BU instead of BU + cy; try to avoid CNI  
(if not possible use TAC instead CSA) for GVHD 
prophylaxis; avoid hepatotoxic drugs (progestogens)
Pharmacological Drug (degree of 
recommendation)
Not recommended Sodium heparin (2B), 
low-molecular-weight 
heparin (2B), 
antithrombin III (2B), 
prostaglandin-1 (1B), 
pentoxifylline (1A)
Suggested Ursodeoxycholic acid 
(2C)a
Defibrotide: In 
high-risk adult patients 
(2B)
Recommended Defibrotide: In 
high-risk children (1A) 
[25 mg/kg/d]
aIn two randomized trials, UDCA reduce the incidence of 
SOS but in other two this effect was not observed. However, 
in all them, patients with UDCA have a lower TRM
49.2.11  Treatment (Degree 
of Recommendation) 
(Dignan et al. 2013;  
Carreras 2015)
Methylprednisolone (2C): Used by some 
authors. Recommended doses not defined 
(and range from high to low) and results dif-
ficult to analyze. Main risk: to delay treatment 
with defibrotide, the only agent with proved 
effectiveness.
Defibrotide (1B): Despite the absence of ran-
domized studies, it is the only agent approved by 
FDA and EMA to treat severe SOS (>80% mor-
tality). In these patients: 50% of complete remis-
sion and > 50% SRV at day +100. Early treatment 
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strongly recommended. Dose: 6.25 mg/kg q6h in 
2 h during ≥21 days, depending on the response.
49.3  Hepatitis After HSCT
Despite the reduction in the incidence of liver 
complications after HSCT, there remain multiple 
hepatic causes of elevations of serum alanine 
aminotransferase (ALT). In addition to the acute 










Very frequent. Wide range of severity 
(see Sect. 49.3.1)
Hepatic GvHD Exceptional. AST/ALT >2000 U/L 
usually observed in patients without 
or with minimal IS (or receiving DLI) 
(see Chaps. 43 and 44)
Autoimmune 
hepatitis
True autoimmune hepatitis or 
GVHD? Often difficult to 
differentiate (see Sect. 49.3.2)
Other causes Severe SOS (see Sect. 49.2), hypoxic 
liver injury (septic or cardiac shock or 
respiratory failure), acute biliary 
obstruction
49.3.1  Drug Induced Hepatitis
Druga,b Comments
Thiazole antifungalsc Cholestaticd or 
hepatocellular hepatitise, 
liver failure




Liposomal AmB Mild-moderate elevation 
of alkaline phosphatase
TMP/SMX Hepatocellular hepatitis
CSA, tacrolimus Cholestasis. Dose- 
dependent effect
Rapamycin Hepatocellular damage, 
increased risk of SOSf
Anticonvulsants Hepatitis, hepatocellular 
or cholestatic
Druga,b Comments
NSAIDs Hepatitis, hepatocellular 
or cholestatic
Acetaminophen Hepatocellular hepatitis. 
Dose-dependent effect
Antidepressants Hepatocellular hepatitis. 
Unrelated to drug dosage










Drugs usually associated 
in patients with metabolic 
syndrome (see Chap. 55)
AMB amphotericin B, TMP/SMX trimethoprim- 
sulfamethoxazole, NSAID nonsteroidal anti-inflammatory 
drug
aOther than cytostatic drugs
bOnline resources for the consultation of toxicities and 
interactions: https://livertox.nlm.nih.gov
cVoriconazole, posaconazole
dLiver damage with predominant elevation of bilirubin 
and alkaline phosphatase
eHepatic damage with predominant elevation of 
transaminases
fEspecially if associated to CNI
49.3.2  Autoimmune Hepatitis (AIH)
The main problem with this hepatitis is how to 
differentiate them from a hepatic GVHD, since 
pathogenesis, clinical manifestations, and bio-











dark urine, acholic 
stools, anorexia, 
usually GVHD in 
other organs
Pathology Inflammatory 




infiltrate, loss of small 
bile duct, 
degeneration of bile 
ductular epithelium, 
cholestasis
Cirrhosis May be present Rare







>GGT Marked Usually normal o 
decreased
Auto-Ab Type AIH-2 
(ALKM, ALC-1)




Excellent Depends on severity
In bold letter main differential data
49.4  Cirrhosis and Heparocellular 
Carcinoma
Cirrhosisa – In HSCT with HBV: exceptional
–  In HSCT with HCV: 11% at 15 years; 
20% at 20 years (Peffault de Latour 
et al. 2004)b
–  In HSCT with HEV: frequency not 
known but rapidly progressive cases 
have been reported (see Chap. 38)
–  Poorly compensated cirrhosis is a 
contraindication for HSCT because of the 
prohibitive risk of developing SOS after 
MAC. Even compensated cirrhosis has a 
high likelihood of hepatic decompensation 
after NMA (Hogan et al. 2004)
Carcinoma In patients with chronic HCV: 5% at 
20 years of new cases per year (Peffault de 
Latour et al. 2004). These patients should 
undergo surveillance with six monthly 
liver ultrasound scans according to 
international guidelines
aThese data correspond to the times when new antiviral 
agents were not available. No updated data are available
bThe cumulative incidence of severe liver complications 
in HSCT infected with the HCV was 11.7% at 20 years in 
multicenter cohort (Ljungman et al. 2012)
49.5  Other Less Frequent Hepatic 
Complications
49.5.1  Nodular Regenerative 
Hyperplasia
After HSCT, occasionally observed in patients 
with a previous SOS/VOD.
Pathogenesis: Probable consequence of changes 
in liver blood flow with atrophy of zone 3 of the 
acinus and hypertrophy of zone 1 (without 
fibrosis).
Clinical Manifestations: Silent evolution (occa-
sionally increase of AP) until the appearance of 
portal hypertension (ascites, splenomegaly, 
thrombocytopenia).
Diagnosis: Investigated by imaging (primarily 
MRI). Liver biopsy can rule out carcinoma and 
cirrhosis; need for a needle biopsy (not transjug-
ular or fine-needle biopsy).
49.5.2  Focal Nodular Hyperplasia
In one series (Sudour et al. 2009) of HSCT survi-
vors undergoing liver MRI, these lesions were 
observed in 12%.
Pathogenesis: The likely cause is sinusoidal 
injury caused by myeloablative conditioning 
regimens.
Clinical Manifestations: Asymptomatic.
Diagnosis: By MRI, lesions have characteristic 
central scars that differentiate them from 
hepatocellular carcinoma and fungal lesions.
49.5.3  Idiopathic Hyperammonemia
Very rare. Observed after conditioning (Frere 
et al. 2000)
Diagnosis: Severe hyperammonemia (>200 
μmol/L) with minimal alteration of other LFTs.
Clinical Manifestations: Lethargy, motor dysco-
ordination, and alkalosis.
T. Ruutu and E. Carreras
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The gastrointestinal (GI) tract is one of the sys-
tems most commonly affected by transplant com-
plications. It is due to the high vulnerability of 
the gut mucosa composed of dividing cells, 
which are susceptible to chemotherapy-induced 
damage, rich vasculature, constant contact with 
intestinal microflora, and high content of 
immune-competent cells. Therefore, when evalu-
ating symptoms from the GI system, various pos-
sible causes must be taken into account, especially 
drug toxicity, infections, and graft-versus-host 
disease. In this chapter selected GI complications 
most frequent after HSCT will be presented. The 
GI aGVHD was already discussed in Chaps. 43 
and 44 and infectious causes in Chaps. 38 and 39.
50.2  Nausea/Vomiting
50.2.1  Definitions
Nausea: a disorder characterized by a queasy sen-
sation and/or the urge to vomit.
Vomiting: a disorder characterized by the 
reflexive act of ejecting the contents of the stom-
ach through the mouth.
50.2.2  Types
Acute onset: within 24 h of chemotherapy admin-
istration (peak at 4–6 h) lasting for 24–48 h.
Delayed onset: occurs more than 24  h after 
chemotherapy (peak at 2–3 days) lasting for pro-
longed period of time.
50.2.3  Pathophysiology
 1. Direct activation of the vomiting center in the 
brain stem by chemotherapy, which triggers 
target organs in GI tract.
 2. Damage to the GI mucosa, causing vagal 
stimulation and neurotransmitter (serotonin, 
neurokinin-1, dopamine) release causing 
reflexive stimulation of the vomiting center.
 3. Radiotherapy-induced neurotransmitter release 
stimulating vomiting center concomitant with 
brain edema.
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Induced directly by conditioning chemoradiotherapy
TBI, TLI, cranio-spinal irradiation
Chemotherapy drugs (NCCN 2017):
 •  High emetic risk (frequency > 90%):  
CY >1500 mg/m2, BCNU >250 mg/m2
 •  Moderate emetic risk (frequency 30–90%): 
bendamustine, BU, BCNU ≤250 mg/m2,  
CY ≤1500 mg/m2, MEL
 •  Minimal to low emetic risk (frequency < 30%):  
VP, TT, FLU, MTX ≤50 mg/m2
Drugs: opioids, CNI, nystatin, AmB, voriconazole, 
itraconazole, TMP-SMX, MMF
GVHD
Hepatic disease: GVHD, VOD, viral hepatitis






50.2.6  Grading (CTCAE v4.0  
[NCI 2009])
Nausea
Grade 1 Loss of appetite without alteration of eating 
habits
Grade 2 Oral intake decreased without significant 
weight loss, dehydration, or malnutrition
Grade 3 Inadequate oral caloric or fluid intake, tube 
feeding, TPN, or hospitalization indicated
Vomiting
Grade 1 1–2 episodes (separated by 5 min) in 24 hs
Grade 2 3–5 episodes (separated by 5 min) in 24 h
Grade 3 ≥6 episodes (separated by 5 min) in 24 h, 
tube feeding, TPN, or hospitalization 
indicated
Grade 4 Life-threatening consequences, urgent 
intervention indicated
50.2.7  Treatment
Prevention of nausea/vomiting is the mainstay of 
clinical management since treatment frequently 
proves ineffective. Delayed nausea should be 
treated with scheduled antiemetics for 2–4 days 
after completion of chemotherapy.
50.2.8  Prophylaxis
Choice of drugs depends on the use of drug with 
highest emetogenic potential (NCCN 2017):
High emetic 
risk
Serotonin (5-HT3 antagonist) (patients 
should be monitored for QT corrected 
prolongation)
•  Short-acting: ondansetron 3 × 8 mg IV 
on days of chemo +24–48 h, 
granisetron, dolasetron
•  Long-acting: palonosetron 0.25 mg IV, 
may be repeated every 3 days
Plus
Neurokinin-1 receptor antagonists, e.g., 
aprepitant
Plus/minus
Dexamethasone 2–10 mg IV (as 
required for a short duration)
Moderate 
emetic risk










TBI Serotonin (5-HT3) antagonists (short- or 
long-acting, as above)
Dexamethasone (4 mg/d or 4 mg bid)
50.2.9  Other Nausea/Vomiting
Breakthrough 
treatment
Addition of a different class 
anti-emetic drug
Prochlorperazine (10 mg IV q6h)
Haloperidol (1–2 mg q4h)








Prevention of nausea/vomiting by 









A disorder characterized by frequent and watery 
bowel movements.
50.3.2  Physiopathogeny
Depending on the cause.
50.3.3  Causes
The diarrhea in preengraftment period is most 
frequently caused by toxicity of condition-
ing. In post transplant period, aGVHD must be 
taken into consideration. The risk of infectious 
causes persists for the whole time with bacterial 
causes predominating relatively earlier than viral 
infections.
Chemotherapy and radiation therapy-related toxicity
Acute GVHD
Intestinal infections:
 –  Clostridium difficile
 –  Viral (CMV, VZV, rotavirus, norovirus, astrovirus, 
adenovirus)
 –  Parasitic (giardia, strongyloides, cryptosporidium)
 –  Fungal (candida)
Medications (antibiotics, mycophenolate mofetil, oral 
nutritional supplements)
Transplant-associated microangiopathy
Other: pancreatitis/pancreatic insufficiency, lactose 
intolerance/disaccharidase deficiency, malabsorption, 
inflammatory bowel disease, liver and gallbladder 
disease
50.3.4  Diagnosis
The standard workup for diarrhea after HSCT 
includes stool cultures, tests for Clostridium dif-
ficile toxin A and B, Clostridium antigen, stool 
and/or blood tests for viruses, and, when nega-
tive, endoscopy with biopsy for aGVHD and 
CMV. However, when these tests are proven neg-
ative, a broad area of causes must be considered 
(Robak et al. 2017).
Stool examination and microbiological workup
 •  C. difficile toxin, antigen, culture
 •  Parasites (giardia, strongyloides, cryptosporidium)
 •  Viruses (CMV, VZV, rotavirus, norovirus, astrovirus, 
adenovirus)
 •  Fungi (culture)
Sigmoidoscopy/colonoscopy ± gastroscopy
 •  Histopathology for GVHD, cryptosporidium,  
and CMV
 •   Viral, parasitic/bacterial cultures
Biochemistry (triglycerides, amylase, lipase),
GVHD biomarkers (calprotectin, REG3-α) (Rodriguez- 
Otero et al. 2012; Ferrara et al. 2011)
Ultrasound, CT (in GVHD distal ileum or proximal 
colon most likely involved)
Capsule endoscopy
50.3.5  Grading
When the diagnosis of gut aGVHD is established 
or suspected, aGVHD grading should be used as 
described in Chap. 43. Otherwise, (CTCAE v4.0) 
grading should be used (NCI 2009).
Grade 1 Increase of <4 stools per day over baseline; mild 
increase in ostomy output compared to baseline
Grade 2 Increase of 4–6 stools per day over baseline; 
moderate increase in ostomy output compared 
to baseline
Grade 3 Increase of ≥7 stools per day over baseline; 
incontinence; hospitalization indicated; severe 
increase in ostomy output compared to baseline; 
limiting self- care activities of daily living
Grade 4 Life-threatening consequences; urgent 
intervention indicated
50.3.6  Treatment
Targeted, according to the known or suspected cause, 
consider overlap with another pathology (e.g., aGVHD 
with gut CMV infection)
Ancillary: modification of diet
 • Lactose- or gluten-free
 •  Restricted diet (low roughage, low residue, low or no 
lactose)
 • Temporarily nothing per os and TPN
Avoid fluid loss and dyselectrolytemia
Monitor and replace protein losses (albumin, gamma 
globulin)
Loperamide 2–4 mg p.o. every 6 h if associated with 






Heartburn and/or epigastric pain observed most 
frequently during conditioning and period of 
mucositis.
50.4.2  Causes
Mucositis, medications, altered gastric pH, pep-
tic ulcer disease, and fungal esophagitis.
50.4.3  Diagnosis
Based on clinical symptoms ± endoscopy.
50.4.4  Treatment
Depending on the cause, elevation of the head of 
bed, and consideration of proton pump inhibitors 
and other symptomatic treatments (e.g., alginate, 
antacid, and topical local anesthetics, such as 
oxetacaine for mucositis). May require systemic 
analgesia if patient unable to swallow.
50.5  GI Bleeding
50.5.1  Definitions/Symptoms
May appear as melena, hematemesis or bloody 
stool, or emergence of normocytic anemia.
50.5.2  Causes
Thrombocytopenia, esophageal trauma, esophagi-
tis, colitis, anal fissures or varices, viral infections, 
GVHD, and plasma coagulation impairment.
50.5.3  Diagnosis
Esophagogastroduodenoscopy, colonoscopy, and 
angioCT.
50.5.4  Treatment
Treatment of underlying disorder
Symptomatic
 • Platelet transfusion to >50 × 109/L
 • RBC transfusion
 •  Fresh frozen plasma, fibrinogen concentrates, vitamin 
K supplementation
 • Octreotide
 • Endoscopic cauterization or embolization
When massive blood loss
 • Desmopressin
 • Tranexamic acid
• Recombinant factor VII
50.6  Typhlitis
50.6.1  Definitions/Symptoms
Necrosis of usually large intestinal wall associ-
ated with chemotherapy toxicity and bacterial 
overgrowth.
Occurs within 30 days after HSCT, patients 
usually complain of pain in right lower abdomi-
nal quadrant, often with associated fever.
Additionally, nausea, emesis, increased 
abdominal wall tension, and watery bloody diar-




Clinical and abdominal ultrasound or CT: bowel 
wall thickening usually limited to single region, 
e.g., ileocecal or ascending colon; may be associ-
ated with perforaton and air within intestinal 
wall.
50.6.4  Treatment




50.7  Pancreatic Disease
50.7.1  Definitions/Symptoms
Pancreatic insufficiency and atrophy or acute 
pancreatitis.
50.7.2  Causes
Medications (prednisone, tacrolimus), stones, 
and pancreatic GVHD.
50.7.3  Diagnosis
Insufficiency and atrophy: low serum trypsino-
gen, high fecal elastase-1, and possible atrophy in 
imaging. Acute pancreatitis: elevated lipase and 
amylase, elevated fecal fat, and edema in ultra-
sound/CT.
50.7.4  Treatment
When insufficiency: enzyme replacement.
50.8  Chronic Esophageal GVHD
50.8.1  Definitions/Symptoms
Dysphagia to solid food, chest discomfort, and 
aspiration (Jagasia et al. 2015; Robak et al. 2017)
50.8.2  Diagnosis
Barium meal: mid/upper esophageal strictures, 
webs, rings, bullae, and desquamation. 
Endoscopy: as above, erythematous, friable 
sloughed mucosa.
50.8.3  Treatment
When severe and chronic, need serial dilations 
and enteral tube placement or esophagectomy.
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Haemorrhagic Cystitis  
and Renal Dysfunction
Simone Cesaro
51.1  Haemorrhagic Cystitis
51.1.1  Introduction
Haemorrhagic cystitis (HC) is a frequent compli-
cation after HSCT.  According to the time of 
occurrence after HSCT, HC is defined as early- 
onset and late-onset. Early-onset HC occurs typi-
cally during or within 48  h after the end of 
conditioning regimen, and it is the result of a 
direct toxic effect of drug metabolites and radio-
therapy on the bladder mucosa. Late-onset HC 
usually starts around the time of the period 
of  neutrophil engraftment (weeks 2–4) or in 
second-third month after HSCT (Hirsch and 
Pergam 2016). The concurrent presence of pro- 
haemorrhagic abnormalities of coagulation, 
severe thrombocytopenia and mucosal inflamma-
tion are predisposing factors for any type of HC.
51.1.2  Risk Factors
The main risk factor for late-onset HC is infec-
tion by polyomavirus BK (BKPyV), whereas 
other viruses such as ADV, CMV, and HHV6 
have been rarely implicated.
BKPyV is a common cause of asymptomatic 
or mild flu-like infection during early infancy 
and childhood, and more than 90% of adults are 
seropositive for BKPyV. The route of transmis-
sion is not clearly defined, but it is thought to be 
through oral saliva or respiratory tract secre-
tions. After the primary infection, the virus per-
sists latently in renal tubular epithelial and 
urothelial cell and can replicate as the host 
immune control loses the capacity to mount a 
virus-specific T-cell response. Mild to moderate 
asymptomatic BKPyV viruria is seen in 5–10% 
of healthy individuals, especially the oldest and 
the pregnant women, whereas high-load BKPyV 
viruria is detected in 50–60% of patients who 
underwent an allo- HSCT due to the delayed 
recovery of immune responses and the use of 
immunosuppressive drugs.
51.1.3  Pathogenesis
The current pathogenetic model of HC following 
HSCT is multifactorial and includes the combined 
effects of the extensive cytopathic damage of blad-
der mucosa layer due to the high-rate replicating 
virus, the chemical or actinic damage induced by 
conditioning regimen, and the donor- cell immune 
alloreactivity targeting bladder mucosa (Cesaro 
et al. 2018). In patients receiving allogeneic HSCT, 
both BKPyV viruria and viremia are specific and 
sensitive predictive factors for BKPyV-HC: a urine 
BKPyV load >1 × 107 genomic copies/mL had a 
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sensitivity of 86% and specificity of 60%, while a 
blood BKPyV load >1 × 103 genomic copies/mL 
had a sensitivity of 100% and a specificity of 86% 
for HC (Cesaro et al. 2015).
BKPyV infection develops in more than 50% of 
allo-HSCT in the peri-engraftment weeks, but overt 
HC occurs in about 20% of patients because its 
development is influenced by the presence of several 
other risk factors: the type of graft (CB and PB vs. 
BM); the type of donor (URD vs. MRD); the type of 
conditioning regimen (MAC vs. RIC); the use in the 
conditioning regimen of ATG, CY, or BU; the occur-
rence of acute GVHD grade 2–4; and, among the 
paediatric patients, a recipient age >7 years.
51.1.4  Diagnosis
The clinical diagnosis of BKPyV-HC is based 
on the presence of clinical symptoms/signs of 
cystitis, such as dysuria, increased urinary fre-
quency, and lower abdominal pain, the presence 
of macrohaematuria, and the demonstration of 
BKPyV viruria, with viral loads of >7 log10 
copies/mL.
The severity of haematuria is described by 
four categories: microscopic (grade 1), macro-
scopic (grade 2), macroscopic with clots (grade 
3), and macroscopic with clots and renal failure 
secondary to urinary tract obstruction.
BKPyV viremia is often detected in patients 
with BKPyV-HC, and plasma viral load of >3 to 
4 log10 copies/mL has been reported in more 
than two thirds of patients (Erard et  al. 2005; 
Cesaro et al. 2015).
The reduction of both BKPyV viruria and 
BKPyV viremia has been correlated with clini-
cal recovery from HC. Despite this, screening 
of asymptomatic HSCT patients at risk for 
BKPyV viruria and viremia remains an area of 
investigation and is presently not recommended 
since pre- emptive therapy is not established.
51.1.5  Prophylaxis
Effective preventive measures are available only 
for early-onset HC, and they are mainly unspe-
cific such as hyperhydration and the use of mesna 
in patients who receive high dose of CY as part of 
the conditioning regimen. The capacity of CY 
and its metabolite acrolein to damage the bladder 
mucosa determining an inflammatory reaction is 
well-known, and both hyperhydration and mesna 
reduce the exposure of bladder mucosa to acro-
lein and other toxic catabolites.
In line with this, the recent increase of unma-
nipulated haplo-HSCT with the administration of 
a PT-CY as prophylaxis of GVHD has resulted in 
a high incidence of HC. The use of bladder irriga-
tion through a two- or three-way urinary catheter 
resulted not more effective in preventing HC 
compared to hyperhydration, and considering its 
invasiveness and discomfort for the patient, its 
use is not recommended.
In the pathogenetic model of late-onset HC, 
BKPyV replication has a key role in exacerbating 
the damage of bladder mucosa through its cyto-
pathic effect and in inducing the donor immune 
alloreactivity to target the bladder mucosa. In 
order to reduce BKPyV replication, ciprofloxacin 
has been used prophylactically by several authors 
because of the in vitro capacity of fluoroquino-
lones to inhibit BKPyV replication. Overall, the 
efficacy of ciprofloxacin was weak and limited 
to  a reduction of BKPyV replication without 
significantly affecting the incidence of 
HC.  Considering the risk of inducing bacterial 
resistance and the risk of tendinitis and joint 
damage in children, the use of fluoroquinolones 
is not recommended for this purpose.
51.1.6  Treatment
BKPyV replication can be controlled more effec-
tively by cidofovir, a nucleotide analogue inhibit-
ing several DNA viruses such as CMV, ADV, 
HHV6, HSV, HVZ, and smallpox. The important 
pharmacokinetic property of cidofovir is the long 
half-life of its active metabolites ranging from 15 
to 65 h that allows the administration on a weekly 
basis. Given the significant risk of tubular neph-
rotoxicity, cidofovir has been used only for thera-
peutic purposes (Cesaro et  al. 2009). The 
nephrotoxicity can be limited by saline hydration 
and by the use of probenecid that inhibits the cap-
ture and transport of cidofovir into the tubular 
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epithelial cells of the kidney. Despite that several 
authors have assessed cidofovir as treatment of 
BKPyV-HC, there is no agreement on the optimal 
dose, modality of administration, and frequency 
of administration. Most authors use intravenous 
cidofovir at the dose of 3–5  mg/kg/weekly or 
fortnightly together with probenecid to prevent 
nephrotoxicity obtaining a complete clinical 
response in 74% of patients and at least 1 log 
decline in urine and blood viral loads in 38% and 
84% of patients. As expected, the main adverse 
effect was renal toxicity with a mild to moderate 
increase in serum creatinine observed in 18% of 
the patients. The second more frequent scheme of 
treatment was a dose of cidofovir of 0.5–1.5 mg/
kg without probenecid, administered 1–3 times a 
week (Ganguly et al. 2010). A complete clinical 
response was observed in 83% of patients, with a 
significant reduction of viral load in the urine and 
in the blood in 62% and 67% of patients, respec-
tively. Also, with this schedule, mild to moderate 
renal toxicity was reported in 20% of patients. An 
alternative route that can reduce the risk of neph-
rotoxicity is the administration of cidofovir intra-
vesically. Although the experience is limited to a 
small number of patients, the dose of 5 mg/kg/
week, left in situ for 1–2  h after clamping the 
vesical catheter, showed an overall clinical 
response in 43% of patients and a virological 
response in about 50% (Bridges et al. 2006).
Preliminary encouraging results have also 
been obtained with leflunomide, an antimetabo-
lite drug with immunomodulatory and antiviral 
activity, whereas a successful treatment has been 
reported anecdotal and in older series with vida-
rabine, oral levofloxacin, FXIII concentrate, 
intravesical sodium hyaluronate, and oestrogens 
(Cesaro et al. 2018).
The recovery from HC, whatever the cause, 
can benefit from treatment aiming to repair and 
regenerate the urothelial mucosa, such as hyper-
baric oxygen therapy and the topical application 
of fibrin glue. Although experienced in a limited 
number of patients, the use of hyperbaric oxygen 
therapy was associated with a complete clinical 
response rate of 86% and a reduced urine BKPyV 
load in 65% of patients. The main drawback of 
hyperbaric oxygen is the limited availability, the 
requirements for dedicated hyperbaric room 
facilities, the risk of ear barotrauma or pressure 
intolerance, and claustrophobia episodes during 
the procedure (Zama et  al. 2013; Cesaro et  al. 
2018). Cystoscopic application of fibrin glue to 
the damaged bladder mucosa to achieve haemo-
stasis has been reported in single-centre retro-
spective series with a complete response rate was 
83%, with most of cases resolved with just one or 
two applications (Tirindelli et al. 2014).
Given the important role of immune response 
in the pathogenesis of late-onset HC and in 
absence of effective antiviral drugs, innovative 
therapies have been trialled, such as the use of 
mesenchymal stromal cells (MSC) and adoptive 
immunotherapy. MSC have the potential to stim-
ulate the tissue repairing process and exercise an 
immune modulatory and anti-inflammatory 
effect. The use of third party MSC infusion into 
seven patients with BKPyV-HC obtained the res-
olution of haematuria in five patients (Ringden 
et al. 2007). This approach needs to be validated 
further to assess the feasibility and also the safety 
of MSC.
Adoptive transfer of donor-derived virus- 
specific T cells (VSTs) has shown efficacy for 
the treatment of several viral infections 
although their use on a larger scale is limited 
by the costs, the complexity of manufacturing, 
the time needed to obtain the final cell product 
that is not suitable for the urgent treatment, and 
the prompt availability of a seropositive donor. 
The use of banked VSTs with multiple speci-
ficity obtained by a third party healthy sero-
positive donor cryopreserved and used as the 
patient developed a viral infection refractory to 
antiviral treatment represents a promising 
development. In a phase II trial, the use of 
VSTs directed against five viruses, CMV, EBV, 
ADV, HHV-6, and BKPyV, obtained an overall 
cumulative response rate of 92%. The virologi-
cal response for BKPyV was 100%, and 13 of 
14 patients treated for HC had a resolution of 
haematuria by 6 weeks. The infusions of VSTs 
resulted safe, and only 2 of 45 infusions were 
followed by a mild GVHD reaction (grade 1). 
Importantly, the functionality of VSTs per-
sisted for up 12 weeks (Tzannou et al. 2017). 
These results are encouraging and support fur-
ther studies.
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51.2  Renal Dysfunction
Acute kidney injury (AKI) occurs in 27–66% of 
patients who underwent allo-HSCT mainly 
within the first 100 days. The incidence of AKI in 
less than 20% in auto-HSCT due to several rea-
sons such as the rapid engraftment and reduced 
cytopenia especially with PBSC grafts, the lower 
incidence of infectious complications, and the 
absence of GVHD that can determine a renal 
damage directly by inducing inflammatory cyto-
kines, CMV reactivation, diarrhoea with severe 
dehydration, and indirectly, through the nephro-
toxicity of the drugs used to prevent or treat 
GVHD such as CNI and high-dose PRD (Lopes 
et al. 2016; Raina et al. 2017).
The diseases associated with AKI act at differ-
ent renal levels: prerenal (sepsis, engraftment 
syndrome, SOS/VOD), renal-glomerular 
(transplant- associated microangiopathy), renal- 
tubular (acute tubular necrosis due to dehydra-
tion, sepsis, shock, engraftment syndrome, 
intratubular obstruction due to drugs, or tumour 
lysis syndrome), renal-interstitial (acute GVHD, 
viral infection by BKPvyV or ADV), and post- 
renal (obstruction by BKPyV or adenovirus cys-
titis, retroperitoneal fibrosis, lymphadenopathy).
Moreover, there are general favouring factors 
for AKI such as the presence pre-HSCT of dia-
betes, hypertension, and renal impairment as 
well as the use of nephrotoxic drugs in the con-
ditioning regimen (ifosphamide, CY, carbopla-
tin, cisplatin), for treatment of GVHD (MTX, 
CNI), for the treatment of infections (AmB, 
aminoglicosydes, vancomycin), and for other 
severe organ damages that require ICU admis-
sion and mechanical ventilation (Hingorani 
2016).
Clinically, the severity of AKI is defined by 
the measure of serum creatinine (SCr) and urine 
output (UO) that permit the identification of 
three classes: risk of AKI (increase of SCr 1.5–
2× and UO <0.5  mL/kg/h for >6  h), kidney 
injury (increase of SCr 2–3×, and UO < 0.5 mL/
kg/h for >12 h), and kidney failure (increase of 
SCr >3× and UO <0.3  mL/kg/h for >24  h or 
anuria >12 h, or initiation of replacement ther-
apy) (Lopes et al. 2016). AKI represents a risk 
factor for the development on the medium-long-
term period of chronic kidney disease, especially 
if the acute damage is not completely resolved 
and proteinuria and hypertension persist and for 
increased of non-relapse and overall mortality 
(Shingai et al. 2015).
Key Points
Early-onset HC Late-onset HC Comments
Incidence <3% 7–25% Early-onset HC is nowadays 
rare





Diagnosis Macrohaematuria with 
dysuria, increased urinary 
frequency, low abdominal 
pain
Macrohaematuria with 
dysuria, increased urinary 
frequency, low abdominal 
pain, high load of BKPyV 
urine and/or plasma
Signs of bladder inflammation 
at ultrasound examination









–  Application of fibrin glue by 
cystoscopy
–   Hyperhydration, forced 
diuresis
–  IV (or intravesical) 
cidofovir
– Hyperbaric O2 therapy
–   Application of fibrin glue 
by cystoscopy
–  Cidofovir: No agreement on 
dose and route of admin
Limited evidence
–  O2 and fibrin glue limited 
experience
Experimental / – Mesenchymal cells
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Lung injury occurs frequently following HSCT 
and significantly contributes to morbidity and 
mortality in the immediate post transplant period 
and in the months and years that follow. It can be 
observed in 25–55% of recipients (Cooke and 
Yanik 2016).
Historically, approximately half of all pulmo-
nary complications seen after HSCT were sec-
ondary to infection, but the judicious use of 
broad-spectrum antimicrobial agents has tipped 
the balance toward noninfectious causes.
Noninfectious lung injury following HSCT 
may be mediated by either immune or nonim-
mune mechanisms and could represent up to the 
50% of noninfectious mortality after allo-HSCT.
These complications have been classified by 
the American Thoracic Society according to the 
tissue primarily injured and its etiology 
(Panoskaltsis-Mortari et al. 2011) (Table 52.1).
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–  Acute interstitial pneumonitisb
–  Acute respiratory distress 
syndrome (ARDS)b
–  BCNU pneumonitis
–  Radiation pneumonitis
–  Delayed pulmonary toxicity 
syndromeb
–  Post-HSCT lymphoproliferative 
disease (see Chap. 45)
–  Eosinophilic pneumonia
–  Pulmonary alveolar proteinosis
Vascular 
endothelium
–  Peri-engraftment respiratory 
distress syndrome (PERDS)b
–  Capillary leak syndrome (CLS)b 
(see Chap. 42)
–  Diffuse alveolar hemorrhage 
(DAH)b
–  Pulmonary VOD
–  Transfusion-assoc. acute lung 
injury
–  Pulmonary cytolytic syndrome
–  Pulmonary arterial hypertension
–  Pulmonary thromboembolism
Airway 
epithelium
–  Cryptogenetic organizing 
pneumonia (COP)b,c
–  Bronchiolitis obliterans syndrome 
(BOS)b
aImportantly, this classification does not include the most 
frequent lung complication after HSCT, i.e., pulmonary 
edema secondary to fluid overload
bAll these complications are categorized as IPS
cFormerly called bronchiolitis obliterans organizing pneu-
monia (BOOP)
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52.2  Diagnostic Methodology 
of Pulmonary Complications
Ideally, any respiratory/pulmonary complication 
observed after HSCT must be evaluated follow-
ing a predetermined institutional protocol 
(Lucena et al. 2014), which should include:
 1. Noninvasive tests: Blood samples for culture 
and antigen determination, sputum culture, 
nasopharyngeal swabs testing CMV, respira-
tory syncytial virus (RSV), Legionella, 
Pneumocystis jirovecii (PJ), parainfluenza 
virus (PIV), adenovirus (ADV), as well as uri-
nary antigen tests and chest x-ray.
 2. If negative → empirical treatment (variable 
behavior; some centers start empirical treat-
ment before the BAL, but many others start 
the treatment after BAL).
 3. If no response in a maximum of 2–3 days (or 
if galactomannan (GM) +) →
 (a) High-resolution chest-computed tomog-
raphy (HRCT).
 (b) Fiber-optic bronchoscopy (FOB) includ-
ing bronchial aspiration and BAL to ana-
lyze: PCR for Legionella, Mycoplasma, 
Chlamydia, herpesvirus (all), polyomavi-
rus, ADV, parvovirus, enterovirus, and 
respiratory virus (RSV; influenza a, B, and 
C; PIV types 1–4; rhinovirus; bocavirus; 
metapneumovirus; and others) and GM.
 4. In some selected cases, a transbronchial 
biopsy could be considered.
52.2.1  Results Reported Using this 
Methodology (Seo et al. 2015; 
Lucena et al. 2014;  
Shannon et al. 2010)
Diagnostic yield could be as high as 80%.
Sixty percent of diagnosis is achieved with 
noninvasive techniques.
FOB/BAL permits an etiological diagnosis in 
up to 78% of cases.
In suspected IPS, a BAL study may detect a 
pathogen in ~50% of cases.
For pathogen detection, early FOB (<5 days) 
offer better yield than late FOB.
The risk of complications with FOB is <5%.
52.3  Pulmonary Edema 
Due to Fluid Overload
Despite not being included in most classifications 
of pulmonary complications after HSCT, pulmo-
nary edema (PE) as a consequence of a fluid 
overload (FO) is extremely frequent (Rondón 
et al. 2017).
Incidence FO may be observed in up to 60% of 
patients in the first days after 
HSCT. The exact incidence of PE is not 




–  Weight gain, moderate breathlessness, 
nonproductive cough, moderate 
hypoxemia
–  Crackles and rales in both lung bases
–  Chest radiology with diffuse alveolar/
interstitial infiltrates
Diagnosis PE should be suspected in the context of 
weight gain, an increased cardiothoracic 
index, and crackles/rales. Though rarely 
necessary, the diagnosis can be 




–  Heart failure (prior anthracycline 
toxicity or conditioning with CY)
–  Endothelial syndromes: SOS, CLS, ES 
(see Chaps. 42 and 49)
–  Respiratory tract infections
–  Post transfusion reactions
Treatment Hydro-saline restriction, diuretics
52.4  Idiopathic Pneumonia 
Syndrome
52.4.1  Definition
Widespread alveolar injury in absence of active 
lower respiratory tract infection, cardiac or renal 
dysfunction, and iatrogenic fluid overload 
(Clark et  al. 1993; Panoskaltsis-Mortari et  al. 
2011)
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52.4.2  Clinical Manifestations
Characterized by development around day +20 
after HSCT of fever and nonproductive cough, 
dyspnea, tachypnea, hypoxemia, rales, and dif-
fuse alveolar or interstitial infiltrates on x-rays or 
CT scans.
52.4.3  Diagnosis
All of the following must be present for accept-
ing the IPS diagnosis:
1. Evidence of widespread alveolar injury
 (a) Multilobar infiltrates on chest radiographs or CT
 (b)  Symptoms and signs of pneumonia (cough, dyspnea, tachypnea, crackles/rales)
 (c)  Evidence of abnormal pulmonary physiology
   Increased alveolar to arterial oxygen difference; need for supplemental O2 therapy
   New or increased restrictive PFTs abnormality
2.  Absence of active lower respiratory tract infection based upon
 (a)  BAL negative for significant bacterial pathogens including acid-fast bacilli, Nocardia, and Legionella species
 (b)  BAL negative for pathogenic nonbacterial microorganisms (Note of the authors: Most of the following 
diagnostic methods despite included in the initial diagnostic methodology have nowadays largely been replaced 
by PCR techniques)
  Routine culture for viruses and fungi
  Shell vial culture for CMV and respiratory RSV
  Cytology for CMV inclusions, fungi, and Pneumocystis jirovecii
   Direct fluorescence staining with antibodies against CMV, RSV, HSV, VZV, influenza virus, parainfluenza 
virus, adenovirus, and other organisms
 (c) Other organisms/tests to also consider:
   PCR for human metapneumovirus, rhinovirus, coronavirus, and HHV6
   PCR for Chlamydia, Mycoplasma, and Aspergillus spp.
   Serum and BAL fluid GM for Aspergillus species
 (d)  Transbronchial biopsy if condition of the patient permits
3. Absence of
Cardiac dysfunction, acute renal failure, or iatrogenic fluid overload as etiology for pulmonary dysfunction
52.4.4  Pathogenesis, Incidence, 
Presentation, and Risk Factors
Pathogenesis The pathophysiology of IPS is complex. Data generated using experimental models support that 
IPS is a process in which the lung is susceptible to two distinct but interrelated pathways of 
immune- mediated injury: a T-cell axis and an inflammatory cytokine axis. These distinct but 
related pathways of inflammation culminate in the recruitment of immune cells to the lung leading 
to tissue damage and dysfunction (Cooke and Yanik 2016)
Incidence –  The strict methodology required to establish IPS diagnosis and the increased use of RIC have 
reduced its incidence of 20% to 25% observed 20 years ago (at that time IPS was called idiopathic 
pneumonia)
–  This reduction runs in parallel of the improvement in the diagnostic methodologies to detect 
infectious pathogens. However, the frequent absence of response to the specific treatment against 
a detected pathogen suggests that the true incidence of IPS may be underestimated
–  Nowadays: <10% of allo-HSCT (8% after MAC; 2% after RIC)
Timing –  Within first 120 days after BMT, usually observed between days +18 and +21  
(20 years ago: around days +40 to +50)





Older age / Karnofsky index <90 / higher interval diagnosis-HSCT
MAC or TBI (≥12 Gy) / HLA disparity / GVHD prophylaxis with MTX
Acute GVHD/previous viral infection / other malignancies than leukemia
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52.4.5  Treatment and Prognosis
Supportive 
measures
–  Supplemental O2 therapy
–  Mechanical ventilation (invasive or not [high-flow nasal O2, CPAP])
–  Empiric broad-spectrum antimicrobials
–  Strict control of fluids balance/hemofiltration
Specific 
treatment
As mentioned, lung injury in IPS can occur through two pathways, the TNF-alfa/LPS dependent and 
IL6/IL17 dependent (Cooke and Yanik 2016); consequently, treatment options are focused in these 
directions
•  Methyl-PDN ≤ 2 mg/kg/d; if not clear response, consider as soon as possible:
•  Anti-TNFα: Etanercept 0.4 mg/kg twice weekly (maximum of 8 doses) + systemic steroids (2 mg/
kg/d). The randomized study of etanercept + steroids vs. steroids + placebo was terminated 
prematurely due to slow accrual. In the limited number of patients examined, there were no 
differences in response rates (≈60%) at day +28. These results do not necessarily imply that this 
agent is not effective (lack of evidence does not imply lack of effectiveness) (Yanik et al. 2014). In a 
phase II trial in children, the CR rate was 71% and 1 y survival was 63% (Yanik et al. 2015). This 
combination has also been shown to be effective in exceptional cases of late IPS with a 42% of CR 
and a 2 y survival of 62% among responders (Thompson et al. 2017)
•  Other investigational agents such as
  –  MoAb anti-IL6: Tocilizumab (experimental IPS; Varelias et al. 2015)
  –  MoAb anti-IL17: Brodalumab (experimental IPS; Varelias et al. 2015)
Evolution Despite the diagnosis and therapeutic advances, the mortality from IPS remains high at 59–80% at 
≈2 weeks of evolution (95% if mechanical ventilation is required)
52.5  Diffuse Alveolar 
Hemorrhage (DAH)
Diffuse alveolar hemorrhage (DAH) is a relevant 
cause of acute respiratory failure that occurs in 
2–14% of recipients, with similar incidence in 
both auto- and allo-HSCT recipients (Afessa 
et al. 2002a).
DAH is probably a consequence of damage to 
the alveolar capillary basement membrane (see 
Chap. 42). It is difficult to differentiate a true 
DAH from the alveolar hemorrhage associated 
with an infection (Majhail et al. 2006).
52.5.1  Clinical Aspects of DAH
Clinical 
manifestations
Usually observed within the first month after HSCT (a median of 23 days), often during the 
pre- engraftment phase; however, later onset is encountered in up to 42% of cases
The clinical manifestations are those of all IPS. Hemoptysis is exceptional
Diagnosis Based on BAL: Same criteria as IPS plus a differential characteristic; the progressive bloodier return of 
BAL fluid aliquots, in at least three segmental bronchi, indicating the presence of blood in the alveoli (or 
20% hemosiderin-laden macrophage, although their absence does not exclude the diagnosis as it can 
take 72 h to appear). Note: DAH can have infectious or noninfectious etiologies (Majhail et al. 2006)
Risk factors –  Higher incidence after TBI and high-dose CY
–  Similar incidence among MAC and RIC
–  There is no correlation with the platelet counts
Differential 
diagnosis with
–  Classic IPS: Very difficult, only by means of BAL. IPS usually appears after the engraftment, 
predominates in allo-HSCT, does not respond to steroids, and progresses to fibrosis in 85% of 
cases (only 15% on DAH). Note: Noninfectious DAH falls under the “diagnostic umbrella” of IPS 
(Panoskaltsis-Mortari et al. 2011)
–  PERDS: Almost impossible except for LBA progressively bloodier
–  Pulmonary hemorrhage: By FOB, no blood is seen in DAH
–  DAH associated with infection: Impossible without detection of the pathogen (Majhail et al. 
2006)
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52.5.2  Treatment and Prognosis of DAH
Treatment –  Although systematically treated with high doses of methyl-PDN (250–500 mg q6h × 5 days, followed by 
tapered dosage over 2–4 weeks) and aminocaproic acid (ACA), the overall response to this treatment is 
disappointing (Rathi et al. 2015)
–  A recent study seems to show that the best treatment is to use low steroid doses (≤250 mg/d) ± ACA 
(Rathi et al. 2015)
–  Factor VIIa addition does not appear to improve the results obtained with PDN (Elinoff et al. 2014)
–  Try to avoid mechanical ventilation by means of CPAP
Prognosis –  Poor: Overall mortality as high as 85% by day 100 (Rathi et al. 2015)
–  Less than 15% of patients die as a direct consequence of DAH, but the frequent evolution to MOF 
increases mortality to >60% (30% in auto and 70% in allo-HSCT) (Afessa et al. 2002b)
–  DAH that appear early after allo-HSCT (32% early vs. 70% late) or after auto- HSCT have a better 
prognosis (Afessa et al. 2002b; Majhail et al. 2006)
Table 52.2 Main clinical characteristics of BOS
Pathogenesis The same as cGVHD but specifically involving the lung (Cooke et al. 2017). Its course may be 
aggravated by respiratory infections, viral infections, and gastroesophageal reflux
Timing and 
incidence
–  Average starting period: 12 (3–24) months




–  Variable clinical course, usually insidious onset with progressive deterioration. Sometimes can 
present as an acute, fulminating course
–  Progressive breathlessness, nonproductive cough, and wheezing, although some asymptomatic 
cases are only detected by PFTs.
–  It is necessary to carry out PFT every 3 m in the first year after HSCT for an early detectiona
–  In >75% of the BOS, there are chronic GVHD in other locations
(continued)
52.6  Late-Onset Noninfectious 
Pulmonary Complications 
(LONIPC)
In addition to late-onset IPS mentioned before 
and some other exceptional complications 
(thromboembolisms, pneumomediastinum), 
there are two forms of chronic pulmonary dys-
function commonly observed in patients surviv-
ing more than 100 days after allo-HSCT. One is 
an obstructive lung disease (bronchiolitis obliter-
ans syndrome, BOS) and the other a restrictive 
lung disease (cryptogenetic organizing pneumo-
nia, COP).
A recent prospective study showed that 
among 198 patients included after day +100, 
the cumulative incidence of LONIPC is 20%, 
and that of BOS is 11% at 3 years among allo-
HSCT recipients (Bergeron et  al. 2018). 
Another study shows the impact of these com-
plications on 5-year survival (28% with vs. 
87% w/o LONIPC) (Nishio et al. 2009).
52.6.1  Bronchiolitis Obliterans 
Syndrome (BOS)
Pathogenesis, timing, incidence, clinical mani-
festations, diagnosis, and radiology of BOS are 
shown in Table 52.2.
Treatment and prognosis of BOS are included 
in Table 52.3.
52.6.2  Cryptogenetic Organizing 
Pneumonia (COP)
Formerly called BOOP (bronchiolitis obliterans 
with organizational pneumonia). COP is a 
LONIPC of that is associated with restrictive pul-
monary dysfunction. Reportedly, the incidence of 
COP among HSCT recipients is increasing due to 
the use of transbronchial biopsies as diagnostic 
tool. The greatest diagnostic challenge is the dif-
ferentiation of COP from BOS (see Table 52.4) 
(Yoshihara et al. 2007; Cooke et al. 2017).
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Table 52.2 (continued)
Diagnosis •  Suspicion: The so-called BOS stage 0p. More than 85% of cases can be diagnosed early by 
observing a 10–19% drop in the FEV1 or a reduction in FEF25–75 > 25% (Abedin et al. 2015)
•  Clinical (NIH consensus) (Chien et al. 2010; Uhlving et al. 2012)
  –  Clinical manifestation (may be asymptomatic and only detected on PFT) +
  –  Absence of active infection (demonstrated by BAL) +
  –  Chronic GVHD in other locationsb +
  –  Obstructive alteration with air entrapment (FEV1 < 75% NV or > 10% decrease; ratio  
FEV1/FVC ratio < 0.7; residual volume > 120%) with nonsignificant bronchodilator test and a 
decreased DLCO +
  –  Compatible radiology (see below)
•  Definitive: Histologic confirmation by thoracotomy, VATS, or transbronchial biopsyc
Radiology –  Chest x-ray: Normal or with signs of hyperinflation
–  CT scan: Radiological pattern of constrictive bronchiolitis with aerial entrapment, attenuation in 
mosaic, bronchiectasis and bronchial wall thickening, characteristic air trapping at exhalation
DLCO transfer capacity of CO, FEV1 maximum expiratory volume in the first second, FVC forced vital capacity, VATS 
video-assisted thoracoscopic surgery
aSome experts consider that a 10% decrease in the FEV1 basal after HSCT should make you suspect in BOS 
diagnosis
bIf the lung is the only organ with cGVHD, a biopsy is needed to confirm the diagnosis (NIH criteria)
cRarely transbronchial biopsy is used (low sensitivity and low predictive value) to establish a diagnosis that is eminently 
clinical. If histology is available, the term bronchiolitis obliterans can be used; if not available, the process is referred to 
as BOS
Table 52.3 Treatment and prognosis of BOS
Treatment Supportive measures:
  Anti-infectious prophylaxis
  If hypogammaglobulinemia: IVIg
  Treatment of gastroesophageal reflux
  Respiratory physiotherapy
Specific treatment
•  Prednisone: 1–1.5 mg/kg/day, transient and unsatisfactory response in most cases. The addition of 
CSA, azathioprine, ATG, or photopheresis has few advantages
•  Budesonide/inhaled formoterol has been shown to be transiently effective in 60% of the patients 
(Bergeron et al. 2015)
•  Etanercept/infliximab: Effective in some cases (Yanik et al. 2012)
•  FAM combination therapy: Effective in disease stabilizationa:
  –  Fluticasone inhaled 440 mcg c/12 h (adult), 220 mcg in children +
  –  Azithromycin 250 mg/d (adults), 5 mg/kg/d (children)b +
  –  Montelukast 10 mg orally at night (adults), 5 mg (children)
  Two weeks before FAM increase (or start) PDN to 1 mg/kg/d, then decrease 0.25 mg/kg/d × week 
(Williams et al. 2015)
•  In BOS controlled but with a severe residual respiratory insufficiency, lung transplantation may be 
considered after a few years (Cheng et al. 2014)
Prognosis –  TRM is very high; 32% (18–57%) at 2 years of HSCT almost always get associated with progressive 
respiratory failure and opportunistic infections
–  SRV around 65% (4%–80%) at 2 years
aFluticasone theoretically decreases the inflammatory pulmonary component; azithromycin reduces IL-8 levels and 
neutrophilia; and montelukast is an antagonist of the leukotriene receptors (bronchodilator)
bHowever, the ALLOZITHRO randomized trial has shown that early administration of azithromycin resulted in worse 
airflow decline-free survival than did placebo; the value of these findings is limited by early termination of the trial 
(Bergeron et al. 2017)
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Table 52.4 Differential diagnosis between BOS and COP
First symptoms BOS: >day +100 HSCT
COP: Mostly in the first 100 daysa
Incidence BOS: 3–11% allo-HSCT (35% if cGVHD)
COP: Up to 10% in URD HSCT
Clinical context BOS: Allo-HSCT with cGVHD
COP: Auto- or allo-HSCT. Almost always previous respiratory infection
Symptoms, signs BOS: Asymptomatic, or progressive breathlessness, dry cough, wheezing. No fever, 
normal blood test
COP: Fever, dry cough. Leukocytosis, increased CRP
Etiology BOS: cGVHD
COP: Idiopathic? Triggered by infectionb or drugsc?
Pulmonary auscultation BOS: Wheezing, hypoventilation
COP: Crackles/rales
RFT BOS: Obstructive pattern: FEV1/FVC <70%, FEV1 <75%, DLCO reduced
COP: Restrictive pattern: FEV1/FVC >80%, TLC <80%, DLCO reduced
Chest radiology BOS: Normal or airtrapping
COP: Alveolar or interstitial pattern
Thoracic CT scan BOS: Thickening of bronchial walls, bronchiectasis, air trapping on expiratory views
COP: Uni- or bilateral patched bindings, glass images dull, or nodular infiltrators
BAL BOS: Neutrophilia
COP: Lymphocytosis, decreased CD4/CD8 ratio
Diagnosis BOS: Clinical manifestations + PFTs + radiology
COP: Requires lung biopsy
Response to steroids BOS: Limited
COP: Response in >80%
Prognosis BOS: SRV <20% at 5 years if no response to steroids
COP: Potentially reversible
CRP C-reactive protein
aIf patients are adequately controlled, it is common to detect restrictive alterations before the day +100 although clinical 
manifestations may appear later
bMycoplasma, Coxiella, Nocardia, and various viruses
cAmiodarone, bleomycin, busulfan, and cephalosporins
Key Points
• Lung injury occurs frequently following 
HSCT and significantly contributes to mor-
bidity and mortality in the immediate post 
transplant period and in the months and 
years that follow. It can be observed in 
25–55% of recipients.
• Noninfectious lung injury following HSCT 
may be mediated by either immune or non-
immune mechanisms and could represent 
up to the 50% of noninfectious mortality 
after allo-HSCT.
• Most relevant noninfectious early pulmo-
nary complications are pulmonary edema 
by fluid overflow, idiopathic pneumonia 
syndrome, and diffuse alveolar hemor-
rhage, a vascular endothelial syndrome.
• The most relevant late-onset noninfectious 
pulmonary complications are bronchiolitis 
obliterans and cryptogenetic organizing 
pneumonia.
• All of them have specific diagnostic crite-
ria, management, treatment, and prognosis.
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Neurological Complications
Rémy Duléry
53.1  Definitions 
and Epidemiology
Neurological complications after HSCT are fre-
quent and can be highly challenging to manage. 
The reported incidence ranges from 8% to 65%, 
depending on types of manifestation included, 
transplant setting, and patient population (Maffini 
et al. 2017). The severity varies widely, ranging 
from mild transient disorders to life-threatening 
illness. Main factors and causative agents include 
neurotoxic drugs, infectious pathogens, cerebro-
vascular illness, metabolic encephalopathy, and 
immune-mediated diseases. CNS relapse of the 
underlying disease, thrombotic microangiopathy 
(TAM), and post transplant lymphoproliferative 
disorder (PTLD) should also be ruled out 
(Table 53.1).
Neurological complications can be classified 
by their time of onset after HSCT. Early events 
are mainly due to drugs used in the conditioning 
regimen and IS therapy, whereas later complica-
tions are usually associated with immunodefi-
ciency. Because clinical manifestations are often 
misleading and nonspecific, finding the right eti-
ology may be long and difficult. Yet, early diag-
nosis and treatment are of paramount importance 
to reduce the risk for irreversible complications, 
impairment of quality of life, and transplantation- 
related death.
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Table 53.1 Main causes of neurological complications 
after HSCT
Causative agents







Fungi and parasites (Toxoplasma 
gondii, Aspergillus spp., Candida 
spp., mucorales, Cryptococcus 
neoformans, Histoplasma 
capsulatum)
Viruses (HHV6, CMV, VZV, HSV, 
JC virus, West Nile virus, 
adenovirus)




















53.2  Causative Agents and Types 
of Neurological 
Complications
53.2.1  Neurotoxic Drugs
Calcineurin inhibitors (CNIs), antibiotics, antivi-
ral drugs, and cytotoxic agents used in condition-
ing regimen are the most frequent causes of drug 
toxicity (Table  53.2). In addition, drug-drug 
interactions are a common cause of neurotoxicity 
and must be carefully checked.
53.2.1.1  Calcineurin Inhibitors
CSA and TAC are associated with neurological 
complications in 25% to 59% of HSCT patients 
(Reece et al. 1991). The clinical picture of CNI- 
induced neurotoxicity ranges from transient iso-
lated symptoms to severe manifestations such as 
TAM (see Chap. 42) or posterior reversible 
encephalopathy syndrome (PRES) (Table 53.2).
PRES refers to a disorder of reversible subcor-
tical vasogenic brain edema and is caused by 
endothelial injury related to abrupt blood pres-
sure changes or direct effects of cytokines on the 
endothelium. It may occur in 1.6–7.2% of HSCT 
recipients and, if diagnosed early, is reversible 
after CNI withdrawal. Headache, visual distur-
bance, seizure, encephalopathy or focal 
 neurologic deficit in the setting of renal failure, or 
blood pressure fluctuations are highly suggestive 
of PRES (Schmidt et al. 2016).
Although vasogenic edema can be visualized 
on CT in some patients, brain MRI is much more 
sensitive. MRI shows bilateral multifocal areas 
of hyperintensivity in T2-weighted sequences, 
especially in the white matter of parieto-occipi-
tal regions. Other variations may exist, such as 
superior frontal sulcus pattern of holohemi-
spheric watershed pattern. Persistent neurologi-
cal sequelae have been reported, especially if 
PRES is not rapidly diagnosed and treated.
53.2.1.2  MTX and Cytotoxic Agents
GVHD prophylaxis with short course of MTX 
may cause minor neurological disorders (leth-
argy, dysarthria, headache) and, very rarely, dif-
fuse necrotizing leukoencephalopathy (Paudyal 
et  al. 2010). BU is associated with seizure and 
requires preventive prophylaxis with benzodiaz-
epines (Eberly et  al. 2008). For FLU, the main 
neurological complication is acute toxic leukoen-
cephalopathy. The clinical syndrome is charac-
terized by visual disturbance, sensitive defects, 
and cognitive impairment.
Brain MRI shows bilateral areas of hyperin-
tensivity in T2-weighted sequences in the white 
matter, which differ significantly from the MRI 
findings seen in PRES.  Classical PRES arises 
from subcortical white matter, whereas acute 
toxic leukoencephalopathy arises from periven-
tricular white matter.
Risk factors include poor renal function, older 
age, fludarabine dose, previously treated CNS 
disease, or previous FLU-based conditioning 
regimen.
Outcomes are very poor with irreversible neu-
rological sequelae and median OS of 2 months 
(Beitinjaneh et al. 2011).
Table 53.2 Neurotoxicity of the main drugs used in 
HSCT
Drug Most common symptoms
Cyclosporine 
A
PRES, confusion, tremor, ataxia, 
seizures, cortical blindness
Methotrexate Leukoencephalopathy, headache, 
lethargy, dysarthria
Busulfan Seizures
Fludarabine Acute toxic leukoencephalopathy
Thiotepa Headache, encephalopathy, seizures, 
paresthesia
Rituximab PML
Blinatumomab Encephalopathy, headache, aphasia, 
ataxia, tremor, seizures
Sorafenib PRES
Imipenem Seizures, tremor, vertigo, paresthesia, 
somnolence, encephalopathy
Cefepime Headache, paresthesia, 
encephalopathy





Headache, encephalopathy, numbness, 
vision changes
Aciclovir Headache, tremor, dysarthria, 
hallucinations, encephalopathy
Foscarnet Headache, vertigo, paresthesia, 
seizures, tremor, encephalopathy
Ganciclovir Headache, numbness, tremor, seizures
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53.2.1.3  Immunotherapy 
and Tyrosine Kinase 
Inhibitors (TKI)
Rituximab, TKI, and bispecific T-cell engaging 
antibodies such as blinatumomab are increas-
ingly used after HSCT.  Their neurological side 
effects are described in Table 53.2.
53.2.1.4  Anti-Infective Drugs
Anti-infective drugs are among the main causes 
of neurological complications. Dose adaptation 
is warranted in case of drug-drug interaction or 
impaired renal function. Their neurological side 
effects are described in Table 53.2.
53.2.2  Infectious Pathogens
Among the long list of pathogens responsible of 
CNS infections after HSCT, the most frequent 
are Toxoplasma gondii, Aspergillus spp., and 
HHV6 (Denier et  al. 2006; Ogata et  al. 2015). 
The clinical symptoms and the time of onset after 
HSCT may be helpful to decipher the correct 
diagnosis.
53.2.3  Metabolic Complications
Pharmacologic sedation with major opioids, sys-
temic inflammatory response, and hemophago-
cytic lymphohistiocytosis are among the first 
causes to exclude in the differential diagnosis of 
metabolic causes of neurological dysfunction. 
Other causes include uremic encephalopathy—
associated with CNI nephrotoxicity or TAM—
and hepatic encephalopathy, associated with 
SOS/VOD or severe hepatic GVHD.
53.2.4  Cerebrovascular Disease
Cerebrovascular hemorrhagic or thrombotic 
events represent potentially lethal complications.
One of the most frequent events is subdural 
hematoma, which may occur in 2.6% of the 
patients (Colosimo et al. 2000). Risk factors for 
CNS hemorrhagic complications include falls, 
prolonged severe thrombocytopenia or refractori-
ness to platelet transfusions, grade III–IV GHVD, 
and arterial hypertension (Zhang et al. 2016). CT 
scans usually confirm the diagnosis but can be 
negative in 20–25% of the patients. Risk factors 
for CNS thrombotic complications include active 
infections, atrial fibrillation, hypercoagulative 
state, chronic GVHD, and corticosteroid treat-
ment (Coplin et al. 2001).
53.2.5  Immune-Mediated Diseases
The most frequent immune-mediated neurologi-
cal diseases include Guillain-Barré-like demye-
linating polyneuropathy, myositis, myasthenia 
gravis, cytokine release syndrome (CRS), and 
CNS manifestations of chronic GVHD. Assigning 
the right diagnosis can be highly challenging and 
may require a neurologic consultation.
53.2.5.1  Demyelinating 
Polyneuropathies
Immune-mediated demyelinating polyneuropa-
thies, which include Guillain-Barré-like syn-
drome, may occur in 1% of the patients, 
especially within the first 3 months after HSCT 
(Rodriguez et  al. 2002). Progressive symmetri-
cal ascending motor deficiency, numbness, 
hyporeflexia, and respiratory insufficiency are 
suggestive of Guillain-Barré-like syndromes. 
Lumbar puncture, MRI, and nerve conduction 
studies should be performed rapidly. Symptoms 
may resolve with polyclonal gamma globulin 
therapy. Rituximab may be used in unresponsive 
patients.
53.2.5.2  Myositis
Myositis is characterized by proximal muscle 
weakness, is often associated with chronic 
GVHD, and may occur in 2–3% of HSCT recipi-
ents (Stephenson et al. 2001). Levels of creatine 
phosphokinase are elevated, electromyography 
shows myopathic pattern, and MRI is useful to 
establish the diagnosis and monitor the response 
to treatment. Diagnosis can be proven by muscle 
biopsy. Patients may respond to corticosteroid 
therapy after 1–6 weeks of treatment.
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53.2.5.3  Myasthenia Gravis
Myasthenia gravis usually occurs after the onset 
of GVHD in less than 1% of HSCT recipients 
(Lefvert and Björkholm 1987). The main symp-
toms include ptosis, facial weakness, diplopia, 
dysarthria, and dysphagia. The diagnosis is con-
firmed with electromyography showing a pro-
gressive decrease in the muscle action potential. 
Cholinesterase inhibitors and corticosteroid ther-
apy are the treatments of choice.
53.2.5.4  Cytokine Release Syndrome
CRS can be observed after haploidentical HSCT 
with PT-CY and infusion of chimeric antigen 
receptor T (CAR T) cells or blinatumomab. CRS 
may cause life-threatening complications, 
including CNS involvement (encephalopathy, 
hemiparesis, ataxia, aphasia). Patients can be 
effectively treated with cytokine blockade using 
the antibodies siltuximab or tocilizumab, respec-
tively, targeting IL-6 or the IL-6 receptor (Frey 
2017).
53.2.5.5  Central Nervous System GVHD
The incidence of CNS manifestations of chronic 
GVHD is probably underestimated. Three main 
clinical manifestations have been described 
(Grauer et  al. 2010; Saad et  al. 2009). 
Demyelinating diseases have been reported in the 
cerebral white matter, optic nerve, or spinal cord. 
Symptoms follow a relapsing-remitting course, 
as observed in multiple sclerosis. The treatment 
consists in corticosteroid pulses. Sphingosine-1- 
phosphate receptor agonists, such as fingolimod, 
could be efficient in refractory/relapsing patients 
(Gauthier et al. 2018).
Vasculitis may involve small- to large-sized 
arterial vessels of cerebral parenchyma and 
meninges. Ischemic lesions, minute hemor-
rhages, and multifocal signal changes in the 
white matter can be observed on MRI. Diagnosis 
can be confirmed by brain biopsy, and treatment 
relies on corticosteroids in combination with 
cyclophosphamide.
Finally, patients may develop immune- 
mediated encephalitis. Definite diagnosis requires 
repeated analysis of CSF to rule out infectious 
encephalitis.
53.3  Diagnostic Algorithm
When faced with neurological complications fol-
lowing HSCT, the following ten steps can be 
helpful to promptly assign the correct diagnosis 
and start the right treatment:
 1. Carefully review the medication history and 
search for (or exclude) metabolic disorders.
 2. Are the clinical signs and/or symptoms gen-
eralized (e.g., altered consciousness, seizure) 
or focal (e.g., stroke, mass lesion)?
 3. What is the time of onset of neurological 
signs and/or symptoms after HSCT?
 4. Perform CT scan or MRI for ruling out 
PRES, encephalitis, infectious or immune 
parenchymal infiltrate, cerebrovascular 
events, or hematological disease relapse.
 5. Analyze CSF for diagnosing infectious com-
plications, Guillain-Barré-like syndrome, or 
underlying disease relapse.
 6. Perform electroencephalography in patients 
with altered consciousness, hallucinations, 
or seizure.
 7. Perform electromyography in patients with 
polyneuropathy or peripheral neuromuscular 
weakness.
 8. Repeat each of the previous steps: Tests may 
be negative when performed early, and 
symptoms may evolve or fluctuate after the 
onset of the disease.
 9. Brain or neuromuscular biopsy may be required 
to confirm/exclude opportunistic infections, 
PML, vasculitis, PTLD, or other malignancies.
 10. The opinion of a neurologist at each step is 
highly recommended, especially for compli-
cated clinical cases.
53.4  Conclusions
Neurological complications after HSCT, and 
especially allo-HSCT, are frequent and may lead 
to lethal complications. The main causative fac-
tors include drug-related toxicities, metabolic 
disorders, infections, cerebrovascular evens, 
immune-mediated disorders, and disease 
 recurrence. Although their clinical diagnosis and 
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management can be highly challenging, early 
treatment is extremely important to reduce mor-
tality and improve quality of life.
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Key Points
• Neurological complications after HSCT 
require prompt diagnosis and timely 
treatment to reduce post transplant mor-
tality and improve the quality of life of 
the patients.
• Their etiology is often multifactorial 
and includes neurotoxic drugs, infec-
tious pathogens, cerebrovascular illness, 
metabolic encephalopathy, and immune- 
mediated diseases.
• TAM, PTLD with CNS involvement, 
and CNS relapse of the underlying 
hematological disease should be 
included in the differential diagnosis.
• CNS manifestations of GVHD are rare 
and often highly challenging to manage.
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Skin, Hair and Musculoskeletal 
Complications
Francis Ayuk and Bipin N. Savani
54.1  Complications Involving 
the Skin and Hair
54.1.1  Introduction
Nearly every recipient of an allo-HSCT will at 
some stage develop complications involving the 
skin and hair. These complications can be 
grouped in drug-related toxicities and allergies, 
graft-versus-host disease, infections and malig-
nant conditions.
54.1.2  Drug-Related Toxicities 
and Allergies
Drug-related toxicities are most often due to the 
conditioning regimen, antibiotics or IS agents. 
Presentation can vary broadly from localised ery-
thema to epidermal necrolysis and Stevens- 
Johnson syndrome.
Diagnosis may be difficult because the mor-
phological and chronological presentations of the 
lesions are generally non-specific. Skin biopsies 
and histological examination can help improve 
diagnostic certainty (Paun et al. 2013).
Management requires discontinuation of sus-
pected causative agents, topical treatment with 
healing ointments, prevention of secondary infec-
tions and in severe cases (or when other organs 
are involved) systemic therapy with corticoste-
roids and antihistamines.
54.1.3  Graft-Versus-Host Disease
The skin is one of the most frequently affected 
organs in acute and chronic GVHD.  Acute 
GVHD of the skin mainly affects the epidermis 
of the skin and adjacent oral, anal and genital 
mucosa. Chronic GVHD may affect all layers of 
the skin including the epidermis, dermis and 
subcutaneous tissue and may also manifest as 
skin dyspigmentation, sweat impairment, alope-
cia and thinning of scalp hair, hair loss in other 
areas (e.g. eye brows) and nail dystrophy. 
Chronic GVHD with sclerosis of the subcutane-
ous tissue including fasciae, joints and the mus-
culoskeletal system can severely impact patients’ 
quality of life. Sclerodermal lesions of the tho-
rax or abdomen may impair breathing, lesions 
adjacent to joints may impair movement, and 
genital lesions may cause phimosis, vaginal 
scarring and narrowing of the introitus that may 
cause dyspareunia and even complete oblitera-
tion of the vaginal tract.
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In the early “inflammatory” phase of GVHD, 
patients often present with oedema and discomfort 
which later progress to fibrosis and joint contrac-
tures. Regular survey of range of motion by patients 
and physicians may enable early detection of revers-
ible lesions. Regular assessment (e.g. via question-
naire or oral interview) during routine clinical visits 
may encourage physicians and patients to address 
issues involving the genital tract, thereby enabling 
early detection and treatment.
General treatment and management of GVHD 
discussed in Chaps. 43 and 44. In patients with 
chronic GVHD of the skin and subcutaneous tis-
sues, treatment is best initiated in the early phase 
prior to development of fibrosis and contractures, 
which otherwise may require protracted immuno-
suppression and other measures, sometimes over 
several years. Physiotherapy including deep myo-
fascial massage and stretching exercises is essen-
tial to restore or maintain range of motion. In 
patients with genital involvement, topical treat-
ment with immunosuppressive agents and hor-
mones and use of vaginal dilators should be 
initiated early to prevent or reduce the degree of 
irreversible fibrosis and avoid the need for surgi-
cal intervention.
54.1.4  Infectious Complications 
Involving the Skin
Infection-associated skin lesions are often due to 
viruses. Unexplained fever and rash are more fre-
quent in patients with HHV6 viremia compared to 
controls (Betts et al. 2011). Due to lack of effec-
tive prophylaxis, HHV6-related complications 
occur during both early and late transplant phases, 
while shingles (varicella zoster) are mostly seen 
beyond 6 months after transplant and mainly after 
discontinuation of prophylactic aciclovir. Other 
infectious conditions of the skin include fungal 
infections (mainly due to dermatophytes and, less 
frequently, Aspergillus or Mucor species) and 
bacterial infections. Management of infections 
mostly consists of systemic antiviral, antifungal 
or antibiotic treatment.
54.1.5  Malignant Complications 
of the Skin
Post transplant malignant conditions of the skin 
include skin cancer (basal cell carcinoma, squa-
mous cell carcinoma and melanoma) and relapse 
of underlying malignant disease. BCC and SCC 
are much more common and have a better prog-
nosis than melanoma. The incidence of mela-
noma has been reported to be higher after 
allo-HSCT with standardised incidence ratios 
ranging from 1.4 to 8.3 (Inamoto et  al. 2015). 
Secondary cancers, risk factors and management 
are discussed in detail in Chap. 47.
Patients should be counselled to perform self- 
examination of the skin and adjacent mucosa, use 
adequate sun protection and avoid excessive sun 
exposure. Country-specific general population 
recommendations for screening for cancer should 
be adapted and modified taking increased risk of 
HSCT survivors into consideration.
54.2  Musculoskeletal 
Complications
54.2.1  Introduction
Complications involving the muscles include 
myopathies, myositis and cramps. Musculoskeletal 
complications are reported in 35% of long-term 
survivors 10 years after allogeneic transplantation 
(Syrjala et al. 2005).
54.2.2  Myopathy
The most frequent causes of myopathy early after 
transplant are corticosteroid therapy and inactiv-
ity. Patients report muscles weakness with no 
pain, and laboratory investigations show normal 
creatinine kinase. The proximal lower limb mus-
cles, particularly the quadriceps muscles are most 
severely affected. The main risk factors include 
increasing dose and duration of corticosteroid 
therapy, older patient age and the extent and 
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duration of inactivity, particularly when intensive 
care is required. Patients should receive 
 physiotherapy as soon as corticosteroid therapy 
is initiated and be advised to exercise on their 
own. Systemic corticosteroids should be tapered 
or avoided when possible.
54.2.3  Myasthenia Gravis
Though rare (<1%), it has been reported after 
allogeneic stem cell transplantation, mostly in 
the context of chronic GVHD.  Patients present 
with fatigable weakness during or after tapering 
of immunosuppression (Grauer et  al. 2010). 
Diagnosis includes detection of antibodies 
against acetylcholine in blood. Treatment con-
sists of cholinesterase inhibitors and IS therapies 
for chronic GVHD.
54.2.4  Muscle Cramps
Muscle cramps are painful and often visible con-
tractions lasting up to 30  min. Though rarely 
reported, they appear to be frequent in patients 
with chronic GVHD (Filipovich et al. 2005); an 
association with chronic IS may also be possible. 
Magnesium deficiency and side effects of medi-
cations (e.g. ganciclovir, valganciclovir) should 
always be ruled out. If magnesium replacement 
and discontinuation of suspected causative drugs 
do not bring relief, treatment with, e.g., quinine 
or antiepileptic drugs may be considered.
54.2.5  Myositis
Myositis has been reported in up to 3% of patients 
after allo-HSCT.  Though frequently associated 
with other symptoms of chronic GVHD, it can 
also be the sole manifestation of GVHD 
(Openshaw et  al. 2009). Patients often present 
with pressure-sensitive muscle pain and increased 
blood creatine kinase. Management is within 
GVHD treatment (Couriel et al. 2002).
54.2.6  Complications Involving 
the Bones and Joints
The most frequent complications involving the 
bones and joints are chronic GVHD, avascular 
osteonecrosis and bone loss (osteopenia/osteopo-
rosis). Chronic GVHD of the joints is discussed 
in Chap. 44.
54.2.6.1  Osteoporosis/Osteopenia
Osteopenia (defined as a T-score between −1 and 
−2.5) and osteoporosis (defined as a T-score less 
than −2.5) have been reported in about 25–50% 
of patients after allo-HSCT and up to 60% in 
patients with severe chronic GVHD (Pirsl et al. 
2016). Risk factors include protracted IS, older 
patient age, higher cumulative corticosteroid 
dose (Schulte and Beelen 2004; Savani et  al. 
2007; Stern et  al. 2001; Yao et  al. 2008; 
Petropoulou et  al. 2010; Abou-Mourad et  al. 
2010) and lower body weight, malnutrition, 
physical inactivity, female gender, higher average 
NIH organ score as well as higher platelet counts 
in patients with severe chronic GVHD (Pirsl 
et al. 2016).
In accordance with these risk factors, decrease 
in bone mineral density occurs most rapidly 
within the first year after transplant. If osteopenia 
or osteoporosis is diagnosed, endocrine causes 
like hyperthyroidism, hyperparathyroidism and 
hypogonadism need to be ruled out. Screening 
using dual energy X-ray absorptiometry (DEXA) 
is recommended 1 year after transplant and repeat 
measurements in patients with recognised defects 
(Majhail et al. 2012).
Measures to prevent bone loss include vitamin 
D supplementation in regions with high preva-
lence of vitamin D deficiency, adequate calcium 
intake preferable through diet and regular weight- 
bearing physical exercise. Beyond the above pre-
ventive measures, specific treatment of patients 
with severe osteopenia or osteoporosis include 
bisphosphonates or denosumab. Hormone 
replacement therapy should be considered in 
patients with hypogonadism. Patients should also 
be counselled to modify negative lifestyle factors 
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(e.g. cease smoking) and take measures to  prevent 
falls (e.g. physical exercise including balance 
training, correct visual disorders).
54.2.6.2  Avascular Necrosis
Avascular necrosis (AVN) has been reported in 
up to 19% of adult patients and up to 29% of 
patients younger than 20 years (Torii et al. 2001; 
Patel et  al. 2008). Risk factors include GVHD, 
steroid therapy, microvascular changes due to 
GVHD and/or its therapy, younger age at trans-
plant and TBI (Socié et  al. 1997; French et  al. 
2008; Patel et  al. 2008; Campbell et  al. 2009; 
Jagasia et al. 2010). Patients usually present with 
joint pain, restricted to one or two affected joints. 
Though most joints can be affected, the hips are 
by far most frequently involved, bilateral in the 
majority of cases.
Screening for AVN is not recommended; how-
ever high index of suspicion and prompt MRI are 
necessary in symptomatic patients with risk fac-
tors, to enable early detection and intervention.
Pain relief and maintenance or restoration of 
patient mobility are the main aims or treatment. 
Discontinuation of corticosteroid and other IST 
should be considered where possible. Drug ther-
apy is limited to pain relief. The role of non- 
surgical causative therapies, such as 
bisphosphonates, statins and prostacyclin ana-
logues, is still unclear. Pressure relief by means 
of surgical core decompression may relief pain 
and slow down progression in early stages, 
whereby additional autologous bone marrow 
grafting further improves long-term outcome 
(Hernigou et al. 2018). In patients with late-stage 
disease with femoral head collapse, joint- 
preserving strategies are not effective, and total 
hip arthroplasty is the recommended long-term 
treatment.
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Cardiovascular disease (CVD) is a broad term 
covering disorders of the heart and blood ves-
sels and includes hypertension, coronary heart 
disease, cerebrovascular disease, peripheral vas-
cular disease, heart failure, rheumatic heart dis-
ease, congenital heart disease and 
cardiomyopathies (WHO 2017).
CVD is common; the World Health 
Organisation (WHO) estimates that more than 
17.5 million people died of CVD such as heart 
attack or stroke in 2012, representing 30% of all 
global deaths. CVDs are the number one cause of 
death globally: more people die annually from 
CVDs than from any other cause. It is predicted 
that by 2030, almost 23.6 million people will die 
from CVDs, mainly from heart disease and 
stroke. These are projected to remain the single 
leading causes of death (WHO 2017).
After HSCT, there is an increased incidence of 
CVD. Retrospective EBMT analyses have shown 
the cumulative incidence of a first cardiovascular 
event 15 years after HSCT rises to 6%. The type 
of transplant may be important. In the EBMT 
analyses, the cumulative incidence of 7.5% for 
the first CV event at 15  years post allo-HSCT 
versus 2.3% post auto-HSCT (Tichelli et  al. 
2007). However, in another study with a 7 year 
median follow-up (range 2–23.7) the 10  year 
cumulative incidence of ischaemic heart disease 
(IHD), cardiomyopathy, stroke and all-cause CV 
death was 3.8%, 6%, 3.5% and 3.7% respectively 
with similar prevalence in auto- and allo-HSCT 
(Chow et al. 2011).
55.2  Risk Factors
A number of pre-transplant risk factors appear to 
predispose to CVD (such as smoking, hyperten-
sion, dyslipidaemia, diabetes and obesity). CV 
toxicity of pre-transplant treatment includes 
anthracyclines and site-specific radiotherapy.
CV toxicity of transplant includes GVHD, 
and CV toxicity of post transplant treatment 
includes corticosteroid use and retransplant. 
Other contributing risk factors emerge as sec-
ondary late effects, such as hypogonadism, pre-
mature menopause and hypothyroidism (Chow 
et al. 2014).
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When risk factors combine; the term meta-
bolic syndrome (MetS) is used. MetS is a cluster 
of interrelated factors which increase the risk of 
cardiovascular disease, diabetes mellitus (DM) 
and all-cause mortality (Alberti et  al. 2009; 
NCEP 2002).
55.3  Metabolic Syndrome 
Definition
The existence of several definitions of MetS led 
to a harmonised definition (IDF 2006): that is, the 
presence of three out of five risk factors as 
follows:
• Abdominal obesity measured by waist cir-
cumference: With population and country spe-
cific definitions.
• Triglycerides ≥1.7 mmol/L or drug treatment 
for elevated levels.
• HDL-C (men) <1.0 mmol/L or drug treatment 
for reduced levels.
• HDL-C (women) <1.3 mmol/L or drug treat-
ment for reduced levels.
• Blood pressure ≥130/≥85  mmHg or drug 
treatment for hypertension (HTN).
• Fasting glucose ≥5.6 mmol/L drug treatment 
for diabetes mellitus (DM).
The International Diabetes Foundation (IDF) 
estimates 25% of the world’s population has 
MetS (IDF 2006).
After HSCT there is an increased incidence of 
MetS, with reported prevalence rates of 31–49% 
(Majhail et  al. 2009b; McMillen et  al. 2014; 
Oudin et  al. 2015; Greenfield et al 2018). In 
HSCT patients, the increased incidence is 
accounted for by the following components:
55.3.1  Abdominal Obesity
Abdominal obesity measured by waist circumfer-
ence represents fat accumulation (visceral adi-
pose deposits) which independently confers 
cardiometabolic risk (Amato et  al. 2013). 
Changes in waist circumferences are seen after 
HSCT with, for example, corticosteroid use and 
with onset of sarcopenic obesity.
55.3.2  Dyslipidaemia
Dyslipidaemia is defined by elevated levels of 
total cholesterol, LDL-C or triglycerides or low 
levels of HDL-C. Prevalence in general popula-
tion is estimated at 25% in the USA (Baker et al. 
2007) and in European countries (Fodor 2010; 
Scheidt-Nave et  al. 2013; Gonzalez-Juanatey 
et al. 2011). Evidence suggests allo-HSCT recip-
ients have significantly higher risk of new onset 
dyslipidaemia (RR2.1 CI 1.1504.65) compared 
with auto-HSCT (Tichelli et  al. 2007) with the 
prevalence post HSCT estimated to be 43–73% 
(FACT-JACIE 2017). Factors predicting dyslipi-
daemia after HSCT include family history, obe-
sity, high dose total body irradiation, grade II–IV 
aGvHD, cGvHD, CLD and IST use (Chow et al. 
2014; Oudin et  al. 2015; Kagoya et  al. 2012; 
Blaser et al. 2012).
55.3.3  Hypertension (HTN)
Hypertension (HTN) in the general population is 
defined as systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg but defined in context of MetS as 
systolic BP ≥135  mmHg or diastolic BP ≥85. 
HTN in people following allo-HSCT is 2.06 
times (95% CI 1.39–3.04) more likely compared 
with sibling donors or auto-HSCT (Baker et al. 
2007).
55.3.4  Insulin Resistance or Diabetes 
Mellitus (IR/DM)
DM is characterised by hyperglycaemia resulting 
from defects in insulin secretion, insulin action 
or both and defined as a fasting pGL ≥7 mmol/L, 
an HbA1C ≥6.5%, a 2  h plasma glucose 
≥11.1  mmol/L during a glucose tolerance test 
(GTT) or a random glucose ≥11.1 mmol/L.
Both allo-HSCT and auto-HSCT recipients 
have been found to report DM more often than 
D. M. Greenfield and J. A. Snowden
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sibling donors (OR for allo-HSCT, 3.65; 95% CI, 
1.82–7.32; OR for auto-HSCT: 2.03; 95% CI, 
0.98–4.21) (Baker et al. 2007). High-dose corti-
costeroids (cumulative PRD dose of >0.25  mg/
kg/day) increase the likelihood of developing 
DM (RR, 3.6; 95% CI, 1.7–7.5) and for having 
persistent DM at 2  years post-HSCT (RR, 4.1; 
95% CI, 1.0–18.2) (Majhail et al. 2009a; b). TBI 
is also a well-evidenced risk factor (Hirabayashi 
et al. 2014).
55.4  Preventative Practices 
in the HSCT and Late Effects 
Clinic: A Practical Approach
Clearly HSCT clinicians cannot be expected to 
manage all cardiovascular risk factors and com-
plications. The logistics would be overwhelming 
and the clinical expertise required to provide up- 
to- date management of cardiological, cerebro-
vascular, endocrinological and metabolic 
conditions lacking.
However, the fact that HSCT survivors require 
HSCT follow-up provides an opportunity to 
deliver screening for late effects and other long- 
term consequences of treatments. Screening for 
cardiovascular risk factors, including MetS and 
CV events, can be straightforwardly integrated 
into a programme of long-term and late effects 
follow-up.
Screening can be provided by a variety of 
clinicians, medical, nursing or other allied 
professions, depending on the model of care. If 
cardiovascular risk factors are detected, given 
the commonality, they can usually be referred 
back to primary care clinicians who are more 
experienced and frequently manage a range of 
long- term conditions including hypertension, 
glycaemic control and often have access to 
weight management, smoking cessation and 
similar relevant serves. Primary care clinicians 
are familiar with using risk assessment 
algorithms, such as the Framingham risk score 
(Framingham 2008) and many others which are 
country specific. These risk assessment tools 
may be useful in estimating a person’s projected 
risk of developing CVD in the general 
population. They have limitations (age ethnicity, 
comorbid conditions) and, importantly, have 
not been validated in HSCT survivors and may 
potentially under- estimate the risk. However, it 
is reasonable for primary care and other 
clinicians to apply them until some more 
specific instrument is developed in HSCT 
survivors.
Non-acute cardiovascular problems detected 
in the late effects clinic can be referred back to 
primary care clinicians who can manage them or 
refer on for specialist treatment. However, there 
should be direct referral for clinically urgent or 
more serious cardiovascular problems to relevant 
hospital specialists, who have a state-of-the art 
knowledge and experience in a rapidly evolving 
field. Ultimately, one indispensable aspect should 
be close communication between all clinicians 
involved in the short- and long-term management 
of the HSCT patient, whether at primary, second-
ary or tertiary levels of care.
Given the specialised complexity of HSCT 
and its many complications, which are relatively 
rarely encountered by many clinicians outside 
of haematology, oncology and immunology, the 
HSCT clinic and associated late effects service 
can have a major role in coordinating care and 
facilitating communication between other 
relevant specialists. This aspect in underpinned 
by the seventh edition of the FACT-JACIE 
standards which feature systematic provision 
for late effects follow-up, including 
cardiovascular risk factors and complications 
(FACT-JACIE 2017).
For the HSCT programme and/or associated 
late effects clinic, Table 55.1 has been published 
as a guide to facilitate screening in the EBMT- 
CIBMTR guidelines (DeFilipp et al. 2017). This 
is a consensus opinion, and there is no good evi-
dence of the safety or clinical effectiveness of 
these recommendations in HSCT patients, which 
are based on the general population. Based on the 
available evidence, it is important to screen for 
other factors in HSCT patients, including (a) per-
sonal history, (b) family history, (c) type of trans-
plant (allo or auto), (d) use of TBI, (e) history of 
acute or chronic GvHD and (f) use of CNI (CSA, 
TAC) (DeFilipp et al. 2017).
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55.5  Future Directions: 
Implementation, Education 
and Research
As survival after HSCT gradually increases, there 
is recognition of an impact on CVD and its risk 
factors, including MetS. Most research has been 
cross-sectional and observational. More prospec-
tive research is needed on both defining the inci-
dence above the normal ageing population and on 
interventional strategies, targeting individual risk 
factors and/or components of the MetS. Indeed, a 
recent review by Armenian and colleagues 
(Armenian et al. 2017) provided consensus rec-
ommendations for cardiovascular disease and 
risk factors identifying research gaps and future 
study priorities to improve the long-term cardio-
vascular health of HSCT survivors.
Consideration of CVD and associated risk fac-
tors may also vary between indications for 
HSCT. For example, the most common indication 
for HSCT, myeloma, although mostly incurable, is 
now associated with relative longevity, and con-
sideration of CV risks are relevant (Snowden et al. 
2017). Likewise, new indications for HSCT, such 
as systemic AID, and newer techniques, such as 
haplo-HSCT, require individualised assessment. 
Whilst pharmacological, lifestyle and rehabilita-
tion interventions are common in the general pop-
ulation in respect to CVD, their impact in HSCT 
recipients (both before and after HSCT) needs to 
be defined in the context of the wide range of indi-
cations and age at which patients receive their 
HSCT, along with the individual prognosis of each 
indication after successful HSCT.
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Increasing numbers of HSCT are being per-
formed annually and outcomes continue to 
improve. As a result, survivorship issues are 
assuming increasing importance. Chemotherapy 
and radiotherapy remain cornerstones of HSCT 
treatment, but whilst lifesaving, they threaten 
endocrine function, fertility and sexual function.
56.1  Endocrine Function
Underlying disease, pre-HSCT treatment, devel-
opment of chronic GVHD and prolonged cortico-
steroid treatment can all contribute to the risks of 
endocrine dysfunction inherent from condition-
ing regimens used for HSCT. Systematic follow-
 up is important to identify and treat endocrine 
defects before clinical impact, and this is particu-
larly important in children where growth and 
puberty are at risk.
56.1.1  Thyroid Dysfunction
56.1.1.1  Background
The most common abnormality of thyroid func-
tion after HSCT is primary compensated hypo-
thyroidism. This may not require treatment and 
commonly resolves. Overt hypothyroidism may 
be primary or less commonly central. Other 
thyroid disorders include autoimmune thyroid 
disease (thyroiditis, Graves’ disease) and thy-
roid cancers (carcinomas or benign adenomas). 
In a single-centre study of 791 patients followed 
up for 38 years, new cases of thyroid dysfunc-
tion continued for 28  years after HSCT high-
lighting the need for indefinite follow-up 
(Sanders et al. 2009).
Risk factors for hypothyroidism post-HSCT 
include the use of TBI with single dose being asso-
ciated with a five to sixfold higher risk than frac-
tionated TBI. BU-based regimens are more likely 
to cause thyroid problems than those containing 
CY only, and patients with malignant disease (e.g. 
Hodgkin lymphoma) are more likely to get thyroid 
dysfunction than patients with non- malignant dis-
eases (e.g. aplastic anaemia). The age of the patient 
is also important with younger patients at higher 
risk. In relation to thyroid cancer, a retrospective 
study which included data on >68000 patients 
showed that the relative risk (RR) of thyroid can-
cer was approximately threefold higher following 
HSCT than in the general population. The RR was 
>20 if transplanted before the age of 10 years and 
close to 5 if transplanted between age 11 and 
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20 years. Female gender and GVHD were addi-
tional risk factors (Cohen et al. 2007).
56.1.1.2  Prevention/Management
Patients should have annual laboratory assess-
ment of thyroid function. Annual clinical exami-
nation should include palpation of the thyroid 
gland, and there should be a low threshold for 
arranging a thyroid ultrasound.
56.1.2  Hypoadrenalism
56.1.2.1  Background
The main risk factor is use of glucocorticoids which 
lead to central corticotrophin deficiency. Adult 
patients receiving 5mg/day prednisolone or more or 
paediatric patients receiving >0.3–0.5 mg/kg/day for 
more than 3 months are at risk. TBI can also cause 
corticotrophin deficiency as can drugs. Symptoms 
can be non-specific including fatigue, weakness, 
nausea, weight loss and hypotension. Some symp-
toms may mimic GVHD. Diagnosis requires paired 
morning cortisol and ACTH levels. If the results are 
nonconclusive, then additional investigations should 
be arranged with an endocrinologist.
56.1.2.2  Prevention/Management
When confirmed hydrocortisone should be given 
with additional doses to cover stresses such as ill-
ness, infection or surgery. Subsequently, regular 




Short stature is multifactorial after transplant. It 
is a recognized side effect of radiation to the 
hypothalamic-pituitary area given in childhood, 
as a result of a reduction in growth hormone 
(GH) secretion. Radiation can also induce bone 
lesions. Pre-transplant cranial radiation (e.g. 
patients with ALL) is also relevant, and single- 
dose TBI rather than fractionated radiation 
increases the risk further.
Additional contributory factors to short stature 
in these patients include underlying disease (e.g. 
Fanconi anaemia), other hormone deficiencies 
(including thyroid and gonadal hormones), nutri-
tional deficits, illness, steroids and GVHD. Male 
sex and young age at time of transplant are addi-
tional risk factors.
56.1.3.2  Prevention/Management
Children’s growth velocity should be closely 
monitored with height and weight documented at 
each clinic visit. A possible increased risk of sec-
ondary malignancies has been described in 
patients receiving GH therapy after previous neo-
plasia; this has raised concerns regarding the use 
of GH in the absence of sufficient long-term fol-
low- up data. As a consequence of this, there are 
currently no clear guidelines for the use of GH in 
these patients. A paediatric endocrinologist 
should be involved if growth rate is abnormal 
based on bone age and pubertal stage (Chow 
et al. 2016) and the use of GH therapy discussed 
for severe growth retardation (-2SD).
56.2  Gonadal Dysfunction 
and Infertility
56.2.1  Background
Normal reproduction in both sexes requires germ 
cells and an intact hypothalamic-pituitary endocrine 
axis. In female patients the uterus must be both 
receptive to implantation and capable of undergoing 
growth during pregnancy. Chemotherapy and radia-
tion can lead to damage in all of these areas and 
compromise the likelihood of successful parent-
hood after HSCT. Before starting any chemoradio-
therapy regimen, the potential effects on the future 
fertility of the patient should be considered and dis-
cussed with the patient together with a discussion of 
fertility- preserving strategies.
56.2.2  Gonadal Dysfunction 
in Women Following 
Chemoradiotherapy
Women are born with a finite number of eggs 
which can be fertilized for pregnancy and depleted 
over time as a result of physiological apoptosis or 
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else menstruation. Chemoradiotherapy depletes 
further the number of follicles by (1) activating 
apoptotic pathways, (2) causing fibrosis of stro-
mal blood vessels, (3) activating resting (antral) 
follicles, leading to a ‘burn-out’ effect (Meirow 
and Nugent 2001; Kalich-Philosoph et al. 2013). 
The degree of ovarian damage is related to the 
dose and type of chemotherapeutic agent used, 
and baseline ovarian reserve which in turn is 
dependent on age and previous treatment. 
Manifestations of premature ovarian failure range 
from premature menopause to varying degrees of 
infertility. Alkylating agents have the highest age-
adjusted odds ratio of ovarian failure (Meirow 
2000). A combination of BU and CY is particu-
larly gonadotoxic to females, but younger patients 
who receive CY only may have some gonadal 
function preserved and pregnancies following CY 
are well described (Salooja et  al. 2001). TBI is 
also potentially sterilizing. The estimated median 
lethal dose of radiation for the human oocyte is 
less than 2 Gy (Wallace et al. 2003). The effective 
sterilizing dose (ESD) decreases with increasing 
age, and whilst estimated as 18.4 Gy at 10 years 
of age, the ESD is approximately 14.3  Gy at 
30 years of age, and only 6 Gy in women over age 
40 (Wallace et al. 2005).
56.2.3  Gonadal Dysfunction in Men 
Following 
Chemoradiotherapy
In male patients, spermatogenesis is impaired, 
but testosterone levels generally remain normal 
because of the relative resistance of testosterone 
producing Leydig cells to chemoradiotherapy. As 
a result, secondary sexual characteristics remain 
normal for male patients and typically testoster-
one levels and luteinizing hormone (LH) levels 
are in the normal range. Spermatogonia are very 
sensitive to irradiation, and it takes approxi-
mately 2 years for sperm counts to recover to pre- 
irradiation levels after a single dose of 1  Gy 
(Meistrich and van Beek 1990). With higher 
doses, azoospermia persists longer or may be 
permanent. Following HSCT conditioned with 
TBI, the majority of men will be azoospermic. 
Chemotherapy only regimens are also associated 
with azoospermia but to a lesser degree (Rovo 
et al. 2013). Following BU, for example, approxi-
mately 50% will be azoospermic, whilst after CY 
alone, recovery of spermatogenesis is more 
frequent.
56.2.4  Uterine Dysfunction 
in Women After Radiation
Uterine development commences at puberty and 
is associated with an increase in both size and 
vascularity (Laursen et  al. 1996). Exposure to 
radiation leads to reduced vascularity, fibrosis 
and hormone-dependent endometrial insuffi-
ciency, which subsequently lead to adverse repro-
ductive outcomes. Increased rates of infertility, 
miscarriage, preterm labour, intrauterine growth 
retardation and low newborn birth weight have 
been described (Reulen et al. 2009), particularly 
if conception occurred within a year of radiother-
apy (Fenig et al. 2001).
56.2.5  Prevention/Management 
of Gonadal Failure
56.2.5.1  Fertility Preservation 
in Males
Sperm cryopreservation is an established fertility 
preservation option for post-pubertal boys and 
men. Sperm can be used either for artificial 
insemination or, if the quantity and/or quality of 
sperm are insufficient, for intracytoplasmic 
sperm injections for in vitro fertilization. There is 
a chance of sperm recovery with time particularly 
if the patient was under the age of 25  years at 
transplant, did not have TBI and has no evidence 
of chronic GVHD (Rovo et  al. 2013). These 
patients require reassessment at intervals to 
ascertain their fertility potential.




Despite success in animal models, the value of 
GnRHa to preserve ovarian function during 
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chemotherapy in human subjects is uncertain. 
A Cochrane database review (2011) concluded 
that the use of GnRH agonists should be con-
sidered for ovarian protection in women of 
reproductive age who are receiving chemother-
apy (Chen et al. 2011).
Embryo and Oocyte Cryopreservation
Embryo and oocyte cryopreservation are pre-
ferred methods of fertility preservation in 
women who require sterilizing treatment. Use of 
donor embryos/oocytes can also be discussed 
with the patient because they offer the possibil-
ity of pregnancy and parenthood albeit with a 
non- genetic child. Mature oocyte collection 
requires ovarian stimulation. These oocytes can 
then either be frozen or else fertilized in  vitro 
before freezing. These options are not open to 
all patients however. Ovarian stimulation takes a 
minimum of 2 weeks, and this delay is prohibi-
tive for many patients with haematological 
malignancies. The requirement for partner or 
donor sperm for embryo cryopreservation is 
another potential drawback; for some patients, 
sperm is not available, and for others the 
involvement of a partner/sperm donor limits 
future reproductive autonomy as consent from 
the sperm provider must be given not only at the 
time of cryopreservation but also at the time of 
reimplantation.
Ovarian Tissue Cryopreservation (OTC)
OTC is considered experimental and is not avail-
able to all patients. Nonetheless, reports of preg-
nancy after OTC are increasing (Van der Ven 
et al. 2016), and it is the only option open to pre-
pubertal patients or to women who cannot toler-
ate a significant delay in treatment due to disease 
severity or progression. Cortical fragments con-
taining primordial follicles with immature 
oocytes can be obtained by laparoscopy and 
cryopreserved. Ideally, ovarian tissue should be 
obtained before the patient has been exposed to 
chemotherapy, but this is not always possible and 
is not an absolute requirement.
A major concern reimplanting cryopreserved 
ovarian tissue is the possibility of reseeding the 
tumour. The risk depends on the individual dis-
ease. Assessment by PCR of ovarian tissue taken 
from patients with leukemia (CML, AML, ALL), 
tested positive for disease in a number of cases 
and assessment of tissue from mice with severe 
combined immunodeficiency confirmed, con-
firms the leukaemic potential of the tissue 
(Rosendahl et al. 2013). As a result, reintroduc-
tion of ovarian tissue from patients with leukemia 
would not currently be recommended. In the 
future, maturation in vitro of follicles from cryo-
preserved tissue may enable production of a via-
ble disease-free alternative. In patients with 
lymphoma, histologically negative samples of 
ovarian issue have been transplanted without ini-
tiating relapse, but in some cases the follow-up 
time was short.
56.2.5.3  Children and Adolescents
Fertility preservation in children has been the 
subject of recent guidelines from the paediatric 
diseases working party of the EBMT (Dalle et al. 
2017; Balduzzi et al. 2017). Extreme sensitivity 
is required, and parents have to be given com-
plete information on the process, associated risks 
and success rates. For prepubertal girls, OTC is 
currently the only potential fertility-sparing 
option. In peri-pubertal boys, it is sometimes 
 possible to extract sperm using surgery/microdis-
section or electroejaculation under general anaes-
thetic. In prepubertal males the only option is 
testicular tissue cryopreservation; although work 
in animal models is encouraging, there have been 
no reports to date of reimplanted testicular tissue 
leading to human live births.
56.2.6  Management of Pregnancy 
After HSCT
Most patients or their partners who conceive 
after HSCT have uncomplicated pregnancies. 
Chemoradiotherapy can potentially affect a vari-
ety of maternal organs relevant to a successful 
pregnancy outcome, for example, renal, cardiac 
and pulmonary toxicity. Patients at risk should 
have an expert medical review early in preg-
nancy and may require regular specialist moni-
toring throughout and review by an anaesthetist 
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prior to delivery. Patients who have had TBI or 
pelvic irradiation have an increased risk of pre-
mature and small birth weight babies. 
Miscarriage rates are typically comparable to the 
background population, however, and no signifi-
cant increase in congenital malformations or 
genetic abnormalities have so far been described 
when conception has taken place long after com-
pletion of therapy (Meirow and Schiff 2005; 
Green et al. 2009). Animal experiments suggest 
that most cytotoxic drugs are mutagenic and ter-
atogenic to oocytes exposed during the matura-
tion phase. In humans, this phase lasts 
approximately 6  months (Meirow and Schiff 
2005), so there is a theoretical advantage to 
delaying conception for 6 months after complet-
ing gonadotoxic treatments.
56.3  Sexual Function
56.3.1  Background
Alterations in sexual function and sexual satisfac-
tion are among the most common of all complica-
tions in long-term survivors of transplantation with 
46% male and 80% female survivors describing 
sexual problems 5 years post transplant (Syrjala 
et al. 2008). Sexual complications in both alloge-
neic and autologous transplant recipients include 
changes in libido, dyspareunia (females) and 
erectile and ejaculatory dysfunction (males) (Li 
et al. 2015). Allogeneic recipients have additional 
problems linked to acute or chronic GVHD 
(Wong et al. 2013).
Sexuality is also affected, and this is multi-
factorial due to decreased self-confidence, 
stress, anxiety and fear of recurrence, together 
with a change in body image (Yi and Syrjala 
2009). The sexual well-being of the survivor is 
also determined by their relationship with their 
partner (Langer et  al. 2007). The partners of 
patients may experience a decrease in sexual 
desire and anxiety about initiating sexual activ-
ity with survivors. Poor communication can 
contribute to long-term sexual dysfunction 
between survivors and their partners (Hawkins 
et al. 2009).
56.3.2  Prevention/Management
It is important to identify relevant issues before 
problems with sexuality and intimacy become 
entrenched. It is recommended that healthcare 
professionals discuss sexual function with patients 
at 6 months, 1 year and at least annually thereafter 
(Majhail et al. 2012). Prompt attention should be 
paid to reversible risk factors such as hypogonad-
ism or symptoms associated with urogenital 
GVHD so that appropriate referrals can be made 
to either gynaecologists or urologists. Some male 
patients benefit from the prescription of erectile 
dysfunction medication, and hormone replace-
ment should be discussed with women prior to 
leaving hospital if onset of menopause is likely. 
Women with vaginal dryness may benefit from 
lubricants or topical oestrogens, and those with 
GVHD may benefit from topical steroids (Tirri 
et al. 2015). The role of vaginal dilators in prevent-
ing vaginal stenosis is not clear (Miles and Johnson 
2014). It is recognized that psychological factors 
can play a large part in sexual dysfunction after 
transplant and this is relevant not only for the 
patient but also for the partner. For the patient it 
can be difficult to separate the psychological issues 
from coexisting physical problems, but many cou-
ples will benefit from review by a sex therapist.
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57.1  Monitoring MRD in ALL
Peter Bader and Hermann Kreyenberg
57.1.1  Introduction
In ALL evaluation of molecular treatment 
response, assessment of minimal residual disease 
(MRD) is a substantial independent predictor of 
outcome, as proven by randomized studies (Conter 
et  al. 2010; Gökbuget et  al. 2012; Bassan and 
Spinelli 2015). Consequently, MRD is imple-
mented in virtually all clinical protocols in order to 
supplement or to redefine multifactorial risk strati-
fication with optional customized treatment inten-
sity. The detection of leukemic cells below the 
limit of classical cytomorphology is feasible either 
by disease-specific alterations of the immune phe-
notype or unique genetic features. Several compet-
ing and complementing MRD methods have been 
developed with preference application according 
to clinical protocols (Van der Velden et al. 2007; 
van Dongen et al. 2015).
57.1.2  MRD Assessment by IG/TCR 
Real-Time PCR
The discontinuous immune receptor genes provide 
the immune repertoire by somatic recombination 
of variable (V)-, diversification (D)-, and junction 
(J)- elements thus forming hypervariable CDR3 
(complement determine region 3) regions during 
lymphocyte maturation. Such rearrangements can 
serve as clonal index of leukemia blasts originat-
ing from lymphoid precursor stages. Additionally, 
due to a relaxed regulatory control, leukemia 
blasts can harbor incomplete rearrangements and 
cross-lineage rearrangements and tend to accu-
mulate simultaneously multiple rearrangements. 
Quantitative real-time PCR using junction com-
plementary allele-specific oligonucleotides (ASO) 
frequently reaches a detection limit of 1E-05 with 
a quantitative range of 1E-04, is applicable to vast 
majority of cases, and has a high degree of stan-
dardization (Van der Velden et al. 2007).
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57.1.3  MRD Assessment by Fusion 
Gene Transcript
Most frequent recurrent reciprocal transloca-
tions are in ALL t(9;22)(q34;q11) (BCR-ABL1), 
t(12;21)(p13;q23) (ETV6-RUNX1), and  t(4;11)
(q21;q22) (MLL-AFF1) with age stage associ-
ated preponderance in adults, childhood, and 
infant ALL, respectively. Derived chimeric 
fusion transcripts are validated marker for 
MRD detection by real-time PCR with an 
achievable detection limit of 1E-06. The meth-
odology has been standardized by the Europe 
Against Cancer (EAC) program (Gabert et  al. 
2003).
57.1.4  NGS (Next-Generation 
Sequencing)
High-throughput sequencing (HTS) of immune 
receptor genes by next-generation sequencing 
(NGS) is a novel option for MRD. This meth-
odology provides comprehensive qualitative 
and quantitative information regarding clonal 
consistence of the diagnostic sample and 
shares one protocol for index determination 
and MRD assessment without need of individ-
ual reagents. Potential sub- and new emerging 
leukemic clones also are covered. PCR steps 
during library construction can introduce bias 
effecting results internal controls and normal-
ization calculations are necessary the gener-
ated data volume is high and data interpretation 
demand biostatistics expertise. Due to high 
sample capacity, NGS favors a centralized 
concept and service is available to commercial 
providers by academic centers (Kotrova et al. 
2015).
57.1.5  Flow Cytometry
MRD by multicomponent flow cytometry (MFC) 
distinguishes leukemia-associated immune phe-
notypes (LAIP) and regular cells. LAIP consists 
of cell lineage maturation stage-specific (back-
bone) markers in combination with illegitimate 
markers. The standard four to six color 
approaches have been developed simultaneously 
by several centers. Therefore, the applied marker 
panels depend on study protocol. The consis-
tently achieved detection limit is 1E-04. 
Recently, increase of specificity and sensitivity 
was enabled by high-throughput procedures 
demanding eight or ten color equipment. Here 
the options for targeted and visualized antigens 
allow simultaneous visualization of all develop-
mental lymphocyte stages serving as background 
to distinguish leukemic cells. The EuroFlow 
Consortium validated available antibody panels 
and controls which can be applied in a standard-
ized way, including automated gating with sup-
portive software, data storage and comparison, 
accurate quantitative result, and option for IVD 
development. Similar to the NGS approach, the 
generated data volume is high and data interpre-
tation demands biostatistics expertise; neverthe-
less, the concept allows decentralized data 
acquisition (Pedreira et al. 2013).
57.1.6  Limitations of MRD 
Assessment
The determined level of MRD always is a result 
of complex interrelation of baseline character-
istics of tumor and patient, time point of MRD 
evaluation, therapeutic agents, course of clear-
ance, and degree of therapy resistance. Several 
measurements therefore are mandatory. 
Adverse circumstances for MRD assessment 
are clonal selection and clonal evolution, since 
the associated index might be missed. 
Potentially impacted are leukemia with initial 
oligoclonality as observed in approximately 
15% of B-ALL and up to 1000 subclones have 
been reported (Wu et  al. 2016). Phenotypic 
plasticity under treatment and massive lympho-
cyte regeneration can cause false negativity or 
positivity, a solvable problem by applying men-
tioned high-throughput methodologies. 
Achievable detection limit is correlated with 
cell count of sample, and aplastic samples are 
challenging. Finally, all methodologies use dif-
ferent sample preparations, and analyses refer 
to different units, a circumstance which inter-
feres result comparison.
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57.1.7  MRD in the Setting of HSCT
As all adult patients with ALL who relapse after 
initial chemotherapy have an absolute indication 
for allo-HSCT, pediatric patients are stratified into 
different treatment groups. Main prognostic deter-
minants in these patients are the blast immune 
phenotype, time to relapse, and site of relapse. 
High-risk patients who experienced early isolated 
BM relapse, early relapse involving BM, and any 
BM relapse of T-lineage ALL have clear indication 
for HSCT. Intermediate-risk patients experienced 
early or late combined BM relapse and a late iso-
lated BM relapse of a B-cell precursor (BCP).
ALL and very early and early isolated extra-
medullary relapse of either BCP-ALL or T-ALL 
have indication for HSCT if post induction MRD 
exceeds a threshold of 1E-03 (Eckert et al. 2013).
During the past decades, it could be clearly 
shown by several studies that the level of MRD 
immediately prior to transplant does have a clear 
prognostic impact on post-HSCT outcome 
(Knechtli et  al. 1998). Retrospective studies in 
children with relapsed ALL revealed an impor-
tant cutoff for post-HSCT outcome. Patients who 
received transplantation with an MRD load of 
≥10 to 4 leukemic cells had a by far inferior 
prognosis than patients with lower MRD loads 
before transplant (Bader et  al. 2009). Based on 
these findings, several studies are now underway 
investigating strategies to improve outcome in 
these ultrahigh-risk patients. Adaption of trans-
plant approaches might allow successful trans-
plantation (Leung et al. 2012).
Spinelli et al. showed that almost half of the 
patients with high levels of MRD before trans-
plantation achieved molecular remission by day 
+100 (Spinelli et al. 2007). This finding indicates 
that MRD detection post transplant provides 
additional value to the MRD assessment prior to 
transplantation. It could be demonstrated in pro-
spective clinical studies that the close monitoring 
of MRD by different approaches allows the pre-
diction of relapse and may therefore form the 
basis of different intervention strategies making 
use of leukemia-specific targeted therapy (Bader 
et al. 2015; Balduzzi et al. 2014). Future perspec-
tives will focus on MRD-guided intervention to 
prevent overt relapse (Rettinger et al. 2017).
57.2  Monitoring MRD in AML
Gert Ossenkoppele
57.2.1  Introduction
The possibility of defining residual disease far 
below the level of 5% leukemic cells is changing 
the landscape of risk classification. This so-called 
measurable/MRD approach at present establishes 
the presence of leukemia cells down to levels of 
1:103 to 1:106 white blood cells, compared to 
1:20 for morphology. Recently the ELN pro-
posed a new response criterium: CR without min-
imal residual disease (CRMRD-) is defined as CR 
with negativity for a genetic marker by RT-qPCR 
or CR with negativity by multicolor flow cytom-
etry (MFC) (Döhner et al. 2017).
The reasons to apply MRD assessment in 
AML are (1) to provide an objective establish-
ment of remission status; (2) to better predict out-
come and guide post-remission treatment; (3) to 
identify early relapse as a robust post transplant 
surveillance, in order to enable early interven-
tion; and (4) to be used as a surrogate endpoint to 
fasten drug testing and approval.
A recent ELN MRD consensus document was 
published with the aim to identify key clinical 
and scientific issues in the measurement and 
application of MRD in AML and to provide 
guidelines for the current and future use of MRD 
in clinical practice (Schuurhuis et al. 2018).
57.2.2  Methods for MRD Detection
57.2.2.1  MRD Detection by PCR
Real-time quantitative PCR (RT-qPCR) allows 
MRD detection in cases with chimeric fusion 
genes generated by balanced chromosomal rear-
rangements (Grimwade and Freeman 2014). 
Other genetic alterations can also be used for 
MRD detection including insertions/duplications, 
point mutations and gene overexpression. Apart 
from t(15;17) and RUNX1–RUNX1T1 and CBFB–
MYH11, currently NPM1 is the best- validated 
molecular marker for MRD  assessment. PCR 
assessment of MRD is in about 50% of patients in 
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principle possible. The methodology has been 
standardized for several molecular markers for 
clinical implementation in the Europe Against 
Cancer (EAC) program (Gabert et al. 2003).
57.2.2.2  Immune MRD by Multicolor 
Flow Cytometry
The basic principle is to identify at diagnosis leu-
kemia-associated immune phenotypes (LAIP). 
These LAIPs consist of normally occurring mark-
ers, present in aberrant combinations in AML but 
in very low frequencies in normal and regenerat-
ing BM. The background levels of LAIP in nor-
mal and regenerating BM levels, in particular, 
although low, prevent specific detection of aber-
rancies with sensitivities higher than 1:10,000.
If no diagnosis sample is present, one can 
make use of “different from normal” approach 
which uses a standard fixed antibody panel to 
recognize leukemic cells based on their differ-
ence with normal hematopoietic cells (Loken 
et al. 2012).
Currently, immune MRD aberrancies may be 
detected in over 90% of AML cases at diagnosis.
57.2.3  MRD in Clinical Studies
Despite a multitude of prognostic factors at diag-
nosis, the outcome of patients is still highly vari-
able and not individually predictable. It thus 
seems that prognosticators at diagnosis will not 
enable clinicians to reach the ultimate goal of 
truly individualized risk assessment. Treatment 
parameters may be more useful (Ossenkoppele 
and Schuurhuis 2013).
Two large, prospective, multicenter studies 
have identified flow cytometry-based MRD as an 
independent prognostic indicator in adults with 
AML (Freeman et al. 2013; Terwijn et al. 2013). 
Flow cytometry-based MRD was assessed in a 
multicenter, multinational study in adults with 
AML between 18 and 60  years of age by 
HOVON/SAKK investigators (Terwijn et  al. 
2013). Patients were treated according to proto-
col, without knowledge of MRD-related data. In 
this study, lower levels of MRD were associated 
with better outcomes than higher levels, and 
MRD levels >0.1% of white blood cells after the 
second cycle of chemotherapy were associated 
with higher risk of relapse in multivariate analy-
sis. The UK NCRI group assessed MRD using 
flow cytometry in 427 patients older than 60 years 
of age (Freeman et  al. 2013). MRD negativity 
after the first cycle of chemotherapy conferred 
significantly better 3-year survival after 
CR.  MRD-positive patients had increased 
relapses and higher risk of early relapse (median 
time to relapse, 8.5 v 17.1 months, respectively).
An example indicative for the usage of molecu-
lar MRD was recently published by Ivey et  al. 
(2016) who showed in a large study by NCRI that 
the presence of MRD, assessed by Q-PCR of 
NPM1-mutated transcripts, provided powerful 
prognostic information independent of other risk 
factors. Persistence of NPM1-mutated transcripts 
in blood was present in 15% of the patients after the 
second chemotherapy cycle and was associated 
with a greater risk of relapse after 3 years of follow-
up than was an absence of such transcripts (82% 
vs. 30%; hazard ratio, 4.80) and a lower rate of sur-
vival (24% vs. 75%; hazard ratio for death, 4.38).
Many other studies point in the same direction 
that MRD status after two cycles of chemother-
apy is highly predictive independently from other 
prognostic factors for outcome (Hourigan et  al. 
2017). However surrogacy for survival has not 
been proven yet (Ossenkoppele and Schuurhuis 
2016).
57.2.4  Pretransplant MRD
Evidence is accumulating that the presence of 
MRD assessed by multicolor flow cytometry 
immediately prior to allogeneic HCT is a strong, 
independent predictor of post transplant out-
comes in AML (Buckley et al. 2017; Walter et al. 
2015). In a recent update, Araki et al. showed that 
in 359 adults, the 3-year relapse rate was 67% in 
MRD- positive patients, compared to 22% in 
MRD- negative patients, resulting in OS of 26% 
vs. 73%, respectively (Araki et  al. 2016). This 
applies for the myeloablative as well as for the 
non-myeloablative transplant setting.
Also molecular MRD as measured by RT-PCR 
in NPM1-mutated AML has a significant impact 
on outcome after allo-HSCT (Balsat et al. 2017). 
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Performing an allo-HSCT in case of a suboptimal 
reduction (<4 log10) of NPM1 levels after chemo-
therapy resulted in improved overall survival. In 
patients with optimal (≥4 log10) reduction of 
NPM1 levels after chemotherapy, allo-HSCT had 
no significant effect on survival. However, no pro-
spective studies using MRD to guide post- 
remission therapy are available at the time of this 
publication. Regardless, it is clear that novel treat-
ment strategies before, during, and after trans-
plant are urgently needed to improve outcomes in 
AML. Thereby depth of response prior to trans-
plant, as measured by level of MRD, has emerged 
as one of the most important predictors of trans-
plant outcome. Randomized trials are warranted 
to determine if MRD-guided preemptive therapy 
is associated with improved outcome.
Currently no clinical trial including transplan-
tation trials should be performed without includ-
ing MRD assessment.
57.2.5  Future Developments
New technologies are emerging to assess 
MRD. Quantifying leukemic stem cells is such a 
promising approach (Terwijn et  al. 2014; 
Zeijlemaker et  al. 2016). Next-generation 
sequencing for MRD assessment can, theoreti-
cally, be applied to all leukemia-specific genetic 
aberrations. In a recent HOVON study, it was 
shown that persistence of gene mutations in CR 
appeared to be a highly significant independent 
prognostic value for relapse and overall survival 
(Jongen-Lavrencic et al. 2018).
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Relapse has become the most frequent cause of 
treatment failure after HSCT (Horowitz et  al. 
2018). Because outcome after relapse remains 
poor, major effect is focused on prevention of 
relapse. Beside adoptive cell-based options, such 
as DLI, the availability of novel effective phar-
macological compounds has opened new avenues 
in clinical research to use those drugs early after 
HSCT in order to prevent relapse (Kroger et al. 
2014). The optimal pharmacological compound 
should have a safe toxicity profile, an antitumor 
effect to the underlying disease, and an immune 
profile which can be used to booster the graft- 
versus- leukemia (GVL) effect and to reduce the 
risk of GVHD.
58.2  Tyrosine Kinase Inhibitors 
(TKI) Targeting BCR/ABL
Beside a direct antitumor effect, TKIs are consid-
ered to induce also immunomodulating effects by 
inducing effect on T-cell cytolytic function, 
reducing T-cell PD-1 expression, and reducing 
myeloid-derived suppressor cells. TKIs targeting 
BCR/ABL such as imatinib induce more than 
60% molecular remission in CML patients who 
relapsed after allograft. Smaller studies have 
investigated second-generation TKI successful as 
maintenance therapy after allo-HSCT for CML 
(Olavarria et al. 2007).
TKIs as maintenance therapy for Ph  +  ALL 
led to nonconclusive results. The CIBMTR did 
not find a difference in Ph + ALL patients who 
received post transplant TKIs regarding relapse 
at 3 years, while in an EBMT study, Ph + ALL 
patients who received TKIs post transplant had 
lower relapse incidence and an improved LFS. In 
a small randomized study comparing TKI pro-
phylactically or preemptive in Ph + ALL, no dif-
ference in survival was observed (Pfeifer et  al. 
2013). In a position statement, EBMT recom-
mended in MRD-negative patients after allo- 
HSCT either prophylactic or preemptive 
treatment (Giebel et al. 2016).
58.3  TKI Targeting FLT3-ITD
TKIs in the setting of FLT3-ITD-positive AML 
are of clinical relevance because a higher risk of 
relapse has been described for FLT3-ITD-positive 
patients who received allo-HSCT CR1 (30% vs. 
16%). Animal experiences had shown that 
sorafenib stimulated immunogenicity by induc-
tion of IL-15 which enhanced T-cell activation 
and GVL effect (Mathew et al. 2018).
Midostaurin which is approved in the treat-
ment of FLT3-positive AML has been tested in 
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a phase II study as maintenance therapy in 
FLT-3- ITD-positive patients with a low relapse 
rate at 12 months of only 9.2%. A retrospective 
study which compared sorafenib with a histori-
cal control showed improved outcome if TKI 
was used prophylactically (Brunner et  al. 
2016). Currently under investigation are ran-
domized trials with quizartinib, gliteritinib, 
and crenolanib.
For relapsed FLT3-ITD-positive patients, 
sorafenib can induce long-lasting CR, and retro-
spective data show better outcome of sorafenib 
plus DLI in comparison to DLI alone (Mathew 
et al. 2018; Metzelder et al. 2012).
58.4  Checkpoint Inhibitors
Checkpoint inhibitors blocking CTLA-4 and 
PD-1 are now widely used in solid tumors and 
also in hematological malignancies such as 
Hodgkin’s disease (Ansell et al. 2015). Because 
of reversal of T-cell exhaustion by checkpoint 
inhibitors which may enhance a graft-versus- 
malignancy effect, this compound has also 
raised interest to be investigated after 
HSCT. After auto-HSCT PD-1 antibody pidili-
zumab as maintenance therapy in DLBCL was 
well tolerated in a phase II study and nivolumab 
has shown high response rate in patients with 
HL who relapsed after auto-HSCT (Younes 
et al. 2016).
There is concern about a higher risk of 
GVHD after checkpoint inhibition post-
allograft, but ipilimumab did not induce high 
incidence of GVHD in phase I and phase II tri-
als although the efficacy was limited with an 
overall response rate of less than 30% (Davids 
et  al. 2016). PD-1 blockade investigated in a 
European trial was reported for 20 patients with 
HL who relapsed after allograft. The remission 
rate was high with 95% and 30% developed 
GVHD which was fatal in one patient. In a simi-
lar trial including 31 lymphoma patients who 
relapsed after allograft, the response rate was 
77%, but 54% developed acute GVHD and eight 
patients died from GVHD-related complica-
tions (Haverkos et al. 2017).
58.5  Hypomethylating Agents
Methylation has a crucial role in epigenetic regu-
lation of gene expression and malignant cells 
using hypermethylation to switch off a variety of 
genes which are responsible for growth inhibition 
and apoptosis. DNA methyltransferase inhibitors 
such as azacytidine or decitabine are active in 
MDS and AML, and according to their toxicity 
profile, they can be used after allo- HSCT. Beside 
their effect on gene modification for differentia-
tion and cell growth, hypomethylating agents 
(HMA) lead also to an upregulation of HLA and 
tumor-associated antigen which may be targeted 
by donor T cells (Hambach et al. 2009; Goodyear 
et al. 2010). Furthermore, CD4 and CD8 T cells 
were strongly suppressed by HMA while an 
increase of regulatory T cells has been described.
Azacytidine and decitabine either as single 
agent or in combination with DLI have been 
reported and up to 28% CR could be achieved 
including long-lasting remission (Schroeder et al. 
2013). In a large EBMT study, an ORR of 25% 
with 15% CR and a 2-year OS of 12% has been 
reported for azacytidine in after allo-HSCT- 
relapsed AML/MDS patients. Overall the inci-
dence of acute GVHD was low and the addition 
of DLI did not improve response or OS. Smaller 
studies also reported efficiency of azacytidine to 
convert decreasing donor cell chimerism into full 
donor cell chimerism (Platzbecker et al. 2012).
Treating patients with HMA prophylactically 
to prevent relapse has been tested (de Lima et al. 
2010) and is currently investigated in prospective 
randomized clinical trials.
58.6  Immunomodulating Drugs 
(IMiDs)
After auto-HSCT thalidomide has been tested 
alone and with glucocorticoids as maintenance to 
prevent relapse/progression. Most of these phase 
III trials demonstrated an improved PFS or EFS 
with variable improvement in OS, but due to toxic-
ity, the drug has not become a standard care of 
treatment (Barlogie et  al. 2008; Spencer et  al. 
2009). Lenalidomide is approved as maintenance 
N. Kröger
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therapy since a significant improvement in PFS 
has been shown in two randomized trials and 
improved OS on one randomized trial (McCarthy 
et al. 2012; Attal et al. 2012). A meta-analysis with 
data from three large studies (CALGB 100104, 
IFM-05-02, and GIMEMA RV-MM-PI-209) dem-
onstrated an OS and a PFS benefit for lenalido-
mide maintenance. However, an increased risk of 
secondary primary malignancies was observed 
after lenalidomide maintenance therapy.
After allo-HSCT a stimulation of T cells has 
been shown for thalidomide, but second- 
generation IMiDs such as lenalidomide and 
pomalidomide are even more potent stimulation 
of T-cell-mediated immunity. IMiDs also stimu-
late the innate immune system including γ/δ-T 
cells and NK T cells. While after thalidomide 
even if combined with DLI, no increased GVHD 
risk was observed (Kroger et al. 2004). Because 
of the stronger T-cell stimulation, lenalidomide 
given early post-allo-HSCT can cause severe 
GVHD (Sockel et al. 2012), but starting with a 
low dose of only 5 mg and given the drug after 
discontinuation of IS reduces the risk of GVHD 
markedly (Wolschke et al. 2013).
Overall, IMiDs are potent agents for prevent-
ing relapse after auto-HSCT, but their use post- 
allo- HSCT remains to be defined primarily due 
to the increased risk of GvHD.
58.7  Proteasome Inhibitors
Proteasome inhibitors are mainly used as induc-
tion therapy prior auto-HSCT.  Some studies 
investigated proteasome inhibitors as mainte-
nance therapy after auto-HSCT to reduce the risk 
of relapse. In a prospective study, bortezomib as 
maintenance therapy was superior to thalidomide 
particularly in patients with renal insufficiency 
and high-risk cytogenetics t(4;14) or del(17q) 
(Goldschmidt et al. 2018).
Bortezomib after allo-HSCT was tested so far 
only in smaller studies with acceptable rates of 
GVHD (Caballero-Velazquez et  al. 2013), and 
novel proteasome inhibitors such as ixazomib are 
currently tested as maintenance therapy after 
allografting in MM.
58.8  Monoclonal Antibodies
Most studies of maintenance therapy with MoAb 
have been conducted after auto-HSCT.  While 
maintenance therapy after autograft with anti-
 CD20 antibody rituximab failed to demonstrate 
an advantage for DLBCL with respect to RFS 
and OS (Gisselbrecht et  al. 2012) for follicular 
lymphoma, an improved PFS but not an improve-
ment in OS has been reported in a randomized 
study (Pettengell et al. 2013). An improved PFS 
and OS with rituximab as maintenance therapy 
has recently been shown for mantle cell lym-
phoma after auto-HSCT (Le Gouill et al. 2017).
After allo-HSCT for DLCBL, rituximab 
maintenance therapy did not improve overall sur-
vival (Glass et  al. 2014). Anti-CD30 antibody 
drugs conjugate brentuximab vedotin as mainte-
nance therapy after auto-HSCT for HL did 
improve PFS but not OS (Moskowitz et al. 2015).
Anti-CD22-conjugated antibody inotuzumab 
ozogamicin has been approved for relapsed ALL 
and has shown also activity in patients with ALL 
who relapsed after HSCT (Kantarjian et al. 2016), 
but the risk of SOS/VOD is about 11% and up to 
22% for those who underwent allo-HSCT after 
inotuzumab ozogamicin.
Bispecific antibodies such as CD19-directed 
CD3 T-cell-engaged blinatumomab are active in 
relapsed and refractory ALL and also in MRD 
positive ALL and has been investigated success-
fully in combination with DLI after relapse post- 
allo- HSCT (Ueda et al. 2016).
58.9  Histone Deacetylase 
Inhibition (HDACI)
Histone deacetylation is a crucial mechanism of 
epigenetic modulation and HDACI promotes 
gene expression by unwinding of histone-bound 
DNA. Since HDACI reduces inflammatory cyto-
kines and increases T-regulatory cells, the drug 
was also used for GVHD prevention in a phase  I/
II study (Choi et  al. 2014). Panobinostat was 
tested in two trials as maintenance therapy after 
allo-HSCT in AML/MDS with or without (Bug 
et  al. 2017) DLI resulting in an encouraging 
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1-year RFS of 66% in combination with DLI and 
2-year RFS of 74% if used as single agent. This 
agent will now be tested as maintenance therapy 
in a prospective randomized phase III trial.
Incorporating novel agents into a transplant 
concept is an exciting new field of investigation, 
because in many cases, auto-HSCT alone does 
not lead to cure. To reduce the risk of relapse, 
well-designed clinical trial with novel agents is 
necessary.
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59.1  Biology of Donor 
Lymphocyte Infusion (DLI)
59.1.1  Diversity of Lymphocyte 
Subsets Used for DLI
In the context of an allogeneic HSCT, the inter-
play between host and donor immune cells is 
considered to be the primary mechanism respon-
sible for graft-versus-leukemia (GVL) reactivity 
and also able to mediate GVHD (Kolb et  al. 
2004). The tissue specificity of the immune 
response determines the balance between GVL 
and GVHD, as well as tropism of GVHD. The 
main population for success and failure of 
HSCT and DLIs originates from αβT cells. 
However, other subsets are also key modulators 
of efficacy, e.g., NK cells most likely provide 
acute control of leukemia and of infections like 
CMV. However, NK cells become rapidly edu-
cated over time (Orr and Lanier 2010) and lose 
their antileukemia activity. Other subsets, like 
γδT cells, appear to have a more prolonged anti-
leukemia effect (Handgretinger and Schilbach 
2018) and are also helpful in controlling CMV 
reactivation (Scheper et al. 2013; de Witte et al. 
2018). NKT cells, like regulatory T cells, have 
been mainly reported to influence GVHD 
effects. While an increase in NKT cells in the 
graft associates with a reduced GVHD inci-
dence (Malard et al. 2016), depletion of T regu-
latory T cells in DLI improves GVL effects, 
although it augments the risk of GVHD (Maury 
et al. 2010). Thus, lymphocyte infusions as part 
of the graft at the time of transplantation, or 
delayed as DLI, have multiple effector cells that 
need to be considered in terms of different allo-
reactive effects.
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59.1.2  Naïve αβT Cell: Host Dendritic 
Cell (DC) Interaction as a Key 
Driver of Immune Response
Since in the context of HLA-matched transplan-
tation, most alloreactive αβT cells are present 
within the naïve repertoire of the donor, recipient- 
derived dendritic cells (DC) play an essential role 
in provoking the αβT cell immune response 
(Stenger et al. 2012). DC are key players in pro-
voking appropriate T cell activation, and because 
DC are derived from the hematopoietic system, 
an immune response of donor origin targeting 
DC from the recipient will likely result in an 
immune response against recipient hematopoi-
etic cells, including the malignant population, 
and therefore give rise to GVL.  The level of 
cross-reactivity against antigens broadly 
expressed on non-hematopoietic cells will deter-
mine the likelihood and severity of GVHD. DCs 
are present in the lympho-hematopoietic system 
but also with relatively high frequencies in the 
target tissues of GVHD. At the time of transplant, 
all DCs are of recipient origin. When activated by 
danger signals provoked by tissue damage and 
pathogens, DCs will present endogenous anti-
gens, as well as cross-present antigens derived 
from the non-hematopoietic tissues and patho-
gens. Therefore, in T-cell-replete HSCT, it is dif-
ficult to dissect the GVL and GVHD effects 
(Boelens et al. 2018; Admiraal et al. 2017).
Consequently, many current transplantation 
techniques deplete immune cells from the graft and 
administer DLIs at later time points as standard 
part of the transplantation regimen. Both a com-
plete immune depletion by selection of CD34-
positive stem cells (Pasquini et al. 2012) and partial 
depletion of alloreactive T-cells through PT-CY 
(Mielcarek et al. 2016) are used. This upfront T-cell 
depletion associates with a lower risk of GVHD 
and allows very early DLIs for the majority of 
patients (e.g., 100  days after HSCT) and an 
improved segregation of GVL and GVHD effects. 
More recent transplantation strategies better con-
sider the sophisticated variety of immune cells. 
These novel strategies utilize either a selective 
depletion of αβT cell (Locatelli et al. 2017) or naïve 
subsets (Bleakley et al. 2015) to abrogate GVHD, 
while maintaining early immune surveillance 
directed against infections as well as leukemia.
59.1.3  Diversity of Immune 
Repertoires and Potential 
Impact on Interventions
After HSCT, the αβ and γδTCR repertoire is 
reconstituted out of the graft of the donor, which 
contains in T-cell-replete transplantations 
between 5 × 107 and 1 × 109 T cells/kg (Czerw 
et al. 2016). Of the T cells, the γδT cells are the 
first to reach normal numbers, followed by the 
CD8+ αβT cells and finally the CD4+ αβT cells 
which do not reach normal levels within the first 
year after HSCT (Kanakry et  al. 2016). It is 
important to note that numerical reconstitution of 
the T cells does not mean that the diversity of the 
repertoire is already normalized, reflected by the 
clinical observations that patients are highly vul-
nerable to many infections for years after HSCT. 
(van Heijst et al. 2013; Ravens et al. 2018).
Factors that influence the T-cell repertoire 
reconstitution after HSCT include the source of 
the graft and occurrence of infectious challenges 
such as CMV and EBV, GVHD, and cellular 
interventions such as DLI. The repertoire of αβT 
cells after HSCT has been studied extensively in 
different HSCT settings. Six months after HSCT, 
the αβTCR repertoire is still very restricted when 
compared to that of healthy individuals. A cord 
blood graft leads to a greater diversity of the 
αβTCR repertoire at 6 and 12 months, compared 
to other graft sources (van Heijst et  al. 2013). 
Even 2–5 years after HSCT, the repertoire is still 
not as diverse as in healthy individuals (Kanakry 
et al. 2016; van Heijst et al. 2013). CMV reacti-
vation shapes the repertoire in such a way that a 
marked contraction of the diversity is observed 
(Kanakry et  al. 2016; van Heijst et  al. 2013; 
Suessmuth et al. 2015). GVHD has been associ-
ated with both an increased (van Heijst et  al. 
2013) and a decreased diversity (Yew et al. 2015). 
We favor the hypothesis that selective GVL reac-
tivity is associated with lower diversity, lower 
magnitude, and relatively tissue- specific recogni-
tion of hematopoiesis by alloreactive αβT cells 
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(van Bergen et al. 2017). Less is known about the 
diversity of the γδTCR repertoire after HSCT. The 
repertoire of the γδT cells seems to be established 
quite early, at 30–60  days after HSCT.  CMV 
reactivation promotes a massive expansion of a 
few γδT cell clonotypes (mainly belonging to the 
δ1 subset), which leads to a so-called repertoire 
focusing (Ravens et  al. 2018). Within this con-
text, it is reasonable to argue that the administra-
tion of a DLI might in the future depend not only 
on the type of the disease or timing but also on 
the size of the αβ and γδT cell repertoire observed 
at a given time point. 
59.2  Guidelines for Prophylactic 
and Preemptive DLI as Well 
as DLI After Relapse
59.2.1  General Considerations
Currently, neither the diversity of the TCR reper-
toire nor the infusion of subsets of lymphocytes is 
used to guide or fine-tune the intervention DLI in 
daily practice. To prevent relapse of the underlying 
disease, timing and dosing of non- manipulated DLI 
after HSCT can be used to relatively skew the 
immune response toward GVL reactivity, as tissue 
damage after transplantation is gradually repaired 
and the donors’ DCs steadily replace the recipients’ 
DCs within the first 6 months after HSCT. Therefore, 
the magnitude and diversity of the interplay between 
host and donor immune subsets will progressively 
diminish. This is evidenced by the clinical observa-
tion that when the interval between HSCT and the 
infusion of DLI increases, the total number of αβT 
cells that can be administered without induction of 
severe GVHD will increase from less than 105/kg 
after 3  months, to more than 106/kg at 6  months 
(Table 59.1) (Yun and Waller 2013). Main prerequi-
site at the time of DLI is therefore also the absence 
of tissue damage and inflammatory circumstances, 
thus a lack of GVHD and uncontrolled infections.
59.2.2  Timing, Dosing, 
and Frequency of DLI
The following recommendations refer to the infu-
sion of non-manipulated donor cells after no or 
in  vivo T-cell-depleted transplantation from 
matched sibling or unrelated donors in patients 
with acute leukemia or MDS, which is the most 
frequently studied scenario. Further aspects, which 
may modify these recommendations, are discussed 
below. With respect to the indication of DLI for 
prevention of overt hematological relapse, two 
situations are distinguished. Furthermore, DLIs 
can be given within the context for overt relapses.
59.2.2.1  Prophylactic DLI
A prophylactic DLI is applied in patients with a 
high-risk of relapse, but at a stage when there is 
no evidence of the underlying disease. Usually, 
prophylactic DLIs are given starting from day 
+90 or +100 after HSCT, provided that the patient 
is off IS and free of GVHD for about 1 month. 
CD3+ doses used for the first infusion depend on 
donor type and timing and vary between 1 × 105/
kg patient and 1  ×  106/kg (Table  59.1). In the 
absence of GvHD, most groups have given pro-
phylactic DLIs as single-shot intervention, but 
also repetitive DLIs are reported (Table  59.1; 
Tsirigotis et al. 2016; Jedlickova et al. 2016).
Table 59.1 Timing and dosing of prophylactic and preemptive DLIa
Timing Related Unrelated Haplo
Preemptive and prophylacticb 3 months 1–5 × 105/kg 1 × 105/kg
6 months 1 × 106/kg 1 × 106/kg 1 × 104/kg
Relapse in combination with chemotherapyc After chemotherapy 1 × 107/kg 1 × 107/kg
Level C evidence
aA DLI can be repeated at 1-log higher 6–8 weeks after the first DLI, when, e.g., MRD is still present and no GVHD is 
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59.2.2.2  Preemptive DLI
DLIs are administered preemptively, i.e., in case 
of persistent MRD or when the first signs of 
relapse are observed, like MRD positivity or a 
decreasing donor chimerism. For persisting MRD, 
either the same initial cell dosages as for prophy-
lactic DLI are used, followed by repetitive DLIs in 
4–12  weeks’ intervals, using an escalated dose 
schedule and increasing the cell dosages by five to 
tenfold at each infusion. Alternatively, five to ten-
fold higher initial cell doses are used in the pre-
emptive situation as compared to prophylaxis. A 
total of three to four DLIs may be administered, 
and subsequent infusions are mostly taken from 
the same apheresis as the first but are frozen in the 
previously planned dosages. Occurrence of GVHD 
after DLI will result in no further DLI administra-
tion. For reappearance of MRD or mixed chime-
rism, obviously timing of DLI depends on the 
occurrence of these circumstances.
59.2.2.3  Overt Relapses
For overt relapses a combination of DLI with che-
motherapy is mandatory (Schmid et al. 2012), and 
cell doses used in that situation are usually one 
order of magnitude higher than in the prophylactic 
or preemptive situation (1 × 107/kg). In particular 
in acute leukemia, DLI alone may not be the pre-
ferred strategy for treatment of relapse. Repetitive 
DLIs can be considered after overt relapses based, 
e.g., on MRD positivity 6–8 weeks after DLI.




Six weekly scheduled DLI with escalating doses 
until the first signs of GVHD as described above 
might no longer be necessary in the era of molec-
ular disease monitoring. A MRD-driven strategy 
with more time between DLIs (8–12  weeks) 
might still allow for control of the hematological 
malignancy while avoiding long-term side effects 
like chronic GVHD.  An alternative is the infu-
sion of donor αβT cells engineered with a suicide 
gene. The thymidine kinase (TK) suicide gene 
has received conditional approval by EMA 
(Chabannon et  al. 2018), and a novel safety 
switch (inducible caspase-9) characterized by 
lack of immunogenicity and rapid mechanism of 
action is under investigation (Zhou et al. 2014).
59.2.3.2  Impact of Underlying 
Disease
The different underlying diseases might require 
different doses, considering their sensitivity to a 
DLI-mediated GvL effect. The relapse workshop 
of the National Cancer Institute has proposed an 
estimate of the sensitivity of different diseases to 
DLI (Alyea et al. 2010). Accordingly, sensitivity 
is regarded as high for CML, myelofibrosis, and 
low-grade NHL; intermediate for AML, MDS, 
multiple myeloma, and Hodgkin’s disease; and 
low for ALL and DLBCL.
59.2.3.3  Donor Origin
Dosage of DLI can under certain circumstances 
relate to the origin of the donor (Table  59.1). 
There is no consensus as to whether the dose 
between an unrelated and a related donor needs 
to differ. Similarly, cells doses in the haploiden-
tical setting are unclear. More importantly and 
not well understood, but of greater impact, is 
most likely the processing of the DLI product 
with higher potency of freshly infused DLI when 
compared to frozen DLIs or DLIs used from the 
mobilized stem cell product due to different via-
bilities and compositions (Lemieux et al. 2016).
59.2.3.4  Combination with Other 
Drugs
DLIs are used in many diseases in combination 
with specific drugs targeting molecular  aberrations 
of the underlying malignancy and/or acting via 
immune-modulating activities. However, the early 
administration of LENA after transplantation has 
been associated with a high incidence of GVHD 
(Kneppers et al. 2011), indicating that doses of DLI 
can also critically depend on the co-administration 
of drugs. Combinations with interferon-α and 
GM-CSF have also been reported as successful 
intervention to enhance the GVL effect (Dickinson 
et  al. 2017). Other drugs currently explored are 
AZA, HDAC inhibitors (Bug et al. 2017), and Flt3-
J. H. Frederik Falkenburg et al.
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inhibiting TKI (Mathew et al. 2018), and dosage 
and timing of combined DLIs might be guided by 
the experience from prophylactic and preemptive 
DLIs but need to be carefully monitored.
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Cellular Therapy with Engineered  
T Cells, Efficacy and Side Effects
Attilio Bondanza, Chiara Bonini, Boris Fehse, 
and Michael Hudecek
60.1  Introduction
The cellular basis of cancer immune surveillance, 
already hypothesized in ancient times, was only 
demonstrated with the advent of HSCT. Indeed, 
the discovery of the nature of GVHD and its anti-
leukemic effects (Weiden et al. 1979) were fol-
lowed by the first successful attempts of adoptive 
immunotherapy using donor leukocytes (Kolb 
et al. 1990).
To address the significant GVHD risk associ-
ated with allogeneic T cells, several approaches 
of T-cell manipulation were developed and tested 
(Table 60.1). Some of these strategies rely on the 
genetic manipulation of T cells. First, suicide 
gene therapy approaches were established to pro-
mote GVL and immune reconstitution while con-
trolling GVHD.
More recently, strategies based on the genetic 
transfer of tumor-specific T-cell receptors (TCRs) 
or chimeric antigen receptors (CARs) were 
developed to improve antitumor efficiency of T 
cells. This chapter provides an overview of this 
vastly evolving area.
60.2  Suicide Gene Therapy
The transfer of a suicide gene into donor lympho-
cytes was designed and tested at preclinical and 
clinical level in the 1990s, with the aim of trans-
ferring the entire donor T-cell repertoire, inclu-
sive of cancer and infectious specificities, to 
transplanted patients, while enabling the selec-
tive elimination of the transferred lymphocytes in 
case of GVHD (Bonini et al. 1997). The first sui-
cide gene, and to date the most extensively tested 
in clinical trials, is thymidine kinase of herpes 
simplex virus (HSV-TK). HSV-TK expression 
confers selective sensitivity to the antiviral drug 
ganciclovir. Upon gene transfer, HSV-TK is sta-
bly expressed by donor T lymphocytes not inter-
fering with their functionality. However, when 
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exposed to ganciclovir, highly proliferating 
HSV-TK expressing T cells (TK-cells) will die in 
a dose-dependent manner. Thus, if ganciclovir is 
administered during GVHD to patients treated 
with TK-cells, activated, highly proliferating 
alloreactive TK-cells will be eliminated. The 
HSV-TK/ganciclovir suicide system proved 
highly effective in controlling GVHD in several 
transplant settings (Table 60.2), including haploi-
dentical HSCT (haplo-HSCT). After TCD haplo- 
HSCT, the infusion of TK-cells promoted broad 
and rapid immune reconstitution that, being asso-
ciated to GVHD control, has led to abrogation of 
late transplant-related mortality (Ciceri et  al. 
2009). Overall, clinical results obtained with 
TK-cells led to their conditional approval by 
EMA in 2016, thus representing the first geneti-
cally engineered medicinal product approved for 
Table 60.1 T-cell-based cellular therapy approaches to increase GVL/GVI while taming GVHD
Strategy Mechanism of action References
Infusions of pathogen (i.e., 
CMV, EBV)-specific T cells
Isolation and infusion of T cells specific for 
opportunistic pathogens, to control post 
transplant infectious morbidity and 
mortality
Riddell et al. (1992), Rooney et al. 
(1995), Koehne et al. (2003)
Infusions of T cells depleted 
of alloreactive specificities
In vitro activation of host-reactive T cells 
followed by their depletion, infusion of 
remaining cells with the aim of promoting 
immune reconstitution with a reduced GVHD 
risk
André-Schmutz et al. (2002), 
Hartwig et al. (2008), Mielke et al. 
(2008)
Infusions of regulatory T cells Isolation and/or expansion T-cell subsets with 
regulatory properties to promote immune 
reconstitution with a reduced GVHD risk
Groux et al. (1997), Chen et al. 
(2003), Trenado et al. (2004), 
Brunstein et al. (2011), Di Ianni 
et al. (2011), Bacchetta et al. (2014)
Infusion of T cells depleted of 
regulatory T cells
Infusion of T cells depleted of regulatory T 
cells to increase the antileukemic activity of 
DLI
Maury et al. (2010)
Infusions of leukemia- specific 
T cells
Isolation and infusion of T cells specific for 
leukemia-associated antigens to boost the 
GVL potency of DLI
Warren et al. (2010), Bornhauser 
et al. (2011), Chapuis et al. (2013), 
Comoli et al. (2017)
Infusion of alpha/beta 
depleted T cells
Infusion of a graft in vitro depleted of 
conventional alpha/beta T cells, thus enriched 
of gammadelta T cells, endowed with 
antitumor activity and a low GVHD potential
Lang et al. (2015), Airoldi et al 
(2015), Mashan et al. (2016)
Infusion naïve- depleted T 
cells
Infusion of donor T-cell subsets in vitro 
depleted of naïve cells, with the aim of 
promoting immune reconstitution with a 
reduced GVHD risk
Bleakley (2015)
Infusions of CIK Infusions of in vitro activated donor CIK 
cells to promote GVL and reduce the risk of 
GVHD
Introna (2007), Introna (2010)
Suicide gene therapy Donor lymphocytes are genetically 
engineered to express a suicide gene and then 
infused after HSCT to promote GVT and 
immune reconstitution while selectively 
controlling GVHD with the prodrug- 
mediated activation of the suicide gene
Bonini et al. (1997), Ciceri, Bonini 
et al (2009), Di Stasi et al. (2011), 
Zhan et al. (2013), Oliveira et al. 
(2015)
CAR/TCR T cells Lymphocytes are genetically engineered to 
express a chimeric antigen receptor (CAR) or 
a T-cell receptor (TCR) that confers to T cells 
specificity for an antigen expressed by cancer 
cells
Kochenderfer et al. (2010), Porter 
et al. (2011), Brentjens et al. (2013), 
Morgan et al. (2006), Robbins et al. 
(2011)
CIK-cytokine-activated killer
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cancer patients in Europe. Although when infused 
after haplo-HSCT TK-cells could be detected for 
more than 14 years (Oliveira et  al. 2015), their 
persistence might be limited when cells are 
infused to immunocompetent patients, due to the 
viral origin of HSV-TK and to its subsequent 
immunogenicity in humans.
Alternative suicide genes were designed and 
tested in clinical trials (Table 60.2). iCasp9, in par-
ticular, is an innovative suicide gene based on 
human components and thus with a reduced risk of 
immunogenicity that was recently proposed and 
successfully tested in clinical trials (Table  60.2) 
(Di Stasi et al. 2011; Zhou et al. 2014). Overall, 
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(pediatrics)




iCasp9/∆CD19l MDS, AML, 
ALL 
(pediatrics)
10 106–107 10h [5b] 4 (I–II) 4/4




iCasp9/∆CD19 ALL (adult) 1 1 1(I) 0
Total 140 79 (56%) 35 28/28 
(100%)
GCV ganciclovir, Ne not evaluable
aBonini et al. (1997), Ciceri et al. (2007), Onodera et al. (2008), Champlin et al. (1999), Munshi et al. (1997)
bClinical outcome is measured as clinical response of the malignant disease
cOne patient with GVHD achieved CR after GCV administration and immunosuppressive drugs
dTiberghien et al. (2001) and Fehse et al. (2004)
eWeissinger et al. (2011, 2014)
fOne patient with GVHD achieved CR after administration of GCV and steroids
gBonini et al. (2007), Ciceri, Bonini et al. (2009), and Lupo-Stanghellini (2017)
hClinical outcome is measured in terms of T-cell immune reconstitution (evaluated as more than 100 circulating CD3+ 
T lymphocytes/μL) and pathogen-specific immunocompetence
iFour patients with GVHD achieved CR after administration of GCV and short-course low-dose steroids; two patients 
with GVHD achieved CR after GCV administration and IS
jZhan et al. (2013)
kDi Stasi et al. (2011) and Zhou et al. (2014)
lT cells were genetically engineered and depleted of host-reactive specificities before infusion
mElshoury et al. (2017)
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more than half of the patients who had received 
suicide gene-expressing donor T cells experienced 
a clinical benefit in terms of immune reconstitu-
tion and GVL (Table 60.2). Of notice, all cases of 
GVHD were completely controlled by the suicide 
gene/prodrug systems (Table 60.2).
60.3  CAR-T Cells
60.3.1  CAR-T Cells, Clinical Efficacy
CARs are designer molecules comprised of sev-
eral components: an extracellular antigen- binding 
domain, usually the variable light and heavy 
chains of a MoAb (scFv); a spacer and trans-
membrane region that anchors the receptor on the 
T-cell surface and provides the reach and flexibil-
ity necessary to bind to the target epitope; and an 
intracellular signaling module, most commonly 
CD3 zeta and one or more costimulatory domains 
that mediate T-cell activation after antigen bind-
ing, resulting in selective tumor cell killing.
The most advanced clinical development is 
the use of CARs specific for the B-lineage marker 
CD19. Several groups have demonstrated that 
CD19 CAR-T cells are able to induce durable 
complete remissions in patients with chemother-
apy- and radiotherapy-refractory B-cell ALL, 
NHL, and CLL (Maude et  al. 2014; Park et  al. 
2018; Turtle et al. 2017).
With longer follow-up, resistance mechanisms 
to CD19 CAR-T-cell therapy have become appar-
ent, including the development of leukemia cell 
variants that lost their CD19 antigen expression, 
particularly in ALL.  Several mechanisms may 
contribute to the development of this phenotype 
including lymphoid-to-myeloid transdifferentia-
tion, selection of pre-existing CD19-low/CD19- 
negative leukemia clones, and emergence of 
clones that lost the specific epitope targeted by 
the CD19-CAR due to alternative splicing 
(Gardner et al. 2016; Sotillo et al. 2015; Ruella 
and June 2016). In ALL, CD19-low/CD19- 
negative leukemia cells may still express CD20, 
CD22, and/or CD123 that are being pursued as 
rescue antigens. A recent study highlighted the 
potential to re-induce remissions in patients that 
had relapsed with CD19-low/CD19-negative leu-
kemia and subsequently received CD22 CAR-T 
cells (Fry et al. 2018). Unfortunately, CD22 itself 
is prone to internalization and downregulation, 
and indeed a significant proportion of patients 
experienced successive CD22-low/CD22- 
negative leukemia relapse. At present, combina-
torial targeting of CD19 with either CD20, CD22, 
or CD123 is being explored, either through bi- 
specific CAR constructs with two scFvs in cis or 
through co-expression of two CAR constructs in 
the same T cells (Zah et al. 2016).
Clinical results obtained with CAR-T cells 
(Table  60.3) led to recent FDA approval of two 
CD19 CAR-T-cell products for the treatment of 
ALL and NHL. Both products are manufactured 
by viral gene transfer and made headlines due to 
their considerable market price and the complex 
logistics behind this treatment. This involves har-
vesting the patient’s T cells at a leukapheresis cen-
ter, shipping to a centralized manufacturing facility 
to perform CAR gene transfer and T-cell expan-
sion and return shipment of the cryopreserved cell 
product. There is a recent increase in the use of 
exportable manufacturing devices that are antici-
pated to provide on-site, point-of-care CAR-T cell 
manufacture to reduce costs and wait-time.
Another clinical proof-of-concept for CAR-T- 
cell therapy has been obtained in MM. The lead 
antigen for CAR-T cells in multiple myeloma is 
B-cell maturation antigen (BCMA). A recent clin-
ical trial with BCMA-specific CAR-T cells has 
highlighted their therapeutic potential with sev-
eral PRs and CRs (Ali et al. 2016), and additional 
data from ongoing trials continue to emerge. Also, 
with BCMA, antigen downregulation and the 
emergence of myeloma cell variants with antigen 
loss were described, underscoring the need to 
explore additional target antigens, e.g., SLAMF7 
(Gogishvili et al. 2017), CD44v6 (Casucci et al. 
2013), and CD38 (Mihara et al. 2009).
60.3.2  Side Effects and Their 
Management
Results from pioneering clinical studies investi-
gating CAR-T cells in patients with hematologi-
A. Bondanza et al.
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cal cancers highlight the frequent occurrence of 
severe adverse reactions, which in some cases 
were fatal. The most obvious toxicity by CAR-T 
cells is the elimination of lineage cells expressing 
the target antigen of choice. For example, pro-
found and, in some cases, long-lasting B-cell 
aplasia was observed after the infusion of CD19 
CAR-T cells in patients with ALL, NHL, and 
CLL (Maude et al. 2014; Park et al. 2018; Turtle 
et al. 2017). By analogy, BCMA CAR-T cells are 
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expected to induce plasma cell ablation in MM 
patients. The depletion of antibody-producing 
cells, or their precursors, in turn causes 
hypogammaglobulinemia, requiring constant 
supplementation with immunoglobulins.
Besides these expected on-target/off-tumor 
effects, a new class of on-target/on-tumor adverse 
reactions is represented by the cytokine release 
syndrome (CRS) and by neurotoxicity. CRS is 
initiated by CAR-T cell recognition of tumor 
cells, igniting the release of massive amounts of 
inflammatory cytokines, possibly by recruiting 
cells of the innate immunity. A master cytokine of 
the CRS is IL-6, as demonstrated by prompt and 
often complete response to the anti-IL-6 receptor 
monoclonal antibody tocilizumab. CRS symp-
toms range from high fever, headache, and myal-
gia to life-threatening cardiocirculatory and renal 
insufficiency. Clinical data reported so far utilize 
three slightly different systems for severity grad-
ing, which makes it difficult to draw meaningful 
comparisons in CRS liability between CAR-T-
cell trials (Table 60.4). Nonetheless, there is gen-
eralized consensus on the fact that severe CRS is 
more frequent in ALL compared to NHL and that 
high tumor burden is an important risk factor.
Differently from CRS, the pathophysiology of 
neurotoxicity by CAR-T cells remains an 
uncharted territory and decisively worthy of fur-
ther research, given its highly dismal prognosis, 
as demonstrated by several cases of lethal cerebral 
edema. Initially thought to be caused by tumor 
recognition by CAR-T cells within the brain, neu-
rotoxicity is now recognized to be independent 
from leukemic localization to the CNS. Moreover, 
unresponsiveness to tocilizumab suggests that 
excessive IL-6 signaling may not be sufficient to 
explain neurotoxicity and that additional pharma-
cological measures should be investigated.
60.4  TCR Gene Transfer 
and Future Perspectives
In contrast to CARs that only bind surface mole-
cules, TCRs recognize small pieces (peptides) 
derived from any cellular protein and presented 
by MHC molecules. Since the vast majority of 
tumor-specific/associated antigens are expressed 
intracellularly, they will only be addressable by 
TCRs, but not CARs. Moreover, therapeutically 
relevant cancer-driver mutations in most cases 
happen in intracellular proteins (e.g., signal 
transducers).
At the same time, the advantage of TCRs rep-
resents a major hurdle for broad clinical applica-
tion: Any transgenic TCR only functions in the 
context of one specific HLA complex. Thus, in 
order to offer TCR-T-cell therapy to virtually all 
candidate patients, for each antigen a whole set 
of active TCRs will have to be established for dif-
ferent HLA molecules.
Table 60.4 CRS severity scoring systems
Penn scale CTCAE Lee (2014)
Grade 1 Mild reaction treated with antipyretics 
and/or antiemetics
Mild reaction, no treatment 
needed
 –  Non-life-threatening reaction 
responsive to symptomatic 
treatment
Grade 2 Moderate reaction requiring 
hospitalization and IV therapy (no fluid 
resuscitation)
Moderate reaction 
responsive to symptomatic 
treatment within 24 h
 –  Moderate reaction requiring 
oxygen <40%, fluid 
resuscitation, or low-dose 
pressors
 –  Any G2 organ toxicity
Grade 3 Severe reaction requiring high-flow 
oxygen or noninvasive lung ventilation, 




 –  Severe reaction requiring 
oxygen >40%, high-dose 
pressors
 –  Any G3 organ toxicity
Grade 4 Life-threatening reaction requiring 
high-dose pressors and/or mechanical 
ventilation
Life-threatening reaction, 
pressor, or ventilator 
requirement
 –  Life-threatening reaction 
requiring mechanical 
ventilation
 –  Any G4 organ toxicity
A. Bondanza et al.
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The first TCR gene therapies were applied to 
melanoma patients (MART-1 antigen), but mean-
while many cancers have been addressed. Based 
on their almost complete absence in adult tissues, 
cancer/testis antigens (MAGE, NY-ESO1) repre-
sent particularly promising targets. Many studies 
showed significant antitumor activity, but on- 
target as well as off-target activities were associ-
ated with severe side effects, including mortality 
(Morris and Stauss 2016).
Genome editing has been proposed to improve 
efficacy and decrease side effects of TCR gene 
therapy. Editing might be used to knock out the 
endogenous TCR to increasing expression of the 
transgenic one and decreasing the mispairing risk 
between endogenous and transgenic TCR chains 
(potentially leading to autoreactive T cells) 
(Provasi et al. 2012). Moreover, targeted integra-
tion in the TCR locus can improve long-term 
expression of transgenic TCRs (Eyquem et  al. 
2017).
In conclusion, T-cell therapies have become a 
promising novel anticancer weapon. Their broad 
application will require (1) identification of addi-
tional targets, (2) availability of TCRs against 
established targets for many HLA molecules, and 
(3) improved methods for large-scale GMP pro-
duction. All these points will become particularly 
relevant in concepts addressing multiple tumor 
neoantigens to decrease the likelihood of escape 
(Tran et al. 2017).
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Key Points
• The cellular basis of cancer immune 
surveillance was demonstrated with the 
discovery of the nature of GVHD and its 
antileukemic effects.
• This observation was followed by the 
first successful attempts of adoptive 
immunotherapy using DLI to promote 
GVL.
• Several approaches of T-cell manipula-
tion have been developed and tested to 
reduce the GVHD risk associated with 
allogeneic T cells. These strategies rely 
on the genetic manipulation of T cells or 
the use of suicide gene therapy.
• More recently, strategies based on the 
genetic transfer of tumor-specific T-cell 
receptors (TCRs) or chimeric antigen 
receptors (CARs) were developed to 
improve antitumor efficiency of T cells.
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It is widely accepted that the curative potential 
of allo-HSCT for malignant diseases relies on 
the transfer of healthy donor immune cells capa-
ble of recognizing transplantation antigens on 
residual tumor cells (graft versus leukemia, 
GvL) and eliminating them. However, as exten-
sively documented in solid cancers, if tumor 
eradication is incomplete, the prolonged immune 
pressure selectively allows immune-resistant 
subclones to survive (Schreiber et  al. 2011). 
There is growing evidence that such an “immu-
noediting” also accounts for relapse after 
HSCT.  Malignant cells evade GvL either by 
reducing their immunogenicity and conveying 
inhibitory signals to the donor immune system 
(intrinsic evasion) or through the microenviron-
ment (extrinsic evasion).
61.2  Mechanisms of Immune 
Evasion
61.2.1  Mechanisms Intrinsic 
to the Malignant Clone
A remarkable example of tumor-intrinsic mecha-
nism of immune evasion is the genomic loss of 
the mismatched HLA haplotype frequently docu-
mented in leukemia relapses after T-cell-replete 
HSCT from HLA haploidentical family donors 
(Vago et al. 2009). In this setting, donor T cells 
mount a vigorous alloreactive response against 
the incompatible HLA molecules, and this reac-
tion is not only responsible for a significant risk 
of severe GvHD but also a major contributor to 
the GvL effect. Yet, this strong and selective 
immune pressure is easily overturned by tumor 
cells which, by losing the allogeneic HLA haplo-
type, find a means to avoid recognition and re- 
emerge. “HLA-loss” variants account for up to 
one third of relapses after HLA-haplo-HSCT 
(Crucitti et  al. 2015) and have been described 
also in the setting of HSCT from partially HLA- 
incompatible URD, although their actual fre-
quency in this setting is yet to be determined 
(Waterhouse et al. 2011). The documentation of 
HLA loss at relapse has an important clinical 
impact, because IS withdrawal or administration 
of DLI would be much less effective against these 
diseases variants (Tsirigotis et al. 2016).
Another evidence that supports “leukemia 
immunoediting” is the occurrence of isolated 
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extramedullary relapses after allo-HSCT or 
even more frequently after DLI. These relapses 
may occur, but not necessarily, in immunologi-
cal sanctuaries, including the CNS. Although to 
date the biological drivers of extramedullary 
relapses remain unknown, some studies have 
suggested a link with immune-related factors 
such as chronic GvHD (Solh et al. 2012; Harris 
et al. 2013).
A number of studies have highlighted a fur-
ther strategy by which hematological cancers can 
evade immune control, whereby they express 
large numbers of molecules capable of dampen-
ing immune responses such as programmed 
death-ligand (PD-L)1. The expression of these 
inhibitory ligands significantly increases at 
relapses after allo-HSCT. This observation pro-
vides a rationale for the use of “checkpoint block-
ade” to restore immune control at relapse. Initial 
experience in patients with relapsed lymphoma 
or extramedullary leukemia with anti-PD1 and 
anti-cytotoxic T-lymphocyte-associated antigen 
(CTLA)-4 MOAb is very promising (Davids 
et al. 2016; Herbaux et al. 2017). However, the 
risks of triggering life-threatening GvHD remain 
to be quantified.
61.2.2  Mechanisms Extrinsic 
to the Leukemic Cells
The alternative, but not mutually exclusive, strat-
egy by which malignant cells enact evasion from 
immune cell recognition relies on hijacking the 
stem cell niches in which normal HSC self-renew 
and differentiate. By doing this, malignant cells 
create a tumor microenvironment (TME) that has 
profound consequences on disease progression 
and relapse. The initial studies conducted on 
solid tumors have shown that the TME consists 
of two major cellular populations that alone or in 
combination drive resistance to conventional 
therapies and suppress antitumor immune 
responses. The first group comprises a diverse 
and heterogeneous group of myeloid-derived 
cells which, according to a yet unresolved debate 
on their nomenclature, can be generally classified 
as tumor-associated monocytes/macrophages 
(TAM) and myeloid-derived suppressor cells 
(MDSC) (Bronte et al. 2016). The IS activity of 
these cells is mediated by factors that include 
nitric oxide synthase-2 (NOS-2), arginase-1, 
heme oxygenase-1 (HO-1), interleukin (IL)-10, 
transforming growth factor (TGF)-β, and prosta-
glandin E2 (PGE2). All these molecules also 
favor the recruitment of regulatory T cell (Tregs) 
that eventually contribute to the inhibition of 
antitumor CD8+ T-cell and natural killer cell 
effector function (Ostuni et al. 2015). Although 
most of these mechanisms have been initially 
demonstrated in solid tumors, there is consistent 
evidence that they are also involved in hemato-
logical malignancies. High-risk AML can actu-
ally behave as MDSC by upregulating NOS and 
suppressing T-cell responses (Mussai et al. 2013). 
The presence of MDSC in AML has later been 
confirmed and also identified in multiple 
myeloma whereby they protect malignant cells 
through MUC1 oncoprotein (Bar-Natan et  al. 
2017; Pyzer et al. 2017).
The second cellular group consists of an equally 
heterogeneous population of mesenchymal origin, 
variously referred to as mesenchymal stromal cells 
(MSC) or cancer-associated fibroblasts (CAF) 
(Raffaghello and Dazzi 2015). Regardless of their 
developmental heterogeneity, they all play a simi-
lar role by protecting the malignant cells from 
cytotoxic agents and immune responses. In the 
bone marrow, MSC protect CML and AML cells 
from imatinib and Ara-C via the CXCR4-CXCL12 
axis (Vianello et al. 2010).
Much information has been provided about the 
IS activity of MSC that is exerted in a non- antigen- 
specific fashion (Jones et  al. 2007). One of the 
primary direct mechanisms responsible for this 
involves the expression of indoleamine 2-3 dioxy-
genase-1 (IDO-1), which consumes the essential 
amino acid tryptophan. Additional IS mechanisms 
include the release of suppressive factors such as 
TGF-β1, hepatocyte growth factor, PGE2, soluble 
human leukocyte antigen G, and TNF-α stimu-
lated gene 6 protein (TSG-6). However, more 
recent data have highlighted the important contri-
bution of tissue-resident  monocytes/macrophages 
in delivering a more sustainable IS effect (Cheung 
and Dazzi 2018).
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Finally, the role of Tregs in generating immune 
resistance has been much discussed. While there 
is plenty of data indicating how these cells exert 
a very negative impact on the outcome of solid 
tumors, data in preclinical models of allogeneic 
HSCT have suggested that Tregs may selectively 
inhibit GvHD without compromising GvL 
(Edinger et  al. 2003). In contrast, clinical data 
suggest to consider Treg levels post transplant 
with caution (Nadal et al. 2007).
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Key Points
• Leukemia can counteract the benefi-
cial graft-versus-leukemia effects post 
transplant.
• This is effected either by changes in 
the tumor cells which make them 
evade immune recognition or by 
instructing different components of the 
microenvironment to deliver in situ 
immunosuppression.
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Regulatory Aspects of ATMP 
Versus Minimally Manipulated 
Immune Cells
Eoin McGrath and Christian Chabannon
Under current European regulations, hematopoi-
etic cellular therapies fall under two categories: 
stem cell transplants and advanced therapy 
medicinal products (ATMPs). Routinely admin-
istered auto- and allo-HSCT—including subse-
quent peripheral blood allogeneic mononuclear 
cells (DLI)—undergo non-substantial manipula-
tions following cell procurement and before 
being administered to the recipient.
Cell processing is performed in facilities 
termed tissue establishments (TEs) under the EU 
Tissues and Cells Directive (see https://ec.europa.
eu/health/blood_tissues_organs/tissues_en. 
Accessed 20 Feb 2018), and these are authorized 
by national and/or regional competent authorities 
(CA). TEs usually operate on a relatively small 
scale, serving the clinical program(s) in their 
immediate vicinity although some national or 
regional services may support a more extensive 
network of clinical programs. The combination 
of a clinical department(s) with a collection and a 
processing facility represents the core structure 
for a transplant program that applies for the 
JACIE accreditation (see Chap. 5). Such an orga-
nization leaves room for significant procedural 
and organizational variations, many driven by 
local or national factors, despite all attempts from 
the various professional associations to harmo-
nize practices through surveys, the publication of 
guidelines, and regularly revised standards for 
these therapies, e.g., FACT-JACIE International 
Standards for Hematopoietic Cellular Therapies 
(see www.jacie.org. Accessed 19 Feb 2018).
ATMPs represent a new category of medici-
nal products defined in EU Regulation 1394/2007 
(see http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2007:324:0121:0137:e
n:PDF. Accessed 20 Feb 2018). ATMPs—known 
in the USA as human cells, tissues, and cellular- 
and tissue-based products (HCT/Ps) regulated 
under Section 351 of the PHS Act and/or the 
FD&C Act (see https://www.fda.gov/biologics-
bloodvaccines/tissuetissueproducts/regulation-
oftissues/ucm150485.htm. Accessed 21 Feb 
2018)—are subdivided in four categories, of 
which two are relevant in the context of hemato-
poietic cellular therapies: somatic cell therapy 
medicinal products (SCTMP) and gene therapy 
medicinal products (GTMP). Examples of 
SCTMP include ex vivo expanded autologous or 
allogeneic stem cells (de Lima et  al. 2012; 
Delaney et  al. 2010), mesenchymal stem cells 
(Le Blanc et al. 2008), and allogeneic T lympho-
cytes depleted of alloreactive T cells (Andre- 
Schmutz et  al. 2002). Examples of GTMP 
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include allogeneic T cells engineered to express 
a suicide gene (Ciceri et al. 2009), autologous or 
allogeneic CAR-T cells (Schuster et  al. 2017; 
Neelapu et  al. 2017), and autologous CD34+ 
cells genetically engineered to express a mini-
globin gene and designed to treat inherited 
β-globin disorders (Cavazzana-Calvo et al. 2010; 
Ribeil et al. 2017).
The regulation was designed in part to foster 
the competitiveness of European pharmaceutical 
companies in this emerging field, but the number 
of ATMPs that have received a centralized mar-
keting authorization remains relatively low and 
with poor overall commercial success so far. In 
the HSCT field, it was not until 2015 that an 
ATMP of interest reached the market with autho-
rization given for Zalmoxis® (allogeneic T cells 
engineered to express a suicide gene). Production, 
distribution, and administration of ATMPs imply 
a totally different organization than that used for 
HSCT, with manufacturing at a central facility in 
compliance with good manufacturing practices 
(GMP) (Wang and Rivière 2016, 2017), a version 
of which was recently released by the European 
Medicines Agency (EMA) to specifically deal 
with manufacturing of ATMPs (see https://
ec.europa.eu/health/sites/health/files/files/
eudralex/vol-4/2017_11_22_guidelines_gmp_
for_atmps.pdf. Accessed 19 Feb 2018). Since a 
majority of the ATMPs that progress to authori-
zation or at least to clinical trials are manufac-
tured from autologous mononuclear cells, starting 
material is currently procured by hospital- or 
blood bank-operated apheresis facilities creating 
a peculiar situation in which a product starts 
under one regulation—Tissues and Cells 
Directive—before passing to another, ATMP 
Regulation, and where a hospital acts as a service 
provider to industry, an interaction that requires 
further definition of the respective responsibili-
ties and liabilities.
Publication of Regulation 1394/2007 created 
a situation in which some cell- or tissue-based 
therapeutic products that were previously pre-
pared and delivered through an organization sim-
ilar to that for cell transplants were classified as 
ATMPs. This had a limited impact in the field of 
hematopoietic cellular therapies, although some 
cell-based products such as allogeneic T cells 
with specific anti-CMV activity engineered 
through the gamma-catch technology 
(Feuchtinger et al. 2010) were affected. In recog-
nizing that many potential ATMP were used for 
limited numbers of patients and with no commer-
cial motivation, Regulation 1394/2007 created 
the so-called hospital exemption (HE) under 
Article 28 exempting from authorization require-
ments those ATMPs manufactured in hospitals, 
universities, or start-up companies where the 
medicine is prescribed for individual patients 
under the care of a medical practitioner. This 
manufacture should occur on a non-routine basis 
according to specific quality standards (GMP) 
(Vives et al. 2015), and the ATMP should be used 
in a hospital and only within the same member 
state. National authorities oversee the approval of 
HE products which has resulted in significant 
variations between member states in how it is 
applied and which has led to criticism from both 
industry and academia that it is unclear and 
inconsistent.
Access to ATMPs including cellular therapies 
is likely to be a particular challenge for patients, 
healthcare professionals, and national health 
systems due to their expected high costs. Even 
access to decades-old HSCT remains strongly 
associated with higher-income countries 
(Gratwohl et  al. 2015). One potential effect of 
limited access could be the so-called stem cell 
tourism whereby patients with the means travel 
to centers outside their own countries for care 
and who may be vulnerable to false promises or 
may not have access to all of the information 
needed to make this important decision. The 
International Society for Cellular Therapy 
(ISCT) leads the publication of patient advice 
and other documentation on this phenomenon 
(see http://www.celltherapysociety.org/page/
UCT. Accessed 21 Feb 2018).
Academic facilities including stem cell trans-
plant practitioners at large should strive to remain 
active players in the development of ATMPs. 
Academia remains very active in the early phases 
of clinical trials designed to evaluate innovative 
SCTMP and GTMP as potential complements, 
substitutes, or bridges to historical forms of 
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hematopoietic cell transplants (Pearce et  al. 
2014). One recent study calculated that only 20% 
of CAR T cell trials are sponsored by pharmaceu-
tical industry (Hartmann et al. 2017). Many pub-
lic institutions have invested significant resources 
to upgrade their processing facilities to GMP- 
compliant levels thus allowing for small-scale 
manufacturing of experimental medicinal prod-
ucts to support phase I and possibly phase II stud-
ies, often with the hope that industry will take 
over in case that promising results warrant fur-
ther development (de Wilde et  al. 2016a). 
Furthermore, academia has to become a proac-
tive stakeholder in the regulatory area by engag-
ing with the authorities, sharing their know-how, 
and voicing their opinion (de Wilde et al. 2016b).
The field is moving at a fast pace. So far, there 
has been proof of concept that tissue-based or 
cell-based medicinal products can be manufac-
tured by a “conventional” pharmaceutical com-
pany (Locke et al. 2017), although with continued 
reliance on critical contributions from academic 
facilities, e.g., basic science and provision of 
starting materials. Some of these innovative 
medicinal products have remarkable clinical effi-
cacy for severe or debilitating diseases although 
sometimes at the expense of equally remarkable 
toxicity. However, a commercial ATMP “hit” is 
still to emerge which could explain why the 
CAR-T cell field is being highly scrutinized by 
clinicians, regulators, and industry after the first 
two marketing authorizations for CAR-T cell 
therapies were granted by FDA in the USA in 
2017 and by EMA in the EU in August 2018. 
These developments carry many regulatory and 
operational uncertainties including the very sus-
tainability of how academic facilities currently 
deliver HSCT, but availability of this new cate-
gory of innovative medicinal products offers new 
hopes to patients. Their therapeutic pathway is 
likely to become increasingly complex 
(Chabannon et  al. 2015) and will require long- 
term follow-up for evidence of sustained clinical 
efficacy and detection of late adverse effects (see 
http://www.ema.europa.eu/ema/index.jsp?curl=p
ages%2Fregulation%2Fgeneral%2Fgeneral_
c o n t e n t _ 0 0 0 6 5 8 . j s p & m i d = W C 0 b 0
1ac0580961211). Academia through continental 
registries such as EBMT will continue to play a 
key role with data and know-how that will be 
very useful not just for researchers but also for 
industry, healthcare regulators, and payers.
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Key Points
• In this chapter, we review the fast- 
evolving regulatory framework that leads 
to the coexistence of two categories of 
hematopoietic cell-based therapeutics.
• Innovative and industry-manufactured 
somatic cell therapy or gene therapy 
medicinal products are now entering the 
field at an accelerating pace and will 
complete or compete with traditional 
HSCT practices in the near future.
• We describe the organizational conse-
quences for academic facilities of this his-
torical shift that brings new opportunities 
to patients and practitioners in the field.
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63.1  Autologous HSCT
63.1.1  Introduction
Toxicity and mortality associated with auto- 
HSCT have been reduced, and outpatient paren-
teral antimicrobial treatment has been proven 
feasible and safe, thanks to modern CVC and 
infusion devices. These advances have led to the 
development of outpatient auto-HSCT programs, 
and several studies have demonstrated their feasi-
bility and safety.
There are various reasons for transferring the 
support of the neutropenic phase of auto-HSCT 
to the ambulatory setting, including patient pref-
erence, reduced exposure to hospital microor-
ganisms, better use of hospital resources, and 
cost-saving issues (Meisenberg et  al. 1997). In 
this model, however, patients experience time- 
consuming daily travel to the outpatient clinic 
for blood tests and physician checkups. “Hospital 
at home” is an alternative, designed to reduce 
hospital outpatient admissions by providing hos-
pital equivalent care to patients in the home set-
ting (Westermann et al. 1999; Fernández Avilés 
et al. 2006).
63.1.2  Ambulatory Auto-HSCT 
Models
Complete outpatient program (Holbro et al. 2013)
Conditioning regimen, 
HPC and management of 
the aplastic phase
Outpatient clinics
Delayed admission (Anastasia et al. 2009)
Conditioning regimen and 
HPC infusion
Inpatient
Management of the 
aplastic phase
Early discharge (+1) and 
readmission (+5)
Mixed inpatient-outpatient (Morabito et al. 2002)
Conditioning regimen Outpatient clinics
HPC infusion Inpatient
Management of the 
aplastic phase
Outpatient clinics
Early discharge outpatient (Martino et al. 2014)
Conditioning regimen and 
HPC infusion
Inpatient
Management of the 
aplastic phase
Outpatient clinics
Early discharge at home (Fernández Avilés et al. 2006)
Conditioning regimen and 
HPC infusion
Inpatient
Management of the 
aplastic phase
At home
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63.1.3  Inclusion Criteria 
for Ambulatory Auto-HSCT
Patient  – Age ≤65 years
 – ECOG ≤2
 –  Normal cardiac, lung, liver, and renal 
function
 –  Recent documented infection with a 
proven secondary prophylaxis
 –  Absence of refractoriness to platelet 
transfusion
 – Signed written informed consent
Transplant 
Center
 –  Outpatient clinics available 24 h per day 
or bed reserved in the transplant unit
 –  Dedicated phone line 24h × 365 days to 
allow patients or their caregivers to 
contact an expert physician of the 
transplant team
Disease  – CR or PR before the auto-HSCT
 – No symptomatic advanced disease
Caregiver Availability of a suitable caregiver 24 h 
per day, 7 days a week
Home  – Clean house
 –  Travel time from home to the hospital 
less than 60 min at rush hours
63.1.4  General Recommendations 
for At-Home Auto-HSCT
Dose of CD34+ cells, use of G-CSF after HPC 
infusion, primary antimicrobial prophylaxis, and 
supportive care (hydration, management of eme-
sis and metabolic disorders, analgesic therapy, 
and transfusion of blood products) should not dif-
fer from that recommended for conventional 
auto-HSCT. All these treatments can routinely be 
performed at home or in outpatient clinic.
63.1.5  Most Frequent Reasons 
for Readmission (Ordered by 
Frequency)
Persistent fever >38 °C without identified infec-
tious focus
Severe oral mucositis or gastrointestinal toxic-
ity (WHO grade III or IV) with insufficient liquid 
intake
Severe sepsis with organic failure
Request of the patient (psychological distress) 
or loss of caregiver support
63.1.6  Treatment of Fever 
in At-Home Setting
If fever occurs, the patient should be evaluated 
quickly by an expert hematologist on call. The use 
of empiric antibacterial treatment should follow 
guidelines/recommendations for patients with 
hematologic malignancies and neutropenic fever. 
IV antibiotics should be preferred and chosen in 
the light of clinical and laboratory findings. After 
at least 6 h monitoring, hemodynamically stable 
patients without relevant clinical problems may 
be followed at home. Table 63.1 shows the differ-
ent empiric antibiotic therapy that could be used 
at home.
63.1.7  Incidence of Readmission 
in Outpatient and At-Home 
Auto-HSCT
The incidence of readmissions is closely related 
to the experience of the group of professionals in 
outpatient or at-home management of complica-
tions and by the support infrastructure available 
in the hospital.
Table 63.1 Empirical antibiotic therapy
Patients not receiving prophylaxis with quinolones
Levofloxacin (PO or IV)
Moxifloxacin PO
Ciprofloxacin PO associated or not to amoxicillin/
clavulanate
Ciprofloxacin PO associated or not to linezolid PO
Patients receiving prophylaxis with quinolones
IV ceftriaxone or piperacillin/tazobactama or 
meropenemb associated to teicoplanin IVc if intense 
oral mucositis
If there is a high suspicion of CVC infection, add 
teicoplanin and an anti-GNB such as amikacin IV and 
evaluate the CVC withdrawal
If allergic to beta-lactam: quinolones PO/IV associated 
with teicoplanin IV and amikacin IV
aStable at room temperature so it can be administered at 
home by electronic intermittent infusion pump
bAccurate refrigeration to achieve adequate stability for 
home administration
cThe first option at home would be teicoplanin once daily 
instead of vancomycin IV (twice a day). Other alternatives 
rarely necessary in the context of auto-HSCT are dapto-
mycin IV or linezolid PO
F. Fernandez-Avilés and G. Gutiérrez-García
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In patients with MM, usually conditioned 
with MEL, the lowest readmission rates have 
been reported (between 10 and 20%) due to the 
low organic toxicity (Martino et al. 2016). They 
are clearly the best option when considering 
starting an outpatient or at-home auto-HSCT 
program.
In patients with NHL or HL usually condi-
tioned with a more toxic regime (BEAM or 
BEAC), there is a significantly higher readmis-
sion rate, between 30 and 90%, according to 
the series (Faucher et  al. 2012; Scortechini 
et al. 2014).
In the hospital clinic at-home auto-HSCT 
experience, the low rate of febrile neutropenia is 
achieved, thanks to the intensification of antibi-
otic prophylaxis (ceftriaxone in MM and piper-
acillin/tazobactam in NHL and LH patients), and 
the successful control of fever at home resulted in 
an overall readmission rate significantly lower 
(8.5%) in a series of 325 patients.
63.1.8  Quality of Life
The data published are limited and contradictory. 
Thus, (Summers et al. 2000) reported signifi-
cantly higher scores for emotional well-being 
and global QOL in outpatients, while (Martino et 
al. 2018) indicated that the outpatient model nei-
ther improves nor impairs global patient QOL on 
the first 30 days after auto-HSCT.  In this sense 
(Schulmeister et al. 2005) reported that the QOL 
decreased immediately post treatment but then 
increased to above pretreatment levels by 
6  months. A good clinical outcome following 
auto-HSCT was associated with better QOL and 
greater satisfaction with care.
63.1.9  Cost Data
The study of “real” costs of these ambulatory/
domiciliary auto-HSCT programs is still to be 
carried out. In the absence of well-designed stud-
ies aimed at evaluating the “real” savings achieved 
with outpatient/at-home auto-HSCT programs, 
some authors cite direct savings between 10% and 
50% (Meisenberg et  al. 1998; Fernández Avilés 
et al. 2006; Holbro et al. 2013), especially influ-
enced by the release of hospital beds and low 
readmission rates.
63.2  Allogeneic HSCT
63.2.1  Introduction
The consolidation of ambulatory auto-HSCT 
modalities as a safe and potentially cost-saving 
procedure and the introduction of NMA and 
RIC conditioning chemotherapies minimizing 
toxicity have allowed the development of allo-
HSCT ambulatory programs. Indeed, the main 
relevant results with this type of modality have 
shown a safe profile in terms of lower rate of 
infection and GVHD improving QOL, condi-
tions that should expand the development of 
ambulatory modalities into the allo-HSCT set-
ting (Svahn et  al. 2002). However, after two 
decades of the first ambulatory allo-HSCT pro-
gram, the experience with this modality is lim-
ited to few BMT groups.
63.2.2  Ambulatory Allo-HSCT 
Models
Complete outpatient program (McDiarmid et al. 2010)




Management of the aplastic phase
Mixed inpatient-outpatient (Solomon et al. 2010)
Conditioning regimen Outpatient clinic
HPC infusion Inpatient
Management of the aplastic phase Outpatient clinic
Early discharge at home (Ringdén et al. 2018)
Conditioning regimen and HPC 
infusion
Inpatient
Management of the aplastic phase At home
63.2.3  Inclusion Criteria for At-Home 
Allo-HSCT Patients
Inclusion criteria for at-home allo-HSCT 




63.2.4  General Recommendations 
for At-Home Allo-HSCT
Apply whole hints described for auto- 
HSCT. Moreover, strictly frequent dosage of IS 
(2–3 times per week) is recommended. 
Monitoring of CMV and Aspergillus should not 
differ from that recommended for conventional 
allo-HSCT. Primary prophylaxis for Aspergillus 
is not established but is strongly suggested.
63.2.5  Which Readmission Criteria?
Which readmission criteria? Apply similar con-
ditions for ambulatory auto-HSCT plus evidence 
of GVHD grades II–IV.
63.2.6  Treatment of Fever 
in At-Home Setting
Treatment of fever in at-home setting: See at- 
home auto-HSCT.
63.2.7  Incidence of Readmission 
in Outpatient and At-Home 
Allo-HSCT
Readmission rate is high (50–80%, according to 
the series) mainly due to organ toxicity associ-
ated with the preparative regimen in MAC with 
TBI and use of MTX or CY-PT such as GVHD 
prophylaxis.
The incidence of infection rate is lower than 
inpatient modality (15–30%, according to the 
series). Particularly, the incidence of Aspergillus 
or other mold infections was low (0–7%, accord-
ing to series).
Severe GVHD is a low frequent cause of read-
mission in the first 30 days.
This incidence is related to the experience of the 
group of professionals and by the support infra-
structure available in the hospital. In our experi-
ence, only 1 of the 28 patients (3.6%) required 
hospital readmission.
63.2.8  Quality of Life and Cost
The limited experience seems to show that at- 
home allo-HSCT modality improves nutrition/
caloric intake, physical activity, and welfare of 
self that probably help to recover quickly and 
reduce toxicity, minimizing infection risk and 
GVHD (Svahn et al. 2008; Ringdén et al. 2013). 
Nevertheless, it is difficult to determine that these 
measures impact on a reduction of the total cost 
taking into account that the readmission rate is 
high and that most experiences include pre- 
planned booking of inpatient beds.
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Umbilical cord blood transplantation (UCBT) 
from unrelated donors is a suitable option of 
HSCT for patients in whom it is indicated, and a 
suitable related or unrelated BM or PB donor is 
not available in due time.
Since the 1990s, the majority of UCBT have 
been performed in children, but the number in 
adults was growing steadily. In fact, since 2004 
the number of UCBT in adults registered in 
Eurocord was higher than in children. However, a 
certain decline in the UCBT activity has been 
observed over the last few years, which is mainly 
due to an increasing activity of partially matched 
related (haploidentical) HSCT. It should be noted 
that, although both options compete in the same 
niche, their comparative data are very limited and 
randomized studies are not yet available. As far 
as we know, two phase III randomized studies are 
currently ongoing to compare UCBT and haplo- 
HSCT in the RIC and MAC setting (NCT0159778 
and NCT02386332, respectively).




 •  Expanded access to 
transplanta
 –  Higher availability of 
donora
 –  Faster search and 
shorter time to 
transplanta
 –  Greater HLA 
disparity allowed with 
low incidence of 
GVHDa
 •  Lower risk of 
transmission of viral 
infections
 •  More versatile transplant 
planninga
 • No risk of donor refusal
 • No risk to the donor
• Slower engraftment
 •  Higher risk of non-
immunological rejection 
(graft failure)
 •  Remote possibility of 
transmission of a genetic 
diseaseb
 •  Greater delay in immune 
reconstitution
 •  No possibility of donor 
lymphocyte infusionb
aAdvantages shared with haplo-HSCT
bDisadvantages not shared with haplo-HSCT
Similar to UCBT, haplo-HSCT can also be used 
on an urgent basis and extends donor availability 
to the vast majority of patients. In addition, 
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haplo-HSCT allows a DLI if necessary. 
Unfortunately, comparative data of these two 
approaches are limited and inconclusive 
(Brunstein et al. 2011; Ruggeri et al. 2015), and 
randomized studies are still lacking.
64.3  Indications
Except for some patients with severe BMF, such 
as aplastic anemia and paroxysmal nocturnal 
hemoglobinuria, UCBT in adults is performed 
almost exclusively in patients with malignant 
hematological diseases. However, UCBT in chil-
dren has been used for many other nonmalignant 
diseases, including primary immunodeficiency 
diseases and inherited metabolic disorders (see 
Eurocord experience in Table 64.1).
The American Society for Blood and Marrow 
Transplantation (ASBMT), EBMT, and British 
Society of Blood and Marrow Transplantation 
(BSBMT) have recently published their respec-
tive guidelines that include recommendations for 
transplant indications in children and adults. It 
should be noted that the ASBMT did not differ-
entiate recommendations for transplant indica-
tions based on donor source (i.e., MRD, URD, 
UCB, or haploidentical donor) or graft source 
(i.e., BM, PBSC, or UCB). This is in contrast to 
guidelines published by the EBMT and BSBMT.
64.4  Approaches to Improve 
Outcomes After UCBT
Apart from refining criteria for UCB unit selec-
tion and optimization of conditioning regimens, 
several strategies have been developed aiming to 




of UCBT Expert point of view
 (a)  Refining criteria 
for UCB unit 
selection
See Chap. 18 of banking, 
processing, and procurement of 
cord blood cells
 (b)  Optimization of 
conditioning 
regimens
Specific conditioning regimen can 
influence transplant outcomes. 
See Sect. 64.5
 (c)  Strategies 
aiming to 
shorten the time 
to engraftment
To date none of these strategies 
have consistently shown to 
improve outcomes over single 
unmanipulated UCBT
  1. Double UCBT  –  In children, two randomized 
trials have demonstrated no 
benefit and increased risk of 
GVHD (Wagner et al. 2014; 
Michel et al. 2016)
 –  In adults, retrospective studies 
showed no advantage when 
single-unit with TNC dose 
>2.5 × 107/kg available 
(Scaradavou et al. 2013)
  2.  Co-infusion 
with third- 
party cells
Has consistently demonstrated 
benefit to accelerate 
hematopoietic recovery. No 
proved benefit on NRM or 
survival (Sanz et al. 2017)
  3.  Ex vivo 
expansion of 
UCB cells
Promising early studies showing 
fast engraftment with different 
expansion techniques. No 
comparative studies or long-term 
data (Mehta et al. 2017)
 (d)  Improvement of 
supportive 
measures
Supportive care to prevent or treat 
opportunistic infections until 
neutrophil and immune recovery 
has occurred which is critical in 
UCBT. See Sect. 64.7
Table 64.1 Distribution by diseases of UCBT registered 
in Eurocord (1994–2017)
Children (n = 
4128) n (%)
Adults (n = 
3733) n (%)
Malignant disorders 2569 (62) 3609 (97)
  – AML 761 (18) 1504 (40)
  – ALL 1329 (32) 706 (19)
  – MDS/MPS 367 (9) 703 (19)
  –  Lymphoid mature 
disorders
86 (2) 544 (15)
  – Plasma cell disorders 0 (0) 114 (3)
  – Others 26 (1) 38 (1)
Nonmalignant disorders 1559 (38) 124 (3)
  –  Primary 
immunodeficiencies
588 (14) 6 (0.1)
  –  Inborn errors of 
metabolism
423 (10) 9 (0.1)
  –  Bone marrow failure 
syndromes
318 (8) 104 (3)
  – Histiocytic disorders 180 (4) 1 (0.1)
  – Others 50 (0.1) 4 (0.1)
AML acute myeloid leukemia, ALL acute lymphoblastic 
leukemia, MDS myelodysplastic syndrome
J. Sanz et al.
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64.5  Conditioning Regimens
The selection of conditioning regimen for HSCT, 
including UCBT, should take into account the risk 
of toxicity and the risk of graft failure and relapse 
in malignant diseases. In UCBT, given the rela-
tively lower cell dose (T-cells and CD34+ cells) 
and the use of HLA-mismatched grafts, graft fail-
ure is of particular concern, especially in adults. 
The choice of the conditioning regimen is as 
important as the graft characteristics and can influ-
ence transplant outcomes (Ruggeri et al. 2014).
In fact, specific conditioning regimens seem 
to tolerate infusion of lower cell doses in the graft 
(Sanz et al. 2013). A comprehensive and exhaus-
tive review of MAC and non-MAC/RIC regimens 
in the UCBT setting has recently been published 
(Ross and Gutman 2017).
The Sorror comorbidity index may be a helpful 
tool to choose the appropriate conditioning intensity 
for a given patient. Some conditioning regimens 
options of varying intensity are to be considered:
Myeloablative conditioning regimens (MAC)
Chemotherapy-based
 •  Adults: TBF regimen 
(Sanz et al. 2012)
TT 10 mg/kg + IV BU 
9.6 mg/kg + FLU 150 mg/m2 
+ ATG 6 mg/kg
 •  Children: FTT 
regimen  
(Hough et al. 2016)
 •  BF regimen (Admiraal 
et al. 2015)
TREO 30–42 g/m2 + FLU 
150 mg/m2 + TT 10 mg/kg
BU (PK guided) + FLU 
160 mg/m2 + ATG 19 mg/kg
TBI-based
 •  TCF regimen (Barker 
et al. 2005)
TBI 13.2 Gy + CY 120 mg/
kg + FLU 75 mg/m2
Medium-intensity conditioning regimens (MIDI)
 •  MIDI regimen (Barker 
et al. 2017)
TT 10 mg/kg + CY 50 mg/kg 
+ FLU 150 mg/m2 + TBI 
4 Gy
Reduced-intensity conditioning regimens (RIC)
 •  rTCF regimen 
(Brunstein et al. 2007)
TBI 2 Gy + CY 50 mg/kg + 
FLU 200 mg/m2 ± ATG
64.6  GVHD Prophylaxis
The most important advantage of UCB over 
unrelated donor grafts is the capability to toler-
ate HLA disparities and facilitate a low inci-
dence of chronic GVHD. However, acute GVHD 
is still one of the most important contributors to 
morbidity and mortality. Different GVHD pro-
phylaxis regimens have been explored with no 
evidence of benefit of any specific strategy. 
MTX is generally not recommended to avoid 
myelotoxicity and delayed neutrophil recovery 
although it is widely used in Asia. The most fre-
quently used regimen worldwide is the combi-
nation of CNI for 6–9  months with MMF for 
2–6 months.
The use of in vivo TCD with ATG is contro-
versial. ATG in the conditioning regimen has 
been used to enhance myeloid engraftment as 
well as to prevent GVHD. Its use has been asso-
ciated with reduced rates of GVHD. However, 
although there is no evidence of a negative 
impact on NRM (Ponce et al. 2015), there is a 
concern of impaired immune reconstitution and 
increased viral infections (Chiesa et al. 2012). 
Recent data suggest that safety of ATG can be 
improved by adjusting dose with ATG pharma-
cokinetics (Admiraal et al. 2016).
64.7  Supportive Care
The supportive measures described below are 
not intended to be recommendations but only to 
be taken into account and to consider their use 
in the context of each institution’s own experi-
ence and epidemiology. The most common 
measures are described merely as a guide since 
they have a very variable level of evidence (see 
Table 64.2).
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Table 64.2 Prophylaxis, monitoring, and treatment options to be considered for infections in UCBT
Prophylaxis Monitoring Treatment
Supportive measures for bacterial infections
Levofloxacin or ciprofloxacin Surveillance cultures to detect 
colonization with MDR gram-negative 
bacteria
Empirical antibacterial therapy 
according to institutional epidemiologic 
patterns
Supportive measures for fungal infections
Mold-covering azole Galactomannan and beta-d-glucan 
assaysa
Liposomal AmB, azoles, and/or 
echinocandins (according to previous 
prophylaxis)
Supportive measures for viral infections
CMV: letermovir (qPCR) Weekly on days 0–100 and 
then as clinically indicated
Ganciclovir, valganciclovir, foscarnet
HHV-6: none (qPCR) as clinically indicated Ganciclovir, valganciclovir, foscarnet
Adenovirus: none (qPCR) weekly on days 0–100 and 
then as clinically indicatedb
Cidofovir
EBV: none (qPCR) weekly on days 0–100 and 
then as clinically indicatedc
Preemptive rituximab
Supportive measures for protozoal infections
Pneumocystis: co-trimoxazole, 
pentamidine, or atovaquone




– Co-trimoxazole, atovaquone, or 
pyrimethamine
MDR multidrug-resistant, AmB amphotericin B, qPCR quantitative PCR
aBoth have been included as microbiological criteria in the definitions of invasive fungal infections by the European 
Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG)
bSpecially in children
cReduced-intensity conditioning and ATG are risk factors for EBV-PTLD
Table 64.3 Expected results overall survival at 2 years after UCBT
Adults 2-years OS (%) Children 2-years OS (%)
Outcomes according to DRI Malignant disorders 49 ± 1
   Low 55 ± 3    Acute leukemia 52 ± 1
   Intermediate 47 ± 1    MDS 55 ± 3
   High 27 ± 2    Lymphoproliferative disorders 55 ± 3
   Very high 19 ± 3 Nonmalignant disorders 63 ± 1
Disease-specific outcomes    Inborn error of metabolism 70 ± 2
   Acute leukemia 37 ± 1    Hemoglobinopathies 68 ± 9
   MDS/MPS 32 ± 2    Primary immunodeficiency 68 ± 2
   Lymphoproliferative disorders 45 ± 2    Histiocytic disorders 60 ± 4
   Plasma cell disorder 37 ± 5    BMF syndrome 52 ± 3
DRI disease risk index, MDS myelodysplastic syndrome, MPS myeloproliferative syndrome, OS overall survival, MDS 
myelodysplastic syndrome, BMF bone marrow failure
64.8  Results (See Table 64.3)
UCBT outcomes have improved in more recent 
years, probably explained by better patient and 
CBU selection, improved conditioning, and sup-
ported care. Registry data also showed important 
center effect with superior survival obtained in 
experienced centers. Eurocord recently updated 
clinical results.
Multiple retrospective studies have demon-
strated that UCBT offers similar long-term out-
comes compared with the gold standard of 
HLA-matched URD transplants in patients with 
hematologic malignancies, both in children and 
adults (Eapen et al. 2007; Brunstein et al. 2010; 
Atsuta et al. 2012). Interestingly, UCBT seems to 
offer a potent antileukemic efficacy, through yet 
unknown mechanisms. A recent report that needs 
J. Sanz et al.
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to be validated suggested a markedly reduced 
relapse rate after UCBT as compared to URD 
transplantation in patients transplanted with 
MRD (Milano et al. 2016).
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Haploidentical HSCT
Fabio Ciceri, Andrea Bacigalupo, Arjan Lankester, 
and Alice Bertaina
65.1  Introduction
Haploidentical hematopoietic stem cell trans-
plantation (haplo-HSCT) is now considered a 
clinical therapeutic option in patients candidate 
to allo-HSCT. Primary prevention and treatment 
of GvHD have been a major challenge in this 
peculiar major HLA-mismatched setting. Two 
main platforms have been developed: ex  vivo 
TCD and unmanipulated graft transplantation. 
Overall, the primary objective of a stable haploi-
dentical hematopoietic engraftment at a low 
GvHD rate resulted feasible in both platforms in 
a significant proportion of patients undergoing 
haplo-HSCT for any clinical indication.
The great interest in transplantation from hap-
loidentical donors arises from the immediate 
availability of a suitable one-haplotype mis-
matched donor for virtually all patients in the 
appropriate timing. In the absence of a HLA full- 
matched donor, alternative family haploidentical 
donors have been intensively investigated in the 
past decade.
Primary prevention and treatment of GvHD 
have been a major challenge in this peculiar 
HLA-mismatched setting of HSCT.  Two main 
clinical platforms have been developed: ex vivo 
TCD and more recently unmanipulated graft 
transplantation.
65.2  Ex Vivo TCD Platforms
The physical removal of donor T-cells from the 
graft has been pioneered by the group of Perugia 
in the late 1990s (Aversa et al. 1998). The origi-
nal concept was to prevent GvHD through a graft 
with a T-cell content not exceeding a total T-cell 
graft dose of 1 × 104/kg of recipient body weight.
65.2.1  Positive CD34 Selection
The most experienced ex vivo manipulation has 
been the positive selection of CD34+ cells real-
ized by CliniMACS® CD34 System Miltenyi, 
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providing a TCD graft with high cell dose of 
CD34+ cells starting from G-CSF-mobilized 
PBSC graft of family haploidentical donors 
(Aversa et  al. 1998; Ciceri et  al. 2008; Reisner 
et  al. 2011). This profound TCD graft required 
the development of conditioning regimens aimed 
at a maximal host IS through the use of ATG, 
full-dose TBI, and the combination of intensive 
IS, FLU, and TT.
Despite the application of intensive immuno-
ablative regimens, the rate of graft rejection has 
been 10–15% requiring a salvage subsequent sec-
ond HSCT providing an overall engraftment rate 
>95%. According to the primary objective, 
ex vivo TCD by CD34+ selection allows a stable 
engraftment with a GvHD rate <10% in the 
absence of any additional post transplant IST.
Unfortunately, this intense graft TCD trans-
lated into a slow post transplant immune recov-
ery with a prolonged and profound T-cell 
lymphopenia (Reisner et al. 2011; Perruccio et al. 
2005). In this clinical platform, TRM have been 
observed in a significant proportion of recipients 
(Ciceri et  al. 2008). Leading causes of deaths 
reported were opportunistic infections occurring 
even as late as 1-year post transplant in the 
absence of GvHD and any IST. The improvement 
of post transplant immune reconstitution while 
controlling GvHD prompted the concurrent 
development of several additional strategies of 
cell therapy (Perruccio et al. 2005; Di Ianni et al. 
2011; Ciceri et al. 2009). Particularly in the pedi-
atric population, virus-specific T-cells have been 
a promising tool (Leen 2009); Feucht 2015). 
Donor T-cells genetically modified to express 
HSV-thymidine kinase suicide gene (Zalmoxis®) 
have been recently registered by the European 
Medicines Agency as adjunctive therapeutic tool 
post haploidentical HSCT.
65.2.2  CD3/CD19 Negative Selection
A partial T-cell depletion less profound than 
CD34+ selection can be provided by alternative 
selections, such as CD3/CD19 negative selection. 
The CliniMACS CD3/CD19 Product Line was 
developed for the simultaneous depletion of 
unwanted T- and B-cells in combination with the 
CliniMACS System. This approach keeps stem 
and progenitor cells untouched and leaves 
immune effector cells, such as NK cells and den-
dritic cells, in the cellular product (Bethge et al. 
2006; Federmann et  al. 2011; Federmann et  al. 
2012). Starting from G-CSF-mobilized PBSC in 
adults, grafts contained a median of 7.0  ×  106 
CD34+ cells/kg, 4.2 × 104 CD3+ T-cells/kg, and 
2.7 × 107 CD56+ cells/kg; incidence of grade II–
IV acute GVHD and chronic GVHD was 46% 
and 18%, respectively, requiring the post trans-
plant use of a CNI as additional GvHD prophy-
laxis in adult patients.
65.2.3  TCRα/β and CD19 Depletion
More recently, Miltenyi developed CliniMACS 
TCRα/β and CD19-depleted stem cell grafts from 
haploidentical donors for HSCT in children and 
adults. The ex vivo protocol has been designed to 
selectively remove donor T-cells with TCRα/β 
that are recognized to mediate GvHD. Preliminary 
clinical experience in children showed a very low 
rate of skin GvHD and no visceral acute or 
chronic GVHD (Bertaina et  al. 2014; Li Pira 
et al. 2016).
Overall, ex vivo TCD is a platform clinically 
useful to provide hematopoietic engraftment with 
low GvHD in haploidentical setting. Furthermore, 
the different cell population selection in the graft 
provides a unique clinical setting to dissect the 
biology of different immune cells as NK, 
TCRα/β, and TCRγ/δ T-cells in the clinical post 
transplant immune reconstitution and antitumor 
and immune protective in vivo effects (Ruggeri 
et  al. 2002; Aversa et  al. 2005; Locatelli et  al. 
2013).
65.2.4  Regulatory T-Cells
The Perugia group has recently presented a varia-
tion of ex vivo TCD, with the addition of regula-
tory T-cells, followed by mature T-cells (Martelli 
et al. 2014): preferential migration of regulatory 
T-cells to the lymph nodes, but not the bone mar-
F. Ciceri et al.
481
row, prevents GvHD (in the lymph nodes) and 
allows, at the same time, a strong graft versus 
leukemia (in the bone marrow). The result is an 
extremely low incidence of leukemia relapse 
(Martelli et al. 2014).
65.3  Unmanipulated 
Haploidentical HSCT
The number of unmanipulated HLA haploidenti-
cal transplants has been rapidly increasing over 
the past 15 years (Passweg et al. 2012), due to the 
successful prevention of two major problems: 
lethal GvHD and graft rejection. There are cur-
rently three main platforms to perform unmanip-
ulated haplo-HSCT (Fig. 65.1).
65.3.1  Anti-thymocyte Globulin 
(ATG) Based
In 2006 the Chinese group led by Dao-Pei Lu 
compared the outcome of 158 leukemia patients 
grafted from HLA-identical siblings with 135 leu-
kemia patients grafted from HLA-haplotype mis-
match family members, after a MAC regimen (Lu 
et al. 2006; Fig. 65.1: ATG-based; GBM + GPB + 
CSA + MMF + MTX). The results were surpris-
ing, with the OS and DFS identical for both 
groups. The conditioning therapy consisted of 
Ara-C (4 g/m2/day, on days −10 to −9), BU (4 mg/
kg/day, orally on days −8 to −6 before January 
2008 and 3.2 mg/kg/day, IV on days −8 to −6 after 
January 2008), CY (1.8 g/m2/day, on days −5 to 
−4), 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-
nitrosourea (Me-CCNU) (250 mg/m2, once on day 
−3), and ATG (2.5  mg/kg/day, rabbit; Sanofi 
Genzyme, France, days −5 to −2).
All patients received CSA, MTX, and MMF; 
the HLA-mismatch group received in addition 
ATG (Lu et  al. 2006). The graft source was a 
combination of G-CSF (G)-mobilized bone mar-
row (G-BM) and G-mobilized PB. The cohort in 
HLA-haplotype mismatch group had a higher 
risk of acute GvHD (P  =  0.02) and of TRM 
(P  =  0.05), but OS was comparable (P  =  0.6). 
This was the first report on a large number of 
family mismatched grafts, showing survival iden-
tical to sibling HLA-matched grafts, and this led 
to the emergence of other programs.
Another group of Chinese investigators devel-
oped an ATG-based program with unmanipulated 
G-BM alone (Ji et al. 2005; Fig. 65.1, G-BM + 
CSA + MMF + MTX + basiliximab). They 





















Fig. 65.1 Different 
modalities of haplo- 














CSA, MTX, and MMF with the addition of basi-
liximab, an anti-CD25 antibody. The same GvHD 
prophylaxis has been reported by an Italian con-
sortium (Di Bartolomeo et al. 2010): acute GvHD 
grade II–IV and III–IV was, respectively, 24% 
and 5%, which is extremely low for family HLA- 
haplotype mismatch, T-cell-replete transplants. 
The TRM was not negligible, being 30% for 
“standard” and 45% for “high-risk” patients (Di 
Bartolomeo et al. 2010). Overall 3-year survival 
was 54% for standard and 33% for high-risk 
patients. Di Bartolomeo et  al. used for most 
patients a conditioning regimen combining TT, 
IV BU, and FLU (TBF), originally described by 
Sanz and coworkers for cord blood transplants 
(Sanz et al. 2012).
65.3.2  Post transplant 
Cyclophosphamide (PT-CY) 
Based
The use of PT-CY on day +3 and +4 after an 
unmanipulated haplo-HSCT has been pioneered 
by the Baltimore group. It is based on the idea that 
high-dose CY (50  mg/kg) will kill alloreactive 
T-cells proliferating on day +3 and +4 after the 
transplant, whereas stem cells would be protected 
because they are not proliferating and with a high 
concentration of aldehyde dehydrogenase.
In 2001, the Baltimore group published their 
first clinical study and showed that PT-CY was 
able to protect patients from GvHD after haplo- 
HSCT (Luznik et al. 2001). Again, this was not 
picked up immediately, not until 2008 when a 
joint Baltimore Seattle study showed that haplo- 
HSCT in Hodgkin’s lymphoma (HL) produces 
DFS superior to sibling or unrelated transplants 
(Chiusolo et al. 2018): not only GvHD could be 
prevented, but GvL seemed superior, at least in 
patients with HL.
There have been numerous variations of the 
Baltimore protocol (Fig. 65.1) with use of G-PB 
instead of BM, rapamycin, and MMF, instead of 
a CNI (Figs. 65.2 and 65.3), the use of a MAC 
regimen instead of the NMA regimen of 
Baltimore.
All these platforms seem to achieve a high 
rate of engraftment, but severe acute GvHD can 
vary from as low as 3% to as high as 30%. A 
modified PT-CY regimen has recently been 
reported in patients with AML (Chiusolo et al. 
2018): in this multicenter retrospective study on 
150 patients, CSA was administered on day 0, 
MMF on day +1, and PT-CY on days +3 and +5 
(Fig. 65.1). The MA regimen consisted mainly 
of TBF: the rate of leukemia relapse was 
extremely low in remission patients (Chiusolo 
et  al. 2018). The major difference here lies in 
the CSA given before PT-CY and in the two 
doses of PT-CY spaced on days +3 and +5. It 
should be noted that this regimen is safe when 
using BM as a stem cell source, with acute 
GvHD III–IV rates of 3%; however, it is not 
known what the outcome would be with PB as a 





Fludarabine 30 mg/m2/day Cy 50 mg/kg/day,
day 3 (n=28) or
days 3,4 (n=40)
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Fig. 65.2 The original Baltimore protocol consisting of 
CY 14.5 mg/kg × 2, fludarabine 30 mg/m2 × 5, and total 
body irradiation (TBI) 2 Gy day −1. CY 50 mg/kg days 
+3 and +4 and CSA, MMF starting day +5. GCSF starts 
on day +6. From Luznik et al. (2001)
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T-cells from PT-CY purging, and these may pro-
duce a beneficial GvL effect but also cause det-
rimental GvHD.
65.3.3  ATG + PT-CY
Some centers are combining the two basic plat-
forms (PT-CY and ATG) and early results seem 
promising. The Baltimore group is using this 
combination for patients with sickle cell disease, 
in the attempt of avoiding GvHD completely. 
Also, the group in Saint-Antoine, Paris, is using a 
combination of ATG 2.5 mg/kg and PT-CY, CSA, 
and MMF for patients with acute leukemia under-
going a MAC haplo-HSCT (Duléry et al. 2018).
65.4  Other Relevant Aspects 
of Haplo-HSCT
65.4.1  Choice of the Best 
Haploidentical Donor
The EBMT ALWP has established younger donor 
age and kinship, as a major determinant of out-
come for leukemia patients grafted from haploi-
dentical donor (Canaani et al. 2018).
The Beijing group has confirmed younger age 
to be relevant, using their ATG-based platform 
together with a mismatch for non-inherited 
maternal antigen (NIMA) (Wang et al. 2014).
The age, CMV status, and ABO matching are 
general rules which should always be considered: 
a CMV+ patient should be grafted with a CMV+ 
donor, if available, and a CMV- patient with a 
CMV− donor.
Table 65.1 summarizes the most relevant gen-
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Fig. 65.3 Modified 
PT-CY regimen. 
Thiotepa (T), busulfan 




BM. Cyclosporin on day 
0, mycophenolate on 
day +1, and CY 50 mg/
kg on days +3 and +5
Table 65.1 Criteria for donor selection
(a) Immunologic criteria (only in malignancies)
 1.  Presence of NK alloreactivity (KIR/KIR-L 
mismatch in GvH direction)
 2. Larger size of NK alloreactive subset
 3. KIR haplotype
 4. Higher B content value in B haplotype donors
 5.  Presence of educated KIR2DS1 in case of C2+ 
patient
 6. Higher % NK cells and T lymphocytes
(b) General criteria
 7. Donor/recipient HCMV serology
 8. Donor age
 9. Donor sex
 10. Donor/recipient body weight
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65.4.1.1  Natural Killer (NK)
Natural killer (NK) cells are the first post-HSCT 
cellular population, reconstituting antiviral and 
antitumor activity. In this setting, donor NK cell 
inhibitory receptors mismatched for cognate 
HLA class I ligands play a key role in the graft- 
versus- leukemia (GVL) effect. Remarkably, 
these cells may be uniquely poised to enhance 
GVL without eliciting GvHD because healthy 
non-hematopoietic tissues lack activating recep-
tor ligands present on tumor cells.
Over 20  years ago, Moretta et  al. 1995 
described the concept of NK cells’ alloreactivity, 
showing that defined NK cell subsets were able 
to kill in vitro allogeneic lymphoblasts. (Ruggeri 
et al. 2016) first reported the positive impact of 
KIR ligand- mismatched donor NK cell alloreac-
tivity after TCD haplo-HSCT resulting in a lower 
risk of relapse and a better OS in adult with 
AML.  Of note, only patients receiving a trans-
plant from a donor who showed NK cell alloreac-
tivity against recipient cells displayed an efficient 
GVL effect. This happens, for example, in the 
presence of a KIR-HLA-I (KIR-L) mismatch in 
the donor- versus- recipient direction. Thus, in 
donor/patient pairs with KIR-HLA-I mismatch, 
the event-free survival (EFS) rate was 60%, while 
in the absence of such mismatch, it was less than 
5%.
However, the contribution of NK cell alloreac-
tivity on HSCT outcome is still controversial due 
to different evaluation criteria, the nature of KIR/
KIR ligand genetic combinations studied, and 
NK cell repertoire size. Given the central role of 
NK cell alloreactivity in preventing leukemia 
relapse, in the setting of haplo-HSCT, it is crucial 
to determine in different potential donors if allo-
reactive NK cells are present and the size of such 
alloreactive populations. More recently, in addi-
tion to the flow analysis of the alloreactive NK 
cell populations, other selection criteria have 
been added (Table 65.1). Among these, the pres-
ence of a KIR B haplotype has been shown to be 
associated with a relevant improvement of the 
survival in both adult AML and pediatric ALL.
While the antileukemic activity of NK cells and 
the role of KIR are well known and established by 
several groups, their impact in preventing graft 
failure and/or infections in patients affected by 
nonmalignant disorders remains unclear.
65.4.2  Comparison of ATG-Based 
Versus PT-CY-Based Platforms
The EBMT Acute Leukemia Working Party has 
compared these two platforms in a recent study 
(Ruggeri et  al. 2017). In a Cox analysis, ATG- 
based haplo grafts had a higher risk of failure, in 
terms of LFS (RR 1.48, p = 0.03), GvHD relapse- 
free survival (RR 1.45, p = 0.03), and OS (HR 
1.43, p = 0.06): there was for all end points a very 
strong center effect (p < 0.001), suggesting that a 
learning curve is required for optimal results in 
haplo-HSCT.
65.4.3  Bone Marrow or Peripheral 
Blood
There are now two studies comparing BM versus 
PB for unmanipulated haplo-HSCT: the EBMT 
study (Ruggeri et  al. 2018) shows increased 
GvHD II–IV and III–IV with PB, same chronic 
GvHD, same relapse, and same 2-year OS (55% 
and 56%). The CIBMTR shows increased GvHD 
II–IV, but not III–IV with PB grafts, increased 
chronic GvHD, and reduced relapse (Bashey 
et al. 2017): survival at 2 years also in this study 
is quite similar, 54% vs 57%.
Key Points
• Following the pioneering work of the 
Perugia group, HLA-haplotype mis-
match family transplants are rapidly 
increasing in numbers, due to improved 
platforms in both TCD, as well as unma-
nipulated grafts, with encouraging 
results in most centers.
• This is true with different stem cell 
sources, different conditioning regi-
mens, and different GvHD prophylaxes: 
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So, it seems that one can use both stem cell 
sources, with some difference in the short term 
(more GvHD with PB) and perhaps some differ-
ences in the long term (cGvHD and relapse): at 
the end survival seems comparable.
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Extracorporeal photopheresis (ECP) is a 
leukapheresis- based treatment that has been used 
during the last decades by many clinicians. Based 
on results of a prospective, multicenter, interna-
tional clinical trial in patients with cutaneous 
T-cell lymphoma (CTCL), ECP was approved by 
the FDA as the first cellular immunotherapy for 
cancer in 1988 (Edelson et al. 1987). During the 
last decades, ECP has been investigated world-
wide for prevention and treatment of a variety of 
T-cell-mediated diseases including acute and 
chronic GvHD, solid organ and tissue transplan-
tation, systemic sclerosis, systemic lupus erythe-
matodes, and Crohn’s disease (Knobler et  al. 
2014). Administering ECP to patients suffering 
of these diseases revealed promising results both 
in prospective and retrospective single and multi-
center clinical studies. Despite its frequent use, 
the mode of action of ECP remains elusive 
including reduction of pro-inflammatory cyto-
kines and induction of anti-inflammatory cyto-
kines and modulation of immune cell 
populations.
66.2  Technical Aspects
During ECP the patient’s blood is collected via 
an antecubital vein or via a permanent catheter, 
and the white blood cells are separated from the 
red blood cells and plasma by centrifugation in a 
device that is specifically constructed for the pro-
cedure (Knobler et  al. 2014; Schoonemann 
2003). Collected mononuclear cells (MNCs) 
using either continuous or discontinuous cell sep-
arators are then exposed ex vivo to a photosensi-
tizing agent, 8-methoxypsoralen (8-MOP), which 
is added directly to the buffy coat/plasma fraction 
followed by photoactivation with ultraviolet A 
(UV-A) irradiation and then reinfusion of the 
photoactivated product (Schoonemann 2003).
ECP has originally been developed as a single 
procedure which combines the separation of the 
MNCs from the whole blood with irradiation of 
the 8-MOP-treated leukapheresis products within 
a single machine (“closed system of ECP”). The 
“offline technique“ (two-step method) of ECP 
treatment includes as the first step cell separation 
with a standard blood cell separator that can also 
be used for the collection of peripheral blood stem 
cells. The apheresis product is transferred into 
another disposable, 8-MOP is added, and irradia-
tion is performed with a separate machine at a 
dosage of 2 J/cm2. After irradiation transfusion of 
the treated cells is carried out manually by a stan-
dard transfusion set. Both ECP techniques have 
demonstrated clinical efficacy, but almost all clin-
ical studies have been performed with the single 
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ECP technique, and studies comparing both sys-
tems are almost completely lacking (Schoonemann 
2003; Andreu et al. 1994; Brosig et al. 2016).
66.3  Results of ECP in Acute GvHD
To date, no consensus on the optimal choice of 
agents for salvage therapy of steroid-refractory 
acute GvHD has been reached, and treatment 
choices are based on physician’s experience, risk 
of toxicity and potential exacerbation of pre- 
existing comorbidity, interactions with other 
agents, and ease of use (Martin et al. 2012). During 
the last years, more and more HSCT centers have 
administered ECP to patients with steroid- 
refractory acute GvHD. Results of larger prospec-
tive studies on the use of ECP in this indication are 
shown in Table 66.1. The intensified schedule of 
ECP with two to three treatments per week on a 
weekly basis significantly improved response rates 
in patients with GI involvement and grade IV 
acute GvHD (Greinix et al. 2006).
In a systematic review of prospective studies 
including 6 studies with 103 patients given ECP 
for steroid-refractory acute GvHD, an overall 
response rate (ORR) of 69% was achieved includ-
ing ORR for skin, liver, and GI involvement of 
84%, 55%, and 65%, respectively (Abu-Dalle 
et al. 2014). Compared to anticytokine treatment, 
administration of ECP for steroid-refractory 
acute GvHD not only achieved significantly 
higher ORR (66% vs 32%) and CR (54% vs 
20%), but ECP was also an independent predictor 
of response and survival and was associated with 
significantly lower NRM and superior survival in 
steroid-refractory grade II acute GvHD (Jagasia 
et al. 2013). Compared to other IST, ECP has an 
excellent safety profile with limited toxicity con-
cerns, no increased concerns for viral reactiva-
tions, and no documented interaction with other 
drugs (Martin et al. 2012).
66.4  Results of ECP in Chronic 
GvHD
Although many therapeutic options have been 
reported for salvage treatment of steroid- 
refractory chronic GvHD, no single class of IS 
agent has been established as standard therapy 
(Wolff et al. 2011). ECP represents a frequently 
used therapeutic approach for treatment of chronic 
GvHD patients failing corticosteroids (Table 66.2) 
(Knobler et  al. 2014; Wolff et  al. 2011; Greinix 
et  al. 1998; Flowers et  al. 2008; Jagasia et  al. 
2009; Greinix et  al. 2011). Most of the clinical 
experience in ECP treatment of steroid- refractory 
chronic GvHD patients is based on retrospective 
analyses with consistently high response rates in 
up to 80% of patients with cutaneous manifesta-
tions and substantial improvement in scleroder-
matous skin involvement (Knobler et  al. 2014; 
Wolff et al. 2011).
Table 66.1 Results of second-line treatment of acute GvHD using extracorporeal photopheresis
Author (year) No. of patients CR skin no. (%) CR liver no. (%) CR gut no. (%) OS%
Salvaneschi (2001) 9 6/9 (67) 1/3 (33) 3/5 (60) 67
Dall’Amico (2002) 14 10/14 (71) 4/7 (57) 6/10 (60) 57
Messina et al. (2003) 33 25/33 (76) 9/15 (60) 15/20 (75) 69 at 5 y
Greinix et al. (2006) 59 47/57 (82) 14/23 (61) 9/15 (60) 47 at 5 y
Garban (2005) 12 8/12 (67) 0/2 (0) 2/5 (40) 42
Kanold (2007) 12 9/10 (90) 5/9 (56) 5/6 (83) 75 at 8.5 m
Calore (2008) 15 12/13 (92) 14/14 (100) 85 at 5 y
Perfetti (2008) 23 15/23 (65) 3/11 (27) 8/20 (40) 48 at 37 m
Gonzalez- Vicent (2008) 8 8/8 (100) 2/2 (100) 4/7 (57) 38
Perotti (2010) 50 39/47 (83) (1) 16/24 (67) (1) 8/11 (73) (1) 64 at 1 y
Jagasia (2013) 57 38/57 (67) (1) 38/57 (67) (1) 38/57 (67) (1) 59 at 2 y
Calore (2015) 72 50/64 (78) 10/12 (84) 42/55 (76) 71 at 5 y
Abbreviations: No number, CR complete resolution, OS overall survival, y years, m months
Results were provided as complete and partial resolution.
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In a multicenter, randomized, controlled, 
prospective phase II study of ECP in 95 patients 
with steroid-refractory/dependent/intolerant 
chronic GvHD, significantly more patients in 
the ECP arm achieved a complete or partial 
response of cutaneous manifestations 
(p < 0.001) as well as a 50% reduction in steroid 
dose and at least a 25% decrease in total skin 
score (p  =  0.04) by week 12 (Greinix et  al. 
1998). A steroid-sparing effect of ECP has also 
been reported by other investigators (Knobler 
et  al. 2014; Wolff et  al. 2011; Flowers et  al. 
2008; Jagasia et al. 2009).
In a systematic review of prospective studies 
on the use of ECP in patients with chronic 
GvHD, an ORR of 71% in cutaneous, 62% in 
GI, 58% in hepatic, 63% in oral mucosal, and 
45% in musculoskeletal manifestations of 
chronic GvHD was reported (Abu-Dalle et  al. 
2014). Rate of IS discontinuation was 23% and 
ECP was tolerated excellently. In another meta-
analysis high response rates in cutaneous and 
extracutaneous manifestations of chronic 
GvHD including 48% of responses in lung 
involvement were confirmed (Del Fante et  al. 
2016). The ECP schedule in chronic GvHD is 
empirical ranging from multiple treatments per 
week on a weekly basis to two treatments 
biweekly and in case of response prolongation 
of the treatment interval to 4–6 weeks, respec-
tively. No clear association between ECP dose 
intensity and response has been reported. 
Higher response rates were achieved in steroid- 
refractory patients given ECP earlier in the 
course of their disease (Malik et  al. 2014; 
Messina et al. 2003). Improvements in quality 
of life and survival in ECP responders have 
been reported (Knobler et al. 2014; Wolff et al. 
2011; Greinix et  al. 1998; Malik et  al. 2014; 
Messina et al. 2003).
ECP is a safe and efficacious treatment for 
patients with chronic GvHD with steroid-spar-
ing capacity. Transient hypotension during 
treatment and mild anemia and/or thrombocy-
topenia have been reported as side effects of 
ECP. Prospective clinical studies are warranted 
to assess the efficacy of ECP in well-defined 
cohorts of chronic GvHD patients treated ear-
lier in the course of their disease. Recently, 
Jagasia and colleagues reported first results of a 
Table 66.2 Results of use of extracorporeal photopheresis in chronic GvHD
Author (year) No of patients CR/PR skin (%) CR/PR liver (%) CR/PR oral (%) ORR (%)
Greinix et al. (1998) 15 80 70 100 na
Salvaneschi (2001) 14 83 67 67 64
Messina (2003) 44 56 60 – 57
Seaton (2003) 28 48 32 21 36
Apisarnthanarax (2003) 32 59 0 na 56
Foss (2005) 25 64 0 46 64
Rubegni (2005) 32 81 77 92 69
Greinix (2006) 47 93 84 95 83
Couriel (2006) 71 57 71 78 61
Kanold (2007) 15 75 82 86 50
Perseghin (2007) 25 67 67 78 73
Flowers (2008) 48 40 29 53 40
Jagasia (2009) 43 65
Perotti (2010) 23 96 100 80 69
Dignan (2012) 82 92 na 91 74
Greinix (2011) 29 31 50 70 na
Del Fante (2012) 102 na na na 81
Ussowicz (2013) 13 67 89 86 69
Hautmann (2013) 32 59 100 60 44
Dignan (2014) 38 65 - 29 50
Abbreviations: No number, CR complete resolution, PR partial resolution, ORR overall response rate, na not available
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randomized, controlled, multicenter study in 
NIH-defined  moderate/severe chronic GvHD 
patients given ECP in the study arm in combi-
nation with standard of care IS (Jagasia et  al. 
2017). Besides an ORR of 74%, and thus, a 
promising efficacy ECP demonstrated to be 
safe and tolerated well.
66.5  Conclusions
ECP has been used for over 30 years in the treat-
ment of CTCL, acute and chronic GvHD, and 
solid organ transplant rejection. Multiple scien-
tific organizations recommend its use due to 
ECP’s efficacy and excellent safety profile 
(Knobler et al. 2014). Due to the lack of interac-
tions with other agents and the avoidance of gen-
eral IS, ECP compares favorably with other IS 
strategies, supporting its increasingly frequent 
use as second-line therapy of steroid-refractory/
dependent acute and chronic GvHD. Of note, the 
corticosteroid-sparing potential of ECP has been 
confirmed in numerous retrospective and pro-
spective studies and translates into immediate 
clinical benefit for patients with GvHD as well as 
a reduction of transplant-associated morbidity 
and mortality.
No general recommendation can be made on 
treatment schedule due to missing evidence. 
Ideally, ECP treatment should be initiated as 
early as possible after the indication is confirmed. 
Especially in patients with steroid-refractory 
acute GvHD, earlier treatment onset and an 
intensified weekly ECP schedule resulted in 
improved response rates and patients’ outcome. 
Prospective studies on the use of ECP as upfront 
treatment in GvHD are warranted as well as its 
investigation for prophylactic/preemptive use 
during allo-HSCT.
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“More obese people in the world than under-
weight” was the headline on BBC News on 
April 1, 2016. This statement is based on a study 
comparing the prevalence of BMI categories of 
more than 19.2 million adult participants in 186 
of 200 countries (N.  C. D.  Risk Factor 
Collaboration 2016). Comparing the age-stan-
dardised mean BMI by country in 1975 and 
2014, there is a significant increase in both men 
(21.7 vs 24.2  kg/m2) and women (22.1 vs 
24.4 kg/m2). Looking for the proportion of over-
weight in selected industrialised countries, it is 
estimated that the prevalence of overweight and 
obesity in the USA will exceed 70% in 2020, 
followed by England and Australia. Korea, 
France and Italy are projected to have less than 
50% of the population being overweight (Lyman 
and Sparreboom 2013).
Obesity is associated with a significant 
increase in morbidity (including metabolic dis-
eases and cancer) and mortality. It has been esti-
mated that worldwide 481,000 (3.6%) of all new 
cancer cases in 2012 were attributable to excess 
body mass index (BMI) (Arnold et al. 2015).
67.1.1  Definitions and Size 
Describers of Obesity
Classification of overweight and obesity is usu-
ally based on BMI that is calculated using height 
and weight of an individual. The World Health 
Organization (WHO), defines adults according to 
their BMI as:
 – Normal weight with 18.5–24.9 kg/m2
 – Overweight with 25–29.9 kg/m2
 – Obese with ≥30 kg/m2
However, one has to keep in mind that 
although BMI has been shown to correlate with 
SC fat (but not with percentage body fat), in indi-
viduals with greater muscle mass, women or the 
elderly, BMI might not be the best describer, as 
muscle mass is more dense than fat mass. In 
those people, percent body fat would better 
describe body composition, but direct measure-
ment is usually not readily available as it requires 
advanced technical equipment (e.g. hydrodensi-
tometry, skinfold measurement, bioelectrical 
impedance analysis or dual-energy X-ray absorp-
tiometry) (Hanley et al. 2010). As a consequence, 
indirect measures of body composition, like BMI 
or ideal body weight (IBW), remain the standard, 
as they are easy to calculate.
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67.2  Influence of Overweight 
and Obesity on the 
Pharmacokinetics of Drugs
Obesity is associated with physiological changes 
that can alter the pharmacokinetic parameters of 
many drugs (Hanley et  al. 2010; Green and 
Duffull 2004; Han et  al. 2007; Alobaid et  al. 
2016). Observed physiological changes in obese 
patients influencing pharmacokinetic behaviour 
of drugs and resulting consequences for drug 
dosing are summarised in Table 67.1.
Nevertheless, it has to be kept in mind that the 
effects of physiological changes are usually drug 
specific and that for the majority of drugs both 
pharmacokinetic and clinical data in obese patients 
are sparse. Due to unusual distribution processes, 
the kinetics of drugs is difficult to predict in obese 
patients.
The impact of obesity on GFR as well as on 
tubular secretion is not completely understood. 
Discrepant results regarding GFR in obese as 
compared with normal-weight individuals might 
be explained by estimating GFR using serum cre-
atinine, as no instrument has been validated for 
obesity. Especially, if using weight-based formu-
las like the widespread Cockroft-Gault formula, 
GFR will be overestimated if total body weight is 
used, but underestimated if ideal body weight is 
used. But also the use of weight-independent for-
mulas, as MDRD (Modification of Diet in Renal 
Disease) or CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration), which has been 
shown to result in more reliable estimates, has 
limitations: As the GFR is provided in ml/
min/1.73 m2, the possibly incorrect calculation of 
body surface area in the obese might negatively 
influence the results.
Taken together, there is only limited evidence- 
based information about drug clearance in obese 
patients due to restrictions of clinical trials and 
the lack of pharmacokinetic (PK) analyses. It is 
important to remember that there is no single- 
size descriptor for all drugs.
Table 67.1 Physiological changes in obese individuals influencing pharmacokinetics of drugs
Changes in obese patients Consequences for drug dosing
Absorption  – Increased gastrointestinal blood flow
 – Accelerated gastric emptying
 – Only little data on oral bioavailability
 –  For a couple of drugs including CSA, midazolam 
or propranolol, no differences in oral 
bioavailability have been observed
Distribution  –  Hydrophilic drugs: Vd is similar in normal-
weight and obese patients
 –  Moderate or high lipophilic drugs: significant 
differences in Vd
 – Tissue blood flow may be reduced
 –  Obesity does not appear to have impact on 
plasma protein binding
 –  Vd is important for the determination of a loading 
dose, in order to achieve a rapid and adequate 
exposition
 –  Vd changes are drug specific (attributable to the 




 – Altered hepatic blood flow
 –  TBW- proportional increase in phase II 
metabolism
 –  GFR and renal perfusion similar, but 
imprecision in GFR estimation  
(see text above)
 –  Obese individuals exhibit higher absolute 
drug clearance
 –  Clearance does not increase linearly with 
TBW
 –  Clearance and lean body weight are linearly 
correlated
 –  Elimination of hydrophilic and extensively renally 
cleared drugs mainly depends upon renal function
 –  No apparent relationship between lipophilicity 
and clearance mechanism
 –  Essential parameter to determine maintenance 
dose
 –  Physicochemical attributes of drugs have little 
impact on clearance
GFR glomerular filtration rate, TBW total body weight, Vd volume of distribution
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67.3  Recommendations for  
Drug Dosing
Besides the above-described physicochemical 
attributes and pharmacokinetic (PK) properties, 
recommendations from the literature and plasma 
concentration monitoring are important to deter-
mine drug dosing in morbidly obese patients 
(Hanley et al. 2010; Green and Duffull 2004; Han 
et al. 2007).
67.3.1  Which Weight to Use 
for Calculation?
For some drugs, the use of adjusted ideal body 
weight (AIBW) resulted in similar drug exposure 
in obese as compared to normal-weight patients 
(Pai and Bearden 2007; Polso et al. 2014; Bearden 
and Rodvold 2000): This is, for example, true for 
aminoglycosides, acyclovir (Turner et  al. 2016) 
or liposomal AmB. AIBW is calculated by add-
ing 25–40% of the difference between total body 
weight (TBW) and IBW to the IBW. This method 
is also well examined using population PK mod-
els for busulfan (Nguyen et  al. 2006). On the 
other hand, initial vancomycin dosing should be 
based on TBW with subsequent therapeutic drug 
monitoring (Polso et al. 2014; Rybak et al. 2009). 
However, for many drugs the optimal basis for 
dose calculation has still to be determined.
67.3.2  Impact on Drug Dosing 
of Chemotherapy
The majority of dosing recommendations in 
obese patients exist for antimicrobial drugs 
(Alobaid et  al. 2016; Pai and Bearden 2007; 
Polso et  al. 2014; Bearden and Rodvold 2000; 
Falagas and Karageorgopoulos 2010) and for 
conventional chemotherapy (Griggs et al. 2012). 
The American Society of Clinical Oncology 
(ASCO) published the following main statements 
in 2012 guidelines:
 – Dose should be selected according to body 
surface area (BSA) using actual body weight.
 – Dose reductions should be based on toxicity 
and comorbidities independent of the obesity 
status.
 – There is no evidence that obese patients expe-
rience increased toxicity when actual weight 
is used for calculation of chemotherapy.
However, some limitations have to be kept in 
mind, as (1) there are no RCTs comparing actual 
body weight with other adjusted dosing 
approaches in obese patients, (2) recommenda-
tions are based on subgroup analyses of obese 
patients from RCTs or observational studies 
using actual versus adjusted weight calculation 
and (3) there are no recommendations for HSCT 
conditioning.
One case report described drug dosing mor-
bidly of an obese patient undergoing allo-HSCT 
(Langebrake et  al. 2011). Here it was observed 
that for hydrophilic and extensively renally 
cleared drugs, standard dosages for adult patients 
or dosing based on ideal body weight can be 
used. For more lipophilic drugs like CSA or digi-
toxin, it could be shown that after achieving suf-
ficient plasma levels using high initial doses, 
maintenance doses similar to those used in nor-
mal-weight patients are sufficient. Monitoring of 
plasma concentrations is highly recommended 
for drugs with a narrow therapeutic index.
67.3.3  Preparative Regimens Prior 
to HSCT
In patients undergoing auto- or allo-HSCT, spe-
cific features and purposes have to be taken into 
account. In auto-HSCT, high-dose chemotherapy 
aims to reduce tumour burden, while in allo- 
HSCT, therapeutic effect is based on donor 
immune cells and myeloablation.
The ASBMT reviewed the current published 
literature on dosing of pharmacologic agents 
used for HCT preparative regimens in obese 
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patients in 2014. They concluded that dose 
adjustments were usually performed empirically 
or have been extrapolated from published data in 
non-transplant patients. Therefore, evidence for 
clear standards or dosing guidelines are currently 
not available as there are insufficient data to 
determine optimal drug dosing in obese patients 
undergoing HSCT (Bubalo et  al. 2014). 
Nevertheless, consensus dosing recommenda-
tions were given (see Table 67.2).
Recently, the approach to use AIBW-based 
BSA for dose calculation of MEL prior to auto- 
HSCT has been shown to be non-inferior as com-
pared to the nonobese population in terms of 
3-year event-free survival (Shultes et al. 2018).
Even for ATG, TBW for dose calculation is 
recommended by ASBMT. However, from a PK 
point of view, it would be more reasonable to use 
the IBW, as ATG has a volume of distribution that 
is almost equal to the whole blood volume. 
Recently, it has been proposed to rather base ATG 
dosing on absolute lymphocyte count, as this is 
the target of ATG (Kennedy et al. 2018).
Reports of obese patients undergoing HCT are 
challenging to interpret because of the heteroge-
neity of obesity definitions, underlying diseases, 
graft sources and chemotherapy regimens 
employed. Compared with normal-weight 
patients, it appears that obese patients undergo-
ing allo-HSCT have a higher risk of non-relapse 
mortality and inferior survival, whereas those 
receiving auto-HSCT appear to have equivalent 
outcomes. Another important limitation for inter-
pretation of published data is that there is no con-
sistent standard for calculating chemotherapy 
dose in this group. Therefore, it is recommended 
that future studies utilise more consistent and 
biologically relevant definitions of obesity and 
that the PK and pharmacodynamics of specific 
conditioning regimens be studied (Weiss et  al. 
2013). In clinical practice, about 80% of HSCT 
centres routinely perform dose adjustment for 
obesity; however, the methods used for determin-
ing the weight for chemotherapy calculation are 
different among the transplant centres (Shem- 
Tov et al. 2015).
Table 67.2 Overview of volume of distribution
Drug Vda Recommendation (ASBMT 2014) Bubalo et al. (2014)
Alemtuzumab Low Flat dosing
Amsacrine High n.a.
ATG Low TBW (for mg/kg)
Busulfan Medium   – AIBW25 in adults (obese and nonobese) for mg/kg
  – TBW (for BSA)
  – PK targeting for regimens >12 mg/kg PO equivalent
Carboplatin Low TBW (for BSA)
Carmustine High TBW (for BSA), unless >120% IBW, then AIBW25
Clofarabine High TBW (for BSA)
Cyclophosphamide Medium   – 200 mg/kg: lesser of IBW or TBW
  –  120 mg/kg: either IBW or TBW until >120% IBW and then dose based 
on AIBW25 (former is preferred for adults, latter for children)
Cytarabine High TBW (for BSA)
Etoposide Low- medium – AIBW25 for mg/kg
– TBW (for BSA)
Fludarabine High TBW (for BSA)
Melphalan Medium TBW (for BSA)
Pentostatin Medium TBW (for BSA)
Thiotepa Medium TBW (for BSA), unless >120% IBW, then AIBW40 for BSA
Treosulfan Medium n.a.
aVd volume of distribution (low, <0.3 L/kg; medium, 0.3–1.5 L/kg; high, >1.5 L/kg), and recommendations for dose 
calculation for adults according to ASBMT. AIBW25 adjusted ideal body weight 25%, AIBW40 adjusted ideal body 
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Key Points
• Obesity is associated with a significant 
increase in morbidity (including meta-
bolic diseases and cancer) and 
mortality.
• Indirect measures of body composition, 
like BMI or ideal body weight, remain the 
standard, as they are easy to calculate.
• There is only limited evidence-based 
information about drug clearance in 
obese patients due to restrictions of clin-
ical trials and the lack of pharmacoki-
netic analyses.
• Evidence for clear standards or dosing 
guidelines are currently not available as 
there are insufficient data to determine 
optimal drug dosing in obese patients 
undergoing HSCT.
• Despite that, in clinical practice, about 
80% of HSCT centres routinely perform 
dose adjustment for obesity. However, 
the methods used for determining the 
weight for chemotherapy calculation are 
different among the transplant centres.
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The hematological malignancies which are the 
most common indications for auto- and allo- 
HSCT (e.g., AML/MDS, NHL, MM, and others) 
are diagnosed at a median age greater than 
65 years old. Thus, if classical chronological age 
exclusion criteria were followed, a majority of 
patients with these malignancies would not be 
offered a HSCT, despite it being their treatment 
of choice and in many cases their only curative 
option (Sureda et al. 2015). While elderly patients 
are more likely to face toxic effects from HSCT, 
this risk must be considered and balanced against 
the poor outcome of transplant candidates with 
these malignancies who do not proceed to HSCT.
68.2  HSCT Activity in Elderly 
Patients
Auto- and allo-HSCT annual activity continues to 
steadily increase in Europe and worldwide with no 
signs of saturation (Gratwohl et  al. 2015). 
Specifically, in elderly patients, HSCT activity at 
EBMT centers has increased markedly in the past 
two decades. Auto-HSCT activity in patients 
≥65  years old increased from 3.4% (443 out of 
13,163 autologous HSCT) in 2000 to 9.8% (2444 
out of 23,883 auto-HSCT) in 2014 (Sánchez- 
Ortega et al. 2016). Allo-HSCT activity in patients 
≥65 years old increased from <1% (37 out of 6413 
allo-HSCT) in 2000 to 6.7% (1057 out of 16,765 
allogeneic HSCT) in 2014 (Basak et al. 2016). In 
the USA, over 50% of auto-HSCT for lymphomas 
and MM were performed in patients over 60 years 
old and 12% in patients ≥70  years old in 2015 
(D’Souza and Zhu 2016). The number of patients 
aged ≥60 undergoing allo-HSCT doubled in 2007–
2013 compared to 2000–2006 (D’Souza and Zhu 
2016), and US allografts for patients ≥70  years 
rose tenfold over the past decade, with AML as the 
leading indication (Muffly et al. 2016).
Improvements in supportive care, HSC mobili-
zation, and the use of RTC and RIC regimens 
have contributed to the increase in HSCT activity 
overall and, in particular, to the increase of HSCT 
activity rates in elderly patients. With sustained 
improvement in these areas, and as the population 
ages, these numbers will only continue to increase.
68.3  HSCT Outcomes in Elderly 
Patients
Compared to younger adults, elderly patients 
may have higher overall rates of transplant fail-
ure. Potential comorbidities, impaired health, 
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and performance status could lead to higher 
transplant- related morbidity and mortality. 
In addition, malignancies in elderly patients 
often have more adverse disease features (e.g., 
higher- risk cytogenetics and molecular patterns 
in AML/MDS patients) and may have been 
treated less aggressively prior to HSCT, which 
may potentially also increase the risk of disease 
relapse.
Historically, HSCT outcome analysis in 
elderly patients has been limited by the fact that 
these patients are underrepresented in clinical 
trials and the majority of data come from rela-
tively small series and subgroup analyses of 
small subsets of elderly patients in larger dis-
ease-specific studies including adults of all 
ages. More recently, HSCT outcomes of elderly 
patients are being analyzed specifically and 
have reported feasibility and safety of autolo-
gous HSCT in MM patients >65  years (Winn 
et  al. 2015), in selected populations of elderly 
patients with R/R DLBCL (Chihara et al. 2014), 
and in R/R HL in patients ≥60  years of age 
(Martínez et  al. 2017). Prospective studies 
addressing the value of allogeneic HSCT com-
pared to non-transplant approaches are limited 
and generally restricted to patients <65  years 
old. Interestingly, several large series in AML/
MDS patients reported that NRM and OS were 
negatively affected by KPS <80–90% but not by 
chronological age (Heidenreich et  al. 2017; 
McClune et  al. 2010). Despite significantly 
poorer outcomes in older patients, additional tri-
als have also not shown a significant impact of 
advanced age on major outcomes including 
NRM (Sorror et al. 2011; Chevallier et al. 2012).
The largest experience reported to date on 
auto- and allo-HSCT outcomes in elderly 
patients comes from two EBMT studies includ-
ing a total of 21,390 auto-HSCT and 6046 allo-
HSCT in patients ≥65 years old between 2000 
and 2014 (Basak et  al. 2016; Sánchez-Ortega 
et  al. 2016). Patient numbers and key HSCT 
outcomes overall and by age group are pre-
sented in Table 68.1.
These studies confirm the feasibility of auto- 
and allo-HSCT in elderly patients, with accept-
able NRM and OS at 1 and 3 years. Multivariate 
analyses in both studies showed that performance 
status (i.e., Karnofsky score) had a more signifi-
cant independent impact on patient outcomes 
than chronological age. Thus, these data in a large 
cohort of elderly patients strongly suggest that 
age per se should not be an exclusion criterion to 
consider HSCT in this population. Undoubtedly, 
this is presumably a highly selected fraction of 
elderly patients considered for auto- and allo-
HSCT.  Nevertheless, this further endorses the 
need to assess comorbidity and frailty beyond 
age in older HSCT candidates to improve out-
comes further.
68.4  Assessment of  
Elderly Candidates  
for HSCT
In addition to the elements already discussed in 
Chap. 11 for younger patients, the evaluation 
and counseling of elderly patients as candidates 
for auto- and allo-HSCT require the evalua-
tion of additional health domains of interest in 
patients of advanced age. The following tables 
address general principles and considerations for 
evaluation and counseling of these patients, dis-
cuss the issue of patient frailty beyond age and 
comorbidities, and describe the key elements of 
a  multidimensional geriatric assessment in this 
population.










 – NRM year 1
 – OS year 1














 – NRM year 1
 – OS year 1













n number of cases
aBasak et al. (2016) and Sánchez-Ortega et al. (2016)
R. F. Duarte and I. Sánchez-Ortega
501
68.4.1  General Principles 
and Considerations for Elderly 
HSCT Candidates
 – HSCT decision should not be driven by chron-
ological age but by a broader multidimen-
sional assessment including fitness, 
comorbidities, physiologic reserve, and frailty.
 – Elderly patients require information and coun-
seling in plain language regarding the HSCT 
process, donor sources, specific protocol, 
timeline, risks, benefits, and outcomes.
 – They also need information regarding patients’ 
quality of life outcomes, caregivers, and psy-
chosocial needs, for which social workers and 
other support staff will be needed.
 – A multidisciplinary individualized assessment 
is required to appropriately address the multi-
dimensional nature of the evaluation of elderly 
patients.
 – Fit older transplant candidates should follow 
the same indications for auto- and allo-HSCT 
as younger adults.
 – In the case of allo-HSCT, particular consider-
ation to RIC and NMA regimens is essential, 
and donor selection must take into account the 
age of the donor, as donor older age may asso-
ciate with impaired outcomes.
 – Outcome analysis in elderly patients may 
require the use of clinically relevant compos-
ite endpoints that, beyond survival, incorpo-
rate quality of life, good overall mental and 
physical condition, and freedom from severe 
complications.
68.4.2  Frailty in Elderly HSCT 
Candidates
 – Frailty is a term used to describe a multidimen-
sional syndrome of loss of physiologic reserves 
(energy, physical ability, cognition, health) that 
leads to vulnerability.
 – The ability to measure frailty in elderly 
patients is useful clinically.
 – Although it appears to be a valid construct to 
assess elderly patients, how exactly to define 
it remains unclear. There is a large abundance 
of possible scales to measure frailty, which 
likely reflects uncertainty about the term and its 
components.
 – A.  Hedge et  al. have recently reported on 
frailty as the missing piece of pre- HSCT 
assessment (Hegde and Murthy 2018). Data 
shows that the prevalence of frailty prior to 
HSCT in patients ≥50 years old is higher than 
in the general geriatric population at around 
25%. Importantly, age has no effect on preva-
lence of frailty.
 – Frailty is associated with poorer OS even after 
adjusting for age and HCT-CI and may be associ-
ated as well with an increased incidence of dis-
ease relapse (Muffly et  al. 2014, Hegde and 
Murthy 2018).
68.4.3  Geriatric Assessment 
for Elderly HSCT Candidates
68.4.3.1  General Concept
 – The geriatric assessment is a multidimensional, 
multidisciplinary assessment designed to eval-
uate an older person’s functional ability, physi-
cal health, cognition, mental health, and 
socioenvironmental circumstances (Artz 2016).
 – The goal of geriatric assessment in this con-
text would be to capture vulnerability pre-
HSCT to help deciding on patient suitability 
for the procedure, as well as to individualize 
post-HSCT support strategies to prevent com-
plications and reduce transplant-associated 
morbidity and mortality (Artz 2016).
68.4.3.2  Elements Involved in Elderly 
HSCT Candidates
 – Ensure appropriate performance status 
(Karnofsky score ≥80).
 – Rule out significant comorbidities by the 
HCT-CI (Sorror et  al. 2005), as their preva-
lence increases with age.
 – Assess the modified EBMT (Armand et  al. 
2014) and the revised PAM scores (Au et al. 
2015), as global prognostic models that incor-
porate both NRM and disease factors.
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 – Measure functional status by self- reported 
function and performance- based testing (abil-
ity to perform tasks necessary to live indepen-
dently in the community [i.e., shopping, food 
preparation, housekeeping, telephone, laun-
dry, transportation and driving, manage 
finances and medication, number of times a 
patient can rise from the chair (i.e., timed up 
and go), gait speed, 6-min walk test, hand grip 
strength, or provocative cardiopulmonary test-
ing], polypharmacy requirements).
 – Cognitive function: if necessary, perform neu-
ropsychological testing and/or consult 
geriatrics.
 – Psychosocial evaluation (assessment of social 
support, availability of a caregiver, financial 
matters, psychological disturbances, etc.).
 – Nutritional status and weight loss.
 – Biomarkers to characterize physiologic age 
(serum C-reactive protein, ferritin, serum 
albumin, or protein biomarkers panels in 
development).
68.4.3.3  Scales
 – No standard geriatric assessment scales have 
been validated for HSCT.
 – Most scales available for geriatric assessment 
in cancer patients are complex and time-con-
suming, which limits its use in daily practice.
 – The Geriatric Assessment in Hematology (GAH) 
scale is a brief, comprehensive geriatric assess-
ment scale designed and validated for older 
patients diagnosed with hematological malig-
nancies (MDS, AML, MM, and CLL) (Bonanad 
et al. 2015).
 – The GAH scale includes 30 items grouped 
into 8 pre-defined dimensions (number of 
drugs, gait speed, mood, activities of daily liv-
ing, subjective health status, nutrition, mental 
status, and comorbidities) and requires a rela-
tively short period of time to be administered 
in routine clinical practice (10–12 min).
 – Thus, the GAH scale could be an interesting 
tool to assess elderly patients with hemato-
logical malignancies who are being consid-
ered for transplantation. However, it still needs 
to be validated in the setting of HSCT.
Key Points
• HSCT activity in elderly patients has 
increased markedly in the past two 
decades and is predicted to continue to 
increase as the population ages, with a 
sustained improvement in HSCT meth-
odology and care.
• Auto- and allo-HSCT in elderly patients 
is feasible and has acceptable outcomes.
• Age should not be an exclusion criterion 
per se to consider elderly patients for 
HSCT.
• Assessing comorbidity is essential in older 
HSCT candidates, but adjusting only for 
comorbidity may not identify frail patients 
vulnerable to adverse outcomes.
• Frailty is a multidimensional syndrome 
of loss of physiologic reserves (energy, 
physical ability, cognition, health) that 
leads to vulnerability, is higher in HSCT 
recipients than the general geriatric 
population, and associates with poorer 
HSCT outcome.
• Geriatric assessment is a multidimen-
sional, multidisciplinary assessment 
designed to evaluate an older person’s 
functional ability, physical health, cog-
nition, mental health, and socioenviron-
mental circumstances.
• The goal of geriatric assessment in 
HSCT would be to capture vulnerabil-
ity to pre-HSCT to help deciding on 
patient suitability for the procedure and 
to adapt post-HSCT support strategies 
to improve outcomes.
• Currently, there are no standard geriatric 
assessment scales validated for HSCT. The 
GAH scale has been described and vali-
dated in elderly patients with hematologi-
cal malignancies, is relatively simple to 
apply in clinical practice, and may be a 
candidate scale for elderly HSCT candi-
dates, validation pending.
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69.1  AML in CR1
Jurjen Versluis, Jan J. Cornelissen
69.1.1  Definition, Subtypes
AML is a malignancy of hematopoietic immature 
precursors (myeloblasts) that accumulate in the 
BM at the expense of their normal counterparts. 
AML is diagnosed by cytomorphology if more 
than 20% myeloblasts are present in the BM or 
PB.  In addition, immunophenotyping and cyto-
genetic and molecular characterization are used 
to identify a number of AML subtypes.
The WHO defines seven major subtypes of 
AML based largely on genetic, morphological, 
and cytochemical characteristics of the disease, 
whereas the most recent update (2016) included 
a new category termed “myeloid neoplasms with 
germ line predisposition” (Arber et al. 2016). In 
addition, risk classification is increasingly done 
according to the latest European LeukemiaNet 
(ELN) recommendations, whereby three risk 
groups are distinguished, including favorable risk, 
intermediate risk, and adverse risk, largely based 
on pretreatment cytogenetic abnormalities and 
aberrations in the NPM1, FLT3, CEBPA, RUNX1, 
ASXL1, and TP53 genes (Dohner et al. 2017).
69.1.2  Clinical Presentation
The median age at diagnosis is approximately 
70  years, and the annual age-standardized inci-
dence rate varies between 3 and 4 cases per 
100,000. Patients with AML may present with 
symptoms such as fatigue and loss of appetite, 
whereas lymphadenopathy and hepatospleno-
megaly may be found by physical examination. 
Analysis of blood work often reveals thrombo-
cytopenia, anemia, and/or neutropenia. In some 
patients a serious bleeding diathesis can occur, 
particularly in the early phase of treatment, 
because the leukemic blasts are able to activate 
the coagulation cascade as well as cause hyper-
fibrinolysis. This particularly occurs in patients 
with acute promyelocytic leukemia (APL).
J. Versluis · J. J. Cornelissen 
Department of Hematology, Erasmus Medical Center 
Cancer Institute, Rotterdam, The Netherlands 
C. Craddock 
Centre for Clinical Haematology, Queen Elizabeth 
Hospital, Birmingham, UK 
M. Á. Sanz 
Department of Hematology, University Hospital La 
Fe, University of Valencia, Valencia, Spain 
J. Canaani · A. Nagler (*) 
Hematology and BMT Division, Chaim Sheba 




69.1.3  First-Line Treatment
Achievement and maintenance of complete remis-
sion (CR) are crucial in younger AML patients 
aged below 60 years, but treatment may largely fail 
because of relapse from CR rather than primary 
resistance or treatment-related mortality (TRM).
With modern supportive care, TRM rates aver-
age <5%. For 30  years standard induction treat-
ment (to produce CR) has consisted of 7–10 days 
of the antimetabolite cytosine arabinoside (Ara-C) 
and 3 days of an anthracycline (i.e., daunorubicin 
or idarubicin). CR rates with standard induction 
estimate between 70 and 90%. Favorable-risk 
patients may experience relatively good outcome 
with overall survival rates of approximately 60%, 
whereas outcome for patients with intermediate-
risk and adverse-risk AML remains unsatisfactory.
Following the introduction of targeted thera-
pies in other malignancies including TKI in 
CML, studies to evaluate targeted treatment in 
AML were initiated 5–10 years ago, and a large 
randomized study in patients with FLT3 AML 
demonstrated a survival benefit for younger 
AML patients treated with the kinase inhibitor 
midostaurin in conjunction with intensive induc-
tion and consolidation chemotherapy (Stone et al. 
2017). That study led to the approval of midostau-
rin, which has now become standard of care in 
AML patients with mutated FLT3. The ability of 
the pretreatment features such as incorporated in 
the ELN risk classification to predict outcome is 
important to direct treatment decisions; however 
probably more prognostically important than the 
pretreatment features is response to treatment 
(CR vs. lesser degrees of “response”) and espe-
cially presence, in hematological remission, of 
“minimal residual disease” (MRD) as assessed 
by flow cytometry or molecular testing in patients 
with abnormalities such as mutated NPM1.
Allo-HSCT clearly reduces relapse rates but is 
associated with TRM (see sect. 69.1.4). Patients 
who do not qualify for HSCT are usually offered 
intensive consolidation chemotherapy based on 
high-dose cytarabine (HDAC). The dose of Ara-C 
has been a subject of study and intense debate 
questioning the application of dosages exceeding 
2  g/m2, which is now generally considered the 
upper dose (Lowenberg 2013). Induction chemo-
therapy in younger patients may include the 3 + 
7 scheme, whereas older patients may not toler-
ate intensive induction therapy and therefore are 
considered for non-intensive induction. However, 
it should be noted that also patients above the age 
of 60 years without comorbidities and no organ 
dysfunctions may be candidates for intensive 
therapy, which has been demonstrated to result 
in superior outcome (Lowenberg et  al. 2009). 
Nevertheless, with a median age of approxi-
mately 70 years, most older patients are offered 
non-intensive therapy. With regard to non-inten-
sive therapy, low-dose cytarabine (LDAC) is gen-
erally preferred over best supportive care (BSC) 
(Burnett et  al. 2007). More recently, demethyl-
ation agents were compared with LDAC or BSC 
in older patients with AML and/or MDS, and 
both azacitidine (AZA) and decitabine showed 
a modest survival advantage. Although these 
agents resulted in a small improvement in over-
all survival, they may be preferred over LDAC 
or BSC in patients who cannot tolerate intensive 
induction therapy. At present the demethylating 
agents are predominantly used in those patients 
with myelodysplastic features.
69.1.4  HSCT and AML Risk 
Categories
69.1.4.1  ELN Risk Categories
Previously, conventional cytogenetics and muta-
tions of NPM1, FLT3-ITD, and CEBPA were 
included in the ELN 2010 risk classification of 
AML patients (Dohner et  al. 2010). The current 
ELN 2017 risk classification has added mutations 
in three genes including RUNX1, ASXL1, and 
TP53 (Table 69.1) (Dohner et  al. 2017). Similar 
to the previous risk classification, the ELN 2017 
AML risk classification is advocated to be used for 
risk-stratifying AML and to a risk-adapted treat-
ment approach of patients with AML. Such a risk-
adapted treatment approach of patients with AML 
depends on the risk of relapse of the underlying 
AML but also on the risk of TRM associated with 
the applied post-remission treatment. The applica-
tion of MRD, detected by either multiparametric 
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flow cytometry or quantitative PCR for specific 
molecular markers, may further improve AML 
risk classifications. MRD may be detected at time 
points early after induction treatment to assess the 
remission status of the AML but also after PRT to 
detect imminent relapse. Consequently, MRD neg-
ativity was introduced as an endpoint in patients 
with a hematological CR (Dohner et al. 2017).
69.1.4.2  Transplant Risk Categories
The risk-adapted approach of patients with AML 
in first CR should also include the assessment of 
TRM for each individual patient. TRM may be 
attributed to GVHD, infectious complications, 
organ toxicity, and other causes (Gooley et  al. 
2010). A number of parameters may relate to 
allo-HSCT-related TRM, including the procedure 
(e.g., conditioning regimen, application of TCD), 
donor characteristics (e.g., HLA-matching), and 
recipient features (e.g., age and comorbidity). 
The risk of mortality may be quantified by com-
posite risk scores, which have been established to 
predict for TRM and overall outcome.
Two generally approved transplant risks were 
developed and validated, including the EBMT 
risk score (Gratwohl et al. 1998) and the hema-
topoietic cell transplantation-comorbidity index 
(HCT-CI) (Sorror et  al. 2005). The EBMT risk 
score is based on patient and transplantation 
characteristics, which was developed in CML 
patients and subsequently validated in other 
patient groups including AML (Gratwohl et  al. 
2009). The HCT-CI originated from the Charlson 
comorbidity index and consists of 17 comor-
bidities which contribute to a cumulative score 
(Sorror et al. 2005). The HCT-CI was extensively 
validated and has been continuously being refined 
including age, disease status, or biomarkers 
Table 69.1 Risk-adapted post-remission treatment for patients with AML in first CRa
AML risk classificationb MRD statusc
Preferred post- remission 
treatment
Favorable
t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Negative Chemotherapy/auto-HSCT
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow Positive Allo-HSCTd, (unless excessive 
TRM can be predicted)Biallelic mutated CEBPA
Intermediate
Mutated NPM1 and FLT3-ITDhigh Negative Allo-HSCTd  
(if acceptable risk of TRM; 
alternative, chemo/auto-HSCT)
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow  
(without adverse risk genetic lesions)
t(9;11)(p21.3;q23.3); MLLT3-KMT2A Positive Allo-HSCTe
Cytogenetic abnormalities not classified as favorable or adverse
Adverse
t(6;9)(p23;q34.1); DEK-NUP214 Negative Allo-HSCTe
t(v;11q23.3); KMT2A rearranged
t(9;22)(q34.1;q11.2); BCR-ABL1 Positive Allo-HSCTe
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)
−5 or del(5q); −7; −17/abn(17p)
Complex karyotype, monosomal karyotype




aAdapted from Cornelissen et al. 2012a, b), Table 4
bAdapted from Dohner et al. (2017), Table 5
cDetected with multiparametric flow cytometry or with for qPCR specific markers
dAllo-HSCT using HLA-identical sibling or 10/10 MUD donors
eAllo-HSCT using HLA-identical sibling, MUD, umbilical cord blood, or haploidentical donors
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(Sorror et  al. 2007, 2014). Other groups have 
also developed predictive models for TRM modi-
fying the weights of the EBMT risk score and the 
HCT-CI (Barba et al. 2010), whereas others com-
bined transplant-related parameters and patient 
characteristics (Parimon et al. 2006; Barba et al. 
2014; Shouval et al. 2015).
A more sophisticated, machine-based learn-
ing model was developed by the EBMT-acute 
leukemia working party (ALWP) based on 10 
variables, which resulted in an alternating deci-
sion tree model highly predicting for mortality at 
100 days and at 2 years (Shouval et al. 2015).
However, with the introduction of RIC, allo- 
HSCT is increasingly being applied as post- 
remission treatment for older or less fit patients 
with comorbidities. Several groups have reported 
less predictive power of the EBMT-score and 
the HCT-CI in these subgroups of patients as a 
number of comorbidities are less strongly asso-
ciated with mortality after RIC than after MAC 
(Gratwohl et al. 2009; Barba et al. 2010; Barba 
et  al. 2014). The EBMT-ALWP has developed 
an integrated score based on the EBMT risk 
score and the HCT-CI with increased predictive 
power in the setting of RIC allo-HSCT (Versluis 
et al. 2015). The lack of predictive power of the 
established risk scores and the development of 
a refined and dedicated model emphasize that 
prediction of TRM requires a continued reassess-
ment of risk scores in specific patient groups.
69.1.5  HSCT in First-Line AML 
Treatment: A Risk-Adapted 
Approach
AML risk classifications are being used for tailor-
ing patients’ optimal post-remission treatment, 
which may include allo-HSCT, auto-HSCT, and 
continued chemotherapy. Allo-HSCT is the most 
optimal post-remission treatment for the preven-
tion of relapse due to a potent GVL effect, which 
has been demonstrated to be exerted irrespective 
of underlying AML cytogenetic subcategories and 
MRD status (Cornelissen et  al. 2012b; Versluis 
et  al. 2017a). However, absolute estimates of 
relapse incidence differ and may reflect molecular 
or cytogenetic differences resulting in resistance 
of the AML.  Although the GVL effect of allo-
HSCT is unequivocally present in patients with 
AML in first CR, concurrent TRM may compro-
mise overall outcome, especially in AML patients 
with a relatively low incidence of relapse. Thus, a 
risk-adapted approach of post-remission treatment 
for patients with AML in first CR should include 
an assessment of the TRM risk profile in addition 
to leukemia characteristics and MRD (Cornelissen 
et  al. 2012a; Cornelissen and Blaise 2016). 
Table  69.1 summarizes a risk-adapted approach 
based on the latest ELN AML risk classification, 
MRD status, and the risk for TRM. The risk for 
TRM should be preferably assessed with dedi-
cated scores for specific subgroups of patients. 
Patients with MRD are considered high-risk for 
relapse and preferably receive an allo-HSCT in 
first CR, unless excessive NRM may be predicted.
Allo-HSCT is generally not being indicated 
in patients with a favorable AML risk profile; for 
those patients auto-HSCT or continued chemo-
therapy may be preferred (Dohner et  al. 2017; 
Cornelissen et al. 2012a; Cornelissen and Blaise 
2016). However, favorable-risk patients with per-
sistent MRD may receive an allo-HSCT, espe-
cially those patients with a low risk for TRM.
Results of allo-HSCT compared with auto- 
HSCT or chemotherapy have yielded contradict-
ing results in intermediate-risk patients, especially 
taking molecular markers into account (Koreth 
et  al. 2009; Schlenk et  al. 2008; Rollig et  al. 
2015; Stelljes et al. 2014; Versluis et al. 2017b). 
Assessment of the MRD status is strongly advo-
cated for patients with an intermediate-risk 
AML. Allo-HSCT may be applied in patients with 
intermediate-risk AML with MRD after induction 
chemotherapy, except for patients with a high risk 
for TRM. Allo-HSCT is also preferred for patients 
with intermediate-risk MRD-negative AML, but 
auto-HSCT or chemotherapy may be considered 
when the predicted risk for TRM is high.
Adverse-risk patients with MRD should be 
transplanted with an allografted as soon as a 
hematological CR is obtained. Adverse-risk 
patients without MRD still have a significant risk 
of relapse and may also receive an allo-HSCT, 
although patients with a very high risk for TRM 
may alternatively receive autologous HSCT or a 
third cycle of chemotherapy.
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69.2  Allo-HSCT in Advanced AML
Charles Craddock
69.2.1  Introduction
Allo-HSCT plays an increasingly important role 
in the management of AML in adults (Cornelissen 
et al. 2012a). The advent of RIC regimens cou-
pled with increased donor availability has dra-
matically increased the number of patients in 
whom allo-HSCT can be contemplated.
At the same molecular characterization at 
diagnosis coupled with measurable MRD quanti-
tation after induction, chemotherapy has consid-
erably improved our ability to predict relapse risk 
in patients treated with intensive chemotherapy 
(IC) alone permitting accurate identification of 
allo-mandatory patients.
As a result, allo-HSCT in patients with AML 
in CR1 is an increasingly important personalized 
component of the treatment algorithm. At the 
same time, transplantation is also emerging as an 
important, potentially curative treatment modal-
ity in patients with advanced AML.
The increasingly important role of allo-HSCT 
in the management of AML mandates the devel-
opment of novel strategies with the potential to 
improve transplant outcome. Although the last 
three decades has witnessed a substantial reduction 
in TRM, the risk of disease relapse post  transplant 
remains stubbornly high and now represents the 
major cause of treatment failure in patients allo-
grafted for AML. There is consequently an urgent 
requirement to develop novel strategies with the 
potential to reduce the risk of disease recurrence.
69.2.2  The Role of Allo-HSCT 
in the Management of AML 
Beyond CR1
While a small proportion of patients with AML in 
CR2 achieve long-term survival if treated with sal-
vage chemotherapy alone, compelling data iden-
tify allo-HSCT as the preferred curative option 
(Gale et al. 1996). Long-term survival rates in the 
region of 30–50% have been reported after both 
transplantation from either a matched sibling or 
MUD (Tauro et al. 2005). Encouraging results are 
also reported in patients transplanted using CBU 
with a good total nucleated cell dose and, more 
recently, haploidentical donors. In patients who 
have achieved a morphological CR2, it is wise to 
proceed immediately to transplant, providing the 
patient is fit and a donor has been identified and 
there is no evidence supporting further courses of 
chemotherapy prior to transplantation.
While a rigorous comparison of MAC and RIC 
regimens has not been performed in fit patients 
under the age of 50, a MAC regimen should prob-
ably be preferred. Retrospective studies have 
demonstrated that auto-HSCT can achieve compa-
rable results to those observed with an allogeneic 
donor in adults with AML associated with a CBF 
abnormality, and this can represent an important 
treatment option in patients with comorbidities 
or in the absence of a well-matched donor (Gorin 
et  al. 2008), particularly if both the patient and 
stem cell graft are MRD negative.
Ten to forty percent of adults with newly diag-
nosed AML fail to achieve a morphological CR 
after two courses of induction chemotherapy 
(Ferguson et al. 2016). Factors determining refrac-
toriness to induction therapy include patient age 
and the presence of an adverse risk karyotype. 
Although recognized as one of the most impor-
tant causes of treatment failure, it is perhaps sur-
prising that there is no consensus definition of 
primary refractory AML (PREF AML). While 
the International Working Group (IWG) and the 
European LeukemiaNet (ELN) define resistant 
disease as persistent leukemic blasts following one 
course of induction chemotherapy in either the PB 
or the BM in a patient alive 7 days or more fol-
lowing treatment (Cheson et al. 2003; Dohner et al. 
2010), most transplant studies instead have classi-
fied PREF AML as a failure to achieve a morpho-
logical CR after two induction courses.
The UK NCRI group recently studied more 
than 8000 patients with the aim of more precisely 
defining a measure of chemo-refractoriness. 
Patients with greater than 15% residual blasts or 
less than a 50% proportional reduction in blast 
count after the first course of induction chemo-
therapy were observed to have similar outcomes 
to patients who fail to achieve a morphological CR 
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after two courses. Such patients were observed to 
possess genuinely chemo-refractory disease with 
long-term survival rates <10% if treated with 
chemotherapy alone (Ferguson et  al. 2016). In 
contrast, patients who fulfilled either definition 
of refractory disease achieved long- term survival 
rates in the region of 25–30% after allo-HSCT.
Evidence that allo-HSCT can deliver long- 
term survival in a significant proportion of 
patients with PREF AML has been accumulating 
over the last decade and represents an important 
advance in management of this sizeable patient 
population for whom no other effective therapy 
exists (Craddock et al. 2011; Todisco et al. 2017; 
Brissot et  al. 2017). Nonetheless outcomes in 
patients allografted for PREF AML remain unsat-
isfactory, and both TRM and disease relapse con-
tinue to represent significant barriers to long-term 
survival. There is also a lack of clarity concern-
ing which patients with PREF AML are the most 
likely to benefit from transplantation. Outcome is 
clearly superior in patients who proceed swiftly 
to transplant after no more than two courses of 
IC, and relapse appears to be lower in those with 
a lower burden of disease at the time of trans-
plantation. Importantly the impact of presentation 
karyotype and genotype on remains undetermined 
although some studies, perhaps unsurprisingly, 
identify worse outcome in patients with a com-
plex karyotype. It is therefore important that fur-
ther studies examining the impact of presentation 
karyotype, mutational status, and pre- transplant 
disease load on outcome after allo-HSCT are pri-
oritized. What is incontrovertible however is that 
adults with high-risk AML should undergo an 
urgent search for sibling and URD at presentation 
so that transplant can be swiftly scheduled if the 
patients are refractory to chemotherapy.
The optimal conditioning regimen in patients 
with PREF AML remains a matter of conjecture. 
While MAC regimens should be preferred in fit 
patients under the age of 50, encouraging results 
have also been reported using the sequential 
FLAMSA regimen which incorporates additional 
tumor debulking, using Ara-C and amsacrine, 
prior to a FLU-based RIC regimen (Schmid et al. 
2006). Importantly this schedule also incorpo-
rates early administration of DLI, at day +120, in 
patients with no evidence of active GVHD.
69.2.3  Strategies to Prevent Disease 
Relapse in Patients 
Allografted for AML
Disease relapse remains the major cause of treat-
ment failure in patients allografted for AML 
(Cornelissen et  al. 2012b). Despite substantial 
progress in reducing the toxicity of allo-HSCT, 
the risk of disease recurrence remains stubbornly 
high, and novel strategies with the potential to 
reduce the risk of disease recurrence are urgently 
required (Craddock et al. 2018). Key to the devel-
opment of effective new interventions is an under-
standing of both the clinical factors determining 
disease relapse and an improved understanding of 
the biology of disease recurrence (Ossenkoppele 
et al. 2016). In addition to the impact of presen-
tation karyotype, next- generation sequencing 
(NGS) studies have identified molecular determi-
nants of disease relapse post  transplant (Lindsley 
et al. 2017). Retrospective studies have also dem-
onstrated that pre- transplant MRD is an impor-
tant predictor of disease relapse after allo-HSCT, 
although confirmation of these data in prospec-
tive trials is still lacking (Walter et al. 2011).
The risk of disease relapse also appears to 
be impacted by the conditioning regimen, and 
retrospective studies consistently demonstrate 
an increased risk of recurrence in patients trans-
planted using a RIC regimen although recent 
prospective randomized trials have yielded con-
flicting data (Fasslrinner et al. 2018; Kroger et al. 
2017; Scott et al. 2017). Finally, the intensity of 
post transplant IS is also a critical factor influenc-
ing relapse risk consistent with the exertion of a 
potent GVL effect in patients allografted for AML 
(Bacigalupo et al. 1991; Craddock et al. 2010).
A number of novel approaches toward 
reducing post transplant relapse are currently 
undergoing evaluation. Firstly, quantitation of 
pre-transplant MRD status, using immunophe-
notypic or molecular methodologies, can iden-
tify patients with a higher risk of relapse and 
has resulted in exploration of approaches which 
reduce the pre-transplant MRD status as a means 
of improving transplant outcome. Pivotal to the 
implementation of such strategies are reproduc-
ible and accurate measurements of pre-transplant 
MRD status, and of note novel NGS technologies 
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with improved sensitivity are emerging (Jongen- 
Lavrencic et al. 2018). Secondly, identification of 
the optimal conditioning regimen remains key to 
optimizing transplant outcome. One of the most 
important considerations in interpretation of 
comparisons of MAC and RIC regimens will be 
whether pre-transplant MRD influences patient 
outcome in a regimen-dependent manner.
Finally, there is increasing interest in the elec-
tive administration of pharmacological agents or 
cellular therapies post transplant. A number of 
agents are currently under evaluation as post trans-
plant maintenance strategies including targeted 
therapies such as Flt3 inhibitors or agents with a 
broader antileukemic activity including demethyl-
ating agents such as AZA or checkpoint inhibitors 
(Craddock et al. 2016; Soiffer et al. 2018). In the 
future it is likely that the choice of maintenance 
strategies will be informed by a greater under-
standing of the biology of disease recurrence. In 
this context it is of interest that a significant num-
ber of patients who relapse post- allograft dem-
onstrate loss or acquisition of candidate driver 
mutations at the time of relapse (Quek et al. 2016).
69.3  Practical Issues in Allo-HSCT 
for AML
Jonathan Canaani, Arnon Nagler
69.3.1  Stem Cell Source  
(See Also Chaps. 14 and 15)
One of the fundamental issues in the initial 
decision- making for transplantation physicians is 
the optimal source for procuring the stem cells 
for transplant. Whereas the initial methodology 
for donor stem cell procurement involved direct 
BM harvesting, the introduction of PBSC mobi-
lization more than two decades ago into routine 
clinical practice has shifted the field toward the 
latter approach. Indeed, it has been estimated that 
PBSC is used in more than 75% of allo-HSCT 
(per National Marrow Donor Program data; 
http://www.marrow.org).
Whether PBSC are preferable to BM har-
vesting as the stem cell source for patients with 
AML is still an open question; however there are 
several noteworthy facts which need to be men-
tioned. In patients receiving grafts from MSD, 
early publications suggested superior engraft-
ment rates in PBSC concomitant to an increased 
risk of acute and chronic GVHD in some of the 
studies (Couban et al. 2002). A phase 3 study was 
conducted by the BMT CTN randomized patients 
with various myeloid malignancies (including 
261 AML patients) to receive PBSC versus BM 
harvested cells from MUD (Anasetti et al. 2012). 
The results of this pivotal study revealed com-
parable rates of survival and relapse between 
both groups with increased rates of graft fail-
ure in the bone marrow group counterbalanced 
by an increased likelihood of chronic GVHD in 
the PBSC group. Two analyses from the EBMT 
and the CIBMTR in the RIC setting also con-
firmed the absence of a survival difference for 
either approach (Nagler et al. 2012; Eapen et al. 
2015). Thus, it seems reasonable to conclude that 
at present both stem cell sources are acceptable 
options to use in AML patients.
69.3.2  Best Donor (See Also Chap. 12)
AML patients referred to transplant are currently 
candidates for several potential donor sources 
including HLA MSD, HLA MUD, UCB grafts, 
and haploidentical donors. Indeed, the rapid 
evolution of the field of HSCT is possibly best 
exemplified by the potential donor pool which 
has expanded from the initial requirement for 
an HLA-matched sibling to include also MUD, 
UCB grafts, and more recently also use of 
 haploidentical donors. While MSD and MUD 
remain the preferred donor source in most clini-
cal settings (Schlenk et  al. 2010), the accumu-
lating experience with UCB and haplo donors 
provides a much-needed donor resource for those 
patients lacking suitable MSD or MUD donors, a 
need especially evident in minority populations.
The original pediatric experience with UCB 
has been successfully translated into adult trans-
plantation protocols both in the RIC and MAC 
settings (Oran et al. 2011). Published data from a 
joint CIBMTR/EBMT retrospective study com-
paring UCB and MUD transplants in over 1500 
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acute leukemia patients suggested equivalent 
LFS rates in both groups (Eapen et al. 2010). Of 
note, UCB patients in this study had higher TRM 
rates but a lower incidence of acute and chronic 
GVHD. Interestingly, an analysis in high-risk AML 
patients who underwent either RIC UCB transplant 
or RIC MSD/MUD revealed that the incidence of 
relapse was more than doubled in the UCB group 
(Devillier et al. 2014), while a CIBMTR/Eurocord 
retrospective study of patients over the age of 50 
showed that UCB transplant is feasible in this age 
group albeit at the price of an increased rate of 
TRM and lower LFS rate (Weisdorf et al. 2014). 
Whether a two- unit UCB transplant is superior to a 
one-unit UCB transplant is not entirely clear at this 
point; however a randomized study conducted in 
pediatric and adolescent patients indicates similar 
survival and relapse rates between both groups in 
addition to improved rates of grade III/IV acute and 
extensive chronic GVHD in those patients receiv-
ing a single unit of UCB (Wagner Jr. et al. 2014).
The inherent benefit in using haplo donors is 
the near-universal availability of several potential 
donors which could be either siblings, parents, or 
children dependent on the patient’s age. The ini-
tial experience with this approach was limited by 
a substantial component of TRM due to the slow 
kinetics of immune reconstitution resulting in 
infectious complications as well as graft rejection 
(Ciurea et  al. 2015). A significant breakthrough 
was realized with the advent of novel IS modula-
tion approaches such as PT-CY-based (Robinson 
et  al. 2016) and ATG-based protocols (Chang 
et al. 2014), which via selective in vivo TCD have 
achieved acceptable rates of engraftment. An 
evolving body of literature suggests comparable 
outcomes between haplo transplantation and trans-
plantation from partially HLA MMUD and possi-
bly MUD and MSD as well (Bashey et al. 2013). 
In conclusion, when available, MSD and 10/10 
HLA MUD remain the first choice for donors. For 
patients lacking MSD/MUD, both UCB and haplo 
donors are reasonable alternative donor sources.
69.3.3  Conditioning (See Also Chap. 13)
The ideal conditioning regimen for patients with 
AML is a yet unsettled question in the field of 
transplantation. Yet, the pivotal point to initially 
consider when deciding on a specific condition-
ing regimen is whether the patient would be eli-
gible to receive MAC or rather RIC. For younger 
(less than 45  years of age for most MAC can-
didates) and fit patients, MAC is the preferred 
choice given its superior antileukemia activity 
shown in previous studies (Martino et al. 2013) 
and especially in light of the recent data pre-
sented by the BMT CTN 0901 trialists underscor-
ing the marked relapse-free survival advantage 
experienced by MAC patients compared to RIC 
patients (67% vs. 47%) (Scott et al. 2017).
From a toxicity standpoint, older patients 
derive the most benefit from RIC resulting in 
more favorable NRM and TRM rates. Notably, 
the incidence of GVHD, late infectious compli-
cations, and CMV reactivation is comparable 
between MAC and RIC, while the incidence of 
acute transplant complications (i.e., SOS/VOD, 
mucositis, IPS, and hemorrhagic cystitis) is more 
common in MAC and provides the advantage 
NRM for RIC (Sengsayadeth et al. 2015).
69.3.4  Graft Versus Host Disease 
Prophylaxis (See Also Chap. 25)
Up to 70% of transplanted patients will experi-
ence acute GVHD to some extent, and these 
patients are at a significant risk of morbidity and 
mortality resulting from this severe inflammatory 
reaction. Thus, from a therapeutic standpoint, 
prophylaxis of acute GVHD is one of the crucial 
intervention points during the process of allo- 
HSCT.  In current practice standard prophylaxis 
regimens for acute GVHD comprise the dual use 
of a CNI, namely, CSA or TAC, added to MTX or 
MMF for the first 180 days following transplan-
tation (Ruutu et  al. 2014). Published data from 
studies conducted two decades ago suggested 
that TAC/MTX was superior to CSA/MTX in 
terms of acute GHVD, however this did not trans-
late into a survival advantage, and in fact the lat-
ter regimen may be more commonly used among 
transplant centers (Nash et  al. 2000). MMF, an 
inosine monophosphate dehydrogenase inhibi-
tor, is not often used in the MAC setting, and 
currently its role is mostly limited to CBT and 
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non- MAC- HSCT.  SIR (rapamycin) was evalu-
ated in several phase I/II with non-heterogeneous 
patient cohorts which limited interpretation of its 
efficacy; however a phase III BMT CTN study 
did not show an improvement in the incidence of 
GVHD over MTX (Cutler et al. 2014).
Whereas the abovementioned therapeutic 
modalities are quite adept at prevention of acute 
GVHD, preventing chronic GVHD is still a major 
challenge with these agents, and thus more spe-
cialized strategies to mitigate GVHD have been 
attempted including TCD accomplished using 
either ex  vivo (via positive selection of CD34- 
positive cells or through negative depletion of 
specific T cell subsets) (Saad and Lamb 2017) or 
in vivo methodologies (by use of TCD drugs such 
as ALEM or ATG). Recent publications from sev-
eral phase III studies clearly demonstrate using 
ATG was beneficial for patients with acute leuke-
mia as well as other hematological malignancies 
(Kroger et al. 2016). Ex vivo TCD is a promis-
ing approach and has been shown to be effective 
for GVHD prophylaxis in smaller trials (Pasquini 
et  al. 2012), although wider application of this 
methodology will require further data.
69.4  Acute Promyelocytic 
Leukemia
Miguel Á. Sanz
69.4.1  Concept and Incidence
APL is a subtype of AML with peculiar clinical 
and morphological characteristics that presents 
a specific genetic alteration, the t (15; 17), with 
its corresponding molecular counterpart, the rear-
rangement PML-RARA, which confer a particular 
sensitivity to all-trans retinoic acid (ATRA) and 
arsenic trioxide (ATO). It also highlights the pres-
ence of a hemorrhagic diathesis associated with a 
peculiar coagulopathy, which causes a high inci-
dence of hemorrhagic complications at presenta-
tion and early during the induction treatment.
APL accounts for 10–15% of AML.
69.4.2  Diagnosis
69.4.2.1  Morphology, 
Immunophenotyping, 
and Other Features





•  Cytoplasm with dense 
granulation. Frequent 
Auer rods
•  Reniform or bilobed 
nucleus













•  Most frequently, low 
WBC counts
•  Less frequently, BCR3 
isoform
•  Most frequently, high 
WBC counts
•  Most frequently, BCR3 
isoform
aIntense and homogeneous expression
bHeterogeneous expression
69.4.2.2  Genetic Diagnosis
Conventional cytogenetics t(15;17)(q22;q21)
Pros  – Very specific
  –  Detects additional anomalies in 30% (+8 
the most frequent)
Cons  – Low sensitivity (80%)
  –  Inadequate, bad metaphases or normal 
karyotype (false negative) in 20%
FISH PML-RARA
Pros –  Very specific and rapid
Cons –  Not very sensitive and does not provide 
information about the isoform
RT-PCR
Pros –  Very specific, rapid, and sensitive
 –  Identifies the isoform, which allows MRD 
monitoring
Cons –  Occasional artifacts and contaminations
Immunostaining with anti-PML antibody (PG-M3)
Pros –  Very specific, rapid, and cheap
 –  Characteristic microspeckled pattern by 
indirect immunofluorescence
Cons –  Does not provide information about the 
isoform
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69.4.2.3  Other Rearrangements of the RARA Gene on Chromosome 17
Chromosomal abnormality RARA rearrangement
•  t(11;17) (q23;q21)
•  t(17;17) (q21;q21)
•  t(11;17) (q23;q21)
•  t(5;17) (q35;q21)
•  t(11;17) (q13;q21)
•  t(17;17)(q21;q24)
•  t(X;17)(p11;q21
•  t(4;17) (q12;q21)
•  t(2;17) (q32;q21)
•  t(3;17) (q26;q21)
•  t(7;17) (q11;q21)
•  t(1;17) (q42;q21)
•  PLZF/RARA (poorly responsive to ATRA)
•  STAT5b/RARA (poorly responsive to ATRA)
•  KMT2a/RARA (ATRA sensitivity unknown)
•  NPM/RARA (ATRA sensitivity unknown)
•  NuMA1-RARA (ATRA sensitivity unknown)
•  PRKAR1A/RARA (ATRA sensitive)
•  BCOR/RARA (ATRA sensitive in two cases)
•  FIP1L1/RARA (ATRA sensitivity unknown)
•  OBFC2A/RARA (ATRA sensitive in one case)
•  TBLR1/RARA (insensitive to ATRA)
•  GTF2l/RARA (ATRA sensitive)
•  IRF2BP2/RARA (ATRA sensitive)
69.4.3  First-Line Treatment
The European LeukemiaNet (ELN) recommen-
dations in 2009 already recognized the promis-
ing results reported in several non-randomized 
studies using ATRA plus ATO, with or without 
minimal use of chemotherapy, but the standard 
of care was still considered the combination of 
ATRA plus anthracycline-based chemotherapy 
(Sanz et al. 2009). However recent findings have 
led to modify this recommendation.
The long-term results of a non-randomized 
study (Abaza et  al. 2017) and two recently 
reported randomized clinical trials (Lo-Coco 
et  al. 2013; Burnett et  al. 2015), comparing the 
efficacy and safety of ATRA plus ATO versus 
the standard ATRA plus chemotherapy approach, 
strongly support the former combination as the 
new standard of care for patients with low-to- 
intermediate-risk APL with WBC counts lower 
than 10 × 109/L at presentation. Nevertheless, in 
countries where chemotherapy is more affordable 
than ATO, the classical combination of ATRA 
and chemotherapy is still an acceptable option. 
For high-risk patients, however, there are two 
valid options, either ATRA plus chemotherapy or 
ATRA plus ATO with a certain amount of cytore-
ductive chemotherapy, at least during the induc-
tion phase.
HSCT is never indicated in patients in CR1, 
except for the small fraction of patients with per-
sistent RQ-PCR positivity of PML-RARA after 
consolidation (<1%), given the poor prognosis 
of this subset of patients. HSCT is also indicated 
in APL patients who relapse and achieve second 
or subsequent CR.
69.4.4  Salvage Therapy
Apart from patients with MRD positivity at the 
end of consolidation (molecular persistence), there 
is a general agreement that patients with the more 
common molecular or hematological relapse later 
on require immediate additional treatment, includ-
ing HSCT. Salvage treatment should be given to 
attempt to achieve molecular remission as a bridge 
to HSCT. Salvage treatment with ATRA plus ATO 
is recommended when ATRA plus chemotherapy 
has been previously used front-line, whereas 
ATRA plus chemotherapy would be the option 
when front-line therapy was ATRA plus ATO.
The use of gemtuzumab ozogamicin may 
also be considered in both situations, but always 
as a bridge to HSCT.  Based on recent studies, 
(Yanada et  al. 2013; Holter Chakrabarty et  al. 
2014; Lengfelder et al. 2015) auto-HSCT should 
be considered the first choice for eligible patients 
achieving second molecular remission. Patients 
unsuitable for HSCT and those with a very pro-
longed CR1 can be managed with some type of 
continuation therapy which would be chosen tak-
ing into account previous treatments and clinical 
condition.
Allo-HSCT should be reserved for patients 
with high risk of relapse and low risk of TRM 
but also as a second option, for those who relapse 
after an auto-HSCT.
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69.4.5  Indications of HSCT
HSCT is never indicated in patients in CR1, 
except for those patients who do not achieve 
molecular remission at the end of consolidation 
(<1%). Indications of HSCT and other recom-
mendations for patients in whom HSCT is indi-
cated are summarized in Table 69.1.
69.4.6  Main Series Reported on HSCT 
in APL
There are no randomized trials to evaluate the effi-
cacy and safety of the different modalities of HSCT 
in refractory/relapsed APL. The data come mostly 
from retrospective studies comparing historical 
cohorts from registries (Tables 69.2 and 69.3).
Table 69.2 Indications of HSCT in patients with APL
Auto-HSCT Allo-HSCT
Not indicated CR1 in molecular remission CR1 in molecular remission
Indicated ≥CR2, but in molecular remission  –  ≥CR2 with PML-RARA (+) after salvage 
therapy
 –  ≥CR2 if an auto-HSCT has failed previously
 –  ≥CR2 in patients with high risk of relapse 
and low risk of TRM
Salvage therapy as 
a bridge to HSCT
Attempt to achieve molecular remission 
with ATRA plus ATO in patient who 
relapsed after ATRA plus chemotherapy as 
front-line therapy, whereas ATRA plus 
chemotherapy is the option when patients 
relapse after ATRA plus ATO
Attempt to achieve molecular remission with 
ATRA plus ATO in patient who relapsed after 
ATRA plus chemotherapy as front-line therapy, 
whereas ATRA plus chemotherapy is the option 
when patients relapse after ATRA plus ATO
Conditioning 
regimen
Either for use in AML, preferably 
containing HDAC (e.g., BEA  
(Gondo et al. 1997): BU/VP/Ara-C)
Either for use in AML
Cell source Mobilized peripheral blood Mobilized peripheral blood
Indication of CNS 
prophylaxis
ITT with MTX, hydrocortisone, and Ara-C, 
especially in those who presented relapse 
in CNS
ITT with MTX, hydrocortisone, and Ara-C, 
especially in those who presented relapse in CNS
Maintenance 
therapy post-HSCT
Not proven, but conceivable that  
ATO + ATRA may be effective




Recommended by RQ-PCR at least every 
3 months for 2–3 years
Recommended by RQ-PCR at least every 
3 months for 2–3 years
Table 69.3 Main series reported on HSCT in APL
Group and reference Patients Type of study Main conclusions
European APL Group 
(Thomas et al. 2000)
33 –  Retrospective
–  Inclusion of patients from the 
pre-ATRA era






 –  Only patients of the pre-ATRA era
–  Higher TRM but lower relapse rate 
with allo-HSCT compared with 
auto-HSCT
– Similar EFS
Japan Adult Leukemia 
Study Group (Yanada 
et al. 2013)
35 – Prospective, phase II, multicenter
–  Salvage therapy with ATO+Ida, 
followed by ATO x 2, HDAC, and 
auto-HSCT
–  Outstanding efficacy and feasibility of 
the sequential treatment featuring ATO 




–  Only patients of the pre-ATRA era





–  Salvage therapy with ATO±ATRA 
for induction and consolidation 
followed by auto- or allo-HSCT
–  Good but similar results with allo- and 
auto-HSCT
–  Unfavorable prognostic impact of 
PML-RAR positivity at time of HSCT 
even in the allogeneic setting
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The outcome for children with acute myeloid 
leukemia (AML) has serially improved over the 
past three decades with an overall survival (OS) 
of 70–75% and event-free survival (EFS) of 
60–65% widely reported. Much of this improve-
ment is due to better supportive care, optimiza-
tion of intensity of treatment including 
employment of  Haematopoietic Stem Cell 
Transplantation (HSCT) in 1st complete remis-
sion (CR1) and better salvage in 2nd complete 
remission (CR2).
Whilst the majority of children (>90%) 
achieve CR, the relapse rate (RR) in CR1 remains 
unacceptably high at 30–35%, albeit varying by 
risk group. This global relapse risk has not 
improved significantly over the past three 
decades, and relapse remains the commonest 
cause of death.
HSCT, compared to chemotherapy as consoli-
dation treatment, reduces the relapse risk in 
CR1 in all risk groups. However, this reduction in 
relapse risk has not always translated into an 
improvement in OS due to the  treatment related 
mortality (TRM).  The challenge is to identify 
children with a relapse risk in CR1, which is suf-
ficiently high, to absorb the TRM and balance the 
risk in favour of HSCT. It is particularly impor-
tant to establish the benefit of HSCT across all 
risk groups and within rare subtypes of AML 
associated with a poor outcome when treated 
with chemotherapy alone and not to assume that 
these children will benefit from HSCT. This will 
require evaluation by clinical trials which in turn 
will require international collaboration. 
Particularly worthy of consideration when weigh-
ing the benefits of transplantation in children are 
the associated late effects.
It is accepted that HSCT offers children with 
relapsed AML, who achieve a CR2, their only 
chance of long-term survival, and that some chil-
dren with relapsed/refractory disease may benefit 
from HSCT.
70.2  Prognostic Factors 
and Indications
70.2.1  First Complete Remission
Consolidation therapy with allogeneic HSCT 
in CR1 of paediatric AML has been shown 
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consistently to reduce the relapse risk through a 
GVL effect, which is stronger in AML than ALL.
Historically, HSCT trials employed a bio-
logical randomisation with children who had a 
matched sibling donor (MSD) receiving a HSCT 
as consolidation therapy and those without a 
MSD receiving consolidation chemotherapy. 
Improvements in HLA typing and donor selec-
tion have made HSCT an option for the majority 
of patients. Historical trials reported a reduc-
tion in RR which was counterbalanced by an 
increased TRM and better salvage for those who 
received chemotherapy only in CR 1 (Stevens 
et al. 1998; Woods et al. 2001; Lie et al. 2003). 
However, delaying transplant to CR2 carries 
risk. The mortality rate for reinduction after 
relapse is high, and those patients who do not 
achieve CR2 may be denied the opportunity of 
HSCT.
The criteria for transplanting patients have 
evolved from transplanting patients irrespective 
of risk group, to transplanting all patients other 
than those with good-risk cytogenetics (about 
80% of all patients), to the current practice of 
restricting transplant to those with poor-risk (PR) 
cytogenetics (about 30% of all patients). These 
are the patients believed to be at the highest risk 
of relapse and therefore those most likely to ben-
efit from HSCT in CR1  in an era of low 
TRM.  There is no universal agreement on how 
high-risk (HR) disease should be defined. 
Different criteria have been, and continue to be, 
used by different national groups to define high 
risk. A combination of cytogenetics/molecular 
aberrations, which are currently considered to be 
the strongest indicator of outcome, and the pres-
ence of minimal residual disease (MRD), which 
may be assessed by morphology, flow cytometry 
or RT-PCR assessments of fusion transcripts, is 
evolving.
The percentage increase in disease free sur-
vival (DFS) or decrease in cumulative incidence 
of relapse (CIR) which would support HSCT as 
the best option in CR1 is undefined. This has 
been set at 10% in adults (Cornelissen et  al. 
2012), but the improved salvage after relapse and 
greater toll from late effects in children suggests 
that the bar should be set higher.
70.2.1.1  Cytogenetics
The cytogenetic abnormalities most commonly 
considered indicative of high risk of relapse 
include monosomy 7, monosomy 5/5q-, abnor-
mal 12p, inv(3)/t(3;3)/abn (3q), CBFA2T3- 
GLIS2, t(4;11), t(5;11), t(6;11), t(10;11), t(6;9) 
,t(9;22), t(7;12), t(11;17), t(8;16), t(3;5) and com-
plex karyotype. There is not complete consensus 
between national groups, and, in particular, not 
all agree that abnormalities of 3q, t (6; 11) and 
complex (4 or more) are poor risk. Most consider 
a FLT3-ITD mutation (approximately 12% of 
children with AML) to be HR.  However, some 
groups require the absence of good-risk cytoge-
netics, whilst other groups restrict this to FLT3 
ITD-WT1 mutations or base the risk on the allelic 
ratio (>0.4). The development of next-generation 
FLT3 inhibitors may challenge the role of HSCT 
in FLT3-ITD-mutated patients. A number of 
more recently recognised poor-risk cytogenetic 
abnormalities are cryptic, and it is expected that 
more cryptic abnormalities will be identified and 
that the list of poor-risk cytogenetic abnormali-
ties may change with time. Currently poor-risk 
cytogenetics comprise about 25–30% of all AML 
in children.
An OS in excess of 70% is reported for HR 
patients after HSCT, although the definition of 
HR is not uniform. However, a combined COG 
and CIBMTR review of 233 children with AML 
between 1989 and 2006 with HR cytogenetics 
(-7, 7q-, -5, 5q-, abn 3q, t (6; 9), complex karyo-
type) reported no benefit for HSCT over chemo-
therapy. 123 children received chemotherapy, 55 
a matched related donor (MRD) HSCT and 55 an 
unrelated donor (URD) HSCT.  The 5-year OS 
from the time of consolidation or conditioning 
was similar: chemotherapy 43%, MRD 46% and 
URD 50% (p = 0.99).
The pattern of failure differed: CIR at 5 years 
61% vs. 51% vs. 30% for chemotherapy, MRD 
and URD, respectively (p  <  0.001), and TRM 
7%, 13% and 23%, respectively (p = 0.005). HR 
was defined by cytogenetics alone and did not 
include FLT3 mutational or MRD status (Kelly 
et al. 2014). The benefit for HSCT in a number of 
poor-risk cytogenetic subgroups has not been 
proven and must not be assumed.
B. E. S. Gibson et al.
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Whilst HSCT is generally directed at patients 
defined as HR by cytogenetic abnormalities, a 
meta-analysis of MRC and POG trials of HSCT vs. 
chemotherapy showed that only  intermediate- risk 
patients, where risk was defined by cytogenetics 
and poor morphological response to treatment, 
benefited from transplant (OS 61% vs. 51%). 
There was no advantage for HSCT in patients 
with poor-risk cytogenetics; however there were 
too few patients in the poor-risk group to make 
firm conclusions (Horan et al. 2008).
70.2.1.2  Minimal Residual Disease 
Assessment (See Chap. 57)
MRD is variably employed in risk stratification 
to direct patients to HSCT. It has been shown to 
be strongly predictive of outcome, and whilst it is 
commonly used to intensify treatment in poor 
responders, it may equally identify those with 
poor-risk cytogenetic aberrations who have a 
favourable early response and may not require 
HSCT. Currently multidimensional flow (MDF) 
cytometry is most commonly employed either by 
measuring leukemia aberrant immunophenotype 
(LAIP) or a “different from normal” phenotype. 
The discretionary level is 0.1%, and the most 
commonly used time point is post course 2. 
Alternatively, discretionary levels of 0.1% or 1% 
post course 1 are used by some groups to guide 
patients to HSCT in CR1. About 20% of patients 
with a MRD level <0.1% after course 1 will 
relapse, which implies that genetic aberrations 
may influence relapse more than MRD. Similarly, 
30% of patients with a MRD level of >0.1% after 
course 1 will remain in remission. MDF cytome-
try is sensitive to a level of 0.1–0.01% and appli-
cable in 90% of patients with AML.
Molecular MRD may be more sensitive and 
informative but data is limited. It is not commonly 
used outwith acute promyelocytic leukemia 
(APL), but our understanding and employment of 
molecular MRD may change with experience. 
MRD assessment by reverse transcription PCR 
(RT-PCR) for fusion transcripts has a sensitivity 
level of 0.01–001% and is applicable in approxi-
mately 50% of patients. The generally accepted 
discriminatory level is a greater than three-log 
reduction in transcript levels.
The relative significance of cytogenetics/
molecular aberrations and MRD status may 
evolve. Digital PCR and next-generation 
sequencing may be more sensitive but remain in 
the research arena. Similarly, leukemia stem cell 
monitoring may be more informative (Schuurhuis 
et al. 2018).
The main benefit of measuring MRD by any 
methodology is that it may allow the tailoring of 
the intensity of treatment. Thirty one of 267 
(12%) children treated on NOPHO-AML 20024 
were defined as poor responders—15% blasts 
morphologically after course 1 or 5% blasts after 
course 2. These patients had time-intensive che-
motherapy followed by HSCT in 25 of 31 with a 
donor. The 3-year probability of survival for 
these HR patients was 70%. Patients classified as 
intermediate risk (defined as 5–14.9% blasts after 
course 1) had a significantly inferior EFS com-
pared to HR patients. Both groups had time-
intensive chemotherapy, but only HR patients 
proceeded to HSCT (Wareham et  al. 2013; 
Abrahamsson et al. 2011).
The level of MRD after course 1 of chemo-
therapy in children treated on AIEOP 2002/01 
correlated with outcome. At 8 years the outcomes 
for the 125 children in morphological remission 
with MRD level post course 1 of <0.1% vs. 
≥0.1% was DFS 73.1% vs. 35.2% (p < 0.01), OS 
82.2% vs. 51.6% (p = 0.0005) and CIR 23.5 % 
vs. 62.8% (p = 0.0005). Post course 2, the out-
comes at 8 years for MRD of <0.1% vs. ≥0.1% 
was DFS 68.4% vs. 21.9% (p < 0.01), OS 77.1% 
vs. 55.5% (p = 0.0275) and CIR 31.6 % vs. 73.9% 
(p = 0.00078).
Thirty-six patients had a MRD level of ≥0.1% 
at the end of course 1:13 achieved a MRD <0.1% 
after course 2, and their DFS was 45.4% vs. 22.8 
% for patients with persisting MRD ≥0.1% 
(p  =  0.037). Therefore, patients who achieve a 
level of MRD <0.1% after course 2 but who were 
MRD positive (>0.1%) after course 1 remain at 
higher risk of relapse and have a poorer outcome 
compared to those who are MRD negative after 
course 1. This suggests that not only clearance of 
MRD but additional effective treatment is 
required to improve outcome (Buldini et al. 2017; 
Loken et al. 2012).
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St Jude’s AML 02 study showed no difference 
in OS between HR patients undergoing HSCT 
compared to those who received chemotherapy. 
When the analysis was restricted to HR patients 
defined by MRD >1% after induction 1, the OS 
for HSCT was 43% vs. 23% for chemotherapy: 
p = 0.14 (Rubnitz et al. 2010). Whilst the differ-
ence was not statistically significant, this may 
have been limited by low patient numbers.
There is no advantage for HSCT in CR1 for 
patients with good-risk cytogenetics—t (8; 21), 
inv (16), normal karyotype with NPM1 and nor-
mal karyotype with biallelic CEBPA.  Some 
groups include t(1;11) (q21; q23) in the good- 
risk cytogenetic group.
The benefit of HSCT in CR1 for patients with 
intermediate-risk cytogenetics is less clear, and 
these may be the patients without PR cytogenet-
ics but with a poor early response to chemother-
apy in whom MRD can identify those at high risk 
of relapse. There is no role for HSCT in CR1 of 
APL or DS AML.  HSCT for patients with 
Fanconi anaemia and MDS/AML and those with 
JMML are discussed elsewhere.
70.2.2  Second Complete Remission
Patients with relapsed AML have a dismal prog-
nosis with chemotherapy alone, and it is gener-
ally accepted that they should proceed to 
transplant in CR2. The chance of achieving a sec-
ond CR after relapse is dependent on the length 
of CR1: CR1 <1 year vs. CR >1 year is 50% vs. 
75% with an overall CR rate of 60%, OS for CR 
<1  year 26% vs. 45% CR >1  year, p  <  0.001 
(Kaspers et al. 2013). Prognostically significant 
are the time to relapse, cytogenetics, no HSCT in 
CR1 and the speed of response to reinduction. 
Cytogenetics are strong prognostic indicators in 
relapse as in de novo disease with patients with 
CBF leukemias fairing the best: CBF leukemias 
vs. others—OS 67% vs. 31%, p < 0.001.
70.2.3  Refractory Disease
It has long been accepted that a poor morphologi-
cal response >5% blasts at day 15 or resistant dis-
ease after course 1 or 2 has a poor outcome with 
chemotherapy alone. If CR cannot be achieved, 
the outlook is poor, but aggressive chemotherapy 
followed by HSCT may benefit some patients. 
Residual disease/MRD positivity pre- HSCT 
increases the risk of relapse post-HSCT, but the 
susceptibility of AML to GVL does not preclude 
transplant. MRD status just prior to HSCT is an 
important prognostic indicator.
A small study reported a 5-year OS of 80.4% 
for children with <0.01% MRD (n = 27), 66.7% for 
those with 0.01–5% MRD (n = 9) and 58.3% for 
those with >5% MRD (Leung et al. 2012). It is not 
clear what level of disease should preclude HSCT.
The role of transplant in CR1, CR2 and refrac-
tory disease may change with time if new effec-
tive chemotherapy agents become available.
70.3  Conditioning Regimens
No advantage has been shown for total body irra-
diation (TBI) in AML and chemotherapy-only 
regimens should be used. Adult data from the 
CIBMTR demonstrated improved non relapse 
mortality (NRM), OS and DFS in patients with 
AML transplanted using IV Busulfan (Bu) with 
therapeutic drug monitoring (TDM) compared 
with TBI (Copelan et  al. 2013). Myeloablative 
conditioning (MAC) regimens are most com-
monly used, but a number of reduced toxicity 
conditioning (RTC) regimens are being tested. 
There is no proven “best” chemotherapy condi-
tioning regimen, though MAC regimens with Bu 
and cyclophosphamide (Cy) with TDM of Bu 
levels are currently the standard of care. A retro-
spective EBMT study of Bu, Cy and Melphalan 
(Mel) (enhanced MAC) in paediatric AML in 
CR1 suggested improved RR and Leukemia free 
survival (LFS) compared with BuCy, but the 
majority of patients receiving  BuCy on this 
study did not undergo TDM (Lucchini et  al. 
2017). Moreover, whilst this regimen is well tol-
erated in children under the age of 12 years, it is 
associated with non-acceptable TRM rates 
between 20 and 30% in teenagers and should 
therefore be avoided or used with caution in this 
group (Sauer et al. 2017). There is an increasing 
body of experience with MAC Bu and 
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Fludarabine (Flu), which is well tolerated, but no 
randomised comparisons are available to deter-
mine relative anti-leukaemic activity of BuFlu vs 
BuCy (Harris et al. 2018). Replacing Bu with 
Treosulfan (Treo) to reduce toxicity whilst main-
taining efficacy is being tested and given in com-
bination with Cy (TreoCy) or with Flu and 
Thiotepa (FTT). The choice of conditioning 
regimen is a balance between efficacy and toxic-
ity. Comorbidity; pretreatment with drugs which 
may contribute to toxicity, i.e. gemtuzumab and 
VOD/SOS, age and HLA disparity may influ-
ence the choice of conditioning regimen. 
Comorbidity or heavy previous treatment may 
indicate a reduced intensity conditioning (RIC) 
with BuFlu or FluMel. Targeted Bu levels will 
differ between MAC, RTC and RIC. Patient tox-
icities may suggest avoidance of specific agents. 
Newer regimens which include clofarabine are 
also being tested.
A retrospective comparison of RIC (39) vs. 
MAC (141) in matched patients has reported no 
difference in a-GVHD, c-GVHD, TRM, LFS and 
OS. The OS was 45% vs. 48%, p = 0.99; RR 39% 
vs. 39%, p  =  0.95; and TRM 16% vs. 16%, 
p = 0.73. However, about 50% of MAC used TBI, 
whilst BuCy was the commonest chemotherapy 
regimen. Patients who received a RIC had had 
more pre-HSCT morbidity. The performance 
score influenced OS, LFS and CIR (Bitan et al. 
2014). The current paediatric AML protocol 
MyeChild01 is prospectively comparing MAC 
BuCy with a reduced toxicity BuFlu regimen.
70.4  Donor Selection Hierarchy 
and Stem Cell Source
70.4.1  Autologous HSCT
There is no evidence from a number of studies and 
meta-analysis that auto-HSCT is superior to inten-
sive chemotherapy as consolidation therapy and it 
is now not employed. AML 2002/01 study reported 
a DFS of 73% for allo-HSCT in HR patients com-
pared to 63% for auto-HSCT, p-ns. The CIR was 
17% vs. 28% in favour of allo- HSCT, p = 0.043. 
There was no difference in TRM at 7% for both 
groups at 8 years (Locatelli et al. 2015).
70.4.2  Allogeneic HSCT
The choice of donor for allo-HSCT is based on 
HLA compatibility and CMV status. Outcomes 
are similar for MSD and well matched unrelated 
donors (UDs). The degree of mismatch which is 
acceptable depends on the risk of relapse and CR 
status. Mismatched unrelated donor (MMUD) or 
cords and haplo-HSCT are generally reserved for 
very HR disease or early relapses.
Patients and their siblings should be tissue- 
typed at diagnosis. In the absence of a HLA 
matched family donor (MFD), an URD and cord 
blood unit (CBU) search should be initiated as 
soon as possible after induction course 1 for 
patients with intermediate or PR cytogenetics. 
Donors should be selected using the selection 
hierarchy of the national group. Medium-/high- 
resolution typing is required for adult URD (HLA 
A, B, C, HLA-DRB1 and HLA-DQB1) and unre-
lated cords (HLA A, B, C and DR loci).
The risk of relapse does not just direct the 
need for transplant but the HLA discrepancy 
which is acceptable. MFD or well-MUD should 
be identified for CR1 patients, whilst mismatched 
donors (8/10 MMUD), cords (4/8 MMUCB) or 
haplo-HSCT should be reserved for very high- 
risk disease, CR2 or refractory disease.
For family/unrelated donors, BM is the pre-
ferred stem cell source, but the use of PBSC is 
permissible and is more commonly used. The use 
of PBSC from mismatched donors should be 
avoided wherever possible.
In the UK, serotherapy is only given to patients 
transplanted from unrelated donors, 9/10 mis-
matched family donors or 5/8 matched cords 
blood units, but not to patients receiving grafts 
from matched family donors or 6–8/8 unrelated 
cord blood units. Other European groups only 
employ T-cell depletion in mismatched donors 
(MMUD).
70.5  GVHD Prophylaxis
All patients should receive immunosuppression 
(IS) with ciclosporin (CSA).  Most, but not all, 
national groups add short-course methotrexate 
(MTX)  for all patients. Patients receiving grafts 
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from a mismatched donor or those in whom the 
stem cell source is PBSC or unrelated cord blood 
should receive prophylaxis in addition to CSA 
with either mycophenolate mofetil (MMF) or 
short-course MTX.  In adult AML, increased 
exposure to CSA was associated with increased 
relapse and decreased survival (Craddock et  al. 
2010), supporting early withdrawal of IS where 
possible. In the absence of GVHD, MMF can be 
stopped at day 28 post  transplant, and CSA tailed 
over 4–6  weeks from day 60 (MFD), day 100 
(MUD) or earlier if mixed chimerism is detected 
in the whole blood.
70.6  Donor Lymphocyte Infusions 
(DLI)
The evidence of benefit for DLI is weak. Rettinger 
et al. investigated the use of pre-emptive immu-
notherapy with reduction of IS and low-dose DLI 
in patients with paediatric AML developing 
mixed chimerism (MC) after HSCT for AML; 
6/13 patients with MC who received immuno-
therapy remained in long-term CR, whereas all 7 
patients with MC who did not receive immuno-
therapy relapsed (Rettinger et al. 2017). Based on 
these limited data, our practice is to use pre- 
emptive immunotherapy in patients with con-
firmed MC (defined as >1% autologous cells in 
the whole blood on two occasions 1 week apart) 
without active acute GVHD >Grade 1 or chronic 
GVHD in the first-year post transplant. If patients 
are still receiving IS, this should be discontinued 
and chimerism reassessed a month later. In 
patients already off IS, chimerism should be reas-
sessed a month off IS.  If mixed chimerism per-
sists, DLI should be given to recipients of MFD 
or MUD. DLI is not recommended in the context 
of 9/10 mismatched donor HSCT. The DLI cell 
dose administered is dependent on the donor 
source and the timing post transplant. In the 
future, the use of pre-emptive DLI is likely to be 
based on detection of flow or molecular MRD in 
the bone marrow.
70.7  Management of Relapse  
Post transplant
For selected patients who relapse late (>1 year) 
post first HSCT and respond to reinduction che-
motherapy, a second transplant may be curative 
with survival rates of 24–35% reported (Yaniv 
et al. 2018; Uden et al. 2017). DLI is of limited 
efficacy in frank relapse post transplant except if 
a further remission can be achieved (Schmid 
et al. 2007; Kolb et al. 1995).
Interestingly, CR has been seen in cutane-
ous (but not bone marrow) relapse of AML 
post  transplant with the checkpoint inhibitor 
ipilimumab (Davids et al. 2016). Novel agents 
targeting specific pathways, e.g. FLT 3 inhibi-
tion, have met with limited success to date. 
Treatment options for patients who relapse 
early after transplant are challenging, and at 
present, for the majority of such patients, we 
recommend symptom care or enrolment in a 
clinical trial. Antibody- drug conjugates, bispe-
cific T-cell-engaging antibodies and chimeric 
antigen receptor (CAR) T cells under develop-
ment may be tested in such patients in the 
future (Table 70.1).






















MFD matched family donor, MUD matched unrelated 
donor, MMUD mismatched unrelated donor, MUCB 
matched unrelated cord blood, MMFD mismatched fam-
ily donor, MMUCB mismatched unrelated cord blood
aFor unrelated cord blood, a single cord is used if the cryo-
preserved TNC dose is >3  ×  107/kg. If <3  ×  107/kg, a 
double cord transplant is preferred
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Acute Lymphoblastic Leukemia 
in Adults
Matthias Stelljes and David I. Marks
71.1  Definition and Epidemiology
ALL is a malignant transformation and prolif-
eration of lymphoid progenitor cells in the bone 
marrow, blood, and extramedullary sites. While 
80% of ALL occurs in children, it represents 
a devastating disease in adults. The incidence 
of ALL is bimodal, with the first peak occur-
ring in childhood and a second peak occurring 
around 50  years. The estimated overall inci-
dence of ALL and lymphoblastic lymphoma in 
Europe is 1.28 per 100,000 individuals annu-
ally, with significant age-related variations 
(0.53 at 45–54 years, ∼1.0 at 55–74 years, and 
1.45 at 75–99  years) (Terwilliger and Abdul-
Hay 2017).
71.2  Diagnosis
Typical but nonspecific clinical manifestations 
of patients with ALL are constitutional symp-
toms, bleeding, infections, and/or bone pain, 
with less than 10% of individuals having symp-
tomatic CNS involvement at diagnosis (Lazarus 
et  al. 2006). Mature B-cell ALL can also pres-
ent as an extramedullary (e.g., GI or testicular 
involvement) disease. Mediastinal mass with 
wheezing and stridor can be a presenting fea-
ture of T-lineage ALL. For diagnostic purposes, 
the addition of flow cytometry to the morpho-
logic identification of neoplastic lymphoblasts is 
essential for classification of ALL.
71.3  Classification
In 1997, the WHO proposed a composite clas-
sification in attempt to account for morphology 
and cytogenetic profile of the leukemic blasts and 
identified three types of ALL: B-lymphoblastic, 
T-lymphoblastic, and Burkitt cell leukemias. Later 
revised in 2008, Burkitt cell leukemia was elimi-
nated as it is no longer seen as a separate entity 
from Burkitt lymphoma, and B-lymphoblastic 
leukemia was divided into two subtypes: B-ALL 
with recurrent genetic abnormalities and B-ALL 
not otherwise specified. B-ALL with recurrent 
genetic abnormalities is further delineated based 
on the specific chromosomal rearrangement pres-
ent. In 2016, two new provisional entities were 
added to the list of recurrent genetic abnormali-
ties, and hypodiploid was redefined as either low 
hypodiploid (<40 chromosomes) or hypodiploid 
with TP53 mutations.
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71.4  Risk Factors
Historically, age and white blood cell count at the 
time of diagnosis have been used to risk stratify 
patients. Increasing age portends a worse progno-
sis. Patients over 55 years have particularly poor 
outcomes, with only 10–15% long-term survival 
(Rowe et al. 2015). In most studies the cut point 
for high-risk ALL has been 30 × 109/L for B-cell 
precursor ALL and 100 × 109/L for T-cell precur-
sor ALL, respectively.
According to the maturation marker profile 
measured by immunophenotyping, both entities, B- 
and T-cell precursor ALL, can be classified as less 
mature ALL, which are associated with an inferior 
prognosis compared to the more mature subtypes. 
In B-lineage ALL, the most important markers for 
subclassification are CD19, CD20, CD22, CD24, 
and CD79a. The earliest B-lineage markers are 
CD19, CD22 (membrane and cytoplasm), and 
CD79a. A positive reaction for any two of these 
three markers, without further differentiation mark-
ers, identifies pro-B ALL. The early T-cell precur-
sor ALL is a subtype of high- risk ALL defined by 
reduced expression of T-cell markers (CD1a, CD8, 
and CD5) and aberrant expression of myeloid or 
stem cell markers (Chiaretti et al. 2014).
Cytogenetics represents an important part of 
ALL classification (Moorman et al. 2007). Probably 
the most well-known aberration in acute leukemia, 
associated with a high-risk disease, is Philadelphia 
chromosome-positive ALL.  This aberration is 
present in approximately 20% to 30% of adults 
with ALL. It can be detected as the translocation 
t(9;22)(q34;q11) by conventional karyotyping 
including FISH and/or by detection of the BCR-
ABL1 rearrangement by PCR. In addition, aberra-
tions like t(4;11)(q21;q23) or MLL rearrangements 
at 11q23 and hypodiploidy/low hypodiploidy (and 
the strictly related near-triploid group) fall also into 
the poor-risk cytogenetic category, with an overall 
disease-free survival rate of about 25%. The prog-
nostic relevance of a complex karyotype (five or 
more chromosomal aberrations) in ALL remains 
controversial among different study groups.
Most ALL cases harbor multiple somatic genetic 
alterations in addition to gross chromosomal altera-
tions. Chromosomal rearrangements and aneu-
ploidy are early events in leukemogenesis, with 
DNA copy number alterations and sequence muta-
tions acquired subsequently. Genes encoding tran-
scriptional regulators of lymphoid development are 
among the most frequently mutated genes, particu-
larly in B-linage ALL. Several key genetic altera-
tions may be associated with an inferior outcome, 
e.g., the IKZF1 alterations with treatment failure 
(Dhedin et al. 2015). However, these findings have 
to be verified in further prospective trials.
Persistence of MRD after induction/early con-
solidation, between weeks 4 and 22 and with a 
level  ≥10−4, indicates intrinsic drug resistance 
(Holowiecki et al. 2008). MRD is evaluable using 
either multichannel flow cytometry or the real- time 
quantitative polymerase chain reaction (RQ-PCR). 
Aberrant phenotypes are identified on the basis 
of different combinations and/or asynchronous 
expression and/or variable intensity staining of 
several antigens. PCR targets are fusion genes 
associated with chromosomal abnormalities (e.g., 
BCR-ABL, MLL-AF4) or rearranged immuno-
globulin or T-cell receptor sequences (TCR β, γ, δ, 
IgH, IgK-Kde) unique to each patient with ALL. A 
MRD level exceeding 10−4 after 2–3  months of 
treatment is an indicator for a high-risk disease, 
whereas an increase above 10−3 represents a very 
high risk for relapse (Bruggemann et al. 2010).
71.5  Prognostic Factors Used 
to Indicate Allo-HSCT in CR1
Although data from prospective randomized 
studies are lacking and are most likely impos-
sible to obtain due to the small numbers in some 
subgroups, some patient−/disease-related risk 
factors might be an indication for an allo-HSCT 
in the first remission.
Prognostic factor Indication of allo-HSCT if
Age >40 years
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Early T-cell precursor ALL (Ph-like 
ALL) (limited data, pending trials)
High-risk 
genetics
IKZF1 deletion in B precursor ALL
(NOTCH1/FBXW7; N/K-RAS; 
PTEN genetics in T-ALL 
(Trinquand et al. 2013)) (limited 
data, pending trials)
Failure to attain 
CR
Within 4 weeks of therapy
Minimal residual 
disease
>1 × 10−4 after two courses of 
therapy
Reappearance of MRD marker (no 
MRD marker at initial diagnosis)
71.6  First-Line Treatment
The first-line chemotherapy usually consists of 
induction, treatment intensification/consolidation, 
and long-term maintenance, with CNS prophylaxis 
given at intervals throughout therapy. The goal of 
induction therapy is to achieve CR remission and 
to restore normal hematopoiesis. The backbone of 
induction therapy typically includes VCR, PRD, 
and an anthracycline with or without L-asp and CY.
Intensive postremission consolidation thera-
pies improve outcome. Most study groups recom-
mend six to eight courses, two to four of which 
contain high-dose MTX, Ara-C, and L-asp, and 
one to two represent reinduction blocks.
Postremission consolidation is most often fol-
lowed by long-term maintenance with daily oral 
mercaptopurine and weekly MTX for 2  years 
or longer, sometimes with periodic applications 
of, e.g., VCR, PRD, or other drugs (Bassan and 
Hoelzer 2011).
The addition of RTX to the induction and consol-
idation therapy for patients with B-precursor ALL 
(Maury et al. 2016), as well as imatinib for patients 
with Ph-positive ALL (Fielding et al. 2014), has sig-
nificantly improved the outcome in these subgroups.
These modern regimens usually allow remis-
sion rates of 90% and more in patients with 
standard- risk ALL. However, in patients of older 
age (e.g., >45 years) treated with pediatric- inspired 
protocols, significantly higher rate of chemother-
apy-related events compared to younger patients 
occurs, and response rates decrease.
The introduction of novel agents like nelara-
bine for patients with T-precursor ALL and 
blinatumomab and inotuzumab ozogamicin for 
B-precursor ALL, as part of the frontline therapy, 
is currently being evaluated in prospective trials.
71.7  Second-Line Treatment
While 85–90% of patients go into remission 
after induction therapy, there are subsets that are 
refractory to induction therapy. In addition, many 
of the patients with complete remission will have 
a relapse, and only approximately 30–50% will 
have disease-free survival lasting 3 years or lon-
ger. Conventional standard chemotherapy regi-
mens for adults with relapsed or refractory B-cell 
ALL are associated with rates of CR of 31–44% 
when they are the first salvage therapy admin-
istered after an early relapse and 18–25% when 
they are the second salvage therapy (Gokbuget 
et al. 2016). Because CR is typically a prerequi-
site for subsequent allo-HSCT, the low rates of 
CR associated with conventional chemotherapy 
regimens mean that few adults with relapsed or 
refractory (R/R) B-cell ALL (5–30%) proceed to 
HSCT, which is considered to be the main goal 
after salvage treatment because it is the only 
potentially curative treatment option.
Recently, two randomized trials compar-
ing conventional salvage regimens with novel 
immunotherapy- based therapies, the Tower trial 
(Kantarjian et  al. 2017) with blinatumomab 
(targeting CD19) and the INO-VATE ALL trial 
(Kantarjian et  al. 2016) with inotuzumab ozo-
gamicin (targeting CD22), demonstrated sig-
nificantly higher remission rates (up to 80%) 
for patients with R/R B-precursor ALL treated 
with either antibody-based therapy. Moreover, 
these novel treatments showed a favorable tox-
icity  profile compared to conventional chemo-
therapies and allowed the treatment, of many of 
the patients, in an outpatient setting. Both trials 
defined a new standard therapy option in patients 
with R/R B-precursor ALL.  Conventional che-
motherapy might be still a reasonable option in 
patients with late relapse. However, with regard 
to treatment toxicity and option of outpatient 
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treatment, antibody-based therapies should be 
discussed with the patients, if available.
In patients with R/R Ph + ALL, usually treated 
with imatinib as part of the first-line treatment, 
molecular testing of mutations leading to the 
resistance to particular tyrosine kinase inhibitors 
(TKIs) should be performed. According to these 
results, a second-generation TKI (e.g., dasatinib 
or ponatinib) should be chosen as salvage therapy.
Anti-CD19 chimeric antigen receptor (CAR)-
expressing T cells have proved extremely effec-
tive against R/R B precursor ALL, at least in 
children and young adult patients with up to 
70–90% response rates reported (Maude et  al. 
2018; Park et al. 2018). With lacking comparative 
trials, highly selected patients, and a clinically 
relevant toxicity profile (e.g., severe cytokine 
release syndrome, neurotoxicity, and long-lasting 
B-cell depletion), CAR-T cells have to be evalu-
ated in further prospective trials.
Despite advantages in the treatment of 
B-precursor ALL, treatment options for patients 
with R/R T-precursor ALL are limited. So far, there 
is no agreed standard of care in adults with relapsed 
T-cell ALL.  Standard chemotherapy regimens 
such as FLAG (FLU, Ara-C, and G-CSF) ± idaru-
bicin only result in 30% to 40% response rates with 
6 months median OS in responders. Nelarabine as 
monotherapy or in combination with other chemo-
therapeutic agents has shown promising response 
rates and is a reasonable option (Gokbuget et al. 
2011(Gokbuget et al. 2011)).
Patients with persisting MRD or reappearance 
of their MRD marker without evidence of a hema-
tological relapse have usually an indication for an 
allo-HSCT.  However, treatment of MRD prior to 
transplant to potentially optimize outcome after 
HSCT should be discussed for patients in case of 
high/increasing MRD and particularly for those with 
an option for a targeted therapy (e.g., change of TKI 
therapy in patients with Ph + ALL of blinatumomab).
71.8  Autologous HSCT
71.8.1  Indication
Auto-HSCT is not considered a standard therapy 
for adult ALL.  Optional for patients with MRD- 
negative high-risk ALL, not eligible for allo-HSCT.
71.8.2  Conditioning
Fractionated TBI (e.g., 6 × 2 Gy) in combination 
with CY and/or VP.
71.8.3  Results
In some trials, patients excluded from allo-HSCT 
were randomly assigned between chemotherapy and 
auto-HSCT. In one of the largest studies, chemother-
apy proved superior, while a marginal superiority of 
auto-HSCT was ascertained in high-risk patients in 
another (Goldstone et al. 2008). In a European retro-
spective analysis on auto-HSCT, a cohort of patients 
who were MRD negative had a significantly better 
survival compared to those being MRD positive. 
Results of another retrospective study comparing 
auto- and allo-HSCT for adults with Philadelphia-
positive ALL in first complete molecular remis-
sion showed similar survival rates for both groups 
(higher rate of relapse after auto-HSCT and higher 
rates of death in remission after allo-HSCT).
It remains a matter of debate if the MRD- negative 
patients in these retrospective trials would have 
shown similar results with conventional chemother-
apy. The value of high-dose therapy, particularly in 
ALL patients being early MRD negative after induc-
tion therapy, has to be evaluated in prospective trials.
71.9  Allogeneic HSCT
71.9.1  Indication
Standard therapy for patients with high-risk ALL 
in CR1 (see Sect. 71.5) and standard therapy for 
patients with subsequent remission after induction 
failure or relapsed ALL (Dhawan and Marks 2017). 
Optional for patients with standard-risk ALL in CR1 
and unexpectable treatment-related toxicities (e.g., 
prolonged severe cytopenia), which preclude contin-
uation of conventional therapy. Optional for patients 
with refractory/active ALL (Pavlu et al. 2017).
71.9.2  Conditioning
For fit patients <45 years and no relevant comor-
bidities, preferable fractionated TBI (cumulative 
dose of 12–13 Gy) in combination with CY or 
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VP (Marks et al. 2006); alternative BU (prefer-
able IV BU targeted plasma-drug level moni-
toring) in combination with CY.  For patients 
aged 45  years and older, dose-adapted/dose- 
reduced conditioning should be considered. So 
far, no standard regimen has been established. 
Reasonable options are TBI-based therapies 
(e.g., 8 Gy TBI in combination with FLU or CY) 
and MEL-, BU-, or TREO-based conditioning 
regimes.
Especially patients transplanted beyond 
first remission are at risk for severe transplant-
related toxicities with cumulative incidence of 
death in remission exceeding 30% and more. 
Consequently, dose-reduced conditioning 
regimes should be discussed in patients being 
in a MRD-negative subsequent remission after 
treatment with novel antibody-based salvage 
therapies. Moreover, conditioning therapies asso-
ciated with significant toxicities (e.g., SOS/VOD 
for patients treated with inotuzumab ozogamic) 
must be avoided (Kebriaei et al. 2018).
71.9.3  Donor
MSD, HLA-MUD (at least matched for HLA-A, 
HLA-B, HLA-C, and DR), HLA-MMUD, hap-
loidentical donor. In patients with HLA-MMUD, 
a transplant with UCB (Marks et  al. 2014) or 
from haploidentical donor (Santoro et al. 2017) 
may be the better choice, particularly in those 
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Fig. 71.1 Outcome of matched sibling donor—HSCT 
adults with ALL in CR1. Changes over time in the period 
1993–2012. (a) Relapse incidence (RI), (b) non-relapse 
mortality (NRM), (c) leukemia-free survival (LFS), (d) 
overall survival (OS) (Giebel et al. 2017)
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71.9.4  Stem Cell Source
Most likely no relevant difference with regard 
to GvHD between BM and PBSC as transplant 
source from an unrelated donor when ATG is part 
of the conditioning. Faster engraftment and low 
risk of graft failure with PBSC.
71.9.5  GvHD Prophylaxis
CSA  +  MTX or CSA  +  MMF are standard 
options. ATG should be considered in all 
patients receiving an allograft from an URD and 
can be discussed in patients transplanted from 
an MSD. For haplo-HSCT, using T cell replete 
allografts combined with post transplant cyclo-
phosphamide (to eliminate alloreactive T cells 
while sparing other T cells, leading to faster 
immune reconstitution) is an established option.
71.9.6  Maintenance
For patients with Ph  +  ALL, maintenance with 
TKI after allo-HSCT should be applied as a 
prophylactic or preemptive therapy. At least in 
patients with B-precursor ALL and positive find-
ings for MRD after allo-HSCT, preemptive thera-
pies with antibodies/antibody-drug conjugates or 
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Fig. 71.2 Outcome of matched sibling donor—hemato-
poietic cell transplantation for adults with acute lympho-
blastic leukemia (ALL) in first complete remission (CR1). 
Changes over time in the period 1993–2012. (a) Relapse 
incidence (RI), (b) non-relapse mortality (NRM), (c) 
leukemia- free survival (LFS), (d) overall survival (OS) 
(Giebel et al. 2017)
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Although the majority of children and adoles-
cents with acute lymphoblastic leukemia (ALL) 
are curable with current chemotherapy regimens, 
poor outcome persists in some individuals (Eckert 
et al. 2011; von Stackelberg et al. 2011; Schrappe 
et al. 2012). Allo-HSCT is the most established 
treatment to control leukemia by means of the 
GVL effect. During the last decade, it was dem-
onstrated in prospective trials that HSCT from 
HLA-MSD and from HLA-MURD results in 
similar outcomes.
Standardized MAC for paediatric patients 
with high relapse risk produced a low incidence 
of TRM and effective control of leukemia (Mann 
et  al. 2010; Pulsipher et  al. 2011; Peters et  al. 
2015). Currently, also HSCT from HLA haplo-
identical family donors or mismatched CB gives 
promising results (Rocha et  al. 2009; Luznik 
et  al. 2012; Ruggeri et  al. 2012; Berger et  al. 
2016; Klein et al. 2017; Locatelli et al. 2017).
To offer the patients the best available treat-
ment options, a close collaboration between 
international therapy study groups and transplant 
consortia are necessary. This is realized within 
the big treatment consortia for childhood leuke-
mia (e.g. IBFM-SG, IntReALL, NOPHO, 
UKALL, AIEOP, FRALLE and others) and the 
paediatric transplant community (e.g. EBMT-PD 
WG, IBFM-SC SCT, GETMON, GITMO). The 
study groups for ALL treatment evaluate out-
come according to their chemotherapy protocols 
and stratify patients to relapse standard-risk, 
medium-risk and high-risk groups. In contrast to 
adult patients, only patients with high-relapse 
risk are eligible for allo-HSCT to protect children 
from the potential long-term consequences of 
myeloablation and GVHD.
72.2  Prognostic Factors 
and Indications for HSCT
HSCT indications have to be defined prospec-
tively and must be re-evaluated and reconfirmed 
at intervals dependent on modifications and 
improvements in non-transplant approaches for 
both front-line and relapse protocols. Some risk 
factors conveying a dismal prognosis in  childhood 
C. Peters (*) 
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ALL can be identified even at diagnosis 
(Moorman 2016; O’Connor et  al. 2018). 
Additionally, response to induction treatment 
measured by MRD has a strong predictive value 
and defines nowadays many indications or HSCT 
(Bader et al. 2009; Conter et al. 2010; Schrappe 
et al. 2011; Eckert et al. 2013).
72.2.1  Indications: CR1
Only patients with high-risk cytogenetic features 
or insufficient response to chemotherapy are eli-
gible for HSCT in first remission. In contrast to 
earlier recommendations, for these patients a 
MSD and a MURD and for the highest relapse 
category also mismatched donors are an option 
(Table 72.1).
72.2.2  Indications: CR2 and Later
All patients with relapse of T-ALL and patients 
who relapse during or within 6 months of cessa-
tion of chemotherapy (very early and early 
relapse) have a dismal prognosis when treated 
with conventional chemotherapy. Allo-HSCT 
from any donor type is the contemporary stan-
dard approach (Table 72.2).
If patients achieve a third or higher remission, 
allo-HSCT should be considered if the physical 
state allows such a procedure. Patient not in mor-
phological remission should not receive 
allografts except in extraordinary experimental 
situations.
72.3  Donor Selection and Stem 
Cell Source
OS and incidence of NRM have constantly 
improved; however it has been shown that in 
children, a BMT from a HLA-identical sibling 
results in quicker myeloid engraftment, immu-
noreconstitution and less severe infections and 
should be therefore the preferred option (Peters 
et  al. 2015). As only 25% of patients have a 
MSD, HSCT from other donors is the most 
applied method. Several groups have demon-
strated that HSCT from unrelated donors, identi-
fied by HLA high- resolution typing and 
matching, has similar outcome results as MSD-
HSCT (Zhang et  al. 2012; Fagioli et  al. 2013; 
Burke et al. 2015).














No CR d33 Noc MMD MMD MMD MMD
t(4;11)d No MD MD MMD MD
Hypodiploidy < 44 
chromosomese
No MD MD MMD MD
PPR + T-ALL No No MD MMD MD
None of the above 
featuresf
No No MD MMD No
PPR Prednisone Poor Response on day 8, NRd33 No Remission day 33 MRDMinimal Residual Disease, no Allo HSCT 
not indicated, MD Permitted donor: HLA-matched sibling or non-sibling donor, MMD Permitted donor: HLA-matched 
or HLA-mismatched donor
aFCM-MRD results have no impact on the allo-HSCT indication
bIncluding MRD-MR SER (MRD TP1 ≥ 10−3 and TP2 10–4/−5)
cNon-remission in patients with this rare constellation should be due to extramedullary disease. Allo-HSCT indication 
in these cases should be discussed with the national study coordinator
dIndependent of prednisone response
eThe finding of exactly 44 chromosomes qualifies for HR treatment but has no impact on allo-HSCT indication
fIncluding patients with 44 chromosomes
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Several methods were developed to overcome 
the HLA barriers. Today it is not clearly proven 
whether HSCT from HLA-mismatched CB, TCD 
(alpha-beta depleted, CD34+ selected or CD3/
CD19 depleted) haplo-identical grafts or PT-CY 
approaches will result in the best outcome (Lang 
and Handgretinger 2008; Smith et  al. 2009; 
Ruggeri et al. 2014; Locatelli et al. 2017) (Tables 
72.3 and 72.4).
72.4  Conditioning Regimen
Most children receive a MAC.  This consists 
either of TBI and VP and/or CY or—especially 
for children below 4 years of age—of BU-/FLU- 
Table 72.2 Indication for HSCT according to IntReALL SR 2010 and HR protocol criteria
Relapse risk group Phenotype Time of relapse Site of relapse MRD-status Donor type
Very High T-ALL Any time I-BM, C-BM, I-EM MSD, MD, MMD
Non-T-ALL
Very early I-BM, C-BM, I-EM
Early I-BM, C-BM PR, ND
High Non-T-ALL MSD, MD
Late I-BM, C-BM PR, ND
Early C-BM GR
I-EM
Late I-BM PR, ND
C-BM ND
I-BM isolated bone marrow, C-BM combined bone marrow and extramedullary site, I-EM isolated extramedullary, 
MRD: GR good response as defined by the specific chemotherapy-protocol, PR poor response, ND not detectable.
Table 72.3 Matching criteria according to HLA typing/
matching and stem cell source for children and AYAs with 
ALL
MSD HLA-genotypically matched sibling, 




MSD 6/6 or 8/8, 5/6 or 7/8a CB




MD 5–6/6 unrelated or 6–7-8/8 unrelated CB
MMD Less than 9/10 matched BM, 
PBSC
MMD Less than 5/6 or 6/8 UCB CB
MSD matched sibling donor, MD matched donor, MMD 
mismatched donor.
a4 digits high-resolution typing recommended also for CB 
matching definition.




Patient CMV IgG positive
1 Donor CMV IgG positive
2 Donor CMV IgG negative
Patient CMV IgG negative
1 Donor CMV IgG negative
2 Donor CMV IgG positive
Gender
Female patient
1 Male or female (preferentially not 
allo-immunized by prior pregnancy) donor
Male patient
1 Male Donor
2 Female (preferentially not allo-immunized 
by prior pregnancy) donor
Age




HSCT from MSD or MD
1 Bone marrow
2 PPBSC (CAVE: adjust GvHD-prophylaxis 
for matched siblings)
2 Cord blood with sufficient cell number 
(>3 × 107 NC/kg)
HSCT from MMD: possible options
BM, 8/10 matches, unmanipulated
PBSC, haploidentical, CD3/CD19 
depleted, α/β depleted
CB, sufficient stem cell dose
PBSC, haploidentical, CD34+ selection
PT-CY
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containing regimen, often combined with TT. An 
increasing use is recognized for TREO which 
results also in myeloablation but seems to have 
less toxic side effects (Wachowiak et  al. 2011; 
Boztug et al. 2015; Lee et al. 2015; Peters et al. 
2015).
To reduce acute organ toxicity, the interval 
between the end of the last chemotherapy and the 
start of conditioning is 3 or at most 6 weeks. If 
infection or toxicity requires a delay of condi-
tioning, patients receive risk-adjusted chemo-
therapy to bridge the time until transplantation. 
Currently, a multinational trial comparing TBI/
VP with either FLU/TT/BU or FLU/TT/TREO 
investigates in a randomized study the value of 
both conditioning regimens (FORUM study: 
allogeneic HSCT for children and AYAs with 
ALL comparing TBI with myeloablative chemo- 
conditioning) (Willasch et al. 2017).
72.5  GVHD Prophylaxis
Children transplanted with BM from matched 
sibling donors might benefit from an augmented 
GVL effect if only single and short GVHD pro-
phylaxis is given (Locatelli et al. 2000). However 
careful monitoring and rapid treatment interven-
tion are crucial to prevent severe GVHD. After 
HSCT from non-sibling donors, a combination of 
CNI and ATG with or without short MTX is given 
in most patients (Veys et  al. 2012; Peters et  al. 
2015).
72.6  Post-transplant Follow-Up 
and Interventions
72.6.1  Mixed Chimerism (MC) 
and MRD
Mixed chimerism (MC) and MRD strongly pre-
dict risk for relapse in children (Bader and 
Kreyenberg 2015).
Preemptive immunotherapy, e.g. withdrawal of 
IS or DLI guided by chimerism and MRD moni-
toring, can prevent impending relapse. However, 
the dynamic of leukaemic reappearance hampers 
the final success of these methods. Therefore, new 
post-transplant intervention strategies with less 
risk for severe complications like bi-specific anti-
bodies or CAR-T-cell interventions may expedite 
the control of impending relapse (Handgretinger 
et al. 2011; Maude et al. 2018).
72.6.2  Children with Ph+
Children with Ph + should receive post- transplant 
TKIs: Whether the prophylactic approach (all 
Ph + patients will receive TKIs) or a preemptive 
therapy (only patients with a Ph  +  signal peri- 
HSCT) is more effective has to be prospectively 
proven (Schultz et  al. 2010; Bernt and Hunger 
2014). Both TKI options are currently under 
investigation.
72.6.2.1  The Amended EsPhALL 
Recommendation
Administration of imatinib prophylaxis post 
HSCT when more than 50,000 platelets are 
reached. Duration, 365 days after HSCT.
72.6.2.2  TKI According to MRD Result
Administration of imatinib post HSCT for all 
MRD-positive patients until two negative results 
are achieved. FACS- and PCR-MRD analyses are 
accepted.
72.7  Results
Figure 72.1 shows the event-free survival (EFS), 
overall survival (OS), relapse incidence (RI) and 
non-relapse mortality (NRM) of the prospective 
international multicentre trial comparing MSD 
with MURD (Peters et al. 2015).
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Myelodysplastic syndromes (MDS) are a hetero-
geneous group of clonal stem cell disorders char-
acterized by hypercellular bone marrow, 
peripheral cytopenias, and dysplastic features in 
blood and bone marrow. The clinical progression 
of these diseases varies from an indolent course, 
over a number of years, to a more rapid transition 
into secondary AML. MDS is mainly diagnosed 
in elderly patients, with an annual incidence of 
4.9/100,000, but this increases to between 20 and 
50 cases per 100,000 persons annually after the 
age of 60. The current WHO classification (2016) 
distinguishes various MDS subtypes, which are 
detailed in Table 73.1 (Arber et al. 2016).
Due to the variable course the disease may 
take, a number of different risk-scoring systems 
have been developed. The most frequently used 
of these is the International Prognostic Scoring 
System (IPSS), introduced by Greenberg et  al. 
(1997) (Table  73.2) and revised in 2012 
(Greenberg et al. 2012) (Table 73.3). As a result, 
intensive treatment strategies are predominantly 
applied in patients with intermediate and higher-
risk MDS. The importance of transfusion depen-
dency is included in a WHO classification-based 
prognostic scoring system (WPSS) (Della Porta 
et al. 2015). The role of somatic mutations has 
been explored recently, highlighting the prog-
nostic role of mutations. SF3B1 mutations are 
commonly associated with refractory anemia 
with ringed sideroblasts and expected survival of 
more than 10 years. Poor prognostic mutations, 
such as TP53 mutations, occur mainly in patients 
with higher-risk MDS and confer a higher risk of 
transition to acute leukemia (Makishima et  al. 
2017). In the setting of allo-HSCT, both somatic 
mutations and cytogenetic characteristics con-
serve their prognostic impacts after transplanta-
tion, and this aspect will be discussed further 
hereafter.
Allo-HSCT is increasingly performed, with 
940 MDS patients transplanted in 2004 and 2646 
patients transplanted in 2015 (EBMT registry). 
This increase is due to rising numbers of trans-
plants in older patients (>60 years), from 22% of 
all transplants in 2004 to 44% in 2015, and more 
MURD, from 37% of all transplants in 2004 to 
58% in 2015. The increasing use of unmanipu-
lated haplo-HSCT using intensified IS therapy 
may also lead to a greater proportion of related 
donors in future.
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73.2  Indication of HSCT in MDS 
and Timing to Transplant
HSCT is an established procedure for MDS lead-
ing to long-term survival. The indications for 
HSCT may change following the introduction of 
new treatment strategies, and the HSCT approach 
itself has consistently evolved over time. TRM 
should always be balanced against the benefits 
associated with HSCT.  Comparisons of several 
transplant and non-transplant cohorts show a gain 
in life expectancy in patients, with higher risks if 
they receive an allo-HSCT at MDS diagnosis, 
while in lower-risk MDS patients, a survival 
Table 73.1 World Health Organization classification (2016 revision) of MDS
Name
Dysplastic 
lineage Cytopeniaa RS as % BME
BM and PB blasts,
Auer rods (AR) Cytogeneticsb
MDS with single-lineage 
dysplasia (MDS-SLD)
1 1 or 2 <15%/<5%b BM < 5%, PB < 1%,
no AR
Any
MDS with multilineage 
dysplasia (MDS-MLD)
2 or 3 1–3 <15%/<5%c BM < 5%, PB < 1%,
no AR
Any
MDS with ring sideroblasts (MDS-RS)
  — MDS-RS SLD










MDS with isolated del(5q) 1–3 1–2 None or any BM < 5%, PB < 1%, 
no AR
Del(5q)d
MDS with excess blasts (MDS-EB)
  — MDS-EB1







BM 5–9% or PB 
2–4%, no AR





  — With 1% blood blasts
  — With SLD and 
pancytopenia





















Refractory cytopenia in 
childhood
1–3 1–3 None BM < 5%, PB < 2% Any
BM bone marrow, PB peripheral (blood) blast, RS as %BME, ring sideroblasts as a % of marrow erythroid elements
aCytopenia defined as hemoglobin <10 g/dL, platelet count <100 g/L, absolute neutrophil count <1.8 g/L
bCytogenetics by conventional karyotype analysis
cIf SF3B1 is present
dAlone or with one additional abnormality except −7 or del(7q)
Table 73.2 “Classic IPSS”
Points 0 0.5 1 1.5 2
Marrow blast <5 5–10 >10 11–20 21–30
Cytogenetica Good Intermediate Poor
Cytopeniab 0–1 2/3
Risk Low Intermediate-1 Intermediate-2 High
Number of points 0 0.5–1 1.5 or more
Median OS (years) 5.7 3.5 1.2 0.4
Median time to 25% AML transformation in years 9.4 3.3 1.1 0.2
OS overall survival
aGood, normal, -Y, del(5q), del(20q); poor, complex karyotype (three or more abnormalities) or chromosome 7 anoma-
lies; intermediate, other abnormalities
bCytopenia was defined as follows: hemoglobin <10 g/dL, platelet <100 g/L, absolute neutrophil count <1 g/L
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advantage can be seen if HSCT is deferred 
(Cutler et  al. 2004; Koreth et  al. 2013; Della 
Porta et al. 2017; Robin et al. 2015). An interna-
tional expert panel has also confirmed the indica-
tion of HSCT in higher-risk patients as well as 
lower-risk patients with specific poor prognostic 
features, including genetic alterations, failure to 
respond to usual treatment, life-threatening cyto-
penias, and high-intensity transfusions (de Witte 
et  al. 2017). Figures  73.1 and 73.2 summarize 
transplant indications in MDS patients.
73.3  Post-HSCT Outcomes
Several recent registry studies including cytoge-
netic classification have reported outcomes for 
transplanted MDS patients (Table 73.4). Overall 
survival (OS) ranged from 35 to 50%, NRM 
from 30 to 40%, and relapse rates from 15 to 
30%. Lower-risk MDS patients had better prog-
noses, and the EBMT cohort of low and interme-
diate-1 MDS patients showed that OS could 
reach 57%, with relapse incidence at 16% after 
7 years (Robin et al. 2017a). Patients with poor 
and very poor risk cytogenetic characteristics, 
including monosomal karyotypes, were associ-
ated with poor outcomes. FAB classification, 
age, platelet count, stage at time of transplanta-
tion, and hematopoietic cell transplant-comor-
bidity index (HCT-CI) were prognostic clinical 
risk factors. Somatic mutations, i.e., TP53, 
TET2, ASXL1, RUNX1, and RAS pathways muta-
tions, have been reported to be prognostic inde-
pendent factors in several reports (Bejar et  al. 
2014; Della Porta et  al. 2016; Lindsley et  al. 
2017; Yoshizato et al. 2017).
Due to the increase in patient age, transplan-
tation results in these patients should be high-
lighted, as outcomes seem to be highly impacted 
by performance status and HCT-CI (McClune 
et al. 2010; Lim et al. 2010). The EBMT recently 
published two studies focusing on transplants in 
elderly patients. The first study included 1333 
MDS patients above the age of 55, transplanted 
between 1998 and 2006 (Lim et al. 2010). Four- 
year OS was 31%, with NRM of 36%. The sec-
ond study reported 313 MDS patients above the 
age of 70, transplanted between 2000 and 2013 
(Heidenreich et  al. 2017). The study findings 
showed 3-year OS of 34% and NRM of 42% 
confirming that transplant was feasible in this 
category of patients.
73.4  Alternative Donors 
and Donor Choice
In recent EBMT studies, HSCT from an URD did 
not appear to be a mortality risk factor compared 
with HSCT using MSD (Onida et  al. 2014; 
Koenecke et al. 2015). Saber et al., on behalf of 
Table 73.3 “Revised IPSS”
Points 0 0.5 1 1.5 2 3 4




Good Intermediate Poor Very 
poor
Cytopeniab No Mild Moderate Severe 
anemia
Risk Very low Low Intermediate High Very high
Number of points ≤ 1.5 2–3 4–4.5 5–6 >6
Median OS (years) 8.8 5.3 3 1.6 0.8
Median time to 25% AML 
transformation in years
10.8 3.2 1.4 0.73
aCytogenetics: very good, -Y, del(11q); good, normal, del(5q), del(12p), del(20q), double including del(5q); intermedi-
ate, del(7q), −8, −19, i(17q), any other single or double independent clones; poor, −7, inv.(3)/t(3q)/del(3q), double 
including −7/del(7q), complex, 3 abnormalities; very poor, complex, > 3 abnormalities
bcytopenia, mild cytopenia, platelet count <100 g/L or neutrophil count <0.8 g/L; moderate cytopenia, hemoglobin 
<10 g/dL but >10 g/dL, platelet count <50 g/L; severe anemia, hemoglobin <8 g/dL
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the CIBMTR, reported the results of HSCT in 
701 MDS patients according to donor type: 
MRD, MUD (8 out of 8 high-resolution HLA 
compatibilities), and MMUD (Saber et al. 2012). 
Multiple-variable analysis showed that NRM was 
significantly lower with the use of MRDs com-
pared with other donors, but that treatment fail-
ure (death or relapse) was similar to MUD, while 
it was significantly higher in patients transplanted 
from a MMUD (Saber et al. 2012).
The EBMT group reported outcomes for 631 
MDS patients transplanted with a MUD 
(n  =  379), a MMUD (n  =  107), or a MMUCB 
(n  =  129) (Robin et  al. 2014). Patients trans-
planted with a MUD had better outcomes for OS, 
relapse-free survival, and NRM, while patients 
transplanted from MMUDs had similar out-
comes, with a trend to a better DFS for MMUD 
compared with UCB.  Recommendations are to 




















Fig. 73.1 Therapeutic flow chart for adult MDS patients 
with (very) low-risk or intermediate-risk IPSS-R scores @
indicates nonfit (patients with multiple comorbidities and/
or poor performance) or fit (patients with no comorbidi-
ties and good performance status). * indicates nontrans-
plant strategies according to most recent versions 
published by international MDS expert groups, including 
ELN and NCCN. & indicates failure of nontransplant 
strategies. ** indicates poor-risk features (defined as 
poor-risk cytogenetic characteristics, persistent blast 
increase [>50% or with >15% BM blasts], life- threatening 
cytopenias, high transfusion intensity >2 units per months 
for 6 months; molecular testing should be seriously con-
sidered, in case of absence of poor-risk cytogenetic char-
acteristics or persistent blast increase). # indicates 
transplant strategies (all forms of HSCT, for details of the 
donor selection, type of conditioning, and post transplant 
strategies, see text; no upper age limit if patients are fit, 
without serious comorbidity, and with good Karnofsky 
status)
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donor as both kinds of donor may lead to similar 
outcomes (Bowen 2017).
HSCT from haplo-identical related donors 
has been revisited due to new GVHD prophy-
laxis strategies, including the use of 
PT-CY. Little data has been published on MDS 
patients, although results in patients with other 
diseases are very promising (Bashey et  al. 
2013; Ciurea et al. 2015). A recent EBMT study 
reported 234 patients transplanted from haplo-
donors between 2007 and 2014. Although NRM 
was relatively high, results were encouraging, 
with better results using PT-CY and RIC (Robin 
et  al. 2017b). A recent issue is the impact of 
donor age on post transplant outcomes, sug-
gesting that outcomes may be better with 
younger donors (Kollman et  al. 2016; Kröger 
et  al. 2013). This is particularly relevant in 
























Fig. 73.2 Therapeutic flow chart for adult MDS patients 
with poor IPSS-R scores. @ indicates nonfit (patients with 
multiple comorbidities and/or poor performance) or fit 
(patients with no comorbidities and good performance 
status). * indicates nontransplant strategies according to 
most recent versions published by international MDS 
expert groups, including ELN and NCCN. & indicates 
failure of nontransplant strategies. ** indicates poor-risk 
features (defined as poor-risk cytogenetic characteristics, 
persistent blast increase [>50% or with >15% BM blasts], 
life-threatening cytopenias, high transfusion intensity 
>2  units per months for 6  months; molecular testing 
should be seriously considered, in case of absence of 
poor-risk cytogenetic characteristics or persistent blast 
increase). # indicates transplant strategies (all forms of 
HSCT, for details of the donor selection, type of condi-
tioning, and post transplant strategies, see text; no upper 
age limit if patients are fit, without serious comorbidity,and 
with good Karnofsky status)
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73.5  Treatment Prior to HSCT
No randomized studies have compared pre-graft 
cytoreduction versus upfront transplants in MDS 
patients. Because hypomethylating agents (HMA) 
have been reported to improve survival in MDS 
patients, they are routinely used before consider-
ing a transplant procedure, leading to a delay in 
transplantation. It is very difficult from registry 
data to gain real insight into the risks or benefits of 
treatment with HMA.  International guidelines 
generally recommend that patients with more than 
10% marrow blast should receive cytoreductive 
treatment, which can be either intensive chemo-
therapy or HMA (de Witte et al. 2017b; Malcovati 
et al. 2013). The EBMT group reported that refrac-
toriness to pre-graft treatment is associated with 
poor outcomes, confirming a French retrospective 
study (Potter et al. 2016; Damaj et al. 2012).
73.6  Preparative Regimen
The use of RIC regimens for HSCT has raised 
considerable interest. Multiple centers have 
developed novel RIC regimens that have reduced 
NRM and morbidity and subsequently expanded 
the curative potential of HSCT to older individu-
als who have historically not been considered to 
be HSCT candidates.
The EBMT group has compared outcomes for 
MDS patients treated by RIC or MAC (Martino 
et al. 2006; Martino et al. 2017). Studies show that 
relapse rates increased after RIC, while NRM was 
higher after MAC, in line with the findings of 
another study (Scott et  al. 2006). Subsequent 
research by the EBMT group reported outcomes 
for 878 MDS or AML patients transplanted with 
less than 10% marrow blasts and classified 
according to the intensity of conditioning regimen 
considering four groups: non- MAC, RIC, stan-
dard regimen and hyperintensive regimen 
(Martino et al. 2013). OS after 7 years was 29, 53, 
56, and 51%, respectively, for each regimen, with 
a disadvantage for the non- MAC. An EBMT pro-
spective study comparing the use of RIC (FLU/
BU) and MAC (CY/BU) in patients with MDS or 
secondary AML was published recently (Kröger 
et al. 2017). Multivariable analysis failed to show 
any impact of the regimen intensity in NRM, 
relapse, and RFS, while there was an advantage 
for RIC in OS, after adjustment for cytogenetics, 
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performance status, and disease stage. The BMT-
CTN performed a prospective study on 272 
patients with MDS or AML who were random-
ized between RIC and MAC. There was no differ-
ence in OS between the two groups, despite a 
higher relapse rate after RIC (Scott et al. 2017).
A novel RIC sequential regimen consisting 
of FLU 30 mg/m2, Ara-C 2 g/m2, and amsacrine 
100  mg/m2 (FLAMSA), followed 3  days later 
by 4  Gy TBI and CY 80–120  mg/kg showed 
promising results (Schmid et al. 2005; Schmid 
et al. 2006). Prospective randomized trials com-
paring sequential regimens with other regimens 
are ongoing.
73.7  Post-HSCT Treatment
MDS patients with relapse after HSCT are often 
refractory to treatment, or not fit enough to be 
treated. A German group recently reported out-
comes for AML (n  =  124) and MDS (n  =  28) 
patients treated with AZA and DLI (Schroeder 
et al. 2015). The main risk factors for treatment 
response were molecular relapse only or marrow 
blast <13%. In these cases, OS was more than 
60%, although it was below 10% in high-risk 
patients. An EBMT study of 181 patients treated 
with AZA for post transplant relapse of MDS 
confirmed that lower blast counts upon relapse 
and relapsing more than 6  months after HSCT 
were both good prognostic factors (Craddock 
et al. 2016a, b). In this study, the addition of DLI 
did not modify outcomes. Another EBMT study 
on cellular therapy after relapse (DLI or second 
transplant) showed that a second allo-HSCT per-
formed in CR may rescue patients with relapse 
after initial HSCT, especially if they have no pre-
vious history of GVHD, and in cases where they 
may be transplanted from a new donor (Schmid 
et  al. 2018). The French SFGM-TC group 
recently reported 147 MDS patients relapsing 
after transplant (Guieze et al. 2016). Only patients 
who received “cellular therapy” (DLI or second 
SCT) were able to achieve long-term survival 
(32% versus 6% for chemotherapy alone).
Other strategies involve preventive or pre-
emptive treatment after transplantation to avoid 
morphological relapse. Preemptive strategies 
based on underlying risk or monitoring of mini-
mal residual disease may be of use in these 
patients who present a high risk of post trans-
plant relapse (Platzbecker et al. 2012). Although 
relapse remains the most common cause of 
transplant failure, particularly in patients with 
high-risk features, novel strategies such as the 
preemptive use of AZA or DLI may be effective 
in improving historically poor outcomes. 
Preventive post transplant treatment testing 
demethylating agents early after transplantation 
have also been reported in small prospective 
studies (de Lima et al. 2010; Pusic et al. 2015; 
Craddock et al. 2016a, b). This kind of treatment 
appears to be especially useful in patients with 
higher-risk MDS.
Key Points
• Allo-HSCT is the treatment of choice 
for all patients with (very) poor-risk 
MDS, or intermediate patients with 
high-risk features, who are fit enough to 
be considered for transplantation.
• Delayed HSCT is associated with 
reduced chances of prolonged relapse- 
free survival. Also, patients with less 
advanced MDS categories may benefit 
from deferred HSCT after they develop 
poor-risk features.
• Allo-HSCT outcomes have improved 
progressively in recent years, mainly 
due to a gradual reduction in non-relapse 
mortality. Reduced-intensity condition-
ing (RIC) regimens have extended the 
use of allo-HSCT to older patients, 
including those entering their eighth 
decade.
• However, a number of questions remain 
to be resolved by prospective studies, 
such as the choice of donor, including 
haplo-identical donors, the role of post 
transplant treatment, and the timing of 
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For pediatric patients with MDS and 2–19% 
blasts in the PB or 5–19% blasts in the BM, the 
same diagnostic criteria utilized for adults with 
MDS with excess blasts (MDS-EB) are applied 
(WHO). Some cases with 20–30% blasts may 
also have slowly progressive disease, may lack 
clinical features of acute leukemia, and thus 
behave more like MDS than AML. These cases 
of MDS-EB in transformation (MDS-EB-t) 
together with cases of MDS-EB account for 
approximately a quarter of all childhood MDS.
In the large cohort of children with MDS-EB/
MDS-EB-t of the European Working Group of 
MDS in Childhood (EWOG-MDS), allo-HSCT 
with a full MAC consisting of the combination of 
BU/CY/MEL resulted in an OS at 5  years of 
63%, with NRM and relapse contributing equally 
to treatment failure (Strahm et  al. 2011). The 
update shows that the outcome for patients who 
received a graft from either a MSD or an UD 
matched for 9/10 or 10/10 HLA-loci by using 
high-resolution typing is superimposable 
(Locatelli and Strahm 2018). Because patients 
≥12  years of age had a high risk of NRM, 
EWOG-MDS recommends an intensified GVHD 
prophylaxis (CSA  +  MTX) for older patients 
transplanted from a MSD (see http://ewog-mds.
org). The presence of a structurally complex 
karyotype was found to be strongly associated 
with poor prognosis (Göhring et al. 2010).
74.2  Refractory Cytopenia 
of Childhood (RCC)
Most children and adolescents with MDS pres-
ent with RCC, a provisional MDS entity charac-
terized by persistent cytopenia and <5% blasts in 
the BM and <2% blasts in the PB (Baumann 
et  al. 2017). BM biopsy shows considerable 
hypocellularity in about 80% of RCC cases. 
Most of these children with RCC have a normal 
karyotype and a low risk of progression to 
MDS-EB, while about 10–15% display an 
abnormal karyotype with monosomy 7, del(7q), 
or ≥2 aberrations.
It recently became evident that approximately 
half of all pediatric patients with primary MDS 
and monosomy 7 or del(7q) have GATA2 defi-
ciency or SAMD9/SAMD9L syndrome 
(Wlodarski et  al. 2016). Most of these children 
present as RCC.  Since the presence of mono-
somy 7 is correlated with a high risk of progres-
sion to more advanced MDS, patients with 
monosomy 7 should generally receive HSCT as 
soon as possible. For RCC with monosomy 7, 
del(7q), or ≥2 aberrations, MAC is recommended. 
EWOG-MDS currently advocates a TREO-based 
regimen which results in prompt initial engraft-
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ment with a low incidence of secondary graft 
failure and an OS of approx. 90% (see http://
ewog-mds.org). Historical data with a BU/CY 
have provided an OS of approx. 75%, NRM 
being the major cause of treatment failure (Starý 
and Locatelli 2005).
In the absence of monosomy 7, RCC patients 
with mild cytopenia (no transfusion dependency 
for red cells or platelets and an absolute neutro-
phil count of ≥1  ×  109/L) may have a stable 
course of disease and therefore qualify for a 
watch-and-wait strategy. For patients with more 
pronounced cytopenia, treatment is stratified 
according to cellularity.
In normo- or hypercellular RCC, a MAC regi-
men like that described for monosomy 7 may be 
utilized irrespective of karyotype. In patients 
with hypocellular BM, Fanconi anemia and dys-
keratosis congenita should be excluded by chro-
mosomal breakage and telomere length/
molecular studies, respectively.
HSCT with a RIC is the treatment of choice 
for hypocellular RCC and normal karyotype 
(Inagaki et al. 2015; Strahm et al. 2007). HSCT 
with a preparative regimen of TT/FLU (Strahm 
et al. 2007) resulted in an OS of 94% and EFS of 
88% (Strahm et al. 2017). However, approx. 10% 
of patients experience primary and secondary 
graft failure requiring a stem cell boost and/or 
second HSCT. Thus, EWOG-MDS currently rec-
ommends a preparative regimen of TREO/FLU 
aiming at an improved rate of engraftment (see 
http://ewog-mds.org). With a very low risk of dis-
ease recurrence, GVHD should be avoided; thus, 
BM is the preferred stem cell source combined 
with an effective GVHD prophylaxis (Locatelli 
and Strahm 2018). In the absence of a suitable 
donor, IST with horse ATG and CSA may be a 
therapeutic option in patients with hypocellular 
RCC and the absence of poor-risk karyotype 
(Yoshimi et al. 2014).
74.3  Juvenile Myelomonocytic 
Leukemia (JMML)
JMML is a unique clonal hematopoietic disorder 
of early childhood with myeloproliferative and 
myelodysplastic features (Locatelli and 
Niemeyer 2015). Splenomegaly, leukocytosis, 
monocytosis, and myeloid and/or erythroid pre-
cursors on PB smear are noted in close to all 
cases. Age ≥ 2 years, platelet count <40 × 109/L, 
and a high hemoglobin F are poor prognostic 
factors.
JMML is characterized by hyperactivation of 
the RAS signal transduction pathway. About 90% 
of patients harbor molecular alteration in 1 of 5 
genes (PTPN11, NRAS, KRAS, NF1, CBL) which 
define genetically and clinically distinct JMML 
subtypes. PTPN11-, NRAS-, and KRAS-mutated 
JMMLs are characterized by heterozygous 
somatic gain-of-function mutations in non- 
syndromic children, while JMML in neurofibro-
matosis type 1 (NF1) and JMML in children with 
CBL syndrome are characterized by germline 
RAS disease (RASopathy) and acquired biallelic 
inactivation of the respective tumor suppressor 
gene in hematopoietic cells.
JMML with somatic PTPN11 mutations is a 
rapidly fatal disorder unless the patient under-
goes HSCT.  HSCT in JMML patients with 
PTPN11 mutations is followed by a significantly 
higher relapse rate when compared to patients of 
the other JMML genetic subtypes. Like PTPN11- 
mutated disease, JMML in patients with NF1 is 
fatal in the absence of HSCT.
Children with somatic heterozygous KRAS 
mutations (14%) often have a clinically particular 
aggressive form of disease. Close to all of these 
children require prompt HSCT. NRAS-associated 
JMML (16%) displays a great clinical diversity. 
While a considerable percentage of patients 
transplanted for JMML with NRAS mutations 
relapse after HSCT, others survive in the absence 
of HSCT with persistence of NRAS mutation but 
slowly regressing disease. Clinically these 
patients are well and show a normal or only 
slightly elevated HbF. Molecular studies suggest 
that children with NRAS mutation and spontane-
ous regression have a low methylation profile and 
no subclonal mutations.
The vast majority of children with CBL- 
mutated JMML myeloproliferation is self- 
limiting with splenomegaly decreasing over 
years without HSCT. In the absence of one of the 
five canonical RAS pathway alterations, rare 
mutations in other RAS genes and non-JMML 
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myeloproliferative disorders need to be excluded. 
Most of these cases require HSCT.
In JMML, allo-HSCT, either from a histocom-
patible sibling or from an HLA-matched/1- 
antigen- disparate URD, results in a DFS of 52% 
(Locatelli et al. 2005). Disease recurrence is the 
most important cause of failure, occurring with a 
cumulative incidence of 35%. UCBT is a suitable 
option for children lacking an HLA-compatible 
relative (Locatelli et al. 2013). Standard prepara-
tive regimen consists of BU/CY/MEL (Locatelli 
et al. 2005; Dvorak et al. 2018). While intensive 
chemotherapy prior to transplantation is gener-
ally not followed by durable responses, azaciti-
dine might be an attractive option to bridge to 
HSCT (Cseh et al. 2015).
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75.1  Definition, Epidemiology, 
Diagnosis, and Classification
The myelodysplastic syndrome- myeloproliferative 
neoplasms (MDS/MPNs) are a heterogeneous 
group of hematologic malignancies characterized 
by dysplastic and myeloproliferative clinical, labo-
ratory, and morphological overlapping features, 
both in marrow and in blood. The MDS/MPN cat-
egory, recently updated by the last revision to the 
WHO classification of myeloid neoplasms and 
acute leukemia (Arber et al. 2016), includes chronic 
myelomonocytic leukemia (CMML), atypical 
chronic myelogenous leukemia (aCML), juvenile 
myelomonocytic leukemia (JMML), MDS/MPN 
with ringed sideroblasts and thrombocytosis (MDS/
MPN- RS- T), as well as unclassifiable forms of 
mixed myelodysplastic/myeloproliferative disor-
ders (MDS/MPN-U) (Table 75.1).
While JMML affects only children from 
birth up to 14 years of age (median age at diag-
nosis 2 years), with an estimated incidence of 
approximately 1.2 cases per million annually 
(Chang et al. 2014), adulthood MDS/MPN are 
typically diagnosed in elderly age with CMML 
being definitely the most frequent subtype 
(incidence of around 1 case/100,000 inhabit-
ants per year, median age 70  years) (Solary 
2014). Being very uncommon, data concerning 
the incidence of aCML, MDS/MPN-RS-T, and 
MDS/MPN-U are currently unknown.
75.2  Risk Factors and Prognostic 
Index
The clinical course of MDS/MPN varies from 
an indolent course over several years for a 
minor fraction of patients with CMML and 
MDS/MPN- RS- T to a more rapid progression 
with dismal prognosis and frequent transfor-
mation into secondary acute myeloid leukemia 
in the preponderance of patients with CMML 
and in the vast majority of patients with aCML 
and MDS/MPN- U, for whom allo-HSCT still 
represents the only curative option (Onida and 
Beran 2008; Onida 2017). Alike, long-term 
survival in the greater part of children with 
JMML may only be achieved by means of 
allo-HSCT.
CMML is highly heterogeneous, with clinical 
and hematological characteristics varying from 
mainly myelodysplastic to predominantly 
myeloproliferative. Based on marrow and 
peripheral blood blast percentage, the last WHO 
classification recognized three disease subtypes 
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 (CMML- 0, CMML-1, and CMML-2), associ-
ated to a corresponding decreasing life expecta-
tions (Arber et al. 2016). Over the latest years, a 
number of disease-specific prognostic systems 
have been developed in CMML in order to allow 
the best treatment strategy allocation (Onida 
2017a). The most recent ones are listed in 
Table 75.2.
Atypical CML, also named as BCR-ABL- 
negative CML, is a rare hematologic malignancy 
with an overall dismal prognosis (median 
24 months). Age, hemoglobin level, and leuko-
cyte count have been identified as variables with 
independent prognostic significance, allowing 
the stratification of two groups with significantly 
different life expectations. Likewise, for MDS/
MPN-RS-T, three risk categories of patients were 
recently differentiated by a Mayo Clinic prog-
nostic model including molecular investigations 
(Table 75.2).
With regard to the JMML, acquisitions from 
modern genetic studies assign uncommon treat-
ment indication in patients with germ line 
PTPN11 and CBL mutations, who frequently 
experience spontaneous disease regression. In 
contrast, patients with neurofibromatosis type 1, 
somatic PTPN11, KRAS, and most of those with 
NRAS mutations require early allo-HSCT as a 
result of rapidly progressive disease (Hasle 
2016).
MDS/MPN-U is the most heterogeneous and 
the least well-characterized entity, with no cur-
rently recognized specific molecular findings. 
Some description of the biological and clinical 
characteristics have been recently reported in two 
series (DiNardo et  al. 2014; Wang et  al. 2014), 
Table 75.1 Classification and diagnostic criteria of MDS/MPNs
Disease Blood findings Bone marrow findings
Chronic myelomonocytic 
leukemia (CMML)




Dysplasia in one or more myeloid lineagesb
No evidence of BCR/ABL1, PDGFRA, PDGFRB, 




Leukocytosis due to increased 








Hypercellularity, with granulocytic proliferation 
and granulocytic dysplasia, ± dysplasia in the 
erythroid and megakaryocytic lineages
No evidence of BCR/ABL1, PDGFRA, PDGFRB, 
or FGFR1 rearrangement or PCM1-JAK2
Juvenile myelomonocytic 
leukemia (JMML)c
Monocytes ≥1 × 109/L, (≥10% of 
the WBC count); <20% blasts
<20% blasts
The absence of BCR/ABL1 rearrangementd




Anemia, ≥15% ring sideroblasts, 
platelet count ≥450 × 109/L
<1% blasts
Erythroid lineage dysplasia with or without 
multilineage dysplasia, <5% blasts
The presence of a SF3B1 mutation or, in its 
absence, no history of recent cytotoxic or growth 
factor therapy that could explain the MD/MP 
features
No rearrangement of BCR/ABL1, PDGFRA, 
PDGFRB, FGFR1, or PCM1-JAK2. No (3;3)
(q21;q26), inv(3)(q21q26) or del(5q)
MDS/MPN unclassifiable
(MDS/MPN-U)e
<20% blasts <20% blasts
IMC immature myeloid cells (promyelocytes, myelocytes, metamyelocytes)
aIncluding monoblasts and promonocytes
bIf myelodysplasia is absent or minimal but other requirements are met, an acquired clonal cytogenetic or molecular 
genetic abnormality should be identified, or a nonreactive monocytosis persisting at least 3 months should be observed
cSplenomegaly is a mandatory feature
dPlus genetic abnormality (at least one) or additional criteria (Arber et al. 2016—Table 14)
eMyeloid neoplasms with mixed proliferative and dysplastic features that do not meet the criteria for CMML, aCML, 
JMML, or MDS/MPN-RS-T are classified as MDS/MPN-U
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with median survival of 12.4 and 21.8  months, 
respectively, and possible association of throm-
bocytosis with a more favorable outcome.
75.3  Pretransplantation 
Treatment
For this rare group of diseases, there are only few 
prospective studies on therapy, most being either 
retrospective analyses or case reports, making it 
difficult to give recommendations. In general, 
because apart from allo-HSCT no therapy has 
been shown to modify the disease course, pre-
transplantation treatments point toward symptom 
control rather than the achievement of disease 
remission (Odenike et al. 2015).
75.3.1  CMML
In general, treatment strategies in patients with 
CMML with symptomatic or progressive disease 
are based on the dysplastic versus proliferative 
features and the percentage of marrow blasts 
(Onida et al. 2013). In the presence of rising leu-
kocytosis and/or organ infiltration (mostly sple-
nomegaly) with low marrow blast percentage, 
hydroxyurea (HU) remains the drug of choice. 
Patients showing high blast percentages may be 
Table 75.2 Prognostic systems in MDS/MPN
MDS/MPN Prognostic model Variables included [score] Risk groups
Median OS 
(months)















CPSS (Such et al. 
2013)
WBC ≥13 x 109/L [1]
WHO CMML-2 subtype [1]


































BM blasts ≥5% [1]




































aCMML-specific cytogenetic risk classification, low, normal, and isolated –Y; intermediate, other abnormalities; and 
high, trisomy 8, complex karyotype (≥3 abnormalities), and abnormalities of chromosome 7




bridged to transplant through AML-like induc-
tion chemotherapy or by means of hypomethylat-
ing agents (HMAs), with a reported 20–50% 
overall response rate. In a recent retrospective 
study including a relatively small number of 
patients, HMAs have been suggested to increase 
progression-free survival (PFS) through the 
reduction of post-transplantation relapse rate 
(Kongtim et al. 2016). Treatment strategies based 
on the combination of HMAs with other agents 
(e.g., lenalidomide) and the advent of new tar-
geted therapies such as JAK2 inhibitors or 
poly(ADP-ribose) polymerase (PARP) inhibitors 
may further increase the response rate leading to 
an overall improvement of post-transplantation 
outcomes.
75.3.2  aCML
Due to its absolute rarity in patients having no 
age or comorbidity barrier to allo-HSCT, no con-
sensus subsists on to whether any pretransplant 
treatment may have an impact on post- 
transplantation outcome and what kind of ther-
apy should be best used. Control of leukocytosis 
is generally achieved with cytoreductive agents 
such as HU or IFN-α immunomodulation. 
Chemotherapy induction treatment is preferred 
when facing high blast count in advanced dis-
ease phases or in patients showing AML 
transformation.
Some efficacy of decitabine and of ruxoli-
tinib single agent has also been reported, 
whereas a phase II trial of AZA and ruxolitinib 
in combination in a series of 35 MDS/MPN 
patients showed promising activity, with an 
overall response rate of 57% according to the 
2015 international consortium response criteria 
for MDS/MPN (Savona et  al. 2015), even 
though median survival of the few aCML 
included patients (n  =  4) was only 8  months 
(Assi et al. 2018). According to the most recent 
discovery, SETBP1 and ETNK1 mutations are 
present in 15–32% and up to 10% of aCML 
patients, respectively, whereas JAK2 mutation is 
rare (0–7%), and CSF3R mutations are only 
occasionally observed. Even though in the near 
future these findings may influence therapeutic 
approaches by means of evolving targeted thera-
pies, currently allo-HSCT remains the only 
treatment strategy with established curative 
potential in eligible patients (Dao et al. 2017).
75.3.3  JMML
For JMML patients the possible therapeutic 
interventions prior to transplantation are rather 
scarce. Different chemotherapeutic agents have 
been used prior to transplant, but there is no con-
sensus on to whether there should be any pre-
transplant therapy and what type should be given. 
HMAs may have potential activity (Cseh et  al. 
2015), but data are too few to make any recom-
mendation. Other potentially active agents 
include JAK, MEK, and SRC inhibitors, but clin-
ical trial with these drugs is still on their way.
75.3.4  MDS/MPN-RS-T
MDS/MPN-RS-T generally represents the dis-
ease entity associated with the best prognosis 
among overlap syndromes, with a median sur-
vival of about 6  years (Broseus et  al. 2012). 
Guidelines for disease management are not for-
mally recognized, and treatment strategies are 
generally extrapolated from low-risk MDS and 
MPN, with adjusted individual management 
depending on presenting problems. While 
lenalidomide has been occasionally reported to 
reduce transfusion need, antiplatelet and cytore-
ductive treatments are often required due to the 
high risk of thrombosis. Based on the different 
gene mutations possibly involved (SF3B1, JAK2, 
TET2, DNMT3A), attentiveness in targeted thera-
pies is developing.
75.3.5  MDS/MPN-U
MDS/MPN-U is a very rare and heterogeneous 
disease entity, with no consensus on which ther-
apy (if any) should be given for patients candidate 
to allo-HSCT. Augmented leukocyte proliferation 
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is generally managed by means of cytoreductive 
agents such as HU or through immunomodula-
tion with IFNα, while HMAs as well as lenalido-
mide may represent an option in case of prevailing 
cytopenias. JAK inhibitors are also potential ther-
apeutic options, either alone or in combination 
with HMAs (Assi et al. 2018). When patients are 
progressing to AML transformation, induction 
chemotherapy should be used as a bridge to 
allo-HSCT.
75.4  Autologous HSCT
Because the harvesting of polyclonal hematopoi-
etic progenitor cells is not feasible through the 
currently available treatment options, autologous 
HSCT is currently not a recommended strategy in 
MDS/MPN.
75.5  Allogeneic HSCT
Currently still representing the only curative 
strategy, the role of allo-HSCT in adult MDS/
MPN patients remains controversial mainly due 
to the lack of prospective studies, being therefore 
generally considered a possible treatment option 
for eligible patients with high-risk diseases.
In CMML benefits and risks of allo-HSCT have 
been analyzed retrospectively in various series, 
with different characteristics at transplant and 
much variable outcomes described (Table  75.3). 
Recent recommendations from an international 
expert panel agreed to limit indication for allo-
HSCT in CMML patients classified in the interme-
diate-2 and high-risk CPSS categories (de Witte 
et al. 2017), representing the preferred treatment 
modality for younger patients with acceptable 
comorbidity index (Patnaik et al. 2015).














































































































































As aCML is extremely rare in people younger 
than 65  years, outcome after allo-HSCT has 
been described only in small single-institution 
series. A 5-years OS and RFS of 51% and 36%, 
respectively, were recently reported by the 
EBMT- CMWP in a retrospective analysis of 42 
patients transplanted between 1997 and 2006. 
With a RR of 40%, a better OS was recognized 
in young patients with low EBMT risk score 
(Onida et al. 2017).
With regard to JMML, 5-years OS and EFS 
out of 100 patients transplanted 1993 through 
2002 within the EWOG-MDS/EBMT trial were 
64% and 52%, respectively, with a 5-years TRM 
of 13% (Locatelli et al. 2005). Overall, younger 
age, male sex, low HbF, and low BM blast per-
centage were associated to better survival. Early 
disease recurrence was the major cause of treat-
ment failure, irrespective of donor type (sibling 
vs unrelated vs CB). Although both acute and 
chronic GvHD are associated with a lower relapse 
risk, DLI in JMML relapse is mostly unsuccess-
ful. In contrast, a second HSCT with the same or 
an alternative donor may cure about 30% of the 
patients (Locatelli and Niemeyer 2015).
In MDS/MPN-RS-T allo-HSCT is generally 
not indicated, being reserved for patients devel-
oping refractory cytopenias or accelerated/blastic 
transformation (Sharma et al. 2017), whereas eli-
gible patients with MDS/MPN-U should always 
be considerate as potential candidate for allo- 
HSCT due to the general dismal prognosis.
75.6  Source of HSC
No impact of HSC source on the transplant out-
come has been observed in the largest CMML 
series reported by the EBMT-CMWP (Symeonidis 
et al. 2015). This was in contrast to the CIBTMR 
study, in which the survival was statistically bet-
ter with PBMC than with BM, with no clear 
explanation outside the small proportion of BM 
transplants (16%) (Liu et al. 2017). The source of 
stem cell is therefore left open, but PBSC may 
potentially be preferred to decrease the risk of 
graft failure and the relapse risk, particularly with 
the use of RIC.
In the pediatric population, the majority of 
transplantation are done with BM, mainly due to 
the potential of decreasing the incidence of 
GVHD.  In the largest series of JMML patients 
reported, BM was the stem cell source in 79% 
with no significant difference on the outcome in 
comparison to PBSC (Locatelli et al. 2005).
For aCML, MDS/MPN-RS-T, and MDS/
MN-U, data are too scarce to make clear 
recommendations.
75.7  Conditioning and GvHD 
Prophylaxis
In MDS/MPN patients, the choice of condition-
ing regimen depends on many different condi-
tions, the major ones being comorbidities, patient 
age, disease phase at transplant, type of donor, 
and HSC source. In the two largest retrospective 
series of CMML patients (Symeonidis et  al. 
2015; Liu et  al. 2017), MAC and RIC were 
almost equal in proportion, with no outcome dif-
ference. Likewise, in the largest reported series 
of aCML patients, conditioning intensity had no 
impact on the outcome (MAC were used in 76%). 
Noteworthy, an improved outcome following a 
combined fractionated 6–8 Gray TBI/FLU condi-
tioning regimen was recently reported in 
advanced CMML (Radujkovic et al. 2017).
In general, for young patients (<60  years), 
with a HSCT-CI (Sorror et al. 2005) less than 2, 
MAC regimens such as BU-CY, TT/BU/FLU 
(TBF), or the reduced-toxicity FLU/BUx4 (FB4) 
may be advisable, particularly in the proliferative 
variant of CMML and in other MDS/MPN with 
predominant proliferative features, whereas a 
RIC regimen such as BU/FLU or reduced TBF 
may be preferred for patients with older age or 
comorbidities and for patients undergoing trans-
plant with disease remission following pre- 
transplant treatment.
Facing an aggressive disease in a very young 
population, MAC regimens are generally pre-
ferred in JMML. In the biggest series published, 
the conditioning included CT, BU and MEL 
(Locatelli et al. 2005), with a 5-years OS of 64%. 
More recently, a conditioning containing BU, 
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FLU, and MEL showed promising results, with 
more than 50% of patients in remission after alter-
native donor transplantation (Yabe et  al. 2015). 
Based on those data, the recommended condition-
ing for JMML patients should rely on the back-
bone of BU and MEL with either CY or FLU.
75.8  Maintenance/Post transplant 
Strategies
As disease recurrence represents the major cause 
of transplant failure in MDS/MPN, there is a 
growing interest toward post transplant strate-
gies, although few data are currently available in 
this particular setting.
Indirect evidence of a graft versus CMML by 
a reduced incidence of relapse in patients with 
GvHD has been recently reported (Itonaga et al. 
2018). Some effect of DLI has also been reported 
in patients with relapsing CMML and low dis-
ease burden.
With more molecular markers potentially 
available, cell therapy-based interventions may 
be planned on the base of residual or increasing 
MRD.
Potential interest both as preemptive and as 
maintenance strategy derive from the use of post 
transplant HMAs, alone or in combination with 
DLI, as reported in AML and MDS.
The use of lenalidomide and checkpoint 
inhibitors, but also JAK2 or PARP inhibitors, 
alone or even in combination, together with post 
transplant targeted therapies represents areas of 
growing interest under development.
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76.1  Primary and Post ET/PV 
Myelofibrosis
Nicolaus Kröger
76.1.1  Definition and Risk Scores
Polycythemia vera (PV) and essential thrombo-
cythemia (ET) have a favorable outcome without 
need for allo-HSCT unless the disease progressed 
to post-ET/PV myelofibrosis or secondary AML 
(Lussana et al. 2014).
Primary myelofibrosis (PMF) or post-ET/PV 
myelofibrosis is one of the Philadelphia-negative 
myeloproliferative neoplasms (MPN) with worst 
survival which is approximately 6  years. Allo- 
HSCT can cure a substantial number of patients 
but is still not universally applicable due to toxic-
ity which leads to therapy-related morbidity and 
mortality.
76.1.2  Transplant Results 
in Myelofibrosis
In the late 1980s and the early 1990s, the feasibility 
of allo-HSCT for myelofibrosis could be shown in 
small reports. One multicenter report described in a 
retrospective study with MAC in relatively young 
patients (median age 42 years) with a NRM of 27% 
and a 9% incidence of graft failure. The OS and PFS 
was 47% and 39% at 5 years (Guardiola et al. 1999). 
A single-center study from Seattle included 104 
patients most of whom received allo-HSCT after 
MAC, and NRM at 5  years of 34% and OS at 
7 years of 61% were reported (Deeg et al. 2003).
The evidence of graft-versus-myelofibrosis 
effect was documented by responses to DLI after 
failure of allo-HSCT (Byrne et al. 2000). RIC for 
myelofibrosis was investigated in two prospec-
tive studies. The EBMT published results of 103 
patients who received a BU/FLU-based RIC fol-
lowed by related or unrelated HSCT. The median 
age was 55  years, and the NRM at 1  year was 
16%. Cumulative incidence of relapse was 22% 
at 3 years. PFS and OS at 5 years were 51% and 
67%, respectively. Advanced age and HLA- 
mismatched donor were independent predictive 
factors for reduced survival (Kroger et al. 2009). 
A recent update of the study after a median fol-
low- up of 60  months showed an 8-year OS of 
65% with stable plateau. Five-year DFS was 
40%, and 5-year cumulative incidence of relapse/
progression was 28% with 3-year NRM of 21%.
The Myeloproliferative Disorders Research 
Consortium performed also a prospective phase 
II trial including 66 patients with primary or post-
ET/PV myelofibrosis investigating a reduced 
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 conditioning regimen with MEL/FLU.  With a 
median follow-up of 25 months, OS was 75% in 
the sibling group and only 32% in the unrelated 
group due to a higher NRM in the URD group 
(59% vs. 22%) (Rondelli et al. 2014). Other studies 
using RIC or MAC confirmed the curative effect of 
allo-HSCT irrespectively of the intensity of the 
conditioning (summarized in Kröger et al. 2015a).
76.1.3  Disease-Specific Risk Factors
Patients with PMF or post-ET/PV myelofibrosis 
have a median survival of approximately 6 years, 
but survival varies from less than 2 to more than 
15 years. Risk scores (see Table 76.1) such as IPSS 
(Cervantes et  al. 2009), dynamic IPSS (DIPSS) 
(Passamonti et al. 2010), or DIPSS plus (Gangat 
et al. 2011) are currently used in clinical practice 
to determine the prognosis of patients with 
PMF. More recently molecular markers have been 
introduced into the PMF risk score, (Guglielmelli 
et  al. 2018) and a specific score for post-ET/PV 
myelofibrosis has been proposed (Passamontiet al. 
2017; Kroger et al. 2015a). The EBMT/ELN con-
sensus paper recommended allo-HSCT for patients 
less than 70 years with an estimated median sur-
vival of less than 5  years. This would include 
patients with IPSS or DIPSS intermediate-2 and 
high risk and is based on a comparison between 
transplanted and non-transplanted patients in the 
pre- ruxolitinib era (Kroger et al. 2015a, b). Patients 
with intermediate-1 risk can be considered for 
allo-HSCT if other high-risk features such as 
ASXL1 mutation, more than 2% peripheral blasts, 
refractory transfusion-dependent anemia, or 
adverse cytogenetics according to DIPSS plus are 
present (Kroger et al. 2015a).
76.1.4  Transplant-Specific Risk 
Factors
In most of the transplant studies, alternative 
donors were associated with a worse outcome 
independent of disease-specific risk factors. CBT 
resulted in a high risk of graft failure (Robin et al. 
2014). Haplo-identical donor with PT-CY as 
GVHD prophylaxis is currently under investiga-
tion, but more recent EBMT data reported a 
5-year survival of only 38% (Raj et al. 2016).
The intensity of the conditioning regimen has 
not been investigated within prospective studies, 
but retrospective comparisons of MAC and RIC 
preparative regimens resulted in similar outcome. 
Because of the reduced toxicity and a generally 
older age of patients with myelofibrosis, RIC 
regimens are currently used more frequently and 
account for about two-thirds of allotransplants 
for myelofibrosis reported to the EBMT registry.
Table 76.1 Prognosis risk scores for myelofibrosis
Score Adverse factors (puntos) Risk group and median SRV
IPSS Age > 65 years (1 p)
Constitutional symptoms (1 p)
Hb <100 g/L (1 p)
Leucocytes >25 × 109/L (1 p)
Blasts in PB ≥1% (1 p)
Low (0 p), 11.3 years
Intermediate-1 (1 p), 7.9 years
Intermediate-2 (2 p), 4 years
High (3–5 p), 2.3 years
DIPSS Age > 65 years (1 p)
Constitutional symptoms (1 p)
Hb <100 g/L (2 p)
Leucocytes >25 × 109/L (1 p)
Blasts in PB ≥1% (1 p)
Low (0 p), not reached
Intermediate-1 (1–2 p):,14.2 years
Intermediate-2 (3–4 p), 4 years
High (5–6 p), 1.5 years
DIPSS plus DIPSS Int-1 (1 p)
DIPSS Int-2 (2 p)
DIPSS High (3 p)
Platelets <100 × 109/L (1 p)
Transfusion requirement (1 p)
Unfavorable karyotypea (1 p)
Low (0 p), 15.4 years
Intermediate-1 (1 p), 6.5 years
Intermediate-2 (2–3 p), 2.9 years
High (4–6 p), 1.3 years
DIPSS: https://qxmd.com/calculate/dipss-prognosis-in-myelofibrosis
DIPSS-plus: https://qxmd.com/calculate/dipss-plus-score-for-prognosis-in-myelofibrosis
a+8; −7/7q-; −5/5q-; i17q; 12p-; rearrangement 11q23
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76.1.5  Patient-Specific Risk Factors
Age is a significant patient-specific risk factor for 
outcome after allo-HSCT (Scott et al. 2012; Kroger 
et al. 2015a). Besides age, comorbidities and geriat-
ric assessments (see Chap. 11) also impact on out-
come after allo- HSCT but have not been studied 
especially in myelofibrosis patients to date.
76.1.6  Role of Splenectomy and JAK 
Inhibition
Splenomegaly is a hallmark of myelofibrosis and 
may have an impact on engraftment and graft 
function after HSCT. Splenectomy is an option to 
reduce spleen size prior to transplantation, but 
high morbidity and even mortality have been 
reported (Tefferi et al. 2000). Spleen irradiation 
to reduce spleen size has been reported success-
fully in single cases prior to conditioning. Since 
ruxolitinib is approved for myelofibrosis, the 
drug can be used prior to transplantation to 
improve constitutional symptoms and to reduce 
spleen size. The European LeukemiaNet and the 
European Society for Blood and Marrow 
Transplantation recommend the use of ruxoli-
tinib at least 2 months prior to HSCT and a care-
ful weaning prior to conditioning to avoid the 
rebound phenomenon. More recent data suggest 
better outcome after HSCT if patients received 
transplant after responding to ruxolitinib rather 
than postponing the transplant until ruxolitinib 
failure (Shanavas et al. 2016).
76.1.7  Impact of Molecular Remission
About 90% of myelofibrosis patients harbor one 
of the driver mutations JAK2V617F, calreticulin 
(CALR), or MPL which are used to monitor 
MRD in PB by highly sensitive qPCR or digital 
PCR to determine molecular remission (Wolschke 
et al. 2017). In a retrospective single center expe-
rience, no achievement of molecular remission 
on day 180 post-allograft was associated with a 
significant higher incidence of a subsequent clin-
ical relapse. Due to a graft-versus-myelofibrosis 
effect, donor lymphocyte infusion has been suc-
cessfully applied in patients with residual to 
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Furthermore, BM fibrosis is another hall-
mark of the disease, with rapid regression after 
allo- HSCT suggesting that fibrogenesis is a 
highly dynamic process (Thiele et  al. 2005). 
Systematic investigations have shown that 
about 60% of the patients have a complete or 
nearly CR of BM fibrosis on day+100, and the 
percentage of patients increased to 90% at 
day+180. Notably, those patients with a rapid 
resolution of BM fibrosis had the best long-
term outcome.
76.2  Chronic Myeloid Leukemia
Yves Chalandon
76.2.1  Definition, Epidemiology, 
Diagnosis, and Classification
Chronic myeloid leukemia (CML) is a clonal 
myeloproliferative disorder of the HSC.  CML 
was the first leukemia described and the first to be 
characterized by a consistent chromosomal aber-
ration, the 22q- or “Philadelphia” (Ph) chromo-
some, later identified as a reciprocal translocation, 
t(9;22), encoding the BCR-ABL oncoprotein.
CML is the most common of the myeloprolifera-
tive disorders. The incidence is 0.4–1.75 per 
100,000 population per year, and it increases with 
age (Höglund et al. 2015). The disease can occur at 
any age, but the median age at presentation ranges 
between 45 and 55 years. There is a slight male pre-
dominance, with a male to female ratio of 1.3:1.
CML present initially as an indolent or chronic 
phase (CP), easily controlled with treatment. The 
natural history continues with a bi- or triphasic 
stage, becoming more aggressive through accel-
erated phase (AP) and then blast crisis (BC) or 
directly from CP to BC.
76.2.2  Risk Factors and Prognostic 
Index
Several multivariate-derived prognostic models and 
staging have been proposed to help define individ-
ual prognosis and allow assigning patients to differ-
ent strategies of therapy based on risks. The most 
commonly used are the Sokal and Hasford one 
(Sokal et al. 1984; Hasford et al. 1998).
The benefit of allo-HSCT is that it can provide 
cure, but the clear disadvantage is its association 
with considerable morbidity and mortality, which 
typically occur early post procedure. Outcome 
can be improved by better selection of those most 
likely to benefit. In this context the EBMT devel-
oped a risk score for patients with CML, based on 
five variables: donor type, disease phase, recipi-
ent age, donor/recipient gender combination, and 
interval from diagnosis to transplant, which 
together results in a score of 0–7 (see risk factors 
in Chap. 11) (Gratwohl et al. 1998).
Results of transplant are now highly predict-
able based on these five factors. It is worth remem-
bering that the EBMT or “Gratwohl” score was 
developed in the mid-1990s and was based on 
3142 patients transplanted between 1989 and 
1996 (Fig. 76.2a). With overall improvements in 
supportive care, it would be reasonable to expect 
that a similar analysis performed on patients 
transplanted more recently would demonstrate 
improved results across all- risk scores. However, 
the analysis is complicated by the change in 
approach to management of CML.  During the 
period of the original analysis, allo-HSCT was the 
treatment of choice for all patients. Since 2000 
Key Points
• Primary or post-ET/PV myelofibrosis 
can only be cured by allo-HSCT which 
can induce molecular remission and 
resolution of bone marrow fibrosis.
• Indication for allo-HSCT is recom-
mended for patients younger than 
70 years and a median survival expecta-
tion of less than 5  years such as risk 
score intermediate or high risk accord-
ing to DIPPS or intermediate-1 risk with 
additional risk factors.
• Splenectomy prior to transplant is not 
recommended, but patients with large 
spleen may benefit from JAK inhibitor 
treatment prior to transplantation.
• Major risk factors for worse outcome 
are advanced age and not fully HLA-
matched donor.
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allo-HSCT has been replaced by tyrosine kinase 
inhibitors (TKI) as frontline therapy, and hence 
the reasons for patients coming to transplant are 
not always clear from registry data. Although this 
should be compensated by the use of factors such 
as age at transplant, disease phase, and time from 
diagnosis to transplant, some caution should be 
exercised in the interpretation of more recent 
results. Having said this, the analysis has been 
repeated recently for 3497 patients transplanted 
from 2007 to 2017 and confirmed improved out-
come of 5-year OS across all-risk scores by 
11–26% (Fig.  76.2b). Although these pretrans-
plant factors are known to affect outcome in all 
diseases, it is worth focusing specifically on the 
impact of disease phase in CML, in particular 
because one of the few problems of TKI therapy is 
that within the cohort of patients receiving trans-
plants, the proportion transplanted in or after blast 
crisis has increased over time (Table 76.2).
Allografts for CML were initially restricted to 
patients in AP, and improvements in survival 
came only when transplant was performed in the 
CP. Data of 138 patients with CML transplanted 
between 1978 and 1982 and reported to the 
IBMTR showed 3-year survivals of 63%, 36%, 
and 12% for patients transplanted in the CP, AP, 
and BC, respectively. The probability of relapse 
for those transplanted in CP was 7% (Speck et al. 
1984). The effect of disease phase on the out-
come of transplantation has not changed over the 
years. To optimize the effect of allo-HSCT for a 
patient who has progressed to blast crisis, a sec-
ond CP should be achieved using TKI and/or con-
ventional combination chemotherapy.
76.2.3  Pretransplantation Treatment
Early descriptions of therapy included radiother-
apy, introduced at the beginning of the twentieth 
century and later oral chemotherapy, in particular 
BU and hydroxycarbamide. These approaches 
could control the signs and symptoms of CML in 
chronic phase but could not prevent its inevitable 














































Fig. 76.2 (a) OS of CML patients after allo-HSCT 
according to EBMT risk score. Original curves published 
in 3142 patients transplanted between 1989 and 1996. 
Modified from (Gratwohl et al. 1998). (b) OS curves sup-
plied by Mrs. Linda Koster for the EBMT CMWP and 
based on 3497 patients transplanted from 2007 to 2017
Table 76.2 Change in proportion of patients trans-















2007 164 (50) 49 (15) 82 (25) 34 (10)
2008 134 (45) 34 (12) 84 (28) 44 (15)
2009 133 (41) 46 (14) 92 (28) 53 (16)
2010 128 (36) 57 (16) 106 (30) 65 (18)
2011 148 (49) 50 (15) 86 (26) 46 (14)
2012 127 (46) 34 (12) 74 (27) 42 (15)
2013 136 (44) 41 (13) 78 (25) 54 (18)
2014 138 (43) 48 (15) 75 (24) 57 (18)
2015 137 (44) 43 (14) 73 (23) 62 (20)
2016 111 (42) 30 (11) 70 (26) 55 (21)
2017 74 (36) 20 (10) 68 (33) 45 (22)




blastic disease. The first treatment that eradicated 
the Ph-positive clone and induced cure was BMT, 
initially described in syngeneic twins and soon 
followed by procedures involving HLA-matched 
siblings and later URD. Transplantation, once the 
treatment of choice for this disease, has been rel-
egated to second-, third-, and even fourth-line 
treatment in parallel with the development of the 
TKI. As more potent TKI move to first-line ther-
apy, patients destined to respond poorly to these 
drugs are identified earlier, and transplant will 
return to use as an earlier line strategy.
76.2.4  Autologous HSCT
Autologous HSCT for CML started about at the 
same time as allo-HSCT in the late 1970s early 
1980s in Europe with the goal to set up the clock 
to early phase with high-dose therapy followed by 
reinfusion of autologous HSC. However, follow-
ing the introduction of targeted therapy with TKI, 
the number of auto-HSCT in Europe has decreased 
rapidly, with only 0–4 per year between 2012 and 
2016 as per the EBMT registry data. Auto-HSCT 
is currently not a recommended strategy in CML; 
however, it should be mentioned that due to the 
lack of randomized studies, the potential role of 
autologous HSCT for CML remains unknown.
76.2.5  Allogeneic HSCT
76.2.5.1  Indication
Although the introduction of TKI in the early 
2000s dramatically changed the therapeutic strat-
egy for CML, allo-HSCT has still a place, offering 
a very long-term PFS. This is particularly true as 
the leukemic quiescent stem cells are not depen-
dent on BCR-ABL signaling for survival, and 
therefore those cells are not targeted by TKIs lead-
ing to a proportion of patients who will relapse or 
will have resistant disease despite TKI treatment. 
With extended follow-up, it appears that some 
60% of patients can achieve excellent long-term 
disease control on imatinib, and a small proportion 
may even be able to stop treatment without experi-
encing disease recurrence. Approximately half of 
this group will achieve or regain remission on one 
of the second-generation TKI (2ndGTKI), bosuti-
nib, dasatinib, and nilotinib, or third-generation 
TKI (3rdGTKI)  ponatinib which is the only one 
that is effective against T315I mutation.
The efficacy of 2ndGTKI has led to their use as 
first-line therapy, and recently completed phase III 
studies suggest that approximately 80% of patients 
will achieve complete cytogenetic remissions 
within the first year, compared to 65% on imatinib. 
Based on these results, dasatinib and nilotinib have 
both been licensed for use in newly diagnosed 
patients. However, allo-HSCT remains the therapy 
of choice for advanced phase CML as well as for 
those with CP who failed to respond, develop TKI-
resistant mutations, and lose an established 
response and/or are intolerant of the drug.
The time to proceed to transplant remains con-
troversial. This is particularly true for the substan-
tial number of patients being started on 2ndGTKI 
as first-line therapy, who, in case of resistance, 
progression, or relapse, may be rescued with 
either another 2ndGTKI or 3rdGTKI, and then the 
question to proceed to transplant immediately or 
wait for another progression and third-line ther-
apy rescue before to have allo- HSCT is a matter 
of debate. This is less true for those who are fail-
ing third-line therapy or have T315I mutation for 
whom allo-HSCT is recommended.
A number of national and international study 
groups are now reporting that long-term response 
to imatinib and 2ndGTKI can be predicted by the 
rate of fall of BCR-ABL transcript levels (as 
measured by RQ-PCR at 3 and 6 months). It is 
therefore possible to identify the patient destined 
for transplant within the first year of diagnosis 
while still in CP and return to a more measured 
approach to transplant. Recently the CMWP of 
the EBMT analyzed the data of patients trans-
planted for CML in the 3rdGTKI era that showed 
that the number of TKI given prior to allo-HSCT 
seems not to impact on the outcome; however, 
the stage of the disease as well as the perfor-
mance status of patients did have an important 
impact (Chalandon et  al. 2018). It is therefore 
very important to try to keep patients in first CP 
and avoid progression, even for those rescued to 
second or more CP after having progressed to 
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advanced phase, as the results after transplanta-
tion are worse in this category. Allo-HSCT is also 
recommended for patients with BC after debulk-
ing with second or 3rdGTKI plus induction che-
motherapy. For AP CML patients, this should be 
individualized, but the search for a donor and 
referral to a transplant center should be done rap-
idly, and transplant should be initiated after 
obtaining a new response to TKI for those pro-
gressing from CP to AP under therapy as their 
outcome is not good without allo-HSCT.
76.2.5.2  Source of SC
About two-thirds of the transplantation done now-
adays for CML use PBSC as source of HSC 
(Chalandon et  al. 2018); this is close to what is 
seen in other hematological malignancies (Holtick 
et al. 2014). It appears that there is no difference in 
general outcome depending on the stem cell 
source, although BM seems to have a decrease 
incidence on chronic GvHD and its severity. The 
source of stem is therefore left open, but PBSC 
may potentially be preferred to decrease the risk of 
graft failure and the relapse risk in more advanced 
disease, particularly with the use of RIC.
76.2.5.3  Conditioning and GvHD 
Prophylaxis
For CML patients, the best conditioning regimen as 
well as the best GvHD prophylaxis remains to be 
determined. Regarding the MAC, CY combined 
either with BU or TBI is still the one that has shown 
the best overall long-term survival (Copelan 2006). 
RIC that has been introduced later to offer trans-
plantation to older patients or with more comorbidi-
ties did not show improved outcome over MAC, 
particularly in relation with a higher incidence of 
relapse with RIC (Kebriaei et al. 2007; Chalandon 
et al. 2018). Therefore, for elderly patients or those 
with comorbidities, RIC (FLU with BU or MEL) 
will be the choice, and for the others, particularly 
with advanced phases in order to control better the 
disease, MAC should be proposed.
For GvHD prophylaxis, CSA combined with 
short course MTX seems also to remain the stan-
dard for allo-HSCT for CML (Copelan 2006). In 
order to reduce the incidence and severity of 
GvHD, TCD was introduced in the 1980s; how-
ever, there was an increase of relapse rate 
(Apperley et al. 1986). This led to many groups 
abandoning the use of TCD in sibling allografts 
for CML and often also in URD procedures. 
Others continued with its use and have reported 
good outcomes in sibling transplants, particularly 
following the introduction of DLI.  In a small 
series of 23 CML patients with a median age of 
36  years (range 18–58  years) transplanted with 
sibling donors and MAC between 1998 and 2016 
at the University Hospital of Geneva using partial 
TCD with Campath-1H (alemtuzumab), the 
15-year OS and LFS was 95% using the strategy 
of escalating doses DLI for early molecular 
relapses with a low incidence of acute and chronic 
GvHD (Chalandon, unpublished data).
76.2.5.4  Post transplant Strategies
After allo-HSCT, rising or persistently high lev-
els of BCR-ABL1 mRNA can be detected prior 
to cytogenetic or hematological relapse. Low or 
falling BCR-ABL1 transcript levels are associ-
ated with continuous remission, while high or ris-
ing transcript levels predict relapse. Therefore 
monitoring BCR-ABL1 post-allo-HSCT for 
CML is of utmost importance, even in the long 
term, due to relapses that have occurred up to 
more than 15 years post-HSCT.
Many CML patients will remain RQ-PCR 
positive during the first 3  months after allo- 
HSCT, especially in the era of RIC or using 
TCD. In patients who are at least 4 months post- 
allo- HSCT, one working definition of molecular 
relapse is one of the following:
 (a) BCR-ABL/ABL1 ratio higher than 0.02% in 
three samples a minimum of 4 weeks apart.
 (b) Clearly rising BCR-ABL/ABL1 ratio in 
three samples a minimum of 4 weeks apart 
with the last two higher than 0.02%.
 (c) BCR-ABL/ABL1 ratio higher than 0.05% in 
two samples a minimum of 4  weeks apart 
(Kaeda et al. 2006).
Administration of DLI can re-induce remission 
in 60–90% of patients with CML transplanted in, 
and relapsing in CP. The use of escalating doses in 
case of persistent disease reduces the risk of GvHD 
76 Myeloproliferative Neoplasms
576
(Mackinnon et al. 1995). An EBMT study showed 
69% 5-year survival in 328 patients who received 
DLI for relapsed CML. DLI-related mortality was 
11%, and disease-related mortality was 20%. 
Some form of GvHD was observed in 38% of 
patients. Risk factors for developing GvHD after 
DLI were T-cell dose at first DLI, time interval 
from transplant to DLI and donor type. In a time- 
dependent multivariate analysis, GvHD after DLI 
was associated with a 2.3-fold increase in risk of 
death as compared with patients without GvHD 
(Chalandon et al. 2010).
With the advent of TKI, the CML post trans-
plant interventions are more complexes but give 
more opportunities to rescue patients. It is possi-
ble to combine DLI and TKI for relapsing 
patients; however, the best order (TKI first, DLI 
first, or both combined) has not yet been defined. 
The CMWP of the EBMT reported 431 patients 
with CML relapses post-allo-HSCT who received 
TKI either alone (55%) or in combination with 
DLI (14.5% before, 4.4% at the same time, and 
26% after TKI). Only 42% of the patient obtained 
either a complete molecular (17.7%), cytogenetic 
(4.4%), or hematological (20.2%) remission with 
a 5-year OS of 60% and of 47% for RFS 
(Chalandon et al. 2017). This rather low response 
rate may be in relation with the fact that 235 
patients were transplanted for advanced phases 
(AP, BC or > CP1).
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Severe Aplastic Anemia and PNH
Régis Peffault de Latour, Antonio Risitano, 
and Carlo Dufour
77.1  Definition and Epidemiology
Severe aplastic anemia (SAA) is an autoimmune 
disorder (AID) due to the attack of autoreactive 
cytotoxic T lymphocytes to the hematopoietic 
component of the bone marrow. The triggering 
antigen is so far unknown. The incidence of SAA 
is about 2.34/million in Europe and the United 
States and threefold higher in East Asia, with two 
age peaks of incidence (in young adults and in 
the elderly) (Young and Kaufman 2008).
Paroxysmal nocturnal hemoglobinuria (PNH) 
is another bone marrow failure syndrome (BMFS) 
which is often embedded with SAA.  PNH is a 
more heterogeneous disease since its clinical pre-
sentation includes hemolytic anemia and throm-
bophilia in addition to bone marrow failure.
77.2  Diagnosis and Indication 
for Treatment for SAA
SAA is usually diagnosed in the setting of pancy-
topenia and a hypocellular BM. Diseases such as 
myelodysplasia, myelofibrosis, hypocellular 
acute leukemia, inherited BMF such as Fanconi’s 
anemia (FA), or telomeropathies need to be 
excluded. Cytogenetic abnormalities can be 
found in up to 10% of true SAA (Rovo et  al. 
2016; Barone et al. 2015).
There is a close relationship between PNH 
and acquired SAA with a concomitant diagnosis 
in 40% of cases. SAA is diagnosed when marrow 
hematopoietic cellularity is <30%, and two of 
three of the following criteria are met: absolute 
neutrophil count <0.5 × 109/L, absolute reticulo-
cyte count <60  ×  109/L, and platelet count 
<20 × 109/L (Camitta et al. 1976).
Treatment requires careful planning and may 
be prolonged. A watch and wait strategy is often 
used initially if there is milder pancytopenia. 
Conversely, in case of transfusion requirement or 
if the criteria for SAA are met, treatment should 
begin with no delay. Prior to treatment the patient 
should be stable clinically with control of bleed-
ing and infections. Once the diagnosis is con-
firmed, and the disease severity is assessed, 
family HLA-typing and matched unrelated donor 
search should be done in the work-up phase. In 
the absence of sign of intravascular hemolysis, 
patient’s treatment algorithm is similar with or 
without PNH.
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77.3  Treatment of SAA
77.3.1  First Line Treatment for SAA
The choice of first-line treatment depends on the 
age of the patient and the availability of an HLA 
MSD (Fig.  77.1). The standard first-line treat-
ments for a newly diagnosed patient with SAA are 
HSCT from a HLA-identical sibling donor or IS 
therapy (IST) using a combination of horse ATG 
and CSA (ATG  +  CSA). Early bone marrow 
HSCT after a conditioning regimen with CY, ATG, 
and GVHD prophylaxis combining CSA and 
MTX promotes excellent engraftment (95%) and 
OS (90% at 2  years) (Bacigalupo et  al. 2012; 
Peffault de Latour 2016). This approach enabled 
also a very good long-term outcome with a rather 
limited number of late effects consisting in avascu-
lar necrosis, endocrine dysfunctions, and very rare 
secondary malignancy (Konopacki et  al. 2012). 
However, toxicity related to transplantation as well 
as increased risk of GvHD is still a problem for 
patients older than 40 years of age and for those 
with high comorbidity index (Marsh et al. 2011).
For these categories first-line IS with horse 
ATG + CSA is recommended. This combination 
showed both in prospective controlled studies 
(Scheinberg et al. 2011; Marsh et al. 2012) and in 
real-life surveys (Peffault de Latour et al. 2018) a 
response rate of about 60%. Frontline IST pro-
vided similar findings in children and adolescents 
(Dufour et al. 2014; Dufour et al. 2015a). After 
IST, responders might experience relapse (20–
30%), CSA dependence (20–30%), or long-term 
clonal evolution (PNH, MDS, or AML) 
(Scheinberg and Young 2012), justifying regular 
follow-up and bone marrow evaluation every 
12–18 months.
Idiopathic aplastic anemia
needed to be treated
HLA-identical sibling donor
and age < 40
HSCT
Marrow/Cy + ATG/CSA MTX
No sibling donor
or age 40 or more
hATG + CSA
Refractory/relapse










10/10 or 8/8 feasible
in 2-3 months and
age < 20 years
Fig. 77.1 Treatment algorithm of SAA in 2019
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77.3.2  Second-Line Treatment 
for SAA
The choice of second-line treatment is also driven 
by age, by comorbidities, and by the presence of 
a matched related (MRD) or unrelated donor 
(MUD):
• In older patients with a MRD and confirmed 
refractory SAA, HSCT should be considered 
in the absence of significant comorbidities.
• In younger patients with a MUD and refrac-
tory or relapsed SAA, HSCT is recom-
mended. Results of MUD HSCT have 
improved to such an extent that OS of idio-
pathic SAA are not statistically inferior to 
MRD transplants (Bacigalupo et  al. 2015). 
This improvement has been largely attributed 
to better donor selection through allele match-
ing, progress in supportive care, prophylaxis 
of GVHD, incorporation of FLU in condi-
tioning regimens, and the addition of low-
dose TBI. Recently some factors were found 
to positively affect OS after MUD HSCT 
including age ≤  30  years, transplant within 
the first year after diagnosis (Devillier et al. 
2016), use of BM vs PB, and CMV status 
(Bacigalupo et al. 2015).
• For patients older than 30 years, monotherapy 
with eltrombopag, an oral thrombopoietin- 
receptor agonist, produced in prospective 
studies in refractory patients an overall 
response of 40% with trilineage responses in 
some cases (Olnes et al. 2012; Desmond et al. 
2014). A retrospective French study found 
similar results on patients with relapsed/
refractory SAA. The overall rates of red blood 
cell and platelet transfusion independence 
were 7%, 33%, 46%, and 46 at 1, 3, and 6, 
months and last follow-up, respectively. No 
clonal evolution has been documented so far 
(Lengline et  al. 2018). Other second-line 
options for patients not eligible to HSCT and 
who relapse or do not respond to frontline IST 
are a second course of ATG (rabbit)  +  CSA 
and alemtuzumab offering a response rate of 
65% (Scheinberg et  al. 2006) and 37% 
(Scheinberg and Young 2012), respectively.
77.3.3  Emerging Strategies for SAA
77.3.3.1  Eltrombopag Added 
to the Standard Horse 
ATG + CSA First Line 
Treatment
Many efforts to improve results of the standard 
treatment with horse ATG and CSA have failed 
since 40  years (Scheinberg 2012). Excellent 
results obtained with eltrombopag in monother-
apy in refractory patients prompted American 
colleagues from the NIH to test if the addition of 
eltrombopag to standard IST as the first treatment 
for SAA would have increased the rate of CR and 
improved the long-term outcome. In the best 
cohort (eltrombopag associated to ATG and CSA 
from day 1), complete and overall response rates 
at 6  months were 58% and 94%, respectively. 
After a median follow-up of 2 years, survival rate 
is 97% (Townsley et al. 2017). Rates of relapse 
and clonal evolution were similar to historical 
experience. Whether eltrombopag might substan-
tially improve horse ATG + CSA platform is at 
the moment under investigation through a large, 
randomized, controlled, prospective European 
trial on behalf of the SAA working party of the 
EBMT (RACE trial; ClinicalTrials.gov number, 
NCT02099747).
77.3.3.2  Up–Front Matched 
Unrelated Donor 
Transplantation
Although pediatric patients respond better to IST, 
the long-term risks of relapse, CSA dependence, 
and clonal evolution are high (Dufour et  al. 
2014). UK investigators reported an excellent 
estimated 5-year FFS of 95% in 44 consecutive 
children who received a 10-antigen (HLA-A, 
HLA-B, HLA-C, HLA-DRB1, HLA-DQB1) 
MUD HSCT; 40 of these children had previously 
failed IST.  HSCT conditioning was with FLU, 
CY, and campath (FCC) (Samarasinghe and 
Webb 2012). Because of those excellent results, 
up-front MUD HSCT became an attractive first- 
line option in children. Between 2005 and 2014, 
a UK cohort of 29 consecutive children with idio-
pathic SAA received UD HSCTs (including five 
patients with 1 Ag mismatched transplants) as 
77 Severe Aplastic Anemia and PNH
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first-line therapy after conditioning with FCC. 
Results were excellent, with OS and EFS of 96% 
and 92%, respectively, low GVHD rates, and 
only one death (from idiopathic pneumonia) 
(Dufour et al. 2015b). This cohort was then com-
pared with historical matched controls who had 
received (1) first-line MRD HSCT, (2) first-line 
IST with horse ATG + CSA, and (3) MUD HSCT 
post-IST failure as second-line therapy. Outcomes 
for the up-front unrelated cohort were similar to 
MRD HSCT and superior to IST and UD HSCT 
post-IST failure. Similar results were observed in 
another pediatric study (Choi et al. 2017).
Currently a North American study aims to 
compare outcomes of children with SAA treated 
de novo with IST vs MUD HSCT (ClinicalTrials.
gov number NCT02845596). While waiting the 
results of this trial, if a 10/10 MUD is available 
and the transplant appears feasible within 
2–3 months since diagnosis, this type of HSCT 
has become a reasonable frontline option for 
young patients in many centers. Another option is 
to perform MUD HSCT early after failure of 
frontline IST within 4–6 months since diagnosis. 
This is why MUD donor search should be started 
at diagnosis in young patients who lack a MRD.
77.3.3.3  Alternative Donor 
Transplantation in SAA
Alternative HSCTs (MMURD, CB, and haplo- 
family donors) are possible for individuals with 
no suitable MUD.  Alternative HSCTs may be 
curative, but the risks of graft rejection, infec-
tious complications, and GVHD are higher than 
those for MRD or MUD HSCT.  Patient age, 
comorbidities, and alternative HSCT specificities 
are thus important issues in the decision-making 
process. Age and comorbidities are the first barri-
ers to this type of procedure. Most numerous 
cohorts (>50 patients) tend to mainly include 
pediatric patients. In older studies long-term OS 
of about 60% (Yagasaki et al. 2011; Horan et al. 
2012; Peffault de Latour et al. 2011)) compared 
to 5-year OS seen in refractory patients receiving 
only supportive care (Valdez et al. 2011). More 
recent studies with shorter follow-up showed OS 
and EFS >80% in unmanipulated haplo-HSCT 
with a high rate of cGVHD greater than 30% (Xu 
et al. 2016, 2017).
Based on this, alternative HSCT can be con-
sidered a salvage option that needs to be carefully 
balanced with best supportive care. The latter 
might be preferable for patients with comorbidi-
ties or advanced age (> 40 years or older) because 
of lower risks.
77.4  Treatment of PNH
Clinical presentation of PNH is extremely het-
erogeneous, including a variable combination of 
bone marrow failure, hemolytic anemia, and 
thromboembolism (Peffault de Latour et  al. 
2008). These clinical manifestations may 
change during the disease course of each indi-
vidual patient so that the treatment of PNH 
should target the specific clinical presentation 
(Risitano 2017).
The treatment of marrow failure in PNH par-
allels that of SAA, and it has been described 
above; indeed, the presence of a PNH clone does 
not change the treatment algorithm of SAA.
In contrast, the treatment of complement- 
mediated hemolytic anemia and of thromboem-
bolic PNH is based on complement inhibition 
through the anti-C5 MoAb eculizumab. 
Eculizumab has proven to be effective in inhibit-
ing intravascular hemolysis of PNH, leading to 
hemoglobin stabilization and transfusion inde-
pendency in about half of patients (Hillmen et al. 
2006; Brodsky et al. 2008). This dramatic effect 
on intravascular hemolysis, eventually resulting 
in improved quality of life, is also associated with 
a significant reduction of the risk of thromboem-
bolic complications (Hillmen et  al. 2007). 
Notably, eculizumab treatment leads to a signifi-
cant improvement of overall survival of PNH 
patients, as documented by two independent 
long-term retrospective studies showing 5-year 
survival rates >90% (Kelly et  al. 2011; Loschi 
et  al. 2016). Based on this, eculizumab is cur-
rently the standard of care for all PNH patients 
presenting with symptomatic hemolytic and/or 
thromboembolic disease; occasionally, when this 
occurs concomitantly with a BMF, the anticom-
plement treatment may be considered also in 
combination with IST (i.e., sequential or con-
comitant treatment) (Pagliuca et al. 2018).
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77.4.1  Emerging Strategies for PNH
Even if currently available anticomplement treat-
ment addresses most clinical needs of patients 
with hemolytic (and thrombotic) PNH, a number 
of novel strategies of complement modulation are 
in their preclinical or clinical development 
(Risitano and Marotta 2016). These strategies 
may target specific unmet clinical needs pertain-
ing PNH patients. Novel anti-C5 agents (either 
MoAb, small molecules or small interfering 
RNA) may represent an improvement of current 
eculizumab, mostly in terms of patient comfort 
due to long-lasting activity (with longer dosing 
interval) and/or self-administration (usually SC). 
In addition, a novel class of compounds targeting 
early steps of the complement cascade at the level 
of C3 or even upstream (inhibitors of comple-
ment factor B and factor B) may anticipate a bet-
ter efficacy in terms of hematological response, 
due to possible effect on C3-mediated extravas-
cular hemolysis. Ongoing clinical trials will 
reveal whether any of this strategy may lead to 
change in the standard of care of anticomplement 
treatment of hemolysis (and thrombophilia) of 
PNH patients (Risitano and Marotta 2018).
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78.1  Introduction
Inherited bone marrow failure syndromes 
(IBMFS) are a heterogeneous group of rare blood 
disorders due to hematopoiesis impairment, with 
different clinical presentations and pathogenic 
mechanisms. Some patients present congenital 
malformations, may progress through clonal evo-
lution (MDS and acute leukemia), and are at risk 
of solid tumors at early ages. The number of 
involved genes rises annually; comprehensive 
next-generation sequencing analyses improve 
diagnostic accuracy. HSCT is an option for these 
congenital disorders. However, it should be well 
understood that it will only improve the hemato-
poietic defect and not cure the congenital malfor-
mations or lower the risk of solid tumors. 
Moreover, the HSCT procedure per se may 
increase this risk. Consequently, the decision to 
transplant a patient should be taken by a multidis-
ciplinary team. HSCT must be performed at spe-
cialized centers owing to patient susceptibilities 
to toxicity and the need for specific management 
during and after the procedure. The general rec-
ommendations for management of IBMFS are 
included in the key points at the end of the 
chapter.
78.2  Fanconi’s Anemia
78.2.1  Pathogenesis and Principal 
Clinical Features
Fanconi’s anemia (FA) is the most common 
IBMFS with an estimated incidence of 1/200,000. 
FA is a disorder of DNA damage repair, leading 
to increased chromosomal breakage in diagnostic 
assays. Twenty underlying genes have been iden-
tified. The presentation is variable with somatic 
abnormalities in 70% of patients, marrow failure, 
and a highly increased risk of malignancies 
(MDS, leukemia, head and neck cancer, gyneco-
logical cancers) at an early age. Patients can be 
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identified at adult age, e.g., in cases of (familial) 
pancytopenia, myelodysplasia, or unexpected 
severe toxicity of treatment. FA patients are 
highly susceptible to chemotherapy and 
irradiation- induced damage such as mucositis.
78.2.2  Indications of HSCT
Indications for transplant include marrow failure 
(transfusion dependency or severe neutropenia) 
and myelodysplasia/leukemia. Since transplanta-
tion implies exposure to chemo/radiotherapy and 
since the outcome is dependent on age at trans-
plant, the decision to proceed to transplant should 
be individualized and discussed with experts in 
the field.
78.2.3  Specific Considerations 
for Conditioning Regimen
Conditioning regimens should be adapted for FA 
patients, with reduced doses of many cytotoxic 
drugs and irradiation. Current conditioning regi-
mens generally contain FLU (cumulative dose 
150 mg/m2), in combination with reduced doses 
of CY (up to 50 mg/kg cumulative) and/or low- 
dose TBI (100–300 cGy) in the case of unrelated 
donors. For adults no clear recommendations can 
be given at this point.
78.2.4  Results
Current results of transplant for marrow failure in 
children with FA show survival rates depending 
on donor type ranging from 50% to more than 
90%. Factors influencing outcome include age at 
transplant, sibling donor availability, and the use 
of FLU in the conditioning regimen. A EBMT 
study of the period 2000–2009 reported 78% and 
65% OS at 5-year post transplant for MSD and 
MUD, respectively (Fig. 78.1).
Clonal disease and adult age at transplant 
remain a challenge. Both TRM and relapse of 
malignant disease contribute to these generally 
poor results.
78.2.5  Recommendations for Long- 
Term Follow-Up
After transplant, the risk of secondary malignan-
cies is high (Fig. 78.2). Patients should be care-
fully monitored for head-neck malignancies 
(regular ear, nose, and throat specialist checks for 
early signs of malignant transformation, and 





































Fig. 78.1 OS for Fanconi’s anemia according to the type 
of donor: transplant period 2000–2009. The EBMT expe-
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Fig. 78.2 Fanconi’s anemia: probability of death and 
secondary malignancies post transplant. The EBMT expe-
rience. Peffault de Latour R. Blood 2013; 122: 4279–86
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screening for breast cancer with ultrasound and 
MRI) and other manifestations of FA (e.g., endo-
crinopathies such as thyroid dysfunction, diabe-
tes, growth problems, and early menopause). As 
more FA patients survive into adulthood, special-
ist multidisciplinary teams taking care of these 
complex patients are needed.
78.3  Dyskeratosis Congenita
78.3.1  Pathogenesis and Principal 
Clinical Features
Dyskeratosis congenita (DC) is a multisystemic 
disorder characterized by the nail dystrophy, skin 
pigment alteration and oral leukoplakia triad fre-
quently associated with bone marrow failure and 
organ involvement (pulmonary fibrosis, liver, 
neurological and gastrointestinal abnormalities, 
ocular impairment and cancer predisposition). 
The causative mechanism of the disease is abnor-
mal telomere shortening due to a defect in one of 
the genes encoding for the telomerase-shelterin 
complex. Bone marrow failure is the main cause 
of death, although pulmonary fibrosis, liver cir-
rhosis, and cancer significantly contribute to 
morbidity and mortality. Androgens have shown 
some effect on hematopoiesis and lung function.
78.3.2  Indications for Transplant
HSCT is the only curative option for bone mar-
row failure in DC. Organ dysfunction is not cor-
rected by HSCT and limits its indication by 
negatively affecting outcome. HSCT is not indi-
cated as a preemptive measure but is recom-
mended in cases of progressive marrow failure 
without significant organ dysfunction.
78.3.3  Specific Considerations 
for Donor Selection 
and Conditioning Regimen
MSD are the donors of choice; MUD and mis-
matched related donors are associated with infe-
rior outcomes. Given tissue “fragility,” a reduced 
intensity combination containing fludarabine 
would be preferable to myeloablative regimen. A 
thorough evaluation of organ status is recom-
mended prior to transplant.
78.3.4  Results
Five- and 10-year survival is 57% and 23%, 
respectively. Age  >20  years at HSCT, HSCT 
before 2000 and alternative donor transplant 
were poor prognostic markers. Patients trans-
planted after 2000 had improved early survival to 
70% at 5-year post transplant.
78.3.5  Specific Recommendations 
for Long-Term Follow-Up
Since HSCT may increase the risk of secondary 
malignancies in these patients, long-term follow-
 up is mandatory.




78.4.1  Pathogenesis and Principal 
Clinical Features
The term “severe congenital neutropenia” (SCN) 
covers a group of inherited disorders character-
ized by a persistent absolute neutrophil count 
(ANC) below 0.5  ×  109/L and early onset of 
severe infections. To date, 24 distinct genes have 
been associated with SCN which may manifest 
as an isolated disorder or associated with various 
extra-hematologic features.
The most common form (60%) of genetic 
neutropenia is due to mutations in the ELANE 
gene. Shwachman-Diamond syndrome (SDS) 
caused by a mutation of SDSB gene is the most 
common form of neutropenia associated with 
extra- hematologic features (exocrine pancreas 
 deficiency, metaphyseal dysplasia, mental 
retardation, cardiomyopathy, and immune 
dysfunction).
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The underlying pathogenic mechanism of 
most genetic SCN is accelerated apoptosis of 
promyelocytes causing blockage of neutrophil 
maturation. In SDS, the defect in the SBDS pro-
tein causes abnormal ribosomal assembly and 
inadequate maintenance of the stromal 
microenvironment.
The SCN clinical phenotype consists of 
predisposition to severe infections. The use of 
G-CSF improved the prognosis of the disease 
which had been lethal in almost 50% of cases. 
The aim of treatment is to maintain protective 
neutrophil values (between 1.0 and 
5.0  ×  109/L) that are usually achieved with 
G-CSF doses of 3–5  μg/kg/day. Patients 
requiring G-CSF between 10 and 15 μg/kg/day 
are defined as “poor responders,” whereas 
those requiring >20 μg/kg/day are considered 
“non-responders.”
Another feature of SCN is its tendency to 
transform into MDS/AL. The overall cumulative 
incidence of MDS/AL is 10.8% and 22% after 
15–20 years of G-CSF treatment according to the 
French and International Severe Chronic 
Neutropenia Registries, respectively. In SDS the 
cumulative incidence is between 18% and 36% at 
20–30 years.
78.4.2  Indications for Transplant
The definitive cure of the hematologic defect is 
HSCT.  Given the non-negligible mortality rate, 
indications are limited to patients with MDS/AL 
and absent or poor response to G-CSF. For SDS 
the indications for transplant are worsening cyto-
penias with increased transfusion dependence 
and transformation into MDS/AL.
78.4.3  Specific Considerations 
for Conditioning Regimen
A MAC regimen is considered appropriate in 
SCN, while a RIC is more indicated in SDS 
owing to possible secondary organ dysfunction 
(e.g., heart disease).
78.4.4  Results
OS has been assessed at 82% with TRM of 17% 
in the largest cohort (136 patients) described. 
Better results have been obtained in patients 
under 10 years of age, in those transplanted after 
2000 and in cases of MSD transplants.
78.5  Diamond-Blackfan Anemia
78.5.1  Pathogenesis and Principal 
Clinical Features
Diamond-Blackfan anemia (DBA) is a rare 
IBMFS caused by heterozygous mutations in 
ribosomal genes. No genetic aberration is identi-
fied in approximately 30% of patients. Patients 
usually present with transfusion-dependent mac-
rocytic anemia at birth or in early infancy. Mild 
neutropenia and progressive thrombocytopenia 
have been observed in the course of the disease. 
Despite various possible physical abnormalities 
(short stature, abnormal thumbs, cleft palate, 
heart defects, urogenital malformations), the 
non-hematologic phenotype is usually rather sub-
tle in around 50% of patients. Patients with DBA 
are at increased risk of developing hematologic 
(AML/MDS) and non-hematologic malignancies 
(osteosarcoma, colon cancer).
After the first year of life, at least two trials of 
steroid therapy are recommended; around 60% of 
the patients are responders. Patients <12 months 
of age or those who are steroid non-responders 
are treated with red blood cell (RBC) transfu-
sions. Iron chelation is essential to prevent organ 
damage from iron overload. About 20% of 
patients become transfusion independent with no 
further treatment (spontaneous remission).
78.5.2  Indications for Transplant
HSCT is the only cure for hematologic manifes-
tations. Indications are non-response to steroids, 
steroid dependency at a dose ≥0.3  mg/kg/day, 
transfusion dependency, alloimmunization to 
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RBC, progressive pancytopenia, or MDS/
AML. Published data indicate that HSCT should 
be performed before the age of 10  years; how-
ever, an earlier time point might be preferable to 
avoid iron overload. Indications must be evalu-
ated taking into account the alternative approach 
with RBC transfusions combined with rigorous 
iron chelation.
78.5.3  Specific Considerations 
for Donor Selection 
and Conditioning Regimen
HSCT from a MSD including cord blood has 
resulted in OS >80% and is recommended for all 
indications. Sibling donors should be carefully 
assessed to rule out silent carrier status. Recent 
reports described improved outcome of MUD 
HSCT with OS ranging from 70 to 85% (Strahm, 
EBMT abstract 2018). By contrast, data support-
ing HSCT from mismatched donors as standard 
procedure are insufficient. The majority of trans-
plants reported were performed with myeloabla-
tive conditioning. Based on available data, a 
standard regimen including FLU and BU or 
TREO is recommended.
78.5.4  Specific Recommendations 
for Long-Term Follow-Up
Long-term care for patients being transplanted 
for DBA should focus on the management of iron 
overload. Depending on its extent, phlebotomies 
and/or iron chelation therapy might be indicated. 
Furthermore, patients and physicians should be 
aware of the increased risk of malignancies 
(especially osteosarcoma, colon cancer).
78.6  Congenital Amegakaryocytic 
Thrombocytopenia
78.6.1  Pathogenesis and Principal 
Clinical Features
Congenital amegakaryocytic thrombocytopenia 
(CAMT) is a rare IBMFS caused by mutations in 
the gene coding for the thrombopoietin receptor 
MPL. Patients usually present with thrombocyto-
penia at birth or within the first year of life. Most 
patients develop hypocellular bone marrow and 
progress to pancytopenia early in the course of 
disease. Clonal evolution with acquired chromo-
somal aberrations and the development of myelo-
dysplastic syndromes are very rare events. 
Characteristic non-hematologic manifestations 
of the disease have not been described.
78.6.2  Indications for Transplant
HSCT is the only curative treatment and should 
be offered to all patients with transfusion- 
dependent thrombocytopenia, pancytopenia, or 
clonal evolution.
78.6.3  Specific Considerations 
for Donor Selection 
and Conditioning Regimen
HSCT from a MSD is the preferred option, and 
successful transplants from heterozygous-related 
donors have been reported. HSCT from MUD (≥ 
9/10) is an acceptable alternative. Successful 
HSCT from mismatched family donors or mis-
matched unrelated cord blood donors have been 
reported. However, these should preferentially be 
performed in clinical trials.
In view of a considerable graft failure rate, a 
MAC with FLU in combination with TREO or BU 
is preferred. However, there have been reports of 
successful engraftment after a RIC, and this might 
be considered in cases with severely hypocellular 
bone marrow in the absence of clonal aberrations 
and alloimmunization to platelet transfusions.
78.6.4  Results
Five-year overall survival was 77% with TRM of 
12.6% in a retrospective EBMT study. However, 
this series included HSCT performed over a 
period of 26 years with a variety of donors, regi-
mens, and stem cell sources, with no difference 
in outcome.
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Key Points
Patient  –  Evaluate carefully hematologic and 
extra-hematologic manifestations of 
the disease prior to transplant
Donor  –  The best donor is MSD; however, it is 
mandatory to test the genetic defect in 
the donor since some IBMFS may 
present different clinical and 
hematologic expression in members 
of the same family
 –  Consider MUD in case of no 
appropriate MSD
 –  Mismatched related and UD and 
unrelated CB only in experienced 




BM is the best source of stem cells
Matched related CB is a good option
PB is associated with higher risk of 
cGVHD and should be avoided
Cell dose It is important for graft failure 
prevention:
NC > 3 × 108/kg recipient bw for BM
NC > 3 × 107/kg recipient bw for 
related CB




MAC or RIC depending on the type of 
IBMF
Irradiation should be avoided owing to 
the known risk of cancer
Patients with Fanconi’s anemia and 




GVHD must be avoided
Include two immunosuppressive drugs
Serotherapy for UD transplants
Long-term 
follow-up
 –  It is mandatory owing to high risk of 
secondary malignancies, extra-
hematologic manifestations and iron 
overload
 –  Patients should be followed-up by a 
multidisciplinary team
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79.1  HSCT for Sickle Cell Disease
Barbara Cappelli and Eliane Gluckman
79.1.1  Definition and Epidemiology
Sickle cell disease (SCD) is the most common 
inherited hemoglobinopathy worldwide. It results 
from a single-nucleotide substitution that leads to 
a propensity toward hemoglobin polymerization 
and sickling of red blood cells. Sickle cell disease 
is characterized by anemia, ongoing hemolysis, 
and acute and chronic vaso-occlusive complica-
tions affecting multiple organs. SCD affects over 
100,000 Americans, and it occurs in about one in 
500 African-American births and in one in every 
1000–1400 Hispanic-American births (NIH 
2014; Piel et al. 2013).
The implementation of newborn screening, 
penicillin prophylaxis, vaccination programs, 
narcotics, chronic transfusions, hydroxyurea, and 
the early detection of cerebral vasculopathy with 
transcranial Doppler (TCD) have improved the 
perspective for children with SCD (Angelucci 
et al. 2014; Yawn et al. 2014; Ware et al. 2016; 
Bernaudin et al. 2016).
79.1.2  Allo-HSCT with an HLA 
Identical Sibling
HSCT remains the only curative therapy for SCD 
(Angelucci et  al. 2014; Arnold et  al. 2016; 
Gluckman et al. 2017). The goal when perform-
ing HSCT is to replace the patient’s marrow with 
genetic functional cells before major organ dys-
function and complications (Bernaudin et  al. 
2007). Some of the most common indications for 
HSCT are listed in Table 79.1 (Angelucci et al. 
2014; Bernaudin et al. 2016).
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Several barriers prevent HSCT widespread 
application including lack of a suitable donor, lack 
of information, and limited understanding of 
HSCT.  Moreover, HSCT encompasses a risk of 
early- and late-onset regimen-related toxicities, 
rejection, and mortality. Nevertheless, the annual 
number of transplants have been increasing and 
has quadrupled in the last decade (CIBMTR per-
sonal communication). The first successful HLA 
identical HSCT was performed in a patient affected 
by both SCD and AML in 1984 (Johnson et  al. 
1984). After that, many groups have described a 
series of patients transplanted from an HLA iden-
tical sibling with an OS that varies between 91 and 
100% and EFS that varies between 73 and 100% 
(Bernaudin et  al. 2007; Walters et  al. 2016). 
Recently, 1000 HLA identical transplants, per-
formed between 1986 and 2013 and reported to 
EBMT, Eurocord, and the CIBMTR, have been 
published with a 5-year EFS and OS of 91.4% 
(95% CI 89.6–93.3%) and 92.9% (95% CI 91.1–
94.6%), respectively. The EFS and OS were both 
lower with increasing age, EFS was higher for 
transplantations performed after 2006, and OS 
was lower for peripheral blood transplant recipi-
ents (Fig. 79.1) (Gluckman et al. 2017).
79.1.3  Indications
Indication for HSCT for “less severe patients” 
before significant organ damage has occurred is 
open to discussion. In fact, on one hand, it would 
be better to transplant them early in order to pre-




One or more of the 
following 
complications:









Recurrent vaso-occlusive painful 
episodes
Failure to benefit or unable or 
unwilling to continue supportive 
care therapy including hydroxyurea
Impaired neuropsychological 
function with abnormal cerebral 
MRI and angiography
Abnormal transcranial Doppler 
velocities




Time from transplant (years)
























































Fig. 79.1 Overall 
survival according to 
stem cell source on 1000 
SCD patients 
transplanted from an 
HLA identical sibling 
(Gluckman et al. 2017)
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vent early organ damage secondary to SCD, avoid 
SCD complications in childhood, and achieve bet-
ter HSCT outcomes secondary to less pre-HSCT 
organ damage and alloimmunization and, on the 
other hand, it could be considered to wait to per-
form an HSCT for the establishment of new avail-
able SCD supportive cares (new medications other 
than hydroxyurea), promising curative therapies 
(gene therapy), and advances in HSCT technology, 
others may be available. Nevertheless, it has been 
demonstrated that patients transplanted at a young 
age have a better 3-year OS and 3-year EFS, with 
lower incidence of aGvHD and cGvHD (Gluckman 
et al. 2017). These findings outline the importance 
of early referral to HSCT for SCD patients.
79.1.4  Conditioning
To date, a myeloablative conditioning regimen 
(especially with BU/CY + ATG) is the gold stan-
dard for HLA identical sibling HSCTs (EFS: 
73–96%, OS: 91–100%) despite the risk of long- 
term transplant-related toxicity (Bernaudin et al. 
2007; Walters et al. 2016). A conditioning regi-
men including FLU and BU has been used but 
with high GvHD risk; therefore, it should be con-
sidered to add ATG to the conditioning regimen 
to lower the GvHD risk in these patients.
A RIC regimen has been explored to decrease 
toxicity and allow a stable, mixed chimerism. 
The aim of a tailored conditioning regimen in 
children is to preserve fertility, whereas in adults 
is to reduce toxicity in severely compromised 
patients due to their underlying disease. Several 
reduced intensity conditioning regimens (FLU/
MEL + ALEM +/− TT or ALEM + TBI 300 cGy 
+/− PT-CY or FLU/CY or TBI 300  cGy +/− 
ATG) have been used in many small patient series 
but with high degree of graft rejection (Talano 
and Cairo 2015; Arnold et  al. 2016). Thus, 
recently, encouraging outcomes and low early- 
and long-term toxicity have been confirmed by 
other groups after FLU-based RIC regimens 
(Bhatia et al. 2014). Lately, 13 high-risk patients 
conditioned with a chemotherapy-free regimen 
(ALEM-TBI 300 cGy) have shown a 92% DFS 
and 100% OS (Saraf et al. 2016).
Moreover, a prospective multicenter trial com-
paring allogeneic matched related HSCT after a 
RIC regimen, with standard of care in adolescents 
and adults with severe SCD, has shown encourag-
ing preliminary results (Dhedin et al. 2016).
Despite MAC dosing in the conditioning regi-
mens, a mixture of both donor and recipient 
hematopoietic cells (mixed donor chimerism) 
can be consistently observed in approximately 
10–20% of these children (Bernaudin et al. 2007; 
Walters et  al. 2016). Interestingly, this mixed 
chimeric state with the presence of both recipi-
ent and donor blood cells is sufficient to direct 
bone marrow to preferentially produce donor-
type hemoglobin (rather than abnormal hemo-
globin of the recipient), and red cells revert the 
SCD phenotype, and minimize the risk of 
GVHD, confirming the therapeutic efficacy of 
mixed chimerism for hemoglobinopathies. New 
studies on mixed chimerism are ongoing.
79.1.5  Alternative Donors
Finding a potential MUD is based on the ethnic 
and racial background; for SCD patients the 
probability for an 8/8 HLA MUD or CB donor is 
less than 18%. Nevertheless, some small series of 
patients using URD have been published, but for 
now relapse rate and GvHD risk remain unac-
ceptable (Justus et al. 2015).
Strategies that explore the use of mismatched 
related (haplo) donors are ongoing (Dallas et al. 
2013; Talano and Cairo 2015). Recently promis-
ing results of CD3+/CD19+ depleted T-cell 
haplo-HSCT after TREO/FLU/TT  +  ATG have 
been shown to be safe and efficient with a low 
incidence of GvHD in advanced stage SCD (Foell 
et al. 2017).
Moreover, new strategies using gene therapy 
have been recently published with encouraging 
results (Ribeil et al. 2017), and the use of gene 
editing is being explored for this single-mutation 
disease (Canver and Orkin 2016).





The outcome of thalassemia major (TM, 
transfusion- dependent thalassemia) has improved 
dramatically over the past two decades due to 
improvements in supportive care and iron chela-
tion therapy (Taher et al. 2018). Life expectancy 
for TM patients exceeds 40 years, and it is no lon-
ger significantly different from the life expec-
tancy of thalassemia intermedia patients, in 
developed countries (Vitrano et al. 2017).
Match family donor (MFD) allo-HSCT is cur-
rently considered the only curative standard ther-
apeutic approach for TM, which despite holding 
its own risks, could release the patient from life-
long treatments, and possible iron accumulation 
complications. Despite encouraging results of 
gene therapy, its use is currently limited to clini-
cal trials.
79.2.2  Best Transplant Candidates
In late 1990s, the Pesaro group has proposed a 
risk classification for pediatric patients undergo-
ing MFD HSCT for TM (Lucarelli et al. 1998). 
The classification depended on three risk factors 
(Table  79.2) and was validated in the pediatric 
population; however, it did not predict risk in 
adult patients (Angelucci et al. 2017). Limitations 
to this risk stratification include the interobserver 
variability regarding hepatomegaly and the lack 
of clear definition of adequate iron chelation. The 
Pesaro classification is applicable in the setting of 
best medical care. In developing countries, where 
medical care might not be optimal, a very- high- 
risk group was identified in Pesaro class 3 patients 
if liver size is >5 cm below the costal margin and 
if the patient age is >7  years (Mathews et  al. 
2007). The EBMT has recently identified the age 
of 14 years as the oldest age for optimal outcome 
in MFD HSCT for TM (Baronciani et al. 2016).
Accurate assessment of iron content in the 
liver and heart is crucial before proceeding to 
transplant. No consensus is currently available 
regarding the best method of iron content assess-
ment in both organs. Serum ferritin level might 
not reflect accurately the severity of iron over-
load. Liver biopsy is the gold standard; however, 
it carries the risks of the invasive procedure. 
Transient elastography (FibroScan) and T2 MRI 
have been shown to be reliable noninvasive meth-
ods to predict liver fibrosis secondary to iron 
overload, for TM patients who are candidates to 
HSCT (Hamidieh et  al. 2014; Hamidieh et  al. 
2015).
79.2.3  Conditioning Regimens
The use of the myeloablative BU and CY as the 
conditioning regimen for HSCT for TM has been 
the standard practice, due to the increased mar-
row activity and the allo-sensitization in heavily 
transfused patients (Lucarelli et  al. 1990). 
However, this regimen was associated with 
hepatic and cardiac toxicity due to the iron over-
load and the toxic hepatic and cardiac effects of 
BU and CY, respectively.
ATG or ALEM have been added in some pro-
tocols to the conditioning regimen to prevent 
GvHD and enhance engraftment (Law et  al. 
2012; Mohty 2012). Despite being effective with 
low incidence of infections, the use of these 
agents is still debatable.
In an attempt to reduce the extramedullary 
toxicity of BU and CY, a non-myeloablative regi-
men of TREO/FLU/TT has been used with 
encouraging results (Bernardo et  al. 2012). 
Defibrotide has been used successfully to prevent 
SOS/VOD in patients with TM undergoing 
Table 79.2 Pesaro classifications for risk assessment 














Portal fibrosis × ×/✓ ✓
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HSCT with conditioning regimen containing IV 
BU (Cappelli et al. 2009). The use of BU phar-
macokinetics was associated with better engraft-
ment and less toxicity (Gaziev et  al. 2010); 
however, these studies are available in limited 
number of institutions worldwide.
79.2.4  Alternative Donors
79.2.4.1  Matched Unrelated Donors 
(MUD)
In case MFD is not available, the discovery of 
high-resolution HLA typing techniques made the 
performance of successful MUD transplant pos-
sible. The probability of finding a matched unre-
lated donor varies between 50% in Caucasians to 
less than 10% in some minorities (Rocha and 
Locatelli 2008). With the use of BU, CY, TT, and 
FLU as conditioning regimen and ATG, MMF, 
and short-course MTX as GvHD prophylaxis, the 
outcome of PBSC MUD in TM was comparable 
to MFD HSCT in regard to OS, TRM, TFS, and 
aGvHD (Li et al. 2012).
79.2.4.2  Unrelated Umbilical Cord
The use of unrelated umbilical cord as a source of 
stem cells for HSCT in TM is hampered by the 
high incidence of graft failure due to the low stem 
cell dose. The graft failure rate could be as high 
as 57% (Ruggeri et al. 2011). This could be par-
tially overcome by the use of double UCB units. 
The 5-year overall and thalassemia-free survival 
rates were 88.3 and 73.9%, respectively, when 
using two units instead of one if no single units 
included more than 25 × 106 total nucleated cells/
kg of recipient weight. Other strategies to over-
come the main barrier of low cell dose include 
co-transplantation of third-party mesenchymal 
stromal or TCD haploidentical cells (Kwon et al. 
2014; Kim et al. 2004).
79.2.4.3  Haploidentical HSCT
Due to the low probability of finding a MUD in 
some ethnicities and the previously mentioned 
issues with umbilical-cord transplant, new strate-
gies have been evolved to develop an effective and 
safe haploidentical transplant procedure for TM 
patients. The use of TCD graft was associated 
with high rate of infections and increased risk of 
graft failure due to allo-sensitization and hyperac-
tive marrow (Gaziev et al. 2000). This was over-
come by pretransplant over-transfusion and 
immunosuppressive therapy and post transplant 
infusion of transduced donor T-cells with gene-
inducible caspase-9 (Bertaina et  al. 2017). The 
use of T-cell replete grafts is still under investiga-
tion to explore the best strategy to prevent GvHD.
79.2.5  Mixed Chimerism
The incidence of mixed chimerism after HSCT 
for TM was reported to be around 12%. the risk 
of graft rejection in patients with mixed chime-
rism was high only if mixed chimerism had been 
observed within two months post-transplant. 
Most cases with late persistent mixed chimerism 
evolved into either stable chimerism or complete 
engraftment and did not require additional PRBC 
transfusion support (Andreani et al. 2000).
79.2.6  Post transplant Iron Chelation
Iron overload remains a problem after HSCT, and 
most investigators rely on phlebotomy to decrease 
excessive iron stores. In a recent phase II, multi-
center, single-arm trial, deferasirox at a dose of 
20 mg/kg/day, starting after a minimum of 6 months 
of transplant, and continued for 1 year, was safe 
and associated with decreased burden of iron over-
load after transplant (serum ferritin, liver, and car-
diac iron content by MRI) (Yesilipek et al. 2018).
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• Match family donor allo-HSCT is cur-
rently considered the only curative 
 standard therapeutic approach for thalas-
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80.1  Definition, Epidemiology, 
and Diagnosis
Multiple myeloma (MM) consists of a malignant 
proliferation of BM plasmatic cells (BMPCs), 
which produce a monoclonal protein that can be 
found in serum and/or urine, resulting in skeletal 
involvement, hypercalcemia, anemia, renal func-
tion impairment, and/or soft-tissue plasmacyto-
mas. The cause is unknown.
The annual incidence is four per 100,000. It 
represents 1% of all malignant diseases and about 
15% of all hematological malignancies. The 
median age at diagnosis is between 65 and 
70 years. Only 15% and 2% are younger than 50 
and 30 years, respectively.
The diagnosis of symptomatic MM requires 
the presence of clonal BMPCs, usually >10%, or 
plasmacytoma, the presence of serum and/or 
urine M-protein (except in the uncommon nonse-
cretory) and related organ or tissue impairment 
(end-organ damage, including bone lesions). In 
the absence of organ damage, the presence of 
>60% BMPCs, a serum-free light-chain (FLC) 
ratio >100 or the presence of more than one focal 
lesion at the MRI defines symptomatic MM 
requiring therapy.
80.2  Risk Stratification
The International Staging System (ISS), based on 
the serum beta2-microglobulin and albumin lev-
els discriminates three prognostics subgroups:
• Stage I (beta2-m <3.5  mg/L and albumin 
>3.3 g/dL),
• Stage III (beta2-m >5.5 mg/L) and
• Stage II (all remaining cases).
FISH can identify the following poor cytoge-
netic findings: t(4;14), t(14;16), and/or del 17p 
which account for about 25% of patients with 
MM, the remaining 75% having a so-called stan-
dard risk. High LDH, the presence of hematoge-
nous extramedullary disease, and the coexistence 
of plasma cell leukemia are also poor prognostic 
indicators. A revised ISS incorporating cytoge-
netics and LDH have been developed as follows:
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• R-ISS I: ISS I, standard-risk cytogenetics and 
normal LDH,
• R-ISS III: ISS III, plus high-risk cytogenetics 
or high LDH and
• R-ISS II: all remaining cases.
An ultra-high-risk group, accounting for 5–7% 
of patients eligible for auto-HSCT and who received 
bortezomib-based regimens, with a median OS of 
less than 2 years, has been recognized (ISS III and 
high-risk cytogenetics or high LDH).
80.3  First-Line Treatment 
(Induction Prior 
to Auto-HSCT)
Conventional chemotherapy (VAD, VBMCP/
VBAD, CY/DEX) or the doublets thalidomide 
(THAL)/DEX or bortezomib (BOR)/DEX results 
in 10% CR pre-auto-HSCT, 25–35% CR post- 
auto- HSCT and in 5–10% in continued CR 
beyond 10 years from HSCT.
The triplets combining BOR/DEX with an 
immunomodulatory drug (IMiD), thalidomide 
(VTD), or lenalidomide (VRD) result in a pre- 
auto- HSCT CR of 20–35%, and a post-auto- HSCT 
CR of 45–55%. However, there is not enough fol-
low-up to determine the proportion of patients in 
continued CR >10 years beyond auto-HSCT.
The results of BOR-based triplets PAD and 
VCD (including Adriamycin or CY), widely used 
in Europe, are inferior to the reported with the 
combination of proteasome inhibitors plus 
IMiDs. Although most groups administer four 
induction cycles, the dose intensity and the induc-
tion exposure with an increased depth of response 
overtime and with higher CR rates pre- and post- 
auto- HSCT with six cycles have been observed 
with both VTD and VRD. The potential benefit of 
adding a MoAb, particularly daratumumab, to 
VTD or VRD is being investigated.
80.4  Criteria of Response 
and Progression
Complete remission (CR): negative serum and 
urine immunofixation, less than 5% BMPCs and 
no soft-tissue plasmacytomas.
Stringent CR: as above plus normal free light- 
chain ratio and absence of clonal plasma cells.
Very good partial response (VGPR): 90% or 
more decrease in the serum M-protein and urine 
M-protein <100 mg/24 h.
Partial response (PR): 50% or more decrease 
in the serum M-protein, 90% or more decrease in 
urine M-protein or to <200 mg/24 h plus 50% or 
more decrease in soft-tissue plasmacytomas.
Progressive disease (PD) requires one or more 
of the following: increase in 25% or more from 
nadir in serum M-protein (absolute increase of at 
least 0.5  g/dL), urine M-protein (absolute 
increase of at least 200 mg/24 h), BMPC (abso-
lute increase of at least 10%), soft-tissue plasma-
cytomas, and development of new bone lesions, 
soft-tissue plasmacytomas, or hypercalcemia.
80.5  High-Dose Therapy (HDT), 
Consolidation, 
and Maintenance
Auto-HSCT remains the standard of care for 
young and fit MM patients. MEL 200  mg/m2 
(MEL-200) is the standard high-dose regimen, 
and the source of PBS. The addition of BOR peri- 
transplant, as well as other attempts, is of no ben-
efit. MEL-140 plus IV BU vs. MEL-200 is being 
investigated. The increase in the CR with HDT is 
15–20%.
Recent trials have shown that early transplant 
is superior to delayed (at relapse) auto-HSCT, 
even in the era of novel agents.
It seems that patients with high-risk cytoge-
netics are the most likely to benefit from tandem 
auto-HSCT.
The TRM with auto-HSCT is very low (1–2%), 
the best reported median PFS is 50–56  months 
and the expected median OS of 8–10 years. The 
proportion of patients  operationally cured (i.e., in 
continued CR beyond 10 years) with the current 
regimens is still unknown.
Although the results of post transplant con-
solidation are controversial, it seems to be a 
promising approach and usually recommended 
by experts. Post-auto-HSCT maintenance with 
lenalinomide (LENA) has been recently 
approved. The optimal maintenance duration 
based on sequential MRD studies, as well as 
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whether or not the association of other drugs such 
as glucocorticoids, proteasome inhibitors or 
MoAb can be of benefit, is currently 
investigated.
80.6  Treatment at Relapse After 
Auto-HSCT
There is a consensus that a rescue or salvage 
auto-HSCT could be tried when the response 
duration to the first transplant in longer than 
18–24  months. Such rescue transplant should 
only be performed in patients with sensitive dis-
ease, so prior salvage chemotherapy is needed. 
The components of the initial therapy, depth and 
the duration of response as well as the toxicity 
are crucial in selecting the rescue regimen. 
Among a number of possible combinations at 
relapse, the more effective combinations are 
IMiD-containing (carfilzomib, LENA, and DEX 
[KRd] or daratumumab, LENA, and DEX [DRd]) 
and non-IMiD-containing (carfilzomib and DEX 
[Kd] or daratumumab, BOR and DEX [DVd]). If 
the rescue auto-HSCT is performed, post trans-
plant maintenance should be considered. In the 
event that the transplant is not done, the above 
treatments are in general until progression.
80.7  Allogenic HSCT in MM
The role of allografting for the treatment of MM 
remains controversial. The first clinical reports 
employing MAC regimens proved to be curative 
for small patient subsets but were associated with 
an unacceptable high TRM. In the late 1990s, the 
introduction of minimal intensive conditioning 
regimens (primarily based on low-dose TBI), 
which relies on the graft-versus-myeloma (GvM) 
effect for tumor eradication, drastically reduced 
TRM, but at the expense of higher disease 
relapse.
Combining cytoreductive high-dose MEL with 
an autograft and a subsequent minimal intensity 
conditioning with an allograft, aimed at inducing 
GvM, was better tolerated up to the age of 
65–70 years old. Before the era of new drugs, seven 
prospective trials were designed to compare clini-
cal outcomes of auto-HSCT versus tandem autolo-
gous-minimal intensity and allo-HSCT in newly 
diagnosed MM patients. Results were discordant 
regarding response, OS, and PFS. This may have 
partly been due to differences in conditioning regi-
mens, GVHD prophylaxis, patient inclusion crite-
ria, and randomization strategies. Thus, 
comparisons between trials are difficult. However, 
allografting has steadily been used in Europe in 
recent years. Sobh et al. recently described use and 
outcomes of allo- HSCT for MM in Europe between 
January 1990 and December 2012. A study popula-
tion of 7333 patients (median age at transplant, 
51  years) was divided into 3 groups: allo-HSCT 
upfront (n  =  1924), tandem auto-allo-HSCT 
(n = 2004), and allo-HSCT as a second-line treat-
ment or beyond (n = 3405). After 2004, 5-year sur-
vival probabilities from transplant were 42%, 54%, 
and 32%, for the three groups, respectively. 
Unfortunately, only a very minority of MM patients 
were enrolled in prospective control trials. 
Remarkable heterogeneity in using allo- HSCT was 
observed among the different European countries.
80.8  Allogenic HSCT and New 
Agents
The role of the combination of “new drugs” 
with GvM has not yet been explored in well-
designed prospective studies. In only a Phase II 
study feasibility of BOR within a RIC and as 
maintenance post-allografting was evaluated. 
Conditioning consisted of FLU/MEL/BOR 
while maintenance treatment of cycles of IV 
BOR.  Sixteen high-risk patients relapsed after 
an auto-HSCT was prospectively enrolled. 
Nine/16 (56%) and 5/16 (31%) achieved CR 
and partial remission. In this heavily pretreated 
high-risk population, 3-year cumulative inci-
dence of NRM, relapse and OS were 25%, 54%, 
and 41%, respectively. The latter trial showed 
the feasibility and efficacy of an intensified con-
ditioning with a “new drug” in poor prognosis 
patients. Moreover, the concept of maintenance 
treatment after an allograft was also introduced. 
A synergy between new drugs and GvM in the 
relapse setting has recently been described 
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clearly suggesting that allo-HSCT and new 
drugs are not mutually exclusive.
Whether long-term persistence of MRD nega-
tivity may coincide with disease eradication 
remains a matter of debate though persistent 
molecular remission of several years may cau-
tiously suggest cure. PCR-based MRD detection 
represents a powerful predictor of clinical 
outcomes.
80.9  Indications of allo-HSCT 
in MM
The role of allo-HSCT in the era of new drugs 
remains highly controversial, and there are no 
clear guidelines, despite the relatively high num-
bers of allo-HSCT yearly performed in Europe. 
Well-designed prospective trials combining 
“graft-vs.-myeloma” and new drugs are needed, 
especially in young high-risk/ultra-high-risk 
patients whose treatment remains an unmet clini-
cal need.
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Systemic Light Chain Amyloidosis
Monique Minnema and Stefan Schönland
81.1  Definition and Epidemiology
Systemic light chain (AL) amyloidosis is a 
protein misfolding and deposition disorder 
with an incidence of 5–12 persons per million 
per year. Clonal plasma cells or rarely B cells 
produce immunoglobulin light chains with the 
potential to misfold. These light chains are 
deposited as extracellular amyloid fibrils in 
peripheral tissues and cause morbidity and 
mortality. Organs most frequently involved are 
the kidney, heart, liver, autonomic and periph-
eral nervous system, gastrointestinal tract, and 
soft tissue.
81.2  Diagnosis
AL amyloidosis should be suspected in any 
patient with a monoclonal gammopathy and a 
compatible clinical syndrome such as heart fail-
ure with a preserved ejection fraction, nephrotic 
range proteinuria, unexplained weight loss, 
peripheral neuropathy, a bleeding diathesis, or 
carpal tunnel syndrome. Gammopathy work-up 
should include a serum-free light chain assay, 
immunofixation of serum and urine, bone mar-
row cytology, flow cytometry, histology and 
iFISH, and a full-body scan to exclude bone 
lesions due to symptomatic MM. AL amyloido-
sis is diagnosed by histopathology with Congo 
red staining and the typical apple-green bire-
fringence under polarized light. Screening biop-
sies such as abdominal fat, rectum, salivary 
gland, or bone marrow as well as symptomati-
cally involved organs can be utilized. The amy-
loid subtype has to be further confirmed by 
immunohistochemistry, immune electron 
microscopy, or laser microdissection and mass 
spectrometry.
81.3  Classification
AL amyloidosis can be classified by the origin of 
the underlying bone marrow disease: a clonal 
plasma cell or a lymphoid dyscrasia. Plasma cell 
dyscrasias can further be divided into monoclo-
nal gammopathy, smoldering MM, and symp-
tomatic MM. Finally, IgM-related AL amyloidosis 
is a specific entity with an underlying lympho-
cytic, lymphoplasmacytic, or a plasma cellular 
clone, commonly with cardiac and peripheral 
nervous system involvement.
M. Minnema 
Department of Hematology, UMC Utrecht Cancer 
Center, Utrecht, The Netherlands 
S. Schönland (*) 
Hematology, Oncology and Rheumatology, Medical 





81.4  Risk Factors and Prognostic 
Scores
The underlying bone marrow disease as well as 
organ damage-related biomarkers can be utilized 
to stratify patients into risk groups. A bone mar-
row plasma cell infiltration above 10% (Hwa 
et  al. 2016) and a high difference between 
involved and uninvolved serum-free light chain 
(dFLC) are negative prognostic factors (Kumar 
et  al. 2012) for overall survival. Comparable to 
MM genetic aberrations can be detected on iFISH 
in plasma cell dyscrasias and be utilized to pre-
dict response to specific treatments (e.g., in 
patients with translocation (11;14) HDM/HSCT 
is more effective) (Bochtler et al. 2016).
The Mayo clinic first published a staging sys-
tem utilizing NT-ProBNP and cardiac troponins 
(cTnI, cTnT) in 2004 which strongly predicted 
outcome. Median survival for patients in Stages 
I, II, and III were 26.4, 10.5., and 3.5  months 
(Dispenzieri et al. 2004a), and for the transplant 
group Stages I and II median were not reached, 
and Stage III median was 8.4 months (Dispenzieri 
et al. 2004b). This staging system was adapted in 
2013 by a European cooperative approach and an 
ultra-high-risk patient group was identified with 
an NT-proBNP cut-off of 8500 ng/L (Stage IIIb) 
which must be considered transplant-ineligible 
(Wechalekar et al. 2013).
For patients with renal involvement, total pro-
teinuria/24 h and estimated glomerular filtration 
rate (eGFR) can anticipate the risk for terminal 
renal failure (Palladini et al. 2014).
The depth of response is also a significant 
prognostic factor as patients achieving an amy-
loidosis VGPR (dFLC below 40  mg/L) or CR 
after treatment have a significantly better out-
come (Palladini et al. 2012).
81.5  First-Line Treatment
Risk-adapted treatment is preferred since most 
patients are fragile and do not tolerate standard 
used dosing regimens (see Table  81.1). Three 
categories are defined with low-risk patients, 
transplant eligible, being a minority (≤20%). 
High-risk patients are defined by Stage IIIb and/
or having NYHA class III or IV heart disease. 
Other factors to consider are age, performance 
status, eGFR, and systolic blood pressure 
(Palladini and Merlini 2016). Frequent assess-
ments of hematological response during treat-
ment are needed, and the goal is to achieve a CR 
or VGPR as a deep hematologic response is 
closely related to survival. Patients having a 
hematologic response may gradually achieve an 
organ response.
81.6  Second-Line Treatment
There is no randomized trial data to guide treat-
ment at relapse. Patients with a good duration of 
response who tolerate initial treatment well may 
be retreated with the same initial regimen. 
Patients with a poor response are best treated 
with an alternative agent combination using 
agents to which the patient has not been exposed, 
palliation or in a clinical trial tailored to the indi-
vidual patient in terms of their age, comorbidi-
ties, extent of organ involvement, and the patient’s 
wishes. Lenalidomide and pomalidomide can be 
considered in relapsed disease although data on 
durability of response are limited (Dispenzieri 
et al. 2007; Palladini et al. 2017). Toxicity with 
lenalidomide is a significant issue, and it is rec-
ommended to start at a dose of 15 mg daily, with 
further dose reduction based on glomerular filtra-
tion rate (GFR) (Dispenzieri et al. 2007).

















• Bortezomib weekly monotherapy
CYBorD cyclophosphamide, bortezomib, 
dexamathasoone
M. Minnema and S. Schönland
611
81.7  Autologous HSCT
81.7.1  Indication
Eligibility criteria for autologous HSCT are 
variable depending on the transplanting center. 
However, the usual eligibility criteria include 
age ≤70 years, performance status 0–2, NYHA 
class I or II, absence of significant clinical car-
diac involvement (NT pro BNP <5000  ng/L. 
left ejection fraction ≥45 to 50%), absence of 
severe orthostatic hypotension (i.e., systolic 
blood pressure ≥90  mm Hg), and eGFR 
>40  mL/min. Induction therapy before stem 
cell mobilization can be given, especially in 
patients who fulfill (smoldering) myeloma defi-
nition criteria, i.e., ≥10% bone marrow plasma 
cell infiltration.
The correct selection of patients is extremely 
important since the mortality associated with 
autologous HCT in AL amyloidosis can be unac-
ceptable high if not done properly. Since the 
selection criteria also include the cardiac bio-
markers, treatment-related mortality has dropped 
from around 20% to 5%; also see Table  81.2 
(Gertz et al. 2013).
81.7.2  Recommended
Stem cell mobilization and leucapheresis can be 
associated with unusual morbidity, and a syn-
drome of hypoxia and hypotension has been 
described both during mobilization with G-CSF 
and during the leucapheresis procedure itself, 
probably as a result of a capillary leak syndrome 
triggered by G-CSF.  Therefore, use of reduced 
doses of G-CSF (such as 10 μg/kg per day for 
4–5  days) is recommended. In low-burden dis-
ease (i.e., plasma cells <10%), the use of CY 
mobilization chemotherapy does not seem to be 
necessary.
Conditioning regimens are based on high- 
dose MEL. The usual MEL dose is 200 mg/m2, 
since lower-dose melphalan is associated with 
decreased hematological response and PFS 
and therefore other treatment non-transplant 
options may be more suitable (Cibeira et  al. 
2011).
81.7.3  Results
Figure 81.1 shows OS of auto-HSCT until 2010. 
In Table 81.2 the more recent publications of the 
last 10 years have been summarized. The use of 
induction therapy before HSCT has been more 
frequently applied and seems to demonstrate bet-
ter hematologic responses than HSCT alone.
81.8  Allogeneic HCT
The largest retrospective analysis on allo-HCT for 
AL amyloidosis was performed by the EBMT in 
2006 (Schönland et  al. 2006). Nineteen patients 
were analyzed. Seven patients received MAC, and 
eight RIC. 40% of patients died of TRM. Long-
term survival and sustained CR were achieved in 
seven patients and were associated with chronic 
GVHD in the majority of them. DLI has been suc-
cessfully performed in a few patients with AL 
amyloidosis, thereby demonstrating a potent 
“graft-versus-plasma cell-dyscrasia” effect.
The EBMT initiated a noninterventional pro-
spective study (NIS) for patients with AL amyloi-
dosis undergoing allo-HSCT. Preliminary results 
have been presented in 2016 with improved over-
all survival (see Fig. 81.2). Allo-HSCT after RIC 
can be discussed as a treatment option for relapse 
after auto-HCT in patients <60  years with pre-
served organ functions and a HLA-identical 
donor. It might be a curative treatment for highly 
selected patients.
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Table 81.2 Summary of the outcome of patients with systemic AL amyloidosis undergoing autologous stem cell trans-
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Fig. 81.1 Autologous 
EBMT data (patients 
treated until 2010)
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Key Points
• AL amyloid therapy is directed against 
the underlying B cell clone
• Hematological response is the goal of 
therapy and improves survival
• Intensity of chemotherapy has to be risk 
adapted
• High-dose chemotherapy with auto- 
HSCT is the therapy of choice for low- 
risk patients
• Allo-HSCT might be a curative treat-
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in younger patients with preserved 
organ functions and a HLA-identical 
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POEMS Syndrome and Disease 
Produced by Other Monoclonal 
Immunoglobulins
Gordon Cook and Montserrat Rovira
82.1  POEMS Syndrome
82.1.1  Introduction
POEMS syndrome (acronym of polyradiculo-
neuropathy, organomegaly, endocrinopathies, 
monoclonal protein, and dermopathy, skin) is 
a rare multisystemic disease due to an underly-
ing plasma cell neoplasm. The pathogenesis of 
the syndrome is not well understood. Other 
names of the POEMS syndrome that are less 
frequently used are osteosclerotic myeloma, 
Takatsuki syndrome, or Crow-Fukase 
syndrome.
82.1.2  Clinical and Laboratory 
Manifestations
POEMS predominate in male being the age of 
maximum incidence (50–60 years).
Characteristic manifestations are:
Polyneuropathy:  Typically demyelinating. Peripheral, 
ascending, symmetrical and affecting both sensation 
and motor function.  It is the dominant characteristic.
Organomegaly: Hepatomegaly (50%), splenomegaly, or 
lymphadenopathy.
Endocrinopathy: Present in 84% of patients: gonadal, 
thyroid, pituitary, parathyroid, pancreatic, adrenal (in 
order of frequency, and many times multiple).
Monoclonal protein: Almost always λ light chain. 
Usually Ig A or IgG and  ≤3 g/dL. Bone marrow smear  
<5 to 10% plasma cells.
Skin changes: Hyperpigmentation, hypertrichosis, 
glomeruloid hemangiomata, white nails, plethora, 
acrocyanosis, flushing.
Other important manifestations are:
— Papilledema (in one third of patients)
 — Extravascular volume overload
 — Sclerotic bone lesionsa (95%)
 — Thrombocytosis (in 54%)
 — VEGF elevationb
 — Castleman disease (in 11–30%)
aRadiology and CT/PET can be useful
bVEGF = Vascular endothelial growth factor is the cyto-
kine that correlates best with disease activity. The helpful 
cutoff for plasma and serum VEGF levels for diagnosis 
are >200  pg/mL (specificity 95%, sensitivity 68%) and 
>1920  pg/mL (specificity 98%, sensibility 73%), 
respectively
82.1.3  Diagnosis
Not all the features within the acronym are 
required to make the diagnosis. There are 
other relevant features not included in the 
POEMS acronym also important: PEST 
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 (papilledema, extravascular volume overload, 
sclerotic bone lesions, thrombocytosis/eryth-
rocytosis), elevated VEGF levels, abnormal 
pulmonary function tests, and a predisposition 
to thrombosis.
There is a Castleman variant of POEMS syn-
drome that may be associated with a clonal 
plasma cell disorder. When Castleman disease 
variant of POEMS syndrome occurs without evi-
dence of plasma cell disorder, then this entity 
should be considered separately.
Clinical criteria for POEMS diagnostic are 
shown in Table 82.1.
82.1.4  Prognosis
Chronic course, median survival of nearly 14 
years, rarely progression to multiple myeloma.
The number of POEMS features does not 
affect survival.
Risk factors associated to better survival 
are: albumin >3.2 g/dL, achievement of a com-
plete hematological response and younger age. 
Lower VEGF levels, better response to 
treatment.
Risk factors associated to shorter survival are: 
clubbing, extravascular volume overload, respi-
ratory symptoms, papilledema, and coexisting 
Castleman disease.
Thrombocytosis and high bone marrow infil-
tration are associated with risk of cerebrovascular 
accidents.
Patients candidates for radiation therapy have 
a better overall survival.
82.1.5  Standard Treatment
82.1.5.1  In Case of an Isolated Bone 
Lesion (or Multiple, But 
Localized)
Radiotherapy to affected site(s) improves the 
symptoms of POEMS syndrome and can be 
curative.
82.1.5.2  Rest of Patients 
(Disseminated Disease)
– MEL/DEX
–  LENA/DEX, THAL/DEX, BOR (these last two 
agents are of limited use due to the intrinsic risk 
of peripheral neuropathy), CY/DEX.
Table 82.1 Criteria for the diagnosis of POEMS syndrome
The diagnosis of POEMS syndrome is confirmed when:
— Both mandatory major criteria +
 — Another of the other three major criteria +
 — At least one of the minor criteria
Mandatory major criteria Other major criteria
Polyneuropathy Castleman disease
Monoclonal immunoglobulin Sclerotic bone lesions
VEGF elevated
Minor criteria Other symptoms and signs





Extravascular volume overload  
(edema, pleural effusion, or ascites)
Low vitamin B12 values
Diarrhea




Adapted from Dispenzieri (2017)
aHypogonadism is the most frequent, and because of the high prevalence of diabetes mellitus and thyroid abnormalities, 
these two last abnormalities alone are not sufficient to meet this minor criterion
bAnemia and/or thrombocytopenia are rare, unless associated with Castleman disease
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–  Plasmapheresis, IVIg, IFN-α, tamoxifen, 
ATRA, bevacizumab (anti-VEGF agent), 
 argatroban, and strontium-89 (mostly single-
case reports).
–  Attention to supportive care is mandatory (phys-
ical therapy, orthotics, etc.).
– Auto-HSCT.
82.1.5.3  Response Criteria
Monitoring the response to treatment in 
POEMS syndrome is a challenge. Patients 
must be followed carefully comparing the defi-
cits to baseline. VEGF is an imperfect marker 
due to discordances between disease activity 
and response. The size of monoclonal protein 
is typically small making standard MM 
response criteria inapplicable. Patients can 
present clinical benefit without M-protein 
response therefore a clinical scoring system 
which can focus on organ- specific response 
would be useful clinically. So, response crite-
ria for POEMS syndrome could be done as fol-
lows: hematological response using a modified 
amyloid response criteria, VEGF response, 
CT/PET response, and a simplified organ 
response (polyneuropathy assessment, pulmo-
nary function tests, and extravascular 
overload).
82.1.6  Autologous HSCT (Table 82.2)
82.2  Monoclonal Ig Deposition 
Disease
82.2.1  Introduction
Monoclonal Ig deposition is a clonal plasma cell 
dyscrasia in which light-chain and/or heavy- 
chain subunits of Igs form non-fibrillar deposits 
in various tissues, causing organ dysfunction. 
Light-chain deposition disease is the most com-
mon of these entities.
82.2.2  Clinical Manifestation/
Laboratory
Kidney
—  Always affected: nephrotic syndrome, hypertension, 
and rapidly progressing renal insufficiency
—  Immunofluorescence shows deposition of light 
chains along glomerular and tubular basement 
membranes → nodular glomerulosclerosis
—  Deposits are non-fibrillar, almost always composed 
of κ chain, and do not stain with Congo red dye
Heart and liver
—  Less frequently affected: restrictive cardiopathy, myo-
cardial infarction, cholestatic jaundice, hepatic failure
Monoclonal gammopathy
—  Electrophoresis, immunofixation of serum and/or 
urine, serum-free light chain measurement
Table 82.2 Main characteristic of auto-HSCT for 
POEMS disease treatment
Background —  In MM, another gammopathy, auto- 
HSCT, has a high rate of responses
—  In amyloidosis, a disease with 
similarities to POEMS syndrome 
with “low tumor” burden, auto-HSCT 
offers encouraging results
Indication POEMS syndrome with disseminated 
disease and:
— Good general condition
—  Without response to standard 
treatment (MEL + DEX 2–3 months)




PBSC, mobilization with G-CSF ± CY 
(3 g/m2)b,c
Morbidity —  High rate of engraftment syndrome  
(up to 50%) (see Chap. 42), important to 
recognize and treat promptly with PRD. 
In these cases, higher than expected trans-
fusion need and delayed engraftment
—  No organ toxicities as observed in 
amyloidosis
Mortality As in other auto-HSCT, recently 
reported 3.3% at 1-year NRMd
Responsed,e Usually delayed, from 6 months 
post-auto-HSCT to 24–72 months
aWith lower dose, inferior responses
bMobilization failure is described, for this reason if there 
is no response after three courses of MEL + DEX, proceed 
to mobilization
cThe incidence of engraftment syndrome can be reduced if 
mobilization is done with CY + G-CSF
dCook et al. (2017)
eIn the largest series, 3-year PFS 84% and OS 94%, and 
5-year PFS 74% and OS 89%
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82.2.3  Diagnosis
Based on the biopsy of the affected organ (almost 
always kidney)
82.2.4  Treatment
Controversial, not standard due to the low inci-
dence. Conventional chemotherapy commonly 
used for MM is unsatisfactory. Possible alterna-
tives are:
– MEL + prednisone
– VAD (vincristine, doxorubicin, DEX)
– THAL/DEX, BOR/DEX
– Auto-HSCT (see Table 82.3)
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clonal Ig deposition disease treatment
Background —  As in POEMS syndrome (see 
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PB, mobilization with G-CSF ± CY  
(3 g/m2)
Morbidity Some patients require hemodialysis 
(HD) before and during the procedure. 
In that case, MEL should be 
administered after HD
Mortality As in other auto-HSCT
Response In the few cases reported:
 —  Hematological responses are 
described secondary to the control of 
the monoclonal gammopathy
 —  It can improve renal function. In 
selected cases, kidney transplantation 
could be an option if the patient 
achieves a CR and remain in HD
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First-line therapy for patients with advanced 
stage follicular lymphoma (FL) in need of treat-
ment is to administer chemoimmunotherapy fol-
lowed by maintenance rituximab (RTX). With 
this approach approximately half of the patients 
will remain progression-free at 10  years. Both 
auto-HSCT and allo-HSCT have been employed 
in the management of patients with FL since the 
1980s. However, the roles of both forms of HSCT 
have continued to evolve as both transplant and 
non-transplant therapies have been refined. The 
current indication for auto-HSCT and allo-HSCT 
are reviewed below.
83.2  Autologous HSCT
83.2.1  Auto-HSCT in First Response
With both the development of auto-HSCT in the 
1980s and the realisation that standard-dose che-
motherapy was not curative for indolent lym-
phoma, investigators explored the role of 
auto-HSCT as a consolidation strategy following 
first-line therapy. Promising initial studies culmi-
nated in the development of several large ran-
domised studies where auto-HSCT was compared 
with either no further therapy or interferon. 
Whilst some of these studies demonstrated an 
improvement in disease control, no overall sur-
vival benefit could be demonstrated (Lenz et al. 
2004; Ladetto et  al. 2008). These observations 
combined with a growing realisation of the acute 
and long-term toxicities of auto-HSCT have led 
to the abandonment of auto-HSCT as a first-line 
consolidation procedure.
83.2.2  Auto-HSCT for Relapsed FL
To date, the CUP trial has been the only ran-
domised study comparing consolidation with an 
auto-HSCT (using either purged or unpurged 
stem cells) with no further therapy in the relapse 
setting (Schouten et  al. 2003). In this trial, 140 
patients with relapsed FL were randomised 
between consolidation with an auto-HSCT (using 
either purged or unpurged stem cells) or chemo-
therapy alone. The 2-year PFS for the chemother-
apy alone arm was 26% compared with 58% and 
55% for those receiving HSCT with either 
purged  or unpurged stem cells, respectively. 
Further there was an overall survival advantage 
in  favour of the two transplant arms (Schouten 
et al. 2003).
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More recently the EBMT-LYM-1 study pro-
spectively examined the role of purging and main-
tenance with Rituximab (RTX) peri-HSCT in 
RTX naïve patients with relapsed FL (Pettengell 
et al. 2013). In this study all patients underwent an 
auto- HSCT, and no benefit could be demonstrated 
for in vivo purging. However, the study did dem-
onstrate that for patients receiving RTX mainte-
nance, the PFS was in excess of 50%. A number 
of other studies have also reported long-term fol-
low-up of auto-HSCT in relapsed FL and describe 
a 10-year PFS ranging between 31 and 50% 
(Kornacker et  al. 2009; Montoto et  al. 2007). 
Taken together these results demonstrate that 
between 25 and 50% of patients experience pro-
longed PFS following an auto-HSCT for relapsed 
FL suggesting that this is a curative procedure for 
a significant minority of patients.
Although promising it is important to recog-
nise both the acute and long-term toxicities asso-
ciated with auto-HSCT which continues to limit 
the application of this therapy. Whilst early TRM 
may be relatively low in younger patients, there 
is evidence that for patients over the age of 60, 
the TRM may be in excess of 10% (Sánchez- 
Ortega et al. 2016). Given that the median age of 
patients with relapsing FL is 69 an auto-HSCT 
will be associated with a significant TRM for the 
majority of patients. An additional concern is the 
late risk of developing secondary malignancies 
including MDS/AML.  In a prospective ran-
domised study, patients undergoing an auto- 
HSCT for FL had a significantly higher rate of 
both solid malignancies and MDS/AML com-
pared to patients not receiving HSCT (Gyan e al. 
2009). Further, in a population-based study of 
more than 7000 patients undergoing auto-HSCT, 
the risk of secondary malignancies was 1.4 times 
greater and the risk of MDS/AML 20.6 times 
greater than the general population (Bilmon et al. 
2014). It is unclear whether the type of condition-
ing therapy used for an auto-HSCT influences the 
risk of secondary malignancy and MDS/
AML. Evaluation of the bone marrow for clonal 
haematopoiesis and cytogenetic abnormalities 
may enable the identification of patients at a 
greater risk of developing MDS/AML following 
an auto-HSCT.  For these patients alternative 
relapse therapies may be more suitable.
83.2.3  The Role of Purging, 
Conditioning Regimen 
and Maintenance
The BM is infiltrated in approximately 75% of 
FL patients at diagnosis, and consequently a 
number of investigators have studied the role of 
marrow purging in auto-HSCT (Gonzalez-Barca 
et al. 2000). However, no clear benefit for purg-
ing could be demonstrated in prospective studies 
(Schouten et al. 2003; Pettengell et al. 2013), and 
there was some evidence that purging resulted in 
significant additional immune suppression 
(IS).  Consequently, purging remains an experi-
mental procedure in auto- HSCT for FL.
There is a wide variety of different conditioning 
regimens that may be employed for auto- HSCT in 
FL but a paucity of randomised trials comparing 
the efficacy and toxicity of these different regi-
mens. The BEAM (BCNU, VP, Ara-C, MEL) regi-
men has become the most widely used regimen 
prior to auto-HSCT in malignant lymphoma and 
has been adopted in many countries. A number of 
investigators have looked to improve upon BEAM 
by including RTX and dexamethasone, substituting 
BCNU with bendamustine (Visani et al. 2014), or 
incorporating bortezomib, mitoxantrone or fote-
mustine. Several groups have also incorporated 
radioimmunotherapy (RIT) into the conditioning 
regimen prior to auto-HSCT in NHL. In one small 
randomised trial comparing Zevalin and BEAM 
(Z-BEAM) with BEAM in relapsed/refractory B 
NHL, there was a survival advantage in the Zevalin 
arm (Shimoni et al. 2012).
Auto-HSCT in FL, Key Points
• Auto-HSCT should not be employed in 
first response.
• Auto-HSCT should be considered in 
patients with relapsed disease respond-
ing to reinduction therapy.
• Auto-HCT achieves a 5-year PFS of 
approximately 50% and may be curative 
in a significant minority of patients.
• There is no proven role for purging 
strategies.
• Maintenance rituximab for four infusions 
should be considered post auto-HSCT.
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83.3  Allogeneic HSCT
Allo-HSCT offers several advantages over auto- 
HSCT in FL: the provision of a graft uncontami-
nated by lymphoma cells or exposed to mutagenic 
agents and the development of an allogeneic GVL 
effect. Early studies employed MAC regimens 
and demonstrated that cure could be achieved in a 
significant proportion of patients (Peniket et  al. 
2003; van Besien et  al. 2003). In retrospective 
studies comparing allo- with auto- HSCT, MAC 
allo-HSCT was associated with a lower relapse 
rate but a higher TRM and consequently a similar 
OS. In an attempt to reduce the toxicity of allo-
HSCT, RIC allo-HSCT has been developed 
(Robinson et al. 2002). A number of groups have 
demonstrated the safety and efficacy of RIC allo-
HSCT and demonstrated that this type of trans-
plant may be employed in older patients with 
significant comorbidities and in those patients 
who have undergone a prior auto- HSCT. Following 
a RIC allo-HSCT, the relapse rate is typically 
below 30%, whether performed as a first trans-
plant procedure (Robinson et al. 2013) or follow-
ing a previous auto-HSCT (Robinson et al. 2016) 
and the 5-year PFS rates range from 50 to 85%.
83.3.1  Conditioning Regimen Intensity
It is currently unclear whether a RIC or a MAC 
allo-HSCT offers superior outcomes in FL. A ret-
rospective registry study demonstrated that the 
two approaches to allo-HSCT resulted in similar 
outcomes in the sibling donor setting (3-year OS 
for the MAC and RIC were 71% and 62% 
(P  =  0.15), respectively) (Hari et  al. 2008). 
However, the EBMT reported that in the unrelated 
donor setting, RIC allo-HSCT was associated with 
a lower NRM and significantly longer PFS and OS 
when compared with MAC allo- HSCT (Avivi 
et al. 2009). The median age at relapse of FL is 69, 
and therefore the majority of patients that may be 
considered for an allo-HSCT will be considered 
too old for MAC regimens, and many authorities 
therefore recommend a RIC allo-HSCT for 
FL. However, in younger patients (<50 years old) 
and without significant comorbidities, more inten-
sive regimens may also be considered.
83.3.2  Donor Source for Allo-HSCT 
and TCD
The outcomes of both matched sibling donor 
(MSD) and MUD allo-HSCT in FL are broadly 
similar. A recent large retrospective study con-
ducted by the EBMT and the CIBMTR demon-
strated that the PFS and OS following MSD and 
MUD were similar (Sureda et  al. 2018). For 
patients lacking a MSD or MUD, either a cord 
blood or haploidentical family donor may now be 
considered. The feasibility of umbilical cord 
blood (Rodrigues et  al. 2009; Brunstein et  al. 
2009) and haplo-HSCT (with PT-CY) (Dietrich 
et  al. 2016) in NHL (including FL) has been 
reported. However, the toxicity of both CBT and 
haplo-HSCT is significant, and it remains to be 
established whether either type of alternative 
donor source is superior to MSD and MUD.
TCD of the graft is a well-established method 
to reduce the incidence of GVHD post-transplant 
but runs the risk of eliminating allo-reactive T 
cells that will mediate the GVL effect and conse-
quently result in a higher relapse rate. The risk of 
relapse may be offset by employing donor lym-
phocyte infusion (DLI), and with this approach, 
the 4  years PFS and relapse risk was 76% and 
24%, respectively, and the incidence of GVHD 
was low (Thomson et al. 2010), suggesting that 
this approach may also be an option for allo-
HSCT in FL.
Allo-HSCT for FL, Key Points
• Allo-HSCT should only be considered 
in patients with relapsed disease.
• Reduced intensity conditioning regi-
mens are most appropriate for patients 
over the age of 50 or with significant 
comorbidities.
• Patients under 50 years may be consid-
ered for more intensive regimens.
• Matched sibling, matched unrelated, 
haploidentical and cord blood stem cell 
sources may be considered.
• T-cell depletion may be employed but 
should be combined with chimerism 
directed donor lymphocyte infusions.
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83.4  Patient Selection for HSCT 
in FL
As discussed above HSCT options are no longer 
considered in first response and are reserved for 
patients with relapsed disease. However, patients 
with relapsed FL represent a highly heterogeneous 
population, and a HSCT will not be appropriate for 
many patients. Therefore, numerous factors have to 
be taken into consideration when selecting patients 
for a HSCT procedure. Patient- related factors such 
as age, comorbidities, performance status, organ 
function, the HSCT comorbidity index (HSCT-CI) 
(Sorror et  al. 2005) and patients’ personal views 
will determine if a patient is fit to undergo a trans-
plant and what the likely TRM rate will be. Certain 
features relating to the patient’s lymphoma are 
prognostic in the relapsed setting, and transplanta-
tion should only be considered in patients where 
the lymphoma is considered to considerably 
shorten survival. Patients that relapse within 2 years 
of the first-line therapy (Casulo et  al. 2015) and 
those with high-grade transformation at relapse 
(Sarkozy et al. 2016) have been shown to have poor 
survival, and these patients should be considered 
for a HSCT procedure once adequate disease con-
trol has been obtained. Patients with a high FLIPPI 
score at relapse and those with multiple relapses 
may also have a poor prognosis, and these patients 
may also be considered for transplant options. It is 
important, however, to carefully counsel the 
patients regarding both the transplant and non-
transplant therapies that are currently available of 
which there are many.
83.5  Auto-HSCT or Allo-HSCT 
as a First Transplant 
Procedure
The decision whether to employ either auto- or 
allo-HSCT in relapsed FL remains challenging. 
There has been only one prospective randomised 
study addressing this issue, which was unfortu-
nately closed early due to poor accrual (Tomblyn 
et al. 2011). An EBMT retrospective comparison 
demonstrated that the PFS at 5 years was 57% for 
patients receiving an allo-HSCT compared with 
48% for those receiving an auto-HSCT, but over-
all survival was similar with both types of trans-
plant (Robinson et  al. 2013). It is therefore 
currently not clear which SCT option is superior 
for relapsed FL, and in the absence of definitive 
data, the decision regarding an auto- or allo- 
HSCT needs to be taken on an individual patient 
basis. Given the excellent results recently 
reported with auto-HSCT (Pettengell et al. 2013), 
the relatively low toxicity and the potential for 
cure a number of authorities now recommend an 
auto-HSCT as the first transplant of choice and 
that an allo-HSCT should be reserved for patients 
relapsing after an auto-HSCT.
83.6  Allo-HSCT in Patients 
Relapsing After Auto-HSCT
The largest series of patients undergoing a RIC 
allo-HSCT after the failure of an auto-HSCT was 
reported by the EBMT. The NRM at 2 years was 
significant (27%), but the 5-year PFS and OS 
were 48% and 51%, respectively (Robinson et al. 
2016). The duration of response following the 
allo-HSCT was also significantly longer than 
after the auto-HSCT illustrating the potential of 
the allogeneic GVL effect in this disease. This 
data demonstrates that a RIC allo-HSCT can act 
as an effective salvage strategy in this setting 
although the toxicity was significant. There is 
also a risk that patients may fail to respond to 
reinduction therapy, and therefore would not be 
eligible for an allo-HSCT.
Patient Selection Key Points
• Only patients with (a) early relapse 
or  (b) high-grade transformation after 
first- line therapy or (c) multiple relapses 
should be considered for HSCT 
consolidation.
• The superiority of either auto-HSCT or 
allo-HSCT has not been established.
• Auto-HSCT may cure some patients 





Both auto- and allo-HSCT have an established 
role in the treatment of relapsed FL, and both 
forms of transplant can deliver curative therapy 
to patients with otherwise poor prognosis dis-
ease. Patient selection for transplant therapy is 
critical, and a current understanding of the rap-
idly evolving field of alternative non-transplant 
lymphoma therapies is mandatory. The treatment 
paradigm for FL will change over the coming 
years as novel agents are incorporated into clini-
cal practice, and the place of these agents relative 
to transplantation will evolve.
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CLL is a rare indication for HSCT since it usu-
ally follows an indolent course. Those patients 
who require treatment have the option of various 
combinations of chemoimmunotherapy (CIT), 
several non-cross-resistant pathway inhibitors, 
and cellular-based immunotherapy.
Three orally available pathway inhibitors with 
an attractive risk-benefit ratio have been approved 
for the treatment of CLL in the past 5 years, the 
Bruton’s tyrosine kinase inhibitor ibrutinib, the 
phosphoinositide 3-kinase inhibitor idelalisib, 
and the BCL2 inhibitor, venetoclax. Second- 
generation compounds are under development.
While CAR treatment is still at an early stage 
of clinical developmental for CLL, already today 
the sequential use of the available treatment 
options offers chances for long-term survival. 
Only a minority of patients shows resistant dis-
ease with the current treatment options and 
requires allo-HSCT.
84.2  Principles of Treatment 
for CLL
The diagnosis of CLL does not justify the start of 
treatment. This holds true even for relapsing 
CLL. Criteria which should trigger treatment are, 
e.g., anemia or thrombocytopenia due to heavy 
marrow involvement, a lymphocyte doubling time 
of less than 6 months, severe constitutional symp-
toms, or bulky lymphadenopathy. Treatment of 
CLL should be stratified by the TP53 genotype. 
Patients with CLL harboring a cytogenetic dele-
tion 17p detected by FISH or karyotyping or with 
a TP53 mutation detected by DNA sequencing 
(combined in this manuscript as TP53 abnormali-
ties) should not be treated with chemotherapy. 
While CIT used to be the standard of care for first-
line treatment for several decades, this standard is 
now challenged also in patients with functional 
TP53 by the treatment with pathway inhibitors 
with or without monoclonal B-cell antibodies.
84.3  Results of CLL Treatment 
with Pathway Inhibitors
Five-year disease control rates in treatment-naive 
elderly patients on ibrutinib monotherapy have 
been reported from two phase II trials (5-year 
PFS of 92% and 100%) (Ahn et al. 2018; O’Brien 
et  al. 2018). Treatment-naive patients with a 
TP53 abnormality had a 5-year PFS of 74% (95% 
CI, 60–92%).
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Five-year PFS in relapsed/refractory patients 
on ibrutinib was 44% (O’Brien et  al. 2018). 
Outcome was worse in patients with a deletion 
17p or a TP53 mutation compared to patients 
without these abnormalities (O’Brien et al. 2018). 
In an NIH trial, patients with TP53 abnormalities 
had a 5-year PFS of 19% (95% CI, 6–60%) com-
pared to 65% (95% CI, 44–96%) without TP53 
abnormalities (Ahn et al. 2018).
Patients with relapsed/refractory (R/R) CLL 
with a deletion 17p who received the BCL inhibi-
tor venetoclax had a 2-year PFS of 54% (95% CI: 
45%, 62%) (Stilgenbauer et  al. 2018). Notably, 
on venetoclax monotherapy, 20% of patients 
achieved a CR according to NCI criteria, and 
30% reached MRD negativity measured by FACS 
at cutoff of 10−4 CLL cells. Patients who achieved 
a complete or MRD-negative remission had a 
very good prognosis despite previously relapsed/
refractory CLL with a deletion 17p. Furthermore, 
venetoclax demonstrated activity in patients who 
failed on ibrutinib or idelalisib (Jones et al. 2018).
Finally, idelalisib in combination with RTX or 
ofatumumab has also demonstrated activity in 
patients with R/R high-risk CLL.  For example, 
the median PFS for patients with del(17p) or 
TP53 mutations who had received idelalisib plus 
ofatumumab was 16  months (95%-CI, 
11–19 months) (Jones et al. 2017).
After failure of ibrutinib or idelalisib, sequen-
tial treatment with another pathway inhibitor is 
efficacious (Jones et al. 2017; Coutre et al. 2018; 
Mato et al. 2016). However, disease control gen-
erally is shorter compared to pathway-inhibitor- 
naïve patients.
84.4  Allogeneic HSCT
The indication for allo-HSCT requires high-risk 
disease and failure on at least one pathway inhib-
itor (Dreger et al. 2014). High-risk CLL can be 
defined clinically by refractory disease or relapse 
within 2 years after CIT and biologically by TP53 
abnormalities. Information on the IGVH muta-
tion status, IGHV3-21 gene usage, deletion 11q, 
or complex karyotype adds to biological risk cat-
egorization, but only TP53 abnormalities are 
broadly accepted for stratified treatment. 
However, even patients with high-risk disease 
should have failed at least one pathway inhibitor 
before being referred for allo-HSCT. Independent 
of PI exposure, patients with a history of Richter’s 
transformation and patients with a therapy- 
related myeloid neoplasia have an indication of 
allo-HSCT.
Available evidence strongly suggests that allo- 
HSCT is currently the only therapy with curative 
potential in CLL (van Gelder et al. 2017; Kramer 
et  al. 2017). Many patients reach CR without 
MRD after allo-HSCT. Allo-HSCT can provide 
long-term disease control even in patients with an 
unfavorable biological and clinical risk profile. 
The timing of allo-HSCT should be individually 
discussed with the patients by taking into consid-
eration the risk of complications after allo-HSCT 
and the chances of sequential treatment with 
pathway inhibitors and or CIT.  Standard risk 
scores like the HCT-CI, the PAM-score, or the 
EBMT risk score can be used to assess the risk of 
non-relapse mortality of an individual patient 
(Schetelig et  al. 2017a, b). When assessing the 
chances of continued conventional treatment, 
several factors have to be considered:
 1. The risk of adverse events during prolonged 
conventional treatment which affect the eligi-
bility for allo-HSCT
 2. The risk of a Richter’s transformation
 3. The risk of a failed salvage attempt at the next 
relapse/progression of CLL
 4. The risk of worse outcome after allo-HSCT in 
patients with more resistant CLL
84.4.1  Remission Induction Prior 
to Start of the Conditioning 
Regimen
Large prospective and retrospective studies uni-
formly show that the results of allo-HSCT deterio-
rate if the disease is not in remission at the time of 
transplant. Thus, allo-HSCT should be performed 
in remission of CLL.  Different options exist for 
remission induction and bridging to allo- 
HSCT. Abundant information exists for CIT prior 
to allo-HSCT.  Data from retrospective registry 
studies also supports the use of ibrutinib or idelal-
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isib plus RTX for remission induction prior to 
transplantation (Dreger et al. 2018; Schetelig et al. 
2017c). So far, no systematic studies addressed the 
use of venetoclax prior to allo- HSCT.  However, 
since this drug does not modulate the immune 
responses, no adverse carry-over effects have to be 
suspected. As a general rule, the treatment with the 
highest chance of short- term tumor debulking 
should be used for remission induction prior to 
allo-HSCT (van Gelder et al. 2016).
84.4.2  Conditioning Regimens
The crucial therapeutic principle of allo-HSCT in 
CLL is GVL activity. Evidence for this comes 
from the observation that even some patients with 
refractory disease benefit from allo-HSCT.  The 
impact of GVL is reflected by a reduced relapse 
risk in the presence of cGVHD and the efficacy 
of immune modulation for the eradication of 
MRD (Ritgen et al. 2008; Hahn et al. 2015).
Accordingly, long-term disease control can be 
achieved with a broad range of conditioning regi-
mens. Current evidence does not allow the defini-
tion of one standard conditioning regimen for 
CLL. The most convincing data supporting allo- 
HSCT in CLL come from studies of NMA condi-
tioning or RIC (Kramer et  al. 2017; Schetelig 
et  al. 2017b; Sorror et  al. 2008). The choice of 
conditioning intensity may vary according to the 
individual situation. In the presence of comorbid-
ity and chemosensitive disease, RIC or NMA 
conditioning appear to be more appropriate, 
whereas high-intensity regimens might be prefer-
able in younger patients with good performance 
status but poorly controlled disease.
84.4.3  Outcome After Allo-HSCT 
for CLL
Based on a large registry cohort, estimated event- 
free survival, overall survival, and NRM 10 years 
after allo-HCT were 28% (95% confidence inter-
val (CI), 25–31), 35% (95% CI, 32–38), and 40% 
(95% CI, 37–42), respectively (van Gelder et al. 
2017). Patients who passed the 5-year landmark 
EFS (N = 394) had a 79% probability (95% CI, 
73–85) of surviving the subsequent 5 years with-
out an event. Relapse and NRM contributed 
equally to late treatment failure. Higher age, 
lower performance status, unrelated donor type, 
and unfavorable sex mismatch have an adverse 
impact on 2-year NRM.  Despite the risks of 
NRM and even late relapse/progression, the pros-
pect of long-term DFS on average in almost one 
out of three patients remains an argument to con-
sider allo-HCT especially for young patients with 
high-risk CLL.
84.4.4  Post transplant Minimal 
Residual Disease Monitoring 
and Immune Intervention 
in CLL
In CLL, sensitive MRD quantification (i.e., 1 cell 
in 104 or less) can be obtained by PCR- or flow 
cytometry-based assays. The decline of the MRD 
level is often delayed and is closely related to 
immuno-reconstitution after allo-HSCT.  GVL- 
induced MRD negativity after allo-HSCT is sus-
tained in the majority of patients and is highly 
predictive of freedom from relapse. MRD moni-
toring is a valid instrument for the guidance of 
preemptive immune interventions directed at dis-
ease eradication after allo-HSCT, such as the 
tapering of IS and the use of DLI. The published 
evidence suggests that CLL is sensitive to timely 
preemptive immune intervention by modulation 
of systemic IS (Ritgen et al. 2008; Moreno et al. 
2006).
84.5  Summary and Perspectives
Allo-HSCT from MRD or MUD can induce 
long-term DFS in patients with high-risk CLL. It 
is a standard treatment option for patients with 
high-risk CLL who have failed at least one path-
way inhibitor. Generally, allo-HSCT should be 
considered before the disease has advanced to a 
status of complete refractoriness. At the same 
time, allo-HSCT should not be recommended 
for patients who face a higher short-term risk of 
mortality after transplantation compared to con-
ventional therapy. In the absence of randomized 
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controlled comparisons of these treatment strat-
egies, the outcome of an individual patient has 
to be predicted based on published data. This 
requires careful individual assessment of the 
risk of allo-HSCT versus prolonged conven-
tional treatment. Patients should be referred to a 
transplant center once their disease proved 
refractory to at least one pathway inhibitor in 
order to get consultation with an expert in the 
field. Finally, all approved drugs for CLL can 
also be used for the treatment of post transplant 
relapse, and further improvements of donor 
selection, patient care, and prevention of com-
plications can be expected; thus, overall out-





•  High-risk CLL after failure of pathway inhibitor treatment
•  CLL in combination with therapy- related MDS
•  History of Richter’s transformation
Remission 
induction prior 
to start of 
conditioning
Patient who receive allo-HSCT in remission enjoy a lower risk of relapse. The most 






No disease-specific criteria have to be considered (Michallet et al. 2010; van Gorkom 
et al. 2018)
Conditioning Patients should receive either NMA conditioning or alkylator-based RIC. A history of 
a Richter’s transformation or concomitant MDS may justify dose intensification 
(Schetelig et al. 2017b; Sorror et al. 2008)
MRD 
monitoring
At least quarterly assessments of MRD by FACS or PCR should be offered after 
allo-HSCT. Early taper of IS with or without administration of DLI, especially in 
patients without GVHD but with persistent disease, may result in MRD-negative CR in 
this group of patients (Ritgen et al. 2008)




• Poor performance status and/or high HCT-CI score
•  Partially matched as compared to matched donor HSCT
Outcomes Estimates based on HSCT performed between 2000 and 2010 reported to EBMT 
registry (van Gelder et al. 2017):
 2-year and 5-year NRM, 30% and 36%
 2-year and 5-year CI of relapse/progression, 21% and 29%
 2-year and 10-year EFS, 49% and 28%
 2-year and 10-year OS, 62% and 35%
Relapse after 
allo-HSCT
Relapse after allo-HSCT may be treated successfully. To current knowledge the history 
of allo-HSCT does not restrict treatment options for patients with relapsed 
CLL. Ibrutinib appears to be especially favorable for the treatment of first relapse after 
transplantation in patients without proven ibrutinib resistance
J. Schetelig and P. Dreger
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Diffuse Large B-Cell Lymphoma
Norbert Schmitz, Matthias Stelljes, 
and Ali Bazarbachi
85.1  Definition and Epidemiology
Diffuse large B-cell lymphoma (DLBCL) is a 
neoplasm of morphologically medium to large 
B-lymphoid cells. The most recent WHO clas-
sification of tumors of hematopoietic and lym-
phoid tissues (Swerdlow et  al. 2017) divides 
DLBCL into DLBCL, NOS with distinct mor-
phological (centroblastic, immunoblastic, ana-
plastic, rare) and molecular (germinal center 
B-cell, activated B-cell) subtypes, other lym-
phomas of large B cells, high-grade B-cell lym-
phoma (with MYC and BCL2 and/or BCL6 
rearrangements or NOS), and B-cell lymphoma, 
unclassifiable.
With some important exceptions, diagnostic 
work-up and treatment are identical in all DLBCL 
subtypes. It is beyond the scope of this article to 
fully describe the exceptions; we mention the 
most important differences but otherwise focus 
on transplantation for patients with relapsed/
refractory DLBCL.
DLBCL is the most frequent lymphoma 
 subtype and accounts for approximately one 
third of newly diagnosed lymphoma cases 
worldwide. In Europe, the 10-year prevalence of 
DLBCL is estimated at 43.3 per 100,000 per 
year (Smith et al. 2015); the age-adjusted inci-
dence rate of DLBCL reported by the US 
Surveillance, Epidemiology, and End Results 
(SEER) program is 7.14/100,000 person-years 
(Howlader et  al. 2017). The disease is slightly 
more frequent in men than in women; it mostly 
is a disease of the elderly (median patient age 
beyond 60 years) but can occur also in children 
and adolescents.
85.2  Diagnosis
The diagnosis is made according to the WHO 
classification from a sufficiently large surgical 
specimen or excisional lymph node biopsy; 
 needle biopsies are not recommended. Beyond 
morphological evaluation by an experienced 
pathologist, determination of the immunopheno-
type of the malignant cells (positivity of malig-
nant cells for CD19 and CD20 must be 
documented because of its therapeutic conse-
quences) and determination of the cell of origin 
by adequate molecular methods are required 
(Swerdlow et al. 2017).
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The large B-cell lymphomas comprise the mor-
phological and molecular subtypes of DLBCL, 
NOS, high-grade B-cell lymphomas, and B-cell 
lymphomas, unclassifiable (see paragraph 1).
The WHO classification describes 12 other 
(and 1 provisional) lymphomas of large B cells. 
Among these, primary diffuse large B-cell lym-
phoma of the CNS (PCNSL), lymphomatoid gran-
ulomatosis (LG), primary mediastinal large B-cell 
lymphoma (PMBCL), and plasmablastic lym-
phoma not only show significant differences in 
pathogenesis and clinical manifestation but in 
most centers are treated different from classical 
DLBCL. Exact subtyping of diagnostic specimens 
taking into account their origin (e.g., primary cuta-
neous DLBCL, leg type; PCNSL; primary effu-
sion lymphoma) is important. In order to fulfill all 
WHO requirements, the cell of origin (GCB- or 
ABC-subtype by IHC or gene expression profil-
ing) and the presence/absence of distinct chromo-
somal translocations (BCL6, BCL2, MYC by 
FISH testing or IHC) must be determined.
85.4  Risk Factors
The International Prognostic Index (IPI) remains 
the most important tool in order to estimate the 
prognosis of patients with DLBCL (Ziepert et  al. 
2010). The IPI takes into account five factors (age, 
stage, LDH, performance status, and number of 
extranodal sites involved). Patients within the low 
(IPI 0, 1), low-intermediate (IPI 2), high- 
intermediate (IPI 3), and high-risk group (IPI 4, 5) 
can expect 3-year overall survival of 91.4%, 80.9%, 
65.1%, and 59.0%, respectively, if treated with 
R-CHOP or one of its variants. Other clinical risk 
factor models (R-IPI; NCCN-IPI) (Sehn et al. 2007; 
Zhou et al. 2014, respectively) have been proposed, 
but advantages over the original IPI seem limited.
85.5  First-Line Treatment
First-line treatment of patients with DLBCL gen-
erally consists of RTX at standard dose (375 mg/
sqm) in combination with CHOP (CY, DOXO, 
VCR, PRD) or one of its variants such as ACVBP, 
CHOEP, or DA-EPOCH chemotherapy. Six 
cycles of R-CHOP are generally used. However, 
the cycle number can be reduced to four without 
jeopardizing treatment outcome in patients with 
IPI 0. Patients with early disease (IPI 0 and 1) 
have been treated with abbreviated chemotherapy 
and involved-field radiotherapy (RT). Recent 
studies do not support a role for RT in such 
patients (Lamy et al. 2018). In patients with IPI 
2–5, radiotherapy to bulky and extranodal disease 
is regularly recommended after R-CHOP in some 
but not in the majority of countries.
Several studies evaluated the role of consoli-
dative high-dose therapy followed by auto-
HSCT in the RTX era. The French (Gouill et al. 
2007), Italian (Chiappella et  al. 2017), and 
German (Schmitz et  al. 2012) studies failed to 
demonstrate an advantage of auto-HSCT over 
conventional chemotherapy. The only American 
study (Stiff et al. 2013) reported an advantage of 
auto- HSCT in younger patients with high-risk 
disease (age-adjusted IPI 3); however, this study 
included patients treated with CHOP only and 
patients with T-cell lymphoma and as a conse-
quence was underpowered in order to show a 
significant advantage of auto-HSCT over 
R-CHOP (Schmitz et al. 2014). In young patients 
who remain PET positive after two cycles of 
chemo- immunotherapy, auto-HSCT is per-
formed in some but not in the majority of 
countries.
Patients with PCNSL or DLBCL with primary 
involvement of testicles must receive chemother-
apy penetrating into the CNS.
More aggressive chemotherapies (CHOEP, 
DA-EPOCH, or ACVBP) in combination with 
RTX with or without RT are recommended in 
patients with PMBCL or plasmablastic lym-
phoma and in patients with high-intermediate 
and high-risk disease (Ghielmini et  al. 2013; 
Recher et al. 2011). If patients with DLBCL of 
ABC subtype or rearrangement of MYC and 
BCL2 and/or BCL6 (double- or triple-hit 
 lymphoma) should receive more aggressive ther-
apy, therapy remains controversial (Friedberg 
2017; Staiger et al. 2017). The same holds true 
for the value of targeted therapies (ibrutinib, 
lenalidomide, and others) given in addition to 
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R-CHOP.  Prospective randomized studies 
addressing these questions have been closed but 
not published yet.
85.6  Second-Line Treatment
The principles of management of relapsed and 
refractory DLBCL are shown in Table 85.1. All 
chemotherapy-based salvage regimens cause 
hematologic toxicity in many cases necessitating 
RBC and platelet transfusions. Mucositis, gas-
trointestinal toxicities, neutropenic fever, and 
infections are reported in a significant proportion 
of patients. Nephrotoxicity, hepatotoxicity, and 
other non-hematologic toxicities are also 
observed. Failure to mobilize hematopoietic 
stem cells in 10–20% of cases occurs with all 
salvage regimens. Efficacy of different salvage 
options is shown in Table 85.2.
85.7  Autologous HSCT
Autologous HSCT is still considered the stan-
dard treatment for patients with refractory or 
relapsed (R/R) DLBCL. In the RTX era, how-
ever, the results of salvage therapy followed by 
auto- HSCT are less convincing than before, 
and the benefit of auto-HSCT even for those 
patients achieving PR or CR with salvage che-
motherapy and RTX is limited (Crump et  al. 
2014, 2017). In particular, patients with refrac-
tory disease or early relapse pretreated with 
RTX as part of first-line therapy rarely achieve 
long-term remissions after auto-HSCT.  In the 
CORAL study, 3-year PFS for such patients 
was only 23% although those proceeding to 
auto-HSCT showed 3-year PFS of 39%. 
Alternative treatment, e.g., allo-HSCT, may be 
more adequate. EBMT indications (Sureda 
et  al. 2015) for auto-HSCT in DLBCL are 
shown in Table  85.3. Auto-HSCT is generally 
not recommended as part of first-line  therapy in 
DLBCL although recent data on  PET- guided 
auto-HSCT are promising (Casasnovas et  al. 
2017). We discourage auto-HSCT for patients 
with refractory disease not responding to sal-
vage therapy.
Table 85.1 Management of relapsed or refractory DLBCL
— New biopsy: Highly recommended in all patients 
with R/R DLBCL. Core biopsies acceptable
—  Radiological evaluation: PET/CT recommended for 
evaluation of treatment outcome
— Salvage therapy followed by auto-HSCT is 
currently considered standard of care for patients 
with R/R DLBCL. Especially in patients with 
refractory disease or early relapse (within 12 months 
from the end of first-line therapy), results are not 
satisfactory
—  Allo-HSCT should be considered in younger 
patients without comorbidities especially in patients 
with refractory disease or early relapse. Patients 
relapsing after auto-HSCT are candidates for 
allo-HSCT
— CAR T cells are a valid option whenever available
—  Selection of salvage therapy: Randomized studies 
failed to show significant differences in terms of 
efficacy or toxicity with different salvage regimens. 
R-DHAP seems superior to R-ICE for patients with 
a GCB subtype (Thieblemont et al. 2011). 
Therefore, salvage strategies should take into 
account individual patient characteristics (age and 
comorbidities) considering potential cumulative 
hematologic and non-hematologic toxicity and the 
possibility of harvesting stem cells. Cardiac, 
pulmonary, renal, and liver function should be 
evaluated prior to treatment
—  The objective of salvage chemotherapy is to induce 
a complete or partial response indicating that the 
tumor remains chemosensitive, this having a major 
impact on outcome after transplantation. PET 
negativity after salvage therapy is a surrogate 
marker of chemosensitivity and predicts patient 
outcome after auto-HSCT
Table 85.2 Response to salvage regimens
Regimens compared in prospective randomized trials




ORR 62.8% (44.1%)a, 
CR 28% (14.6%)a
GDP (Crump et al. 2014) Gemcitabine, 
dexamethasone, cisplatin
ORR 45.1%, CR 13.8% 
after 2 cycles




ORR 63.5%, CR 24%
Addition of new drugs (lenalidomide, ibrutinib, 
brentuximab vedotin, polatuzumab, other) to RTX- 
chemo in order to improve response rates of salvage 
regimens is not recommended outside clinical trials
aPercentages in brackets from Crump et al. (2014)
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85.7.1  HSC Source
PBSC is used in >90% of auto-HSCT.
85.7.2  Consolidation (High-Dose 
Therapy)
Consolidation (high-dose therapy) should elimi-
nate malignant cells with minimal impact on 
organ systems other than hematopoiesis. The 
choice of the preparative regimen varies and is 
based on institutional experience rather than evi-
dence. The BEAM regimen typically consisting 
of BCNU (300 mg/m2 × 1, day-6), VP (200 mg/
m2, days -5 to -2), Ara-C (200 mg/m2 bid, days -5 
to -2), and MEL (140 mg/kg/day ×1, days -1) is 
the preferred regimen in EBMT centers.
Acute toxicities of BEAM include severe 
mucositis, nausea and vomiting, diarrhea, hepa-
totoxicity, nephrotoxicity, and non-infective pul-
monary complications. Late toxicities include 
pulmonary complications such as chronic inter-
stitial fibrosis and decrease in lung diffusion 
capacity (21%), infection (30%), metabolic syn-
drome (17%), cardiovascular complications 
(12%), secondary tumors (20%), and other tox-
icities (20%). The most frequent cause of NRM is 
subsequent malignancy (12-fold increased risk 
compared with the general population). Late 
death is also attributed to cardiac toxicity (2%), 
pulmonary complications (2%), and other 
treatment- related toxicities (15%).
Other high-dose regimens have been used 
sometimes because of shortage of MEL or 
BCNU.  Recent publications suggest that the 
BEAC (CY) and TEAM (TT) regimens show 
efficacy and toxicity similar to BEAM in most if 
not all lymphoma subtypes (Robinson et al. 2018; 
Sellner et al. 2016).
85.7.3  Prognostic Factors
Adverse prognostic factors for auto-HSCT iden-
tified in prospective studies include early relapse 
within 12  months of induction therapy, prior 
exposure to R, secondary age-adjusted IPI, poor 
performance status, and involvement of two or 
more extranodal sites at relapse.
85.7.4  Results of Auto-HSCTa
NRM OS at 3 years EFS at 3 years
Gisselbrecht 
et al. (2012)
1.4% 51% (DHAP) 35% (DHAP)
Crump et al. 
(2014)




aResults from prospective randomized studies. Differences 
in OS and EFS may be explained by differing patient 
characteristics and study design
85.7.5  Consolidation Treatment After 
Auto-HSCT
There are no data and no recommendation for con-
solidative therapy after auto-HSCT for DLBCL. In 
the CORAL study Gisselbrecht et al. (2012), RTX 
maintenance did not improve outcome.
85.7.6  Tandem Transplantation
No data from the RTX era are available.
85.7.7  Relapse After Auto-HSCT
Patients relapsing after auto-HSCT generally have 
a poor prognosis. Therapeutic options are limited. 
Data on new drugs specifically used post auto-
HSCT are not available. Results of allo- HSCT 
after failure of auto-HSCT are reported below. 
CAR T cells may be a therapeutic option; how-
ever, no more than anecdotal data are available.
Table 85.3 Indications for auto-HSCT in DLBCL
Disease status Recommendations
First complete remission Clinical option
Level of evidence I
Sensitive relapse/> 2nd complete 
response
Standard of care
Level of evidence I
Refractory disease Clinical option
Level of evidence 
II
N. Schmitz et al.
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85.8  Allogeneic HSCT
Allo-HSCT is considered a curative treatment 
option for patients with DLBCL who relapse or 
progress after auto-HSCT. The EBMT reported 
on 101 such patients who had been allografted 
for DLBCL between 1997 and 2006; 37 patients 
were transplanted after MAC and 64 patients 
after RIC (van Kampen et al. 2011). Three-year 
NRM was 28.2%, relapse rate was 30.1%, PFS 
was 41.7%, and OS was 53.8% after 3  years. 
No statistically significant differences were 
seen between patients transplanted after MAC 
or RIC or patients transplanted from MRS or 
MUDs.
The only prospective randomized clinical trial 
reported so far (Glass et  al. 2014) compared 
GVHD prophylaxis including RTX or not after 
MAC and allo-HSCT for R/R DLBCL. No sig-
nificant difference between patients receiving or 
not receiving RTX in addition to standard MMF 
and TAC for GVHD prophylaxis was found. OS 
was 52% for all 82 patients randomized with sig-
nificant differences between patients transplanted 
from a MUD or MMUD and patients receiving or 
not receiving ATG.  For patients transplanted 
from matched family donors or MUD receiving 
ATG, OS was 64.7%. These data show that allo- 
HSCT is a valid alternative to any other treatment 
for patients relapsing after failure from auto- 
HSCT. Allo-HSCT should also be considered for 
patients with early relapse after first-line R-CHOP 
or similar.
85.8.1  Stem Cell Source
PBSC is the preferred stem cell source for allo- 
HSCT.  The use of haploidentical donors has 
somewhat increased the use of BM in some of the 
series.
85.8.2  Donor Selection
In recent years, there has been a significant 
increase in the use of haploidentical donors for 
allo-HSCT after the introduction of PT-CY. 
Retrospective analyses from EBMT and CIBMTR 
(Kanate et  al. 2016; Ghosh et  al. 2016) suggest 
that allo-HSCT from HLA-identical family and 
URD or from haploidentical donors give compa-
rable results. However, no prospective clinical tri-
als comparing haploidentical donors versus 
HLA-identical siblings and MUD have been pub-
lished so far.
85.8.3  Conditioning
RIC regimens reduce NRM after transplantation 
in many indications but also tend to increase RI 
after transplantation. Because no prospective 
clinical trials demonstrating the superiority of 
one conditioning regimen over another have been 
reported, the question if RIC or MAC should 
be preferred cannot generally be answered. 
Aggressive disease not completely responding 
to salvage therapy and high tumor are situations 
where MAC should strongly be considered.
85.8.4  Prognostic Factors
The most important adverse prognostic factor that 
impacts long-term outcome of patients being 
treated with allo-HSCT is disease status before the 
treatment. However, unlike the situation with auto-
HSCT, also patients not perfectly  responding to 
salvage therapy, e.g., patients with minor response 
or stable disease, may benefit from allo-HSCT.
85.8.5  The Use of Allo-HSCT 
in the Era of New Drugs 
and CAR T Cells
In contrast to the situation for other lympho-
mas, e.g., Hodgkin’s disease, new drugs have 
not really affected the role and positioning of 
allo- HSCT in patients relapsing/progressing 
after auto-HSCT.  Lenalidomides, ibrutinib, 
polatuzumab, or checkpoint inhibitors with or 
without chemotherapy can be used to bring 
more patients to transplantation. None of these 
drugs can substitute for allo-HSCT because 
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remissions are mostly transient, and no cures 
have been achieved.
CAR T cells (Schuster et  al. 2017; Neelapu 
et al. 2018) are an option for patients failing an 
autograft for DLBCL.  However, results in day- 
to- day routine are not yet clear, and CAR T cells 
are not available outside clinical trials.
85.8.6  Results of Allo-HSCT
NRM OS at 3 years PFS at 3 years
25–35% 40–60% 30–50%
85.8.7  Disease Relapse After 
Allo-HSCT
Disease relapse carries a dim prognosis. Beyond 
DLI, therapeutic options are few, clinical trials 
should be actively sought, and palliative care is a 
reality in many cases. Checkpoint inhibitors may 
be an option with mixed results and risk of GVHD.
85.9  Therapeutic Algorithm 
Recommended by 
the Authors (See Fig. 85.1)
85.10  Long-Term Outcomes 
of Auto- and Allo-HSCT 
in Patients with R/R DLBCL 
(See Fig. 85.2)
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Fig. 85.1 Allogeneic and autologous HSCT in R/R lymphoma: treatment decision
Key Points
• In the RTX era, auto-HSCT is generally 
not recommended as part of first-line 
therapy in DLBCL although recent data 
on PET-guided auto-HSCT are promis-
ing. Auto-HSCT is still the standard of 
care for those DLBCL patients with 
chemosensitive first relapse. Results of 
auto-HSCT might improve with better 
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Fig. 85.2 Long-term outcomes of auto- and allo-HSCT in patients with R/R DLBCL (EBMT data base, with 
permission)
selection of patients (e.g., including PET 
imaging for patient selection), and 
improved salvage strategies results.
• Allo-HSCT is the only curative treatment 
option for patients with refractory disease 
and those relapsing after auto- 
HSCT.  Patients with early relapse (< 12 
months after first-line treatment) should 
be considered for allo-HSCT. Conditioning 
should be guided by the individual clinical 
situation. Haploidentical transplants may 
substitute for unrelated donor transplants 
in the near future. New drugs have not 
really changed the treatment algorithm for 
DLBCL. The role of CAR T cells is under 
study.
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Mantle cell lymphoma (MCL) is an aggressive 
B-cell lymphoma, which is characterized by the 
chromosomal translocation t(11;14)(q13;q32) 
and overexpression of cyclin D1  in the vast 
majority of cases. Most patients present with 
advanced stage disease, often with extra-nodal 
dissemination, and an unfavourable clinical 
course. Treatment with conventional chemother-
apy resulted in unsatisfactory outcomes and a 
median survival of less than 3 years after diagno-
sis of MCL (Zucca et al. 1995).
86.2  Autologous HSCT
During recent years, the prognosis of patients 
with MCL has improved considerably, and the 
refinement of dose-intensified approaches such 
as auto-HSCT has contributed significantly to 
this development. A prospective randomized trial 
by the European Mantle Cell Lymphoma Network 
(EMCLN) has demonstrated the superiority of 
auto-HSCT consolidation over interferon mainte-
nance (Dreyling et al. 2005) in the pre-RTX era. 
The introduction of RTX and the addition of 
high-dose cytarabine (HD-ARAC) to the induc-
tion treatment before auto-HSCT have further 
improved PFS and OS of MCL patients (Geisler 
et al. 2008). The benefit of high-dose HD-ARAC 
before auto-HSCT could be confirmed in pro-
spective clinical trial (Hermine et al. 2016). RTX- 
and HD-ARAC-based induction treatment 
followed by auto-HSCT is therefore recom-
mended as a first-line treatment standard for 
young and fit MCL patients (Cheah et al. 2016; 
Dreyling et al. 2017).
Although a significant proportion of patients 
with MCL enjoy long-term disease control after 
auto-HSCT, relapse remains the main cause of 
treatment failure. The prognosis of patients with 
MCL recurrence after auto-HSCT appears to be 
extremely poor, especially if occurring early after 
transplant (Dietrich et  al. 2011; Dietrich et  al. 
2014a). A proportion of almost 40% of MCL 
patients relapsing after auto-HSCT were reported 
to suffer from chemotherapy-refractory disease 
(Dietrich et al. 2014a) with a high prevalence of 
clonal TP53 mutations (Halldorsdottir et  al. 
2011). In order to prevent these refractory 
courses, treatment strategies, which effectively 
reduce the risk of relapse after ASCT, are 
warranted.
Retrospective studies suggested a significantly 
improved outcome with RTX maintenance subse-
quent to high-dose chemotherapy and auto- HSCT 
for patients with MCL (Dietrich et al. 2014b; Graf 
et al. 2015). The French study group conducted a 
prospective randomized phase III trial (LyMa 
trial) that investigated RTX  maintenance versus 
S. Dietrich (*) 





observation after auto-HSCT in previously 
untreated MCL patients. Final results of the LyMa 
trial confirmed the superiority of RTX mainte-
nance with regard to PFS and OS (Le Gouill et al. 
2017). The beneficial effect of RTX maintenance 
was observed in both PET-positive and PET-
negative patients after induction treatment prior to 
auto-HSCT (Mei et al. 2017). This finding implies 
that the benefit of RTX maintenance after auto-
HSCT is present for low- and high-risk MCL 
patients.
86.3  Allogeneic HSCT
In a large EBMT) registry study, which investi-
gated the outcome of MCL patients after first-line 
auto-HSCT failure, 24% of all MCL patients 
received a rescue consolidation HSCT.  Only a 
minority of 2% received a second auto-HSCT of 
whom only one patient experienced a long-term 
survival. These limited results do not justify a 
rescue auto-HSCT as reasonable salvage strategy 
in this situation. In contrast, the majority of 
patients who received a second HSCT underwent 
allo-HSCT, and a significant proportion of them 
achieved a durable remission, translating into a 
3-year OS of 43% (Dietrich et al. 2014a). Other 
registry studies and single-centre experiences 
report similar results (Cook et al. 2010; Tam et al. 
2009; Le Gouill et al. 2012).
Long-term efficacy of RIC allo-HSCT was 
recently demonstrated in a large cohort of MCL 
patients (Robinson et al. 2018). The cumulative 
incidence of relapse was 40% at 5  years, and 
OS was 40% at 5 years. Patients who developed 
a chronic GVHD and/or patients who did not 
receive an in vivo TCD with CAMPATH had a 
significantly lower relapse rate, suggesting the 
existence of a graft versus MCL effect. Despite 
long-term remissions after allo-HSCT, chemo-
refractory disease (Robinson et  al. 2018) or 
early relapse after first-line auto-HSCT 
(Dietrich et al. 2014a) significantly reduced the 
long-term survival of MCL patients after allo- 
HSCT.  Chemotherapy-free salvage treatments 
are obvious options for these highly refractory 
patients. A recent EBMT survey suggested that 
ibrutinib may improve the perspective of refrac-
tory patients scheduled for allo-HSCT (Dreger 
et al. 2018). It is important to note that there is 
a small group of relapsed MCL patients who 
survived longer than 5 years even without allo- 
HSCT, suggesting a rather indolent disease 
course in a subset of patients (Dietrich et  al. 
2014a). Such patients with a low percentage of 
Ki67-positive tumour cells might not benefit 
from an allo-HSCT.
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87.1  Burkitt Lymphoma (BL)
87.1.1  Definition and Epidemiology
BL accounts for around 2% of all adult NHL with 
a higher incidence in patients with immunodefi-
ciency and in patients who are HIV positive. 
There is an endemic pediatric subtype in 
Equatorial Africa which is strongly associated 
with EBV. The clinical course of BL usually is 
highly aggressive with a Ki67 expression of 
nearly 100% requiring prompt institution of 
therapy.
87.1.2  Diagnosis
A tissue biopsy/cytology sample is mandatory 
for the diagnosis. The hallmark of the tumor is 
the rearrangement of a gene encoding MYC, but 
the diagnosis requires a combination of morphol-
ogy, immunophenotype, and genetic analysis.
87.1.3  Risk Factors
Several studies have identified risk factors for 
poor outcome. Beside older age, advanced stage, 
and comorbidities, such risk factors are an ele-
vated serum LDH, failure to achieve CR, anemia, 
CNS involvement, and BM infiltration.
87.1.4  First-Line Treatment
The optimal first-line therapy in BL has not been 
defined yet. To achieve a fast and stable remis-
sion, an intensive regimen combining several 
compounds is used in most centers. Combinations 
of RTX, doxorubicin (DOX), alkylators, VCR, 
and VP with direct therapy to prevent CNS dis-
ease are highly active.
The HOVON CODOX-M/IVAC regimen (CY, 
DOX, VCR, MTX, IFO, Ara-C, and VP) achieved 
a 2-year EFS of 65% and a 2-year OS of 73% and 
is very active especially in high-risk patients 
(Mead et al. 2002).
The B-ALL protocol (MTX, Ara-C, CY, VP, 
IFO) of the German GMALL study group 
achieved a CR in 88% of patients, with a 5-year 
PFS of 71% and a 5-year OS of 80% (Hoelzer 
et al. 2014). This means that a significant portion 
of patients have a chance to get cured with first- 
line therapy.
Recently, using modifications of R-EPOCH 
(RTX, VP, VCR, CY, DOX), high activity in BL 
was reported (Roschewski et al. 2017).
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87.1.5  Autologous HSCT
There are several studies exploring the role of auto-
HSCT in first remission. In a prospective trial, the 
HOVON group treated 27 patients with 2 cycles of 
intensive induction followed by BEAM-conditioned 
auto-HSCT for those patients achieving at least a 
PR (van Imhoff et al. 2005). The 5-year EFS and 
OS was 73% and 81%, respectively. In a retrospec-
tive analysis of 117 patients receiving auto-HSCT 
as part of first- line therapy between 1984 and 1994, 
patients in CR at time of transplant had a 3-year OS 
of 72% (Sweetenham et  al. 1996). In the relapse 
situation, patients who were chemotherapy-sensi-
tive had a 3-year OS of 37% following auto-HSCT 
compared to just 7% for those who were chemo-
therapy resistant (Sweetenham et al. 1996). In sum-
mary, auto-HSCT in BL is feasible, but there is no 
documented advantage compared to standard com-
bination chemotherapy for patients responding suf-
ficiently to first-line treatment. Auto-HSCT may be 
used to optimize remission in patients with insuffi-
cient response or as bridging to allo-HSCT. In the 
relapse setting, given the intensive regimens usually 
used as first-line treatment, the difficulty lies in 
achieving a response good enough to proceed to 
auto-HSCT and to collect HSC; hence, auto-HSCT 
is rarely used in BL.








87.2  Lymphoblastic Lymphoma 
(LBL)
87.2.1  Definition and Epidemiology
LBL is an aggressive neoplasm of precursor B 
cells (B-LBL) or T cells (T-LBL) with features of 
acute leukemia. It accounts for approximately 
2% of all NHL. In adults, around 90% of all LBL 
are T-LBL.
87.2.2  Diagnosis
The diagnosis is based on a LN biopsy. T-LBL is 
usually TdT-positive with a variable expression 
of other T-cell markers (CD7 and CD3 are often 
positive).
87.2.3  Risk Factors
At this time, no convincing prognostic model 
for these patients is available. Several studies 
tried to identify risk factors; the following may 
be associated with an unfavorable outcome: ele-
vated LDH, BM or CNS involvement, and stage 
IV disease. The role of MRD in LBL has not 
been defined yet, but as we learned from acute 
leukemias and other lymphomas, persisted 
MRD positivity might be a predictor of poor 
outcome.
87.2.4  First-Line Treatment
Standard approaches for patients with LBL are 
adapted to ALL protocols. These regimens con-
tain multiple drugs, such as CY, MTX, VCR, 
Ara-C, thioguanine, L-asp, VP, nitrosoureas, and 
anthracyclines. With these protocols, a CR rate of 
80% and a DFS of 56% have been reported (Estey 
et al. 2008).
87.2.5  Autologous HSCT
There are only very few studies evaluating the role 
of auto-HSCT in LBL.  In CR1, the use of auto-
HSCT as a consolidation may improve relapse-
free survival but has no effect on OS (Sweetenham 
et al. 2001). In another study in 128 patients with 
LBL receiving auto-HSCT, RR at 5 years was 
56% (Levine et al. 2003). No documented role in 
more advanced disease >CR1 is reported either. In 
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conclusion, data for auto- HSCT in LBL are too 
scarce to come to firm conclusions.
87.2.6  Allogeneic HSCT
There is also no established role for allo-HSCT in 
patients with LBL.  Compared to auto-HSCT, 
allo- HSCT is associated with a higher TRM but 
lower RR.  In 76 patients receiving allo-HSCT, 
5-year RR was 34% (Levine et al. 2003). In this 
retrospective study, there was no significant dif-
ference in OS at 1 year and 5 years between auto- 
HSCT and allo-HSCT. In general, the indication 
for allo-HSCT should be based on risk factors, 
remission, and MRD.
87.3  Peripheral T-Cell Lymphomas 
(PTCLs)
87.3.1  Definition and Epidemiology
PTCLs are a very heterogeneous group of lym-
phomas originating from the T-cell lineage. 
They account for approximately 10–15% of all 
NHL. Because of this low incidence, large ran-
domized studies are difficult to perform.
87.3.2  Diagnosis
The diagnosis, as in any NHL, should be based 
on a LN biopsy. The differential diagnosis 
between PTCL and other types of T-NHL is cru-
cial for the outcomes, and in some specific cases, 
the treatments are very different.
87.3.3  Risk Factors
The IPI is the most commonly used prognostic tool 
in PTCL. The following factors are associated with 
worse outcome: age >60 years, ECOG >1, elevated 
LDH, stages II–IV, and extranodal involvement >1 
site. In anaplastic large cell lymphoma (ALCL), 
the tumors are categorized in ALK+ or ALK- with 
better prognosis for ALK+ lymphomas.
87.3.4  First-Line Treatment
The primary goal of first-line treatment is to get a 
deep and continuing remission. Standard regi-
mens are anthracycline-containing combinations 
like CHOP or CHOEP, achieving a 3-year EFS of 
50–70% and a 3-year OS of 75–80% (Schmitz 
et al. 2010). In the relapse situation, the overall 
prognosis of PTLC is dismal, and the optimal 
treatment for these patients has not been defined 
yet. Relapse patients not able to receive intensive 
treatment including HSCT may be offered single- 
agent therapy, e.g., gemcitabine, or in case of 
CD30 expression, brentuximab vedotin.
87.3.5  Autologous HSCT (Kyriakou 
et al. 2008; d’Amore et al. 2012; 
Kewalramani et al. 2006; 
Wilhelm et al. 2016)
Indicated in CR1 (IPI > 1), CR ≥ 2
Conditioning BEAC, BEAM, LEAM, CBV
TRM (1 year) 5–7%
REL (3 years) 40–50%
OS (5 years) 70% (CR1), 50% (CR≥2)
PFS (5 years) 50 % (CR1), 20–35% (CR≥2)
87.3.6  Allogeneic HSCT (Schmitz et al. 
2014, 2018; Dodero et al. 2012)
Indicated in CR ≥ 2, relapse post auto-HSCT
Donor MRS > MUD > MMUD
Conditioning RIC > MAC






87.4  HIV-Associated Lymphomas
87.4.1  Definition and Epidemiology
Patients infected with HIV have an increased risk 
of developing NHLs as compared to the general 
population. The most frequent subtypes are 
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DLBCL and BL.  Both are AIDS-defining ill-
nesses, while HL is one of the non-AIDS- defining 
malignancies.
87.4.2  Risk Factors
In the era of combined antiretroviral therapy 
(cART), the risk factors that determine prognosis 
in patients with HIV-related lymphoma are the 
same as in the general population and, hence, 
depend on the subtype of lymphoma, rather than 
on HIV-related factors.
87.4.3  First-Line Therapy
The optimal therapy for these patients has not 
been defined yet, but since the availability of 
cART, the outcome of HIV-lymphoma has con-
siderably improved. The consequent use of cART 
during therapy is of major importance for suc-
cessful treatment. In first-line treatment, patients 
will receive treatment comparable with HIV- 
negative patients. The indication for HSCT has to 
be discussed in the relapse situation.
87.4.4  Autologous HSCT (Hübel et al. 
2017; Diez-Martin et al. 2009; 
Balsalobre et al. 2009)
Indicated in CR ≥ 2; same indications as in the 
general population with the same type 
of lymphoma









87.4.5  Allogeneic HSCT
Experience on the use of allo-HSCT in patients 
with lymphoma and HIV infection is very lim-
ited, and no definitive recommendation can be 
given at this time. There are some case reports or 
small retrospective analysis showing that allo- 
HSCT in HIV-positive patients using MRD, 
MUD, or CB is feasible, but application of cART 
and viroimmunological reconstitution is a matter 
of debate. In a recent report of five HIV-positive 
patients who underwent allo-HSCT with various 
hematologic malignancies, there was no TRM or 
major infections (Mulanovich et al. 2016). HIV 
virus load remained undetectable with continu-
ous cART.  Three patients relapsed 6, 7, and 
13  months after transplant, and two were alive 
and well after 42 and 55 months.
References
Balsalobre P, Diez-Martin JL, Re A, et  al. Autologous 
stem-cell transplantation in patients with HIV-related 
lymphoma. J Clin Oncol. 2009;27:2192–8.
d’Amore F, Relander T, Lauritzsen GF, et  al. Up-front 
autologous stem-cell transplantation in periph-
eral T-cell lymphoma: NLG-T-01. J Clin Oncol. 
2012;30:3093–9.
Diez-Martin JL, Balsalobre P, Re A, et  al. Comparable 
survival between HIV+ and HIV- non-Hodgkin and 
Hodgkin lymphoma patients undergoing autologous 
peripheral blood stem cell transplantation. Blood. 
2009;113:6011–4.
Dodero A, Spina F, Narni F, et al. Allogeneic transplan-
tation following a reduced-intensity conditioning 
regimen in relapsed/refractory peripheral T-cell lym-
phomas: long-term remissions and response to donor 
lymphocyte infusions support the role of a graft- 
versus- lymphoma effect. Leukemia. 2012;26:520–6.
Estey EH, Faderl SH, Kantarjian H.  Acute leukemias. 
Berlin: Springer; 2008. p. 167–76.
Hoelzer D, Walewski J, Dohner H, et al. Improved out-
come of adult Burkitt lymphoma/leukemia with ritux-
imab and chemotherapy: report of a large prospective 
multicenter trial. Blood. 2014;124:3870–9.
Hübel K, Re A, Boumendil A, Finel H, Hentrich M. HIV- 
associated lymphoma and autologous stem cell trans-
plantation in the rituximab era: a retrospective analysis 
on indication, outcome and risk factors by the EBMT 
Lymphoma Working Party. Bone Marrow Transplant. 
2017;52(S1):141.
Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et  al. 
Autologous transplantation for relapsed or primary 
refractory peripheral T-cell lymphoma. Br J Haematol. 
2006;134:202–7.
Kyriakou C, Canals C, Goldstone A, et  al. High-dose 
therapy and autologous stem-cell transplantation in 
angioimmunoblastic lymphoma: complete remis-
sion at transplantation is the major determinant of 
K. Hübel and S. Montoto
651
Outcome-Lymphoma Working Party of the European 
Group for Blood and Marrow Transplantation. J Clin 
Oncol. 2008;26:218–24.
Levine JE, Harris RE, Loberiza FR Jr, et  al. A com-
parison of allogeneic and autologous bone marrow 
transplantation for lymphoblastic lymphoma. Blood. 
2003;101:2476–82.
Mead GM, Sydes MR, Walewski J, et al. An international 
evaluation of CODOX-M and CODOX-M alternating 
with IVAC in adult Burkitt’s lymphoma: results of 
United Kingdom Lymphoma Group LY06 study. Ann 
Oncol. 2002;13:1264–74.
Mulanovich VE, Desai PA, Popat UR.  Allogeneic stem 
cell transplantation for HIV-positive patients with 
hematologic malignancies. AIDS. 2016;30:2653–7.
Peniket AJ, Ruiz de Elvira MC, et  al. An EBMT regis-
try matched study of allogeneic stem cell transplants 
for lymphoma: allogeneic transplantation is associ-
ated with a lower relapse rate but a higher procedure- 
related mortality rate than autologous transplantation. 
Bone Marrow Transplant. 2003;31:667–78.
Roschewski M, Dunleavy K, Abramson JS, Link 
BK.  Risk-adapted therapy in adults with Burkitt 
lymphoma: results of NCI 9177, a multicenter pro-
spective phase II study of DA-EPOCH-R.  Blood. 
2017;130(Suppl 1):188.
Schmitz N, Trumper L, Ziepert M, et al. Treatment and 
prognosis of mature T-cell and NK-cell lymphoma: 
an analysis of patients with T-cell lymphoma treated 
in studies of the German High-Grade Non-Hodgkin 
Lymphoma Study Group. Blood. 2010;116:3418–25.
Schmitz N, Wu HS, Glass B. Allogeneic transplantation 
in T-cell lymphomas. Semin Hematol. 2014;51:67–72.
Schmitz N, Lenz G, Stelljes M.  Allogeneic hemato-
poietic stem cell transplantation (HSCT) for T-cell 
lymphomas. Blood. 2018. https://doi.org/10.1182/
blood-2018-01-791335. [Epub ahead of print].
Sweetenham JW, Pearce R, Taghipour G, et  al. Adult 
Burkitt’s and Burkitt-like non-Hodgkin’s lym-
phoma—outcome for patients treated with high-dose 
therapy and autologous stem-cell transplantation in 
first remission or at relapse: results from the European 
Group for Blood and Marrow Transplantation. J Clin 
Oncol. 1996;14:2465–72.
Sweetenham JW, Santini G, Qian W, et al. High-dose ther-
apy and autologous stem-cell transplantation versus 
conventional-dose consolidation/maintenance ther-
apy as postremission therapy for adult patients with 
lymphoblastic lymphoma: results of a randomized 
trial of the European Group for Blood and Marrow 
Transplantation and the United Kingdom Lymphoma 
Group. J Clin Oncol. 2001;19:2927–36.
van Imhoff GW, van der Holt B, MacKenzie MA, et al. 
Short intensive sequential therapy followed by 
autologous stem cell transplantation in adult Burkitt, 
Burkitt-like and lymphoblastic lymphoma. Leukemia. 
2005;19:945–52.
Wilhelm M, Smetak M, Reimer P, et al. First-line therapy 
of peripheral T-cell lymphoma: extension and long- 
term follow-up of a study investigating the role of 
autologous stem cell transplantation. Blood Cancer J. 
2016;6:e452.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
87 Other T- and B-Aggressive Lymphomas and Lymphomas Associated with HIV
653© EBMT and the Author(s) 2019 
E. Carreras et al. (eds.), The EBMT Handbook, https://doi.org/10.1007/978-3-030-02278-5_88
Classical Hodgkin’s Lymphoma
Anna Sureda and Carmen Martínez
88.1  Definition and Epidemiology
HL is a malignancy arising from germinal centre 
or post-germinal centre B cells. The cancer cells 
form a minority of the tumour and are surrounded 
by a reactive inflammatory milieu comprising 
lymphocytes, eosinophils, neutrophils, histio-
cytes and plasma cells. These malignant cells can 
be pathognomonic, multinucleate giant cells or 
large mononuclear cells and, together, are 
referred to as Hodgkin and Reed-Sternberg 
(HRS) cells.
HL accounts for approximately 10% of cases 
of newly diagnosed lymphoma. The incidence of 
HL in Europe is 2.2 per 100,000 per year with a 
mortality rate of 0.7 cases/100,000 a year. The 
disease is more frequent in men than in women, 
and peaks in incidence are noted in young adults 
and in people older than 60 years. Incidence has 
remained mostly unchanged during the past two 
decades.
88.2  Diagnosis
Pathological diagnosis should be made according 
to the WHO classification from a sufficiently large 
surgical specimen or excisional lymph node biopsy 
to provide enough material for fresh frozen and 
formalin-fixed samples (Eichenauer et al. 2018).
88.3  Classification
HL is classified as either classical (cHL, defined 
by the presence of HRS cells) or nodular 
lymphocyte- predominant (NLPHL). The immu-
nophenotype of the malignant cells in cHL and 
NLPHL differs significantly and helps to estab-
lish the diagnosis. Four subtypes of cHL exist 
(nodular sclerosis, mixed cellularity, rich in lym-
phocytes, and lymphocyte depleted), which differ 
in presentation, sites of involvement, epidemiol-
ogy and association with EBV.  Management, 
however, is broadly similar in all subtypes. 
NLPHL has a distinct clinical course, and it only 
represents less than 5% of the cases of HL.
88.4  Risk Factors
The outlook for patients with early-stage disease 
(stages I–IIA) is excellent, with OS exceeding 
90% in many trials. In advanced-stage disease 
(IIB, III–IV), OS is 75–90%. Risk factors for 
patients with early-stage disease are size of 
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 mediastinal mass, age, erythrocyte sedimentation 
rate, number of nodal areas, B symptoms and 
mixed cellularity or lymphocyte-depleted histol-
ogy. Different risk stratification systems combin-
ing these factors are defined by the EORTC, 
GHSG, NCCN and National Cancer Institute of 
Canada and are currently used in clinical prac-
tice. Risk factors for advance stages consist of 
albumin <4 g/dL, haemoglobin <10.5 g/dL, male, 
age ≥45  years, stage IV disease, leucocytosis 
≥15 x 109/L and lymphocytopenia (lymphocyte 
count less than 8% of white blood cell count and/
or lymphocyte count less than 0.6  x  109/L) 
(International Prognosis Score, 1 point per fac-
tor) (Eichenauer et al. 2018).
88.5  First-Line Treatment
The treatment of patients with cHL is primarily 
guided by the clinical stage and prognostic fac-
tors of disease. Patients with early-stage disease 
are usually treated with a combination of chemo-
therapy (ABVD) plus RTx. The amount of che-
motherapy and dose of radiation differ for 
patients with favourable and unfavourable prog-
nosis of disease. Chemotherapy (ABVD, esca-
lated BEACOPP or Stanford V) is the main 
treatment for patients with advanced stage, and 
RTx may be used for selected patients as consoli-
dation (Eichenauer et al. 2018).
88.6  Second-Line Treatment 
Before Auto-HSCT
The principles of management of relapse or 
refractory cHL are shown in Table  88.1 (von 
Tresckow and Moskowitz 2016). All 
chemotherapy- based salvage regimens are 
associated with haematologic toxicity. Infection 
and neutropenic fever are reported in 10–24% 
of cases. Nephrotoxicity, hepatotoxicity, muco-
sitis and gastrointestinal toxicity are observed 
in <10%. Haematopoietic stem cell mobiliza-
tion appears adequate with all regimens. 
Efficacy of different salvage options is shown 
in Table 88.2.
Table 88.1 Principles of management of relapse or refractory cHL
New biopsy:
—  Mandatory if relapse is >12 months after the end of primary treatment in order to exclude alternative diagnoses. 
Highly recommended for patients with suspected relapse <12 months
—  If apparent primary refractory disease, histological confirmation of HL is only recommended if progression is 
suspected within new sites of disease. Biopsy may not be mandatory in patients with clear radiological 
progression in sites of primary disease during treatment
Radiological evaluation:
— A whole-body CT scan with contrast dye injection and a PET are recommended for further comparison
Therapy:
—  Salvage therapy followed by high-dose chemotherapy and auto-HSCT is currently considered the standard of 
care for relapsed cHL patients
— No study has compared effectiveness of different salvage regimens
—  Salvage strategy should be tailored on an individual basis taking into account the initial therapy given, the risk of 
adding cumulative non-haematologic toxicity and the possibility of harvesting stem cells
— Cardiac and pulmonary function should be evaluated prior to treatment
— If indicated, reproductive counselling should be proposed prior to treatment
—  Objective of salvage chemotherapy: to produce a response (tumour remains chemosensitive), which has a major 
impact on post-auto-HSCT outcome. Achievement of PET negativity defines chemosensitivity and should be the 
goal of salvage chemotherapy
A. Sureda and C. Martínez
655
88.7  Autologous HSCT
Auto-HSCT is currently considered the standard 
treatment for relapsed/refractory (R/R) cHL 
patients. Two landmark randomized clinical tri-
als, the British National Lymphoma Investigation 
(BNLI) in 1993 and the joint German Hodgkin 
Study Group (GHSG)/EBMT HD-R1 trial in 
2002, compared high-dose chemotherapy fol-
lowed by auto-HSCT versus chemotherapy and 
showed significant a benefit of auto-HSCT in 
terms of EFS and FFTF in front of conventional 
salvage chemotherapy; however, there was no 
significant OS benefit. EBMT current indica-
tions for autologous HSCT in HL are shown in 
Table 88.3 (Sureda et al. 2015).
88.7.1  Stem Cell Source 
and Conditioning Regimen
Haematopoietic stem cells from mobilized PB 
are the preferred stem cell source for auto-HSCT.
Although the choice of preparative regimen 
varies and is typically based on institutional 
experience, BEAM is the preferred option. 
Standard BEAM consists of BCNU (300 mg/m2 
×1, day -6), VP (200 mg/m2, days -5 to -2), Ara-C 
(200 mg/m2 bid, days -5 to -2) and MEL (140 mg/
kg/day ×1, days -1). The CY, BCNU and VP 
(CBV) regimen is also commonly used in North 
America. The use of TBI-based regimens is not 
recommended due to the higher risk of develop-
ing secondary malignancies.
Late toxicities of BEAM include pulmonary 
complications (chronic interstitial fibrosis and 
decrease in lung diffusing capacity, 21%), infec-
Table 88.2 Salvage regimens
Conventional chemotherapy
DHAP ORR 89%, CR 21%
ESHAP ORR 67%, CR 50%








ORR 81%, CR 54%
ORR 70%, CR 19%
ORR 62%, CR 1%




Currently approved after failure of 
at least two prior multiagent 
chemotherapy regimens in patients 
who are not auto-HSCT 
candidates. ORR 50%, CR 12%
Pembrolizumab Currently approved for the 
treatment of patients with 
refractory cHL or who have 
relapsed after three or more prior 
lines of therapy. ORR 69%, CR 
22%
New drugs in association with chemotherapya,b
Sequential 
strategies





•  BV plus 
bendamustine
•  BV plus 
ESHAP
•  BV plus ICE
•  BV plus DHAP







aThese combinations are not currently approved for this 
indication
bPET-negative response rate
Table 88.3 EBMT current indications for autologous 
HSCT in cHL (Sureda et al. 2015)
Disease status Recommendations
First complete remission Generally not 
recommended




Level of evidence I
Refractory disease Clinical option
Level of evidence II
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tion (30%), metabolic syndrome (17%), cardio-
vascular complications (12%), secondary 
tumours (20%) and other toxicities (20%). The 
most frequent cause of NRM is subsequent 
malignancy (12-fold increased risk compared 
with the general population).
88.7.2  Prognostic Factors
Adverse prognostic factors for post-auto-HSCT 
outcome consistent across many reported trials 
included primary induction failure, initial remis-
sion duration of <3  months, relapse within 
12 months of induction therapy, extranodal dis-
ease, B symptoms, advanced stage at relapse, 
resistance to salvage chemotherapy and persis-
tent disease at the time of transplant.















88.7.4  Consolidation Treatment After 
Auto-HSCT
Brentuximab vedotin (BV) is currently the 
only drug approved for consolidation treatment 
after auto-HSCT in patients at risk of relapse 
or progression. This approval was obtained 
after the results of the phase III AETHERA 
trial. In this multicentre randomized trial, 329 
patients with relapsed or refractory HL were 
allocated to either consolidation therapy of up 
to 16 cycles of BV or placebo after auto-
HSCT. PFS was significantly longer in patients 
in the BV group (median PFS 43  months vs. 
24  months, P  =  0.0013). When patients were 
grouped by the number of risk factors, a higher 
number led to more notable benefits in the con-
solidation arm (Moskowitz et al. 2015).
88.8  Tandem Auto-HSCT
Several groups have explored a tandem transplant 
approach to improve post-transplant outcomes of 
patients with poor risk factors. These studies 
showed that tandem auto-HSCT is feasible and 
associated with a NRM of 0–5%, 5-year OS of 
54–84%, and 5-year PFS of 49–55% (Smith et al. 
2018). According to these results, risk-adapted 
tandem auto-HSCT can be considered an option 
for poor-risk patients, but integration of PET 
findings and new drugs such as BV and check-
point inhibitors may help to refine the need for a 
second auto-HSCT and possibly improve out-
comes of these patients.
88.9  Disease Relapse After 
Auto-HSCT
Patients relapsing following auto-HSCT have an 
overall poor prognosis with an OS of 30% at 
5  years. Early relapse, stage IV, bulky disease, 
poor performance status and age ≥50  years at 
auto-HSCT failure have been identified as pre-
dictors of poor outcome (Jethava et al. 2017; 
Kallam and Armitage 2018; Lapo and Blum 
2016). Therapeutic options are very heteroge-
neous (Table 88.4) (Martínez et al. 2013; Hahn 
et al. 2013).
88.10  Allogeneic HSCT
Allo-HSCT is still considered a curative treat-
ment strategy for patients with cHL who relapse 
or progress after auto-HSCT (Peggs et al. 
2008). Our knowledge on the curative capacity of 
allo-HSCT relies on the results of several retro-
spective analyses, some of them registry-based, 
phase II prospective clinical trials Sureda et al. 
(2012) that included low number of patients and 
retrospective analyses that in a donor-versus-no- 
donor strategy demonstrate that allo-HSCT offers 
a significant benefit in terms of both PFS and 
OS. EBMT current indications for allo-HSCT in 
cHL are shown in Table 88.5.
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88.10.1  Stem Cell Source, Type 
of Donor and Conditioning 
Regimen
HSC from mobilized PB are the preferred stem 
cell source for allo-HSCT. The use of  haploidentical 
donors has increased the use of BM in some of the 
series. Later studies have demonstrated no signifi-
cant differences in terms of GVHD incidence with 
the use of PB in this setting.
In recent years, there has been a significant 
increase in the use of haploidentical donors with 
the introduction of the PT-CY approach. The 
interesting results observed with this type of 
transplant have already decreased the use of 
MUD and MRD in the EBMT reporting centres 
(Gayoso et al. 2016). Retrospectively, registry-
based studies from both EBMT and CIBMTR 
indicate that outcomes of PT-CY-based haplo-
HSCT are similar to those of MRD and MUD; 
cumulative incidence of GVHD seems to be 
lower with the haploidentical approach and trans-
lates into a better PFS-cGVHD in some of the 
series (Martínez et al. 2017).
More than 50% of the patients with HL 
treated with allo-HSCT receive a RIC protocol. 
RIC regimens have demonstrated to significantly 
reduce NRM after transplantation but also to 
increase RI after transplant (Sureda et al. 2008). 
There are no formal prospective clinical trials 
demonstrating the superiority of a given condi-
tioning protocol in front of the others. 
Retrospective analysis indicates that low-dose 
TBI-containing regimens are associated with a 
higher RI and lower survival than non-TBI- 
containing protocols.
Table 88.4 Therapeutic options after auto-HSCT relapse
Brentuximab vedotin (Chen et al. 
2016)
Currently approved for the treatment of cHL relapsed after auto-HSCT
ORR 75%, CR 34%
PFS 5.6 months
Nivolumab Currently approved for the treatment of cHL relapsed after auto-HSCT and 
BV
ORR 69%, CR 16%
1-year OS 92%, median PFS 12–18 months
Pembrolizumab Currently approved for the treatment of cHL relapsed after auto-HSCT
ORR 69%, CR 22%
PFS 72% at 6 months
Gemcitabine-based chemotherapy ORR 69–86%, EFS 10%
Bendamustine ORR 53–78%, CR 29–33%
Lenalidomide ORR 19%
Histone deacetylase inhibitors ORR 4–74%, CR 0–4%
1-year OS 78%
Everolimus ORR 47%
Second auto-HSCT NRM 15%, 5-year OS and PFS 30%
Allogeneic transplantation See Sect. 88.10
Table 88.5 EBMT current indications for allogeneic HSCT in cHL (Sureda et al. 2015)
Disease risk MSD MUD Alternative donorsa
First remission GNR
Level of evidence III
GNR
Level of evidence III
GNR
Level of evidence III
CR > 1, previous auto-HSCT: no Developmental
Level of evidence III
Developmental
Level of evidence III
GNR
Level of evidence III
CRF > 1, previous auto-HSCT: yes Standard
Level of evidence II
Standard
Level of evidence II
Clinical option
Level of evidence III
Refractory disease Developmental
Level of evidence II
Developmental
Level of evidence II
Developmental
Level of evidence III
aMMUD haploidentical donors, CB, GNR generally not recommended
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88.10.2  Prognostic Factors
The most important adverse prognostic factor 
associated with long-term outcome after allo- 
HSCT is the disease status before transplant. 
However, the impact of a PET-negative CR before 
the procedure is not as straightforward as in the 
auto-HSCT setting.
88.10.3  The Use of Allo-HSCT 
in the Era of New Drugs
The role and positioning of allo-HSCT in 
patient’s relapsing/progressing after auto-HSCT 
are less clear with the introduction of new drugs. 
Numbers of allo-HSCT for this indication seem 
to have decreased over the last 2 years.
BV has been used as a bridge to allo- 
HSCT. There is no evidence of a need of a wash-
out period between the last dose of BV and day 0 
of HSCT. The number of BV cycles being given 
before allo-HSCT is usually between four and 
six. The use of BV before transplant does not 
modify post-transplant-related toxicities and 
might improve results by improving performance 
status and disease status before allo-HSCT.  It 
might also allow more patients to successfully go 
through the transplant.
Checkpoint inhibitors (nivolumab, pembroli-
zumab) before allo-HSCT seem very effective 
with promising survival results (Dada 2018). 
However, follow- up is still too short, and it has 
been suggested that their use could be associated 
with increase in transplant-related toxicity (SOS/
VOD, post- transplant hyperacute febrile syn-
drome). A retrospective study does not indicate a 
higher NRM and higher incidence of acute 
GVHD in patients pretreated with checkpoint 
inhibitors. There is no clear information on the 
need of a washout period when using this com-
bined strategy although it seems that nivolumab 
levels on day 0 do not correlate with incidence of 
GVHD and NRM.
The final decision of whether to allograft a 
patient that relapses after auto-HSCT might rely 
on the risk profile of the underlying disease as 
well as the transplant-related risk.

















88.10.5  Disease Relapse After 
Allo-HSCT
Disease relapse carries out a dim prognosis. 
Therapeutic options are variable and heteroge-
neous (Table 88.6), and in some cases, palliative 
care is the only feasible one.
Table 88.6 Therapeutic options after allo-HSCT relapse




ORR 69% (CR 54%/PR 
15%), PFS 5.5 months
ORR 55% (CR 16%/39%), 
PFS 6 months
Brentuximab vedotin 
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88.11  Therapeutic Algorithm Recommended by the Authors 
(Modified from Yethava et al.)
Primary Refractory cHL
cHL in 1st Relapse
2nd line / 3rd line chemotherapy to test chemosensitivity
AutoHSCT
Disease relapse after autoHSCT







Conventional salvage / PCT
No
ResponseYes Yes
Nivolumab / Pembrolizumab or PCT
Yes
 
PCT, prospective clinical trials. 1In young and fit patients 
with responding disease and an adequate donor available. 
Grey arrows. Both options can eventually be considered 
acceptable after a careful balance of adverse prognostic 
factors of the patient/transplant-related comorbidities/
careful discussion with the patient
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88.12  Long-term outcomes of Auto-HSCT and Allo-HSCT in Patients 
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OS of auto-HSCT in relapsed/refractory cHL over time
OS of allo-HSCT in relapsed/refractory cHL over time
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Key Points
• Auto-HSCT is still the standard of care 
for those patients with primary refrac-
tory/chemosensitive first relapse. 
Results of auto-HSCT might improve in 
the future with better selection of 
patients, improved results of salvage 
strategies and consolidation treatment in 
those patients with high risk of relapse 
after auto-HSCT.
• Allo-HSCT is the only curative treat-
ment options for those patients relaps-
ing after auto-HSCT.  The use of 
allo-HSCT is being modified by the 
introduction of haploidentical donors as 
well as targeted therapies in this 
setting.
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patients with relapsed or refractory Hodgkin's lym-
phoma. Results of the HDR-ALLO study - a prospec-
tive clinical trial by the Grupo Español de Linfomas/
Trasplante de Médula Osea (GEL/TAMO) and the 
Lymphoma Working Party of the European Group for 
Blood and Marrow Transplantation. Haematologica. 
2012;97:310–7.
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auto-SCT for haematological diseases, solid tumours 
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Primary immunodeficiency (PID) diseases arise 
from genetic defects that lead to abnormalities in 
immune cell development or function with a wide 
spectrum in severity and clinical manifestations. 
A subgroup of patients with an immunodeficiency 
present as a medical emergency which is associ-
ated with a chronic disabling and life- threatening 
clinical course. In these cases, allo- HSCT pro-
vides a life-saving and curative treatment modal-
ity. Replacement of the defective cell lineage by 
HSCT from healthy allogeneic donors remains 
the curative approach for these patients. Other 
management options including enzyme replace-
ment therapy, gene transfer into autologous hema-
topoietic stem cells, and targeted therapies (see 
below) may provide an alternative approach to 
HSCT in specific immune deficiencies.
89.2  Diseases
For HSCT purposes and thus for this handbook, 
PID may be broadly categorized into severe com-
bined immunodeficiencies (SCID) and non- 
SCID.  To further subdivide non-SCID, the 
phenotypic classification as suggested by the 
International Union of Immunological Societies 
(IUIS) Inborn Errors of Immunity Committee 
can be used, which encompasses >300 genetic 
causes of PID (Table 89.1).
Overall guidelines for HSCT for SCID and 
non-SCID diseases together with detailed proto-
cols have been produced by the EBMT Inborn 
Errors Working Party (EBMT IEWP) and can be 
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Table 89.1 Phenotypic classification of PID as sug-
gested by the International Union of Immunological 
Societies (IUIS) Inborn Errors of Immunity Committee 
(Picard et al. 2018)
1. Combined immunodeficiency (CID)
2. CID with associated or syndromic features
3. Predominantly antibody deficiencies
4. Diseases of immune dysregulation
5. Congenital defects of phagocyte number, function, 
or both
6. Defects in intrinsic and innate immunity
7. Auto-inflammatory disorders
8. Complement deficiencies
9. Phenocopies of PID
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2017.pdf. An update of these guidelines is 
planned for 2018 based on current IEWP 
studies.
89.3  SCID
The overall frequency of SCID was for a long 
time estimated to be 1  in 50,000–100,000 live 
births. However, in recent years newborn screen-
ing programs making use of the T-cell receptor 
excision circles (TREC) technology have demon-
strated that the frequency may actually be two- or 
more-fold higher with clear geographical and 
ethnic differences (Kwan et  al. 2014; Rechavi 
et al. 2017).
The immunological phenotypes of SCID are 
shown in Table  89.2 representing monogenic 
inherited defects in T-, B-, and NK-cell differen-
tiation leading to the absence or inactivity of cor-
responding mature cells. Over the past two 
decades, the genetic basis of an increasing num-
ber of SCID variants has been identified 
(Table  89.2) leading to modifications in trans-
plant strategy dependent on the underlying defect 
particularly in SCID variants caused by defects in 
DNA repair genes.
In the absence of newborn screening pro-
grams, most patients present within the first 
3–6 months with unusually severe and recurrent 
infections or with opportunistic infections, the 
most common being Pneumocystis jiroveci pneu-
monia. Other common symptoms include diar-
rhea, dermatitis, and failure to thrive. Survival in 
SCID patients depends on expeditious T-cell 
reconstitution, and in the absence of successful 
HSCT, or in selected cases autologous stem cell 
gene therapy, most children die usually during 
the first year of life from overwhelming infec-
tion. It is recognized that as many as 50% of 
SCID patients are engrafted with maternal T-cells 
but in most instances these cells do not initiate 
GvHD.  Transfusion-associated GvHD, on the 
other hand, is frequently lethal in SCID, and any 
patient with a possible diagnosis of SCID should 
receive irradiated blood products. Bacille 
Calmette-Guérin (BCG) vaccination can give rise 
to disseminated BCG-osis in SCID patients and 
should be avoided at birth if there is any suspi-
cion or family history of immunodeficiency.
89.3.1  General Principles in Allo- 
HSCT for SCID
The Stem CEll Transplant for primary Immune 
Deficiencies in Europe (SCETIDE) registry has 
now collected data on SCID transplants compris-
ing 50 years of HSCT experience, and a number 
of important publications have documented the 
outcomes and important risk factors (Fischer 
et  al. 1990; Antoine et  al. 2003; Gennery et  al. 
2010). Recently, studies from the North American 
group have reported similar findings (Pai et  al. 
2014; Heimall et  al. 2017). The major factors 
influencing outcome reported in these studies 
include:
 1. Preceding comorbidity (particularly infec-
tious complications at HSCT) adversely 
affecting outcome
 2. The type of donor with matched sibling donors 
having the best outcome1
1 Recent data show that the type of donor and the immuno-
logical SCID phenotype have an ever-diminishing influ-
ence on outcome.
Table 89.2 Gene defects typically associated with spe-
cific SCID phenotypes
























Adapted from Picard et al. (2018)
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 3. The type of SCID, with T-B- forms of SCID 
having an inferior outcome (see footnote 1)
 4. Age at transplant with patients <3.5  months 
having a favorable outcome
89.3.2  Matched Sibling Donor HSCT 
for SCID
During the last decade, the overall survival for 
MSD HSCT in SCID has improved to over 90%. 
Somewhat remarkably, sibling donor BM may be 
infused into SCID recipients without the require-
ment for conditioning or GvHD prophylaxis. 
Infusion of sibling BM leads to the rapid devel-
opment of T- and B-cell function post-HSCT, 
although usually only T-cells of donor origin 
develop and myeloid and erythroid cells remain 
of recipient origin. In T-/B+ SCID, the majority 
of patients achieve humoral reconstitution despite 
lack of donor B-cells, whereas following uncon-
ditioned HSCT in T-/B- SCID immunoglobulin 
dependence often persists.
89.3.3  Other Matched Family 
and URD HSCT for SCID
Overall survival rate following phenotypically 
matched related as well as URD transplants has 
steadily improved and is approaching MSD results 
(Gennery et al. 2010; Pai et al. 2014; Heimall et al. 
2017). It is generally considered that the risk of 
rejection and particularly GvHD is too high for 
simple infusion of phenotypically matched mar-
row into SCID patients, so conditioning/GvHD 
prophylaxis is recommended. In a recent transat-
lantic study, survival rate in unconditioned URD 
HSCT was comparable with MSD HSCT, how-
ever at the expense of increased acute GvHD and 
inferior B-cellular immune reconstitution (Dvorak 
et  al. 2014). A variety of conditioning regimes 
have been used, and current IEWP recommenda-
tions include the use of an IV BU/FLU- or TREO/
FLU-based protocol (details at http://www.ebmt.
org/5WorkingParties/IEWP/wparties-ie5.html). 
Comparison of survival rates and immune func-
tion with these regimens is part of ongoing studies.
89.3.4  HLA-Mismatched Family 
Donor for SCID
Virtually all children have a haploidentical paren-
tal donor, and this is an alternative option espe-
cially as the donor is readily available. HLA 
disparity necessitates rigorous in vitro or in vivo 
TCD in order to avoid GvHD. Using mobilized 
PBSC as a preferred stem cell source, most cen-
ters employ either CD34-positive selection or 
CD3-/CD19-negative depletion methods to 
achieve a 4–5 log TCD achieving a threshold of 
1–5  ×  104/kg CD3+ cells, below which GvHD 
prophylaxis is not required.
More recently, alternative haploidentical pro-
cedures including TCR alpha/beta depletion 
(Balashov et  al. 2015; Shah et  al. 2018) and 
PT-CY have emerged as HSCT options. Although 
promising survival rates have been reported, lon-
ger follow-up in a larger cohort of patients is 
required to determine the position of these 
approaches.
Some centers advocate performing transplants 
without the use of any conditioning, and survival 
rates of over 80% have been reported (Dvorak 
et al. 2014). However, the best results are seen in 
those transplanted at <3.5 months of age and in 
the absence of active infections. Despite general 
improvements in survival rate, the best results are 
still seen in the T-B+ subgroup of SCID patients. 
Even in these cases, B-cell function is only 
restored in the minority of patients. Conditioning 
regimes can be used to improve outcome, but the 
use of MAC regimes in children often <1 year of 
age is associated with significant comorbidity 
and leads to survival figures of 50–60%. 
Individualized approaches making use of thera-
peutic drug monitoring or antibody-based condi-
tioning strategies may provide novel and less 
toxic options to improve HSCT outcome in these 
vulnerable young infants.
89.3.5  Unrelated CBT for SCID
During the last decade, the availability of CBU 
plus the increased level of HLA matching degree 
has made CB a suitable alternative source of stem 
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cells (Fernandes et  al. 2012). There are some 
theoretical advantages for the use of cord blood 
stem cells for SCID, namely, rapid availability, as 
with haplotype-matched parental donors but with 
no requirement for TCD; less risk of GvHD com-
pared to adult URD; no medical risk to the donor; 
and a greater proliferative life span which might 
be particularly important in such young recipi-
ents. Moreover, the usual limitation of cell dose 
in CBT is usually no issue in infants with 
SCID.  There are also some specific disadvan-
tages including slower engraftment, lack of viral- 
specific cytotoxic T-cells, and lack of availability 
of the donor for a boost HSCT.
89.3.6  Omenn’s Syndrome
Omenn’s syndrome (OS) is characterized by 
SCID typically associated with the triad of eryth-
roderma, hepatosplenomegaly, and lymphade-
nopathy. There is a marked eosinophilia and a 
variable number of autologous, activated, and 
oligoclonal T lymphocytes (leaky SCID/CID), 
which infiltrate target organs and are generally 
poorly responsive to mitogens. Whereas out-
comes in HSCT for OS were traditionally more 
difficult compared the classical SCID, results 
have improved in recent years (Gennery et  al. 
2010; Heimall et al. 2017). The overall mortality 
in these studies was lower than previously 
reported and was due to early recognition of OS 
and rapid initiation of treatment with topical/sys-
temic immune suppression with steroids and/or 
cyclosporin A to control immune dysreactivity 
before proceeding to HSCT.
89.3.7  HSCT for Radiosensitive SCID
Patients with T-B- SCID due to radiosensitive 
disorders such as DNA ligase 4 deficiency, 
Cernunnos deficiency, DNA-PKcs deficiency are 
increasingly being identified and being consid-
ered for HSCT. As many of the conditioning regi-
mens are particularly damaging to DNA, less 
toxic regimens are required to successfully treat 
these patients (Slack et  al. 2018). No definitive 
studies are available, but a low-dose FLU/CY 
regime has been suggested by the EBMT IEWP 
(http://www.ebmt.org/5WorkingParties/IEWP/
wparties-ie5.html).
89.4  Non-SCID Immunodeficiency
From a HSCT viewpoint, the major difference 
with non-SCID patients in comparison with 
SCID patients is the requirement for a condition-
ing regimen to achieve engraftment. It is the goal 
to establish sufficient long-term donor chimerism 
in the affected cell lineage. The required degree 
of donor chimerism for full disease correction 
varies depending on PID and has not been estab-
lished for all entities.
Many children with non-SCID PID have 
 significant comorbidities at the time of HSCT. 
Conventional MAC preparation with BU-/
CY-based regimes has historically been associ-
ated with significant treatment-related toxicity 
and TRM. The Inborn Errors Working Party of 
EBMT has therefore in 2005 published detailed 
recommendations for conditioning and PID as 
discussed above. These recommendations 
include:
 1. Replacement of CY with FLU, as the combi-
nation of BU/FLU appears to be better toler-
ated in these patients
 2. Adding the option to replace BU with a struc-
tural analogue, TREO, which is similarly 
immuno- and myelosuppressive but causes 
less hepatic SOS/VOD (Slatter et al. 2018)
 3. Establishing RIC to achieve stable engraft-
ment of immunocompetent donor cells with 
reduced procedure-related morbidity and 
mortality (Veys 2010)
The latest outcome data for HSCT in non- 
SCID patients come from Europe (Gennery et al. 
2010). In the 2000–2005 period, HSCT using an 
URD (n = 124) gave a 3-year survival rate similar 
to a genoidentical donor (n = 73), 79% for both. 
Survival was 76% in phenoidentical transplants 
(n = 23) and worse in mismatched related donor 
transplants (n = 47, 46%, p = 0.016), in contrast 
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to SCID patients (see above). Ten-year survival 
was significantly better for patients with WAS, 
phagocytic, and hemophagocytic disorders than 
for patients with T-lymphocyte immunodeficien-
cies (71, 63, 58, 47%, respectively).
Unrelated CB donors appear to also give 
promising results in non-SCID immunodefi-
ciency with 29/32 (91%) patients surviving CBT 
matched for 4–6/6 HLA antigens.
The landscape of non-SCID PID and HSCT 
has dramatically changed over the last decade:
• HSCT outcomes have further improved with 
80–90% overall survival and low GVHD rates 
after MSD or MUD HSCT in almost every 
non-SCID PID entity (Güngör et al. 2014; 
Moratto et al. 2011).
• Haplo-HSCT has become a safe alternative, at 
least in the hands of experienced centers 
(Balashov et al. 2015; Shah et al. 2018).
• New genetic causes of PID are being described 
in accelerating frequency thanks to next- 
generation sequencing techniques.
• The concept of “pure” immunodeficiencies 
with predisposition to infections has been 
abandoned with newly described autoim-
mune, auto-inflammatory conditions or syn-
dromal disorders with immunodeficiency. 
Many of these diseases can be cured by HSCT, 
while in syndromal disorders only the hema-
topoietic portion of the disease can be cor-
rected, which may nevertheless be indicated 
and result in not just increased survival but 
also quality of life in selected patients.
• More PID patients are discovered with very 
mild or atypical phenotypes of well-known 
PID, and these often hypomorphic genetic 
variants are especially challenging with 
respect to timely recognition and management 
(Notarangelo et al. 2016).
• Especially in these “milder” cases, quality of 
life is increasingly a factor in HSCT decision 
making, especially compared to diseases with 
an immediate indication for HSCT such as 
SCID (Cole et al. 2013).
• The importance of DFS as compared to OS is 
increasingly appreciated and addressed in 
medium- to long-term outcome studies, also 
in comparison to non-HSCT approaches 
(Speckmann et al. 2017; Barzaghi et al. 2018).
• Adolescents and young adults with PID are 
appreciated as candidates for HSCT, and out-
comes are encouragingly good (Albert et  al. 
2018; Fox et al. 2018).
• Patients with DNA double-strand repair 
 disorders can safely undergo HSCT with 
irradiation- free, reduced-intensity regimens 
(Slack et al. 2018).
The consequence of all this has been that 
many more patients with PID are today consid-
ered for, referred for, and counselled about 
HSCT. On the other hand, it has made decision 
making with respect to HSCT much more diffi-
cult. A genetic diagnosis may make the decision 
to proceed to HSCT easier in patients with severe 
symptoms, but a genetic diagnosis alone should 
never be sufficient to indicate HSCT.
89.5  Alternative Therapies
Alternative treatments to HSCT have been devel-
oped for specific immunodeficiencies over the 
last three decades.




Enzyme replacement has been used in the treat-
ment of ADA deficiency since 1987 (Chan et al. 
2005). PEG-ADA is administered weekly or 
twice weekly by IM injection and leads to rapid 
metabolic correction with normalization of meta-
bolic parameters which is then followed by cel-
lular and humoral immune reconstitution. The 
extent of immune recovery is variable, and a sig-
nificant number (~50%) remain on Ig replace-
ment. Over a longer time period, patients show a 
decline in T-cell numbers and remain lymphope-
nic. Long-term follow-up shows that patients 
remain clinically well, but a number of cases of 
EBV-related lymphoma have been reported, sug-
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gesting decreased immune surveillance with 
time. Given the improved outcomes of HSCT in 
recent times and the availability of gene therapy, 
ERT may predominantly be considered a bridge 
to stem cell-based curative therapy.
89.5.2  Gene Therapy for Specific 
Immune Deficiencies
Autologous stem cell gene therapy (GT) via 
vector- mediated transfer of healthy copies of an 
affected gene into autologous CD34+ cells has 
progressed from a highly experimental therapy to 
the first licensed gene therapy for a PID (ADA- 
SCID) within the last two decades. One of the 
major advantages of GT is the elimination of the 
inherent risk of GVHD connected to any HSCT 
procedures.
Clinical trials performed with gamma retro-
viral vectors for ADA-SCID, X-linked SCID 
(SCID-X1), chronic granulomatous disease 
(CGD), and Wiskott-Aldrich syndrome (WAS) 
demonstrated that gene therapy can be an effec-
tive treatment option in patients lacking an 
HLA- identical donor (Hacein-Bey-Abina et al. 
2002; Boztug et  al. 2010; Stein et  al. 2010; 
Aiuti et al. 2009). However, a high rate of inser-
tional mutagenesis was observed in trials for 
SCID-X1, WAS, and CGD but not for ADA-
SCID (Ott et al. 2006; Hacein-Bey-Abina et al. 
2003; Braun et al. 2014). This has prompted the 
development of safer vectors based on self-
inactivating retroviral or lentiviral vectors. 
Currently, a number of trials are ongoing or 
concluded for the diseases named above. All 
share the concept of submyeloablative or lym-
phodepleting conditioning followed by the 
infusion of auto-HSCT with added copies of 
the gene of interest. Promising results were 
published, especially for ADA-SCID (Cicalese 
et  al. 2016), WAS (Aiuti et  al. 2013) and 
SCID-X1 (Hacein-Bey-Abina et al. 2014). It is 
expected that gene editing approaches as alter-
native for gene addition technologies as cur-
rently employed will be developed in the next 
few years and may be employed to correct 
mature cells in diseases like CD40 ligand defi-
ciency and IPEX Syndrome, as well as HSC.
In theory autologous stem cell gene therapy 
offers the appealing prospect of avoiding alloim-
mune reactions such as GVHD or rejection and a 
lower conditioning-related toxicity compared to 
allo-HSCT. But its exact role in treatment algo-
rithms still needs to be defined in the absence of 
comparative studies. Also, logistic, regulatory, 
and economic hurdles still have to be overcome 
before its widespread application in the treatment 
of PID.  Nevertheless, it has widened the thera-
peutic repertoire for patients with some PID. The 
rapid evolution of novel gene correction 
approaches promises to lead to even safer and 
more effective treatment options.
89.5.3  Targeted Therapies
The unravelling of new genetic PID entities, 
especially those caused by gain-of-function 
(GOF) variants and their pathophysiology, has 
for the first time opened the possibility to treat 
these diseases with highly specific, often small 
molecule inhibitors, some of which are already 
approved for other indications. These include but 
are not limited to abatacept for CTLA4 haploin-
sufficiency, ruxolitinib for STAT1 GOF, leni-
olisib for PIK3CD and PIK3R1, etanercept for 
ADA2 deficiency, and IL-1-targeted therapies 
(anakinra, rilonacept, and canakinumab) for 
auto-inflammatory recurrent fever syndromes 
(Jhamnani and Rosenzweig 2017; Ochs and 
Petroni 2018). At this point in time, the exact role 
of these agents in the treatment algorithm of PID 
is however unclear. Ideally, they could make 
HSCT unnecessary for some patients. On the 
other hand, concerns about long-term infection 
(and lymphoma) risk exist. In any case, in some 
patients with excessive autoimmunity and/or 
inflammation, these therapies can be viewed as 
an ideal bridge to HSCT and considered as a 
remission induction strategy to control the under-
lying PID, because they have the ability to bring 
the patient into the best possible clinical condi-
tion for HSCT.
M. Albert et al.
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Inborn Errors of Metabolism 
and Osteopetrosis
Robert Wynn and Ansgar Schulz
90.1  Inborn Errors of Metabolism
90.1.1  Definition and Epidemiology
Inborn errors of metabolism (IEM) comprise a 
large group of inherited disease, some of which 
are due to disordered lysosomal, peroxisomal, or 
mitochondrial function and only some of which 
might be improved following HSCT. This review 
will be limited to the commoner indications 
reported in HSCT registries and which together 
account for the most transplanted IEM.
90.1.2  Diagnosis
Timely diagnosis is imperative in IEM since in 
all such diseases HSCT is better at preventing 
disease progression than reversing established 
disease manifestations.
Diagnosis is made in three ways:
 – Through early recognition of disease 
manifestations
 – Through screening of presymptomatic indi-
viduals within a known affected kindred
 – Population screening for disease, such as in 
the neonatal period
90.1.3  Classification (See Table 90.1)
90.1.4  Risk Factors
Patient performance score at transplant predicts 
transplant outcome. Patients with an adverse 
performance score at transplant also have an 
inferior long-term survival as the transplant 
fails in advanced disease to prevent disease 
progression.
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90.1.5  Prognostic Index
Not available
90.1.6  First-Line Treatment 
(Summary)
Multimodality therapies are usual in IEM.
 – Residual disease manifestations will require 
management beyond the HSCT episode. This 
will include orthopedics, ENT, and speech 
therapies in lysosomal storage disorders 
(LSDs), as well as family and educational sup-
port in all.
 – Pharmacological enzyme replacement therapy 
(ERT) is used in MPSI but does not correct 
neurological disease as it does not cross the 
blood-brain barrier, and alloantibody forma-
tion might limit its utility in somatic disease. It 
is used to improve pre-HSCT performance, 
but it has not been shown to influence trans-
plant outcomes.
90.1.7  Second-Line Treatment 
(Summary)
See Sect. 90.1.6., above.
90.1.8  Autologous HSCT
Gene-modified auto-HSCT approaches have been 
shown to improve outcomes in late infantile MLD 
as the graft delivers more enzyme than possible in 
a conventional HSCT.  Similar approaches have 
been successful in X-ALD and are likely to be a 
significant part of the future of HSCT in IEM.
Table 90.1 Classification of inborn errors of metabolism
IEM
Hurler syndrome,  
MPSIH
Hurler syndrome. This is the most severe phenotype of iduronidase 
deficiency, a lysosomal storage disorder (LSD) which results in the 
accumulation of glycosaminoglycans. There is progressive multi-
organ dysfunction including psychomotor retardation, severe skeletal 
disease, life-threatening cardiopulmonary complications, and 
premature death
HSCT prevents early death and attenuates the multi- system disease 
manifestations as the deficient enzyme is donated by engrafted donor 
leucocytes to host tissues (“cross-correction”)
X-linked  
adrenoleukodystrophy
In this X-linked disorder, there is accumulation of very long-chain fatty 
acids in the brain and adrenal glands arising from their defective 
metabolism by a peroxisomal, membrane protein encoded by the ABCD1 
gene
Clinical manifestations in genetically affected boys are highly variable, 
even within a kindred. The principle role of HSCT is to prevent 
progression of early cerebral ALD, an inflammatory demyelinating 
disease of childhood that is seen in about 40% of genetically affected 
individuals
HSCT does not influence other illness such as adrenal insufficiency or the 
later myeloneuropathy of the spinal cord
Metachromatic  
leukodystrophy (MLD)
This is a recessive LSD, and there is accumulation of sulfatides, a myelin 
component, due to deficiency of the arylsulfatase A enzyme. There is 
demyelination in the central and peripheral nervous systems, and clinical 
manifestations are related to residual enzyme activity. In the late infantile 
disease, the commonest and most severe phenotype, there is progressive 
neurological dysfunction and early death usually by the age of 4 years
HSCT is ineffective in preventing progression of early presenting disease, 
although it may have a greater impact later, attenuated disease especially 
when applied early in the course of that illness
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90.1.9  Allogeneic HSCT in MPSIH (Hurler), MLD, and X-ALD (See Table 90.2)
90.2  Osteopetrosis
90.2.1  Definition and Epidemiology
Osteopetrosis (OP) is a generic name of a number 
of rare single gene diseases characterized by scle-
rosis of the skeleton. At least nine forms are 
known with different modes of inheritance and 
severity, which cumulatively have an incidence 
~1:100,000. The disease originates from reduced 
or complete lack of osteoclast function and, as a 
consequence, impairment of bone resorption
Table 90.2 Main characteristics of allo-HSCT for MPSIH (Hurler), MLD, and X-ALD
Indicated in
MPSIH (Hurler) is a standard indication for HSCT
In MLD, HSCT is usually reserved for later (attenuated) forms of the disease, namely, juvenile and adult forms
In X-ALD, HSCT is indicated in early cerebral inflammatory disease. Ordinarily, a genetically affected individual 
has serial (annual) MRI scans from early childhood, and HSCT is carried out when there are early MRI changes of 
demyelination (the MRI changes are scored as a Loes score)
Contraindications
Where MPSIH is diagnosed late then the opportunity for HSCT to meaningfully alter the natural history of the 
disease might be lost. No hard and fast rules can be applied, but often HSCT is not offered to a child presenting 
beyond the age of 30 months, but careful multidisciplinary assessment is required
Late infantile MLD is not usually considered for HSCT. Note that such disease—if diagnosed in a timely fashion—
has been shown to be markedly improved using an autologous, ex vivo HSC gene therapy approach
Advanced cerebral X-ALD is considered a contraindication to HSCT. Disease will progress through transplant. The 
MRI scan-derived Loes score might predict those that will benefit most from HSCT
Donor
In LSD, non-carrier MFD > MUD > carrier MFD
In LSD, UCB is frequently preferred to BM, since the post-HSCT chimerism is higher in scuh recipients, and the 
interval between referral and HSCT is likely shortest (rejection might be higher using UCB)
PB is rarely used as a donor cell source
In X-ALD, MFD > MUD
Haplo-HSCT is rarely indicated in IEM
Conditioning:  standard
Engraftment is difficult in IEM. Generally reduced intensity conditioning and ex vivo TCD are associated with high 
rates of graft loss
MSD/MFD: IV BU (MAC AUC)/FLU (160 mg/m2)
MUD: IV BU (MAC AUC)/FLU (160 mg/m2)
Conditioning:  reduced toxicity
Occasionally reduced toxicity conditioning might be employed
In somatic IEM, such as Wolman or attenuated MPS: TREO/FLU (160 mg/m2)/TT (10 mg/kg)
Source of SC
UCB often preferred in LSD
BM rather than PB in MUD donors




MUC UCB: Proximal ATG, CSA + MMF or CSA + PRD
TRM in MPSIH OS in MPSIH
MSD: < 5%
MUD: <10%
Engrafted survival of >80% and
overall survival of 90%
MAC AUC doses adjusted to achieve MAC AUC, MSD match sibling donor, MFD match family donor, MUD much 
unrelated donor, LSD lysosomal storage disorder, EIM inborn errors of metabolism
90 Inborn Errors of Metabolism and Osteopetrosis
674
90.2.2  Diagnosis
In addition to the obligate increased bone density of 
all bones (X-ray), a combination of symptoms can 
be found in classical infantile osteopetrosis after 
birth. These symptoms include characteristic 
changes of the head (macrocephalus, frontal boss-
ing, choanal stenosis), vision impairment (due to 
narrowed foramina), hematological insufficiency 
(thrombocytopenia, anemia, leukocytosis), hepato-
splenomegaly (due to extramedullar hematopoiesis), 
and hypocalcemia (with secondary hyperparathy-
roidism). Cave: OP is a genetical and phenotypical 
heterogenous disease with atypical presentations 
(incomplete and/or delayed onset of symptoms). In 
these cases, an intensive work-up including spine 








Clinical symptoms in infancy, death 
without HSCT usually in the first 
decade of life, biallelic mutations in 
TCIRG1, CLCN7, SNX10, TNFRSF11A/ 
RANK, and FERMT3/KINDLIN-3; 
HSCT indicated, if excluded:
 –  “Neurodegenerative OP” (all OSTM1 
and about half of CLCN7 cases)




Clinical symptoms in the first decade, 
HSCT may be indicated in severe 
forms with hematological insufficiency 
and (imminent) visual impairment
Specific from: CA2 deficiency (renal 
tubular acidosis with cerebral 




M. Albers Schoenberg (monoallelic 
CLCN7 mutations): HSCT not indicated
90.2.4  Risk Factors
There is an increased risk of pulmonary hyper-
tension (pre and post HSCT) and SOS/VOD 
(post BMT). The risk of non-engraftment and 
rejection increases with severity of disease and 
age.
90.2.5  Prognostic Index
Not available
90.2.6  First-Line Treatment 
(Summary)
Symptomatic, steroids may be beneficial to 
improve hematological symptoms
90.2.7  Second-Line Treatment 
(Summary)
Not available
90.2.8  Autologous HSCT
Preclinical trials for gene-modified auto-HSCT 
for TCIRG1 defects in preparation.
90.2.9  Allogeneic HSCT 
(See Table 90.3)
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Table 90.3 Main characteristics of allo-HSCT for osteopetrosis
Indicated in Infantile osteopetrosis: clinical symptoms and exclusion of neurodegenerative and extrinsic 
osteoclast defect
Contraindications Neurodegenerative osteopetrosis: symptoms (non-hypocalcemic convulsions/EEC changes, 
severe progredient developmental delay) and/or biallelic mutations in OSTM1 and CLCN7; cave: 
only about half of CLCN7 mutations cause neurodegeneration
Osteopetrosis not intrinsic to defects in differentiation or function in osteoclasts: TNFSF11/
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post Cy protocol
In patients >10 months of age and haplo donors, an adapted PT-CY protocol should be 
considered (see updated EBMT guidelines)
Source of SC Matched donors, PT-CY protocol: T replete BM > PB
Haplo (standard protocol): TCD PB
GvHD 
prophylaxis
MSD/MFD: CSA + MMF (consider ATG or Campath in MFD)
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Haplo—TCD: ATG (or Campath), consider MMF
Haplo—T replete: Campath, PT-CY, TAC (or CSA) + MMF
TRM MSD/MUD: 10–20%




MAC AUC doses adjusted to achieve MAC AUC, MSD match sibling donor, MFD match family donor, MUD much 
unrelated donor, MMUD mismatch unrelated donor
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Autoimmune diseases (ADs) are a heterogeneous 
group of diseases affecting 8–10% of the Western 
population, which constitute a heavy burden to 
society and are often debilitating and disabling 
for affected individuals. Current therapeutic 
strategies for AD are based on systemic immuno-
suppression (IS), which ameliorates symptoms 
and halts progression in the vast majority of 
patients, but usually require continuous adminis-
tration and may be associated with long-term 
side effects and substantial costs. Although intro-
duction of modern biological therapies dramati-
cally improved the treatment landscape in AD, 
cure remains elusive, and many patients still suf-
fer from progressive disability with shortened life 
expectancy and comorbidity.
Initially supported by preclinical animal 
models and ‘serendipitous’ case reports, auto-
HSCT has grown as a promising and feasible 
treatment option for severe treatment-resistant 
patients, especially in diseases for which effec-
tive therapies are lacking. Allo-HSCT has also 
been undertaken, although caution related to its 
intrinsic risks has precluded widespread 
application.
Following the first international meeting for 
the use of HSCT in AD in September 1996, the 
EBMT Autoimmune Diseases Working Party 
(ADWP) was established in 1997 by Alois 
Gratwohl, Alberto Marmont, Alan Tyndall and 
Athanasios Fassas, who developed the registry 
covering AD indications and produced early 
guidelines based on consensus opinion (Tyndall 
and Gratwohl 1997).
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Subsequently the ADWP built productively on 
these initial achievements, generating studies 
from the growing registry and developing rela-
tionships with other specialist societies, culmi-
nating with successful publication of three 
randomised controlled trials (van Laar et  al. 
2014; Mancardi et al. 2015; Hawkey et al. 2015) 
along with updated guidelines for clinical prac-
tice (Snowden et al. 2012) and immune monitor-
ing and biobanking (Alexander et al. 2015).
With the increase in evidence, the guidelines 
have become more disease specific. A successful 
collaboration involving significant non-European 
collaborating partners resulted in the EBMT 
guidelines for auto-HSCT in systemic sclerosis 
(Farge et al. 2017). A further collaborative review 
with the European Crohn’s and Colitis 
Organisation (ECCO), which has recently been 
published, includes recommendations for patient 
selection, transplant technique and follow-up of 
HSCT in patients with Crohn’s disease (Snowden 
et al. 2018). Guidelines for MS and neurological 
diseases are in preparation.
The current state of the EBMT database in 
relation to various ADs is summarised in Tables 
91.1 and 91.2. At the time of writing, over 2500 
patients receiving HSCT for an AD have been 
reported to the EBMT, the largest international 
database, with activity reported to other regis-
tries adding substantially to the worldwide 
numbers. The most recent EBMT activity sur-
vey identified autoimmune diseases as the fast-
est growing indication group for HSCT 
(Passweg et  al. 2018). Based on this reported 
activity, this chapter will cover the main neuro-
logical, rheumatological and gastroenterologi-
cal indications for auto- HSCT, along with 
reference to the rare AD indications and alloge-
neic HSCT.  More detailed literature can be 
sourced from recently published reviews 
(Snowden et  al. 2017, 2018; Burt and Farge 
2018; Alexander and Hiepe 2017).
91.2  HSCT for Multiple Sclerosis 
(MS)
Since the first case report of using auto-HSCT as 
a treatment for MS was published in 1995, the 
EBMT registry has now accumulated over 1000 
patients (Table 91.2). This treatment was initially 
used in patients with advanced progressive dis-
ease as a rescue therapy with limited efficacy. 
More recently, its use in patients with active 
relapsing MS has been associated with prolonged 
clinical and MRI responses and, in some cases, 
significant improvement in disability to a degree 
rarely seen with other disease-modifying drugs 
(Muraro et al. 2017). Only one randomised con-
trolled phase II trial of auto-HSCT has been 
reported in the literature (Mancardi et al. 2015). 
The bulk of the data has been provided by obser-
vational cohort studies in which patients failing 
to respond to standard disease-modifying drugs 
were treated with HSCT. Burman et al. identified 
the four most rigorously conducted cohort stud-
ies in which a total of 188 relapsing MS patients 
received auto-HSCT (Burman et  al. 2018). In 
these studies, PFS was observed in 70–91% of 
patients at 5 years (where progression is defined 
as a deterioration of at least 0.5–1 points from 
baseline in the Expanded Disability Status Scale 
or EDSS). Furthermore, no evidence of disease 
activity (NEDA), defined as the absence of clini-
cal relapses, disability progression, and MRI dis-
ease activity, was observed in 70–92% of patients 
at 2  years post-transplantation (Burman et  al. 
2018; Burt et al. 2015; Atkins et al. 2016; Nash 
et al. 2017).
The conditioning regimens used in MS vary 
between treatment centres. The balance of effi-
cacy and acceptable safety profile of ‘intermedi-
ate intensity’ regimens, i.e. either the specific 
‘BEAM  +  ATG’ regimen or the more generic 
regimen of CY 200 mg/kg combined with ATG, 
led to their recommended use in the current 
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EBMT ADWP guidelines (Snowden et al. 2012). 
More recent data suggests that ‘high-intensity’ 
regimens, incorporating BU, have higher rates of 
PFS but potentially greater toxicity, including 
TRM (Atkins et al. 2016). Retrospective registry 
data suggest that graft purging has no added ben-
efit to the transplant outcome (Snowden et  al. 
2012).
Currently, auto-HSCT is considered to be 
most effective in patients with relapsing MS, who 
are not older than 45 years, have had the illness 
for less than 10  years, are not very disabled 
(EDSS ≤6) and have very active disease with evi-
dence of enhancement on their MRI (Muraro 
et  al. 2017). An international randomised con-
trolled phase III trial is currently being conducted 
to compare auto-HSCT with currently available 
MDTs (MIST Study, ClinicalTrials.gov 
Identifier: NCT00273364) and is anticipated to 
report in full in 2021.
91.3  HSCT for Systemic Sclerosis 
(SSc)
Over the past 10  years, results from large 
European prospective observational studies con-
firmed that SSc patients benefit only marginally 
from standard immunosuppressive drugs, includ-
ing CY, with a progressive increase in SSc- 
specific mortality, predominantly related to 
cardiac (31%) and pulmonary causes (18%). 
Indications for auto-HSCT in SSc have increased 
(Snowden et al. 2018) since three successive ran-
domised trials, namely, ASSIST (Burt et  al. 
2011), ASTIS (van Laar et al. 2014) and SCOT 
(Sullivan et  al. 2018), have now demonstrated 
that auto-HSCT is superior to CY for early rap-
idly progressive SSc in terms of long-term sur-
vival as well as improvement of lung function 
and skin fibrosis.
In addition, patient selection was shown to 
directly affect transplant outcomes (Farge et  al. 
2017) with specific concern for cardiac involve-
ment, undetected by echocardiography alone, 
becoming clinically overt during the transplant 
procedure, under the stress of fluid overload, CY 
and ATG administration and sepsis. Current 
guidelines recommend auto-HSCT for patients 
with early diffuse SSc with a modified Rodnan 
skin score ≥15 plus major organ involvement in 
respiratory, cardiovascular or renal systems and 
treatment should be performed in JACIE- 
accredited centres where combined expertise 
from SSc disease specialist and dedicated trans-
plant team can assess and follow patients before, 
Table 91.2 Distribution of diagnosis in the EBMT database (October 2018)
Multiple sclerosis (MS) 1285 Haematological diseases 113
Connective tissue diseases 735 immune thrombocytopenia purpura (ITP) 33
Systemic sclerosis 559 Haemolytic anaemia 27
Systemic lupus erythemathosus 117 Evans syndrome 25
Polymalgia/dermatomyositis 18 Other 28
Sjögren’s syndrome 5 Vasculitis 56
Antiphospholipid syndrome 6 Granulomatosis with polyangiitis (GPA) 14
Other 30 Behcet's disease 11
Arthritis 186 Takayasu’s arteriitis 2
Rheumatoid arthritis 82 Microscopic polyangiitis (MPA) 3
Juvenile chronic arthritis (JIA): Polyarteritis nodosa (PAN) 1
 • Systemic JIA 59 Eosinophilic granulomatosis with polyangiitis (EGPA) (EGPA) 2
 • Other JIA 18 Other 23
 • Polyarticular JIA 17 Other neurological diseases 114
Psoriatic arthritis 3 Chronic inflammatory demyelinating polyneuropathy (CIDP) 52
Other 7 Neuromyelitis optica 26
Inflammatory bowel diseases 220 Myasthenia gravis 8
Crohn's disease 182 Other 28
Ulcerative colitis 4 Insulin dependent diabetes mellitus (IDDM) 20
Other 34 Other 51
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during and after the procedure according to Good 
Clinical Practice (Snowden et  al. 2018). Since 
toxicity and efficacy arise from individual patient 
selection and the conditioning regimen, different 
chemotherapies may account for subtle differ-
ences in results, and further studies are warranted 
to analyse the use of attenuated conditioning reg-
imen, according to cardiac function and risk for 
renal crises (Burt and Farge 2018).
91.4  HSCT for Systemic Lupus 
Erythematosus (SLE)
Following the first transplant performed in 1996 
by Alberto Marmont and colleagues, several 
phase I/phase II clinical trials have been reported 
covering approximately 300 SLE patients world-
wide to date (Alexander and Hiepe 2017). The 
two largest experiences on auto-HSCT for SLE 
so far come from EBMT data registry (n = 53; 
mean follow-up, 25 months) and from the single- 
centre trial by Northwestern University (n = 50; 
mean follow-up, 29 months), both demonstrating 
a probability of 5-year DFS of 50% despite dis-
continuation of chronic IS. Subsequently, a fol-
low- up study from the EBMT registry reported 
the outcome of auto-HSCT in SLE with various 
regimens between 2001 and 2008 (n = 28; median 
follow-up, 38  months; range, 1–110  months) 
(Alchi et  al. 2013). Although PFS in this study 
was only 29% at 5  years, TRM had gradually 
improved. In addition, this study indicated that 
CD34-selection was associated with a signifi-
cantly reduced relapse incidence.
More recently, reports from two independent 
Chinese groups, both with 10-year follow-up, 
demonstrated remarkable clinical responses with 
PFS of 86% and 68%, respectively, while TRM 
across both studies was only 2%. Current rec-
ommendations suggest HSCT in patients with 
sustained or relapsed active disease (BILAG cate-
gory A) remaining steroid dependent after at least 
6 months of the best standard therapy (including 
MMF and CY with or without anti- CD20), with 
documented evidence of visceral involvement 
(Snowden et al. 2012). The only controlled study 
conducted to compare auto- HSCT with cur-
rently available MDTs in SLE is currently ongo-
ing in a phase II multicentre trial in Germany 
(ClinicalTrials.gov Identifier: NCT00750971).
91.5  HSCT for Crohn’s 
Disease (CD)
Despite the major recent progress in the treat-
ment of CD, based around corticosteroids, IS 
(thiopurines, MTX) and biologic therapies (Ab 
targeting TNFα, α4β7 integrin or IL-12/IL-23), 
some patients fail all available therapies. In many 
cases, surgery may be an option but may lead to 
short bowel syndrome or to a definitive stoma, 
which may be unacceptable to patients. With this 
background, in the past few years, auto-HSCT 
has emerged as a promising therapy in a subset of 
patients in whom the disease is refractory to all 
available therapies, with progressive tissue dam-
age and potentially reduced life expectancy.
Auto-HSCT has been investigated in several 
studies with encouraging responses, some pro-
longed, although a progressive incidence of 
relapse with long-term follow-up is recognised 
(Burt et  al. 2010; Lopez-Garcia et  al. 2017). 
Furthermore, patients regain response to anti- 
TNF therapy although they had been refractory to 
this drug class prior to HSCT.
In Europe, the EBMT sponsored ASTIC trial 
in patients with refractory CD and produced 
apparently negative results as few patients after 
auto-HSCT met the stringent primary composite 
endpoint of clinical remission for 3  months 
(Hawkey et al. 2015). However, it should not be 
assumed that this single trial provides the defini-
tive answer to the benefit of auto-HSCT in CD, as 
the number of patients included was limited and 
encouraging long-term follow-up of ASTIC trial 
patients has since been reported (Lindsay et  al. 
2017). Encouraging results have also been 
reported by an EBMT retrospective analysis of 
82 treatment-resistant patients who were not in 
the ASTIC trial. In this difficult-to-treat group of 
patients, around a quarter maintained remission 
without further medical therapy, and long-term 
disease control was maintained with 
 reintroduction of salvage therapies in the major-
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ity of patients who relapsed. TRM occurred in 
one patient (Brierley 2018).
Recently, the EBMT ADWP and ECCO 
(European Crohn’s and Colitis Organisation) have 
published a joint position paper of auto- HSCT in 
CD, which recommends auto-HSCT ideally in the 
context of a multicentre clinical trial but on an 
individual basis may currently be considered for 
patients with active CD refractory to IS and bio-
logical treatments or unacceptable risks of surgi-
cal management (Snowden et al. 2018).
91.6  Allogeneic HSCT 
for Autoimmune Diseases
Autoimmune diseases have also been treated 
with allo-HSCT from MRD, URD and CB 
sources. In the last 20 years, the EBMT registry 
has collated 165 cases, representing just 6% of 
the total. Because of the higher procedural risks 
and potential long-term impact on quality of life 
from late effects, allo-HSCT has been largely 
restricted to life-threatening AD in paediatric 
practice with the most common indications in 
immune cytopenia followed by arthritis (Snowden 
et al. 2017). In a recent summary of cases in the 
registry between 1997 and 2015, 105 patients 
undergoing allo-HSCT were treated with condi-
tioning regimens. The median age was 12 years 
(range 1–62). Outcome following first allo-HSCT 
included 3- and 5-year OS of 67% and 64%, PFS 
59% and 56% and incidence of relapse 21% and 
24%, respectively. Compared with auto-HSCT, 
NRM is relatively high at 13% at 100  days, 
although this plateaus at 20% at 3 and 5 years.
In summary, experience in allo-HSCT is lim-
ited, but long-term data is supportive of basic 
biological differences in the responses of AD to 
allo- and auto-HSCT in terms of the ability to 
cure. However, with the risks NRM of around 
20%, allo-HSCT will remain limited and devel-
opmental in its application to AD.  With time, 
allo-HSCT in AD has become safer, perhaps with 
better patient selection, and activity continues, 
particularly in the paediatric field. In addition, 
there has been increasing recognition that the 
nature of the genetic component of some AD 
means that allo-HSCT is the only realistic 
approach for long-term disease control. Thus 
there is renewed interest in this area, particularly 
where there is overlap with autoinflammatory 
and immunodeficiency diseases.
91.7  Other Indications
A variety of other ADs have been treated 
(Table 91.2). Haematological immune cytopenias 
have been treated with a mixture of auto-HSCT 
and allo-HSCT. Type 1 diabetes in early ‘honey-
moon’ phase has been the subject of clinical tri-
als, with some ability to prevent or reduce insulin 
requirements. Otherwise there is a mixture of 
rarer neurological, rheumatological and gastro-
enterological indications for which the registry is 
essential for developing an evidence base. 
Cautious recommendations for these rare indica-
tions are provided in the EBMT ADWP guide-
lines (Snowden et al. 2012).
91.8  Mechanisms of Action
HSCT represented an opportunity to gain insights 
into the aetiology and pathogenesis of 
AD. Through destroying a dysfunctional autore-
active immune system and rebuilding it with 
auto-HSCT, it has been possible to demonstrate 
immune ‘rebooting’ that can occur through thy-
mic reactivation and re-diversification and other 
changes in T-cell and B-cell repertoire and regu-
latory cell function in various disease settings. 
Allo-HSCT has been less well explored, although 
there is an element of immune replacement and 
evidence for a ‘graft-versus-autoimmune effect’ 
(Alexander et al. 2016).
91.9  Conclusions and Future 
Directions
With accumulating evidence and improved out-
comes along with recognition that modern bio-
logical and other therapies are not universally 
effective (Snowden et  al. 2017), ADs have 
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become the fastest-growing indication for HSCT 
(Passweg et al. 2018). Initially applied as salvage 
therapy in patients with poor prognosis, HSCT 
has emerged as a promising treatment option for 
AD patients earlier in the treatment algorithm. 
This is the result of positive results from large 
phase II and randomised controlled phase III tri-
als and updated guidelines for patient selection 
and transplant technique (Snowden et  al. 2012, 
2018; Farge et al. 2017). In 2018, the major indi-
cations for HSCT for AD are MS, SSc and CD 
for which significant subsets of patients still 
show an unsatisfactory response to both conven-
tional and targeted biologic therapies.
Moving forward, further efforts are needed to 
drive HSCT into routine clinical care. It is recom-
mended that patients should be treated in experi-
enced and JACIE-accredited transplant centres in 
a multidisciplinary setting. A future goal is to 
optimise the conditioning regimens according to 
disease-specific requirements and to outbalance 
the intensity to maintain outcomes while mini-
mising toxicity and TRM risk. In addition, com-
prehensive data reporting, harmonisation and 
exploitation of existing biobanking infrastructure 
(Alexander et al. 2015), education at individual 
centre and network level and health economic 
evaluations along with evidence-based recom-
mendations will establish the future place of 
HSCT in the treatment algorithms for various 
autoimmune and inflammatory diseases.
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In the absence of randomized prospective trials, 
the EBMT registry remains an important source 
to survey indications, outcome and clinical risk 
factors in patients with solid tumours treated by 
auto- and allo-HSCT. In early 2018, the EBMT 
registry includes 57,888 transplant procedures in 
42,106 patients, with a slight prevalence in adults 
compared with children (58% vs. 42%). Auto- 
HSCT represents 97% of the total HSCT, whereas 
allo-HSCT was used in 3% of the procedures. 
Multiple transplants were performed in 1/3 of the 
cases (Table 92.1). More than 10,000 transplants 
were performed in the last 5 years (Passweg et al. 
2018). Figures  92.1 and 92.2 compare activity 
and indications between adults and children.




The EBMT registry remains an important source to 
survey indications, outcome and clinical risk fac-
tors in children and adolescents with solid tumours 
treated by high-dose therapy (HDT) and HSCT.
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Table 92.1 EBMT registry on HSCT for solid tumours 
(data updated on January 2018)





Nb of HSCT Auto 
(n = 55,240)
Allo (n = 1755)
First HSCT 40,412 1173
Second HSCT 10,144 440
Third HSCT 3589 100
Fourth HSCT 651 27
≥ Fifth HSCT 194 9
Median follow up 
(year < 2016)








































Fig. 92.1 EBMT registry on auto-HSCT for solid tumours in the period 2012–2017 (n = 9519). Adults vs. paediatric 


















































Fig. 92.2 EBMT registry showing numbers of auto- HSCT for solid tumour indication over the years: 1990/2017 in 
both adults and children
R. Ladenstein et al.
687
In view of evolving diagnostic and therapeutic 
strategies, the definition of high risk needs care-
ful consideration. To date evidence for HDT/
HSCT from prospective randomized trials is still 
limited to high-risk neuroblastoma and Ewing 
sarcoma (Matthay et al. 2009; Whelan 2018).
92.2.2  2018 EBMT Data on HSCT 
for Solid Tumours in Children 
and Adolescents
In 2018 the EBMT database contained informa-
tion on 17,159 transplants in young people with 
solid tumours. Their median age is 5.2  years 
(0.1–18.0); 58% are male. Auto-HSCT is the 
most frequent procedure with 14,135 transplants 
performed, whereas only 446 allo-HSCTs are 
registered. Data was gathered in 43 countries and 
reported by 390 centres. The first HSCT was 
autologous in 16,814 patients and allogeneic in 
345 patients. Table  92.2 summarizes the out-
comes with auto-HSCT for the most frequent 
indications for 13,838 with adequate event infor-
mation in the EBMT database.
92.2.2.1  General Lessons from 
EBMT Data
The experience of more than 17,000 HSCT pro-
cedures in the paediatric age group over 35 years 
conveys a number of important messages:
Transplant-related mortality. TRM markedly 
decreased over time and is related with the HDT 
regimen (i.e. elimination of TBI) and most 
importantly use of peripheral stem cells. TRM 
rates associated to auto-HSCT dropped to under 
5% after 1992 and is since 2012 only 1%.
Total body irradiation. TBI showed no advantage 
in any of the solid tumour indications and 
should thus be avoided in children with solid 
tumours in view of late effects.
Remission status. First-line high-risk patients 
perform significantly better than after relapse. 
Response to induction treatments prior to 
HDT/HSCT is critical in all indications. 
A short summary is:
CR > VGPR/PR > SR/MR > NR (SD) > RR/UR
[CR complete response, VGPR very good partial 
response, PR partial response (>50%), SR sensitive 
relapse = >50% response, MR minor response (<50%), 
NR no response, SD stable disease, RR/UR resistant or 
untreated relapse (<50% response)]
Patients in good response to first-line treatment 
(CR/VGPR/PR) and sensitive relapse (SR) are 
good indications for most high-risk solid tumour 
patients, while patients with stable disease or 
minor response (<50%) (SD/MR) should only be 
considered for well-defined phase I/phase II tri-
als. Patients with no response (NR) or tumour 
progression or resistant relapse (RR) have a very 
short life expectancy even after HDT/HSCT and 
thus should not be considered.
Age (see Table 92.3). Age plays a crucial role for 
outcome predictions. Adolescent age is gener-
ally associated with inferior outcome. While 
age <10  years is a favourable factor in 
 sarcomas (Ewing tumours and rhabdomyosar-
Table 92.2 EBMT database outcomes after HDT/ASCT in paediatric solid tumours
Diagnoses Patients
All patients First line patients Relapsed   patients
p-valuea5-years pSU 5-years pEFS Patients 5-years pEFS Patients 5-years pEFS
Neuroblastoma 7303 0.44 ± 0.01 0.36 ± 0.01 5993 0.37 ± 0.01 432 0.25 ± 0.02 <0.001
Ewing tumors 2886 0.47 ± 0.01 0.40 ± 0.01 2101 0.44 ± 0.01 483 0.29 ± 0.02 <0.001
Wilms tumors 601 0.55 ± 0.02 0.51 ± 0.02 208 0.52 ± 0.04 345 0.53 ± 0.03 0.567
Soft tissue sa. 1097 0.29 ± 0.02 0.24 ± 0.01 673 0.26 ± 0.02 260 0.20 ± 0.03 0.003
Brain tumors 2733 0.45 ± 0.01 0.39 ± 0.01 2020 0.43 ± 0.01 444 0.22 ± 0.02 <0.001
Germ cell tu. 529 0.59 ± 0.03 0.49 ± 0.02 270 0.50 ± 0.03 201 0.44 ± 0.04 0.083
Retinoblastomas 162 0.64 ± 0.04 0.59 ± 0.04 98 0.64 ± 0.05 53 0.50 ± 0.07 0.099
Kidney tumors 73 0.49 ± 0.07 0.48 ± 0.07 30 0.51 ± 0.10 30 0.48 ± 0.10 0.615
Osteosarcomas 290 0.28 ± 0.03 0.24 ± 0.03 129 0.34 ± 0.05 128 0.13 ± 0.03 <0.001
Miscellaneous 784 0.40 ± 0.02 0.33 ± 0.02 511 0.34 ± 0.02 146 0.21 ± 0.04 0.057
aLog-rank test: first line versus relapse patients
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coma), neuroblastoma has an earlier cut-off at 
5  years. Patients with neuroblastoma 
≤18 months at diagnosis need biological pro-
filing and are only eligible with high-risk bio-
logical features, in particular MYCN 
amplification (Canete et al. 2009).
Double HSCT approaches. The EBMT data on 
repetitive HDT/HSCT approaches shows no 
advantage over single HDT/HSCT. However, 
the elective selection of particular poor- 
prognosis patients in phase II settings is a 
likely bias. Recent data from a randomized 
trial in neuroblastoma emerged with superior-
ity for the tandem strategy for high-risk neuro-
blastoma front-line patients (Park et al. 2016).
Busulfan-melphalan. This HDT combination is 
the only one in the EBMT database resulting 
in significantly improved survival rates in neu-
roblastoma and Ewing tumours.
Allo-HSCT. No advantage for allo-HSCT can be 
detected in the EBMT data for any paediatric 
solid tumour indication. The potential bias of 
negative selection of particular poor- prognosis 
patients needs to be considered.
92.2.3  Neuroblastoma
High-risk neuroblastoma (NBL) is defined by 
widespread disease >18 months, including any 
stage and age in the presence of MYCN oncogene 
amplification (Cohn et  al. 2009; Moroz et  al. 
2011). In 2018 standard treatments include multi-
cycle induction, extensive surgery to the primary 
tumour site, HDT/auto-HSCT, at least local 
 radiotherapy and maintenance with 13-cis reti-
noid acid, ideally with ch14.18 antibody- based 
immunotherapy in addition (Park et al. 2016; Yu 
et al. 2010; Ladenstein et al. 2017, 2018).
Age <18  months is an important prognostic 
discriminator (Cohn et  al. 2009; Moroz et  al. 
2011). The European high-risk NBL study 
(HR-NBL-1/SIOPEN) randomized BU/MEL 
and CEM (CBP, VP, MEL) after an adequate 
response to COJEC induction. BU/MEL HDT 
resulted in a better EFS and OS with fewer 
severe adverse events than CEM reporting a 
3-year EFS of 50% (95% CI 45–56) for BU/
MEL versus 38% (32–43) for CEM prior immu-
notherapy was available for all trial patients in 
Europe (Ladenstein et al. 2017).
After decades of dose escalation being 
explored by many teams, the randomized results 
of the ANBL0532 COG as presented at ASCO 
2016 finally found superiority for double HDT/
HSCT [1st HDT, CY and TT; 2nd HDT, CBP, VP 
and MEL (with reduced doses of single HDT 
CEM) vs. single HDT (CEM)/auto-HSCT (Park 
et al. 2016)]. The 3-year EFS and OS were sig-
nificantly higher for tandem transplant patients 
(73.2%; 85.6%) in comparison with the single 
transplant arm (55.5%; 75.8%). Anti-GD2 
antibody- based immunotherapy was beneficial 
for both arms (Yu et al. 2010).
Targeted therapies, in particular iodine- 131- 
metaiodobenzylguanidine (mIBG) therapy with 
and without chemotherapy and/or HDT followed 
by HSCT, have generated increasing interest (Lee 
et al. 2017; Johnson et al. 2011).
Further HDT tandem approaches with or 
without mIBG are currently explored by the 
COG as well as SIOPEN in planned randomized 
Table 92.3 EBMT database outcomes after HDT/ASCT in paediatric solid tumours according to patient age
Diagnoses Patients
Age ≤ 5 years 5 < age ≤ 10 years 10 < age ≤ 18 years
p-valuePatients 5-years pEFS Patients 5-years pEFS Patients 5-years pEFS
Neuroblastoma 7303 5267 0.41 ± 0.01 1742 0.26 ± 0.01 361 0.18 ± 0.03 <0.001
Ewing tumors 2886 388 0.38 ± 0.03 622 0.47 ± 0.02 1913 0.39 ± 0.01 0.001
Wilms tumors 601 201 0.57 ± 0.04 318 0.49 ± 0.03 96 0.43 ± 0.06 0.173
Soft tissue sa. 1097 286 0.30 ± 0.03 287 0.29 ± 0.03 453 0.17 ± 0.02 <0.001
Brain tumors 2733 1243 0.44 ± 0.02 799 0.37 ± 0.02 751 0.33 ± 0.02 0.039
Germ cell tu. 529 165 0.52 ± 0.04 47 0.41 ± 0.08 328 0.49 ± 0.03 0.273
Retinoblastomas 162 132 0.58 ± 0.05 26 0.69 ± 0.10 10 0.50 ± 0.18 0.727
Kidney tumors 73 33 0.51 ± 0.10 22 0.53 ± 0.11 12 0.36 ± 0.15 0.631
Osteosarcomas 290 4 0.75 ± 0.22 35 0.29 ± 0.08 248 0.22 ± 0.03 0.260
Miscellaneous 784 342 0.40 ± 0.03 145 0.23 ± 0.05 302 0.29 ± 0.03 0.016
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trials. Published mIBG treatments refer to tan-
dem mIBG in rapid sequence, to mIBG as com-
ponent of HDT (CEM or BU/MEL) and mIBG 
combination therapies. They vary in dose, single 
vs. tandem schedules applied and various combi-
nations with chemotherapy (topotecan or irinote-
can and VCR) or radiation sensitizers (i.e. 
vorinostat increasing mIBG uptake).
In relapse patients the EBMT data (Ladenstein 
et al. 1993) showed a benefit from salvage HDT/
HSCT in responding patients relapsing after 
12 months from diagnosis and without a previ-
ous HDT.
Allo-HSCT as immunotherapy received spe-
cial attention after introduction of RIC and NMA 
transplants. Some reports highlight a graft- 
versus- tumour (GvT) effect with adopted allo- 
HSCT approaches, while the EBMT data shows 
no benefit with classical allo-HSCT (Ladenstein 
et al. 1994). Research on experimental approaches 
to allogeneic HSCT is ongoing. Haplo-HSCT is a 
feasible option in very high-risk R/R patients 
capable to induce long-term remission in some 
with tolerable side effects allowing addition of 
post-transplant immune adoptive strategies 
(Illhardt et al. 2018).
92.2.3.1  EBMT Data (See Tables 92.2 and 
92.3)
Median age of 7672 patients is 3.7 years (7,504 
auto-HSCT, 168 allo-HSCT). EBMT registry 
data pointed at an early stage to the superiority 
of the BU/MEL HDT (Ladenstein et al. 2017). 
A multivariate analysis of the EBMT data found 
significantly better EFS associated with age 
<2 years at ASCT (p < 0.0001), a good remis-
sion status (≥PR) before HDT/HSCT 
(p < 0.0001), use of PBSC (p = 0.014), ASCT 
(vs. allo-HSCT) (p = 0.031), as well as with the 
BU/MEL combination for HDT (p  <  0.01) 
(Ladenstein et al. 2008).
92.2.3.2  Indications 2018
Standard indications include first-line high-risk 
NBL >18 months at diagnosis with widespread 
metastatic disease or those of any age with 
MYCN amplified tumours with INSS stages 2–4. 
Any responding metastatic relapse in patients 
>18  months and any MYCN amplified tumour 
without prior HDT/HSCT are good indications. 
Any other indication is reserved for well- designed 
experimental phase I/phase II trials. Children 
<18 months need to be evaluated for a high-risk 
biological risk profile prior to being considered 
for HDT/auto-HSCT (Canete et al. 2009; Moroz 
et al. 2011; Cohn et al. 2009).
92.2.4  Ewing Tumours
A number of publications proposed a potential 
role of HDT/HSCT in Ewing tumours (Ladenstein 
et al. 2010; Luksch et al. 2012) during primary 
treatments for patients with multifocal bone or 
BM metastases, whereas indications for those 
with lung metastases is more questionable 
(Burdach and Jürgens 2002). Some publications 
found BU/MEL HDT more active in comparison 
to other HDT regimes (Tenneti et al. 2018). TBI 
was investigated (Burdach and Jürgens 2002) 
without any clear benefit but high toxicity and 
mortality.
The Euro-EWING 99 study group (Ladenstein 
et  al. 2010) published the largest population of 
HSCT on primary disseminated multifocal 
Ewing sarcomas (PDMES) with 281 patients 
receiving BU/MEL HDT/auto-HSCT after VIDE 
(VCR, IFO, DOX, VP) induction. The 3-year 
EFS and OS were 27 ± 3% and 34 ± 4% and were 
45% for patients ≤14 years. Patients ≥14 years 
(HR  =  1.6), with a primary tumour volume 
>200 mL (HR = 1.8), more than one bone meta-
static site (HR = 2.0), BM metastases (HR = 1.6) 
and additional lung metastases (HR = 1.5), carry 
an increased risk at diagnosis. A score based on 
these factors identified patients with an EFS rate 
of 50% for scores ≤3 (82 patients), 25% for a 
score >3 and ≤5 (102 patients) and 10% for score 
≥5 (70 patients; p < 0.0001).
In 2018 the Euro-EWING 99 study group 
published the results of the randomized com-
parison of BU/MEL over standard chemother-
apy with VAI (7 courses) which was offered to 
patients if aged <50 with poor histologic 
response (≥10% viable cells) after VIDE induc-
tion (6 courses) or large tumour volume at 
 diagnosis (≥200  mL). The risk of event was 
significantly decreased by BU/MEL compared 
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to VAI (VCR, actinomycin, IFO) (HR = 0.64, 
95% CI = 0.43–0.95; p = 0.026); 3- and 8-year 
EFS were, respectively, 69.0% (60.2–76.6%) 
versus 56.1% (47.6–65.4%) and 60.7% (51.1–
69.6%) versus 47.1% (37.7–56.8%). OS results 
also favoured BU/MEL.  For this group of 
patients, BU/MEL is now a standard of care 
(Whelan 2018).
Tandem HDT and allo-HSCT were part of the 
EICESS92 and Meta-EICESS protocols yielding 
long-term DFS in patients with advanced Ewing 
tumours (Burdach and Jürgens 2002).
Patients suffering a relapse generally have a 
poor prognosis with conventional chemotherapy. 
The role of HDT/auto-HSCT still awaits clarifi-
cation in randomized controlled studies (Tenneti 
et  al. 2018; Ferrari et  al. 2015). A GvT or 
improved survival following allo-HSCT effect 
was highlighted in some reports, but a retrospec-
tive review (Thiel et al. 2011) could not identify 
benefits with either RIC or MAC or with either 
HLA-matched or HLA-mismatched grafts.
92.2.4.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age of 3019 (2970 autologous, 49 
allogeneic) evaluable Ewing tumour patients is 
12.5  years with 2161 patients who received 
HDT during primary treatment and 498 after 
relapse (disease status not specified in 360). 
BU/MEL HDT achieved better results in first-
line settings, while TBI clearly was associated 
with poorer outcomes. Multivariate analysis of 
the EBMT data showed increased risks for 
patients >14 years, a remission status less than 
CR1, PR or CR2, BM as stem cell source and 
HDT other than BU/MEL.
92.2.4.2  Indications 2018
BU/MEL HDT for patients with a poor histologi-
cal response after induction and/or a tumour vol-
ume ≥200 mL is now standard of care. Patients 
with primary metastatic disease at sites other 
than the lungs and a low-risk score may be con-
sidered good candidates in the absence of a con-
trolled trial. Any metastatic relapse without prior 
HDT may be considered for controlled phase II 
HDT protocols.
92.2.5  Soft Tissue Sarcoma (STS)
Rhabdomyosarcoma (RMS) is the most common 
STS of childhood. A multivariate analysis of 269 
patients with metastatic RMS found age (>10 years, 
p < 0.0001) and bone/BM involvement (p < 0.019) 
to be the most important predictors for fatal out-
come (Thiel et al. 2013). In STS dose escalation 
with auto-HSCT produced only short-lived remis-
sions with generally disappointing outcome data 
unless patients were chemosensitive and receiving 
HDT as consolidation in CR (Admiraal et al. 2010). 
Results of a recent review do not justify the use of 
HDC/HSCT as standard therapy for children with 
metastatic RMS (Admiraal et al. 2010).
A systematic review of HDT/auto-HSCT 
in  locally advanced or metastatic non- 
rhabdomyosarcoma soft tissue sarcoma (NRSTS) 
was undertaken and evaluated 294 patients with 
19 different subtypes of malignant NRSTS in 62 
studies covering an age span between 10 and 
46  years. This analysis found no advantage for 
HDT over standard chemotherapy (Peinemann 
and Labeit 2014).
The use of allo-HSCT in patients with advanced 
RMS is still experimental. No patients with resid-
ual disease before allo-SCT were converted to 
CR.  In a subset of patients, it may constitute a 
valuable approach for consolidating CR, but this 
awaits prospective validation (Thiel et al. 2013).
92.2.5.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age of 1116 evaluable patients (1035 
autologous, 81 allogeneic) is 9  years with 718 
receiving HDT during primary treatment and 
275 after relapse (disease status not specified in 
123 patients).
92.2.5.2  Indications 2018
Currently there is no evidence-based standard 
indication for HDT/HSCT in STS.
92.2.6  Brain Tumours
Paediatric embryonal brain tumour patients 
treated with craniospinal irradiation (CSI) are at 
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risk for adverse effects, with greater severity in 
younger patients. Two publications in 2017 
refer to this situation. Outcomes of CSI vs. 
HDT/auto- HSCT and delayed CSI were com-
pared in 201 newly diagnosed patients [medul-
loblastoma (72%), supratentorial primitive 
neuroectodermal tumour (sPNET; 18%) or 
pineoblastoma (10%)]. Outcomes with adjuvant 
HD/HSCT followed by delayed CSI are compa-
rable to upfront CSI for young paediatric 
embryonal brain tumour patients, but benefits 
regarding neurocognitive outcomes await future 
assessment (Raleigh et al. 2017).
The second report summarizing HDT/HSCT 
(29 with 3 tandem transplants and 15 with 2 tan-
dem transplants) as irradiation-avoiding or 
irradiation- minimizing approach reported 
encouraging irradiation-free survival in children 
with newly diagnosed malignant brain tumours 
[medulloblastoma/primitive neuroectodermal 
tumour (21 patients), atypical teratoid/rhabdoid 
tumour (8), high-grade glioma (5), malignant 
germ cell tumour (4), ependymoma (3) and cho-
roid plexus carcinoma (3)] (Guerra et al. 2017). 
The PFS and OS for newly diagnosed patients 
were 68.9 ± 9.9% and 73.5 ± 9.3%, while it was 
only 11.8 ± 9.8% (p < 0.001) and 15.1 ± 12.3% 
(p = 0.0231) at relapse, respectively.
The Children’s Cancer Group 99703 study 
assessed 92 patients receiving 3 consolidation 
cycles of HDT (TT and CBP) and auto-HSCT 
after biopsy/resection and 3 conventional-dose 
chemotherapy cycles. Response rates to induc-
tion and consolidation were high in patients with 
residual tumour with 73.3% and 66.7%, respec-
tively, resulting in 5-year EFS and OS of 
43.9 ± 5.2% and 63.6 ± 5%. Gross total resection 
versus less than gross total resection was the 
only significant outcome comparison (Cohen 
et al. 2015).
The HIT97 national trial tested a stratified 
relapse protocol using either intensive chemo-
therapy, potentially high dose, or oral chemother-
apy. Adding HDT in patients who responded to 
the initial courses of chemotherapy did not 
improve survival. Patients with relapsed cerebral 
PNET responding to conventional chemotherapy 
did not profit from HDT (Bode et al. 2014).
92.2.6.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age for 2818 evaluable brain tumour 
patients (2809 autologous, 9 allogeneic) is 
6 years with 2039 receiving HDT during primary 
treatments and 442 after relapse (disease status 
not specified in 337).
Medulloblastoma is the leading indication 
with 69% followed by astrocytoma (7%), glio-
blastoma (7%), ependymoma (6%) and other non-
specified CNS tumours (11%). Medulloblastoma 
patients’ outcome is better when submitted to 
HDT/SCT in first remission and if younger 
<3  years. A more detailed analysis by various 
brain tumours histologies and distinct risk factors 
is not possible in the current dataset.
92.2.6.2  Indications 2018
Patients with high-risk medulloblastoma (pri-
mary metastases/relapse) of any age older than 
3 years are eligible for HDT/HSCT in combina-
tion with radiation, while in infants HDT/HSCT 
is used with the aim of reducing (volumes and 
doses) or avoiding radiation (Finlay and 
Massimino 2010).
Metastatic PNETs at diagnosis or with addi-
tional high-risk features such as incomplete resec-
tion or young age (younger than 3 or 5 years) as 
well as infants and young children (<4 years) with 
malignant brain tumours are further indications. 
Very controversial indications include high-grade 
glioma. Currently there is little or no indication 
for HDT/HSCT in ependymoma, brain stem gli-
oma or pineoblastoma. More investigations are 
required to define the optimal HDT for each 
tumour type. Most groups use similar HDT regi-
mens, i.e. BU/TT (SFOP, Spain), VP/TT/CBDCA 
(US/CCG, Germany, Spain) or a tandem approach 
Vp16/CBDCA - TTP/L-PAM (Italy).
92.2.7  Wilms’ Tumour (WT)
Pooling data of 19 publications (5 HDT, 6 NoHDT, 
8 both), an advantage to HDT with a hazard ratio 
(HR) of 0.87 for EFS and 0.94 for OS was 
observed. Further analyses of risk groups, defined 
by treatment and/or histology prior to first relapse, 
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suggested a HR for EFS of 0.90 for those of high- 
and 0.50 for the very high-risk patients. However, 
a great uncertainty persists in the absence of ran-
domized trials concerning the role of HDT follow-
ing relapse after treatment for WT (Ha et al. 2013).
The CIBMTR retrospective analysis on 253 
relapsed WT receiving HDT/auto-HSCT reports 
5-year EFS and OS rates of 36% (95% CI, 
29–43%) and 45% (95% CI, 38–51%), respec-
tively. Outcomes are similar to those reported in 
the literature. So far attempts to conduct a ran-
domized trial comparing maintenance chemo-
therapy with consolidation versus HDT/
auto-HSCT have failed in this indication 
(Malogolowkin et al. 2017).
92.2.7.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age in 625 patients with auto-HSCT 
(212 HDT during primary treatment; 348 after 
relapse) is 6 years. Reported superior results for 
patients receiving MEL alone may be correlated 
to the favourable response status prior HDT: 76% 
in CR1 and 64% in CR2.
92.2.7.2  Indications 2018
Experience of the SIOP, GPOH, NWTS, MRC 
and respective national groups over the last 
20 years found the probability of cure of 30% at 
best in the presence of adverse prognostic factors. 
High-risk factors are unfavourable histology and 
metastatic disease (Presson et  al. 2010) and are 
after relapse again unfavourable histology and 
one of the following criteria: extra- pulmonary 
relapse or abdominal relapse after radiation, stage 
IV, more than two drugs in the first-line regimen 
or relapse within 1  year. HDT is indicated if a 
response to second-line treatment is achieved.
92.2.8  Germ Cell Tumours
CNS germ cell tumours (GCTs) can be divided 
into major groups including germinomas (having 
a superior prognosis) and non-germinomatous 
GCTs (NGGCTs), with teratomas often consid-
ered a separate category- and represent approxi-
mately 3% of primary paediatric brain tumours. 
NGGCTs are less radiosensitive, but adjuvant 
chemotherapy improved survival.
CNS GCT relapses commonly occur at the pri-
mary tumour site, and in about 30% there is con-
comitant leptomeningeal spread. Salvage therapies 
include additional surgery, focal or CSI and HDT/
auto-HSCT.  For pure germinoma patients previ-
ously receiving radiation therapy, HDT/auto-
HSCT is often recommended. HDT/HSCT showed 
curative potential for some relapsed systemic 
NGGCTs, in particular for those achieving a CR to 
chemotherapy (Echevarria et al. 2008).
The management of intracranial GCTs is 
complex because of varied clinical presentations, 
tumour sites, treatments and outcomes and the 
need for multidisciplinary input.
In an international Delphi approach, key areas 
of consensus were defined to guide and stream-
line clinical management of patients with intra-
cranial germ cell tumours (Murray et al. 2015).
92.2.8.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age of 553 patients with HDT/ASCT 
(270 during primary treatment, 211 after relapse, 
disease status not reported in 72) registered as 
GCT and considered high risk is 13  years. 
However, differentiation of subgroups is poor.
92.2.8.2  Indications 2018
As paediatric patients with extracranial GCTs 
may expect an excellent outcome with conven-
tional chemotherapy approaches, there is no stan-
dard indication for HDT/ASCT.
High-risk patients with extracranial GCTs are 
initial nonresponders or poor responders (no local 
control achieved) and patients after relapse failing 
to achieve second CR.  In high-risk CNS GCT 
patients <18 years, the following criteria for HDT 
may be adopted: recurrent CNS GCT when bio-
logical remission is achieved prior to HDC and 
insufficient response to primary chemotherapy.
92.2.9  Osteosarcoma
Even in responding high-risk patients treated 
with HDT/HSCT in first or second remission, the 
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length of remission is short, and relapse occurs 
early after HDT. High-risk features include poor 
histological response or nonresponse of the pri-
mary tumour at the time of definitive surgery, 
inoperable, axial tumours (large volume), pri-
mary dissemination or relapse other than iso-
lated, late lung metastases.
The French Society of Paediatric Oncology 
(SFCE) explored HDT with high-dose TT and 
auto-HSCT in 45 children with relapsed osteosar-
coma (median age 15.9 years) after initial progres-
sion of metastatic disease (2), first relapse (26) and 
second or third relapse (17). Three-year OS was 
40% and 3-year PFS 24%. A randomized study for 
recurrent osteosarcoma between standard salvage 
chemotherapy and high-dose TT with auto-HSCT 
is ongoing (Marec-Berard et al. 2014).
Earlier reports did not encourage HDT regi-
mens (Sauerbrey et al. 2001) and included MEL 
and VP, with additional CBP by the Cooperative 
Osteosarcoma Study Group, or two courses of 
high-dose VP and CBP by the Italian Sarcoma 
Group (Boye et al. 2014; Fagioli et al. 2002).
92.2.9.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age in 294 evaluable patients (134 
HDT during primary treatment; 130 after relapse, 
disease status not specified in 30; 288 autolo-
gous, only 6 allogeneic) is 14.3 years.
92.2.9.2  Indications 2018
There is no standard indication for HSCT based 
on published results or EBMT data.
92.2.10  Retinoblastoma
There is one systematic review on HDT/auto- 
HSCT based on 15 studies and a total of 101 
patients (Jaradat et  al. 2012). Following treat-
ment for metastatic and relapsed disease, 44 of 
77 patients (57.1%) were alive with no evidence 
of disease at the time of follow-up. However, a 
higher rate of local relapse developed in patients 
with CNS metastases (73.1%), which dropped to 
47.1% in patients who received thiotepa. 
In  patients with trilateral or bilateral advanced 
retinoblastoma, five of seven (71.4%) with 
reported outcome data as well as patients with 
tumour at the surgical margin of the optic nerve 
and/or extrascleral extension, six of seven 
patients (85.7%) were alive without evidence of 
disease at last follow-up. Durable tumour control 
was achieved in patients with non-CNS metasta-
ses, trilateral or bilateral advanced retinoblas-
toma, and with tumour at the surgical margin of 
the optic nerve and/or extrascleral extension. 
Patients with CNS metastases require TT to 
improve tumour control (Dunkel et al. 2010).
Advocated HDT/auto-HSCT approaches are 
CARBOPEC (CBP, VP, CY) (Jaradat et  al. 
2012), but for CNS-positive patients, TT or BU 
was introduced. Other groups used combina-
tions including MEL and CBDCA and/or VP for 
metastatic retinoblastoma and reported promis-
ing survival results for patients without CNS 
involvement.
92.2.10.1  EBMT Data (See Tables 92.2 
and 92.3)
The median age for 170 evaluable patients (99 
during primary treatment (40% with localized/
regional disease; 60% with metastatic disease); 
54 after relapse; 17 disease status not specified; 
169 autologous, 1 allogeneic) is 3.5 years.
92.2.10.2  Indications 2018
Future trials should take the following high-risk 
factors into consideration: involvement of the cut 
end or subarachnoidal space of the optic nerve 
after enucleation, orbital involvement and distant 
metastatic disease and CNS disease.
Key Points
• In neuroblastoma and Ewing sarcoma, 
there is clear evidence for the advantage 
of HDT/auto-HSCT with an increasing 
interest in tandem transplants.
• In other paediatric solid tumour, indica-
tion still lacks randomized trials, and 
indications are based on observational 




92.3  Solid Tumours in Adults
Francesco Lanza
92.3.1  Auto-HSCT
Supported by a strong rationale from laboratory 
studies and apparently “convincing” results of 
early phase II studies, in the 1990s auto-HSCT 
was uncritically adopted as a potentially curative 
option for solid tumours. For this reason, ran-
domized trials comparing high-dose therapy with 
conventional control arm were difficult to con-
duct. As a result, the number and size of clinical 
studies initiated (and often abandoned before 
completion) to prove or disprove its value were 
largely insufficient. Nowadays, after 25 years of 
clinical research and thousands of patients receiv-
ing auto-HSCT, the benefit of autotransplant in 
solid tumours, with the possible exception of 
selected patients with breast cancer (BC) and 
germ cell tumours (GCTs), is still unsettled 
(Fig. 92.1) (Sureda et al. 2015).
92.3.1.1  Breast Cancer (BC)
The role of auto-HSCT for primary breast cancer 
at high risk of recurrence (at least four involved 
axillary lymph nodes) has been assessed by sev-
eral randomized trials, recently evaluated by a 
meta-analysis of individual patient data (Berry 
et al. 2011; Pedrazzoli et al. 2015). Overall, it was 
shown that auto-HSCT prolonged DFS when 
used as adjuvant therapy and showed a benefit on 
BC-specific survival and OS in selected cohorts of 
patients (Nitz et al. 2005; Pedrazzoli et al. 2015).
Whether auto-HSCT has benefit in the context 
of contemporary taxane-based regimens and tar-
geted therapies is largely unknown. Seven phase 
III studies have been published in peer-reviewed 
journals. Most of these trials showed improved 
PFS in the auto-HSCT arm but only one OS 
advantage. Six randomized trials, including 866 
metastatic breast cancer (MBC) patients, have 
been analysed in the parallel meta-analysis of 
individual patient data (Berry et al. 2011) show-
ing a significant improvement in PFS but no 
improvement in OS.
Overall, based on the randomized studies so 
far, meta-analyses and retrospective studies, auto-
HSCT may still represent a therapeutic option for 
younger patients harbouring HER2- negative 
tumours and having gross involvement of axillary 
nodes (adjuvant setting) or highly chemosensitive 
disease (advanced setting) (Martino et al. 2016).
92.3.1.2  Germ Cell Tumours (GCTs)
Auto-HSCT is not recommended as first-line 
therapy in GCT. In relapsed GCT high-dose ther-
apy is considered a therapeutic option, especially 
when poor prognostic factors are present (Lorch 
et al. 2011; Necchi et al. 2015; De Giorgi et al. 
2017a; b). A randomized study (Tiger study) 
comparing conventional-dose therapy with high- 
dose therapy is ongoing. Auto-HSCT is a stan-
dard of care for patients that are (primary) 
refractory to platinum-based chemotherapy or for 
those with a second or further relapse (Necchi 
et  al. 2015). Multiple intensified cycles with 
CBP/VP are recommended as the standard HDT 
for GCT also due to concerns that using a three- 
drug regimen would require dose reductions of 
the two most active drugs in this disease.
Furthermore, auto-HSCT can be safely admin-
istered in high-risk patients older than 45 years. 
However, since the prognosis is poorer for older 
patients with non-seminoma histology, a compre-
hensive risk-benefit evaluation should include 
co-morbidities and the patient’s risk category.
The assessment of a large series of EBMT 
centres, including 46 cases with pure seminoma, 
seems to support the notion that auto-HSCT may 
represent a valuable therapeutic option after 
standard- dose chemotherapy failure in this 
patient category (Necchi et al. 2017).
EBMT conducted a retrospective analysis on 
29 patients with refractory gestational tropho-
blastic neoplasia (GTN) treated with auto- 
HSCT.  Data showed that HDT based on CBP 
seems to be active in this heavily pretreated 
patient population and that auto-HSCT repre-
sents a possible option for patients with refrac-
tory GNT (Necchi et al. 2016).
The role of auto-HSCT in mediastinal non- 
seminoma (MnS) GCT disease category is under 
evaluation. Data from EBMT confirmed that the 
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MnS was characterized by the poorest outcome 
with 5-year OS ranging from 40% to 45%. The 
use of auto-HSCT as both early intensification 
and at disease recurrence proved to be effective, 
given upfront, and may produce a 15–20% abso-
lute improvement in survival compared with 
standard-dose CT.
92.3.1.3  Soft Tissue Sarcoma (STS)
STS accounts for about 1% of adult cancers. 
Based on the observation of a dose-response cor-
relation for some drugs used in STS, e.g. DOX 
and IFO, HDT with auto-HSCT has been investi-
gated in some, mostly non-randomized phase II 
trials. Most of these trials found few patients to 
possibly benefit from auto-HSCT but, owing to 
the small patient numbers of each of the included 
histologic subgroups, could not establish robust 
markers for identifying these patients. A recent 
meta-analysis on this subject found no evidence 
for a benefit of auto-HSCT but, again, did not 
sufficiently report on outcomes in the different 
histologic subgroups. However, taking into 
account that the current WHO classification dif-
ferentiates more than 50 histological subtypes of 
STS, it might be hypothesized that clinical 
response to auto-HSCT may vary significantly 
from different histological varieties.
92.3.1.4  Other Solid Tumours
Data from randomized phase III studies compar-
ing HDT vs. conventional-dose chemotherapy 
for first-line treatment of advanced ovarian can-
cer and limited or extensive small cell lung can-
cer have shown no statistically significant 
difference in PFS or OS. Limitations due to study 
design, difficulty in recruitment and toxicity may 
have accounted for the lack of favourable results 
that were expected based on previous phase II 
and retrospective analyses of such highly chemo-
sensitive diseases.
In other chemosensitive histologies, including 
sarcomas and CNS tumours, data regarding auto- 
HSCT in adult patients are limited, again based 
on clinical trials without randomization and ret-
rospective analyses. For this reason, auto-HSCT 
cannot be recommended as standard of care. 
High-dose therapy can be regarded as a potential 
clinical option in selected patients with Ewing’s 
sarcoma and medulloblastoma.
92.3.2  Allo-HSCT
Immune therapy for cancer is being pursued with 
extraordinary interest by researchers all over the 
world, given the recent scientific acquisitions on 
immune mechanisms that control cancer and the 
introduction in the marketplace of checkpoint 
inhibitor molecules, such as nivolumab/pembro-
lizumab (PD-1/PDL-1 inhibitors), ipilimumab 
(anti-CTLA4), etc. The paradigm for immune 
therapy of cancer is allo-HSCT, whose therapeu-
tic effect is carried out by immunocompetent T 
cells of the donor, an effect known as GvT or 
graft-versus-tumour effect. Several studies of 
allo-HSCT in selected solid tumours, namely, 
renal cell cancer (RCC), ovarian cancer, BC, 
colorectal cancer and others, with some evidence 
of GvT and occurrence of transplant- related tox-
icities, mostly GvHD have been reported.  In 
RCC, a long-term survival effect in a fraction 
(20%) of patients was documented. Since 2004, 
when molecularly targeted drugs were introduced 
into the clinic for renal cell cancer, patient refer-
ral for transplant dropped precipitously, and 
transplant rate evaluation for solid tumours from 
2009 was limited to a few patients in Europe.
A recent survey provided a picture of the sta-
tus of allo-HSCT for solid tumours in EBMT 
centres (Bregni et  al. 2016). In contrast to our 
expectations, allo-HSCT for solid tumour indica-
tions has not been abandoned, even if its use has 
been markedly reduced. Based on these findings, 
allograft for solid tumours as adoptive immuno-
therapy is still being used in EBMT centres, in a 
few institutions and in a few selected indications, 
thus confirming the willingness of several centres 
to share data, adopt common protocols and con-
tinue to use this strategy in highly selected cases.
92.3.2.1  Renal Cell Cancer
There is no clinical experience of allografting in 
RCC, that is, TKI and mTOR refractory; nowa-
days, allo-HSCT should be considered only in 
the context of prospective studies.
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92.3.2.2  Soft Tissues Sarcomas
The use of allo-HSCT has been investigated in 
paediatric sarcoma and rhabdomyosarcoma. 
Original data on allo-HSCT in adult STS is rare 
and stems from small case series (Sureda et  al. 
2015). In 2007, a retrospective study of the 
EBMT investigated the use of reduced- 
conditioning allo-HSCT in 14 STS patients. The 
authors concluded that an immune-mediated 
effect might have contributed to tumour control 
in some patients. Interestingly, the low number of 
patients examined did not permit a histotype- 
stratified analysis.
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 Appendix: EBMT Registry
Carmen Ruiz de Elvira  
and  Shelley Hewerdine
 Introduction
The EBMT maintains a Registry which encom-
passes all HSCT procedures for all indications. It 
also stores immunosuppressive treatments for 
bone marrow failure syndromes (i.e., aplastic 
anaemias), cell therapy treatments other than 
HSCT and donor information pertaining to col-
lection and donor follow-up.
 Content of the Registry
The clinical content of the EBMT Registry is 
decided by EBMT researchers through the 
Working Parties (WP). All requests have to be 
endorsed by the relevant WP Chair and must be 
accompanied by adequate definitions of the new 
data items. The final structure, format and clini-
cal definitions of the data collection forms are 
supported by EBMT staff and important stake-
holders of the Registry. This is done through rec-
ognised structures such as the Registry 
Committee, the Definitions Group and the Data 
Registries Group. For more details on these 
groups, please refer to the EBMT website. Final 
decisions are made by the Scientific Council and 
the Board of the Association.
 Data Collection Forms
The EBMT has four main types of Data Collection 
Form which are implemented in the Registry IT 
system. For reference you can download data 




Minimum Essential Data. All EBMT 
member centres that perform transplants 
need to submit MED A for every HSCT to 
retain full membership. Transplant centres 
that do not report for 2 years or more will 




Contains more data than MED A and is 
optimal for studies. Includes all items from 




Contains the minimum essential data for 
this type of treatment
Donor 
Outcome
Minimum essential data to follow stem 
cell donors
 IT System
At the time of writing the EBMT Registry is 
using ProMISe software designed by Ronald 
Brand, who worked as a Professor of Biostatistics 
at LUMC in the Netherlands prior to his retire-
ment in 2017. The data is stored in an SQL server 
database based in the same location. During 
2018, the EBMT Registry is continuing with an 
upgrade project and intends to switch to an elec-
tronic data capture system named MACRO, part 




of the company Elsevier. Again, this will be a 
hosted environment and the server will abide by 
all standards in safety and security, and any other 
data protection standards required by the EU 
GDPR, that has become law in May 2018.
 IT Security
The IT system uses all reasonable, appropriate, 
practical and effective security measures to pro-
tect our important processes and assets. The sys-
tem utilises NEN7510 (2011) with the ISO27001 
internal foundation as a framework for guiding 
our approach to managing security. The system 
provider continually reviews its use of security 
measures to improve the way in which we protect 
our systems, and the data entrusted to us.
 Data Protection
The EBMT Registry follows EU directives 
regarding data protection. It is the responsibility 
of the EBMT to ensure that centres and donor 
registries are aware of this. The EBMT requests 
that all centres outside the EU sign an EU 
Regulations Statement declaring they will follow 
EU regulations regarding data safety. The most 
up-to-date information on EBMT data protection 
can be found on the Data Management pages of 
the EBMT website, in particular the full Registry 
Function document. As the Registry Office is 
located in London, the database has been regis-
tered with the Information Commissioner’s 
Office in the United Kingdom.
All EBMT centres must obtain informed con-
sent from their patients and/or donors before the 
data can be submitted to the EBMT. Data is semi- 
anonymised: we store date of birth and usually 
the patient initials; never full names. Emailing, 
downloading or transferring EBMT data contain-
ing even semi-anonymous identifiers is NOT 
allowed, unless strong password protection or an 
EBMT approved secure server is used. In the 
unlikely cases of patients refusing consent to 
their data being stored, then fully anonymous, 
bare minimum data can be registered, purely to 
include these transplants in the centre counts.
 Registry Function
The main function of the Registry is to collect 
pertinent and good quality clinical data. The main 
use of these data is clinical research, but it will 
also be used to support the mission of the EBMT 
in aspects such as the inspection, auditing and 
accreditation of transplant centres.
EBMT led studies is the single most important 
use of the Registry data. The EBMT registry can 
use all the data submitted to them. It is under-
stood that data submitted to the EBMT can be 
used for research and published by the EBMT 
WP as long as the existing Guidelines for the 
Conduct of Registry Studies using the EBMT 
Registry Database and the Authorship guidelines 
for EBMT publications are followed. Both docu-
ments are mandatory reading for any WP investi-
gator wishing to perform a registry study. 
Although the EBMT Registry Office has the pri-
mary responsibility for cleaning, and updating 
the data, the EBMT study coordinators contribute 
to this for specific studies.
 Registry Stakeholders
 Centres
Member centres use the Registry to store their 
own data while simultaneously making it avail-
able to the EBMT. Each EBMT member can be 
considered as the main owner of their data, 
although it is understood that the ultimate owner 
is the patient. Members submitting data can use 
their own data for their own purposes without 
having to require permission or notify the 
EBMT. Members have access to their own data at 
all times and can actively block access to selected 
patients by other authorised users. Member cen-
tres can also obtain aggregate anonymised data of 
the entire Registry, where neither the patient nor 
the centre is identifiable.
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 National Registries for HSCT
National registries operating in some countries, 
usually under the umbrella of a medical associa-
tion, have become part of the EBMT data flow by 
mutual consent and are using the same central data-
base. These national registries use their data for 
their own purposes, which may encompass national 
requirements for registration of transplants, 
research, demographics, etc. Where these registries 
exist, the responsibility of the EBMT Registry for 
data management may be partially devolved to 
them. That said, EBMT centres belonging to a 
National Registry have as much access to the 
EBMT Registry staff and services as any other cen-
tre member. We enjoy a close collaboration with a 
number of national societies and a list of partners 
can be found on the EBMT website.
 Government Agencies
Registry data may be accessed by public agencies in 
one of two ways: (1) they can request direct access to 
data submitted by centres in their country. As with 
any other type of access, centres need to make the 
request to the Registry for their data to be accessed 
directly by these agencies. (2) National registries 
may collaborate with public agencies providing 
them with data extracted from the EBMT Registry.
 Donor Registries
Donor Registries can use the EBMT Registry to 
store their own data while simultaneously mak-
ing it available to the EBMT.  Donor Registries 
submitting donor data can use their own data for 
their own purposes without having to require per-
mission or notify the EBMT.  Donor Registries 
have access to their own data at all times.
Donor registries may also request access to 
the Registry in order to follow the donors or the 
patients that have received donations from them. 
In the latter case, the centre has to give permis-
sion for the donor registry to be able to see 
selected patient data.
 Study Groups
Groups of centres can set up studies and use the 
EBMT Registry as their database. The study 
group requests explicit permission from the 
Principal Investigator of each centre involved and 
forwards these to the EBMT. All centres must be 
members of the EBMT. Permission templates are 
available.
 International Research Organisations
Centres that submit data to other organisations 
can request the EBMT to provide data access to 
these organisations, so they do not have to do 
double reporting. In these cases, the EBMT can 
set up “virtual registries” that replicate the scope 
of the organisation and provide access to a data 
manager of this organisation to access the permit-
ted data. Such requests have to be submitted 
explicitly by the Principal Investigator of the 
involved centre. All centres must be members of 
the EBMT. Permission templates are available.
 Corporate Sponsors
Corporate members can obtain aggregate ano-
nymised data as part of their contract, where nei-
ther the patient nor the centre is identifiable. 
Sponsors cannot obtain outcome data. To safe-
guard centre anonymity, all countries with less 
than ten member centres appear under the label 
of “Other”.
 Access to the Registry
All individuals must submit an Access request for 
internet access to the data. Accepted signatories are:
• Principal investigator of a transplant centre 
(centre’s data only) or donor registry (donor 
registry’s data only)
• Working Party chair (for access to data within 
the remit of that WP)
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• The President of the EBMT (for data within 
the remit of an EBMT Committee)
• Director of an institution or study group with 
which we have a partnership. In this case, the 
partner must also submit a signed form from 
every centre involved granting access of their 
data to that institution or study group.
• Registry head for EBMT Registry staff
Individuals who by the nature of their work 
have direct access to the EBMT Registry data-
bases (IT system/server managers) have no 
access rights to the data and would be in breach 
of contract if they manipulate it.
Some individuals work in multiple roles and it 
is possible to request multiple user roles and rights, 
as long as the above procedures are followed.
 Types of Access
Users of the Registry system can access their own 
data in which case they can request permission to 
do any of the following:
• Data entry*
• Lists of patient data*
• Data download*
• Tables with aggregated data (frequencies and 
cross tabulations)
The types of access marked with (*) are 
restricted since they may include identification of 
the patients. This type of access can only be 
requested by an accepted signatory for a set of 
nominated individuals. The access provided is 
personal and cannot be transferred to other indi-
viduals, not even within the same centre. The 
Central Registry Office reserves the right to can-
cel access without warning if it is felt that patient 
confidentiality might be at risk.
The unrestricted access, tables with aggregated 
data, is available to all members and sponsors. 
This statistical function does not allow patients or 
centres to be identified. Transplant centres who are 
members can access statistics of the entire registry 
as part of their database access. Aggregated data 
requests from other recognised groups should be 
made to the Central Registry Office.
 Data Flow
For MED A or B for HSCT, the first registration 
must be submitted on the day of transplant (day 
0) or within a week of day 0. An update should be 
submitted when 100 days have elapsed from the 
date of transplant, or when the patient dies, 
whichever comes first. Regular annual follow-up 
data must be submitted for all patients from then 
onwards.
For MED A for cell therapy (without HSCT), 
the first registration must be submitted on the day 
of infusion (day 0) or within a week of day 0. An 
update should be submitted every 6 months.
For more detailed and up-to-date information, 
see document Submitting data to the EBMT
The data can reach the Registry through two 
channels:
 (a) Direct data entry by a centre. This is the pre-
ferred and most common method.
 (b) Direct data entry by a small number of 
national registries on behalf of specific cen-
tres that submit paper forms to them.
Centres can enter the data directly (option a), 
or fill in the MED A or MED B paper forms and 
send it to their national registry if available 
(option b).
When the data is entered directly by the centre 
into the EBMT database, this ensures immediate 
access by the EBMT and authorised users to the 
centre’s data. This is the preferred method. 
Centres who use this system may be approached 
by the national registry, if they belong to one, or 
by the EBMT registry with requests for data cor-
rections or clarifications. All centres can request 
to view their data, even if it has been entered by a 
National Registry on their behalf.
 Support
The Registry has a small team of staff based in 
London who work on the database structure, 
form design, data quality, user support and docu-
mentation. Contact details can be found on the 
EBMT website.
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